<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />




<title>GI</title>

<script src="data:application/javascript;base64,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"></script>
<script src="data:application/javascript;base64,/*! jQuery v3.6.0 | (c) OpenJS Foundation and other contributors | jquery.org/license */
!function(e,t){"use strict";"object"==typeof module&&"object"==typeof module.exports?module.exports=e.document?t(e,!0):function(e){if(!e.document)throw new Error("jQuery requires a window with a document");return t(e)}:t(e)}("undefined"!=typeof window?window:this,function(C,e){"use strict";var t=[],r=Object.getPrototypeOf,s=t.slice,g=t.flat?function(e){return t.flat.call(e)}:function(e){return t.concat.apply([],e)},u=t.push,i=t.indexOf,n={},o=n.toString,v=n.hasOwnProperty,a=v.toString,l=a.call(Object),y={},m=function(e){return"function"==typeof e&&"number"!=typeof e.nodeType&&"function"!=typeof e.item},x=function(e){return null!=e&&e===e.window},E=C.document,c={type:!0,src:!0,nonce:!0,noModule:!0};function b(e,t,n){var r,i,o=(n=n||E).createElement("script");if(o.text=e,t)for(r in c)(i=t[r]||t.getAttribute&&t.getAttribute(r))&&o.setAttribute(r,i);n.head.appendChild(o).parentNode.removeChild(o)}function w(e){return null==e?e+"":"object"==typeof e||"function"==typeof e?n[o.call(e)]||"object":typeof e}var f="3.6.0",S=function(e,t){return new S.fn.init(e,t)};function p(e){var t=!!e&&"length"in e&&e.length,n=w(e);return!m(e)&&!x(e)&&("array"===n||0===t||"number"==typeof t&&0<t&&t-1 in e)}S.fn=S.prototype={jquery:f,constructor:S,length:0,toArray:function(){return s.call(this)},get:function(e){return null==e?s.call(this):e<0?this[e+this.length]:this[e]},pushStack:function(e){var t=S.merge(this.constructor(),e);return t.prevObject=this,t},each:function(e){return S.each(this,e)},map:function(n){return this.pushStack(S.map(this,function(e,t){return n.call(e,t,e)}))},slice:function(){return this.pushStack(s.apply(this,arguments))},first:function(){return this.eq(0)},last:function(){return this.eq(-1)},even:function(){return this.pushStack(S.grep(this,function(e,t){return(t+1)%2}))},odd:function(){return this.pushStack(S.grep(this,function(e,t){return t%2}))},eq:function(e){var t=this.length,n=+e+(e<0?t:0);return this.pushStack(0<=n&&n<t?[this[n]]:[])},end:function(){return this.prevObject||this.constructor()},push:u,sort:t.sort,splice:t.splice},S.extend=S.fn.extend=function(){var e,t,n,r,i,o,a=arguments[0]||{},s=1,u=arguments.length,l=!1;for("boolean"==typeof a&&(l=a,a=arguments[s]||{},s++),"object"==typeof a||m(a)||(a={}),s===u&&(a=this,s--);s<u;s++)if(null!=(e=arguments[s]))for(t in e)r=e[t],"__proto__"!==t&&a!==r&&(l&&r&&(S.isPlainObject(r)||(i=Array.isArray(r)))?(n=a[t],o=i&&!Array.isArray(n)?[]:i||S.isPlainObject(n)?n:{},i=!1,a[t]=S.extend(l,o,r)):void 0!==r&&(a[t]=r));return a},S.extend({expando:"jQuery"+(f+Math.random()).replace(/\D/g,""),isReady:!0,error:function(e){throw new Error(e)},noop:function(){},isPlainObject:function(e){var t,n;return!(!e||"[object Object]"!==o.call(e))&&(!(t=r(e))||"function"==typeof(n=v.call(t,"constructor")&&t.constructor)&&a.call(n)===l)},isEmptyObject:function(e){var t;for(t in e)return!1;return!0},globalEval:function(e,t,n){b(e,{nonce:t&&t.nonce},n)},each:function(e,t){var n,r=0;if(p(e)){for(n=e.length;r<n;r++)if(!1===t.call(e[r],r,e[r]))break}else for(r in e)if(!1===t.call(e[r],r,e[r]))break;return e},makeArray:function(e,t){var n=t||[];return null!=e&&(p(Object(e))?S.merge(n,"string"==typeof e?[e]:e):u.call(n,e)),n},inArray:function(e,t,n){return null==t?-1:i.call(t,e,n)},merge:function(e,t){for(var n=+t.length,r=0,i=e.length;r<n;r++)e[i++]=t[r];return e.length=i,e},grep:function(e,t,n){for(var r=[],i=0,o=e.length,a=!n;i<o;i++)!t(e[i],i)!==a&&r.push(e[i]);return r},map:function(e,t,n){var r,i,o=0,a=[];if(p(e))for(r=e.length;o<r;o++)null!=(i=t(e[o],o,n))&&a.push(i);else for(o in e)null!=(i=t(e[o],o,n))&&a.push(i);return g(a)},guid:1,support:y}),"function"==typeof Symbol&&(S.fn[Symbol.iterator]=t[Symbol.iterator]),S.each("Boolean Number String Function Array Date RegExp Object Error Symbol".split(" "),function(e,t){n["[object "+t+"]"]=t.toLowerCase()});var d=function(n){var e,d,b,o,i,h,f,g,w,u,l,T,C,a,E,v,s,c,y,S="sizzle"+1*new Date,p=n.document,k=0,r=0,m=ue(),x=ue(),A=ue(),N=ue(),j=function(e,t){return e===t&&(l=!0),0},D={}.hasOwnProperty,t=[],q=t.pop,L=t.push,H=t.push,O=t.slice,P=function(e,t){for(var n=0,r=e.length;n<r;n++)if(e[n]===t)return n;return-1},R="checked|selected|async|autofocus|autoplay|controls|defer|disabled|hidden|ismap|loop|multiple|open|readonly|required|scoped",M="[\\x20\\t\\r\\n\\f]",I="(?:\\\\[\\da-fA-F]{1,6}"+M+"?|\\\\[^\\r\\n\\f]|[\\w-]|[^\0-\\x7f])+",W="\\["+M+"*("+I+")(?:"+M+"*([*^$|!~]?=)"+M+"*(?:'((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\"|("+I+"))|)"+M+"*\\]",F=":("+I+")(?:\\((('((?:\\\\.|[^\\\\'])*)'|\"((?:\\\\.|[^\\\\\"])*)\")|((?:\\\\.|[^\\\\()[\\]]|"+W+")*)|.*)\\)|)",B=new RegExp(M+"+","g"),$=new RegExp("^"+M+"+|((?:^|[^\\\\])(?:\\\\.)*)"+M+"+$","g"),_=new RegExp("^"+M+"*,"+M+"*"),z=new RegExp("^"+M+"*([>+~]|"+M+")"+M+"*"),U=new RegExp(M+"|>"),X=new RegExp(F),V=new RegExp("^"+I+"$"),G={ID:new RegExp("^#("+I+")"),CLASS:new RegExp("^\\.("+I+")"),TAG:new RegExp("^("+I+"|[*])"),ATTR:new RegExp("^"+W),PSEUDO:new RegExp("^"+F),CHILD:new RegExp("^:(only|first|last|nth|nth-last)-(child|of-type)(?:\\("+M+"*(even|odd|(([+-]|)(\\d*)n|)"+M+"*(?:([+-]|)"+M+"*(\\d+)|))"+M+"*\\)|)","i"),bool:new RegExp("^(?:"+R+")$","i"),needsContext:new RegExp("^"+M+"*[>+~]|:(even|odd|eq|gt|lt|nth|first|last)(?:\\("+M+"*((?:-\\d)?\\d*)"+M+"*\\)|)(?=[^-]|$)","i")},Y=/HTML$/i,Q=/^(?:input|select|textarea|button)$/i,J=/^h\d$/i,K=/^[^{]+\{\s*\[native \w/,Z=/^(?:#([\w-]+)|(\w+)|\.([\w-]+))$/,ee=/[+~]/,te=new RegExp("\\\\[\\da-fA-F]{1,6}"+M+"?|\\\\([^\\r\\n\\f])","g"),ne=function(e,t){var n="0x"+e.slice(1)-65536;return t||(n<0?String.fromCharCode(n+65536):String.fromCharCode(n>>10|55296,1023&n|56320))},re=/([\0-\x1f\x7f]|^-?\d)|^-$|[^\0-\x1f\x7f-\uFFFF\w-]/g,ie=function(e,t){return t?"\0"===e?"\ufffd":e.slice(0,-1)+"\\"+e.charCodeAt(e.length-1).toString(16)+" ":"\\"+e},oe=function(){T()},ae=be(function(e){return!0===e.disabled&&"fieldset"===e.nodeName.toLowerCase()},{dir:"parentNode",next:"legend"});try{H.apply(t=O.call(p.childNodes),p.childNodes),t[p.childNodes.length].nodeType}catch(e){H={apply:t.length?function(e,t){L.apply(e,O.call(t))}:function(e,t){var n=e.length,r=0;while(e[n++]=t[r++]);e.length=n-1}}}function se(t,e,n,r){var i,o,a,s,u,l,c,f=e&&e.ownerDocument,p=e?e.nodeType:9;if(n=n||[],"string"!=typeof t||!t||1!==p&&9!==p&&11!==p)return n;if(!r&&(T(e),e=e||C,E)){if(11!==p&&(u=Z.exec(t)))if(i=u[1]){if(9===p){if(!(a=e.getElementById(i)))return n;if(a.id===i)return n.push(a),n}else if(f&&(a=f.getElementById(i))&&y(e,a)&&a.id===i)return n.push(a),n}else{if(u[2])return H.apply(n,e.getElementsByTagName(t)),n;if((i=u[3])&&d.getElementsByClassName&&e.getElementsByClassName)return H.apply(n,e.getElementsByClassName(i)),n}if(d.qsa&&!N[t+" "]&&(!v||!v.test(t))&&(1!==p||"object"!==e.nodeName.toLowerCase())){if(c=t,f=e,1===p&&(U.test(t)||z.test(t))){(f=ee.test(t)&&ye(e.parentNode)||e)===e&&d.scope||((s=e.getAttribute("id"))?s=s.replace(re,ie):e.setAttribute("id",s=S)),o=(l=h(t)).length;while(o--)l[o]=(s?"#"+s:":scope")+" "+xe(l[o]);c=l.join(",")}try{return H.apply(n,f.querySelectorAll(c)),n}catch(e){N(t,!0)}finally{s===S&&e.removeAttribute("id")}}}return g(t.replace($,"$1"),e,n,r)}function ue(){var r=[];return function e(t,n){return r.push(t+" ")>b.cacheLength&&delete e[r.shift()],e[t+" "]=n}}function le(e){return e[S]=!0,e}function ce(e){var t=C.createElement("fieldset");try{return!!e(t)}catch(e){return!1}finally{t.parentNode&&t.parentNode.removeChild(t),t=null}}function fe(e,t){var n=e.split("|"),r=n.length;while(r--)b.attrHandle[n[r]]=t}function pe(e,t){var n=t&&e,r=n&&1===e.nodeType&&1===t.nodeType&&e.sourceIndex-t.sourceIndex;if(r)return r;if(n)while(n=n.nextSibling)if(n===t)return-1;return e?1:-1}function de(t){return function(e){return"input"===e.nodeName.toLowerCase()&&e.type===t}}function he(n){return function(e){var t=e.nodeName.toLowerCase();return("input"===t||"button"===t)&&e.type===n}}function ge(t){return function(e){return"form"in e?e.parentNode&&!1===e.disabled?"label"in e?"label"in e.parentNode?e.parentNode.disabled===t:e.disabled===t:e.isDisabled===t||e.isDisabled!==!t&&ae(e)===t:e.disabled===t:"label"in e&&e.disabled===t}}function ve(a){return le(function(o){return o=+o,le(function(e,t){var n,r=a([],e.length,o),i=r.length;while(i--)e[n=r[i]]&&(e[n]=!(t[n]=e[n]))})})}function ye(e){return e&&"undefined"!=typeof e.getElementsByTagName&&e}for(e in d=se.support={},i=se.isXML=function(e){var t=e&&e.namespaceURI,n=e&&(e.ownerDocument||e).documentElement;return!Y.test(t||n&&n.nodeName||"HTML")},T=se.setDocument=function(e){var t,n,r=e?e.ownerDocument||e:p;return r!=C&&9===r.nodeType&&r.documentElement&&(a=(C=r).documentElement,E=!i(C),p!=C&&(n=C.defaultView)&&n.top!==n&&(n.addEventListener?n.addEventListener("unload",oe,!1):n.attachEvent&&n.attachEvent("onunload",oe)),d.scope=ce(function(e){return a.appendChild(e).appendChild(C.createElement("div")),"undefined"!=typeof e.querySelectorAll&&!e.querySelectorAll(":scope fieldset div").length}),d.attributes=ce(function(e){return e.className="i",!e.getAttribute("className")}),d.getElementsByTagName=ce(function(e){return e.appendChild(C.createComment("")),!e.getElementsByTagName("*").length}),d.getElementsByClassName=K.test(C.getElementsByClassName),d.getById=ce(function(e){return a.appendChild(e).id=S,!C.getElementsByName||!C.getElementsByName(S).length}),d.getById?(b.filter.ID=function(e){var t=e.replace(te,ne);return function(e){return e.getAttribute("id")===t}},b.find.ID=function(e,t){if("undefined"!=typeof t.getElementById&&E){var n=t.getElementById(e);return n?[n]:[]}}):(b.filter.ID=function(e){var n=e.replace(te,ne);return function(e){var t="undefined"!=typeof e.getAttributeNode&&e.getAttributeNode("id");return t&&t.value===n}},b.find.ID=function(e,t){if("undefined"!=typeof t.getElementById&&E){var n,r,i,o=t.getElementById(e);if(o){if((n=o.getAttributeNode("id"))&&n.value===e)return[o];i=t.getElementsByName(e),r=0;while(o=i[r++])if((n=o.getAttributeNode("id"))&&n.value===e)return[o]}return[]}}),b.find.TAG=d.getElementsByTagName?function(e,t){return"undefined"!=typeof t.getElementsByTagName?t.getElementsByTagName(e):d.qsa?t.querySelectorAll(e):void 0}:function(e,t){var n,r=[],i=0,o=t.getElementsByTagName(e);if("*"===e){while(n=o[i++])1===n.nodeType&&r.push(n);return r}return o},b.find.CLASS=d.getElementsByClassName&&function(e,t){if("undefined"!=typeof t.getElementsByClassName&&E)return t.getElementsByClassName(e)},s=[],v=[],(d.qsa=K.test(C.querySelectorAll))&&(ce(function(e){var t;a.appendChild(e).innerHTML="<a id='"+S+"'></a><select id='"+S+"-\r\\' msallowcapture=''><option selected=''></option></select>",e.querySelectorAll("[msallowcapture^='']").length&&v.push("[*^$]="+M+"*(?:''|\"\")"),e.querySelectorAll("[selected]").length||v.push("\\["+M+"*(?:value|"+R+")"),e.querySelectorAll("[id~="+S+"-]").length||v.push("~="),(t=C.createElement("input")).setAttribute("name",""),e.appendChild(t),e.querySelectorAll("[name='']").length||v.push("\\["+M+"*name"+M+"*="+M+"*(?:''|\"\")"),e.querySelectorAll(":checked").length||v.push(":checked"),e.querySelectorAll("a#"+S+"+*").length||v.push(".#.+[+~]"),e.querySelectorAll("\\\f"),v.push("[\\r\\n\\f]")}),ce(function(e){e.innerHTML="<a href='' disabled='disabled'></a><select disabled='disabled'><option/></select>";var t=C.createElement("input");t.setAttribute("type","hidden"),e.appendChild(t).setAttribute("name","D"),e.querySelectorAll("[name=d]").length&&v.push("name"+M+"*[*^$|!~]?="),2!==e.querySelectorAll(":enabled").length&&v.push(":enabled",":disabled"),a.appendChild(e).disabled=!0,2!==e.querySelectorAll(":disabled").length&&v.push(":enabled",":disabled"),e.querySelectorAll("*,:x"),v.push(",.*:")})),(d.matchesSelector=K.test(c=a.matches||a.webkitMatchesSelector||a.mozMatchesSelector||a.oMatchesSelector||a.msMatchesSelector))&&ce(function(e){d.disconnectedMatch=c.call(e,"*"),c.call(e,"[s!='']:x"),s.push("!=",F)}),v=v.length&&new RegExp(v.join("|")),s=s.length&&new RegExp(s.join("|")),t=K.test(a.compareDocumentPosition),y=t||K.test(a.contains)?function(e,t){var n=9===e.nodeType?e.documentElement:e,r=t&&t.parentNode;return e===r||!(!r||1!==r.nodeType||!(n.contains?n.contains(r):e.compareDocumentPosition&&16&e.compareDocumentPosition(r)))}:function(e,t){if(t)while(t=t.parentNode)if(t===e)return!0;return!1},j=t?function(e,t){if(e===t)return l=!0,0;var n=!e.compareDocumentPosition-!t.compareDocumentPosition;return n||(1&(n=(e.ownerDocument||e)==(t.ownerDocument||t)?e.compareDocumentPosition(t):1)||!d.sortDetached&&t.compareDocumentPosition(e)===n?e==C||e.ownerDocument==p&&y(p,e)?-1:t==C||t.ownerDocument==p&&y(p,t)?1:u?P(u,e)-P(u,t):0:4&n?-1:1)}:function(e,t){if(e===t)return l=!0,0;var n,r=0,i=e.parentNode,o=t.parentNode,a=[e],s=[t];if(!i||!o)return e==C?-1:t==C?1:i?-1:o?1:u?P(u,e)-P(u,t):0;if(i===o)return pe(e,t);n=e;while(n=n.parentNode)a.unshift(n);n=t;while(n=n.parentNode)s.unshift(n);while(a[r]===s[r])r++;return r?pe(a[r],s[r]):a[r]==p?-1:s[r]==p?1:0}),C},se.matches=function(e,t){return se(e,null,null,t)},se.matchesSelector=function(e,t){if(T(e),d.matchesSelector&&E&&!N[t+" "]&&(!s||!s.test(t))&&(!v||!v.test(t)))try{var n=c.call(e,t);if(n||d.disconnectedMatch||e.document&&11!==e.document.nodeType)return n}catch(e){N(t,!0)}return 0<se(t,C,null,[e]).length},se.contains=function(e,t){return(e.ownerDocument||e)!=C&&T(e),y(e,t)},se.attr=function(e,t){(e.ownerDocument||e)!=C&&T(e);var n=b.attrHandle[t.toLowerCase()],r=n&&D.call(b.attrHandle,t.toLowerCase())?n(e,t,!E):void 0;return void 0!==r?r:d.attributes||!E?e.getAttribute(t):(r=e.getAttributeNode(t))&&r.specified?r.value:null},se.escape=function(e){return(e+"").replace(re,ie)},se.error=function(e){throw new Error("Syntax error, unrecognized expression: "+e)},se.uniqueSort=function(e){var t,n=[],r=0,i=0;if(l=!d.detectDuplicates,u=!d.sortStable&&e.slice(0),e.sort(j),l){while(t=e[i++])t===e[i]&&(r=n.push(i));while(r--)e.splice(n[r],1)}return u=null,e},o=se.getText=function(e){var t,n="",r=0,i=e.nodeType;if(i){if(1===i||9===i||11===i){if("string"==typeof e.textContent)return e.textContent;for(e=e.firstChild;e;e=e.nextSibling)n+=o(e)}else if(3===i||4===i)return e.nodeValue}else while(t=e[r++])n+=o(t);return n},(b=se.selectors={cacheLength:50,createPseudo:le,match:G,attrHandle:{},find:{},relative:{">":{dir:"parentNode",first:!0}," ":{dir:"parentNode"},"+":{dir:"previousSibling",first:!0},"~":{dir:"previousSibling"}},preFilter:{ATTR:function(e){return e[1]=e[1].replace(te,ne),e[3]=(e[3]||e[4]||e[5]||"").replace(te,ne),"~="===e[2]&&(e[3]=" "+e[3]+" "),e.slice(0,4)},CHILD:function(e){return e[1]=e[1].toLowerCase(),"nth"===e[1].slice(0,3)?(e[3]||se.error(e[0]),e[4]=+(e[4]?e[5]+(e[6]||1):2*("even"===e[3]||"odd"===e[3])),e[5]=+(e[7]+e[8]||"odd"===e[3])):e[3]&&se.error(e[0]),e},PSEUDO:function(e){var t,n=!e[6]&&e[2];return G.CHILD.test(e[0])?null:(e[3]?e[2]=e[4]||e[5]||"":n&&X.test(n)&&(t=h(n,!0))&&(t=n.indexOf(")",n.length-t)-n.length)&&(e[0]=e[0].slice(0,t),e[2]=n.slice(0,t)),e.slice(0,3))}},filter:{TAG:function(e){var t=e.replace(te,ne).toLowerCase();return"*"===e?function(){return!0}:function(e){return e.nodeName&&e.nodeName.toLowerCase()===t}},CLASS:function(e){var t=m[e+" "];return t||(t=new RegExp("(^|"+M+")"+e+"("+M+"|$)"))&&m(e,function(e){return t.test("string"==typeof e.className&&e.className||"undefined"!=typeof e.getAttribute&&e.getAttribute("class")||"")})},ATTR:function(n,r,i){return function(e){var t=se.attr(e,n);return null==t?"!="===r:!r||(t+="","="===r?t===i:"!="===r?t!==i:"^="===r?i&&0===t.indexOf(i):"*="===r?i&&-1<t.indexOf(i):"$="===r?i&&t.slice(-i.length)===i:"~="===r?-1<(" "+t.replace(B," ")+" ").indexOf(i):"|="===r&&(t===i||t.slice(0,i.length+1)===i+"-"))}},CHILD:function(h,e,t,g,v){var y="nth"!==h.slice(0,3),m="last"!==h.slice(-4),x="of-type"===e;return 1===g&&0===v?function(e){return!!e.parentNode}:function(e,t,n){var r,i,o,a,s,u,l=y!==m?"nextSibling":"previousSibling",c=e.parentNode,f=x&&e.nodeName.toLowerCase(),p=!n&&!x,d=!1;if(c){if(y){while(l){a=e;while(a=a[l])if(x?a.nodeName.toLowerCase()===f:1===a.nodeType)return!1;u=l="only"===h&&!u&&"nextSibling"}return!0}if(u=[m?c.firstChild:c.lastChild],m&&p){d=(s=(r=(i=(o=(a=c)[S]||(a[S]={}))[a.uniqueID]||(o[a.uniqueID]={}))[h]||[])[0]===k&&r[1])&&r[2],a=s&&c.childNodes[s];while(a=++s&&a&&a[l]||(d=s=0)||u.pop())if(1===a.nodeType&&++d&&a===e){i[h]=[k,s,d];break}}else if(p&&(d=s=(r=(i=(o=(a=e)[S]||(a[S]={}))[a.uniqueID]||(o[a.uniqueID]={}))[h]||[])[0]===k&&r[1]),!1===d)while(a=++s&&a&&a[l]||(d=s=0)||u.pop())if((x?a.nodeName.toLowerCase()===f:1===a.nodeType)&&++d&&(p&&((i=(o=a[S]||(a[S]={}))[a.uniqueID]||(o[a.uniqueID]={}))[h]=[k,d]),a===e))break;return(d-=v)===g||d%g==0&&0<=d/g}}},PSEUDO:function(e,o){var t,a=b.pseudos[e]||b.setFilters[e.toLowerCase()]||se.error("unsupported pseudo: "+e);return a[S]?a(o):1<a.length?(t=[e,e,"",o],b.setFilters.hasOwnProperty(e.toLowerCase())?le(function(e,t){var n,r=a(e,o),i=r.length;while(i--)e[n=P(e,r[i])]=!(t[n]=r[i])}):function(e){return a(e,0,t)}):a}},pseudos:{not:le(function(e){var r=[],i=[],s=f(e.replace($,"$1"));return s[S]?le(function(e,t,n,r){var i,o=s(e,null,r,[]),a=e.length;while(a--)(i=o[a])&&(e[a]=!(t[a]=i))}):function(e,t,n){return r[0]=e,s(r,null,n,i),r[0]=null,!i.pop()}}),has:le(function(t){return function(e){return 0<se(t,e).length}}),contains:le(function(t){return t=t.replace(te,ne),function(e){return-1<(e.textContent||o(e)).indexOf(t)}}),lang:le(function(n){return V.test(n||"")||se.error("unsupported lang: "+n),n=n.replace(te,ne).toLowerCase(),function(e){var t;do{if(t=E?e.lang:e.getAttribute("xml:lang")||e.getAttribute("lang"))return(t=t.toLowerCase())===n||0===t.indexOf(n+"-")}while((e=e.parentNode)&&1===e.nodeType);return!1}}),target:function(e){var t=n.location&&n.location.hash;return t&&t.slice(1)===e.id},root:function(e){return e===a},focus:function(e){return e===C.activeElement&&(!C.hasFocus||C.hasFocus())&&!!(e.type||e.href||~e.tabIndex)},enabled:ge(!1),disabled:ge(!0),checked:function(e){var t=e.nodeName.toLowerCase();return"input"===t&&!!e.checked||"option"===t&&!!e.selected},selected:function(e){return e.parentNode&&e.parentNode.selectedIndex,!0===e.selected},empty:function(e){for(e=e.firstChild;e;e=e.nextSibling)if(e.nodeType<6)return!1;return!0},parent:function(e){return!b.pseudos.empty(e)},header:function(e){return J.test(e.nodeName)},input:function(e){return Q.test(e.nodeName)},button:function(e){var t=e.nodeName.toLowerCase();return"input"===t&&"button"===e.type||"button"===t},text:function(e){var t;return"input"===e.nodeName.toLowerCase()&&"text"===e.type&&(null==(t=e.getAttribute("type"))||"text"===t.toLowerCase())},first:ve(function(){return[0]}),last:ve(function(e,t){return[t-1]}),eq:ve(function(e,t,n){return[n<0?n+t:n]}),even:ve(function(e,t){for(var n=0;n<t;n+=2)e.push(n);return e}),odd:ve(function(e,t){for(var n=1;n<t;n+=2)e.push(n);return e}),lt:ve(function(e,t,n){for(var r=n<0?n+t:t<n?t:n;0<=--r;)e.push(r);return e}),gt:ve(function(e,t,n){for(var r=n<0?n+t:n;++r<t;)e.push(r);return e})}}).pseudos.nth=b.pseudos.eq,{radio:!0,checkbox:!0,file:!0,password:!0,image:!0})b.pseudos[e]=de(e);for(e in{submit:!0,reset:!0})b.pseudos[e]=he(e);function me(){}function xe(e){for(var t=0,n=e.length,r="";t<n;t++)r+=e[t].value;return r}function be(s,e,t){var u=e.dir,l=e.next,c=l||u,f=t&&"parentNode"===c,p=r++;return e.first?function(e,t,n){while(e=e[u])if(1===e.nodeType||f)return s(e,t,n);return!1}:function(e,t,n){var r,i,o,a=[k,p];if(n){while(e=e[u])if((1===e.nodeType||f)&&s(e,t,n))return!0}else while(e=e[u])if(1===e.nodeType||f)if(i=(o=e[S]||(e[S]={}))[e.uniqueID]||(o[e.uniqueID]={}),l&&l===e.nodeName.toLowerCase())e=e[u]||e;else{if((r=i[c])&&r[0]===k&&r[1]===p)return a[2]=r[2];if((i[c]=a)[2]=s(e,t,n))return!0}return!1}}function we(i){return 1<i.length?function(e,t,n){var r=i.length;while(r--)if(!i[r](e,t,n))return!1;return!0}:i[0]}function Te(e,t,n,r,i){for(var o,a=[],s=0,u=e.length,l=null!=t;s<u;s++)(o=e[s])&&(n&&!n(o,r,i)||(a.push(o),l&&t.push(s)));return a}function Ce(d,h,g,v,y,e){return v&&!v[S]&&(v=Ce(v)),y&&!y[S]&&(y=Ce(y,e)),le(function(e,t,n,r){var i,o,a,s=[],u=[],l=t.length,c=e||function(e,t,n){for(var r=0,i=t.length;r<i;r++)se(e,t[r],n);return n}(h||"*",n.nodeType?[n]:n,[]),f=!d||!e&&h?c:Te(c,s,d,n,r),p=g?y||(e?d:l||v)?[]:t:f;if(g&&g(f,p,n,r),v){i=Te(p,u),v(i,[],n,r),o=i.length;while(o--)(a=i[o])&&(p[u[o]]=!(f[u[o]]=a))}if(e){if(y||d){if(y){i=[],o=p.length;while(o--)(a=p[o])&&i.push(f[o]=a);y(null,p=[],i,r)}o=p.length;while(o--)(a=p[o])&&-1<(i=y?P(e,a):s[o])&&(e[i]=!(t[i]=a))}}else p=Te(p===t?p.splice(l,p.length):p),y?y(null,t,p,r):H.apply(t,p)})}function Ee(e){for(var i,t,n,r=e.length,o=b.relative[e[0].type],a=o||b.relative[" "],s=o?1:0,u=be(function(e){return e===i},a,!0),l=be(function(e){return-1<P(i,e)},a,!0),c=[function(e,t,n){var r=!o&&(n||t!==w)||((i=t).nodeType?u(e,t,n):l(e,t,n));return i=null,r}];s<r;s++)if(t=b.relative[e[s].type])c=[be(we(c),t)];else{if((t=b.filter[e[s].type].apply(null,e[s].matches))[S]){for(n=++s;n<r;n++)if(b.relative[e[n].type])break;return Ce(1<s&&we(c),1<s&&xe(e.slice(0,s-1).concat({value:" "===e[s-2].type?"*":""})).replace($,"$1"),t,s<n&&Ee(e.slice(s,n)),n<r&&Ee(e=e.slice(n)),n<r&&xe(e))}c.push(t)}return we(c)}return me.prototype=b.filters=b.pseudos,b.setFilters=new me,h=se.tokenize=function(e,t){var n,r,i,o,a,s,u,l=x[e+" "];if(l)return t?0:l.slice(0);a=e,s=[],u=b.preFilter;while(a){for(o in n&&!(r=_.exec(a))||(r&&(a=a.slice(r[0].length)||a),s.push(i=[])),n=!1,(r=z.exec(a))&&(n=r.shift(),i.push({value:n,type:r[0].replace($," ")}),a=a.slice(n.length)),b.filter)!(r=G[o].exec(a))||u[o]&&!(r=u[o](r))||(n=r.shift(),i.push({value:n,type:o,matches:r}),a=a.slice(n.length));if(!n)break}return t?a.length:a?se.error(e):x(e,s).slice(0)},f=se.compile=function(e,t){var n,v,y,m,x,r,i=[],o=[],a=A[e+" "];if(!a){t||(t=h(e)),n=t.length;while(n--)(a=Ee(t[n]))[S]?i.push(a):o.push(a);(a=A(e,(v=o,m=0<(y=i).length,x=0<v.length,r=function(e,t,n,r,i){var o,a,s,u=0,l="0",c=e&&[],f=[],p=w,d=e||x&&b.find.TAG("*",i),h=k+=null==p?1:Math.random()||.1,g=d.length;for(i&&(w=t==C||t||i);l!==g&&null!=(o=d[l]);l++){if(x&&o){a=0,t||o.ownerDocument==C||(T(o),n=!E);while(s=v[a++])if(s(o,t||C,n)){r.push(o);break}i&&(k=h)}m&&((o=!s&&o)&&u--,e&&c.push(o))}if(u+=l,m&&l!==u){a=0;while(s=y[a++])s(c,f,t,n);if(e){if(0<u)while(l--)c[l]||f[l]||(f[l]=q.call(r));f=Te(f)}H.apply(r,f),i&&!e&&0<f.length&&1<u+y.length&&se.uniqueSort(r)}return i&&(k=h,w=p),c},m?le(r):r))).selector=e}return a},g=se.select=function(e,t,n,r){var i,o,a,s,u,l="function"==typeof e&&e,c=!r&&h(e=l.selector||e);if(n=n||[],1===c.length){if(2<(o=c[0]=c[0].slice(0)).length&&"ID"===(a=o[0]).type&&9===t.nodeType&&E&&b.relative[o[1].type]){if(!(t=(b.find.ID(a.matches[0].replace(te,ne),t)||[])[0]))return n;l&&(t=t.parentNode),e=e.slice(o.shift().value.length)}i=G.needsContext.test(e)?0:o.length;while(i--){if(a=o[i],b.relative[s=a.type])break;if((u=b.find[s])&&(r=u(a.matches[0].replace(te,ne),ee.test(o[0].type)&&ye(t.parentNode)||t))){if(o.splice(i,1),!(e=r.length&&xe(o)))return H.apply(n,r),n;break}}}return(l||f(e,c))(r,t,!E,n,!t||ee.test(e)&&ye(t.parentNode)||t),n},d.sortStable=S.split("").sort(j).join("")===S,d.detectDuplicates=!!l,T(),d.sortDetached=ce(function(e){return 1&e.compareDocumentPosition(C.createElement("fieldset"))}),ce(function(e){return e.innerHTML="<a href='#'></a>","#"===e.firstChild.getAttribute("href")})||fe("type|href|height|width",function(e,t,n){if(!n)return e.getAttribute(t,"type"===t.toLowerCase()?1:2)}),d.attributes&&ce(function(e){return e.innerHTML="<input/>",e.firstChild.setAttribute("value",""),""===e.firstChild.getAttribute("value")})||fe("value",function(e,t,n){if(!n&&"input"===e.nodeName.toLowerCase())return e.defaultValue}),ce(function(e){return null==e.getAttribute("disabled")})||fe(R,function(e,t,n){var r;if(!n)return!0===e[t]?t.toLowerCase():(r=e.getAttributeNode(t))&&r.specified?r.value:null}),se}(C);S.find=d,S.expr=d.selectors,S.expr[":"]=S.expr.pseudos,S.uniqueSort=S.unique=d.uniqueSort,S.text=d.getText,S.isXMLDoc=d.isXML,S.contains=d.contains,S.escapeSelector=d.escape;var h=function(e,t,n){var r=[],i=void 0!==n;while((e=e[t])&&9!==e.nodeType)if(1===e.nodeType){if(i&&S(e).is(n))break;r.push(e)}return r},T=function(e,t){for(var n=[];e;e=e.nextSibling)1===e.nodeType&&e!==t&&n.push(e);return n},k=S.expr.match.needsContext;function A(e,t){return e.nodeName&&e.nodeName.toLowerCase()===t.toLowerCase()}var N=/^<([a-z][^\/\0>:\x20\t\r\n\f]*)[\x20\t\r\n\f]*\/?>(?:<\/\1>|)$/i;function j(e,n,r){return m(n)?S.grep(e,function(e,t){return!!n.call(e,t,e)!==r}):n.nodeType?S.grep(e,function(e){return e===n!==r}):"string"!=typeof n?S.grep(e,function(e){return-1<i.call(n,e)!==r}):S.filter(n,e,r)}S.filter=function(e,t,n){var r=t[0];return n&&(e=":not("+e+")"),1===t.length&&1===r.nodeType?S.find.matchesSelector(r,e)?[r]:[]:S.find.matches(e,S.grep(t,function(e){return 1===e.nodeType}))},S.fn.extend({find:function(e){var t,n,r=this.length,i=this;if("string"!=typeof e)return this.pushStack(S(e).filter(function(){for(t=0;t<r;t++)if(S.contains(i[t],this))return!0}));for(n=this.pushStack([]),t=0;t<r;t++)S.find(e,i[t],n);return 1<r?S.uniqueSort(n):n},filter:function(e){return this.pushStack(j(this,e||[],!1))},not:function(e){return this.pushStack(j(this,e||[],!0))},is:function(e){return!!j(this,"string"==typeof e&&k.test(e)?S(e):e||[],!1).length}});var D,q=/^(?:\s*(<[\w\W]+>)[^>]*|#([\w-]+))$/;(S.fn.init=function(e,t,n){var r,i;if(!e)return this;if(n=n||D,"string"==typeof e){if(!(r="<"===e[0]&&">"===e[e.length-1]&&3<=e.length?[null,e,null]:q.exec(e))||!r[1]&&t)return!t||t.jquery?(t||n).find(e):this.constructor(t).find(e);if(r[1]){if(t=t instanceof S?t[0]:t,S.merge(this,S.parseHTML(r[1],t&&t.nodeType?t.ownerDocument||t:E,!0)),N.test(r[1])&&S.isPlainObject(t))for(r in t)m(this[r])?this[r](t[r]):this.attr(r,t[r]);return this}return(i=E.getElementById(r[2]))&&(this[0]=i,this.length=1),this}return e.nodeType?(this[0]=e,this.length=1,this):m(e)?void 0!==n.ready?n.ready(e):e(S):S.makeArray(e,this)}).prototype=S.fn,D=S(E);var L=/^(?:parents|prev(?:Until|All))/,H={children:!0,contents:!0,next:!0,prev:!0};function O(e,t){while((e=e[t])&&1!==e.nodeType);return e}S.fn.extend({has:function(e){var t=S(e,this),n=t.length;return this.filter(function(){for(var e=0;e<n;e++)if(S.contains(this,t[e]))return!0})},closest:function(e,t){var n,r=0,i=this.length,o=[],a="string"!=typeof e&&S(e);if(!k.test(e))for(;r<i;r++)for(n=this[r];n&&n!==t;n=n.parentNode)if(n.nodeType<11&&(a?-1<a.index(n):1===n.nodeType&&S.find.matchesSelector(n,e))){o.push(n);break}return this.pushStack(1<o.length?S.uniqueSort(o):o)},index:function(e){return e?"string"==typeof e?i.call(S(e),this[0]):i.call(this,e.jquery?e[0]:e):this[0]&&this[0].parentNode?this.first().prevAll().length:-1},add:function(e,t){return this.pushStack(S.uniqueSort(S.merge(this.get(),S(e,t))))},addBack:function(e){return this.add(null==e?this.prevObject:this.prevObject.filter(e))}}),S.each({parent:function(e){var t=e.parentNode;return t&&11!==t.nodeType?t:null},parents:function(e){return h(e,"parentNode")},parentsUntil:function(e,t,n){return h(e,"parentNode",n)},next:function(e){return O(e,"nextSibling")},prev:function(e){return O(e,"previousSibling")},nextAll:function(e){return h(e,"nextSibling")},prevAll:function(e){return h(e,"previousSibling")},nextUntil:function(e,t,n){return h(e,"nextSibling",n)},prevUntil:function(e,t,n){return h(e,"previousSibling",n)},siblings:function(e){return T((e.parentNode||{}).firstChild,e)},children:function(e){return T(e.firstChild)},contents:function(e){return null!=e.contentDocument&&r(e.contentDocument)?e.contentDocument:(A(e,"template")&&(e=e.content||e),S.merge([],e.childNodes))}},function(r,i){S.fn[r]=function(e,t){var n=S.map(this,i,e);return"Until"!==r.slice(-5)&&(t=e),t&&"string"==typeof t&&(n=S.filter(t,n)),1<this.length&&(H[r]||S.uniqueSort(n),L.test(r)&&n.reverse()),this.pushStack(n)}});var P=/[^\x20\t\r\n\f]+/g;function R(e){return e}function M(e){throw e}function I(e,t,n,r){var i;try{e&&m(i=e.promise)?i.call(e).done(t).fail(n):e&&m(i=e.then)?i.call(e,t,n):t.apply(void 0,[e].slice(r))}catch(e){n.apply(void 0,[e])}}S.Callbacks=function(r){var e,n;r="string"==typeof r?(e=r,n={},S.each(e.match(P)||[],function(e,t){n[t]=!0}),n):S.extend({},r);var i,t,o,a,s=[],u=[],l=-1,c=function(){for(a=a||r.once,o=i=!0;u.length;l=-1){t=u.shift();while(++l<s.length)!1===s[l].apply(t[0],t[1])&&r.stopOnFalse&&(l=s.length,t=!1)}r.memory||(t=!1),i=!1,a&&(s=t?[]:"")},f={add:function(){return s&&(t&&!i&&(l=s.length-1,u.push(t)),function n(e){S.each(e,function(e,t){m(t)?r.unique&&f.has(t)||s.push(t):t&&t.length&&"string"!==w(t)&&n(t)})}(arguments),t&&!i&&c()),this},remove:function(){return S.each(arguments,function(e,t){var n;while(-1<(n=S.inArray(t,s,n)))s.splice(n,1),n<=l&&l--}),this},has:function(e){return e?-1<S.inArray(e,s):0<s.length},empty:function(){return s&&(s=[]),this},disable:function(){return a=u=[],s=t="",this},disabled:function(){return!s},lock:function(){return a=u=[],t||i||(s=t=""),this},locked:function(){return!!a},fireWith:function(e,t){return a||(t=[e,(t=t||[]).slice?t.slice():t],u.push(t),i||c()),this},fire:function(){return f.fireWith(this,arguments),this},fired:function(){return!!o}};return f},S.extend({Deferred:function(e){var o=[["notify","progress",S.Callbacks("memory"),S.Callbacks("memory"),2],["resolve","done",S.Callbacks("once memory"),S.Callbacks("once memory"),0,"resolved"],["reject","fail",S.Callbacks("once memory"),S.Callbacks("once memory"),1,"rejected"]],i="pending",a={state:function(){return i},always:function(){return s.done(arguments).fail(arguments),this},"catch":function(e){return a.then(null,e)},pipe:function(){var i=arguments;return S.Deferred(function(r){S.each(o,function(e,t){var n=m(i[t[4]])&&i[t[4]];s[t[1]](function(){var e=n&&n.apply(this,arguments);e&&m(e.promise)?e.promise().progress(r.notify).done(r.resolve).fail(r.reject):r[t[0]+"With"](this,n?[e]:arguments)})}),i=null}).promise()},then:function(t,n,r){var u=0;function l(i,o,a,s){return function(){var n=this,r=arguments,e=function(){var e,t;if(!(i<u)){if((e=a.apply(n,r))===o.promise())throw new TypeError("Thenable self-resolution");t=e&&("object"==typeof e||"function"==typeof e)&&e.then,m(t)?s?t.call(e,l(u,o,R,s),l(u,o,M,s)):(u++,t.call(e,l(u,o,R,s),l(u,o,M,s),l(u,o,R,o.notifyWith))):(a!==R&&(n=void 0,r=[e]),(s||o.resolveWith)(n,r))}},t=s?e:function(){try{e()}catch(e){S.Deferred.exceptionHook&&S.Deferred.exceptionHook(e,t.stackTrace),u<=i+1&&(a!==M&&(n=void 0,r=[e]),o.rejectWith(n,r))}};i?t():(S.Deferred.getStackHook&&(t.stackTrace=S.Deferred.getStackHook()),C.setTimeout(t))}}return S.Deferred(function(e){o[0][3].add(l(0,e,m(r)?r:R,e.notifyWith)),o[1][3].add(l(0,e,m(t)?t:R)),o[2][3].add(l(0,e,m(n)?n:M))}).promise()},promise:function(e){return null!=e?S.extend(e,a):a}},s={};return S.each(o,function(e,t){var n=t[2],r=t[5];a[t[1]]=n.add,r&&n.add(function(){i=r},o[3-e][2].disable,o[3-e][3].disable,o[0][2].lock,o[0][3].lock),n.add(t[3].fire),s[t[0]]=function(){return s[t[0]+"With"](this===s?void 0:this,arguments),this},s[t[0]+"With"]=n.fireWith}),a.promise(s),e&&e.call(s,s),s},when:function(e){var n=arguments.length,t=n,r=Array(t),i=s.call(arguments),o=S.Deferred(),a=function(t){return function(e){r[t]=this,i[t]=1<arguments.length?s.call(arguments):e,--n||o.resolveWith(r,i)}};if(n<=1&&(I(e,o.done(a(t)).resolve,o.reject,!n),"pending"===o.state()||m(i[t]&&i[t].then)))return o.then();while(t--)I(i[t],a(t),o.reject);return o.promise()}});var W=/^(Eval|Internal|Range|Reference|Syntax|Type|URI)Error$/;S.Deferred.exceptionHook=function(e,t){C.console&&C.console.warn&&e&&W.test(e.name)&&C.console.warn("jQuery.Deferred exception: "+e.message,e.stack,t)},S.readyException=function(e){C.setTimeout(function(){throw e})};var F=S.Deferred();function B(){E.removeEventListener("DOMContentLoaded",B),C.removeEventListener("load",B),S.ready()}S.fn.ready=function(e){return F.then(e)["catch"](function(e){S.readyException(e)}),this},S.extend({isReady:!1,readyWait:1,ready:function(e){(!0===e?--S.readyWait:S.isReady)||(S.isReady=!0)!==e&&0<--S.readyWait||F.resolveWith(E,[S])}}),S.ready.then=F.then,"complete"===E.readyState||"loading"!==E.readyState&&!E.documentElement.doScroll?C.setTimeout(S.ready):(E.addEventListener("DOMContentLoaded",B),C.addEventListener("load",B));var $=function(e,t,n,r,i,o,a){var s=0,u=e.length,l=null==n;if("object"===w(n))for(s in i=!0,n)$(e,t,s,n[s],!0,o,a);else if(void 0!==r&&(i=!0,m(r)||(a=!0),l&&(a?(t.call(e,r),t=null):(l=t,t=function(e,t,n){return l.call(S(e),n)})),t))for(;s<u;s++)t(e[s],n,a?r:r.call(e[s],s,t(e[s],n)));return i?e:l?t.call(e):u?t(e[0],n):o},_=/^-ms-/,z=/-([a-z])/g;function U(e,t){return t.toUpperCase()}function X(e){return e.replace(_,"ms-").replace(z,U)}var V=function(e){return 1===e.nodeType||9===e.nodeType||!+e.nodeType};function G(){this.expando=S.expando+G.uid++}G.uid=1,G.prototype={cache:function(e){var t=e[this.expando];return t||(t={},V(e)&&(e.nodeType?e[this.expando]=t:Object.defineProperty(e,this.expando,{value:t,configurable:!0}))),t},set:function(e,t,n){var r,i=this.cache(e);if("string"==typeof t)i[X(t)]=n;else for(r in t)i[X(r)]=t[r];return i},get:function(e,t){return void 0===t?this.cache(e):e[this.expando]&&e[this.expando][X(t)]},access:function(e,t,n){return void 0===t||t&&"string"==typeof t&&void 0===n?this.get(e,t):(this.set(e,t,n),void 0!==n?n:t)},remove:function(e,t){var n,r=e[this.expando];if(void 0!==r){if(void 0!==t){n=(t=Array.isArray(t)?t.map(X):(t=X(t))in r?[t]:t.match(P)||[]).length;while(n--)delete r[t[n]]}(void 0===t||S.isEmptyObject(r))&&(e.nodeType?e[this.expando]=void 0:delete e[this.expando])}},hasData:function(e){var t=e[this.expando];return void 0!==t&&!S.isEmptyObject(t)}};var Y=new G,Q=new G,J=/^(?:\{[\w\W]*\}|\[[\w\W]*\])$/,K=/[A-Z]/g;function Z(e,t,n){var r,i;if(void 0===n&&1===e.nodeType)if(r="data-"+t.replace(K,"-$&").toLowerCase(),"string"==typeof(n=e.getAttribute(r))){try{n="true"===(i=n)||"false"!==i&&("null"===i?null:i===+i+""?+i:J.test(i)?JSON.parse(i):i)}catch(e){}Q.set(e,t,n)}else n=void 0;return n}S.extend({hasData:function(e){return Q.hasData(e)||Y.hasData(e)},data:function(e,t,n){return Q.access(e,t,n)},removeData:function(e,t){Q.remove(e,t)},_data:function(e,t,n){return Y.access(e,t,n)},_removeData:function(e,t){Y.remove(e,t)}}),S.fn.extend({data:function(n,e){var t,r,i,o=this[0],a=o&&o.attributes;if(void 0===n){if(this.length&&(i=Q.get(o),1===o.nodeType&&!Y.get(o,"hasDataAttrs"))){t=a.length;while(t--)a[t]&&0===(r=a[t].name).indexOf("data-")&&(r=X(r.slice(5)),Z(o,r,i[r]));Y.set(o,"hasDataAttrs",!0)}return i}return"object"==typeof n?this.each(function(){Q.set(this,n)}):$(this,function(e){var t;if(o&&void 0===e)return void 0!==(t=Q.get(o,n))?t:void 0!==(t=Z(o,n))?t:void 0;this.each(function(){Q.set(this,n,e)})},null,e,1<arguments.length,null,!0)},removeData:function(e){return this.each(function(){Q.remove(this,e)})}}),S.extend({queue:function(e,t,n){var r;if(e)return t=(t||"fx")+"queue",r=Y.get(e,t),n&&(!r||Array.isArray(n)?r=Y.access(e,t,S.makeArray(n)):r.push(n)),r||[]},dequeue:function(e,t){t=t||"fx";var n=S.queue(e,t),r=n.length,i=n.shift(),o=S._queueHooks(e,t);"inprogress"===i&&(i=n.shift(),r--),i&&("fx"===t&&n.unshift("inprogress"),delete o.stop,i.call(e,function(){S.dequeue(e,t)},o)),!r&&o&&o.empty.fire()},_queueHooks:function(e,t){var n=t+"queueHooks";return Y.get(e,n)||Y.access(e,n,{empty:S.Callbacks("once memory").add(function(){Y.remove(e,[t+"queue",n])})})}}),S.fn.extend({queue:function(t,n){var e=2;return"string"!=typeof t&&(n=t,t="fx",e--),arguments.length<e?S.queue(this[0],t):void 0===n?this:this.each(function(){var e=S.queue(this,t,n);S._queueHooks(this,t),"fx"===t&&"inprogress"!==e[0]&&S.dequeue(this,t)})},dequeue:function(e){return this.each(function(){S.dequeue(this,e)})},clearQueue:function(e){return this.queue(e||"fx",[])},promise:function(e,t){var n,r=1,i=S.Deferred(),o=this,a=this.length,s=function(){--r||i.resolveWith(o,[o])};"string"!=typeof e&&(t=e,e=void 0),e=e||"fx";while(a--)(n=Y.get(o[a],e+"queueHooks"))&&n.empty&&(r++,n.empty.add(s));return s(),i.promise(t)}});var ee=/[+-]?(?:\d*\.|)\d+(?:[eE][+-]?\d+|)/.source,te=new RegExp("^(?:([+-])=|)("+ee+")([a-z%]*)$","i"),ne=["Top","Right","Bottom","Left"],re=E.documentElement,ie=function(e){return S.contains(e.ownerDocument,e)},oe={composed:!0};re.getRootNode&&(ie=function(e){return S.contains(e.ownerDocument,e)||e.getRootNode(oe)===e.ownerDocument});var ae=function(e,t){return"none"===(e=t||e).style.display||""===e.style.display&&ie(e)&&"none"===S.css(e,"display")};function se(e,t,n,r){var i,o,a=20,s=r?function(){return r.cur()}:function(){return S.css(e,t,"")},u=s(),l=n&&n[3]||(S.cssNumber[t]?"":"px"),c=e.nodeType&&(S.cssNumber[t]||"px"!==l&&+u)&&te.exec(S.css(e,t));if(c&&c[3]!==l){u/=2,l=l||c[3],c=+u||1;while(a--)S.style(e,t,c+l),(1-o)*(1-(o=s()/u||.5))<=0&&(a=0),c/=o;c*=2,S.style(e,t,c+l),n=n||[]}return n&&(c=+c||+u||0,i=n[1]?c+(n[1]+1)*n[2]:+n[2],r&&(r.unit=l,r.start=c,r.end=i)),i}var ue={};function le(e,t){for(var n,r,i,o,a,s,u,l=[],c=0,f=e.length;c<f;c++)(r=e[c]).style&&(n=r.style.display,t?("none"===n&&(l[c]=Y.get(r,"display")||null,l[c]||(r.style.display="")),""===r.style.display&&ae(r)&&(l[c]=(u=a=o=void 0,a=(i=r).ownerDocument,s=i.nodeName,(u=ue[s])||(o=a.body.appendChild(a.createElement(s)),u=S.css(o,"display"),o.parentNode.removeChild(o),"none"===u&&(u="block"),ue[s]=u)))):"none"!==n&&(l[c]="none",Y.set(r,"display",n)));for(c=0;c<f;c++)null!=l[c]&&(e[c].style.display=l[c]);return e}S.fn.extend({show:function(){return le(this,!0)},hide:function(){return le(this)},toggle:function(e){return"boolean"==typeof e?e?this.show():this.hide():this.each(function(){ae(this)?S(this).show():S(this).hide()})}});var ce,fe,pe=/^(?:checkbox|radio)$/i,de=/<([a-z][^\/\0>\x20\t\r\n\f]*)/i,he=/^$|^module$|\/(?:java|ecma)script/i;ce=E.createDocumentFragment().appendChild(E.createElement("div")),(fe=E.createElement("input")).setAttribute("type","radio"),fe.setAttribute("checked","checked"),fe.setAttribute("name","t"),ce.appendChild(fe),y.checkClone=ce.cloneNode(!0).cloneNode(!0).lastChild.checked,ce.innerHTML="<textarea>x</textarea>",y.noCloneChecked=!!ce.cloneNode(!0).lastChild.defaultValue,ce.innerHTML="<option></option>",y.option=!!ce.lastChild;var ge={thead:[1,"<table>","</table>"],col:[2,"<table><colgroup>","</colgroup></table>"],tr:[2,"<table><tbody>","</tbody></table>"],td:[3,"<table><tbody><tr>","</tr></tbody></table>"],_default:[0,"",""]};function ve(e,t){var n;return n="undefined"!=typeof e.getElementsByTagName?e.getElementsByTagName(t||"*"):"undefined"!=typeof e.querySelectorAll?e.querySelectorAll(t||"*"):[],void 0===t||t&&A(e,t)?S.merge([e],n):n}function ye(e,t){for(var n=0,r=e.length;n<r;n++)Y.set(e[n],"globalEval",!t||Y.get(t[n],"globalEval"))}ge.tbody=ge.tfoot=ge.colgroup=ge.caption=ge.thead,ge.th=ge.td,y.option||(ge.optgroup=ge.option=[1,"<select multiple='multiple'>","</select>"]);var me=/<|&#?\w+;/;function xe(e,t,n,r,i){for(var o,a,s,u,l,c,f=t.createDocumentFragment(),p=[],d=0,h=e.length;d<h;d++)if((o=e[d])||0===o)if("object"===w(o))S.merge(p,o.nodeType?[o]:o);else if(me.test(o)){a=a||f.appendChild(t.createElement("div")),s=(de.exec(o)||["",""])[1].toLowerCase(),u=ge[s]||ge._default,a.innerHTML=u[1]+S.htmlPrefilter(o)+u[2],c=u[0];while(c--)a=a.lastChild;S.merge(p,a.childNodes),(a=f.firstChild).textContent=""}else p.push(t.createTextNode(o));f.textContent="",d=0;while(o=p[d++])if(r&&-1<S.inArray(o,r))i&&i.push(o);else if(l=ie(o),a=ve(f.appendChild(o),"script"),l&&ye(a),n){c=0;while(o=a[c++])he.test(o.type||"")&&n.push(o)}return f}var be=/^([^.]*)(?:\.(.+)|)/;function we(){return!0}function Te(){return!1}function Ce(e,t){return e===function(){try{return E.activeElement}catch(e){}}()==("focus"===t)}function Ee(e,t,n,r,i,o){var a,s;if("object"==typeof t){for(s in"string"!=typeof n&&(r=r||n,n=void 0),t)Ee(e,s,n,r,t[s],o);return e}if(null==r&&null==i?(i=n,r=n=void 0):null==i&&("string"==typeof n?(i=r,r=void 0):(i=r,r=n,n=void 0)),!1===i)i=Te;else if(!i)return e;return 1===o&&(a=i,(i=function(e){return S().off(e),a.apply(this,arguments)}).guid=a.guid||(a.guid=S.guid++)),e.each(function(){S.event.add(this,t,i,r,n)})}function Se(e,i,o){o?(Y.set(e,i,!1),S.event.add(e,i,{namespace:!1,handler:function(e){var t,n,r=Y.get(this,i);if(1&e.isTrigger&&this[i]){if(r.length)(S.event.special[i]||{}).delegateType&&e.stopPropagation();else if(r=s.call(arguments),Y.set(this,i,r),t=o(this,i),this[i](),r!==(n=Y.get(this,i))||t?Y.set(this,i,!1):n={},r!==n)return e.stopImmediatePropagation(),e.preventDefault(),n&&n.value}else r.length&&(Y.set(this,i,{value:S.event.trigger(S.extend(r[0],S.Event.prototype),r.slice(1),this)}),e.stopImmediatePropagation())}})):void 0===Y.get(e,i)&&S.event.add(e,i,we)}S.event={global:{},add:function(t,e,n,r,i){var o,a,s,u,l,c,f,p,d,h,g,v=Y.get(t);if(V(t)){n.handler&&(n=(o=n).handler,i=o.selector),i&&S.find.matchesSelector(re,i),n.guid||(n.guid=S.guid++),(u=v.events)||(u=v.events=Object.create(null)),(a=v.handle)||(a=v.handle=function(e){return"undefined"!=typeof S&&S.event.triggered!==e.type?S.event.dispatch.apply(t,arguments):void 0}),l=(e=(e||"").match(P)||[""]).length;while(l--)d=g=(s=be.exec(e[l])||[])[1],h=(s[2]||"").split(".").sort(),d&&(f=S.event.special[d]||{},d=(i?f.delegateType:f.bindType)||d,f=S.event.special[d]||{},c=S.extend({type:d,origType:g,data:r,handler:n,guid:n.guid,selector:i,needsContext:i&&S.expr.match.needsContext.test(i),namespace:h.join(".")},o),(p=u[d])||((p=u[d]=[]).delegateCount=0,f.setup&&!1!==f.setup.call(t,r,h,a)||t.addEventListener&&t.addEventListener(d,a)),f.add&&(f.add.call(t,c),c.handler.guid||(c.handler.guid=n.guid)),i?p.splice(p.delegateCount++,0,c):p.push(c),S.event.global[d]=!0)}},remove:function(e,t,n,r,i){var o,a,s,u,l,c,f,p,d,h,g,v=Y.hasData(e)&&Y.get(e);if(v&&(u=v.events)){l=(t=(t||"").match(P)||[""]).length;while(l--)if(d=g=(s=be.exec(t[l])||[])[1],h=(s[2]||"").split(".").sort(),d){f=S.event.special[d]||{},p=u[d=(r?f.delegateType:f.bindType)||d]||[],s=s[2]&&new RegExp("(^|\\.)"+h.join("\\.(?:.*\\.|)")+"(\\.|$)"),a=o=p.length;while(o--)c=p[o],!i&&g!==c.origType||n&&n.guid!==c.guid||s&&!s.test(c.namespace)||r&&r!==c.selector&&("**"!==r||!c.selector)||(p.splice(o,1),c.selector&&p.delegateCount--,f.remove&&f.remove.call(e,c));a&&!p.length&&(f.teardown&&!1!==f.teardown.call(e,h,v.handle)||S.removeEvent(e,d,v.handle),delete u[d])}else for(d in u)S.event.remove(e,d+t[l],n,r,!0);S.isEmptyObject(u)&&Y.remove(e,"handle events")}},dispatch:function(e){var t,n,r,i,o,a,s=new Array(arguments.length),u=S.event.fix(e),l=(Y.get(this,"events")||Object.create(null))[u.type]||[],c=S.event.special[u.type]||{};for(s[0]=u,t=1;t<arguments.length;t++)s[t]=arguments[t];if(u.delegateTarget=this,!c.preDispatch||!1!==c.preDispatch.call(this,u)){a=S.event.handlers.call(this,u,l),t=0;while((i=a[t++])&&!u.isPropagationStopped()){u.currentTarget=i.elem,n=0;while((o=i.handlers[n++])&&!u.isImmediatePropagationStopped())u.rnamespace&&!1!==o.namespace&&!u.rnamespace.test(o.namespace)||(u.handleObj=o,u.data=o.data,void 0!==(r=((S.event.special[o.origType]||{}).handle||o.handler).apply(i.elem,s))&&!1===(u.result=r)&&(u.preventDefault(),u.stopPropagation()))}return c.postDispatch&&c.postDispatch.call(this,u),u.result}},handlers:function(e,t){var n,r,i,o,a,s=[],u=t.delegateCount,l=e.target;if(u&&l.nodeType&&!("click"===e.type&&1<=e.button))for(;l!==this;l=l.parentNode||this)if(1===l.nodeType&&("click"!==e.type||!0!==l.disabled)){for(o=[],a={},n=0;n<u;n++)void 0===a[i=(r=t[n]).selector+" "]&&(a[i]=r.needsContext?-1<S(i,this).index(l):S.find(i,this,null,[l]).length),a[i]&&o.push(r);o.length&&s.push({elem:l,handlers:o})}return l=this,u<t.length&&s.push({elem:l,handlers:t.slice(u)}),s},addProp:function(t,e){Object.defineProperty(S.Event.prototype,t,{enumerable:!0,configurable:!0,get:m(e)?function(){if(this.originalEvent)return e(this.originalEvent)}:function(){if(this.originalEvent)return this.originalEvent[t]},set:function(e){Object.defineProperty(this,t,{enumerable:!0,configurable:!0,writable:!0,value:e})}})},fix:function(e){return e[S.expando]?e:new S.Event(e)},special:{load:{noBubble:!0},click:{setup:function(e){var t=this||e;return pe.test(t.type)&&t.click&&A(t,"input")&&Se(t,"click",we),!1},trigger:function(e){var t=this||e;return pe.test(t.type)&&t.click&&A(t,"input")&&Se(t,"click"),!0},_default:function(e){var t=e.target;return pe.test(t.type)&&t.click&&A(t,"input")&&Y.get(t,"click")||A(t,"a")}},beforeunload:{postDispatch:function(e){void 0!==e.result&&e.originalEvent&&(e.originalEvent.returnValue=e.result)}}}},S.removeEvent=function(e,t,n){e.removeEventListener&&e.removeEventListener(t,n)},S.Event=function(e,t){if(!(this instanceof S.Event))return new S.Event(e,t);e&&e.type?(this.originalEvent=e,this.type=e.type,this.isDefaultPrevented=e.defaultPrevented||void 0===e.defaultPrevented&&!1===e.returnValue?we:Te,this.target=e.target&&3===e.target.nodeType?e.target.parentNode:e.target,this.currentTarget=e.currentTarget,this.relatedTarget=e.relatedTarget):this.type=e,t&&S.extend(this,t),this.timeStamp=e&&e.timeStamp||Date.now(),this[S.expando]=!0},S.Event.prototype={constructor:S.Event,isDefaultPrevented:Te,isPropagationStopped:Te,isImmediatePropagationStopped:Te,isSimulated:!1,preventDefault:function(){var e=this.originalEvent;this.isDefaultPrevented=we,e&&!this.isSimulated&&e.preventDefault()},stopPropagation:function(){var e=this.originalEvent;this.isPropagationStopped=we,e&&!this.isSimulated&&e.stopPropagation()},stopImmediatePropagation:function(){var e=this.originalEvent;this.isImmediatePropagationStopped=we,e&&!this.isSimulated&&e.stopImmediatePropagation(),this.stopPropagation()}},S.each({altKey:!0,bubbles:!0,cancelable:!0,changedTouches:!0,ctrlKey:!0,detail:!0,eventPhase:!0,metaKey:!0,pageX:!0,pageY:!0,shiftKey:!0,view:!0,"char":!0,code:!0,charCode:!0,key:!0,keyCode:!0,button:!0,buttons:!0,clientX:!0,clientY:!0,offsetX:!0,offsetY:!0,pointerId:!0,pointerType:!0,screenX:!0,screenY:!0,targetTouches:!0,toElement:!0,touches:!0,which:!0},S.event.addProp),S.each({focus:"focusin",blur:"focusout"},function(e,t){S.event.special[e]={setup:function(){return Se(this,e,Ce),!1},trigger:function(){return Se(this,e),!0},_default:function(){return!0},delegateType:t}}),S.each({mouseenter:"mouseover",mouseleave:"mouseout",pointerenter:"pointerover",pointerleave:"pointerout"},function(e,i){S.event.special[e]={delegateType:i,bindType:i,handle:function(e){var t,n=e.relatedTarget,r=e.handleObj;return n&&(n===this||S.contains(this,n))||(e.type=r.origType,t=r.handler.apply(this,arguments),e.type=i),t}}}),S.fn.extend({on:function(e,t,n,r){return Ee(this,e,t,n,r)},one:function(e,t,n,r){return Ee(this,e,t,n,r,1)},off:function(e,t,n){var r,i;if(e&&e.preventDefault&&e.handleObj)return r=e.handleObj,S(e.delegateTarget).off(r.namespace?r.origType+"."+r.namespace:r.origType,r.selector,r.handler),this;if("object"==typeof e){for(i in e)this.off(i,t,e[i]);return this}return!1!==t&&"function"!=typeof t||(n=t,t=void 0),!1===n&&(n=Te),this.each(function(){S.event.remove(this,e,n,t)})}});var ke=/<script|<style|<link/i,Ae=/checked\s*(?:[^=]|=\s*.checked.)/i,Ne=/^\s*<!(?:\[CDATA\[|--)|(?:\]\]|--)>\s*$/g;function je(e,t){return A(e,"table")&&A(11!==t.nodeType?t:t.firstChild,"tr")&&S(e).children("tbody")[0]||e}function De(e){return e.type=(null!==e.getAttribute("type"))+"/"+e.type,e}function qe(e){return"true/"===(e.type||"").slice(0,5)?e.type=e.type.slice(5):e.removeAttribute("type"),e}function Le(e,t){var n,r,i,o,a,s;if(1===t.nodeType){if(Y.hasData(e)&&(s=Y.get(e).events))for(i in Y.remove(t,"handle events"),s)for(n=0,r=s[i].length;n<r;n++)S.event.add(t,i,s[i][n]);Q.hasData(e)&&(o=Q.access(e),a=S.extend({},o),Q.set(t,a))}}function He(n,r,i,o){r=g(r);var e,t,a,s,u,l,c=0,f=n.length,p=f-1,d=r[0],h=m(d);if(h||1<f&&"string"==typeof d&&!y.checkClone&&Ae.test(d))return n.each(function(e){var t=n.eq(e);h&&(r[0]=d.call(this,e,t.html())),He(t,r,i,o)});if(f&&(t=(e=xe(r,n[0].ownerDocument,!1,n,o)).firstChild,1===e.childNodes.length&&(e=t),t||o)){for(s=(a=S.map(ve(e,"script"),De)).length;c<f;c++)u=e,c!==p&&(u=S.clone(u,!0,!0),s&&S.merge(a,ve(u,"script"))),i.call(n[c],u,c);if(s)for(l=a[a.length-1].ownerDocument,S.map(a,qe),c=0;c<s;c++)u=a[c],he.test(u.type||"")&&!Y.access(u,"globalEval")&&S.contains(l,u)&&(u.src&&"module"!==(u.type||"").toLowerCase()?S._evalUrl&&!u.noModule&&S._evalUrl(u.src,{nonce:u.nonce||u.getAttribute("nonce")},l):b(u.textContent.replace(Ne,""),u,l))}return n}function Oe(e,t,n){for(var r,i=t?S.filter(t,e):e,o=0;null!=(r=i[o]);o++)n||1!==r.nodeType||S.cleanData(ve(r)),r.parentNode&&(n&&ie(r)&&ye(ve(r,"script")),r.parentNode.removeChild(r));return e}S.extend({htmlPrefilter:function(e){return e},clone:function(e,t,n){var r,i,o,a,s,u,l,c=e.cloneNode(!0),f=ie(e);if(!(y.noCloneChecked||1!==e.nodeType&&11!==e.nodeType||S.isXMLDoc(e)))for(a=ve(c),r=0,i=(o=ve(e)).length;r<i;r++)s=o[r],u=a[r],void 0,"input"===(l=u.nodeName.toLowerCase())&&pe.test(s.type)?u.checked=s.checked:"input"!==l&&"textarea"!==l||(u.defaultValue=s.defaultValue);if(t)if(n)for(o=o||ve(e),a=a||ve(c),r=0,i=o.length;r<i;r++)Le(o[r],a[r]);else Le(e,c);return 0<(a=ve(c,"script")).length&&ye(a,!f&&ve(e,"script")),c},cleanData:function(e){for(var t,n,r,i=S.event.special,o=0;void 0!==(n=e[o]);o++)if(V(n)){if(t=n[Y.expando]){if(t.events)for(r in t.events)i[r]?S.event.remove(n,r):S.removeEvent(n,r,t.handle);n[Y.expando]=void 0}n[Q.expando]&&(n[Q.expando]=void 0)}}}),S.fn.extend({detach:function(e){return Oe(this,e,!0)},remove:function(e){return Oe(this,e)},text:function(e){return $(this,function(e){return void 0===e?S.text(this):this.empty().each(function(){1!==this.nodeType&&11!==this.nodeType&&9!==this.nodeType||(this.textContent=e)})},null,e,arguments.length)},append:function(){return He(this,arguments,function(e){1!==this.nodeType&&11!==this.nodeType&&9!==this.nodeType||je(this,e).appendChild(e)})},prepend:function(){return He(this,arguments,function(e){if(1===this.nodeType||11===this.nodeType||9===this.nodeType){var t=je(this,e);t.insertBefore(e,t.firstChild)}})},before:function(){return He(this,arguments,function(e){this.parentNode&&this.parentNode.insertBefore(e,this)})},after:function(){return He(this,arguments,function(e){this.parentNode&&this.parentNode.insertBefore(e,this.nextSibling)})},empty:function(){for(var e,t=0;null!=(e=this[t]);t++)1===e.nodeType&&(S.cleanData(ve(e,!1)),e.textContent="");return this},clone:function(e,t){return e=null!=e&&e,t=null==t?e:t,this.map(function(){return S.clone(this,e,t)})},html:function(e){return $(this,function(e){var t=this[0]||{},n=0,r=this.length;if(void 0===e&&1===t.nodeType)return t.innerHTML;if("string"==typeof e&&!ke.test(e)&&!ge[(de.exec(e)||["",""])[1].toLowerCase()]){e=S.htmlPrefilter(e);try{for(;n<r;n++)1===(t=this[n]||{}).nodeType&&(S.cleanData(ve(t,!1)),t.innerHTML=e);t=0}catch(e){}}t&&this.empty().append(e)},null,e,arguments.length)},replaceWith:function(){var n=[];return He(this,arguments,function(e){var t=this.parentNode;S.inArray(this,n)<0&&(S.cleanData(ve(this)),t&&t.replaceChild(e,this))},n)}}),S.each({appendTo:"append",prependTo:"prepend",insertBefore:"before",insertAfter:"after",replaceAll:"replaceWith"},function(e,a){S.fn[e]=function(e){for(var t,n=[],r=S(e),i=r.length-1,o=0;o<=i;o++)t=o===i?this:this.clone(!0),S(r[o])[a](t),u.apply(n,t.get());return this.pushStack(n)}});var Pe=new RegExp("^("+ee+")(?!px)[a-z%]+$","i"),Re=function(e){var t=e.ownerDocument.defaultView;return t&&t.opener||(t=C),t.getComputedStyle(e)},Me=function(e,t,n){var r,i,o={};for(i in t)o[i]=e.style[i],e.style[i]=t[i];for(i in r=n.call(e),t)e.style[i]=o[i];return r},Ie=new RegExp(ne.join("|"),"i");function We(e,t,n){var r,i,o,a,s=e.style;return(n=n||Re(e))&&(""!==(a=n.getPropertyValue(t)||n[t])||ie(e)||(a=S.style(e,t)),!y.pixelBoxStyles()&&Pe.test(a)&&Ie.test(t)&&(r=s.width,i=s.minWidth,o=s.maxWidth,s.minWidth=s.maxWidth=s.width=a,a=n.width,s.width=r,s.minWidth=i,s.maxWidth=o)),void 0!==a?a+"":a}function Fe(e,t){return{get:function(){if(!e())return(this.get=t).apply(this,arguments);delete this.get}}}!function(){function e(){if(l){u.style.cssText="position:absolute;left:-11111px;width:60px;margin-top:1px;padding:0;border:0",l.style.cssText="position:relative;display:block;box-sizing:border-box;overflow:scroll;margin:auto;border:1px;padding:1px;width:60%;top:1%",re.appendChild(u).appendChild(l);var e=C.getComputedStyle(l);n="1%"!==e.top,s=12===t(e.marginLeft),l.style.right="60%",o=36===t(e.right),r=36===t(e.width),l.style.position="absolute",i=12===t(l.offsetWidth/3),re.removeChild(u),l=null}}function t(e){return Math.round(parseFloat(e))}var n,r,i,o,a,s,u=E.createElement("div"),l=E.createElement("div");l.style&&(l.style.backgroundClip="content-box",l.cloneNode(!0).style.backgroundClip="",y.clearCloneStyle="content-box"===l.style.backgroundClip,S.extend(y,{boxSizingReliable:function(){return e(),r},pixelBoxStyles:function(){return e(),o},pixelPosition:function(){return e(),n},reliableMarginLeft:function(){return e(),s},scrollboxSize:function(){return e(),i},reliableTrDimensions:function(){var e,t,n,r;return null==a&&(e=E.createElement("table"),t=E.createElement("tr"),n=E.createElement("div"),e.style.cssText="position:absolute;left:-11111px;border-collapse:separate",t.style.cssText="border:1px solid",t.style.height="1px",n.style.height="9px",n.style.display="block",re.appendChild(e).appendChild(t).appendChild(n),r=C.getComputedStyle(t),a=parseInt(r.height,10)+parseInt(r.borderTopWidth,10)+parseInt(r.borderBottomWidth,10)===t.offsetHeight,re.removeChild(e)),a}}))}();var Be=["Webkit","Moz","ms"],$e=E.createElement("div").style,_e={};function ze(e){var t=S.cssProps[e]||_e[e];return t||(e in $e?e:_e[e]=function(e){var t=e[0].toUpperCase()+e.slice(1),n=Be.length;while(n--)if((e=Be[n]+t)in $e)return e}(e)||e)}var Ue=/^(none|table(?!-c[ea]).+)/,Xe=/^--/,Ve={position:"absolute",visibility:"hidden",display:"block"},Ge={letterSpacing:"0",fontWeight:"400"};function Ye(e,t,n){var r=te.exec(t);return r?Math.max(0,r[2]-(n||0))+(r[3]||"px"):t}function Qe(e,t,n,r,i,o){var a="width"===t?1:0,s=0,u=0;if(n===(r?"border":"content"))return 0;for(;a<4;a+=2)"margin"===n&&(u+=S.css(e,n+ne[a],!0,i)),r?("content"===n&&(u-=S.css(e,"padding"+ne[a],!0,i)),"margin"!==n&&(u-=S.css(e,"border"+ne[a]+"Width",!0,i))):(u+=S.css(e,"padding"+ne[a],!0,i),"padding"!==n?u+=S.css(e,"border"+ne[a]+"Width",!0,i):s+=S.css(e,"border"+ne[a]+"Width",!0,i));return!r&&0<=o&&(u+=Math.max(0,Math.ceil(e["offset"+t[0].toUpperCase()+t.slice(1)]-o-u-s-.5))||0),u}function Je(e,t,n){var r=Re(e),i=(!y.boxSizingReliable()||n)&&"border-box"===S.css(e,"boxSizing",!1,r),o=i,a=We(e,t,r),s="offset"+t[0].toUpperCase()+t.slice(1);if(Pe.test(a)){if(!n)return a;a="auto"}return(!y.boxSizingReliable()&&i||!y.reliableTrDimensions()&&A(e,"tr")||"auto"===a||!parseFloat(a)&&"inline"===S.css(e,"display",!1,r))&&e.getClientRects().length&&(i="border-box"===S.css(e,"boxSizing",!1,r),(o=s in e)&&(a=e[s])),(a=parseFloat(a)||0)+Qe(e,t,n||(i?"border":"content"),o,r,a)+"px"}function Ke(e,t,n,r,i){return new Ke.prototype.init(e,t,n,r,i)}S.extend({cssHooks:{opacity:{get:function(e,t){if(t){var n=We(e,"opacity");return""===n?"1":n}}}},cssNumber:{animationIterationCount:!0,columnCount:!0,fillOpacity:!0,flexGrow:!0,flexShrink:!0,fontWeight:!0,gridArea:!0,gridColumn:!0,gridColumnEnd:!0,gridColumnStart:!0,gridRow:!0,gridRowEnd:!0,gridRowStart:!0,lineHeight:!0,opacity:!0,order:!0,orphans:!0,widows:!0,zIndex:!0,zoom:!0},cssProps:{},style:function(e,t,n,r){if(e&&3!==e.nodeType&&8!==e.nodeType&&e.style){var i,o,a,s=X(t),u=Xe.test(t),l=e.style;if(u||(t=ze(s)),a=S.cssHooks[t]||S.cssHooks[s],void 0===n)return a&&"get"in a&&void 0!==(i=a.get(e,!1,r))?i:l[t];"string"===(o=typeof n)&&(i=te.exec(n))&&i[1]&&(n=se(e,t,i),o="number"),null!=n&&n==n&&("number"!==o||u||(n+=i&&i[3]||(S.cssNumber[s]?"":"px")),y.clearCloneStyle||""!==n||0!==t.indexOf("background")||(l[t]="inherit"),a&&"set"in a&&void 0===(n=a.set(e,n,r))||(u?l.setProperty(t,n):l[t]=n))}},css:function(e,t,n,r){var i,o,a,s=X(t);return Xe.test(t)||(t=ze(s)),(a=S.cssHooks[t]||S.cssHooks[s])&&"get"in a&&(i=a.get(e,!0,n)),void 0===i&&(i=We(e,t,r)),"normal"===i&&t in Ge&&(i=Ge[t]),""===n||n?(o=parseFloat(i),!0===n||isFinite(o)?o||0:i):i}}),S.each(["height","width"],function(e,u){S.cssHooks[u]={get:function(e,t,n){if(t)return!Ue.test(S.css(e,"display"))||e.getClientRects().length&&e.getBoundingClientRect().width?Je(e,u,n):Me(e,Ve,function(){return Je(e,u,n)})},set:function(e,t,n){var r,i=Re(e),o=!y.scrollboxSize()&&"absolute"===i.position,a=(o||n)&&"border-box"===S.css(e,"boxSizing",!1,i),s=n?Qe(e,u,n,a,i):0;return a&&o&&(s-=Math.ceil(e["offset"+u[0].toUpperCase()+u.slice(1)]-parseFloat(i[u])-Qe(e,u,"border",!1,i)-.5)),s&&(r=te.exec(t))&&"px"!==(r[3]||"px")&&(e.style[u]=t,t=S.css(e,u)),Ye(0,t,s)}}}),S.cssHooks.marginLeft=Fe(y.reliableMarginLeft,function(e,t){if(t)return(parseFloat(We(e,"marginLeft"))||e.getBoundingClientRect().left-Me(e,{marginLeft:0},function(){return e.getBoundingClientRect().left}))+"px"}),S.each({margin:"",padding:"",border:"Width"},function(i,o){S.cssHooks[i+o]={expand:function(e){for(var t=0,n={},r="string"==typeof e?e.split(" "):[e];t<4;t++)n[i+ne[t]+o]=r[t]||r[t-2]||r[0];return n}},"margin"!==i&&(S.cssHooks[i+o].set=Ye)}),S.fn.extend({css:function(e,t){return $(this,function(e,t,n){var r,i,o={},a=0;if(Array.isArray(t)){for(r=Re(e),i=t.length;a<i;a++)o[t[a]]=S.css(e,t[a],!1,r);return o}return void 0!==n?S.style(e,t,n):S.css(e,t)},e,t,1<arguments.length)}}),((S.Tween=Ke).prototype={constructor:Ke,init:function(e,t,n,r,i,o){this.elem=e,this.prop=n,this.easing=i||S.easing._default,this.options=t,this.start=this.now=this.cur(),this.end=r,this.unit=o||(S.cssNumber[n]?"":"px")},cur:function(){var e=Ke.propHooks[this.prop];return e&&e.get?e.get(this):Ke.propHooks._default.get(this)},run:function(e){var t,n=Ke.propHooks[this.prop];return this.options.duration?this.pos=t=S.easing[this.easing](e,this.options.duration*e,0,1,this.options.duration):this.pos=t=e,this.now=(this.end-this.start)*t+this.start,this.options.step&&this.options.step.call(this.elem,this.now,this),n&&n.set?n.set(this):Ke.propHooks._default.set(this),this}}).init.prototype=Ke.prototype,(Ke.propHooks={_default:{get:function(e){var t;return 1!==e.elem.nodeType||null!=e.elem[e.prop]&&null==e.elem.style[e.prop]?e.elem[e.prop]:(t=S.css(e.elem,e.prop,""))&&"auto"!==t?t:0},set:function(e){S.fx.step[e.prop]?S.fx.step[e.prop](e):1!==e.elem.nodeType||!S.cssHooks[e.prop]&&null==e.elem.style[ze(e.prop)]?e.elem[e.prop]=e.now:S.style(e.elem,e.prop,e.now+e.unit)}}}).scrollTop=Ke.propHooks.scrollLeft={set:function(e){e.elem.nodeType&&e.elem.parentNode&&(e.elem[e.prop]=e.now)}},S.easing={linear:function(e){return e},swing:function(e){return.5-Math.cos(e*Math.PI)/2},_default:"swing"},S.fx=Ke.prototype.init,S.fx.step={};var Ze,et,tt,nt,rt=/^(?:toggle|show|hide)$/,it=/queueHooks$/;function ot(){et&&(!1===E.hidden&&C.requestAnimationFrame?C.requestAnimationFrame(ot):C.setTimeout(ot,S.fx.interval),S.fx.tick())}function at(){return C.setTimeout(function(){Ze=void 0}),Ze=Date.now()}function st(e,t){var n,r=0,i={height:e};for(t=t?1:0;r<4;r+=2-t)i["margin"+(n=ne[r])]=i["padding"+n]=e;return t&&(i.opacity=i.width=e),i}function ut(e,t,n){for(var r,i=(lt.tweeners[t]||[]).concat(lt.tweeners["*"]),o=0,a=i.length;o<a;o++)if(r=i[o].call(n,t,e))return r}function lt(o,e,t){var n,a,r=0,i=lt.prefilters.length,s=S.Deferred().always(function(){delete u.elem}),u=function(){if(a)return!1;for(var e=Ze||at(),t=Math.max(0,l.startTime+l.duration-e),n=1-(t/l.duration||0),r=0,i=l.tweens.length;r<i;r++)l.tweens[r].run(n);return s.notifyWith(o,[l,n,t]),n<1&&i?t:(i||s.notifyWith(o,[l,1,0]),s.resolveWith(o,[l]),!1)},l=s.promise({elem:o,props:S.extend({},e),opts:S.extend(!0,{specialEasing:{},easing:S.easing._default},t),originalProperties:e,originalOptions:t,startTime:Ze||at(),duration:t.duration,tweens:[],createTween:function(e,t){var n=S.Tween(o,l.opts,e,t,l.opts.specialEasing[e]||l.opts.easing);return l.tweens.push(n),n},stop:function(e){var t=0,n=e?l.tweens.length:0;if(a)return this;for(a=!0;t<n;t++)l.tweens[t].run(1);return e?(s.notifyWith(o,[l,1,0]),s.resolveWith(o,[l,e])):s.rejectWith(o,[l,e]),this}}),c=l.props;for(!function(e,t){var n,r,i,o,a;for(n in e)if(i=t[r=X(n)],o=e[n],Array.isArray(o)&&(i=o[1],o=e[n]=o[0]),n!==r&&(e[r]=o,delete e[n]),(a=S.cssHooks[r])&&"expand"in a)for(n in o=a.expand(o),delete e[r],o)n in e||(e[n]=o[n],t[n]=i);else t[r]=i}(c,l.opts.specialEasing);r<i;r++)if(n=lt.prefilters[r].call(l,o,c,l.opts))return m(n.stop)&&(S._queueHooks(l.elem,l.opts.queue).stop=n.stop.bind(n)),n;return S.map(c,ut,l),m(l.opts.start)&&l.opts.start.call(o,l),l.progress(l.opts.progress).done(l.opts.done,l.opts.complete).fail(l.opts.fail).always(l.opts.always),S.fx.timer(S.extend(u,{elem:o,anim:l,queue:l.opts.queue})),l}S.Animation=S.extend(lt,{tweeners:{"*":[function(e,t){var n=this.createTween(e,t);return se(n.elem,e,te.exec(t),n),n}]},tweener:function(e,t){m(e)?(t=e,e=["*"]):e=e.match(P);for(var n,r=0,i=e.length;r<i;r++)n=e[r],lt.tweeners[n]=lt.tweeners[n]||[],lt.tweeners[n].unshift(t)},prefilters:[function(e,t,n){var r,i,o,a,s,u,l,c,f="width"in t||"height"in t,p=this,d={},h=e.style,g=e.nodeType&&ae(e),v=Y.get(e,"fxshow");for(r in n.queue||(null==(a=S._queueHooks(e,"fx")).unqueued&&(a.unqueued=0,s=a.empty.fire,a.empty.fire=function(){a.unqueued||s()}),a.unqueued++,p.always(function(){p.always(function(){a.unqueued--,S.queue(e,"fx").length||a.empty.fire()})})),t)if(i=t[r],rt.test(i)){if(delete t[r],o=o||"toggle"===i,i===(g?"hide":"show")){if("show"!==i||!v||void 0===v[r])continue;g=!0}d[r]=v&&v[r]||S.style(e,r)}if((u=!S.isEmptyObject(t))||!S.isEmptyObject(d))for(r in f&&1===e.nodeType&&(n.overflow=[h.overflow,h.overflowX,h.overflowY],null==(l=v&&v.display)&&(l=Y.get(e,"display")),"none"===(c=S.css(e,"display"))&&(l?c=l:(le([e],!0),l=e.style.display||l,c=S.css(e,"display"),le([e]))),("inline"===c||"inline-block"===c&&null!=l)&&"none"===S.css(e,"float")&&(u||(p.done(function(){h.display=l}),null==l&&(c=h.display,l="none"===c?"":c)),h.display="inline-block")),n.overflow&&(h.overflow="hidden",p.always(function(){h.overflow=n.overflow[0],h.overflowX=n.overflow[1],h.overflowY=n.overflow[2]})),u=!1,d)u||(v?"hidden"in v&&(g=v.hidden):v=Y.access(e,"fxshow",{display:l}),o&&(v.hidden=!g),g&&le([e],!0),p.done(function(){for(r in g||le([e]),Y.remove(e,"fxshow"),d)S.style(e,r,d[r])})),u=ut(g?v[r]:0,r,p),r in v||(v[r]=u.start,g&&(u.end=u.start,u.start=0))}],prefilter:function(e,t){t?lt.prefilters.unshift(e):lt.prefilters.push(e)}}),S.speed=function(e,t,n){var r=e&&"object"==typeof e?S.extend({},e):{complete:n||!n&&t||m(e)&&e,duration:e,easing:n&&t||t&&!m(t)&&t};return S.fx.off?r.duration=0:"number"!=typeof r.duration&&(r.duration in S.fx.speeds?r.duration=S.fx.speeds[r.duration]:r.duration=S.fx.speeds._default),null!=r.queue&&!0!==r.queue||(r.queue="fx"),r.old=r.complete,r.complete=function(){m(r.old)&&r.old.call(this),r.queue&&S.dequeue(this,r.queue)},r},S.fn.extend({fadeTo:function(e,t,n,r){return this.filter(ae).css("opacity",0).show().end().animate({opacity:t},e,n,r)},animate:function(t,e,n,r){var i=S.isEmptyObject(t),o=S.speed(e,n,r),a=function(){var e=lt(this,S.extend({},t),o);(i||Y.get(this,"finish"))&&e.stop(!0)};return a.finish=a,i||!1===o.queue?this.each(a):this.queue(o.queue,a)},stop:function(i,e,o){var a=function(e){var t=e.stop;delete e.stop,t(o)};return"string"!=typeof i&&(o=e,e=i,i=void 0),e&&this.queue(i||"fx",[]),this.each(function(){var e=!0,t=null!=i&&i+"queueHooks",n=S.timers,r=Y.get(this);if(t)r[t]&&r[t].stop&&a(r[t]);else for(t in r)r[t]&&r[t].stop&&it.test(t)&&a(r[t]);for(t=n.length;t--;)n[t].elem!==this||null!=i&&n[t].queue!==i||(n[t].anim.stop(o),e=!1,n.splice(t,1));!e&&o||S.dequeue(this,i)})},finish:function(a){return!1!==a&&(a=a||"fx"),this.each(function(){var e,t=Y.get(this),n=t[a+"queue"],r=t[a+"queueHooks"],i=S.timers,o=n?n.length:0;for(t.finish=!0,S.queue(this,a,[]),r&&r.stop&&r.stop.call(this,!0),e=i.length;e--;)i[e].elem===this&&i[e].queue===a&&(i[e].anim.stop(!0),i.splice(e,1));for(e=0;e<o;e++)n[e]&&n[e].finish&&n[e].finish.call(this);delete t.finish})}}),S.each(["toggle","show","hide"],function(e,r){var i=S.fn[r];S.fn[r]=function(e,t,n){return null==e||"boolean"==typeof e?i.apply(this,arguments):this.animate(st(r,!0),e,t,n)}}),S.each({slideDown:st("show"),slideUp:st("hide"),slideToggle:st("toggle"),fadeIn:{opacity:"show"},fadeOut:{opacity:"hide"},fadeToggle:{opacity:"toggle"}},function(e,r){S.fn[e]=function(e,t,n){return this.animate(r,e,t,n)}}),S.timers=[],S.fx.tick=function(){var e,t=0,n=S.timers;for(Ze=Date.now();t<n.length;t++)(e=n[t])()||n[t]!==e||n.splice(t--,1);n.length||S.fx.stop(),Ze=void 0},S.fx.timer=function(e){S.timers.push(e),S.fx.start()},S.fx.interval=13,S.fx.start=function(){et||(et=!0,ot())},S.fx.stop=function(){et=null},S.fx.speeds={slow:600,fast:200,_default:400},S.fn.delay=function(r,e){return r=S.fx&&S.fx.speeds[r]||r,e=e||"fx",this.queue(e,function(e,t){var n=C.setTimeout(e,r);t.stop=function(){C.clearTimeout(n)}})},tt=E.createElement("input"),nt=E.createElement("select").appendChild(E.createElement("option")),tt.type="checkbox",y.checkOn=""!==tt.value,y.optSelected=nt.selected,(tt=E.createElement("input")).value="t",tt.type="radio",y.radioValue="t"===tt.value;var ct,ft=S.expr.attrHandle;S.fn.extend({attr:function(e,t){return $(this,S.attr,e,t,1<arguments.length)},removeAttr:function(e){return this.each(function(){S.removeAttr(this,e)})}}),S.extend({attr:function(e,t,n){var r,i,o=e.nodeType;if(3!==o&&8!==o&&2!==o)return"undefined"==typeof e.getAttribute?S.prop(e,t,n):(1===o&&S.isXMLDoc(e)||(i=S.attrHooks[t.toLowerCase()]||(S.expr.match.bool.test(t)?ct:void 0)),void 0!==n?null===n?void S.removeAttr(e,t):i&&"set"in i&&void 0!==(r=i.set(e,n,t))?r:(e.setAttribute(t,n+""),n):i&&"get"in i&&null!==(r=i.get(e,t))?r:null==(r=S.find.attr(e,t))?void 0:r)},attrHooks:{type:{set:function(e,t){if(!y.radioValue&&"radio"===t&&A(e,"input")){var n=e.value;return e.setAttribute("type",t),n&&(e.value=n),t}}}},removeAttr:function(e,t){var n,r=0,i=t&&t.match(P);if(i&&1===e.nodeType)while(n=i[r++])e.removeAttribute(n)}}),ct={set:function(e,t,n){return!1===t?S.removeAttr(e,n):e.setAttribute(n,n),n}},S.each(S.expr.match.bool.source.match(/\w+/g),function(e,t){var a=ft[t]||S.find.attr;ft[t]=function(e,t,n){var r,i,o=t.toLowerCase();return n||(i=ft[o],ft[o]=r,r=null!=a(e,t,n)?o:null,ft[o]=i),r}});var pt=/^(?:input|select|textarea|button)$/i,dt=/^(?:a|area)$/i;function ht(e){return(e.match(P)||[]).join(" ")}function gt(e){return e.getAttribute&&e.getAttribute("class")||""}function vt(e){return Array.isArray(e)?e:"string"==typeof e&&e.match(P)||[]}S.fn.extend({prop:function(e,t){return $(this,S.prop,e,t,1<arguments.length)},removeProp:function(e){return this.each(function(){delete this[S.propFix[e]||e]})}}),S.extend({prop:function(e,t,n){var r,i,o=e.nodeType;if(3!==o&&8!==o&&2!==o)return 1===o&&S.isXMLDoc(e)||(t=S.propFix[t]||t,i=S.propHooks[t]),void 0!==n?i&&"set"in i&&void 0!==(r=i.set(e,n,t))?r:e[t]=n:i&&"get"in i&&null!==(r=i.get(e,t))?r:e[t]},propHooks:{tabIndex:{get:function(e){var t=S.find.attr(e,"tabindex");return t?parseInt(t,10):pt.test(e.nodeName)||dt.test(e.nodeName)&&e.href?0:-1}}},propFix:{"for":"htmlFor","class":"className"}}),y.optSelected||(S.propHooks.selected={get:function(e){var t=e.parentNode;return t&&t.parentNode&&t.parentNode.selectedIndex,null},set:function(e){var t=e.parentNode;t&&(t.selectedIndex,t.parentNode&&t.parentNode.selectedIndex)}}),S.each(["tabIndex","readOnly","maxLength","cellSpacing","cellPadding","rowSpan","colSpan","useMap","frameBorder","contentEditable"],function(){S.propFix[this.toLowerCase()]=this}),S.fn.extend({addClass:function(t){var e,n,r,i,o,a,s,u=0;if(m(t))return this.each(function(e){S(this).addClass(t.call(this,e,gt(this)))});if((e=vt(t)).length)while(n=this[u++])if(i=gt(n),r=1===n.nodeType&&" "+ht(i)+" "){a=0;while(o=e[a++])r.indexOf(" "+o+" ")<0&&(r+=o+" ");i!==(s=ht(r))&&n.setAttribute("class",s)}return this},removeClass:function(t){var e,n,r,i,o,a,s,u=0;if(m(t))return this.each(function(e){S(this).removeClass(t.call(this,e,gt(this)))});if(!arguments.length)return this.attr("class","");if((e=vt(t)).length)while(n=this[u++])if(i=gt(n),r=1===n.nodeType&&" "+ht(i)+" "){a=0;while(o=e[a++])while(-1<r.indexOf(" "+o+" "))r=r.replace(" "+o+" "," ");i!==(s=ht(r))&&n.setAttribute("class",s)}return this},toggleClass:function(i,t){var o=typeof i,a="string"===o||Array.isArray(i);return"boolean"==typeof t&&a?t?this.addClass(i):this.removeClass(i):m(i)?this.each(function(e){S(this).toggleClass(i.call(this,e,gt(this),t),t)}):this.each(function(){var e,t,n,r;if(a){t=0,n=S(this),r=vt(i);while(e=r[t++])n.hasClass(e)?n.removeClass(e):n.addClass(e)}else void 0!==i&&"boolean"!==o||((e=gt(this))&&Y.set(this,"__className__",e),this.setAttribute&&this.setAttribute("class",e||!1===i?"":Y.get(this,"__className__")||""))})},hasClass:function(e){var t,n,r=0;t=" "+e+" ";while(n=this[r++])if(1===n.nodeType&&-1<(" "+ht(gt(n))+" ").indexOf(t))return!0;return!1}});var yt=/\r/g;S.fn.extend({val:function(n){var r,e,i,t=this[0];return arguments.length?(i=m(n),this.each(function(e){var t;1===this.nodeType&&(null==(t=i?n.call(this,e,S(this).val()):n)?t="":"number"==typeof t?t+="":Array.isArray(t)&&(t=S.map(t,function(e){return null==e?"":e+""})),(r=S.valHooks[this.type]||S.valHooks[this.nodeName.toLowerCase()])&&"set"in r&&void 0!==r.set(this,t,"value")||(this.value=t))})):t?(r=S.valHooks[t.type]||S.valHooks[t.nodeName.toLowerCase()])&&"get"in r&&void 0!==(e=r.get(t,"value"))?e:"string"==typeof(e=t.value)?e.replace(yt,""):null==e?"":e:void 0}}),S.extend({valHooks:{option:{get:function(e){var t=S.find.attr(e,"value");return null!=t?t:ht(S.text(e))}},select:{get:function(e){var t,n,r,i=e.options,o=e.selectedIndex,a="select-one"===e.type,s=a?null:[],u=a?o+1:i.length;for(r=o<0?u:a?o:0;r<u;r++)if(((n=i[r]).selected||r===o)&&!n.disabled&&(!n.parentNode.disabled||!A(n.parentNode,"optgroup"))){if(t=S(n).val(),a)return t;s.push(t)}return s},set:function(e,t){var n,r,i=e.options,o=S.makeArray(t),a=i.length;while(a--)((r=i[a]).selected=-1<S.inArray(S.valHooks.option.get(r),o))&&(n=!0);return n||(e.selectedIndex=-1),o}}}}),S.each(["radio","checkbox"],function(){S.valHooks[this]={set:function(e,t){if(Array.isArray(t))return e.checked=-1<S.inArray(S(e).val(),t)}},y.checkOn||(S.valHooks[this].get=function(e){return null===e.getAttribute("value")?"on":e.value})}),y.focusin="onfocusin"in C;var mt=/^(?:focusinfocus|focusoutblur)$/,xt=function(e){e.stopPropagation()};S.extend(S.event,{trigger:function(e,t,n,r){var i,o,a,s,u,l,c,f,p=[n||E],d=v.call(e,"type")?e.type:e,h=v.call(e,"namespace")?e.namespace.split("."):[];if(o=f=a=n=n||E,3!==n.nodeType&&8!==n.nodeType&&!mt.test(d+S.event.triggered)&&(-1<d.indexOf(".")&&(d=(h=d.split(".")).shift(),h.sort()),u=d.indexOf(":")<0&&"on"+d,(e=e[S.expando]?e:new S.Event(d,"object"==typeof e&&e)).isTrigger=r?2:3,e.namespace=h.join("."),e.rnamespace=e.namespace?new RegExp("(^|\\.)"+h.join("\\.(?:.*\\.|)")+"(\\.|$)"):null,e.result=void 0,e.target||(e.target=n),t=null==t?[e]:S.makeArray(t,[e]),c=S.event.special[d]||{},r||!c.trigger||!1!==c.trigger.apply(n,t))){if(!r&&!c.noBubble&&!x(n)){for(s=c.delegateType||d,mt.test(s+d)||(o=o.parentNode);o;o=o.parentNode)p.push(o),a=o;a===(n.ownerDocument||E)&&p.push(a.defaultView||a.parentWindow||C)}i=0;while((o=p[i++])&&!e.isPropagationStopped())f=o,e.type=1<i?s:c.bindType||d,(l=(Y.get(o,"events")||Object.create(null))[e.type]&&Y.get(o,"handle"))&&l.apply(o,t),(l=u&&o[u])&&l.apply&&V(o)&&(e.result=l.apply(o,t),!1===e.result&&e.preventDefault());return e.type=d,r||e.isDefaultPrevented()||c._default&&!1!==c._default.apply(p.pop(),t)||!V(n)||u&&m(n[d])&&!x(n)&&((a=n[u])&&(n[u]=null),S.event.triggered=d,e.isPropagationStopped()&&f.addEventListener(d,xt),n[d](),e.isPropagationStopped()&&f.removeEventListener(d,xt),S.event.triggered=void 0,a&&(n[u]=a)),e.result}},simulate:function(e,t,n){var r=S.extend(new S.Event,n,{type:e,isSimulated:!0});S.event.trigger(r,null,t)}}),S.fn.extend({trigger:function(e,t){return this.each(function(){S.event.trigger(e,t,this)})},triggerHandler:function(e,t){var n=this[0];if(n)return S.event.trigger(e,t,n,!0)}}),y.focusin||S.each({focus:"focusin",blur:"focusout"},function(n,r){var i=function(e){S.event.simulate(r,e.target,S.event.fix(e))};S.event.special[r]={setup:function(){var e=this.ownerDocument||this.document||this,t=Y.access(e,r);t||e.addEventListener(n,i,!0),Y.access(e,r,(t||0)+1)},teardown:function(){var e=this.ownerDocument||this.document||this,t=Y.access(e,r)-1;t?Y.access(e,r,t):(e.removeEventListener(n,i,!0),Y.remove(e,r))}}});var bt=C.location,wt={guid:Date.now()},Tt=/\?/;S.parseXML=function(e){var t,n;if(!e||"string"!=typeof e)return null;try{t=(new C.DOMParser).parseFromString(e,"text/xml")}catch(e){}return n=t&&t.getElementsByTagName("parsererror")[0],t&&!n||S.error("Invalid XML: "+(n?S.map(n.childNodes,function(e){return e.textContent}).join("\n"):e)),t};var Ct=/\[\]$/,Et=/\r?\n/g,St=/^(?:submit|button|image|reset|file)$/i,kt=/^(?:input|select|textarea|keygen)/i;function At(n,e,r,i){var t;if(Array.isArray(e))S.each(e,function(e,t){r||Ct.test(n)?i(n,t):At(n+"["+("object"==typeof t&&null!=t?e:"")+"]",t,r,i)});else if(r||"object"!==w(e))i(n,e);else for(t in e)At(n+"["+t+"]",e[t],r,i)}S.param=function(e,t){var n,r=[],i=function(e,t){var n=m(t)?t():t;r[r.length]=encodeURIComponent(e)+"="+encodeURIComponent(null==n?"":n)};if(null==e)return"";if(Array.isArray(e)||e.jquery&&!S.isPlainObject(e))S.each(e,function(){i(this.name,this.value)});else for(n in e)At(n,e[n],t,i);return r.join("&")},S.fn.extend({serialize:function(){return S.param(this.serializeArray())},serializeArray:function(){return this.map(function(){var e=S.prop(this,"elements");return e?S.makeArray(e):this}).filter(function(){var e=this.type;return this.name&&!S(this).is(":disabled")&&kt.test(this.nodeName)&&!St.test(e)&&(this.checked||!pe.test(e))}).map(function(e,t){var n=S(this).val();return null==n?null:Array.isArray(n)?S.map(n,function(e){return{name:t.name,value:e.replace(Et,"\r\n")}}):{name:t.name,value:n.replace(Et,"\r\n")}}).get()}});var Nt=/%20/g,jt=/#.*$/,Dt=/([?&])_=[^&]*/,qt=/^(.*?):[ \t]*([^\r\n]*)$/gm,Lt=/^(?:GET|HEAD)$/,Ht=/^\/\//,Ot={},Pt={},Rt="*/".concat("*"),Mt=E.createElement("a");function It(o){return function(e,t){"string"!=typeof e&&(t=e,e="*");var n,r=0,i=e.toLowerCase().match(P)||[];if(m(t))while(n=i[r++])"+"===n[0]?(n=n.slice(1)||"*",(o[n]=o[n]||[]).unshift(t)):(o[n]=o[n]||[]).push(t)}}function Wt(t,i,o,a){var s={},u=t===Pt;function l(e){var r;return s[e]=!0,S.each(t[e]||[],function(e,t){var n=t(i,o,a);return"string"!=typeof n||u||s[n]?u?!(r=n):void 0:(i.dataTypes.unshift(n),l(n),!1)}),r}return l(i.dataTypes[0])||!s["*"]&&l("*")}function Ft(e,t){var n,r,i=S.ajaxSettings.flatOptions||{};for(n in t)void 0!==t[n]&&((i[n]?e:r||(r={}))[n]=t[n]);return r&&S.extend(!0,e,r),e}Mt.href=bt.href,S.extend({active:0,lastModified:{},etag:{},ajaxSettings:{url:bt.href,type:"GET",isLocal:/^(?:about|app|app-storage|.+-extension|file|res|widget):$/.test(bt.protocol),global:!0,processData:!0,async:!0,contentType:"application/x-www-form-urlencoded; charset=UTF-8",accepts:{"*":Rt,text:"text/plain",html:"text/html",xml:"application/xml, text/xml",json:"application/json, text/javascript"},contents:{xml:/\bxml\b/,html:/\bhtml/,json:/\bjson\b/},responseFields:{xml:"responseXML",text:"responseText",json:"responseJSON"},converters:{"* text":String,"text html":!0,"text json":JSON.parse,"text xml":S.parseXML},flatOptions:{url:!0,context:!0}},ajaxSetup:function(e,t){return t?Ft(Ft(e,S.ajaxSettings),t):Ft(S.ajaxSettings,e)},ajaxPrefilter:It(Ot),ajaxTransport:It(Pt),ajax:function(e,t){"object"==typeof e&&(t=e,e=void 0),t=t||{};var c,f,p,n,d,r,h,g,i,o,v=S.ajaxSetup({},t),y=v.context||v,m=v.context&&(y.nodeType||y.jquery)?S(y):S.event,x=S.Deferred(),b=S.Callbacks("once memory"),w=v.statusCode||{},a={},s={},u="canceled",T={readyState:0,getResponseHeader:function(e){var t;if(h){if(!n){n={};while(t=qt.exec(p))n[t[1].toLowerCase()+" "]=(n[t[1].toLowerCase()+" "]||[]).concat(t[2])}t=n[e.toLowerCase()+" "]}return null==t?null:t.join(", ")},getAllResponseHeaders:function(){return h?p:null},setRequestHeader:function(e,t){return null==h&&(e=s[e.toLowerCase()]=s[e.toLowerCase()]||e,a[e]=t),this},overrideMimeType:function(e){return null==h&&(v.mimeType=e),this},statusCode:function(e){var t;if(e)if(h)T.always(e[T.status]);else for(t in e)w[t]=[w[t],e[t]];return this},abort:function(e){var t=e||u;return c&&c.abort(t),l(0,t),this}};if(x.promise(T),v.url=((e||v.url||bt.href)+"").replace(Ht,bt.protocol+"//"),v.type=t.method||t.type||v.method||v.type,v.dataTypes=(v.dataType||"*").toLowerCase().match(P)||[""],null==v.crossDomain){r=E.createElement("a");try{r.href=v.url,r.href=r.href,v.crossDomain=Mt.protocol+"//"+Mt.host!=r.protocol+"//"+r.host}catch(e){v.crossDomain=!0}}if(v.data&&v.processData&&"string"!=typeof v.data&&(v.data=S.param(v.data,v.traditional)),Wt(Ot,v,t,T),h)return T;for(i in(g=S.event&&v.global)&&0==S.active++&&S.event.trigger("ajaxStart"),v.type=v.type.toUpperCase(),v.hasContent=!Lt.test(v.type),f=v.url.replace(jt,""),v.hasContent?v.data&&v.processData&&0===(v.contentType||"").indexOf("application/x-www-form-urlencoded")&&(v.data=v.data.replace(Nt,"+")):(o=v.url.slice(f.length),v.data&&(v.processData||"string"==typeof v.data)&&(f+=(Tt.test(f)?"&":"?")+v.data,delete v.data),!1===v.cache&&(f=f.replace(Dt,"$1"),o=(Tt.test(f)?"&":"?")+"_="+wt.guid+++o),v.url=f+o),v.ifModified&&(S.lastModified[f]&&T.setRequestHeader("If-Modified-Since",S.lastModified[f]),S.etag[f]&&T.setRequestHeader("If-None-Match",S.etag[f])),(v.data&&v.hasContent&&!1!==v.contentType||t.contentType)&&T.setRequestHeader("Content-Type",v.contentType),T.setRequestHeader("Accept",v.dataTypes[0]&&v.accepts[v.dataTypes[0]]?v.accepts[v.dataTypes[0]]+("*"!==v.dataTypes[0]?", "+Rt+"; q=0.01":""):v.accepts["*"]),v.headers)T.setRequestHeader(i,v.headers[i]);if(v.beforeSend&&(!1===v.beforeSend.call(y,T,v)||h))return T.abort();if(u="abort",b.add(v.complete),T.done(v.success),T.fail(v.error),c=Wt(Pt,v,t,T)){if(T.readyState=1,g&&m.trigger("ajaxSend",[T,v]),h)return T;v.async&&0<v.timeout&&(d=C.setTimeout(function(){T.abort("timeout")},v.timeout));try{h=!1,c.send(a,l)}catch(e){if(h)throw e;l(-1,e)}}else l(-1,"No Transport");function l(e,t,n,r){var i,o,a,s,u,l=t;h||(h=!0,d&&C.clearTimeout(d),c=void 0,p=r||"",T.readyState=0<e?4:0,i=200<=e&&e<300||304===e,n&&(s=function(e,t,n){var r,i,o,a,s=e.contents,u=e.dataTypes;while("*"===u[0])u.shift(),void 0===r&&(r=e.mimeType||t.getResponseHeader("Content-Type"));if(r)for(i in s)if(s[i]&&s[i].test(r)){u.unshift(i);break}if(u[0]in n)o=u[0];else{for(i in n){if(!u[0]||e.converters[i+" "+u[0]]){o=i;break}a||(a=i)}o=o||a}if(o)return o!==u[0]&&u.unshift(o),n[o]}(v,T,n)),!i&&-1<S.inArray("script",v.dataTypes)&&S.inArray("json",v.dataTypes)<0&&(v.converters["text script"]=function(){}),s=function(e,t,n,r){var i,o,a,s,u,l={},c=e.dataTypes.slice();if(c[1])for(a in e.converters)l[a.toLowerCase()]=e.converters[a];o=c.shift();while(o)if(e.responseFields[o]&&(n[e.responseFields[o]]=t),!u&&r&&e.dataFilter&&(t=e.dataFilter(t,e.dataType)),u=o,o=c.shift())if("*"===o)o=u;else if("*"!==u&&u!==o){if(!(a=l[u+" "+o]||l["* "+o]))for(i in l)if((s=i.split(" "))[1]===o&&(a=l[u+" "+s[0]]||l["* "+s[0]])){!0===a?a=l[i]:!0!==l[i]&&(o=s[0],c.unshift(s[1]));break}if(!0!==a)if(a&&e["throws"])t=a(t);else try{t=a(t)}catch(e){return{state:"parsererror",error:a?e:"No conversion from "+u+" to "+o}}}return{state:"success",data:t}}(v,s,T,i),i?(v.ifModified&&((u=T.getResponseHeader("Last-Modified"))&&(S.lastModified[f]=u),(u=T.getResponseHeader("etag"))&&(S.etag[f]=u)),204===e||"HEAD"===v.type?l="nocontent":304===e?l="notmodified":(l=s.state,o=s.data,i=!(a=s.error))):(a=l,!e&&l||(l="error",e<0&&(e=0))),T.status=e,T.statusText=(t||l)+"",i?x.resolveWith(y,[o,l,T]):x.rejectWith(y,[T,l,a]),T.statusCode(w),w=void 0,g&&m.trigger(i?"ajaxSuccess":"ajaxError",[T,v,i?o:a]),b.fireWith(y,[T,l]),g&&(m.trigger("ajaxComplete",[T,v]),--S.active||S.event.trigger("ajaxStop")))}return T},getJSON:function(e,t,n){return S.get(e,t,n,"json")},getScript:function(e,t){return S.get(e,void 0,t,"script")}}),S.each(["get","post"],function(e,i){S[i]=function(e,t,n,r){return m(t)&&(r=r||n,n=t,t=void 0),S.ajax(S.extend({url:e,type:i,dataType:r,data:t,success:n},S.isPlainObject(e)&&e))}}),S.ajaxPrefilter(function(e){var t;for(t in e.headers)"content-type"===t.toLowerCase()&&(e.contentType=e.headers[t]||"")}),S._evalUrl=function(e,t,n){return S.ajax({url:e,type:"GET",dataType:"script",cache:!0,async:!1,global:!1,converters:{"text script":function(){}},dataFilter:function(e){S.globalEval(e,t,n)}})},S.fn.extend({wrapAll:function(e){var t;return this[0]&&(m(e)&&(e=e.call(this[0])),t=S(e,this[0].ownerDocument).eq(0).clone(!0),this[0].parentNode&&t.insertBefore(this[0]),t.map(function(){var e=this;while(e.firstElementChild)e=e.firstElementChild;return e}).append(this)),this},wrapInner:function(n){return m(n)?this.each(function(e){S(this).wrapInner(n.call(this,e))}):this.each(function(){var e=S(this),t=e.contents();t.length?t.wrapAll(n):e.append(n)})},wrap:function(t){var n=m(t);return this.each(function(e){S(this).wrapAll(n?t.call(this,e):t)})},unwrap:function(e){return this.parent(e).not("body").each(function(){S(this).replaceWith(this.childNodes)}),this}}),S.expr.pseudos.hidden=function(e){return!S.expr.pseudos.visible(e)},S.expr.pseudos.visible=function(e){return!!(e.offsetWidth||e.offsetHeight||e.getClientRects().length)},S.ajaxSettings.xhr=function(){try{return new C.XMLHttpRequest}catch(e){}};var Bt={0:200,1223:204},$t=S.ajaxSettings.xhr();y.cors=!!$t&&"withCredentials"in $t,y.ajax=$t=!!$t,S.ajaxTransport(function(i){var o,a;if(y.cors||$t&&!i.crossDomain)return{send:function(e,t){var n,r=i.xhr();if(r.open(i.type,i.url,i.async,i.username,i.password),i.xhrFields)for(n in i.xhrFields)r[n]=i.xhrFields[n];for(n in i.mimeType&&r.overrideMimeType&&r.overrideMimeType(i.mimeType),i.crossDomain||e["X-Requested-With"]||(e["X-Requested-With"]="XMLHttpRequest"),e)r.setRequestHeader(n,e[n]);o=function(e){return function(){o&&(o=a=r.onload=r.onerror=r.onabort=r.ontimeout=r.onreadystatechange=null,"abort"===e?r.abort():"error"===e?"number"!=typeof r.status?t(0,"error"):t(r.status,r.statusText):t(Bt[r.status]||r.status,r.statusText,"text"!==(r.responseType||"text")||"string"!=typeof r.responseText?{binary:r.response}:{text:r.responseText},r.getAllResponseHeaders()))}},r.onload=o(),a=r.onerror=r.ontimeout=o("error"),void 0!==r.onabort?r.onabort=a:r.onreadystatechange=function(){4===r.readyState&&C.setTimeout(function(){o&&a()})},o=o("abort");try{r.send(i.hasContent&&i.data||null)}catch(e){if(o)throw e}},abort:function(){o&&o()}}}),S.ajaxPrefilter(function(e){e.crossDomain&&(e.contents.script=!1)}),S.ajaxSetup({accepts:{script:"text/javascript, application/javascript, application/ecmascript, application/x-ecmascript"},contents:{script:/\b(?:java|ecma)script\b/},converters:{"text script":function(e){return S.globalEval(e),e}}}),S.ajaxPrefilter("script",function(e){void 0===e.cache&&(e.cache=!1),e.crossDomain&&(e.type="GET")}),S.ajaxTransport("script",function(n){var r,i;if(n.crossDomain||n.scriptAttrs)return{send:function(e,t){r=S("<script>").attr(n.scriptAttrs||{}).prop({charset:n.scriptCharset,src:n.url}).on("load error",i=function(e){r.remove(),i=null,e&&t("error"===e.type?404:200,e.type)}),E.head.appendChild(r[0])},abort:function(){i&&i()}}});var _t,zt=[],Ut=/(=)\?(?=&|$)|\?\?/;S.ajaxSetup({jsonp:"callback",jsonpCallback:function(){var e=zt.pop()||S.expando+"_"+wt.guid++;return this[e]=!0,e}}),S.ajaxPrefilter("json jsonp",function(e,t,n){var r,i,o,a=!1!==e.jsonp&&(Ut.test(e.url)?"url":"string"==typeof e.data&&0===(e.contentType||"").indexOf("application/x-www-form-urlencoded")&&Ut.test(e.data)&&"data");if(a||"jsonp"===e.dataTypes[0])return r=e.jsonpCallback=m(e.jsonpCallback)?e.jsonpCallback():e.jsonpCallback,a?e[a]=e[a].replace(Ut,"$1"+r):!1!==e.jsonp&&(e.url+=(Tt.test(e.url)?"&":"?")+e.jsonp+"="+r),e.converters["script json"]=function(){return o||S.error(r+" was not called"),o[0]},e.dataTypes[0]="json",i=C[r],C[r]=function(){o=arguments},n.always(function(){void 0===i?S(C).removeProp(r):C[r]=i,e[r]&&(e.jsonpCallback=t.jsonpCallback,zt.push(r)),o&&m(i)&&i(o[0]),o=i=void 0}),"script"}),y.createHTMLDocument=((_t=E.implementation.createHTMLDocument("").body).innerHTML="<form></form><form></form>",2===_t.childNodes.length),S.parseHTML=function(e,t,n){return"string"!=typeof e?[]:("boolean"==typeof t&&(n=t,t=!1),t||(y.createHTMLDocument?((r=(t=E.implementation.createHTMLDocument("")).createElement("base")).href=E.location.href,t.head.appendChild(r)):t=E),o=!n&&[],(i=N.exec(e))?[t.createElement(i[1])]:(i=xe([e],t,o),o&&o.length&&S(o).remove(),S.merge([],i.childNodes)));var r,i,o},S.fn.load=function(e,t,n){var r,i,o,a=this,s=e.indexOf(" ");return-1<s&&(r=ht(e.slice(s)),e=e.slice(0,s)),m(t)?(n=t,t=void 0):t&&"object"==typeof t&&(i="POST"),0<a.length&&S.ajax({url:e,type:i||"GET",dataType:"html",data:t}).done(function(e){o=arguments,a.html(r?S("<div>").append(S.parseHTML(e)).find(r):e)}).always(n&&function(e,t){a.each(function(){n.apply(this,o||[e.responseText,t,e])})}),this},S.expr.pseudos.animated=function(t){return S.grep(S.timers,function(e){return t===e.elem}).length},S.offset={setOffset:function(e,t,n){var r,i,o,a,s,u,l=S.css(e,"position"),c=S(e),f={};"static"===l&&(e.style.position="relative"),s=c.offset(),o=S.css(e,"top"),u=S.css(e,"left"),("absolute"===l||"fixed"===l)&&-1<(o+u).indexOf("auto")?(a=(r=c.position()).top,i=r.left):(a=parseFloat(o)||0,i=parseFloat(u)||0),m(t)&&(t=t.call(e,n,S.extend({},s))),null!=t.top&&(f.top=t.top-s.top+a),null!=t.left&&(f.left=t.left-s.left+i),"using"in t?t.using.call(e,f):c.css(f)}},S.fn.extend({offset:function(t){if(arguments.length)return void 0===t?this:this.each(function(e){S.offset.setOffset(this,t,e)});var e,n,r=this[0];return r?r.getClientRects().length?(e=r.getBoundingClientRect(),n=r.ownerDocument.defaultView,{top:e.top+n.pageYOffset,left:e.left+n.pageXOffset}):{top:0,left:0}:void 0},position:function(){if(this[0]){var e,t,n,r=this[0],i={top:0,left:0};if("fixed"===S.css(r,"position"))t=r.getBoundingClientRect();else{t=this.offset(),n=r.ownerDocument,e=r.offsetParent||n.documentElement;while(e&&(e===n.body||e===n.documentElement)&&"static"===S.css(e,"position"))e=e.parentNode;e&&e!==r&&1===e.nodeType&&((i=S(e).offset()).top+=S.css(e,"borderTopWidth",!0),i.left+=S.css(e,"borderLeftWidth",!0))}return{top:t.top-i.top-S.css(r,"marginTop",!0),left:t.left-i.left-S.css(r,"marginLeft",!0)}}},offsetParent:function(){return this.map(function(){var e=this.offsetParent;while(e&&"static"===S.css(e,"position"))e=e.offsetParent;return e||re})}}),S.each({scrollLeft:"pageXOffset",scrollTop:"pageYOffset"},function(t,i){var o="pageYOffset"===i;S.fn[t]=function(e){return $(this,function(e,t,n){var r;if(x(e)?r=e:9===e.nodeType&&(r=e.defaultView),void 0===n)return r?r[i]:e[t];r?r.scrollTo(o?r.pageXOffset:n,o?n:r.pageYOffset):e[t]=n},t,e,arguments.length)}}),S.each(["top","left"],function(e,n){S.cssHooks[n]=Fe(y.pixelPosition,function(e,t){if(t)return t=We(e,n),Pe.test(t)?S(e).position()[n]+"px":t})}),S.each({Height:"height",Width:"width"},function(a,s){S.each({padding:"inner"+a,content:s,"":"outer"+a},function(r,o){S.fn[o]=function(e,t){var n=arguments.length&&(r||"boolean"!=typeof e),i=r||(!0===e||!0===t?"margin":"border");return $(this,function(e,t,n){var r;return x(e)?0===o.indexOf("outer")?e["inner"+a]:e.document.documentElement["client"+a]:9===e.nodeType?(r=e.documentElement,Math.max(e.body["scroll"+a],r["scroll"+a],e.body["offset"+a],r["offset"+a],r["client"+a])):void 0===n?S.css(e,t,i):S.style(e,t,n,i)},s,n?e:void 0,n)}})}),S.each(["ajaxStart","ajaxStop","ajaxComplete","ajaxError","ajaxSuccess","ajaxSend"],function(e,t){S.fn[t]=function(e){return this.on(t,e)}}),S.fn.extend({bind:function(e,t,n){return this.on(e,null,t,n)},unbind:function(e,t){return this.off(e,null,t)},delegate:function(e,t,n,r){return this.on(t,e,n,r)},undelegate:function(e,t,n){return 1===arguments.length?this.off(e,"**"):this.off(t,e||"**",n)},hover:function(e,t){return this.mouseenter(e).mouseleave(t||e)}}),S.each("blur focus focusin focusout resize scroll click dblclick mousedown mouseup mousemove mouseover mouseout mouseenter mouseleave change select submit keydown keypress keyup contextmenu".split(" "),function(e,n){S.fn[n]=function(e,t){return 0<arguments.length?this.on(n,null,e,t):this.trigger(n)}});var Xt=/^[\s\uFEFF\xA0]+|[\s\uFEFF\xA0]+$/g;S.proxy=function(e,t){var n,r,i;if("string"==typeof t&&(n=e[t],t=e,e=n),m(e))return r=s.call(arguments,2),(i=function(){return e.apply(t||this,r.concat(s.call(arguments)))}).guid=e.guid=e.guid||S.guid++,i},S.holdReady=function(e){e?S.readyWait++:S.ready(!0)},S.isArray=Array.isArray,S.parseJSON=JSON.parse,S.nodeName=A,S.isFunction=m,S.isWindow=x,S.camelCase=X,S.type=w,S.now=Date.now,S.isNumeric=function(e){var t=S.type(e);return("number"===t||"string"===t)&&!isNaN(e-parseFloat(e))},S.trim=function(e){return null==e?"":(e+"").replace(Xt,"")},"function"==typeof define&&define.amd&&define("jquery",[],function(){return S});var Vt=C.jQuery,Gt=C.$;return S.noConflict=function(e){return C.$===S&&(C.$=Gt),e&&C.jQuery===S&&(C.jQuery=Vt),S},"undefined"==typeof e&&(C.jQuery=C.$=S),S});
"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="data:text/css,html%7Bfont%2Dfamily%3Asans%2Dserif%3B%2Dwebkit%2Dtext%2Dsize%2Dadjust%3A100%25%3B%2Dms%2Dtext%2Dsize%2Dadjust%3A100%25%7Dbody%7Bmargin%3A0%7Darticle%2Caside%2Cdetails%2Cfigcaption%2Cfigure%2Cfooter%2Cheader%2Chgroup%2Cmain%2Cmenu%2Cnav%2Csection%2Csummary%7Bdisplay%3Ablock%7Daudio%2Ccanvas%2Cprogress%2Cvideo%7Bdisplay%3Ainline%2Dblock%3Bvertical%2Dalign%3Abaseline%7Daudio%3Anot%28%5Bcontrols%5D%29%7Bdisplay%3Anone%3Bheight%3A0%7D%5Bhidden%5D%2Ctemplate%7Bdisplay%3Anone%7Da%7Bbackground%2Dcolor%3Atransparent%7Da%3Aactive%2Ca%3Ahover%7Boutline%3A0%7Dabbr%5Btitle%5D%7Bborder%2Dbottom%3A1px%20dotted%7Db%2Cstrong%7Bfont%2Dweight%3A700%7Ddfn%7Bfont%2Dstyle%3Aitalic%7Dh1%7Bmargin%3A%2E67em%200%3Bfont%2Dsize%3A2em%7Dmark%7Bcolor%3A%23000%3Bbackground%3A%23ff0%7Dsmall%7Bfont%2Dsize%3A80%25%7Dsub%2Csup%7Bposition%3Arelative%3Bfont%2Dsize%3A75%25%3Bline%2Dheight%3A0%3Bvertical%2Dalign%3Abaseline%7Dsup%7Btop%3A%2D%2E5em%7Dsub%7Bbottom%3A%2D%2E25em%7Dimg%7Bborder%3A0%7Dsvg%3Anot%28%3Aroot%29%7Boverflow%3Ahidden%7Dfigure%7Bmargin%3A1em%2040px%7Dhr%7Bheight%3A0%3B%2Dwebkit%2Dbox%2Dsizing%3Acontent%2Dbox%3B%2Dmoz%2Dbox%2Dsizing%3Acontent%2Dbox%3Bbox%2Dsizing%3Acontent%2Dbox%7Dpre%7Boverflow%3Aauto%7Dcode%2Ckbd%2Cpre%2Csamp%7Bfont%2Dfamily%3Amonospace%2Cmonospace%3Bfont%2Dsize%3A1em%7Dbutton%2Cinput%2Coptgroup%2Cselect%2Ctextarea%7Bmargin%3A0%3Bfont%3Ainherit%3Bcolor%3Ainherit%7Dbutton%7Boverflow%3Avisible%7Dbutton%2Cselect%7Btext%2Dtransform%3Anone%7Dbutton%2Chtml%20input%5Btype%3Dbutton%5D%2Cinput%5Btype%3Dreset%5D%2Cinput%5Btype%3Dsubmit%5D%7B%2Dwebkit%2Dappearance%3Abutton%3Bcursor%3Apointer%7Dbutton%5Bdisabled%5D%2Chtml%20input%5Bdisabled%5D%7Bcursor%3Adefault%7Dbutton%3A%3A%2Dmoz%2Dfocus%2Dinner%2Cinput%3A%3A%2Dmoz%2Dfocus%2Dinner%7Bpadding%3A0%3Bborder%3A0%7Dinput%7Bline%2Dheight%3Anormal%7Dinput%5Btype%3Dcheckbox%5D%2Cinput%5Btype%3Dradio%5D%7B%2Dwebkit%2Dbox%2Dsizing%3Aborder%2Dbox%3B%2Dmoz%2Dbox%2Dsizing%3Aborder%2Dbox%3Bbox%2Dsizing%3Aborder%2Dbox%3Bpadding%3A0%7Dinput%5Btype%3Dnumber%5D%3A%3A%2Dwebkit%2Dinner%2Dspin%2Dbutton%2Cinput%5Btype%3Dnumber%5D%3A%3A%2Dwebkit%2Douter%2Dspin%2Dbutton%7Bheight%3Aauto%7Dinput%5Btype%3Dsearch%5D%7B%2Dwebkit%2Dbox%2Dsizing%3Acontent%2Dbox%3B%2Dmoz%2Dbox%2Dsizing%3Acontent%2Dbox%3Bbox%2Dsizing%3Acontent%2Dbox%3B%2Dwebkit%2Dappearance%3Atextfield%7Dinput%5Btype%3Dsearch%5D%3A%3A%2Dwebkit%2Dsearch%2Dcancel%2Dbutton%2Cinput%5Btype%3Dsearch%5D%3A%3A%2Dwebkit%2Dsearch%2Ddecoration%7B%2Dwebkit%2Dappearance%3Anone%7Dfieldset%7Bpadding%3A%2E35em%20%2E625em%20%2E75em%3Bmargin%3A0%202px%3Bborder%3A1px%20solid%20silver%7Dlegend%7Bpadding%3A0%3Bborder%3A0%7Dtextarea%7Boverflow%3Aauto%7Doptgroup%7Bfont%2Dweight%3A700%7Dtable%7Bborder%2Dspacing%3A0%3Bborder%2Dcollapse%3Acollapse%7Dtd%2Cth%7Bpadding%3A0%7D%40media%20print%7B%2A%2C%3Aafter%2C%3Abefore%7Bcolor%3A%23000%21important%3Btext%2Dshadow%3Anone%21important%3Bbackground%3A0%200%21important%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%21important%3Bbox%2Dshadow%3Anone%21important%7Da%2Ca%3Avisited%7Btext%2Ddecoration%3Aunderline%7Da%5Bhref%5D%3Aafter%7Bcontent%3A%22%20%28%22%20attr%28href%29%20%22%29%22%7Dabbr%5Btitle%5D%3Aafter%7Bcontent%3A%22%20%28%22%20attr%28title%29%20%22%29%22%7Da%5Bhref%5E%3D%22javascript%3A%22%5D%3Aafter%2Ca%5Bhref%5E%3D%22%23%22%5D%3Aafter%7Bcontent%3A%22%22%7Dblockquote%2Cpre%7Bborder%3A1px%20solid%20%23999%3Bpage%2Dbreak%2Dinside%3Aavoid%7Dthead%7Bdisplay%3Atable%2Dheader%2Dgroup%7Dimg%2Ctr%7Bpage%2Dbreak%2Dinside%3Aavoid%7Dimg%7Bmax%2Dwidth%3A100%25%21important%7Dh2%2Ch3%2Cp%7Borphans%3A3%3Bwidows%3A3%7Dh2%2Ch3%7Bpage%2Dbreak%2Dafter%3Aavoid%7D%2Enavbar%7Bdisplay%3Anone%7D%2Ebtn%3E%2Ecaret%2C%2Edropup%3E%2Ebtn%3E%2Ecaret%7Bborder%2Dtop%2Dcolor%3A%23000%21important%7D%2Elabel%7Bborder%3A1px%20solid%20%23000%7D%2Etable%7Bborder%2Dcollapse%3Acollapse%21important%7D%2Etable%20td%2C%2Etable%20th%7Bbackground%2Dcolor%3A%23fff%21important%7D%2Etable%2Dbordered%20td%2C%2Etable%2Dbordered%20th%7Bborder%3A1px%20solid%20%23ddd%21important%7D%7D%40font%2Dface%7Bfont%2Dfamily%3A%27Glyphicons%20Halflings%27%3Bsrc%3Aurl%28data%3Aapplication%2Fvnd%2Ems%2Dfontobject%3Bbase64%2Cn04AAEFNAAACAAIABAAAAAAABQAAAAAAAAABAJABAAAEAExQAAAAAAAAAAIAAAAAAAAAAAEAAAAAAAAAJxJ%2FLAAAAAAAAAAAAAAAAAAAAAAAACgARwBMAFkAUABIAEkAQwBPAE4AUwAgAEgAYQBsAGYAbABpAG4AZwBzAAAADgBSAGUAZwB1AGwAYQByAAAAeABWAGUAcgBzAGkAbwBuACAAMQAuADAAMAA5ADsAUABTACAAMAAwADEALgAwADAAOQA7AGgAbwB0AGMAbwBuAHYAIAAxAC4AMAAuADcAMAA7AG0AYQBrAGUAbwB0AGYALgBsAGkAYgAyAC4ANQAuADUAOAAzADIAOQAAADgARwBMAFkAUABIAEkAQwBPAE4AUwAgAEgAYQBsAGYAbABpAG4AZwBzACAAUgBlAGcAdQBsAGEAcgAAAAAAQlNHUAAAAAAAAAAAAAAAAAAAAAADAKncAE0TAE0ZAEbuFM3pjM%2FSEdmjKHUbyow8ATBE40IvWA3vTu8LiABDQ%2BpexwUMcm1SMnNryctQSiI1K5ZnbOlXKmnVV5YvRe6RnNMFNCOs1KNVpn6yZhCJkRtVRNzEufeIq7HgSrcx4S8h%2Fv4vnrrKc6oCNxmSk2uKlZQHBii6iKFoH0746ThvkO1kJHlxjrkxs%2BLWORaDQBEtiYJIR5IB9Bi1UyL4Rmr0BNigNkMzlKQmnofBHviqVzUxwdMb3NdCn69hy%2BpRYVKGVS%2F1tnsqv4LL7wCCPZZAZPT4aCShHjHJVNuXbmMrY5LeQaGnvAkXlVrJgKRAUdFjrWEah9XebPeQMj7KS7DIBAFt8ycgC5PLGUOHSE3ErGZCiViNLL5ZARfywnCoZaKQCu6NuFX42AEeKtKUGnr%2FCm2Cy8tpFhBPMW5Fxi4Qm4TkDWh4IWFDClhU2hRWosUWqcKLlgyXB%2BlSHaWaHiWlBAR8SeSgSPCQxdVQgzUixWKSTrIQEbU94viDctkvX%2BVSjJuUmV8L4CXShI11esnp0pjWNZIyxKHS4wVQ2ime1P4RnhvGw0aDN1OLAXGERsB7buFpFGGBAre4QEQR0HOIO5oYH305G%2BKspT%2FFupEGGafCCwxSe6ZUa%2B073rXHnNdVXE6eWvibUS27XtRzkH838mYLMBmYysZTM0EM3A1fbpCBYFccN1B%2FEnCYu%2FTgCGmr7bMh8GfYL%2BBfcLvB0gRagC09w9elfldaIy%2FhNCBLRgBgtCC7jAF63wLSMAfbfAlEggYU0bUA7ACCJmTDpEmJtI78w4%2FBO7dN7JR7J7ZvbYaUbaILSQsRBiF3HGk5fEg6p9unwLvn98r%2BvnsV%2B372uf1xBLq4qU%2F45fTuqaAP%2BpssmCCCTF0mhEow8ZXZOS8D7Q85JsxZ%2BAzok7B7O%2Ff6J8AzYBySZQB%2FQHYUSA%2BEeQhEWiS6AIQzgcsDiER4MjgMBAWDV4AgQ3g1eBgIdweCQmCjJEMkJ%2BPKRWyFHHmg1Wi%2F6xzUgA0LREoKJChwnQa9B%2B5RQZRB3IlBlkAnxyQNaANwHMowzlYSMCBgnbpzvqpl0iTJNCQidDI9ZrSYNIRBhHtUa5YHMHxyGEik9hDE0AKj72AbTCaxtHPUaKZdAZSnQTyjGqGLsmBStCejApUhg4uBMU6mATujEl%2BKdDPbI6Ag4vLr%2BhjY6lbjBeoLKnZl0UZgRX8gTySOeynZVz1wOq7e1hFGYIq%2BMhrGxDLak0PrwYzSXtcuyhXEhwOYofiW%2BEcI%2Fjw8P6IY6ed%2BetAbuqKp5QIapT77LnAe505lMuqL79a0ut4rWexzFttsOsLDy7zvtQzcq3U1qabe7tB0wHWVXji%2BzDbo8x8HyIRUbXnwUcklFv51fvTymiV%2BMXLSmGH9d9%2BaXpD5X6lao41anWGig7IwIdnoBY2ht%2FpO9mClLo4NdXHAsefqWUKlXJkbqPOFhMoR4aiA1BXqhRNbB2Xwi%2B7u%2FjpAoOpKJ0UX24EsrzMfHXViakCNcKjBxuQX8BO0ZqjJ3xXzf%2B61t2VXOSgJ8xu65QKgtN6FibPmPYsXbJRHHqbgATcSZxBqGiDiU4NNNsYBsKD0MIP%2FOfKnlk%2FLkaid%2FO2NbKeuQrwOB2Gq3YHyr6ALgzym5wIBnsdC1ZkoBFZSQXChZvlesPqvK2c5oHHT3Q65jYpNxnQcGF0EHbvYqoFw60WNlXIHQF2HQB7zD6lWjZ9rVqUKBXUT6hrkZOle0RFYII0V5ZYGl1JAP0Ud1fZZMvSomBzJ710j4Me8mjQDwEre5Uv2wQfk1ifDwb5ksuJQQ3xt423lbuQjvoIQByQrNDh1JxGFkOdlJvu%2FgFtuW0wR4cgd%2BZKesSV7QkNE2kw6AV4hoIuC02LGmTomyf8PiO6CZzOTLTPQ%2BHW06H%2Btx%2BbQ8LmDYg1pTFrp2oJXgkZTyeRJZM0C8aE2LpFrNVDuhARsN543%2FFV6klQ6Tv1OoZGXLv0igKrl%2FCmJxRmX7JJbJ998VSIPQRyDBICzl4JJlYHbdql30NvYcOuZ7a10uWRrgoieOdgIm4rlq6vNOQBuqESLbXG5lzdJGHw2m0sDYmODXbYGTfSTGRKpssTO95fothJCjUGQgEL4yKoGAF%2F0SrpUDNn8CBgBcSDQByAeNkCXp4S4Ro2Xh4OeaGRgR66PVOsU8bc6TR5%2FxTcn4IVMLOkXSWiXxkZQCbvKfmoAvQaKjO3EDKwkwqHChCDEM5loQRPd5ACBki1TjF772oaQhQbQ5C0lcWXPFOzrfsDGUXGrpxasbG4iab6eByaQkQfm0VFlP0ZsDkvvqCL6QXMUwCjdMx1ZOyKhTJ7a1GWAdOUcJ8RSejxNVyGs31OKMyRyBVoZFjqIkmKlLQ5eHMeEL4MkUf23cQ%2F1SgRCJ1dk4UdBT7OoyuNgLs0oCd8RnrEIb6QdMxT2QjD4zMrJkfgx5aDMcA4orsTtKCqWb%2FVeyceqa5OGSmB28YwH4rFbkQaLoUN8OQQYnD3w2eXpI4ScQfbCUZiJ4yMOIKLyyTc7BQ4uXUw6Ee6%2FxM%2B4Y67ngNBknxIPwuppgIhFcwJyr6EIj%2BLzNj%2FmfR2vhhRlx0BILZoAYruF0caWQ7YxO66UmeguDREAFHYuC7HJviRgVO6ruJH59h%2FC%2FPkgSle8xNzZJULLWq9JMDTE2fjGE146a1Us6PZDGYle6ldWRqn%2FpdpgHKNGrGIdkRK%2BKPETT9nKT6kLyDI8xd9A1FgWmXWRAIHwZ37WyZHOVyCadJEmMVz0MadMjDrPho%2BEIochkVC2xgGiwwsQ6DMv2P7UXqT4x7CdcYGId2BJQQa85EQKmCmwcRejQ9Bm4oATENFPkxPXILHpMPUyWTI5rjNOsIlmEeMbcOCEqInpXACYQ9DDxmFo9vcmsDblcMtg4tqBerNngkIKaFJmrQAPnq1dEzsMXcwjcHdfdCibcAxxA%2Bq%2Fj9m3LM%2FO7WJka4tSidVCjsvo2lQ%2F2ewyoYyXwAYyr2PlRoR5MpgVmSUIrM3PQxXPbgjBOaDQFIyFMJvx3Pc5RSYj12ySVF9fwFPQu2e2KWVoL9q3Ayv3IzpGHUdvdPdrNUdicjsTQ2ISy7QU3DrEytIjvbzJnAkmANXjAFERA0MUoPF3%2F5KFmW14bBNOhwircYgMqoDpUMcDtCmBE82QM2YtdjVLB4kBuKho%2FbcwQdeboqfQartuU3CsCf%2BcXkgYAqp%2F0Ee3RorAZt0AvvOCSI4JICIlGlsV0bsSid%2FNIEALAAzb6HAgyWHBps6xAOwkJIGcB82CxRQq4sJf3FzA70A%2BTRqcqjEMETCoez3mkPcpnoALs0ugJY8kQwrC%2BJE5ik3w9rzrvDRjAQnqgEVvdGrNwlanR0SOKWzxOJOvLJhcd8Cl4AshACUkv9czdMkJCVQSQhp6kp7StAlpVRpK0t0SW6LHeBJnE2QchB5Ccu8kxRghZXGIgZIiSj7gEKMJDClcnX6hgoqJMwiQDigIXg3ioFLCgDgjPtYHYpsF5EiA4kcnN18MZtOrY866dEQAb0FB34OGKHGZQjwW%2FWDHA60cYFaI%2FPjpzquUqdaYGcIq%2BmLez3WLFFCtNBN2QJcrlcoELgiPku5R5dSlJFaCEqEZle1AQzAKC%2B1SotMcBNyQUFuRHRF6OlimSBgjZeTBCwLyc6A%2BP%2FoFRchXTz5ADknYJHxzrJ5pGuIKRQISU6WyKTBBjD8WozmVYWIsto1AS5rxzKlvJu4E%2FvwOiKxRtCWsDM%2BeTHUrmwrCK5BIfMzGkD%2B0Fk5LzBs0jMYXktNDblB06LMNJ09U8pzSLmo14MS0OMjcdrZ31pyQqxJJpRImlSvfYAK8inkYU52QY2FPEVsjoWewpwhRp5yAuNpkqhdb7ku9Seefl2D0B8SMTFD90xi4CSOwwZy9IKkpMtI3FmFUg3%2FkFutpQGNc3pCR7gvC4sgwbupDu3DyEN%2BW6YGLNM21jpB49irxy9BSlHrVDlnihGKHwPrbVFtc%2Bh1rVQKZduxIyojccZIIcOCmhEnC7UkY68WXKQgLi2JCDQkQWJRQuk60hZp0D3rtCTINSeY9Ej2kIKYfGxwOs4j9qMM7fYZiipzgcf7TamnehqdhsiMiCawXnz4xAbyCkLAx5EGbo3Ax1u3dUIKnTxIaxwQTHehPl3V491H0%2BbC5zgpGz7Io%2BmjdhKlPJ01EeMpM7UsRJMi1nGjmJg35i6bQBAAxjO%2FENJubU2mg3ONySEoWklCwdABETcs7ck3jgiuU9pcKKpbgn%2B3YlzV1FzIkB6pmEDOSSyDfPPlQskznctFji0kpgZjW5RZe6x9kYT4KJcXg0bNiCyif%2BpZACCyRMmYsfiKmN9tSO65F0R2OO6ytlEhY5Sj6uRKfFxw0ijJaAx%2Fk3QgnAFSq27%2F2i4GEBA%2BUvTJKK%2F9eISNvG46Em5RZfjTYLdeD8kdXHyrwId%2FDQZUaMCY4gGbke2C8vfjgV%2FY9kkRQOJIn%2FxM9INZSpiBnqX0Q9GlQPpPKAyO5y%2BW5NMPSRdBCUlmuxl40ZfMCnf2Cp044uI9WLFtCi4YVxKjuRCOBWIb4XbIsGdbo4qtMQnNOQz4XDSui7W%2FN6l54qOynCqD3DpWQ%2BmpD7C40D8BZEWGJX3tlAaZBMj1yjvDYKwCJBa201u6nBKE5UE%2B7QSEhCwrXfbRZylAaAkplhBWX50dumrElePyNMRYUrC99UmcSSNgImhFhDI4BXjMtiqkgizUGCrZ8iwFxU6fQ8GEHCFdLewwxYWxgScAYMdMLmcZR6b7rZl95eQVDGVoUKcRMM1ixXQtXNkBETZkVVPg8LoSrdetHzkuM7DjZRHP02tCxA1fmkXKF3VzfN1pc1cv%2F8lbTIkkYpqKM9VOhp65ktYk%2BQ46myFWBapDfyWUCnsnI00QTBQmuFjMZTcd0V2NQ768Fhpby04k2IzNR1wKabuGJqYWwSly6ocMFGTeeI%2BejsWDYgEvr66QgqdcIbFYDNgsm0x9UHY6SCd5%2B7tpsLpKdvhahIDyYmEJQCqMqtCF6UlrE5GXRmbu%2Bvtm3BFSxI6ND6UxIE7GsGMgWqghXxSnaRJuGFveTcK5ZVSPJyjUxe1dKgI6kNF7EZhIZs8y8FVqwEfbM0Xk2ltORVDKZZM40SD3qQoQe0orJEKwPfZwm3YPqwixhUMOndis6MhbmfvLBKjC8sKKIZKbJk8L11oNkCQzCgvjhyyEiQSuJcgCQSG4Mocfgc0Hkwcjal1UNgP0CBPikYqBIk9tONv4kLtBswH07vUCjEaHiFGlLf8MgXKzSgjp2HolRRccAOh0ILHz9qlGgIFkwAnzHJRjWFhlA7ROwINyB5HFj59PRZHFor6voq7l23EPNRwdWhgawqbivLSjRA4htEYUFkjESu67icTg5S0aW1sOkCiIysfJ9UnIWevOOLGpepcBxy1wEhd2WI3AZg7sr9WBmHWyasxMcvY%2FiOmsLtHSWNUWEGk9hScMPShasUA1AcHOtRZlqMeQ0OzYS9vQvYUjOLrzP07BUAFikcJNMi7gIxEw4pL1G54TcmmmoAQ5s7TGWErJZ2Io4yQ0ljRYhL8H5e62oDtLF8aDpnIvZ5R3GWJyAugdiiJW9hQAVTsnCBHhwu7rkBlBX6r3b7ejEY0k5GGeyKv66v%2B6dg7mcJTrWHbtMywbedYqCQ0FPwoytmSWsL8WTtChZCKKzEF7vP6De4x2BJkkniMgSdWhbeBSLtJZR9CTHetK1xb34AYIJ37OegYIoPVbXgJ%2FqDQK%2BbfCtxQRVKQu77WzOoM6SGL7MaZwCGJVk46aImai9fmam%2BWpHG%2B0BtQPWUgZ7RIAlPq6lkECUhZQ2gqWkMYKcYMYaIc4gYCDFHYa2d1nzp3%2BJ1eCBay8IYZ0wQRKGAqvCuZ%2FUgbQPyllosq%2BXtfKIZOzmeJqRazpmmoP%2F76YfkjzV2NlXTDSBYB04SVlNQsFTbGPk1t%2FI4Jktu0XSgifO2ozFOiwd%2F0SssJDn0dn4xqk4GDTTKX73%2FwQyBLdqgJ%2BWx6AQaba3BA9CKEzjtQYIfAsiYamapq80LAamYjinlKXUkxdpIDk0puXUEYzSalfRibAeDAKpNiqQ0FTwoxuGYzRnisyTotdVTclis1LHRQCy%2FqqL8oUaQzWRxilq5Mi0IJGtMY02cGLD69vGjkj3p6pGePKI8bkBv5evq8SjjyU04vJR2cQXQwSJyoinDsUJHCQ50jrFTT7yRdbdYQMB3MYCb6uBzJ9ewhXYPAIZSXfeEQBZZ3GPN3Nbhh%2FwkvAJLXnQMdi5NYYZ5GHE400GS5rXkOZSQsdZgIbzRnF9ueLnsfQ47wHAsirITnTlkCcuWWIUhJSbpM3wWhXNHvt2xUsKKMpdBSbJnBMcihkoDqAd1Zml%2FR4yrzow1Q2A5G%2Bkzo%2FRhRxQS2lCSDRV8LlYLBOOoo1bF4jwJAwKMK1tWLHlu9i0j4Ig8qVm6wE1DxXwAwQwsaBWUg2pOOol2dHxyt6npwJEdLDDVYyRc2D0HbcbLUJQj8gPevQBUBOUHXPrsAPBERICpnYESeu2OHotpXQxRGlCCtLdIsu23MhZVEoJg8Qumj%2FUMMc34IBqTKLDTp76WzL%2FdMjCxK7MjhiGjeYAC%2Fkj%2FjY%2FRde7hpSM1xChrog6yZ7OWTuD56xBJnGFE%2BpT2ElSyCnJcwVzCjkqeNLfMEJqKW0G7OFIp0G%2B9mh50I9o8k1tpCY0xYqFNIALgIfc2me4n1bmJnRZ89oepgLPT0NTMLNZsvSCZAc3TXaNB07vail36%2FdBySis4m9%2FDR8izaLJW6bWCkVgm5T%2Bius3ZXq4xI%2BGnbveLbdRwF2mNtsrE0JjYc1AXknCOrLSu7Te%2Fr4dPYMCl5qtiHNTn%2BTPbh1jCBHH%2BdMJNhwNgs3nT%2BOhQoQ0vYif56BMG6WowAcHR3DjQolxLzyVekHj00PBAaW7IIAF1EF%2BuRIWyXjQMAs2chdpaKPNaB%2BkSezYt0%2BCA04sOg5vx8Fr7Ofa9sUv87h7SLAUFSzbetCCZ9pmyLt6l6%2FTzoA1%2FZBG9bIUVHLAbi%2FkdBFgYGyGwRQGBpkqCEg2ah9UD6EedEcEL3j4y0BQQCiExEnocA3SZboh%2Bepgd3YsOkHskZwPuQ5OoyA0fTA5AXrHcUOQF%2BzkJHIA7PwCDk1gGVmGUZSSoPhNf%2BTklauz98QofOlCIQ%2FtCD4dosHYPqtPCXB3agggQQIqQJsSkB%2Bqn0rkQ1toJjON%2FOtCIB9RYv3PqRA4C4U68ZMlZn6BdgEvi2ziU%2BTQ6NIw3ej%2BAtDwMGEZk7e2IjxUWKdAxyaw9OCwSmeADTPPleyk6UhGDNXQb%2B%2BW6Uk4q6F7%2Frg6WVTo82IoCxSIsFDrav4EPHphD3u4hR53WKVvYZUwNCCeM4PMBWzK%2BEfIthZOkuAwPo5C5jgoZgn6dUdvx5rIDmd58cXXdKNfw3l%2BwM2UjgrDJeQHhbD7HW2QDoZMCujgIUkk5Fg8VCsdyjOtnGRx8wgKRPZN5dR0zPUyfGZFVihbFRniXZFOZGKPnEQzU3AnD1KfR6weHW2XS6KbPJxUkOTZsAB9vTVp3Le1F8q5l%2BDMcLiIq78jxAImD2pGFw0VHfRatScGlK6SMu8leTmhUSMy8Uhdd6xBiH3Gdman4tjQGLboJfqz6fL2WKHTmrfsKZRYX6BTDjDldKMosaSTLdQS7oDisJNqAUhw1PfTlnacCO8vl8706Km1FROgLDmudzxg%2BEWTiArtHgLsRrAXYWdB0NmToNCJdKm0KWycZQqb%2BMw76Qy29iQ5up%2FX7oyw8QZ75kP5F6iJAJz6KCmqxz8fEa%2FxnsMYcIO%2FvEkGRuMckhr4rIeLrKaXnmIzlNLxbFspOphkcnJdnz%2FChp%2FVlpj2P7jJQmQRwGnltkTV5dbF9fE3%2FfxoSqTROgq9wFUlbuYzYcasE0ouzBo%2BdDCDzxKAfhbAZYxQiHrLzV2iVexnDX%2FQnT1fsT%2Fxuhu1ui5qIytgbGmRoQkeQooO8eJNNZsf0iALur8QxZFH0nCMnjerYQqG1pIfjyVZWxhVRznmmfLG00BcBWJE6hzQWRyFknuJnXuk8A5FRDCulwrWASSNoBtR%2BCtGdkPwYN2o7DOw%2FVGlCZPusRBFXODQdUM5zeHDIVuAJBLqbO%2Ff9Qua%2BpDqEPk230Sob9lEZ8BHiCorjVghuI0lI4JDgHGRDD%2FprQ84B1pVGkIpVUAHCG%2Biz3Bn3qm2AVrYcYWhock4jso5%2BJ7HfHVj4WMIQdGctq3psBCVVzupQOEioBGA2Bk%2BUILT7%2BVoX5mdxxA5fS42gISQVi%2FHTzrgMxu0fY6hE1ocUwwbsbWcezrY2n6S8%2F6cxXkOH4prpmPuFoikTzY7T85C4T2XYlbxLglSv2uLCgFv8Quk%2FwdesUdWPeHYIH0R729JIisN9Apdd4eB10aqwXrPt%2BSu9mA8k8n1sjMwnfsfF2j3jMUzXepSHmZ%2FBfqXvzgUNQQWOXO8YEuFBh4QTYCkOAPxywpYu1VxiDyJmKVcmJPGWk%2Fgc3Pov02StyYDahwmzw3E1gYC9wkupyWfDqDSUMpCTH5e5N8B%2F%2FlHiMuIkTNw4USHrJU67bjXGqNav6PBuQSoqTxc8avHoGmvqNtXzIaoyMIQIiiUHIM64cXieouplhNYln7qgc4wBVAYR104kO%2BCvKqsg4yIUlFNThVUAKZxZt1XA34h3TCUUiXVkZ0w8Hh2R0Z5L0b4LZvPd%2Fp1gi%2F07h8qfwHrByuSxglc9cI4QIg2oqvC%2Fqm0i7tjPLTgDhoWTAKDO2ONW5oe%2B%2FeKB9vZB8K6C25yCZ9RFVMnb6NRdRjyVK57CHHSkJBfnM2%2Fj4ODUwRkqrtBBCrDsDpt8jhZdXoy%2F1BCqw3sSGhgGGy0a5Jw6BP%2FTExoCmNFYjZl248A0osgPyGEmRA%2BfAsqPVaNAfytu0vuQJ7rk3J4kTDTR2AlCHJ5cls26opZM4w3jMULh2YXKpcqGBtuleAlOZnaZGbD6DHzMd6i2oFeJ8z9XYmalg1Szd%2FocZDc1C7Y6vcALJz2lYnTXiWEr2wawtoR4g3jvWUU2Ngjd1cewtFzEvM1NiHZPeLlIXFbBPawxNgMwwAlyNSuGF3zizVeOoC9bag1qRAQKQE%2FEZBWC2J8mnXAN2aTBboZ7HewnObE8CwROudZHmUM5oZ%2FUgd%2FJZQK8lvAm43uDRAbyW8gZ%2BZGq0EVerVGUKUSm%2FIdn8AQHdR4m7bue88WBwft9mSCeMOt1ncBwziOmJYI2ZR7ewNMPiCugmSsE4EyQ%2BQATJG6qORMGd4snEzc6B4shPIo4G1T7PgSm8PY5eUkPdF8JZ0VBtadbHXoJgnEhZQaODPj2gpODKJY5Yp4DOsLBFxWbvXN755KWylJm%2BoOd4zEL9Hpubuy2gyyfxh8oEfFutnYWdfB8PdESLWYvSqbElP9qo3u6KTmkhoacDauMNNjj0oy40DFV7Ql0aZj77xfGl7TJNHnIwgqOkenruYYNo6h724%2BzUQ7%2BvkCpZB%2BpGA562hYQiDxHVWOq0oDQl%2FQsoiY%2BcuI7iWq%2FZIBtHcXJ7kks%2Bh2fCNUPA82BzjnqktNts%2BRLdk1VSu%2BtqEn7QZCCsvEqk6FkfiOYkrsw092J8jsfIuEKypNjLxrKA9kiA19mxBD2suxQKCzwXGws7kEJvlhUiV9tArLIdZW0IORcxEzdzKmjtFhsjKy%2F44XYXdI5noQoRcvjZ1RMPACRqYg2V1%2BOwOepcOknRLLFdYgTkT5UApt%2FJhLM3jeFYprZV%2BZow2g8fP%2BU68hkKFWJj2yBbKqsrp25xkZX1DAjUw52IMYWaOhab8Kp05VrdNftqwRrymWF4OQSjbdfzmRZirK8FMJELEgER2PHjEAN9pGfLhCUiTJFbd5LBkOBMaxLr%2FA1SY9dXFz4RjzoU9ExfJCmx%2FI9FKEGT3n2cmzl2X42L3Jh%2BAbQq6sA%2BSs1kitoa4TAYgKHaoybHUDJ51oETdeI%2F9ThSmjWGkyLi5QAGWhL0BG1UsTyRGRJOldKBrYJeB8ljLJHfATWTEQBXBDnQexOHTB%2BUn44zExFE4vLytcu5NwpWrUxO%2F0ZICUGM7hGABXym0V6ZvDST0E370St9MIWQOTWngeoQHUTdCJUP04spMBMS8LSker9cReVQkULFDIZDFPrhTzBl6sed9wcZQTbL%2BBDqMyaN3RJPh%2Fanbx%2BIv%2BqgQdAa3M9Z5JmvYlh4qop%2BHo1F1W5gbOE9YKLgAnWytXElU4G8GtW47lhgFE6gaSs%2Bgs37sFvi0PPVvA5dnCBgILTwoKd%2F%2BDoL9F6inlM7H4rOTzD79KJgKlZO%2FZgt22UsKhrAaXU5ZcLrAglTVKJEmNJvORGN1vqrcfSMizfpsgbIe9zno%2BgBoKVXgIL%2FVI8dB1O5o%2FR3Suez%2FgD7M781ShjKpIIORM%2FnxG%2BjjhhgPwsn2IoXsPGPqYHXA63zJ07M2GPEykQwJBYLK808qYxuIew4frk52nhCsnCYmXiR6CuapvE1IwRB4%2FQftDbEn%2BAucIr1oxrLabRj9q4ae0%2BfXkHnteAJwXRbVkR0mctVSwEbqhJiMSZUp9DNbEDMmjX22m3ABpkrPQQTP3S1sib5pD2VRKRd%2BeNAjLYyT0hGrdjWJZy24OYXRoWQAIhGBZRxuBFMjjZQhpgrWo8SiFYbojcHO8V5DyscJpLTHyx9Fimassyo5U6WNtquUMYgccaHY5amgR3PQzq3ToNM5ABnoB9kuxsebqmYZm0R9qxJbFXCQ1UPyFIbxoUraTJFDpCk0Wk9GaYJKz%2F6oHwEP0Q14lMtlddQsOAU9zlYdMVHiT7RQP3XCmWYDcHCGbVRHGnHuwzScA0BaSBOGkz3lM8CArjrBsyEoV6Ys4qgDK3ykQQPZ3hCRGNXQTNNXbEb6tDiTDLKOyMzRhCFT%2BmAUmiYbV3YQVqFVp9dorv%2BTsLeCykS2b5yyu8AV7IS9cxcL8z4Kfwp%2BxJyYLv1OsxQCZwTB4a8BZ%2F5EdxTBJthApqyfd9u3ifr%2FWILTqq5VqgwMT9SOxbSGWLQJUUWCVi4k9tho9nEsbUh7U6NUsLmkYFXOhZ0kmamaJLRNJzSj%2Fqn4Mso6zb6iLLBXoaZ6AqeWCjHQm2lztnejYYM2eubnpBdKVLORZhudH3JF1waBJKA9%2BW8EhMj3Kzf0L4vi4k6RoHh3Z5YgmSZmk6ns4fjScjAoL8GoOECgqgYEBYUGFVO4FUv4%2FYtowhEmTs0vrvlD%2FCrisnoBNDAcUi%2FteY7OctFlmARQzjOItrrlKuPO6E2Ox93L4O%2F4DcgV%2FdZ7qR3VBwVQxP1GCieA4RIpweYJ5FoYrHxqRBdJjnqbsikA2Ictbb8vE1GYIo9dacK0REgDX4smy6GAkxlH1yCGGsk%2BtgiDhNKuKu3yNrMdxafmKTF632F8Vx4BNK57GvlFisrkjN9WDAtjsWA0ENT2e2nETUb%2Fn7qwhvGnrHuf5bX6Vh%2Fn3xffU3PeHdR%2BFA92i6ufT3AlyAREoNDh6chiMWTvjKjHDeRhOa9YkOQRq1vQXEMppAQVwHCuIcV2g5rBn6GmZZpTR7vnSD6ZmhdSl176gqKTXu5E%2BYbfL0adwNtHP7dT7t7b46DVZIkzaRJOM%2BS6KcrzYVg%2BT3wSRFRQashjfU18NutrKa%2F7PXbtuJvpIjbgPeqd%2BpjmRw6YKpnANFSQcpzTZgpSNJ6J7uiagAbir%2F8tNXJ%2FOsOnRh6iuIexxrmkIneAgz8QoLmiaJ8sLQrELVK2yn3wOHp57BAZJhDZjTBzyoRAuuZ4eoxHruY1pSb7qq79cIeAdOwin4GdgMeIMHeG%2BFZWYaiUQQyC5b50zKjYw97dFjAeY2I4Bnl105Iku1y0lMA1ZHolLx19uZnRdILcXKlZGQx%2FGdEqSsMRU1BIrFqRcV1qQOOHyxOLXEGcbRtAEsuAC2V4K3p5mFJ22IDWaEkk9ttf5Izb2LkD1MnrSwztXmmD%2FQi%2FEmVEFBfiKGmftsPwVaIoZanlKndMZsIBOskFYpDOq3QUs9aSbAAtL5Dbokus2G4%2FasthNMK5UQKCOhU97oaOYNGsTah%2BjfCKsZnTRn5TbhFX8ghg8CBYt%2FBjeYYYUrtUZ5jVij%2Fop7V5SsbA4mYTOwZ46hqdpbB6Qvq3AS2HHNkC15pTDIcDNGsMPXaBidXYPHc6PJAkRh29Vx8KcgX46LoUQBhRM%2B3SW6Opll%2FwgxxsPgKJKzr5QCmwkUxNbeg6Wj34SUnEzOemSuvS2OetRCO8Tyy%2BQbSKVJcqkia%2BGvDefFwMOmgnD7h81TUtMn%2BmRpyJJ349HhAnoWFTejhpYTL9G8N2nVg1qkXBeoS9Nw2fB27t7trm7d%2FQK7Cr4uoCeOQ7%2F8JfKT77KiDzLImESHw%2F0wf73QeHu74hxv7uihi4fTX%2BXEwAyQG3264dwv17aJ5N335Vt9sdrAXhPOAv8JFvzqyYXwfx8WYJaef1gMl98JRFyl5Mv5Uo%2FoVH5ww5OzLFsiTPDns7fS6EURSSWd%2F92BxMYQ8sBaH%2Bj%2BwthQPdVgDGpTfi%2BJQIWMD8xKqULliRH01rTeyF8x8q%2FGBEEEBrAJMPf25UQwi0b8tmqRXY7kIvNkzrkvRWLnxoGYEJsz8u4oOyMp8cHyaybb1HdMCaLApUE%2B%2F7xLIZGP6H9xuSEXp1zLIdjk5nBaMuV%2FyTDRRP8Y2ww5RO6d2D94o%2B6ucWIqUAvgHIHXhZsmDhjVLczmZ3ca0Cb3PpKwt2UtHVQ0BgFJsqqTsnzZPlKahRUkEu4qmkJt%2Bkqdae76ViWe3STan69yaF9%2BfESD2lcQshLHWVu4ovItXxO69bqC5p1nZLvI8NdQB9s9UNaJGlQ5mG947ipdDA0eTIw%2FA1zEdjWquIsQXXGIVEH0thC5M%2BW9pZe7IhAVnPJkYCCXN5a32HjN6nsvokEqRS44tGIs7s2LVTvcrHAF%2BRVmI8L4HUYk4x%2B67AxSMJKqCg8zrGOgvK9kNMdDrNiUtSWuHFpC8%2Fp5qIQrEo%2FH%2B1l%2F0cAwQ2nKmpWxKcMIuHY44Y6DlkpO48tRuUGBWT0FyHwSKO72Ud%2BtJUfdaZ4CWNijzZtlRa8%2BCkmO%2FEwHYfPZFU%2FhzjFWH7vnzHRMo%2BaF9u8qHSAiEkA2HjoNQPEwHsDKOt6hOoK3Ce%2F%2B%2F9boMWDa44I6FrQhdgS7OnNaSzwxWKZMcyHi6LN4WC6sSj0qm2PSOGBTvDs%2FGWJS6SwEN%2FULwpb4LQo9fYjUfSXRwZkynUazlSpvX9e%2BG2zor8l%2BYaMxSEomDdLHGcD6YVQPegTaA74H8%2BV4WvJkFUrjMLGLlvSZQWvi8%2FQA7yzQ8GPno%2F%2F5SJHRP%2FOqKObPCo81s%2F%2B6WgLqykYpGAgQZhVDEBPXWgU%2FWzFZjKUhSFInufPRiMAUULC6T11yL45ZrRoB4DzOyJShKXaAJIBS9wzLYIoCEcJKQW8GVCx4fihqJ6mshBUXSw3wWVj3grrHQlGNGhIDNNzsxQ3M%2BGWn6ASobIWC%2BLbYOC6UpahVO13Zs2zOzZC8z7FmA05JhUGyBsF4tsG0drcggIFzgg%2Fkpf3%2BCnAXKiMgIE8Jk%2FMhpkc8DUJEUzDSnWlQFme3d0sHZDrg7LavtsEX3cHwjCYA17pMTfx8Ajw9hHscN67hyo%2BRJQ4458RmPywXykkVcW688oVUrQhahpPRvTWPnuI0B%2BSkQu7dCyvLRyFYlC1LG1gRCIvn3rwQeINzZQC2KXq31FaR9UmVV2QeGVqBHjmE%2BVMd3b1fhCynD0pQNhCG6%2FWCDbKPyE7NRQzL3BzQAJ0g09aUzcQA6mUp9iZFK6Sbp%2FYbHjo%2B%2B7%2FWj8S4YNa%2BZdqAw1hDrKWFXv9%2BzaXpf8ZTDSbiqsxnwN%2FCzK5tPkOr4tRh2kY3Bn9JtalbIOI4b3F7F1vPQMfoDcdxMS8CW9m%2FNCW%2FHILTUVWQIPiD0j1A6bo8vsv6P1hCESl2abrSJWDrq5sSzUpwoxaCU9FtJyYH4QFMxDBpkkBR6kn0LMPO%2B5EJ7Z6bCiRoPedRZ%2FP0SSdii7ZnPAtVwwHUidcdyspwncz5uq6vvm4IEDbJVLUFCn%2FLvIHfooUBTkFO130FC7CmmcrKdgDJcid9mvVzsDSibOoXtIf9k6ABle3PmIxejodc4aob0QKS432srrCMndbfD454q52V01G4q913mC5HOsTzWF4h2No1av1VbcUgWAqyoZl%2B11PoFYnNv2HwAODeNRkHj%2B8SF1fcvVBu6MrehHAZK1Gm69ICcTKizykHgGFx7QdowTVAsYEF2tVc0Z6wLryz2FI1sc5By2znJAAmINndoJiB4sfPdPrTC8RnkW7KRCwxC6YvXg5ahMlQuMpoCSXjOlBy0Kij%2BbsCYPbGp8BdCBiLmLSAkEQRaieWo1SYvZIKJGj9Ur%2FeWHjiB7SOVdqMAVmpBvfRiebsFjger7DC%2B8kRFGtNrTrnnGD2GAJb8rQCWkUPYHhwXsjNBSkE6lGWUj5QNhK0DMNM2l%2BkXRZ0KLZaGsFSIdQz%2FHXDxf3%2FTE30%2BDgBKWGWdxElyLccJfEpjsnszECNoDGZpdwdRgCixeg9L4EPhH%2BRptvRMVRaahu4cySjS3P5wxAUCPkmn%2BrhyASpmiTaiDeggaIxYBmtLZDDhiWIJaBgzfCsAGUF1Q1SFZYyXDt9skCaxJsxK2Ms65dmdp5WAZyxik%2FzbrTQk5KmgxCg%2Ff45L0jywebOWUYFJQAJia7XzCV0x89rpp%2Ff3AVWhSPyTanqmik2SkD8A3Ml4NhIGLAjBXtPShwKYfi2eXtrDuKLk4QlSyTw1ftXgwqA2jUuopDl%2B5tfUWZNwBpEPXghzbBggYCw%2Fdhy0ntds2yeHCDKkF%2FYxQjNIL%2FF%2F37jLPHCKBO9ibwYCmuxImIo0ijV2Wbg3kSN2psoe8IsABv3RNFaF9uMyCtCYtqcD%2BqNOhwMlfARQUdJ2tUX%2BMNJqOwIciWalZsmEjt07tfa8ma4cji9sqz%2BQ9hWfmMoKEbIHPOQORbhQRHIsrTYlnVTNvcq1imqmmPDdVDkJgRcTgB8Sb6epCQVmFZe%2BjGDiNJQLWnfx%2BdrTKYjm0G8yH0ZAGMWzEJhUEQ4Maimgf%2Fbkvo8PLVBsZl152y5S8%2BHRDfZIMCbYZ1WDp4yrdchOJw8k6R%2B%2F2pHmydK4NIK2PHdFPHtoLmHxRDwLFb7eB%2BM4zNZcB9NrAgjVyzLM7xyYSY13ykWfIEEd2n5%2FiYp3ZdrCf7fL%2Ben%2BsIJu2W7E30MrAgZBD1rAAbZHPgeAMtKCg3NpSpYQUDWJu9bT3V7tOKv%2BNRiJc8JAKqqgCA%2FPNRBR7ChpiEulyQApMK1AyqcWnpSOmYh6yLiWkGJ2mklCSPIqN7UypWj3dGi5MvsHQ87MrB4VFgypJaFriaHivwcHIpmyi5LhNqtem4q0n8awM19Qk8BOS0EsqGscuuydYsIGsbT5GHnERUiMpKJl4ON7qjB4fEqlGN%2FhCky89232UQCiaeWpDYCJINXjT6xl4Gc7DxRCtgV0i1ma4RgWLsNtnEBRQFqZggCLiuyEydmFd7WlogpkCw5G1x4ft2psm3KAREwVwr1Gzl6RT7FDAqpVal34ewVm3VH4qn5mjGj%2BbYL1NgfLNeXDwtmYSpwzbruDKpTjOdgiIHDVQSb5%2FzBgSMbHLkxWWgghIh9QTFSDILixVwg0Eg1puooBiHAt7DzwJ7m8i8%2Fi%2BjHvKf0QDnnHVkVTIqMvIQImOrzCJwhSR7qYB5gSwL6aWL9hERHCZc4G2%2BJrpgHNB8eCCmcIWIQ6rSdyPCyftXkDlErUkHafHRlkOIjxGbAktz75bnh50dU7YHk%2BMz7wwstg6RFZb%2BTZuSOx1qqP5C66c0mptQmzIC2dlpte7vZrauAMm%2F7RfBYkGtXWGiaWTtwvAQiq2oD4YixPLXE2khB2FRaNRDTk%2B9sZ6K74Ia9VntCpN4BhJGJMT4Z5c5FhSepRCRWmBXqx%2BwhVZC4me4saDs2iNqXMuCl6iAZflH8fscC1sTsy4PHeC%2BXYuqMBMUun5YezKbRKmEPwuK%2BCLzijPEQgfhahQswBBLfg%2FGBgBiI4QwAqzJkkyYAWtjzSg2ILgMAgqxYfwERRo3zruBL9WOryUArSD8sQOcD7fvIODJxKFS615KFPsb68USBEPPj1orNzFY2xoTtNBVTyzBhPbhFH0PI5AtlJBl2aSgNPYzxYLw7XTDBDinmVoENwiGzmngrMo8OmnRP0Z0i0Zrln9DDFcnmOoBZjABaQIbPOJYZGqX%2BRCMlDDbElcjaROLDoualmUIQ88Kekk3iM4OQrADcxi3rJguS4MOIBIgKgXrjd1WkbCdqxJk%2F4efRIFsavZA7KvvJQqp3Iid5Z0NFc5aiMRzGN3vrpBzaMy4JYde3wr96PjN90AYOIbyp6T4zj8LoE66OGcX1Ef4Z3KoWLAUF4BTg7ug%2FAbkG5UNQXAMkQezujSHeir2uTThgd3gpyzDrbnEdDRH2W7U6PeRvBX1ZFMP5RM%2BZu6UUZZD8hDPHldVWntTCNk7To8IeOW9yn2wx0gmurwqC60AOde4r3ETi5pVMSDK8wxhoGAoEX9NLWHIR33VbrbMveii2jAJlrxwytTHbWNu8Y4N8vCCyZjAX%2FpcsfwXbLze2%2BD%2Bu33OGBoJyAAL3jn3RuEcdp5If8O%2Ba4NKWvxOTyDltG0IWoHhwVGe7dKkCWFT%2B%2Btm%2BhaBCikRUUMrMhYKZJKYoVuv%2FbsJzO8DwfVIInQq3g3BYypiz8baogH3r3GwqCwFtZnz4xMjAVOYnyOi5HWbFA8n0qz1OjSpHWFzpQOpvkNETZBGpxN8ybhtqV%2FDMUxd9uFZmBfKXMCn%2FSqkWJyKPnT6lq%2B4zBZni6fYRByJn6OK%2BOgPBGRAJluwGSk4wxjOOzyce%2FPKODwRlsgrVkdcsEiYrqYdXo0Er2GXi2GQZd0tNJT6c9pK1EEJG1zgDJBoTVuCXGAU8BKTvCO%2FcEQ1Wjk3Zzuy90JX4m3O5IlxVFhYkSUwuQB2up7jhvkm%2BbddRQu5F9s0XftGEJ9JSuSk%2BZachCbdU45fEqbugzTIUokwoAKvpUQF%2FCvLbWW5BNQFqFkJg2f30E%2F48StNe5QwBg8zz3YAJ82FZoXBxXSv4QDooDo79NixyglO9AembuBcx5Re3CwOKTHebOPhkmFC7wNaWtoBhFuV4AkEuJ0J%2B1pT0tLkvFVZaNzfhs%2FKd3%2BA9YsImlO4XK4vpCo%2FelHQi%2F9gkFg07xxnuXLt21unCIpDV%2BbbRxb7FC6nWYTsMFF8%2B1LUg4JFjVt3vqbuhHmDKbgQ4e%2BRGizRiO8ky05LQGMdL2IKLSNar0kNG7lHJMaXr5mLdG3nykgj6vB%2FKVijd1ARWkFEf3yiUw1v%2FWaQivVUpIDdSNrrKbjO5NPnxz6qTTGgYg03HgPhDrCFyYZTi3XQw3HXCva39mpLNFtz8AiEhxAJHpWX13gCTAwgm9YTvMeiqetdNQv6IU0hH0G%2BZManTqDLPjyrOse7WiiwOJCG%2BJ0pZYULhN8NILulmYYvmVcV2MjAfA39sGKqGdjpiPo86fecg65UPyXDIAOyOkCx5NQsLeD4gGVjTVDwOHWkbbBW0GeNjDkcSOn2Nq4cEssP54t9D749A7M1AIOBl0Fi0sSO5v3P7LCBrM6ZwFY6kp2FX6AcbGUdybnfChHPyu6WlRZ2Fwv9YM0RMI7kISRgR8HpQSJJOyTfXj%2F6gQKuihPtiUtlCQVPohUgzfezTg8o1b3n9pNZeco1QucaoXe40Fa5JYhqdTspFmxGtW9h5ezLFZs3j%2FN46f%2BS2rjYNC2JySXrnSAFhvAkz9a5L3pza8eYKHNoPrvBRESpxYPJdKVUxBE39nJ1chrAFpy4MMkf0qKgYALctGg1DQI1kIymyeS2AJNT4X240d3IFQb%2F0jQbaHJ2YRK8A%2Bls6WMhWmpCXYG5jqapGs5%2FeOJErxi2%2F2KWVHiPellTgh%2FfNl%2F2KYPKb7DUcAg%2BmCOPQFCiU9Mq%2FWLcU1xxC8aLePFZZlE%2BPCLzf7ey46INWRw2kcXySR9FDgByXzfxiNKwDFbUSMMhALPFSedyjEVM5442GZ4hTrsAEvZxIieSHGSgkwFh%2FnFNdrrFD4tBH4Il7fW6ur4J8Xaz7RW9jgtuPEXQsYk7gcMs2neu3zJwTyUerHKSh1iTBkj2YJh1SSOZL5pLuQbFFAvyO4k1Hxg2h99MTC6cTUkbONQIAnEfGsGkNFWRbuRyyaEZInM5pij73EA9rPIUfU4XoqQpHT9THZkW%2BoKFLvpyvTBMM69tN1Ydwv1LIEhHsC%2BueVG%2Bw%2BkyCPsvV3erRikcscHjZCkccx6VrBkBRusTDDd8847GA7p2Ucy0y0HdSRN6YIBciYa4vuXcAZbQAuSEmzw%2BH%2FAuOx%2BaH%2BtBL88H57D0MsqyiZxhOEQkF%2F8DR1d2hSPMj%2FsNOa5rxcUnBgH8ictv2J%2Bcb4BA4v3MCShdZ2vtK30vAwkobnEWh7rsSyhmos3WC93Gn9C4nnAd%2FPjMMtQfyDNZsOPd6XcAsnBE%2FmRHtHEyJMzJfZFLE9OvQa0i9kUmToJ0ZxknTgdl%2FXPV8xoh0K7wNHHsnBdvFH3sv52lU7UFteseLG%2FVanIvcwycVA7%2BBE1Ulyb20BvwUWZcMTKhaCcmY3ROpvonVMV4N7yBXTL7IDtHzQ4CCcqF66LjF3xUqgErKzolLyCG6Kb7irP%2FMVTCCwGRxfrPGpMMGvPLgJ881PHMNMIO09T5ig7AzZTX%2F5PLlwnJLDAPfuHynSGhV4tPqR3gJ4kg4c06c%2FF1AcjGytKm2Yb5jwMotF7vro4YDLWlnMIpmPg36NgAZsGA0W1spfLSue4xxat0Gdwd0lqDBOgIaMANykwwDKejt5YaNtJYIkrSgu0KjIg0pznY0SCd1qlC6R19g97UrWDoYJGlrvCE05J%2F5wkjpkre727p5PTRX5FGrSBIfJqhJE%2FIS876PaHFkx9pGTH3oaY3jJRvLX9Iy3Edoar7cFvJqyUlOhAEiOSAyYgVEGkzHdug%2BoRHIEOXAExMiTSKU9A6nmRC8mp8iYhwWdP2U%2F5EkFAdPrZw03YA3gSyNUtMZeh7dDCu8pF5x0VORCTgKp07ehy7NZqKTpIC4UJJ89lnboyAfy5OyXzXtuDRbtAFjZRSyGFTpFrXwkpjSLIQIG3N0Vj4BtzK3wdlkBJrO18MNsgseR4BysJilI0wI6ZahLhBFA0XBmV8d4LUzEcNVb0xbLjLTETYN8OEVqNxkt10W614dd1FlFFVTIgB7%2FBQQp1sWlNolpIu4ekxUTBV7NmxOFKEBmmN%2BnA7pvF78%2FRII5ZHA09OAiE%2F66MF6HQ%2BqVEJCHxwymukkNvzqHEh52dULPbVasfQMgTDyBZzx4007YiKdBuUauQOt27Gmy8ISclPmEUCIcuLbkb1mzQSqIa3iE0PJh7UMYQbkpe%2BhXjTJKdldyt2mVPwywoODGJtBV1lJTgMsuSQBlDMwhEKIfrvsxGQjHPCEfNfMAY2oxvyKcKPUbQySkKG6tj9AQyEW3Q5rpaDJ5Sns9ScLKeizPRbvWYAw4bXkrZdmB7CQopCH8NAmqbuciZChHN8lVGaDbCnmddnqO1PQ4ieMYfcSiBE5zzMz%2BJV%2F4eyzrzTEShvqSGzgWimkNxLvUj86iAwcZuIkqdB0VaIB7wncLRmzHkiUQpPBIXbDDLHBlq7vp9xwuC9AiNkIptAYlG7Biyuk8ILdynuUM1cHWJgeB%2BK3wBP%2FineogxkvBNNQ4AkW0hvpBOQGFfeptF2YTR75MexYDUy7Q%2F9uocGsx41O4IZhViw%2F2FvAEuGO5g2kyXBUijAggWM08bRhXg5ijgMwDJy40QeY%2FcQpUDZiIzmvskQpO5G1zyGZA8WByjIQU4jRoFJt56behxtHUUE%2Fom7Rj2psYXGmq3llVOCgGYKNMo4pzwntITtapDqjvQtqpjaJwjHmDzSVGLxMt12gEXAdLi%2FcaHSM3FPRGRf7dB7YC%2BcD2ho6oL2zGDCkjlf%2FDFoQVl8GS%2F56wur3rdV6ggtzZW60MRB3g%2BU1W8o8cvqIpMkctiGVMzXUFI7FacFLrgtdz4mTEr4aRAaQ2AFQaNeG7GX0yOJgMRYFziXdJf24kg%2FgBQIZMG%2FYcPEllRTVNoDYR6oSJ8wQNLuihfw81UpiKPm714bZX1KYjcXJdfclCUOOpvTxr9AAJevTY4HK%2FG7F3mUc3GOAKqh60zM0v34v%2BELyhJZqhkaMA8UMMOU90f8RKEJFj7EqepBVwsRiLbwMo1J2zrE2UYJnsgIAscDmjPjnzI8a719Wxp757wqmSJBjXowhc46QN4RwKIxqEE6E5218OeK7RfcpGjWG1jD7qND%2B%2FGTk6M56Ig4yMsU6LUW1EWE%2BfIYycVV1thldSlbP6ltdC01y3KUfkobkt2q01YYMmxpKRvh1Z48uNKzP%2FIoRIZ%2FF6buOymSnW8gICitpJjKWBscSb9JJKaWkvEkqinAJ2kowKoqkqZftRqfRQlLtKoqvTRDi2vg%2FRrPD%2Fd3a09J8JhGZlEkOM6znTsoMCsuvTmywxTCDhw5dd0GJOHCMPbsj3QLkTE3MInsZsimDQ3HkvthT7U9VA4s6G07sID0FW4SHJmRGwCl%2BMu4xf0ezqeXD2PtPDnwMPo86sbwDV%2B9PWcgFcARUVYm3hrFQrHcgMElFGbSM2A1zUYA3baWfheJp2AINmTJLuoyYD%2FOwA4a6V0ChBN97E8YtDBerUECv0u0TlxR5yhJCXvJxgyM73Bb6pyq0jTFJDZ4p1Am1SA6sh8nADd1hAcGBMfq4d%2FUfwnmBqe0Jun1n1LzrgKuZMAnxA3NtCN7Klf4BH%2B14B7ibBmgt0TGUafVzI4uKlpF7v8NmgNjg90D6QE3tbx8AjSAC%2BOA1YJvclyPKgT27QpIEgVYpbPYGBsnyCNrGz9XUsCHkW1QAHgL2STZk12QGqmvAB0NFteERkvBIH7INDsNW9KKaAYyDMdBEMzJiWaJHZALqDxQDWRntumSDPcplyFiI1oDpT8wbwe01AHhW6%2BvAUUBoGhY3CT2tgwehdPqU%2F4Q7ZLYvhRl%2FogOvR9O2%2BwkkPKW5vCTjD2fHRYXONCoIl4Jh1bZY0ZE1O94mMGn%2FdFSWBWzQ%2FVYk%2BGezi46RgiDv3EshoTmMSlioUK6MQEN8qeyK6FRninyX8ZPeUWjjbMJChn0n%2FyJvrq5bh5UcCAcBYSafTFg7p0jDgrXo2QWLb3WpSOET%2FHh4oSadBTvyDo10IufLzxiMLAnbZ1vcUmj3w7BQuIXjEZXifwukVxrGa9j%2BDXfpi12m1RbzYLg9J2wFergEwOxFyD0%2FJstNK06ZN2XdZSGWxcJODpQHOq4iKqjqkJUmPu1VczL5xTGUfCgLEYyNBCCbMBFT%2FcUP6pE%2FmujnHsSDeWxMbhrNilS5MyYR0nJyzanWXBeVcEQrRIhQeJA6Xt4f2eQESNeLwmC10WJVHqwx8SSyrtAAjpGjidcj1E2FYN0LObUcFQhafUKTiGmHWRHGsFCB%2BHEXgrzJEB5bp0QiF8ZHh11nFX8AboTD0PS4O1LqF8XBks2MpjsQnwKHF6HgaKCVLJtcr0XjqFMRGfKv8tmmykhLRzu%2BvqQ02%2BKpJBjaLt9ye1Ab%2BBbEBhy4EVdIJDrL2naV0o4wU8YZ2Lq04FG1mWCKC%2BUwkXOoAjneU%2FxHplMQo2cXUlrVNqJYczgYlaOEczVCs%2FOCgkyvLmTmdaBJc1iBLuKwmr6qtRnhowngsDxhzKFAi02tf8bmET8BO27ovJKF1plJwm3b0JpMh38%2BxsrXXg7U74QUM8ZCIMOpXujHntKdaRtsgyEZl5MClMVMMMZkZLNxH9%2Bb8fH6%2Bb8Lev30A9TuEVj9CqAdmwAAHBPbfOBFEATAPZ2CS0OH1Pj%2F0Q7PFUcC8hDrxESWdfgFRm%2B7vvWbkEppHB4T%2F1ApWnlTIqQwjcPl0VgS1yHSmD0OdsCVST8CQVwuiew1Y%2Bg3QGFjNMzwRB2DSsAk26cmA8lp2wIU4p93AUBiUHFGOxOajAqD7Gm6NezNDjYzwLOaSXRBYcWipTSONHjUDXCY4mMI8XoVCR%2FRrs%2FJLKXgEx%2BqkmeDlFOD1%2FyTQNDClRuiUyKYCllfMiQiyFkmuTz2vLsBNyRW%2Bxz%2B5FElFxWB28VjYIGZ0Yd%2B5wIjkcoMaggxswbT0pCmckRAErbRlIlcOGdBo4djTNO8FAgQ%2BlT6vPS60BwTRSUAM3ddkEAZiwtEyArrkiDRnS7LJ%2B2hwbzd2YDQagSgACpsovmjil5wfPuXq3GuH0CyE7FK3M4FgRaFoIkaodORrPx1%2BJpI9psyNYIFuJogZa0%2F1AhOWdlHQxdAgbwacsHqPZo8u%2FngAH2GmaTdhYnBfSDbBfh8CHq6Bx5bttP2%2BRdM%2BMAaYaZ0Y%2FADkbNCZuAyAVQa2OcXOeICmDn9Q%2FeFkDeFQg5MgHEDXq%2FtVjj%2Bjtd26nhaaolWxs1ixSUgOBwrDhRIGOLyOVk2%2FBc0UxvseQCO2pQ2i%2BKrfhu%2FWeBovNb5dJxQtJRUDv2mCwYVpNl2efQM9xQHnK0JwLYt%2FU0Wf%2BphiA4uw8G91slC832pmOTCAoZXohg1fewCZqLBhkOUBofBWpMPsqg7XEXgPfAlDo2U5WXjtFdS87PIqClCK5nW6adCeXPkUiTGx0emOIDQqw1yFYGHEVx20xKjJVYe0O8iLmnQr3FA9nSIQilUKtJ4ZAdcTm7%2BExseJauyqo30hs%2B1qSW211A1SFAOUgDlCGq7eTIcMAeyZkV1SQJ4j%2Fe1Smbq4HcjqgFbLAGLyKxlMDMgZavK5NAYH19Olz3la%2FQCTiVelFnU6O%2FGCvykqS%2FwZJDhKN9gBtSOp%2F1SP5VRgJcoVj%2Bkmf2wBgv4gjrgARBWiURYx8xENV3bEVUAAWWD3dYDKAIWk5opaCFCMR5ZjJExiCAw7gYiSZ2rkyTce4eNMY3lfGn%2B8p6%2BvBckGlKEXnA6Eota69OxDO9oOsJoy28BXOR0UoXNRaJD5ceKdlWMJlOFzDdZNpc05tkMGQtqeNF2lttZqNco1VtwXgRstLSQ6tSPChgqtGV5h2DcDReIQadaNRR6AsAYKL5gSFsCJMgfsaZ7DpKh8mg8Wz8V7H%2BgDnLuMxaWEIUPevIbClgap4dqmVWSrPgVYCzAoZHIa5z2Ocx1D%2FGvDOEqMOKLrMefWIbSWHZ6jbgA8qVBhYNHpx0P%2BjAgN5TB3haSifDcApp6yymEi6Ij%2FGsEpDYUgcHATJUYDUAmC1SCkJ4cuZXSAP2DEpQsGUjQmKJfJOvlC2x%2FpChkOyLW7KEoMYc5FDC4v2FGqSoRWiLsbPCiyg1U5yiHZVm1XLkHMMZL11%2Fyxyw0UnGig3MFdZklN5FI%2FqiT65T%2BjOXOdO7XbgWurOAZR6Cv9uu1cm5LjkXX4xi6mWn5r5NjBS0gTliHhMZI2WNqSiSphEtiCAwnafS11JhseDGHYQ5%2BbqWiAYiAv6Jsf79%2FVUs4cIl%2Bn6%2BWOjcgB%2F2l5TreoAV2717JzZbQIR0W1cl%2FdEqCy5kJ3ZSIHuU0vBoHooEpiHeQWVkkkOqRX27eD1FWw4BfO9CJDdKoSogQi3hAAwsPRFrN5RbX7bqLdBJ9JYMohWrgJKHSjVl1sy2xAG0E3sNyO0oCbSGOxCNBRRXTXenYKuwAoDLfnDcQaCwehUOIDiHAu5m5hMpKeKM4sIo3vxACakIxKoH2YWF2QM84e6F5C5hJU4g8uxuFOlAYnqtwxmHyNEawLW%2FPhoawJDrGAP0JYWHgAVUByo%2FbGdiv2T2EMg8gsS14%2FrAdzlOYazFE7w4OzxeKiWdm3nSOnQRRKXSlVo8HEAbBfyJMKqoq%2BSCcTSx5NDtbFwNlh8VhjGGDu7JG5%2FTAGAvniQSSUog0pNzTim8Owc6QTuSKSTXlQqwV3eiEnklS3LeSXYPXGK2VgeZBqNcHG6tZHvA3vTINhV0ELuQdp3t1y9%2BogD8Kk%2FW7QoRN1UWPqM4%2BxdygkFDPLoTaumKReKiLWoPHOfY54m3qPx4c%2B4pgY3MRKKbljG8w4wvz8pxk3AqKsy4GMAkAtmRjRMsCxbb4Q2Ds0Ia9ci8cMT6DmsJG00XaHCIS%2Bo3F8YVVeikw13w%2BOEDaCYYhC0ZE54kA4jpjruBr5STWeqQG6M74HHL6TZ3lXrd99ZX%2B%2B7LhNatQaZosuxEf5yRA15S9gPeHskBIq3Gcw81AGb9%2FO53DYi%2F5CsQ51EmEh8Rkg4vOciClpy4d04eYsfr6fyQkBmtD%2BP8sNh6e%2BXYHJXT%2FlkXxT4KXU5F2sGxYyzfniMMQkb9OjDN2C8tRRgTyL7GwozH14PrEUZc6oz05Emne3Ts5EG7WolDmU8OB1LDG3VrpQxp%2BpT0KYV5dGtknU64JhabdqcVQbGZiAxQAnvN1u70y1AnmvOSPgLI6uB4AuDGhmAu3ATkJSw7OtS%2F2ToPjqkaq62%2F7WFG8advGlRRqxB9diP07JrXowKR9tpRa%2BjGJ91zxNTT1h8I2PcSfoUPtd7NejVoH03EUcqSBuFZPkMZhegHyo2ZAITovmm3zAIdGFWxoNNORiMRShgwdYwFzkPw5PA4a5MIIQpmq%2Bnsp3YMuXt%2FGkXxLx%2FP6%2BZJS0lFyz4MunC3eWSGE8xlCQrKvhKUPXr0hjpAN9ZK4PfEDrPMfMbGNWcHDzjA7ngMxTPnT7GMHar%2BgMQQ3NwHCv4zH4BIMYvzsdiERi6gebRmerTsVwZJTRsL8dkZgxgRxmpbgRcud%2BYlCIRpPwHShlUSwuipZnx9QCsEWziVazdDeKSYU5CF7UVPAhLer3CgJOQXl%2Fzh575R5rsrmRnKAzq4POFdgbYBuEviM4%2BLVC15ssLNFghbTtHWerS1hDt5s4qkLUha%2FqpZXhWh1C6lTQAqCNQnaDjS7UGFBC6wTu8yFnKJnExCnAs3Ok9yj5KpfZESQ4lTy5pTGTnkAUpxI%2ByjEldJfSo4y0QhG4i4IwkRFGcjWY8%2BEzgYYJUK7BXQksLxAww%2FYYWBMhJILB9e8ePEJ4OP7z%2B4%2FwOQDl64iOYDp26DaONPxpKtBxq%2FaTzRGarm3VkPYTLJKx6Z%2FMw2YbBGseJhPMwhhNswrIkyvV2BYzrvZbxLpKwcWJhYmFtVZ%2BlPEq91FzVp1HlQY1bZVLqeNR9SAUn6n0E28k%2FUuGkNpP1DBI5ch%2FEehZfjUQ9aE41NhETExoPT2gGQz0IhWJbEOvTQ4wgcXCHHFBhewYUiFHuhRSAUVmEHeCRQHQkXGFwkAgyzREJCVN7TRnTon36Zw3tPhx4EALwNdwDv%2BJ41YSP4B2CQqz0EFgARZ4ESgBHQgROwAVn9GTI%2BHYexTUevLUeta4%2FDqKrbMVS%2BYqb8hUwYCrlgKtmAq1YCrFgKrd4qpXiqZcKn1oqdWipjYKpWwVPVYqW6xUpVipKqFR3QKjagVEtAqHpxUMTitsnFaJOKx2cVhswq35RVpyiq9lFVNIKnOQVMkgqtYxVNxiqQjFS7GKlSIVIsQqPIhUWwioigFQ%2B%2BKkN8VHr49HDw9Ebo9EDo9DTo9Crg9BDg9%2FWx7gWx7YWwlobYrOGxWPNisAaAHEyALpkAVDIAeWAArsABVXACYuAD5cAF6wAKFQAQqgAbVAAsoAAlQAUaYAfkwAvogBWQACOgAD9AAHSAAKT4GUdMiOvFngBTwCn2AZ7Dv6B6k%2F90B8%2ByRnkV144AIBoAMTQATGgAjNAA4YABgwABZgB%2FmQCwyAVlwCguASlwCEuAQFwB4uAMlwBYuAJlQAUVAAhUD2KgdpUDaJgaRMDFJgX5MC1JgWJEAokQCWRAHxEAWkQBMRADpEAMkQAYROAEecC484DRpwBDTnwNOdw05tjTmiNOYwtswhYFwLA7BYG4LA2BYGOLAwRYFuLAsxYFQJAohIEyJAMwkAwiQC0JAJgkAeiQBkJAFokAPCQA0JABwcD4Dgc4cDdDgaYcDIDgYgUC6CgWgUClCgUYUAVBQBOFAEYMALgwAgDA9QYAdIn8AZzeBB2L5EcWrenUT1KXienEsuJJ7x5U8XlTjc1NVzUyXFTGb1LlpUtWlTDIjqwE4LsagowoCi2gJLKAkpoBgJQNpAIhNqaEoneI6kiiqQ6Go%2Fn6j0cS%2Ba2gEU8gIHJ%2BBwfgZX4GL%2BBd%2FgW34FZ%2BBS%2FgUH4FN6BTegTvoEv6BJegRnYEF2A79gOvYDl2BdEjCkqkGtwXp0LNToIskOTXzh%2FF062yJ7AAAAEDAWAAABWhJ%2BKPEIJgBFxMVP7w2QJBGHASQnOBKXKFIdUK4igKA9IEaYJg%29%3Bsrc%3Aurl%28data%3Aapplication%2Fvnd%2Ems%2Dfontobject%3Bbase64%2Cn04AAEFNAAACAAIABAAAAAAABQAAAAAAAAABAJABAAAEAExQAAAAAAAAAAIAAAAAAAAAAAEAAAAAAAAAJxJ%2FLAAAAAAAAAAAAAAAAAAAAAAAACgARwBMAFkAUABIAEkAQwBPAE4AUwAgAEgAYQBsAGYAbABpAG4AZwBzAAAADgBSAGUAZwB1AGwAYQByAAAAeABWAGUAcgBzAGkAbwBuACAAMQAuADAAMAA5ADsAUABTACAAMAAwADEALgAwADAAOQA7AGgAbwB0AGMAbwBuAHYAIAAxAC4AMAAuADcAMAA7AG0AYQBrAGUAbwB0AGYALgBsAGkAYgAyAC4ANQAuADUAOAAzADIAOQAAADgARwBMAFkAUABIAEkAQwBPAE4AUwAgAEgAYQBsAGYAbABpAG4AZwBzACAAUgBlAGcAdQBsAGEAcgAAAAAAQlNHUAAAAAAAAAAAAAAAAAAAAAADAKncAE0TAE0ZAEbuFM3pjM%2FSEdmjKHUbyow8ATBE40IvWA3vTu8LiABDQ%2BpexwUMcm1SMnNryctQSiI1K5ZnbOlXKmnVV5YvRe6RnNMFNCOs1KNVpn6yZhCJkRtVRNzEufeIq7HgSrcx4S8h%2Fv4vnrrKc6oCNxmSk2uKlZQHBii6iKFoH0746ThvkO1kJHlxjrkxs%2BLWORaDQBEtiYJIR5IB9Bi1UyL4Rmr0BNigNkMzlKQmnofBHviqVzUxwdMb3NdCn69hy%2BpRYVKGVS%2F1tnsqv4LL7wCCPZZAZPT4aCShHjHJVNuXbmMrY5LeQaGnvAkXlVrJgKRAUdFjrWEah9XebPeQMj7KS7DIBAFt8ycgC5PLGUOHSE3ErGZCiViNLL5ZARfywnCoZaKQCu6NuFX42AEeKtKUGnr%2FCm2Cy8tpFhBPMW5Fxi4Qm4TkDWh4IWFDClhU2hRWosUWqcKLlgyXB%2BlSHaWaHiWlBAR8SeSgSPCQxdVQgzUixWKSTrIQEbU94viDctkvX%2BVSjJuUmV8L4CXShI11esnp0pjWNZIyxKHS4wVQ2ime1P4RnhvGw0aDN1OLAXGERsB7buFpFGGBAre4QEQR0HOIO5oYH305G%2BKspT%2FFupEGGafCCwxSe6ZUa%2B073rXHnNdVXE6eWvibUS27XtRzkH838mYLMBmYysZTM0EM3A1fbpCBYFccN1B%2FEnCYu%2FTgCGmr7bMh8GfYL%2BBfcLvB0gRagC09w9elfldaIy%2FhNCBLRgBgtCC7jAF63wLSMAfbfAlEggYU0bUA7ACCJmTDpEmJtI78w4%2FBO7dN7JR7J7ZvbYaUbaILSQsRBiF3HGk5fEg6p9unwLvn98r%2BvnsV%2B372uf1xBLq4qU%2F45fTuqaAP%2BpssmCCCTF0mhEow8ZXZOS8D7Q85JsxZ%2BAzok7B7O%2Ff6J8AzYBySZQB%2FQHYUSA%2BEeQhEWiS6AIQzgcsDiER4MjgMBAWDV4AgQ3g1eBgIdweCQmCjJEMkJ%2BPKRWyFHHmg1Wi%2F6xzUgA0LREoKJChwnQa9B%2B5RQZRB3IlBlkAnxyQNaANwHMowzlYSMCBgnbpzvqpl0iTJNCQidDI9ZrSYNIRBhHtUa5YHMHxyGEik9hDE0AKj72AbTCaxtHPUaKZdAZSnQTyjGqGLsmBStCejApUhg4uBMU6mATujEl%2BKdDPbI6Ag4vLr%2BhjY6lbjBeoLKnZl0UZgRX8gTySOeynZVz1wOq7e1hFGYIq%2BMhrGxDLak0PrwYzSXtcuyhXEhwOYofiW%2BEcI%2Fjw8P6IY6ed%2BetAbuqKp5QIapT77LnAe505lMuqL79a0ut4rWexzFttsOsLDy7zvtQzcq3U1qabe7tB0wHWVXji%2BzDbo8x8HyIRUbXnwUcklFv51fvTymiV%2BMXLSmGH9d9%2BaXpD5X6lao41anWGig7IwIdnoBY2ht%2FpO9mClLo4NdXHAsefqWUKlXJkbqPOFhMoR4aiA1BXqhRNbB2Xwi%2B7u%2FjpAoOpKJ0UX24EsrzMfHXViakCNcKjBxuQX8BO0ZqjJ3xXzf%2B61t2VXOSgJ8xu65QKgtN6FibPmPYsXbJRHHqbgATcSZxBqGiDiU4NNNsYBsKD0MIP%2FOfKnlk%2FLkaid%2FO2NbKeuQrwOB2Gq3YHyr6ALgzym5wIBnsdC1ZkoBFZSQXChZvlesPqvK2c5oHHT3Q65jYpNxnQcGF0EHbvYqoFw60WNlXIHQF2HQB7zD6lWjZ9rVqUKBXUT6hrkZOle0RFYII0V5ZYGl1JAP0Ud1fZZMvSomBzJ710j4Me8mjQDwEre5Uv2wQfk1ifDwb5ksuJQQ3xt423lbuQjvoIQByQrNDh1JxGFkOdlJvu%2FgFtuW0wR4cgd%2BZKesSV7QkNE2kw6AV4hoIuC02LGmTomyf8PiO6CZzOTLTPQ%2BHW06H%2Btx%2BbQ8LmDYg1pTFrp2oJXgkZTyeRJZM0C8aE2LpFrNVDuhARsN543%2FFV6klQ6Tv1OoZGXLv0igKrl%2FCmJxRmX7JJbJ998VSIPQRyDBICzl4JJlYHbdql30NvYcOuZ7a10uWRrgoieOdgIm4rlq6vNOQBuqESLbXG5lzdJGHw2m0sDYmODXbYGTfSTGRKpssTO95fothJCjUGQgEL4yKoGAF%2F0SrpUDNn8CBgBcSDQByAeNkCXp4S4Ro2Xh4OeaGRgR66PVOsU8bc6TR5%2FxTcn4IVMLOkXSWiXxkZQCbvKfmoAvQaKjO3EDKwkwqHChCDEM5loQRPd5ACBki1TjF772oaQhQbQ5C0lcWXPFOzrfsDGUXGrpxasbG4iab6eByaQkQfm0VFlP0ZsDkvvqCL6QXMUwCjdMx1ZOyKhTJ7a1GWAdOUcJ8RSejxNVyGs31OKMyRyBVoZFjqIkmKlLQ5eHMeEL4MkUf23cQ%2F1SgRCJ1dk4UdBT7OoyuNgLs0oCd8RnrEIb6QdMxT2QjD4zMrJkfgx5aDMcA4orsTtKCqWb%2FVeyceqa5OGSmB28YwH4rFbkQaLoUN8OQQYnD3w2eXpI4ScQfbCUZiJ4yMOIKLyyTc7BQ4uXUw6Ee6%2FxM%2B4Y67ngNBknxIPwuppgIhFcwJyr6EIj%2BLzNj%2FmfR2vhhRlx0BILZoAYruF0caWQ7YxO66UmeguDREAFHYuC7HJviRgVO6ruJH59h%2FC%2FPkgSle8xNzZJULLWq9JMDTE2fjGE146a1Us6PZDGYle6ldWRqn%2FpdpgHKNGrGIdkRK%2BKPETT9nKT6kLyDI8xd9A1FgWmXWRAIHwZ37WyZHOVyCadJEmMVz0MadMjDrPho%2BEIochkVC2xgGiwwsQ6DMv2P7UXqT4x7CdcYGId2BJQQa85EQKmCmwcRejQ9Bm4oATENFPkxPXILHpMPUyWTI5rjNOsIlmEeMbcOCEqInpXACYQ9DDxmFo9vcmsDblcMtg4tqBerNngkIKaFJmrQAPnq1dEzsMXcwjcHdfdCibcAxxA%2Bq%2Fj9m3LM%2FO7WJka4tSidVCjsvo2lQ%2F2ewyoYyXwAYyr2PlRoR5MpgVmSUIrM3PQxXPbgjBOaDQFIyFMJvx3Pc5RSYj12ySVF9fwFPQu2e2KWVoL9q3Ayv3IzpGHUdvdPdrNUdicjsTQ2ISy7QU3DrEytIjvbzJnAkmANXjAFERA0MUoPF3%2F5KFmW14bBNOhwircYgMqoDpUMcDtCmBE82QM2YtdjVLB4kBuKho%2FbcwQdeboqfQartuU3CsCf%2BcXkgYAqp%2F0Ee3RorAZt0AvvOCSI4JICIlGlsV0bsSid%2FNIEALAAzb6HAgyWHBps6xAOwkJIGcB82CxRQq4sJf3FzA70A%2BTRqcqjEMETCoez3mkPcpnoALs0ugJY8kQwrC%2BJE5ik3w9rzrvDRjAQnqgEVvdGrNwlanR0SOKWzxOJOvLJhcd8Cl4AshACUkv9czdMkJCVQSQhp6kp7StAlpVRpK0t0SW6LHeBJnE2QchB5Ccu8kxRghZXGIgZIiSj7gEKMJDClcnX6hgoqJMwiQDigIXg3ioFLCgDgjPtYHYpsF5EiA4kcnN18MZtOrY866dEQAb0FB34OGKHGZQjwW%2FWDHA60cYFaI%2FPjpzquUqdaYGcIq%2BmLez3WLFFCtNBN2QJcrlcoELgiPku5R5dSlJFaCEqEZle1AQzAKC%2B1SotMcBNyQUFuRHRF6OlimSBgjZeTBCwLyc6A%2BP%2FoFRchXTz5ADknYJHxzrJ5pGuIKRQISU6WyKTBBjD8WozmVYWIsto1AS5rxzKlvJu4E%2FvwOiKxRtCWsDM%2BeTHUrmwrCK5BIfMzGkD%2B0Fk5LzBs0jMYXktNDblB06LMNJ09U8pzSLmo14MS0OMjcdrZ31pyQqxJJpRImlSvfYAK8inkYU52QY2FPEVsjoWewpwhRp5yAuNpkqhdb7ku9Seefl2D0B8SMTFD90xi4CSOwwZy9IKkpMtI3FmFUg3%2FkFutpQGNc3pCR7gvC4sgwbupDu3DyEN%2BW6YGLNM21jpB49irxy9BSlHrVDlnihGKHwPrbVFtc%2Bh1rVQKZduxIyojccZIIcOCmhEnC7UkY68WXKQgLi2JCDQkQWJRQuk60hZp0D3rtCTINSeY9Ej2kIKYfGxwOs4j9qMM7fYZiipzgcf7TamnehqdhsiMiCawXnz4xAbyCkLAx5EGbo3Ax1u3dUIKnTxIaxwQTHehPl3V491H0%2BbC5zgpGz7Io%2BmjdhKlPJ01EeMpM7UsRJMi1nGjmJg35i6bQBAAxjO%2FENJubU2mg3ONySEoWklCwdABETcs7ck3jgiuU9pcKKpbgn%2B3YlzV1FzIkB6pmEDOSSyDfPPlQskznctFji0kpgZjW5RZe6x9kYT4KJcXg0bNiCyif%2BpZACCyRMmYsfiKmN9tSO65F0R2OO6ytlEhY5Sj6uRKfFxw0ijJaAx%2Fk3QgnAFSq27%2F2i4GEBA%2BUvTJKK%2F9eISNvG46Em5RZfjTYLdeD8kdXHyrwId%2FDQZUaMCY4gGbke2C8vfjgV%2FY9kkRQOJIn%2FxM9INZSpiBnqX0Q9GlQPpPKAyO5y%2BW5NMPSRdBCUlmuxl40ZfMCnf2Cp044uI9WLFtCi4YVxKjuRCOBWIb4XbIsGdbo4qtMQnNOQz4XDSui7W%2FN6l54qOynCqD3DpWQ%2BmpD7C40D8BZEWGJX3tlAaZBMj1yjvDYKwCJBa201u6nBKE5UE%2B7QSEhCwrXfbRZylAaAkplhBWX50dumrElePyNMRYUrC99UmcSSNgImhFhDI4BXjMtiqkgizUGCrZ8iwFxU6fQ8GEHCFdLewwxYWxgScAYMdMLmcZR6b7rZl95eQVDGVoUKcRMM1ixXQtXNkBETZkVVPg8LoSrdetHzkuM7DjZRHP02tCxA1fmkXKF3VzfN1pc1cv%2F8lbTIkkYpqKM9VOhp65ktYk%2BQ46myFWBapDfyWUCnsnI00QTBQmuFjMZTcd0V2NQ768Fhpby04k2IzNR1wKabuGJqYWwSly6ocMFGTeeI%2BejsWDYgEvr66QgqdcIbFYDNgsm0x9UHY6SCd5%2B7tpsLpKdvhahIDyYmEJQCqMqtCF6UlrE5GXRmbu%2Bvtm3BFSxI6ND6UxIE7GsGMgWqghXxSnaRJuGFveTcK5ZVSPJyjUxe1dKgI6kNF7EZhIZs8y8FVqwEfbM0Xk2ltORVDKZZM40SD3qQoQe0orJEKwPfZwm3YPqwixhUMOndis6MhbmfvLBKjC8sKKIZKbJk8L11oNkCQzCgvjhyyEiQSuJcgCQSG4Mocfgc0Hkwcjal1UNgP0CBPikYqBIk9tONv4kLtBswH07vUCjEaHiFGlLf8MgXKzSgjp2HolRRccAOh0ILHz9qlGgIFkwAnzHJRjWFhlA7ROwINyB5HFj59PRZHFor6voq7l23EPNRwdWhgawqbivLSjRA4htEYUFkjESu67icTg5S0aW1sOkCiIysfJ9UnIWevOOLGpepcBxy1wEhd2WI3AZg7sr9WBmHWyasxMcvY%2FiOmsLtHSWNUWEGk9hScMPShasUA1AcHOtRZlqMeQ0OzYS9vQvYUjOLrzP07BUAFikcJNMi7gIxEw4pL1G54TcmmmoAQ5s7TGWErJZ2Io4yQ0ljRYhL8H5e62oDtLF8aDpnIvZ5R3GWJyAugdiiJW9hQAVTsnCBHhwu7rkBlBX6r3b7ejEY0k5GGeyKv66v%2B6dg7mcJTrWHbtMywbedYqCQ0FPwoytmSWsL8WTtChZCKKzEF7vP6De4x2BJkkniMgSdWhbeBSLtJZR9CTHetK1xb34AYIJ37OegYIoPVbXgJ%2FqDQK%2BbfCtxQRVKQu77WzOoM6SGL7MaZwCGJVk46aImai9fmam%2BWpHG%2B0BtQPWUgZ7RIAlPq6lkECUhZQ2gqWkMYKcYMYaIc4gYCDFHYa2d1nzp3%2BJ1eCBay8IYZ0wQRKGAqvCuZ%2FUgbQPyllosq%2BXtfKIZOzmeJqRazpmmoP%2F76YfkjzV2NlXTDSBYB04SVlNQsFTbGPk1t%2FI4Jktu0XSgifO2ozFOiwd%2F0SssJDn0dn4xqk4GDTTKX73%2FwQyBLdqgJ%2BWx6AQaba3BA9CKEzjtQYIfAsiYamapq80LAamYjinlKXUkxdpIDk0puXUEYzSalfRibAeDAKpNiqQ0FTwoxuGYzRnisyTotdVTclis1LHRQCy%2FqqL8oUaQzWRxilq5Mi0IJGtMY02cGLD69vGjkj3p6pGePKI8bkBv5evq8SjjyU04vJR2cQXQwSJyoinDsUJHCQ50jrFTT7yRdbdYQMB3MYCb6uBzJ9ewhXYPAIZSXfeEQBZZ3GPN3Nbhh%2FwkvAJLXnQMdi5NYYZ5GHE400GS5rXkOZSQsdZgIbzRnF9ueLnsfQ47wHAsirITnTlkCcuWWIUhJSbpM3wWhXNHvt2xUsKKMpdBSbJnBMcihkoDqAd1Zml%2FR4yrzow1Q2A5G%2Bkzo%2FRhRxQS2lCSDRV8LlYLBOOoo1bF4jwJAwKMK1tWLHlu9i0j4Ig8qVm6wE1DxXwAwQwsaBWUg2pOOol2dHxyt6npwJEdLDDVYyRc2D0HbcbLUJQj8gPevQBUBOUHXPrsAPBERICpnYESeu2OHotpXQxRGlCCtLdIsu23MhZVEoJg8Qumj%2FUMMc34IBqTKLDTp76WzL%2FdMjCxK7MjhiGjeYAC%2Fkj%2FjY%2FRde7hpSM1xChrog6yZ7OWTuD56xBJnGFE%2BpT2ElSyCnJcwVzCjkqeNLfMEJqKW0G7OFIp0G%2B9mh50I9o8k1tpCY0xYqFNIALgIfc2me4n1bmJnRZ89oepgLPT0NTMLNZsvSCZAc3TXaNB07vail36%2FdBySis4m9%2FDR8izaLJW6bWCkVgm5T%2Bius3ZXq4xI%2BGnbveLbdRwF2mNtsrE0JjYc1AXknCOrLSu7Te%2Fr4dPYMCl5qtiHNTn%2BTPbh1jCBHH%2BdMJNhwNgs3nT%2BOhQoQ0vYif56BMG6WowAcHR3DjQolxLzyVekHj00PBAaW7IIAF1EF%2BuRIWyXjQMAs2chdpaKPNaB%2BkSezYt0%2BCA04sOg5vx8Fr7Ofa9sUv87h7SLAUFSzbetCCZ9pmyLt6l6%2FTzoA1%2FZBG9bIUVHLAbi%2FkdBFgYGyGwRQGBpkqCEg2ah9UD6EedEcEL3j4y0BQQCiExEnocA3SZboh%2Bepgd3YsOkHskZwPuQ5OoyA0fTA5AXrHcUOQF%2BzkJHIA7PwCDk1gGVmGUZSSoPhNf%2BTklauz98QofOlCIQ%2FtCD4dosHYPqtPCXB3agggQQIqQJsSkB%2Bqn0rkQ1toJjON%2FOtCIB9RYv3PqRA4C4U68ZMlZn6BdgEvi2ziU%2BTQ6NIw3ej%2BAtDwMGEZk7e2IjxUWKdAxyaw9OCwSmeADTPPleyk6UhGDNXQb%2B%2BW6Uk4q6F7%2Frg6WVTo82IoCxSIsFDrav4EPHphD3u4hR53WKVvYZUwNCCeM4PMBWzK%2BEfIthZOkuAwPo5C5jgoZgn6dUdvx5rIDmd58cXXdKNfw3l%2BwM2UjgrDJeQHhbD7HW2QDoZMCujgIUkk5Fg8VCsdyjOtnGRx8wgKRPZN5dR0zPUyfGZFVihbFRniXZFOZGKPnEQzU3AnD1KfR6weHW2XS6KbPJxUkOTZsAB9vTVp3Le1F8q5l%2BDMcLiIq78jxAImD2pGFw0VHfRatScGlK6SMu8leTmhUSMy8Uhdd6xBiH3Gdman4tjQGLboJfqz6fL2WKHTmrfsKZRYX6BTDjDldKMosaSTLdQS7oDisJNqAUhw1PfTlnacCO8vl8706Km1FROgLDmudzxg%2BEWTiArtHgLsRrAXYWdB0NmToNCJdKm0KWycZQqb%2BMw76Qy29iQ5up%2FX7oyw8QZ75kP5F6iJAJz6KCmqxz8fEa%2FxnsMYcIO%2FvEkGRuMckhr4rIeLrKaXnmIzlNLxbFspOphkcnJdnz%2FChp%2FVlpj2P7jJQmQRwGnltkTV5dbF9fE3%2FfxoSqTROgq9wFUlbuYzYcasE0ouzBo%2BdDCDzxKAfhbAZYxQiHrLzV2iVexnDX%2FQnT1fsT%2Fxuhu1ui5qIytgbGmRoQkeQooO8eJNNZsf0iALur8QxZFH0nCMnjerYQqG1pIfjyVZWxhVRznmmfLG00BcBWJE6hzQWRyFknuJnXuk8A5FRDCulwrWASSNoBtR%2BCtGdkPwYN2o7DOw%2FVGlCZPusRBFXODQdUM5zeHDIVuAJBLqbO%2Ff9Qua%2BpDqEPk230Sob9lEZ8BHiCorjVghuI0lI4JDgHGRDD%2FprQ84B1pVGkIpVUAHCG%2Biz3Bn3qm2AVrYcYWhock4jso5%2BJ7HfHVj4WMIQdGctq3psBCVVzupQOEioBGA2Bk%2BUILT7%2BVoX5mdxxA5fS42gISQVi%2FHTzrgMxu0fY6hE1ocUwwbsbWcezrY2n6S8%2F6cxXkOH4prpmPuFoikTzY7T85C4T2XYlbxLglSv2uLCgFv8Quk%2FwdesUdWPeHYIH0R729JIisN9Apdd4eB10aqwXrPt%2BSu9mA8k8n1sjMwnfsfF2j3jMUzXepSHmZ%2FBfqXvzgUNQQWOXO8YEuFBh4QTYCkOAPxywpYu1VxiDyJmKVcmJPGWk%2Fgc3Pov02StyYDahwmzw3E1gYC9wkupyWfDqDSUMpCTH5e5N8B%2F%2FlHiMuIkTNw4USHrJU67bjXGqNav6PBuQSoqTxc8avHoGmvqNtXzIaoyMIQIiiUHIM64cXieouplhNYln7qgc4wBVAYR104kO%2BCvKqsg4yIUlFNThVUAKZxZt1XA34h3TCUUiXVkZ0w8Hh2R0Z5L0b4LZvPd%2Fp1gi%2F07h8qfwHrByuSxglc9cI4QIg2oqvC%2Fqm0i7tjPLTgDhoWTAKDO2ONW5oe%2B%2FeKB9vZB8K6C25yCZ9RFVMnb6NRdRjyVK57CHHSkJBfnM2%2Fj4ODUwRkqrtBBCrDsDpt8jhZdXoy%2F1BCqw3sSGhgGGy0a5Jw6BP%2FTExoCmNFYjZl248A0osgPyGEmRA%2BfAsqPVaNAfytu0vuQJ7rk3J4kTDTR2AlCHJ5cls26opZM4w3jMULh2YXKpcqGBtuleAlOZnaZGbD6DHzMd6i2oFeJ8z9XYmalg1Szd%2FocZDc1C7Y6vcALJz2lYnTXiWEr2wawtoR4g3jvWUU2Ngjd1cewtFzEvM1NiHZPeLlIXFbBPawxNgMwwAlyNSuGF3zizVeOoC9bag1qRAQKQE%2FEZBWC2J8mnXAN2aTBboZ7HewnObE8CwROudZHmUM5oZ%2FUgd%2FJZQK8lvAm43uDRAbyW8gZ%2BZGq0EVerVGUKUSm%2FIdn8AQHdR4m7bue88WBwft9mSCeMOt1ncBwziOmJYI2ZR7ewNMPiCugmSsE4EyQ%2BQATJG6qORMGd4snEzc6B4shPIo4G1T7PgSm8PY5eUkPdF8JZ0VBtadbHXoJgnEhZQaODPj2gpODKJY5Yp4DOsLBFxWbvXN755KWylJm%2BoOd4zEL9Hpubuy2gyyfxh8oEfFutnYWdfB8PdESLWYvSqbElP9qo3u6KTmkhoacDauMNNjj0oy40DFV7Ql0aZj77xfGl7TJNHnIwgqOkenruYYNo6h724%2BzUQ7%2BvkCpZB%2BpGA562hYQiDxHVWOq0oDQl%2FQsoiY%2BcuI7iWq%2FZIBtHcXJ7kks%2Bh2fCNUPA82BzjnqktNts%2BRLdk1VSu%2BtqEn7QZCCsvEqk6FkfiOYkrsw092J8jsfIuEKypNjLxrKA9kiA19mxBD2suxQKCzwXGws7kEJvlhUiV9tArLIdZW0IORcxEzdzKmjtFhsjKy%2F44XYXdI5noQoRcvjZ1RMPACRqYg2V1%2BOwOepcOknRLLFdYgTkT5UApt%2FJhLM3jeFYprZV%2BZow2g8fP%2BU68hkKFWJj2yBbKqsrp25xkZX1DAjUw52IMYWaOhab8Kp05VrdNftqwRrymWF4OQSjbdfzmRZirK8FMJELEgER2PHjEAN9pGfLhCUiTJFbd5LBkOBMaxLr%2FA1SY9dXFz4RjzoU9ExfJCmx%2FI9FKEGT3n2cmzl2X42L3Jh%2BAbQq6sA%2BSs1kitoa4TAYgKHaoybHUDJ51oETdeI%2F9ThSmjWGkyLi5QAGWhL0BG1UsTyRGRJOldKBrYJeB8ljLJHfATWTEQBXBDnQexOHTB%2BUn44zExFE4vLytcu5NwpWrUxO%2F0ZICUGM7hGABXym0V6ZvDST0E370St9MIWQOTWngeoQHUTdCJUP04spMBMS8LSker9cReVQkULFDIZDFPrhTzBl6sed9wcZQTbL%2BBDqMyaN3RJPh%2Fanbx%2BIv%2BqgQdAa3M9Z5JmvYlh4qop%2BHo1F1W5gbOE9YKLgAnWytXElU4G8GtW47lhgFE6gaSs%2Bgs37sFvi0PPVvA5dnCBgILTwoKd%2F%2BDoL9F6inlM7H4rOTzD79KJgKlZO%2FZgt22UsKhrAaXU5ZcLrAglTVKJEmNJvORGN1vqrcfSMizfpsgbIe9zno%2BgBoKVXgIL%2FVI8dB1O5o%2FR3Suez%2FgD7M781ShjKpIIORM%2FnxG%2BjjhhgPwsn2IoXsPGPqYHXA63zJ07M2GPEykQwJBYLK808qYxuIew4frk52nhCsnCYmXiR6CuapvE1IwRB4%2FQftDbEn%2BAucIr1oxrLabRj9q4ae0%2BfXkHnteAJwXRbVkR0mctVSwEbqhJiMSZUp9DNbEDMmjX22m3ABpkrPQQTP3S1sib5pD2VRKRd%2BeNAjLYyT0hGrdjWJZy24OYXRoWQAIhGBZRxuBFMjjZQhpgrWo8SiFYbojcHO8V5DyscJpLTHyx9Fimassyo5U6WNtquUMYgccaHY5amgR3PQzq3ToNM5ABnoB9kuxsebqmYZm0R9qxJbFXCQ1UPyFIbxoUraTJFDpCk0Wk9GaYJKz%2F6oHwEP0Q14lMtlddQsOAU9zlYdMVHiT7RQP3XCmWYDcHCGbVRHGnHuwzScA0BaSBOGkz3lM8CArjrBsyEoV6Ys4qgDK3ykQQPZ3hCRGNXQTNNXbEb6tDiTDLKOyMzRhCFT%2BmAUmiYbV3YQVqFVp9dorv%2BTsLeCykS2b5yyu8AV7IS9cxcL8z4Kfwp%2BxJyYLv1OsxQCZwTB4a8BZ%2F5EdxTBJthApqyfd9u3ifr%2FWILTqq5VqgwMT9SOxbSGWLQJUUWCVi4k9tho9nEsbUh7U6NUsLmkYFXOhZ0kmamaJLRNJzSj%2Fqn4Mso6zb6iLLBXoaZ6AqeWCjHQm2lztnejYYM2eubnpBdKVLORZhudH3JF1waBJKA9%2BW8EhMj3Kzf0L4vi4k6RoHh3Z5YgmSZmk6ns4fjScjAoL8GoOECgqgYEBYUGFVO4FUv4%2FYtowhEmTs0vrvlD%2FCrisnoBNDAcUi%2FteY7OctFlmARQzjOItrrlKuPO6E2Ox93L4O%2F4DcgV%2FdZ7qR3VBwVQxP1GCieA4RIpweYJ5FoYrHxqRBdJjnqbsikA2Ictbb8vE1GYIo9dacK0REgDX4smy6GAkxlH1yCGGsk%2BtgiDhNKuKu3yNrMdxafmKTF632F8Vx4BNK57GvlFisrkjN9WDAtjsWA0ENT2e2nETUb%2Fn7qwhvGnrHuf5bX6Vh%2Fn3xffU3PeHdR%2BFA92i6ufT3AlyAREoNDh6chiMWTvjKjHDeRhOa9YkOQRq1vQXEMppAQVwHCuIcV2g5rBn6GmZZpTR7vnSD6ZmhdSl176gqKTXu5E%2BYbfL0adwNtHP7dT7t7b46DVZIkzaRJOM%2BS6KcrzYVg%2BT3wSRFRQashjfU18NutrKa%2F7PXbtuJvpIjbgPeqd%2BpjmRw6YKpnANFSQcpzTZgpSNJ6J7uiagAbir%2F8tNXJ%2FOsOnRh6iuIexxrmkIneAgz8QoLmiaJ8sLQrELVK2yn3wOHp57BAZJhDZjTBzyoRAuuZ4eoxHruY1pSb7qq79cIeAdOwin4GdgMeIMHeG%2BFZWYaiUQQyC5b50zKjYw97dFjAeY2I4Bnl105Iku1y0lMA1ZHolLx19uZnRdILcXKlZGQx%2FGdEqSsMRU1BIrFqRcV1qQOOHyxOLXEGcbRtAEsuAC2V4K3p5mFJ22IDWaEkk9ttf5Izb2LkD1MnrSwztXmmD%2FQi%2FEmVEFBfiKGmftsPwVaIoZanlKndMZsIBOskFYpDOq3QUs9aSbAAtL5Dbokus2G4%2FasthNMK5UQKCOhU97oaOYNGsTah%2BjfCKsZnTRn5TbhFX8ghg8CBYt%2FBjeYYYUrtUZ5jVij%2Fop7V5SsbA4mYTOwZ46hqdpbB6Qvq3AS2HHNkC15pTDIcDNGsMPXaBidXYPHc6PJAkRh29Vx8KcgX46LoUQBhRM%2B3SW6Opll%2FwgxxsPgKJKzr5QCmwkUxNbeg6Wj34SUnEzOemSuvS2OetRCO8Tyy%2BQbSKVJcqkia%2BGvDefFwMOmgnD7h81TUtMn%2BmRpyJJ349HhAnoWFTejhpYTL9G8N2nVg1qkXBeoS9Nw2fB27t7trm7d%2FQK7Cr4uoCeOQ7%2F8JfKT77KiDzLImESHw%2F0wf73QeHu74hxv7uihi4fTX%2BXEwAyQG3264dwv17aJ5N335Vt9sdrAXhPOAv8JFvzqyYXwfx8WYJaef1gMl98JRFyl5Mv5Uo%2FoVH5ww5OzLFsiTPDns7fS6EURSSWd%2F92BxMYQ8sBaH%2Bj%2BwthQPdVgDGpTfi%2BJQIWMD8xKqULliRH01rTeyF8x8q%2FGBEEEBrAJMPf25UQwi0b8tmqRXY7kIvNkzrkvRWLnxoGYEJsz8u4oOyMp8cHyaybb1HdMCaLApUE%2B%2F7xLIZGP6H9xuSEXp1zLIdjk5nBaMuV%2FyTDRRP8Y2ww5RO6d2D94o%2B6ucWIqUAvgHIHXhZsmDhjVLczmZ3ca0Cb3PpKwt2UtHVQ0BgFJsqqTsnzZPlKahRUkEu4qmkJt%2Bkqdae76ViWe3STan69yaF9%2BfESD2lcQshLHWVu4ovItXxO69bqC5p1nZLvI8NdQB9s9UNaJGlQ5mG947ipdDA0eTIw%2FA1zEdjWquIsQXXGIVEH0thC5M%2BW9pZe7IhAVnPJkYCCXN5a32HjN6nsvokEqRS44tGIs7s2LVTvcrHAF%2BRVmI8L4HUYk4x%2B67AxSMJKqCg8zrGOgvK9kNMdDrNiUtSWuHFpC8%2Fp5qIQrEo%2FH%2B1l%2F0cAwQ2nKmpWxKcMIuHY44Y6DlkpO48tRuUGBWT0FyHwSKO72Ud%2BtJUfdaZ4CWNijzZtlRa8%2BCkmO%2FEwHYfPZFU%2FhzjFWH7vnzHRMo%2BaF9u8qHSAiEkA2HjoNQPEwHsDKOt6hOoK3Ce%2F%2B%2F9boMWDa44I6FrQhdgS7OnNaSzwxWKZMcyHi6LN4WC6sSj0qm2PSOGBTvDs%2FGWJS6SwEN%2FULwpb4LQo9fYjUfSXRwZkynUazlSpvX9e%2BG2zor8l%2BYaMxSEomDdLHGcD6YVQPegTaA74H8%2BV4WvJkFUrjMLGLlvSZQWvi8%2FQA7yzQ8GPno%2F%2F5SJHRP%2FOqKObPCo81s%2F%2B6WgLqykYpGAgQZhVDEBPXWgU%2FWzFZjKUhSFInufPRiMAUULC6T11yL45ZrRoB4DzOyJShKXaAJIBS9wzLYIoCEcJKQW8GVCx4fihqJ6mshBUXSw3wWVj3grrHQlGNGhIDNNzsxQ3M%2BGWn6ASobIWC%2BLbYOC6UpahVO13Zs2zOzZC8z7FmA05JhUGyBsF4tsG0drcggIFzgg%2Fkpf3%2BCnAXKiMgIE8Jk%2FMhpkc8DUJEUzDSnWlQFme3d0sHZDrg7LavtsEX3cHwjCYA17pMTfx8Ajw9hHscN67hyo%2BRJQ4458RmPywXykkVcW688oVUrQhahpPRvTWPnuI0B%2BSkQu7dCyvLRyFYlC1LG1gRCIvn3rwQeINzZQC2KXq31FaR9UmVV2QeGVqBHjmE%2BVMd3b1fhCynD0pQNhCG6%2FWCDbKPyE7NRQzL3BzQAJ0g09aUzcQA6mUp9iZFK6Sbp%2FYbHjo%2B%2B7%2FWj8S4YNa%2BZdqAw1hDrKWFXv9%2BzaXpf8ZTDSbiqsxnwN%2FCzK5tPkOr4tRh2kY3Bn9JtalbIOI4b3F7F1vPQMfoDcdxMS8CW9m%2FNCW%2FHILTUVWQIPiD0j1A6bo8vsv6P1hCESl2abrSJWDrq5sSzUpwoxaCU9FtJyYH4QFMxDBpkkBR6kn0LMPO%2B5EJ7Z6bCiRoPedRZ%2FP0SSdii7ZnPAtVwwHUidcdyspwncz5uq6vvm4IEDbJVLUFCn%2FLvIHfooUBTkFO130FC7CmmcrKdgDJcid9mvVzsDSibOoXtIf9k6ABle3PmIxejodc4aob0QKS432srrCMndbfD454q52V01G4q913mC5HOsTzWF4h2No1av1VbcUgWAqyoZl%2B11PoFYnNv2HwAODeNRkHj%2B8SF1fcvVBu6MrehHAZK1Gm69ICcTKizykHgGFx7QdowTVAsYEF2tVc0Z6wLryz2FI1sc5By2znJAAmINndoJiB4sfPdPrTC8RnkW7KRCwxC6YvXg5ahMlQuMpoCSXjOlBy0Kij%2BbsCYPbGp8BdCBiLmLSAkEQRaieWo1SYvZIKJGj9Ur%2FeWHjiB7SOVdqMAVmpBvfRiebsFjger7DC%2B8kRFGtNrTrnnGD2GAJb8rQCWkUPYHhwXsjNBSkE6lGWUj5QNhK0DMNM2l%2BkXRZ0KLZaGsFSIdQz%2FHXDxf3%2FTE30%2BDgBKWGWdxElyLccJfEpjsnszECNoDGZpdwdRgCixeg9L4EPhH%2BRptvRMVRaahu4cySjS3P5wxAUCPkmn%2BrhyASpmiTaiDeggaIxYBmtLZDDhiWIJaBgzfCsAGUF1Q1SFZYyXDt9skCaxJsxK2Ms65dmdp5WAZyxik%2FzbrTQk5KmgxCg%2Ff45L0jywebOWUYFJQAJia7XzCV0x89rpp%2Ff3AVWhSPyTanqmik2SkD8A3Ml4NhIGLAjBXtPShwKYfi2eXtrDuKLk4QlSyTw1ftXgwqA2jUuopDl%2B5tfUWZNwBpEPXghzbBggYCw%2Fdhy0ntds2yeHCDKkF%2FYxQjNIL%2FF%2F37jLPHCKBO9ibwYCmuxImIo0ijV2Wbg3kSN2psoe8IsABv3RNFaF9uMyCtCYtqcD%2BqNOhwMlfARQUdJ2tUX%2BMNJqOwIciWalZsmEjt07tfa8ma4cji9sqz%2BQ9hWfmMoKEbIHPOQORbhQRHIsrTYlnVTNvcq1imqmmPDdVDkJgRcTgB8Sb6epCQVmFZe%2BjGDiNJQLWnfx%2BdrTKYjm0G8yH0ZAGMWzEJhUEQ4Maimgf%2Fbkvo8PLVBsZl152y5S8%2BHRDfZIMCbYZ1WDp4yrdchOJw8k6R%2B%2F2pHmydK4NIK2PHdFPHtoLmHxRDwLFb7eB%2BM4zNZcB9NrAgjVyzLM7xyYSY13ykWfIEEd2n5%2FiYp3ZdrCf7fL%2Ben%2BsIJu2W7E30MrAgZBD1rAAbZHPgeAMtKCg3NpSpYQUDWJu9bT3V7tOKv%2BNRiJc8JAKqqgCA%2FPNRBR7ChpiEulyQApMK1AyqcWnpSOmYh6yLiWkGJ2mklCSPIqN7UypWj3dGi5MvsHQ87MrB4VFgypJaFriaHivwcHIpmyi5LhNqtem4q0n8awM19Qk8BOS0EsqGscuuydYsIGsbT5GHnERUiMpKJl4ON7qjB4fEqlGN%2FhCky89232UQCiaeWpDYCJINXjT6xl4Gc7DxRCtgV0i1ma4RgWLsNtnEBRQFqZggCLiuyEydmFd7WlogpkCw5G1x4ft2psm3KAREwVwr1Gzl6RT7FDAqpVal34ewVm3VH4qn5mjGj%2BbYL1NgfLNeXDwtmYSpwzbruDKpTjOdgiIHDVQSb5%2FzBgSMbHLkxWWgghIh9QTFSDILixVwg0Eg1puooBiHAt7DzwJ7m8i8%2Fi%2BjHvKf0QDnnHVkVTIqMvIQImOrzCJwhSR7qYB5gSwL6aWL9hERHCZc4G2%2BJrpgHNB8eCCmcIWIQ6rSdyPCyftXkDlErUkHafHRlkOIjxGbAktz75bnh50dU7YHk%2BMz7wwstg6RFZb%2BTZuSOx1qqP5C66c0mptQmzIC2dlpte7vZrauAMm%2F7RfBYkGtXWGiaWTtwvAQiq2oD4YixPLXE2khB2FRaNRDTk%2B9sZ6K74Ia9VntCpN4BhJGJMT4Z5c5FhSepRCRWmBXqx%2BwhVZC4me4saDs2iNqXMuCl6iAZflH8fscC1sTsy4PHeC%2BXYuqMBMUun5YezKbRKmEPwuK%2BCLzijPEQgfhahQswBBLfg%2FGBgBiI4QwAqzJkkyYAWtjzSg2ILgMAgqxYfwERRo3zruBL9WOryUArSD8sQOcD7fvIODJxKFS615KFPsb68USBEPPj1orNzFY2xoTtNBVTyzBhPbhFH0PI5AtlJBl2aSgNPYzxYLw7XTDBDinmVoENwiGzmngrMo8OmnRP0Z0i0Zrln9DDFcnmOoBZjABaQIbPOJYZGqX%2BRCMlDDbElcjaROLDoualmUIQ88Kekk3iM4OQrADcxi3rJguS4MOIBIgKgXrjd1WkbCdqxJk%2F4efRIFsavZA7KvvJQqp3Iid5Z0NFc5aiMRzGN3vrpBzaMy4JYde3wr96PjN90AYOIbyp6T4zj8LoE66OGcX1Ef4Z3KoWLAUF4BTg7ug%2FAbkG5UNQXAMkQezujSHeir2uTThgd3gpyzDrbnEdDRH2W7U6PeRvBX1ZFMP5RM%2BZu6UUZZD8hDPHldVWntTCNk7To8IeOW9yn2wx0gmurwqC60AOde4r3ETi5pVMSDK8wxhoGAoEX9NLWHIR33VbrbMveii2jAJlrxwytTHbWNu8Y4N8vCCyZjAX%2FpcsfwXbLze2%2BD%2Bu33OGBoJyAAL3jn3RuEcdp5If8O%2Ba4NKWvxOTyDltG0IWoHhwVGe7dKkCWFT%2B%2Btm%2BhaBCikRUUMrMhYKZJKYoVuv%2FbsJzO8DwfVIInQq3g3BYypiz8baogH3r3GwqCwFtZnz4xMjAVOYnyOi5HWbFA8n0qz1OjSpHWFzpQOpvkNETZBGpxN8ybhtqV%2FDMUxd9uFZmBfKXMCn%2FSqkWJyKPnT6lq%2B4zBZni6fYRByJn6OK%2BOgPBGRAJluwGSk4wxjOOzyce%2FPKODwRlsgrVkdcsEiYrqYdXo0Er2GXi2GQZd0tNJT6c9pK1EEJG1zgDJBoTVuCXGAU8BKTvCO%2FcEQ1Wjk3Zzuy90JX4m3O5IlxVFhYkSUwuQB2up7jhvkm%2BbddRQu5F9s0XftGEJ9JSuSk%2BZachCbdU45fEqbugzTIUokwoAKvpUQF%2FCvLbWW5BNQFqFkJg2f30E%2F48StNe5QwBg8zz3YAJ82FZoXBxXSv4QDooDo79NixyglO9AembuBcx5Re3CwOKTHebOPhkmFC7wNaWtoBhFuV4AkEuJ0J%2B1pT0tLkvFVZaNzfhs%2FKd3%2BA9YsImlO4XK4vpCo%2FelHQi%2F9gkFg07xxnuXLt21unCIpDV%2BbbRxb7FC6nWYTsMFF8%2B1LUg4JFjVt3vqbuhHmDKbgQ4e%2BRGizRiO8ky05LQGMdL2IKLSNar0kNG7lHJMaXr5mLdG3nykgj6vB%2FKVijd1ARWkFEf3yiUw1v%2FWaQivVUpIDdSNrrKbjO5NPnxz6qTTGgYg03HgPhDrCFyYZTi3XQw3HXCva39mpLNFtz8AiEhxAJHpWX13gCTAwgm9YTvMeiqetdNQv6IU0hH0G%2BZManTqDLPjyrOse7WiiwOJCG%2BJ0pZYULhN8NILulmYYvmVcV2MjAfA39sGKqGdjpiPo86fecg65UPyXDIAOyOkCx5NQsLeD4gGVjTVDwOHWkbbBW0GeNjDkcSOn2Nq4cEssP54t9D749A7M1AIOBl0Fi0sSO5v3P7LCBrM6ZwFY6kp2FX6AcbGUdybnfChHPyu6WlRZ2Fwv9YM0RMI7kISRgR8HpQSJJOyTfXj%2F6gQKuihPtiUtlCQVPohUgzfezTg8o1b3n9pNZeco1QucaoXe40Fa5JYhqdTspFmxGtW9h5ezLFZs3j%2FN46f%2BS2rjYNC2JySXrnSAFhvAkz9a5L3pza8eYKHNoPrvBRESpxYPJdKVUxBE39nJ1chrAFpy4MMkf0qKgYALctGg1DQI1kIymyeS2AJNT4X240d3IFQb%2F0jQbaHJ2YRK8A%2Bls6WMhWmpCXYG5jqapGs5%2FeOJErxi2%2F2KWVHiPellTgh%2FfNl%2F2KYPKb7DUcAg%2BmCOPQFCiU9Mq%2FWLcU1xxC8aLePFZZlE%2BPCLzf7ey46INWRw2kcXySR9FDgByXzfxiNKwDFbUSMMhALPFSedyjEVM5442GZ4hTrsAEvZxIieSHGSgkwFh%2FnFNdrrFD4tBH4Il7fW6ur4J8Xaz7RW9jgtuPEXQsYk7gcMs2neu3zJwTyUerHKSh1iTBkj2YJh1SSOZL5pLuQbFFAvyO4k1Hxg2h99MTC6cTUkbONQIAnEfGsGkNFWRbuRyyaEZInM5pij73EA9rPIUfU4XoqQpHT9THZkW%2BoKFLvpyvTBMM69tN1Ydwv1LIEhHsC%2BueVG%2Bw%2BkyCPsvV3erRikcscHjZCkccx6VrBkBRusTDDd8847GA7p2Ucy0y0HdSRN6YIBciYa4vuXcAZbQAuSEmzw%2BH%2FAuOx%2BaH%2BtBL88H57D0MsqyiZxhOEQkF%2F8DR1d2hSPMj%2FsNOa5rxcUnBgH8ictv2J%2Bcb4BA4v3MCShdZ2vtK30vAwkobnEWh7rsSyhmos3WC93Gn9C4nnAd%2FPjMMtQfyDNZsOPd6XcAsnBE%2FmRHtHEyJMzJfZFLE9OvQa0i9kUmToJ0ZxknTgdl%2FXPV8xoh0K7wNHHsnBdvFH3sv52lU7UFteseLG%2FVanIvcwycVA7%2BBE1Ulyb20BvwUWZcMTKhaCcmY3ROpvonVMV4N7yBXTL7IDtHzQ4CCcqF66LjF3xUqgErKzolLyCG6Kb7irP%2FMVTCCwGRxfrPGpMMGvPLgJ881PHMNMIO09T5ig7AzZTX%2F5PLlwnJLDAPfuHynSGhV4tPqR3gJ4kg4c06c%2FF1AcjGytKm2Yb5jwMotF7vro4YDLWlnMIpmPg36NgAZsGA0W1spfLSue4xxat0Gdwd0lqDBOgIaMANykwwDKejt5YaNtJYIkrSgu0KjIg0pznY0SCd1qlC6R19g97UrWDoYJGlrvCE05J%2F5wkjpkre727p5PTRX5FGrSBIfJqhJE%2FIS876PaHFkx9pGTH3oaY3jJRvLX9Iy3Edoar7cFvJqyUlOhAEiOSAyYgVEGkzHdug%2BoRHIEOXAExMiTSKU9A6nmRC8mp8iYhwWdP2U%2F5EkFAdPrZw03YA3gSyNUtMZeh7dDCu8pF5x0VORCTgKp07ehy7NZqKTpIC4UJJ89lnboyAfy5OyXzXtuDRbtAFjZRSyGFTpFrXwkpjSLIQIG3N0Vj4BtzK3wdlkBJrO18MNsgseR4BysJilI0wI6ZahLhBFA0XBmV8d4LUzEcNVb0xbLjLTETYN8OEVqNxkt10W614dd1FlFFVTIgB7%2FBQQp1sWlNolpIu4ekxUTBV7NmxOFKEBmmN%2BnA7pvF78%2FRII5ZHA09OAiE%2F66MF6HQ%2BqVEJCHxwymukkNvzqHEh52dULPbVasfQMgTDyBZzx4007YiKdBuUauQOt27Gmy8ISclPmEUCIcuLbkb1mzQSqIa3iE0PJh7UMYQbkpe%2BhXjTJKdldyt2mVPwywoODGJtBV1lJTgMsuSQBlDMwhEKIfrvsxGQjHPCEfNfMAY2oxvyKcKPUbQySkKG6tj9AQyEW3Q5rpaDJ5Sns9ScLKeizPRbvWYAw4bXkrZdmB7CQopCH8NAmqbuciZChHN8lVGaDbCnmddnqO1PQ4ieMYfcSiBE5zzMz%2BJV%2F4eyzrzTEShvqSGzgWimkNxLvUj86iAwcZuIkqdB0VaIB7wncLRmzHkiUQpPBIXbDDLHBlq7vp9xwuC9AiNkIptAYlG7Biyuk8ILdynuUM1cHWJgeB%2BK3wBP%2FineogxkvBNNQ4AkW0hvpBOQGFfeptF2YTR75MexYDUy7Q%2F9uocGsx41O4IZhViw%2F2FvAEuGO5g2kyXBUijAggWM08bRhXg5ijgMwDJy40QeY%2FcQpUDZiIzmvskQpO5G1zyGZA8WByjIQU4jRoFJt56behxtHUUE%2Fom7Rj2psYXGmq3llVOCgGYKNMo4pzwntITtapDqjvQtqpjaJwjHmDzSVGLxMt12gEXAdLi%2FcaHSM3FPRGRf7dB7YC%2BcD2ho6oL2zGDCkjlf%2FDFoQVl8GS%2F56wur3rdV6ggtzZW60MRB3g%2BU1W8o8cvqIpMkctiGVMzXUFI7FacFLrgtdz4mTEr4aRAaQ2AFQaNeG7GX0yOJgMRYFziXdJf24kg%2FgBQIZMG%2FYcPEllRTVNoDYR6oSJ8wQNLuihfw81UpiKPm714bZX1KYjcXJdfclCUOOpvTxr9AAJevTY4HK%2FG7F3mUc3GOAKqh60zM0v34v%2BELyhJZqhkaMA8UMMOU90f8RKEJFj7EqepBVwsRiLbwMo1J2zrE2UYJnsgIAscDmjPjnzI8a719Wxp757wqmSJBjXowhc46QN4RwKIxqEE6E5218OeK7RfcpGjWG1jD7qND%2B%2FGTk6M56Ig4yMsU6LUW1EWE%2BfIYycVV1thldSlbP6ltdC01y3KUfkobkt2q01YYMmxpKRvh1Z48uNKzP%2FIoRIZ%2FF6buOymSnW8gICitpJjKWBscSb9JJKaWkvEkqinAJ2kowKoqkqZftRqfRQlLtKoqvTRDi2vg%2FRrPD%2Fd3a09J8JhGZlEkOM6znTsoMCsuvTmywxTCDhw5dd0GJOHCMPbsj3QLkTE3MInsZsimDQ3HkvthT7U9VA4s6G07sID0FW4SHJmRGwCl%2BMu4xf0ezqeXD2PtPDnwMPo86sbwDV%2B9PWcgFcARUVYm3hrFQrHcgMElFGbSM2A1zUYA3baWfheJp2AINmTJLuoyYD%2FOwA4a6V0ChBN97E8YtDBerUECv0u0TlxR5yhJCXvJxgyM73Bb6pyq0jTFJDZ4p1Am1SA6sh8nADd1hAcGBMfq4d%2FUfwnmBqe0Jun1n1LzrgKuZMAnxA3NtCN7Klf4BH%2B14B7ibBmgt0TGUafVzI4uKlpF7v8NmgNjg90D6QE3tbx8AjSAC%2BOA1YJvclyPKgT27QpIEgVYpbPYGBsnyCNrGz9XUsCHkW1QAHgL2STZk12QGqmvAB0NFteERkvBIH7INDsNW9KKaAYyDMdBEMzJiWaJHZALqDxQDWRntumSDPcplyFiI1oDpT8wbwe01AHhW6%2BvAUUBoGhY3CT2tgwehdPqU%2F4Q7ZLYvhRl%2FogOvR9O2%2BwkkPKW5vCTjD2fHRYXONCoIl4Jh1bZY0ZE1O94mMGn%2FdFSWBWzQ%2FVYk%2BGezi46RgiDv3EshoTmMSlioUK6MQEN8qeyK6FRninyX8ZPeUWjjbMJChn0n%2FyJvrq5bh5UcCAcBYSafTFg7p0jDgrXo2QWLb3WpSOET%2FHh4oSadBTvyDo10IufLzxiMLAnbZ1vcUmj3w7BQuIXjEZXifwukVxrGa9j%2BDXfpi12m1RbzYLg9J2wFergEwOxFyD0%2FJstNK06ZN2XdZSGWxcJODpQHOq4iKqjqkJUmPu1VczL5xTGUfCgLEYyNBCCbMBFT%2FcUP6pE%2FmujnHsSDeWxMbhrNilS5MyYR0nJyzanWXBeVcEQrRIhQeJA6Xt4f2eQESNeLwmC10WJVHqwx8SSyrtAAjpGjidcj1E2FYN0LObUcFQhafUKTiGmHWRHGsFCB%2BHEXgrzJEB5bp0QiF8ZHh11nFX8AboTD0PS4O1LqF8XBks2MpjsQnwKHF6HgaKCVLJtcr0XjqFMRGfKv8tmmykhLRzu%2BvqQ02%2BKpJBjaLt9ye1Ab%2BBbEBhy4EVdIJDrL2naV0o4wU8YZ2Lq04FG1mWCKC%2BUwkXOoAjneU%2FxHplMQo2cXUlrVNqJYczgYlaOEczVCs%2FOCgkyvLmTmdaBJc1iBLuKwmr6qtRnhowngsDxhzKFAi02tf8bmET8BO27ovJKF1plJwm3b0JpMh38%2BxsrXXg7U74QUM8ZCIMOpXujHntKdaRtsgyEZl5MClMVMMMZkZLNxH9%2Bb8fH6%2Bb8Lev30A9TuEVj9CqAdmwAAHBPbfOBFEATAPZ2CS0OH1Pj%2F0Q7PFUcC8hDrxESWdfgFRm%2B7vvWbkEppHB4T%2F1ApWnlTIqQwjcPl0VgS1yHSmD0OdsCVST8CQVwuiew1Y%2Bg3QGFjNMzwRB2DSsAk26cmA8lp2wIU4p93AUBiUHFGOxOajAqD7Gm6NezNDjYzwLOaSXRBYcWipTSONHjUDXCY4mMI8XoVCR%2FRrs%2FJLKXgEx%2BqkmeDlFOD1%2FyTQNDClRuiUyKYCllfMiQiyFkmuTz2vLsBNyRW%2Bxz%2B5FElFxWB28VjYIGZ0Yd%2B5wIjkcoMaggxswbT0pCmckRAErbRlIlcOGdBo4djTNO8FAgQ%2BlT6vPS60BwTRSUAM3ddkEAZiwtEyArrkiDRnS7LJ%2B2hwbzd2YDQagSgACpsovmjil5wfPuXq3GuH0CyE7FK3M4FgRaFoIkaodORrPx1%2BJpI9psyNYIFuJogZa0%2F1AhOWdlHQxdAgbwacsHqPZo8u%2FngAH2GmaTdhYnBfSDbBfh8CHq6Bx5bttP2%2BRdM%2BMAaYaZ0Y%2FADkbNCZuAyAVQa2OcXOeICmDn9Q%2FeFkDeFQg5MgHEDXq%2FtVjj%2Bjtd26nhaaolWxs1ixSUgOBwrDhRIGOLyOVk2%2FBc0UxvseQCO2pQ2i%2BKrfhu%2FWeBovNb5dJxQtJRUDv2mCwYVpNl2efQM9xQHnK0JwLYt%2FU0Wf%2BphiA4uw8G91slC832pmOTCAoZXohg1fewCZqLBhkOUBofBWpMPsqg7XEXgPfAlDo2U5WXjtFdS87PIqClCK5nW6adCeXPkUiTGx0emOIDQqw1yFYGHEVx20xKjJVYe0O8iLmnQr3FA9nSIQilUKtJ4ZAdcTm7%2BExseJauyqo30hs%2B1qSW211A1SFAOUgDlCGq7eTIcMAeyZkV1SQJ4j%2Fe1Smbq4HcjqgFbLAGLyKxlMDMgZavK5NAYH19Olz3la%2FQCTiVelFnU6O%2FGCvykqS%2FwZJDhKN9gBtSOp%2F1SP5VRgJcoVj%2Bkmf2wBgv4gjrgARBWiURYx8xENV3bEVUAAWWD3dYDKAIWk5opaCFCMR5ZjJExiCAw7gYiSZ2rkyTce4eNMY3lfGn%2B8p6%2BvBckGlKEXnA6Eota69OxDO9oOsJoy28BXOR0UoXNRaJD5ceKdlWMJlOFzDdZNpc05tkMGQtqeNF2lttZqNco1VtwXgRstLSQ6tSPChgqtGV5h2DcDReIQadaNRR6AsAYKL5gSFsCJMgfsaZ7DpKh8mg8Wz8V7H%2BgDnLuMxaWEIUPevIbClgap4dqmVWSrPgVYCzAoZHIa5z2Ocx1D%2FGvDOEqMOKLrMefWIbSWHZ6jbgA8qVBhYNHpx0P%2BjAgN5TB3haSifDcApp6yymEi6Ij%2FGsEpDYUgcHATJUYDUAmC1SCkJ4cuZXSAP2DEpQsGUjQmKJfJOvlC2x%2FpChkOyLW7KEoMYc5FDC4v2FGqSoRWiLsbPCiyg1U5yiHZVm1XLkHMMZL11%2Fyxyw0UnGig3MFdZklN5FI%2FqiT65T%2BjOXOdO7XbgWurOAZR6Cv9uu1cm5LjkXX4xi6mWn5r5NjBS0gTliHhMZI2WNqSiSphEtiCAwnafS11JhseDGHYQ5%2BbqWiAYiAv6Jsf79%2FVUs4cIl%2Bn6%2BWOjcgB%2F2l5TreoAV2717JzZbQIR0W1cl%2FdEqCy5kJ3ZSIHuU0vBoHooEpiHeQWVkkkOqRX27eD1FWw4BfO9CJDdKoSogQi3hAAwsPRFrN5RbX7bqLdBJ9JYMohWrgJKHSjVl1sy2xAG0E3sNyO0oCbSGOxCNBRRXTXenYKuwAoDLfnDcQaCwehUOIDiHAu5m5hMpKeKM4sIo3vxACakIxKoH2YWF2QM84e6F5C5hJU4g8uxuFOlAYnqtwxmHyNEawLW%2FPhoawJDrGAP0JYWHgAVUByo%2FbGdiv2T2EMg8gsS14%2FrAdzlOYazFE7w4OzxeKiWdm3nSOnQRRKXSlVo8HEAbBfyJMKqoq%2BSCcTSx5NDtbFwNlh8VhjGGDu7JG5%2FTAGAvniQSSUog0pNzTim8Owc6QTuSKSTXlQqwV3eiEnklS3LeSXYPXGK2VgeZBqNcHG6tZHvA3vTINhV0ELuQdp3t1y9%2BogD8Kk%2FW7QoRN1UWPqM4%2BxdygkFDPLoTaumKReKiLWoPHOfY54m3qPx4c%2B4pgY3MRKKbljG8w4wvz8pxk3AqKsy4GMAkAtmRjRMsCxbb4Q2Ds0Ia9ci8cMT6DmsJG00XaHCIS%2Bo3F8YVVeikw13w%2BOEDaCYYhC0ZE54kA4jpjruBr5STWeqQG6M74HHL6TZ3lXrd99ZX%2B%2B7LhNatQaZosuxEf5yRA15S9gPeHskBIq3Gcw81AGb9%2FO53DYi%2F5CsQ51EmEh8Rkg4vOciClpy4d04eYsfr6fyQkBmtD%2BP8sNh6e%2BXYHJXT%2FlkXxT4KXU5F2sGxYyzfniMMQkb9OjDN2C8tRRgTyL7GwozH14PrEUZc6oz05Emne3Ts5EG7WolDmU8OB1LDG3VrpQxp%2BpT0KYV5dGtknU64JhabdqcVQbGZiAxQAnvN1u70y1AnmvOSPgLI6uB4AuDGhmAu3ATkJSw7OtS%2F2ToPjqkaq62%2F7WFG8advGlRRqxB9diP07JrXowKR9tpRa%2BjGJ91zxNTT1h8I2PcSfoUPtd7NejVoH03EUcqSBuFZPkMZhegHyo2ZAITovmm3zAIdGFWxoNNORiMRShgwdYwFzkPw5PA4a5MIIQpmq%2Bnsp3YMuXt%2FGkXxLx%2FP6%2BZJS0lFyz4MunC3eWSGE8xlCQrKvhKUPXr0hjpAN9ZK4PfEDrPMfMbGNWcHDzjA7ngMxTPnT7GMHar%2BgMQQ3NwHCv4zH4BIMYvzsdiERi6gebRmerTsVwZJTRsL8dkZgxgRxmpbgRcud%2BYlCIRpPwHShlUSwuipZnx9QCsEWziVazdDeKSYU5CF7UVPAhLer3CgJOQXl%2Fzh575R5rsrmRnKAzq4POFdgbYBuEviM4%2BLVC15ssLNFghbTtHWerS1hDt5s4qkLUha%2FqpZXhWh1C6lTQAqCNQnaDjS7UGFBC6wTu8yFnKJnExCnAs3Ok9yj5KpfZESQ4lTy5pTGTnkAUpxI%2ByjEldJfSo4y0QhG4i4IwkRFGcjWY8%2BEzgYYJUK7BXQksLxAww%2FYYWBMhJILB9e8ePEJ4OP7z%2B4%2FwOQDl64iOYDp26DaONPxpKtBxq%2FaTzRGarm3VkPYTLJKx6Z%2FMw2YbBGseJhPMwhhNswrIkyvV2BYzrvZbxLpKwcWJhYmFtVZ%2BlPEq91FzVp1HlQY1bZVLqeNR9SAUn6n0E28k%2FUuGkNpP1DBI5ch%2FEehZfjUQ9aE41NhETExoPT2gGQz0IhWJbEOvTQ4wgcXCHHFBhewYUiFHuhRSAUVmEHeCRQHQkXGFwkAgyzREJCVN7TRnTon36Zw3tPhx4EALwNdwDv%2BJ41YSP4B2CQqz0EFgARZ4ESgBHQgROwAVn9GTI%2BHYexTUevLUeta4%2FDqKrbMVS%2BYqb8hUwYCrlgKtmAq1YCrFgKrd4qpXiqZcKn1oqdWipjYKpWwVPVYqW6xUpVipKqFR3QKjagVEtAqHpxUMTitsnFaJOKx2cVhswq35RVpyiq9lFVNIKnOQVMkgqtYxVNxiqQjFS7GKlSIVIsQqPIhUWwioigFQ%2B%2BKkN8VHr49HDw9Ebo9EDo9DTo9Crg9BDg9%2FWx7gWx7YWwlobYrOGxWPNisAaAHEyALpkAVDIAeWAArsABVXACYuAD5cAF6wAKFQAQqgAbVAAsoAAlQAUaYAfkwAvogBWQACOgAD9AAHSAAKT4GUdMiOvFngBTwCn2AZ7Dv6B6k%2F90B8%2ByRnkV144AIBoAMTQATGgAjNAA4YABgwABZgB%2FmQCwyAVlwCguASlwCEuAQFwB4uAMlwBYuAJlQAUVAAhUD2KgdpUDaJgaRMDFJgX5MC1JgWJEAokQCWRAHxEAWkQBMRADpEAMkQAYROAEecC484DRpwBDTnwNOdw05tjTmiNOYwtswhYFwLA7BYG4LA2BYGOLAwRYFuLAsxYFQJAohIEyJAMwkAwiQC0JAJgkAeiQBkJAFokAPCQA0JABwcD4Dgc4cDdDgaYcDIDgYgUC6CgWgUClCgUYUAVBQBOFAEYMALgwAgDA9QYAdIn8AZzeBB2L5EcWrenUT1KXienEsuJJ7x5U8XlTjc1NVzUyXFTGb1LlpUtWlTDIjqwE4LsagowoCi2gJLKAkpoBgJQNpAIhNqaEoneI6kiiqQ6Go%2Fn6j0cS%2Ba2gEU8gIHJ%2BBwfgZX4GL%2BBd%2FgW34FZ%2BBS%2FgUH4FN6BTegTvoEv6BJegRnYEF2A79gOvYDl2BdEjCkqkGtwXp0LNToIskOTXzh%2FF062yJ7AAAAEDAWAAABWhJ%2BKPEIJgBFxMVP7w2QJBGHASQnOBKXKFIdUK4igKA9IEaYJg%29%20format%28%27embedded%2Dopentype%27%29%2Curl%28data%3Aapplication%2Ffont%2Dwoff%3Bbase64%2Cd09GRgABAAAAAFuAAA8AAAAAsVwAAQAAAAAAAAAAAAAAAAAAAAAAAAAAAABGRlRNAAABWAAAABwAAAAcbSqX3EdERUYAAAF0AAAAHwAAACABRAAET1MvMgAAAZQAAABFAAAAYGe5a4ljbWFwAAAB3AAAAsAAAAZy2q3jgWN2dCAAAAScAAAABAAAAAQAKAL4Z2FzcAAABKAAAAAIAAAACP%2F%2FAANnbHlmAAAEqAAATRcAAJSkfV3Cb2hlYWQAAFHAAAAANAAAADYFTS%2FYaGhlYQAAUfQAAAAcAAAAJApEBBFobXR4AABSEAAAAU8AAAN00scgYGxvY2EAAFNgAAACJwAAAjBv%2B5XObWF4cAAAVYgAAAAgAAAAIAFqANhuYW1lAABVqAAAAZ4AAAOisyygm3Bvc3QAAFdIAAAELQAACtG6o%2BU1d2ViZgAAW3gAAAAGAAAABsMYVFAAAAABAAAAAMw9os8AAAAA0HaBdQAAAADQdnOXeNpjYGRgYOADYgkGEGBiYGRgZBQDkixgHgMABUgASgB42mNgZulmnMDAysDCzMN0gYGBIQpCMy5hMGLaAeQDpRCACYkd6h3ux%2BDAoPD%2FP%2FOB%2FwJAdSIM1UBhRiQlCgyMADGWCwwAAAB42u2UP2hTQRzHf5ekaVPExv6JjW3fvTQ0sa3QLA5xylBLgyBx0gzSWEUaXbIoBBQyCQGHLqXUqYNdtIIgIg5FHJxEtwqtpbnfaV1E1KFaSvX5vVwGEbW6OPngk8%2FvvXfv7pt3v4SImojIDw6BViKxRgIVBaZwVdSv%2BxvXA%2BIuzqcog2cOkkvDNE8Lbqs74k64i%2B5Sf3u8Z2AnIRLbyVCyTflVSEXVoEqrrMqrgiqqsqqqWQ5xlAc5zWOc5TwXucxVnuE5HdQhHdFRHdNJndZZndeFLc%2FzsKJLQ%2FWV6BcrCdWkwspVKZVROaw0qUqqoqZZcJhdTnGGxznHBS5xhad5VhNWCuturBTXKZ3RObuS98pb9c57k6ql9rp2v1as5deb1r6s9q1GV2IrHSt73T631424YXzjgPwqt%2BRn%2BVG%2BlRvyirwsS%2FKCPCfPytPypDwhj8mjctRZd9acF86y89x55jxxHjkPnXstXfbt%2FpNjj%2FnwXW%2BcHa6%2FSYvZ7yEwbDYazDcIgoUGzY3h2HtqgUcs1AFPWKgTXrRQF7xkoQhRf7uF9hPFeyzUTTSwY6EoUUJY6AC8bSGMS4Ys1Au3WaiPSGGsMtkdGH2rzJgYHAaYjxIwQqtB1CnYkEZ9BM6ALOpROAfyqI%2FDBQudgidBETXuqRIooz4DV0AV9UV4GsyivkTEyMMmw1UYGdhkuAYjA5sMGMvIwCbDDRgZeAz1TXgcmDy3YeRhk%2BcOjCxsMjyAkYFNhscwMrDJ8BQ2886gXoaRhedQvyTSkDZ7uA6HLLQBI5vGntAbGHugTc53cMxC7%2BE4SKL%2BACOzNpk3YWTWJid%2BiRo5NXIKM3fBItAPW55FdJLY3FeHBDr90606JCIU9Jk%2BMs3%2FY%2F8L8jUq3y79bJ%2F0%2F%2BROoP4v9v%2F4%2Fmj%2Bi7HBXUd0%2FelU6IHfHt8Aj9EPGAAoAvgAAAAB%2F%2F8AAnjaxb0JfBvVtTA%2BdxaN1hltI1m2ZVuSJVneLVlSHCdy9oTEWchqtrBEJRAgCYEsQNhC2EsbWmpI2dqkQBoSYgKlpaQthVL0yusrpW77aEubfq%2Fly%2BujvJampSTW5Dvnzmi1E%2Bjr%2F%2F3%2BXmbu3Llz77nnbuece865DMu0MAy5jGtiOEZkOp8lTNeUwyLP%2FDH%2BrEH41ZTDHAtB5lkOowWMPiwayNiUwwTjE46AI5xwhFrINPXYn%2F7ENY0dbWHfZAiTZbL8ID%2FInAd5xz2NpIH4STpDGonHIJNE3OP1KG4ISaSNeBuITAyRLgIxoiEUhFAnmUpEiXSRSGqAQEw0kuyFUIb0k2gnGSApyBFi0il2SI5YLGb5MdFjXCey4mNHzQ7WwLGEdZiPPgYR64we8THZHAt%2BwnT84D%2Fx8YTpGPgheKH4CMEDVF9xBOIeP3EbQgGH29BGgpGkIxCMTCW9qUTA0Zsir%2BQUP1mt%2BP2KusevwIO6Bx%2FIaj8%2FOD5O0VNrZW2EsqZBWbO1skRiEKE0DdlKKaSVO5VAuRpqk8VQJAqY7ydxaK44YJvrO2EWjOoDBoFYzQbDNkON%2BUbiKoRkywMWWf1j4bEY2iIY1AeMgvmEz%2FkVo9v4FSc%2FaMZMrFbjl4zWLL0%2BY5FlyzNlEVYDudJohg8gPUP7kcB%2Fmn%2BG6cd%2B5PV4Q72dXCgocWJADBgUuDTwiXiGSyZo14HOEQ2lE6k0XDIEusexDzZOMXwt1Dutz%2BtqmxTvlskNWXXUQIbhaurum9GrePqm9Yaeabjkiqf%2BbUvzDOvb2Y1E%2BEX2DnemcTP%2FzLcuu7xjQXdAtjR0Lo5n4%2FHs%2FGtntMlysHt%2B29NXbH6se%2F%2FWbFcyu%2Br28H0MwzI30DYeYTLMXIA2EG8QlHpAsyS0EfEToR0a3utIxFPJ3kiIHCCrZ66b0e2xEmL1dM9YN%2FMwS5p01N5jMX%2FBLKt%2F1R83l0LyC29M6%2BiYxo%2FUNg%2FEF7c2WyyW5tYl8WnhWg2%2FhyySbD5UhnDyS7OcU0dnrFw%2BDfGdI7v4QfYIIzOMq9hFtY55gmvC7jZ2FK7sEdrn6IXBuucYhjsGdQ8z0yEbWkkczjjsE5hNAIZrPx2zOLZDmKNXcXtg7EMqidAEEWg%2BSJCBBNwxvxJfc%2FbZa%2BKKf%2BxoKZybnq5vaqpPTye7CiF%2BZFjxZ8%2F7Qij0hfOG%2FcowPA1rT1l4ymWnrKmxxqfErTVrpgwPlz1kC%2BOy8NMDz6c%2BIO38K%2Fx0xkPnLW8Kx6qGAoQdL%2BTD9V9rb%2B%2Fctn%2F%2Ftrxz8dUrZrD%2Fzk%2FferF0cNt1BzctmX2FZPXt%2FjnFCQNz4Ah%2FiKllGiCMs1w5Lkg0kiEwj6VTXCDKsX9rMpnvIj9pcDecXAIXMnqn2dTUbN6w0XQ9ue6FV%2FnnXCH7S3lPWGltVcLsH75ub3ab7A8M28caNrIeOr3o5Q0yFsYL80xaa0EY%2FUEczV7icUMY5pnelAkmUAXmHYjvFWFGxuqlSaow3OM%2B%2FiYY7%2Fl%2FhVELF4EjRqNR%2FbvRbOY%2BDUGzGR%2FOh3EqmE%2FugIQQguGt%2FeMYz%2F%2BL0cimjeZfQDI3phXMbMQsqH%2BCjwVz%2Fhf4idHovgVmB8gLvjbicDcC%2FNypP536E%2F9N%2FpuMibExdohBmNwyiaZdJGoigos7GpF222xrfnZhML%2F7Z%2BylaqP63Hr%2Bm7bdUkQ6%2F2cXqdfmvwixY%2Bs2ksXFeXcE%2BiX0Z%2BIow76DBNgjJ7TOdUK18iPsPflfQD%2BDPsZG2Aj9VmKMMJ4fYRrhIaxhTDR0Elh2vA6h%2FAE6xUb29mj3sjmL72petXjejPy%2Boel60M99tFduCI59N3221xe7apOvxs6aHs7vab1IqY2tv7q2xsHeHGml%2FcV06u%2F8S%2FxTjJ%2BJYc0bWEX0ukW6YmIbGkJRMdjJ9mYIH5QIdJF4hvRGyK7cC7ctImQRcUET99fGXOoft35GYLMQu%2Bg2smnkgZUrH8AL%2F9Si217IssJ916nv14ZrJrvdxLkQvrvtBcjgPC0NXOicO8Qf4mcxPqh3hgUw3DDfdvLJXngg7N3dN2zbPJSaed3OfZnMU7dvmznp3C3bruO%2BNmue0LFsy7S%2B6265%2BfCKFYdvvuW6vmlblnUI8xCXp37CrOZv4B9gauDBlYp7adcUXB5DNCwYImlXOJJKkAdvExXxVvKEYnCo%2B3eIskP9qrrfIYs71CccBjfXRC52udTHHdaP1A1ui%2FVvH1otbrLrpNXBsGX5B89QghDyimlvNB2KfkxZ5C9%2Fem3%2Bd1%2Bd%2F%2FIfFp2%2B2Oxn%2Fs%2B9n%2F79p39S3s8idN6g0yZObwJOgKUpNB3GyU0Ls0PbRzIRq4lcarLKOJBkLRzJQD4j2090XrbA7DW8K3jNF5hlGS5e4V2D17zgss4T20egOJte5iD0bReM9yjTxnQxCRj3c5kFzGJmGbNKmwGw39IJDJcXJZGMkaAB4jyJAKw0jt5IAuIE%2BA%2BU3cVAZZrq9zhDyBrU8oosuxcGNTzCKJfla7JjNVmuSb%2F%2BtuzN2H%2BX4vlB%2BPpdfMXXmuVsNiub1T34SFbjYw5itEvVi0K0Nt9pNJUMI7SLGRhf2xipfCYf8z5OdlGKayOucFeVPeS%2Fdbo3lBrbSMmwUiQN5%2Fed7g0Ds1s17IuZC5kNzM3MZ6EWCa0DtekdJfAxz%2BR%2FOX28sND7yRMTBcf%2B%2Bs8mQCQWHya4qBv%2FufeMoWyslPA9DtMxUknxkH%2FyfTnm2CMYzs%2BCq3r7PxY%2FMXomrvTEsRpfEGHa%2BWN8E1AHjElb7d06ddA7oK%2F%2B5Mdsv9EtPms0jv0Z5kf1FqPxWdFtfFr0kHfgDX0Y%2B5PRSG7RUj0tQr7rmfX8DH4G5W28kKeJLtmQsQkuwMP1pk16EV4sl7vrMJATfyUWo%2FGwEco4rh4XFQgaiUX9qxZHrMQqKnz%2Fc2d8b9TysYrAuXpP%2FRf%2FGr8b1qwwc5a%2BeuLa6S6sneNXToG2XrEJi4R5SGs8Sq2S3d97bsfCRaTdaLwKClRHt37mkudvXbjwVrLhuYeGhh56bvfQkHpk2CwvwClqgWwuBfndC3c8dwmstj81KkagcUgbfPY8Zje0W%2F82VPWJHmSq6pP8hPWpotc%2FEexDOK3qU%2BwngPhOCiO9MJRm8TJefjelrzoKnG2Bn%2B1NCUmPE4gHFmBN9jrTigRIpsACrc9Gstg58ULkp9467%2BGf%2FeFnD5%2F31lNrt2967dhrm7bzI%2BVT5m%2BfzKhvf2MzpICEm79Bopkn07lt1762adNr127LwVqQLdJ5%2BlpQDcvHPQtVY5knhYrK6q8%2FJsiP6EuhGZdFdaNszjvpqvc%2BPI0CdjN0AXsFOC3ZfALDJwr4q2Xq%2BGF%2BGNbsxUg5NLLIEXi8otcDQcUts0D8eQ1iVDRAMBTsYiNdRIxE09EIBJO9A2xqgERTaW86BUFn0OD2xFO97FAgFhF6OoQ7prYt4XwSeUgQHiJyDbeke9IdQntciLQ1FlJMaYcUNvZBg%2BFB1ubjlnRNvl3o6IEU2w7fdNPhm%2Fhh%2BFLysUu6%2B%2BDLHkOkrSHYEjH0tEPe7WdD3uyDgvAgK%2Fm4szFFR7ch0toUgBTdWHr7EpaWru6%2B6dmbbnqWEbV2EtxAsXiZAPTtGPSbHsotI2leoM8TePEqgSQprs7AGFf8kuOkPdZPXGb55POAW1d%2FjLST9v5YflasP6v%2FCO7%2BGNAPC2BMZWmsOjp2NNbfHwMCJD%2BLPVL%2BD%2FOYlWEEI%2F9jpPddOFkB5d1GSuKZYggmCCd7JUxD7EXAzxyirYnNDLdDZoFdx14kivkvGc3579Jm36reTTvDgBnaO6vzyQ6chQmlsMoIkIQ2%2BbBDWBud1Va4pcCn8CPqxlh%2FfgtG8IPaPH8C5wk6%2FnZDv69jurV5QhtwE0x2iqOsj9Mx8B9%2F0EaUdiPfOYYDCi%2Fq9jhWRuupMDEU0%2BCtX0sDFxv07T%2FK5niBPqN9%2BtQjgEc31NGCXFeMcCEuQBIc%2FBK4CO78u7EPYvl3yaEfK3vcb6qP1R2tI7vUjVDDUdKubsSrNjYKY1qBEa2P50SJoaXiksIoLiCwnxS6EBuBde87botNfdEWwYvF%2FR0%2Fu5yCqhGeEOR2ynSeyXjt6ka7neyye8kryBSWE52y%2BRBgogrXPZ8E1yIHoHIFUM%2BAbJhE7lbMtt8ApL%2BxmZW7PwbjAO0fAVoXQOuiSP%2FksIVdFZ0aulsamKUzwPZ%2FNYDMJRBPCxsBqLzqHyneXF6Ej9HlIFo7%2Bpg%2BjUb3unRmGpstGkm6etOuDBGA5wCMefp1gTHcdZlvPBXlOslvYTp1cd8UjYLVd%2FJ5awNrIOKLnIt9MD9qdrKrWCvA6ALm3QV9VrsPm60Q7%2BRHJHP%2B2hqfugo%2FMvI2H%2Fmqr4b9tFnKSRY1Y5Ek80Nm%2FWIhr1ikKnxGz9TWXrokf9xwujfvcOTtNTWnxd0F37Y2W79tteBqZ4G5qLCuomw%2BnSr28QESCRVLTyYKILGJOPfcnaIFOsewhRdvv%2BrWa%2FWih0vlbX6Zb75T5C0qNKVFvH1QL%2FvazSWgC2s6oWXXIuUxQelKiJbowuJDQViatLmLijg9CQBMg8WiPgiw3LEeYRmm5f%2BXdnvkDnxLLjMLxtvX74C3OlwPQqx4xwIdpPx38LrlDphiyWUWHWKAzzxurS%2FxTo%2BP5wGFak62ap1PVFFN4v%2Fy%2BxuR39WnIO7lsWfwgVsK17wxrs9K8ltIKuhkw7f%2F6dhK6gQokFKhWX3urrjk%2FrnI0pgfpGMeuQIUaEM7%2BGF5q2iMkCaMQwxxOzcvU0eXbsnS9XknXvP7Gtw5dwPXlFu2ecvSHEZgNDsU6x%2FGdXBYXyOQjzZReSedeEPY6nEv9gJR4oBQJtFO6Kd0fwC6BO4LNHDeBujB6dSNcUQC9zIv2LnAzGk99bUDrdFY%2B9yGFQtEo0GQPNv6vS2drj4%2B1jHbv3aJSMUWP%2BQTZrmbNTjU8wyG%2FiXNNpskybLcJ3CiTF5Ir%2BJYzmJwE0mSVhlxbtbmvweB3ulB6Til5UuUZydpgiFVeobhU0WaBqpJ198d%2B%2FXeNRTZ9%2F1OPfG7%2B2hwzd5W3D%2BhmyjsRcUg%2F%2BCavb%2B%2BVh2ls3L7zT%2FetOnHNxeerv313vzLVqPai4nJv%2BK1FC6040%2F4udw7sAb3laSg0XCkAAs0npBO6VJabS4Elk%2FU%2BD4gTXW%2Bj0wnrMlqNamq4tMIYB87tE10i0FR3LZNhJsb7%2FR561btmes8YBCRkhYNByRtKd55mqTas9FYhJnbRGHuOh3M4QTdgQSqmgRxuzGdSvZGcbMxNQGk5C3ebLjoXIOFM4l%2BWKHmLTJwRv9E8GWJ6dYvf%2FFmEyEGr%2Bgyrr1p5zrgkz0Cw2j94Hv8Jdx7dIVegBSNtgsqGsRQEYiIBoXwD0LNvQ5d7s5Z00QzwNhqZA0b%2BtMG1tQq5nd84uq8R0zPvX35G8uRaze4jcOHzz0w1%2BQ2BIRvf6J6Kgatnrbiem%2BCFvAxfkrndzD9MFPP1GWTUHclpASUkCNAQkpCCcCgDSUDAhDZ%2BCuEkgn8J7i9nMA7pA4lISappxILKfAeSAbIcSDuN2bJcfZILqeO5rLs0MnngSHYRdrHjmaz7JEsEPw51ZqDJDmUIOZIe34WaQeegNsJn1qz8AIpT3yCjyEih%2FxELkuJ0lEMYTLVCiWpo5oYMleMH6USyYJcD%2BuOe%2BkWKpn1Qns34iyYDjkSLvgnZXcgVQNeqINXr48m3iS7cjm8tedyY0f1QvTnHHdsrKby%2F%2BSSbPY8%2FNH6vpl%2FEsq3Ae4ZU1HC44KFiI9o7CEgab%2FRqHbj7s5KAg06s39ZP%2FzxI%2FmVuF%2FTbTSy%2B3Fb8If9%2Fcv7%2Bwt91yy8RfP1QXtW5RzQn7qIiZyuFM5QfJ5E9uVnqT85TanFx0lkP3ukBAMprvsRyi%2FC8NAJL1xbIIirSvnSj4O5netb4JxmNANHPssHAcHMHsFRgEug816gDBeMbdfiuRcghqYcm0%2BXxx%2F5IAEtN3fqFF3LzAXqwoT0PN0OVTNqxo8sxMkd5Ig6k79Zk7VxxX6gMLOZFQgvpW2RrMW1D0BDihaXQ9wVRoBxPLfpknmkeMtoB%2FqM9cRc9IqmMD2XUmdZ7GSRKPUZvChf8BoykriM2MnKYbOHX8R7cLdNCxSFFVQqoYswnlWtlFS2mNkhswVpZiQW1J%2FUKFfipHGlUkM6UKBhMz1istELIHJLMSctu3ugzfaVSOjKvUgc%2FTHK4Sdg2Wscz69leKIkkrwuuWiOe9yGYKQXRumkC3qbRcMwrvhjNXgdZk3RxAUEhuSPvn3nnd%2B%2BU%2F3vlVOmrJzCD8JLxV1OHRjrZifbcFDOuRNTGqdgQm1tSNJ2OcQ04YiEXuxtII1ECSQRoQGYioEsgCfchB4ghAtw7FfJre4WZ9hkVi9MtjuWqtdNDlpMrfEG9fOT6q21okg%2Be4As38MfGquNt7oUws6Ysarj1%2FefE%2Byst86YUVNvDdts3Pv5c8m%2FaP0C%2Bf8%2FQb%2BIMnGq09BgwN01oIOAnAdagI8mBSrqk1gxTDUBOtk2ousEtBH2z4Ir2d3f6k8PXXVlt2qN9RODxRuoJT%2Fv27wm09jRYVc%2Fe%2B%2Biyx2tyzJb%2Fn3J0htXP87eSsQaf2Ly0s6Zmxela88REy1cf4273mI3iXNJ7KxrZibOm9xm6rl4fqy%2Ft27smU8tOfdW2ucBzg2UfmOIVyLIl3kpYlwphDISTXJXsctmiDtN7fNV6zelgxwnWxsVr83Aj%2FS5ki1jL%2Fa0GC6%2B2L6Um%2BaoddlNFuj%2BbJ8mH%2FiaLh8I0%2FU51NspIEfq0dohwyFXKgm4NggwQ4rRhCOUFtxxo8XnitT4cnGfT93IS8FaT85XE3H5LMY4zIEPL1hw443wz%2B1UmhTJyJGxZzw%2BwsKkKZgUiVtKOKMEb2AKHTv61FNc01PQFwKnvsZ%2F9pPA4RKTASWahmh%2B8MxwzHxKy74IRn5LGRjsPUUwTu64UYNY38caqd7HKucZ%2FtHnODtENw%2F2UfHRMaq1UUPDJQ0OKkWCeet5fYOhII1VRz8%2B%2FElg5j4Gxur3J8o2PJ4rg%2B2d08T%2FfwEzSVbyZ9XPro95T477lRKqUSRXQnauHNsISAl27oWi6Fv9z48JMv8r%2FaMMj8onCP%2FDuDZOuN%2BGPPr%2F%2Bp7bx%2B7JlbYdppcNhzKU%2F1Px5aiaGDn%2Fs1iGMaBcleKUo%2Fv9rcxkZj7DBEKOfrayytXNLYiUdBY%2BpleQXdnscKlQcpzuWluxsieeyuXIK6SdxozitWyGOV3vOHHjguyCQ6fpIYy2JwvrQEF%2FQa9Pdf%2FQqOSqCiE%2FEE1%2FXIVKTc2tzWbHnimrEd%2BVyz311Ml3P0GVTj7PD5aDnsvCvH36alEaPMePcMegXs7x8igTu4B9v7G9vTHvhCu%2FkzIdx%2BBxC0ay9zRSvoS0F2lIxI%2BX7klU63I40gLQ3w5ep5na%2BSFnba3z5D64zv%2BQtM4n4ffG3tq4aNHGRfxgrXPMim%2B5487abL7xhdseIRn1KDl%2B7aINixdv0OD%2BJSPwKf5%2BxoP6aiTeQIDVlIhMcL1H5R9PYXvprs3fv2bO7MOplCmweuiq2JRZ1zz%2B9a%2Fv2PH1Hfz9236w%2BZrPXvWfAxlj4NLLHpq3c%2FPQ3uvmvbrjG7fe%2Bo2y%2FcLdtE6VUlXi0ASb1VLUBVSUWSU4HdvAraTyS8xzM8NxvxFkXV6pUVRiJwcgC5zEeht4rwcp7ki0k41G0qlQhG1Vzlq8alEmnFi58caB5Q9vn988MLhqyVlHvLEWjtQFeupdiocF%2FtkkOGPW2ibWaBTkeZ%2FdvPWazXfOnnvL6jkRXpi85sFzZt%2B55ZptW3bl1cCCHZPD06MhySha7UFzjcjbp8fOecFCirzAG%2FyVjBX6OFIaadSjQq1nNhyIe8tVbaaSdHlXIWKacMeuZA1uxS95zILhyrxAdsXTL6m7kNQlx2P9uZf2qhufePFFbpI6%2FOU0WcP99RrCsrwseVot5mtytpf6Y0gm9sdeyKnPQ7onyK4nXlR%2Frg7H95M1upzu89DH6pgUcikoiihJ6NJKmRxV1x%2BMJiOA3YwhDRQrWU0u%2F0rvq0VYXnyCwsLeTJYBq3dAtJDavuzyoVpzZ99Z0%2Ba0uoiFH%2FxcqgDR7rUFeOrUn6Cywb8ZeNMbhLV5ugP9l0zv9UN5b5mFkjzxUcpPJCn3V402pRxtJd2GrnLdhtVk9ZSZh9W91fCSH5B7ofxPiWL%2Bj3D%2FuwhBRdyAyozeZwvQzs79soi%2BBKSnafLviZCcfrpBpLyimfLfTyJtbyruIQKD01tUwJyKEo%2FybaxkSNFUMdMkhQoJyRBQFhnUkDQSXhTM%2B3NmY0EDM7ffLIjqWEGt8lCO6mLia3PukFnghosJD5p5SIho%2FVDkzQfLE%2BIrYoJXkD19pdP7OwG%2FvoIUtagiWiZ4PAFTHHlTVhRZ7dYmPar%2BNJ%2B8JhmR6DFK5DV1foHoLNO%2FpHrvZfmWZ15RQlwvoVDKhCWNK3CCch9lfFBuAqUgpFSShmNaPj%2Bi5%2B%2BWZfKeViJfW5HnUakVL4UCNVkA4%2BETfIqx4B5xSaP2L1yn0zn2ltPn4%2BOqZGmwwEVCaCSqG53ldtL1oLGAhdMLd09MpCCF6tD6ZnAZBY9hDaYsP0jzZ0j5ZjKsF4i1UmLuhbJMCnYJPt5VwFNvmZawXjEvLJqIH8STonZjq7BZ8gKgR20C9MDFqJAX1H64QW2NEup6qgzLP8cvppL%2FNNTOBTCJABOHeWoXzLhw4Wuy7gaBtjKr9kgKq8ZlRYBS32Lpxc8vIhpNDTfyNXWybMJbn2RyQ5EmWc2QF9wmSZ0KYCE%2BcPuYO6b15Uotj2Kd4MItLS7gtFbkTdrFND6pvEZqv5Yv7jXAus7Pg7avo7KDot50NX3CPkP%2BKps8J9%2F3mGQIteY%2FLGPC%2BL7872SPR2br5fy8MtKBMHedGuM28%2FMZmPJMrGgi3Gb1S%2BSi1%2FL%2FzrZwO9XH1ce%2Fz7ZQ1WSoY%2F%2BpMb5FT4ua0Wm%2BJf%2F298nFmChEQ%2BTi71est4mq9VYI6RsymoRJKYidElT2FGnDTZvqtfhGAFTbeqEw68GqtfmbVa%2F1IFO1%2FjdWr%2F8BDRRtQh9XNjubEm4aWVpVonpTGR7PVGc%2BKJNoBIWF7kYi4gUV3r1U6723i6TxUl3n3%2FtM27aZfKb7THiHW9VzFSwHJ05VfK6Ar7kaB0XgPPE0BSkSFKsBUpaLihEWoA9wBt8qirh2VSOkZwXEwyrxZ5jyt2rJmSo9gX7cg6jsEUGJU9z9xJPOEM3uQQxKgkh35DNATnVyrmJ3mbCNyIB%2Fyox4wH1bg2DwN7q9kov4pFqny8oSm3RQbGgJ1QQTs6ZMLilOVYJ9v6Wha3HcJ9jddsXp9YhGUXLXt%2FqMDnvLpPNTXfNa60z5%2FyjXQOMq%2BlNmwh5egpYrdfZQZV9rI47xlRkuyTjpzsmCBSWNkAXVoK8sgYWqQJWbo1RLo6QH0YW6pxqfCnRgkd%2BRiFjUQUQ7poIaYoakgXxwFd9BuuI38H1xBxXSFb%2FpBDIKQFn7YB3dB36l7sG1FLaKiBdp1KxLvfswap%2F30lnVESgNnvjbUoT6w9N%2BXoio0qcYOIM%2Bheg940YimsucQVvli9NEcft2UZwGQwLuilj1fFr1i3NP94X%2BPE7Hpvtj6lBJfJ4R6NvWiaL6MgzWHxiN66DExa%2BdAdAbMYX6HVF8A%2B7rjEZIXAVbDe7PVI9rmN69JOLV1DOSvRPxWNPZBZf%2FNf%2BNy65BhYxxxV%2B77XJ2wfQ389%2FIQPgajXbwMsuAz%2F0IaQcXJavKbRqR2IqyZruXjVC2%2Bhdee%2F5vdnYOedpmVtR3NGXldxSzDSIiBVpkGb9by89UpEPKrSLZmyFDzMab%2FwXl2CNe7s%2FqCtTvWgG5kpBmCBlSzDS%2Fr8N4uwBwohRW63JTS1y32f0TQsPfXVGEHQrV8%2FNCfiOUVirYcBbIeA2%2BiF68rQIo3B%2FS628vYESr79ehzS7Q9LEL9UXmik9XVHb1yBO3Ngvt5935%2Bk1efkV51mzzrM0LL3%2F20avnwMeKuWyOUZg2TasSqZ%2BKcZQiOn1Iu2Vh497ALUVZiCKt%2Fgh6IvTIj1ZLRjWAkpHKOKovNwp00eqPROiAbiNEKieXwMLcXhVJ1%2FuzmLP4tfxaHR59cBdJVG1kTAgl9ze9QKUEQ946Hkb%2BokJ5JRDyf54Axur1D%2BWS49cLr0tTPEu7UmXrxcSr3XNvumv4yXzInXKH4F7Tc7p17Zt%2Bt%2FqW2%2B93k063X7VW6lALxTY7i1nBXMxcxmzQbabxz%2BtJo%2BwijYaIGMNS8AoSMgAPt84DdHOoMPfjXhF%2BkuH1tZvuFQrRCN07xGcXRX9MYxYchDe5BcHj%2BZ4i%2B42WyPc8Xofi7bbZJN5nJLJ5qr6IqRtzqNlM17SpFsnkEyTWoABEjz4JXOQvzWYuwdnV5LNGOwTM5v9r4RpQ8ZXsYodks3o31JBlzbYtNotisnm22MxiwGFXam5oN1n0TA%2FhRvshvTSDwHff4nNzRo9Dum6PaJbMXzDz%2Bx%2BFkj4L4bFNBb1asqsgH7Dyh4DvbkPtf5yMDKzEwyoaESMSNS9P9gJVA3%2FRTlwoMwZvxECFWxIPNw9gi01nOHjP32esZTtmXHnxvZd8ZtakqQ7ekajbXetpNa6ocTVxJtY%2BuSe69OLz77zh5bDR3xjZMzUz6fxrz1nqrZGcHQHfPVefN%2BfiK86LeXj%2BSc5lPKy%2Bk%2FvCUI%2FDaLFYCWHr6nbXuILTIsb5imNKY%2FrCm28fSMxPhkN1XbNMNZGuqwOBhtTSxWuTk6bw0ZaG86b1hKddePOKuBvmiguYBn4T%2FyOqOyGRBt7bKUI1GjioBC8aUKwF7Q319UgcmtFGIzCJGBqwQij0ynDsfdFGc3TS3BlNfJ25xmzniMkpXXTPvCaD3ZaZvyzjmZdudBostmhb0ORZNN2sJBeed1HXkrUsywueQH%2BL0eCPxmsa5ZpgRJSDZ11yDv%2Bjmbd86vxZfc1WcZJ3UkMq1BOOOVtvu%2F%2BpB%2Ben186d3GTwWAw2jheaJs09%2F%2BLNfZft37DALyrNj1wABMuUKbODyTVnT%2FKYbJ3Tpq8IrNh92dkxOj5P%2FYpZx4%2FycyiVcDYdn4JbEoKdQi9054iBKsygLW46FRGxAb0NPNCm8BSNCPjoKcj6EAus4SuP3rB%2BcV99%2FeTF6294dA8%2BTK6v74MHVpYNRt%2FI30e8QGTOOdfGWzzxcy%2B87a7bLjw37rHw1nPzp0KyyRSeZO%2BQQhInt3dYgvycjrPOv%2BT8s1rptaP84VeywdWX2T4ysr0%2F7TLIs6%2Bx9zib56ye1dM9e%2FXsZmePY3NDs9zlnNVt4%2BWgHJbbz3Livg4P9WWgviOMm4kCRT6I8vw0NbUUEnFvOuFKoxQW1gTsvFirsF5pb7qTUCx4i7VmtToveaDxvK9uOaedVvPRpVOnNz0Q6bry7uiSdQ8t7Vy4JQKVS%2BXPplV2ts4bvCwZu%2BKzgITtxepaPRzWdpv74muvv6RO0SorX6cu%2FdqKn%2FXWnrtp%2FZragz13DUCl5myiFW2Ycvb0PtsXnU%2Btx8pvLFbUspLX68mdegwmOif%2FNPDONajTGoUh6tU56HBJCTBASVvNUB5VIiKpc9kd7kludodSFz7xQbiOmMk5dOYk56gzL6uaf7N8a6MQOHm0ae6snZpFDfuT3%2FjdYzjzwkXXIVHoXNuCfQslQZqBZjTsoHMqrkE4jaYdgkGz2ATOgB3cPkSukD01DnV3ttb1wx%2B6arPqbkcNAHoFPzKUUQ%2BqL0k97pjbZv1I%2FegC9zTFbrrlFpNdmea%2BgIgfWW3wqkcis8ky5FAcRd1If5nNZrl2FFpungc8wpoCl1BpQV%2FScS%2BzjlASyUTVv%2FAJ46gkJI4bHX4lTnloctxPZE1ckS3%2BjG2fKIjkQFyzuo8jvYQG1OrGvJPSTu%2FnSp9PHNTl4z5hK%2F8gtXVKF6gEKiglgcKiRlCESsQCV5QIlKWKpr34lt%2FwkSx%2FJCmP5%2FcBKQfl%2F5gd%2BrOS%2F%2Bp91%2F%2BYCg5CXK2W4M9fu%2B%2F6xxX%2BvnelVuldIDCG0VQTpU9Dw4pRfei%2B6zWx0MLie0gPbyrkmRU7OwT16JGeyXLHqOLqAfVN1GPlBzWtFNzj0TRTCjogtP1NjIvu5habN5Aoa1k66wGpqriVetJgiGdwDZtKhnN0y4n9sXYnsqGmZfDSR15%2B5NLBlhoDaedEm7sxmpqRija6ZEEg2EAnTiAC8IrmFbGz1q08P9PSkjl%2F5bqzYqT9hMmptEXDgTqP3Wiye%2BsD4Wir4jCeoHbbp5hRfpB7BakUIppIlPCD30dR1GtslDz8OsqbXmejFC%2Fv8wu5X2myq7SJ8Avzv9DFUJySf5uNvq4%2BTi7W9D%2FOZrLChdwxmPNiBRqVjnpK%2FaGxRCDspVYKAW9AN1JANoo8wP4BJUlGqdgw6m1qPQ2QW3%2BOfU5%2FieLS%2FNuKpDU3uf8bcAXyBal5jMR2NEAbPAZt0K3hvxHBEDlUxfIGcD%2BN2gNSNx36nfqlAYow0puatNpRz0e4W2oahKzQHsjf2c16ad%2F3t2KTtPobnX6D8C8pd0MDP%2BKx7wnXqGGlLQcvikMErm6TmfsuxJXbSAxqNjOogJLQBLiKEHAE%2BJGTS3JoEhTrz8%2FCB%2B5YlupJ58aOat8Kv4JvregxwcU5Cp8GFAFm1FyOfto6GS2m1NGTS6CPNKkbsTdCBlnN9onMho55BX8IJZtEQ35lk%2BhtwN5A0V3RCPoD%2FyXAcv6pAtbZczRUA64JmcUf4q7Q89ZHLeJVZ5D1Ps%2Ft%2B0iCT3AHVtZC7JDCXfR7OSb%2FXja5H3zQbZL1B%2BULX1BMTEk3AseSpmnKEK4T9ekMIidUCRQFfcbj7z8gNLvzF7mbhQN8h6ZbRset%2BnQWdS%2FZX3k7WpS8P9sfo0iGS64wV516pOhjI6TZ2dApgI5%2BLhxywYoWxKUrykKJsIoDsR4mSrCTg0egMPnLW%2F3Q5Nn8BZEuzqEI7HK3n0%2BzFmuO3TtWQ5WJoG9YqCD6Gc32SxnbnVPfsxvrFXK2dILl7bLthDp6glhcsfp4bYvbSmj%2FmQ94uBTw0E73x2jbNRCvC6VL6GCFDwU7eWQDcC5FY5s0slieRDwtAbRsbLXbaXAuu14e2OJw1dc6jQ3ZdY8v7rv2%2FBWZLqvFWVvvcmwZkK9f5jS4muO9yR5res4kfkRxhV03L1RfPOiPtYi8pd7jNEsOpyTwxpaY%2FyCZu%2FAmd5Or9uS3DYaeqVOhH7gZN%2F8I%2Fwi1fEuLXvyNivibjuKvN%2B1Nc01HF%2F3h%2Bef%2FsOhox8MPd5SFucPjorQwXT%2BytA8EmA5mamHNFDVhBI5pjZbQpugBNkO8MvRub8KVDKST1Wag7D3xlin1ZF7LFP%2F79nbvCXFOY%2BPUjrT7%2FotsPXXZ4exdPzuhZuL5LUXVAn7k7PbhG89uz3b41X01gbjP1xwlu5rrvvf9%2Bpbs6E%2FVu7Nk642%2FPYRaAiUBdrmO6CDTBLPQFA1ur0uXoBR1INDMkypKpoTqnSMx5GiEdTEaSHLs0Alvu%2F19%2F5QW9Rv1U1ridT22i%2B53pzumbs%2BXFFXYC%2B%2BCGsTj5JUT%2FGCgRt3n78i2n71FHG4%2Fu6X%2B%2B9%2Braya7os3ZbDmgWfXun44e%2Bu2NZKuGZ0HiF8M4TlMPR%2BEU6rPKRJ8wOU2RFUFLex3egEsz3YqEAq0cqhAAW19dBZIlVzR61tuIdTnpXH7l%2BuXrbjPUyep%2B8cl6aXKWhPHpDcXl9KiTWDNr4mBQc8Tq%2BNzK%2FOKSbsfl79o9G20R%2BbrBXYvUg0rLHhtrc4TN81TTOWSZ0gL1ZVlOYH2ery%2F7XVUjFMbzYpg7UswcqJPQwBd0LKLabJ8IaCr2otcjSkIrGwootKECaUd4XH1%2BSdazRrfddkBU98t1htvWrbjqSqjaCguxrffM%2F5zDCpBALUycmajhd%2BR6ww4SWafuZ5eU%2BtPid4lgd3gt%2Bb%2FY9rQoZNmiXYPXyRHbRs8zX%2Ff4WIFjWZJtUdSD55AP3xtXH%2BZipC0EqdBGDA4CoYEU6gRLGPU11QhkLTBiEYPiqOeQgwTCl9aok1Qr5pFf71qEeNxjy%2F8F0GoqYPv75Yh9j3x4DuJ%2BuEzHRpAq2lMqb%2BqfTdiq6kGtzfOWsv0c7lSeMXDHBDe1MT%2BLUgx0Pg%2Fp87u2UicdIvqQi8DkxhcUwUXCedMpb4NQjwY3npTmgsURJavLwCRyEcN2HfWsDVGfv%2Fu9ZUWUx%2BPYFueUKwaNvbtu%2BXps3eVWbN1GcgVrdMnWJ7WmJz9SD66EBidag0NF1Ukep0t5A7sFCWdhzvYwHv6L%2FBehXuHqfaBwBEU7hfVLcXvS4VQv%2BT%2FvaSIl7cbeMc7ekv9i8S3e1L5xxpvMGcu1EYPbKyCiijjGXcDKckm43PqU2qNWlXusZMiqF82cuVzolUHN9NNR0HZPxFPV9V0wLtvq%2Bk4DqOwVWDlzuQLVdqFiP08cRX7aRlBVfR8cb55bWe5LExnlcsDp1vAP8Q9BucPMk1Ulh4GnN0SAdxcNHv3q9ohx1Ati4S%2FtkWjIDe3hQdkUGrGRaFBiUdiTSkI41UkMuuQHP%2BEaSQYlPQTFWJF03BNPpTu5KFAdkWgDukzsZKMG0Q1TAQQglScOaP%2FdsZ8%2BfP75D%2F9Uu5Gs3FY%2F2SxPld0DHOciXI9gqjcEidXjE%2B3BLosy0OcX3T7O5g65ROGyzQ2BZs7WbZVnO5ydLe32hMwTQ4wnnKXW6XW5LAa7oaXOIHoUl0FgLQLH2by8wSTWeAx2Y5PDazK3BqZbeJZwXGPaYhX87ZNszoDdaRxotXO1nNlpdvAPFWHDm8PqEE0sZxDEqGzxisFNnuCWetPcGrObN0p23tTZwMuRVodSV8%2BLTrOV3eRvzjQZiSjaLYS1WEJe0kNsJlZu9LFun7%2B%2BwW4gRDRbaxw2nrOGm%2BxOj9cmtbp9ZqeTM1m8UXfQQCSTVSQox6pvtjot%2FFpHvIUjJovFEoYvHYV9C5Y%2FxN9OfcalvII37UEhTbTg%2FAQIaPb4Vz6j5u8%2FaViycMod%2FfkDcpu8QZbZoeBi%2FvbzP3XPsZvOubMtaPHkD9jt6%2BU2O7vqU%2F9C9SMvgrXpQNG%2FE0oJxun%2BCiElUa0IKQSUwERxOntKSV7ekcuh9VBZBBo3VUcB58ofKBHCwLyf9qFosz9Ibf8dGqwaBMjRig4SGOZ2UkWI7UiO9OfUPdxOYFApUZyfpY7mgEc5rtNGGk2H1lPhAk1Hp%2FVAMqQEHEUfEYkkUQq1JMdzsX7kklRrTrUi1wMcDjmu1YYfATj7Y%2BpGpPEBXuoQIj8rR9mgCl4C9yqmF7xnVWxGVniNqtpVmXBvQ6iwni5YQ8a1jYrXtc2J13HvgkvqWxuva1sbr%2BP2S5ceKGyBwDv2DbrToe1u6BkAJV7xnVLUaq0sJB8pFqcUIPi3yuwxi4JuLr%2BP30f3OkPQ72aO0xYo3%2FEsmO3QO5qEF8S0qQH0UsKXv0brnl9%2B8M7jF174%2BDsfvPOl1au%2FRL5%2F9DsbNnwHL2pHR1NTRxMZhJtHktOOxLxErPF6YlLvpC9YP73x%2B4ofw%2B3xVdrHcDE0dQQCmCRgvt9b35xINDf1CDcRSfJ%2BpYl%2BSf8YcurfmXP5F%2Fkj6J82jNsrkWiEuhVlgFfyNkB3S5MUzLhoNiwSCYcxQ7Ui4J0Xh7fmqRbaPa1tzujxkBRlsEHy0%2FOM4pYLPb7g9O6BQJN6l9zQ0OGyCaZz0vMTbHOzXfQ7a2tsterTcqxeInODoemdktw%2B1SbVhKwtW9ffe8VKadK0OVuC3bWzyKm5LeddsWTeorWyY9IMtUFutdu5g%2BRn533qkocdvLs2HmhU75br%2FMmWtD8zA3OP2t1ea636jEzqYxJZGAwFiDEd61oTsrRuW3%2F3pYNi3bS%2BRd%2BGjOfVpAPNd6y64Gsz1GaZleWIPoYL%2Fv9mTeQBENVEguiF1aC4YeXxFETw6QyPfn0m9g8IrMFAvKM1EI11DARnbqibHk%2FIojy5rSdgCyZi06y8sS024PeuO4MfwQ5Y9yKRZCqyYaF30vzeHlmUprR21tR0t0yz8KZY66zWuGvxVQB%2F36kP%2BK38t2Hu6NQ9SFJfw0AdpqPEK2qTMpf2VCqJwqPoJezTL824b8akoL%2Bx03nhh%2BoNo5e77psxg9Q5LzebIKD%2BfsY34f2MtB9fk9v5b8PT6tYrgv4kRPwd0q9z3gdJSJ0653KjCYPwCaR5aUY63eW48O%2Fkdo33yxX9wCiMv2QTrk8eGSI6Ag6moG9t2P%2FF7GRNlDjl0gw7pJ5aOXXqyqn8SENnXBmbSwUYLyqJjv3UmY1nKr4t80no0faXsaIEiF%2FBRaIBnItSce4OUif7W6Vm9T9H1X9Vj71BEm%2BRdmIJQST%2FZfVdudUvh9S%2FqqNvqT98g9SQ3lHibZY0mRVHooyDN%2FFHmTgzjdozKw28NwQ0hwN6BCoPKaEk3YtKwNhwRLXuk076CGoZNXDQcRwZvreTZY9EZi%2Bd0s4%2Bztv8iei04JQl6ZbDD2eHV7X4uHuFVfPrOmcs6m6Kr7hssr%2B1VZFcEZ%2FPdJkn1hOs8SXS%2FNFFgqt94PIZzZ3tdaL6Q5vo6piSzdy737pwsX1VyxUrF15iJ4uNkq%2Brbyg1Z%2BO8VsNC1UmcvORPRfxtPrfRwL2p%2FoA1eZp6Z%2FaGffoewaXcA%2FxBlKlQLfhQL%2FoPgBGP3qsA7IQS8qDVNswHKRSheDUvA3Q7MZoRcJMxlEygujn1QdyzfPfq3dEp%2FbXh5e5YXW2Ngfvza0ZF6UgFL%2FE0fTq4LBlvTE2qb%2FKuuzYSXVnjTfM1osvqMHVbm9950quIZlbqaL6YP7jk3kUtA0GnX2nvq53f3WoSsvEdDRnULgo2fN7lNZJgI8%2FVWi33c3bBZnGY05%2Bdm%2B3qc7fNmj4YGKLj2nfqFP%2Bg7jdDlxEV5XsJQZP6hYrS1l0VQr4c69Xueixp90gnZPmE5OF22j%2BSYEWHlZ0K%2FHgsh%2FZtsbh6h2DNRlvv6jJh9XaJaHCZDiUDKNTMkvb8vsqCyf3ZNdSmO0fa0Y4baJTtpbKzuVzeeSI7fCKr2Z0WypapnXJ4gnoWy3PoUIlIQ1TXdqhQJIXp9Wx5fYdpeWh2TY5D%2BYVyKd0jw3iumwi%2FBC3cEy4o83QlZnW79MrCgCjbhWXBlRZVVZZv4rIKpXC01HFlHdHLoeWVl6UVc%2FJ5uGm6CViW5mulYMk%2BHqNYr0AyUPivLg2oMs2MPqtuhHyRyiwvNJej1Br%2BfcLyoAyu8D9B7bgmzUqfFobF5nKnK4%2Bt8MPJkI%2FxHUNWk117jugWF%2BxazTAALQn6%2BUE9lhoI5ApGA%2FiuJOsrlNP28SVVuBVajXmircLel46w2bJS1Q0Ft0KDuikDFL%2F3pYrid1Q4FvofwRIo4R9h2ftSwc6jHAMqLcCql8YPHtlzGoByNXYN6v8hXnRaOhUvx0sVLCexwupGDR4NOYC7PePa5keIPACnuAdD7dEadRuTIiS6Lb7uskb381My5yjzF8lGCjBRqdwrWJCagfB3yCy7XT1i92hbcZ5Ci1FJkgYMDf6n%2BjspIsHFjJrTOdzSMuOa9DbDcj%2FnH9N9bIoGVgzHPWIQuFuYtaMRaq8eCKI0gEF6lPOZjBz3EEvaaxwSUT9U%2F8JbJZPJJLBLolH1La%2FRbF9AbC8JJjv%2FmMnssKjLRBJyqj9QXxNko0Ux%2FX79epfiXkm6fmKwF%2Fen1HLc6LxloXWKvGa5rVCVL83VuiPcDEX%2FK5pTXOxHfx6HHB0t2FI0qI2rCZFTrvPWU67zVuS%2FkTsLnc7IKhFg30e4FOkqNSfH5PtkmUy6Cpiv%2F36k2sbqCeCFNa%2BURpoY0sZoYmCgCr3qgZz6s8I0gP1bYiR%2BD79H56NOz0EVWCTy2%2FfffvSCCx59W7uRV9995eqrX8GLesOXNm360iZ%2BT%2FEl3uZqL%2BFyzSZ8XxpTiI%2FG0nkT4zznFZ0t4ipMz5v4q9ssqbdKUZt6u82knPCrt6PZwsnn0XySVnyPR1ZXAn72yx48bWJsu7apnI3Hy8bygUK5Js32qcytapqgmn95uexccj205vGgJ%2BeuOeG2SORmKZr%2FqKzcx9SFctMJdwMUFZDJITs7dnOp1EKZCxg304Cevyfya%2BvlKqv6aXK1qIj3imL%2BL6hL%2ByvUlFfE0VKZ7E8gBY3M%2F8VoJCFgizH1W6VyC76nH6b7jiibYVxUmVIEspry%2FLgZIlCeP11Z4zs%2FAwvVwtGFEut5S1JY4lfyT0N%2FevOLo%2BrUEgjcqc9IkGpQbv3iW7Co5b%2BKgjvpzYdH85PLcc4X21ouwEGl%2FS4qnUAvoSlXUUhR1eKr2VWFTB%2BGMl6FsiQsVD1R3urlAAIoSn7JQkmiVVCHSpCwDH%2FqPepXQ0Db77CJOAImohB%2BRPWr31ev5g%2FkE%2BzTa4lbvZo8xdWPffQu9yJTPCNB66s%2BzXoJt%2F0L6hSoCuBIoK8fnBGG87OoRckJpLqyWe4YbpGi50g0%2B3I3UD85Oa0fzubfoXxPLbW3FDWzigmyJeM0tQkax7PqTy80%2BUxfUHPlBZIRVNQ%2Bv0xRm8REKPoLmNr0%2BUo48v9GFbXPKylqQ2IKm00QddgyWGMROCTxdLB9nCY8P7j2DjlsV%2F%2Bmfr0C0r%2FNkeXbbpPlOTBBwT0mVz1zx9S%2FwJecBF9Wgv3p032iP2v4VSgfgW2G%2BHUEdEXU6iq4CtpLJfIN9XQG8dwa1VoO8XC2SrPDDyCOQptXgbcPvlAgBfxBoGwftQKeKFrNTASPt3pGGqDt%2FQRasn2kri%2BH6L80MJRsmVYJrAKyDItpJUy3%2F15WYIJqcJ9Q5N%2FLFJ4c3dc1URpWl9hW6mu50MUIelg4ucTPf15zs5DFo1c0VSp1tKB9jkwIyuM45kb%2BIP8gHed%2B6jO3v0KbIknzLy636E8KPTdCuUpB0wLo9JKnAO6pv0vS31EtBha%2FfJemkgLVVnd8KCk4qBTpQ5m7FbifBKrPJcq0pZAFVG%2FXbOFz%2BTcq2MLrcmV28Nmi%2FOHskh82bau0k8eWCaPijQPWQ5lUvslwVCfHkXBMIehqUgtDNLeauH1huvZTbYmw%2BluPjyWoNGEuxRLR7LK5fSyXFUyK7PURQv2v8D3XOt2NJ6liBbmPGOsakw1kbeOs%2B31Wm5qpH%2BiJWSzqdPr2O7zc2TmtnrzCig6bBd%2FvgQmzOlz0STWIlmZEQfupogOZFHUZ7EkUnMn0RrpIMqAgHRJAOjIJ3yGw1I%2FMAp9q9S3Q%2FclADNm1wEeO%2Bxbwg5OIYHZLY3ehG5lJk2xhco%2B6JWybpEVz2wrR6hZyD0QXZbeDVB%2BonmlimpkWprdAs4WEZDSQppsDlcdCBJJESIYFuAtUnC4GIF2C3Uu2Kv7L1bdz6FxtqxpG4TqQOqOUNAJ2HLvPWA2GgDy4O4vaDrtyl6P%2B1fAll%2BSyFcQ28GHqh7fvvf37udylf0fNwhzgz87Y%2Bcf5x9GnF6ygHu18sAbipWeF0YPBgp2GaKeQduxxdEr3SgbH1kvH7tvqSLhedomOvZyts2dw8acu3dY%2Ff%2BucuMtCuP%2Fe4zC4XnH3OLZ8ZuxTWxy8dJfU5dhDeKPSlJy5pn%2F%2B7u3XrJhmr9C5CuleGflGQocKnlAUaRKp0BAHV0ZwUt9VCqk6zYOgRIuMfePJzdmBdpPJ7%2F6B23%2Bf%2Bsp9NMDZevovvfYHG5dGPISQq1DojqNckchVrCcCYz%2FQ0hI0m3NKDRfkgsrnamo%2Bp0CAq1FyvC3a3Nak%2Fs5VX282x9Ufy3E39VAx6o7LpCvO2wK%2Bch9jNqpJCutcIOooKnYWtDK8gTRVYygRQfwgzKM5%2BjP2jOZdx3r32Py7rQUPOzAnoRs95NvRAR0qLGU11Taqu1bUYSzMcWjMEir067JQQHfIrLBHsrgv00%2FWavd8HRLMEEYFSW3HCSNQehnrHztKqHcDyo4VfZ6gPKCR%2BgufwA8GegxUEo4A%2Bgd0BASHiH6jYMLIsUdQJTs%2FC641KN4oCHWolCMLlMfIdtWKScjx7SM5LD9HnfmhrGI0S139UWfUnxgOXdJFW%2BAMcGjKr6eHAttHF5sUoeArYKDcxMSYcKA%2FxUDhPiEOEAPafSIUFArN0r24ynI91EPARDXvIDYyvqZaWeroBOUABQA%2FE%2BDXC7PWafDLQY2oiwpUEyj4RQtVlUp1GrM7In2p2A7VuiOW6otMiGOo5Mrp05ejVuTy6dNX%2Fk%2F7mybZQ0nUmfrbx3U4KueDnlHm5wdh8FFeKnoaKKh%2FTK18StOPhwG9Xo5mqXAxvw%2F79YQwwDR%2BnAKQQ4izVXioB84qcppWB7IqjU45z4CE17OvF1Dw%2BoTFqxtz8dxwtogBnF9MjIl%2Fin%2BK8s3hM9laIn0TiCbTAXL0T798bPXqx36p3chrv0O%2BGC9Xaj48Ecv8U8UEeBvUEsDlTepiU5OvlpeNGvpnKF0RvUooWhIjnx6GeBapXCQYTw9DNg6%2FOC3gZjp76oNTj9Kz6Jqobxb9NDqc08vcKReOpcsQV2K8InXFaXW3aI6Ofr1k48rp7CX7rx%2Bv1UKPsfvzQU0Kc83i2VdILmd2%2FyX55zT9luN2%2BCu4nKfwPcK%2FCvDVU%2BpHh8%2BLaldIf1fA5h3ndT6Fln9%2FW%2F9Ce1vndfvJtnPVO2xhm3qbafHVCN1X363UXHq9xuVD8OSD29Z8pZ5cZrern9cAdGW%2Fuib%2Fud%2BVK0L9a42r6C90kL8KzxwLQw9NkIQJL0ASU8M%2BVG0KsUdgdvpgP%2F6NqqP0%2FgHZFUfGEijZLHpiIgvV5%2FBltrj8Qd7XQd5p4P%2B7tJo30NMO6VGBwahSPMYiaaBYoLY6uEnciyhhh1Z%2FvvacG%2Frjpsvnpzs0B1Id6fmX8119l88XnOxe%2FuGrzzHcdu7UtY3%2B2vmXN5zUyj3ZcPl8p1sZSs6%2FnGXtwrV7Ka0XZdz83fwjjINpZWYw85lL8BRK4nGyIir2RiOsEyipuEcIakpGjWgBjLiHWOgj0Yi34gW1kKPxHt2Na5q%2Blwg1RdRSpFDNzosb44YJXnAfoEOpZW%2F%2F6u1lhYA6leevezbI26zNHO811M2dc5HFxpk4i1jPC0s21%2FBWW5DnPQbn2X1WK43%2FaM2n18DfSoybbNHijFpamzXI31eRibGUOxSu%2FlT96YZlq1Yt20DaSBuG6knw2eusHs5EPBfNmVvHKdaQzcDfz9ZsXmLDWGXy2U5OsYSsIn8CS12jQIyD12KKqZrLPy7mSPdICmd6WGHG8NDZkkHuE4h9TU8FpmUO%2FVjC%2FEinToFyoNDz2p9XD6g78WgQdPG7Z3R0T%2FZ5dTM9lsL8Ktek7szl2L%2BgQwGgwkZHc2g5Su7NvVqwGy2Ua4KSXUwt1X4PaM5paaEu6jQ5zVFyNabxvUksVt2T%2F4VeamYPlLtffdQsk%2B2sUTY%2FzDXl%2F05W53%2FBz9UK3p7LjapZ2ZxOm%2BUlZXrL3HHGqO8%2BwVroDaCTTnTxitMxmiAAYQzVJQH%2Bnj3oIHnPaN6Zq6sNSLjBl8tKgVr2mj%2F9CWi9dnKca8rBQBsd5R1tzVlgrl5pbnPw6kZclCr2CHxMnHohLz%2B3KRQokzALyeIKFU1TNCiayJdoHvDYe7K6mZLm8S3uJ9dojuaJ62%2FqN%2FtjQxnSnhnKPw%2BLNrLi8ZKyJ3x1YhiI1aNAtP6NzCGzYv3DmaGh%2FLvQZnt0evgIhTFV0kE%2FPYxAnOHhCQUZdCWY5JWJwMzlAGl1mpNbDU7yyGnhRMILsYhH3VRAijrPcBU8%2FCj1Y9NY6cnGVW0CjTLaz7E3epvaT%2FLtTV72Rs%2B0WVVmd0dz%2FMGTI5F0OsIviaqDlbbO5X6xT3PeXbXHRtf%2Fz%2Bfdka%2BeKPr8KF7IF4vBsT9MFPuPJMBTBMq9hQxXelQ%2Bbewnf18ap4Ib%2BmSMrtDU5zqlD8QANa5MBGh%2FOwOvSDfcV2d66mfEWsbGWmIz6nsyZDWQSmqmxDneYyvjHPmRXHZxeueyRGLZzvRioKnGto9nIPkibAJA16adcOZRQr1iAP3bUyBR7T4RgAWTKxhkCYFwshq%2B7iV9r0whk50cmRcTg4fy5x4OmmNkHndIA2%2BYuMbmE9dwGYB4KFTsvnDE6Ah47r%2FfE3AYI%2BoXADpkdlENcZ8OZEEf8FFGZNxMs6ZLpG3SUFLL7Q2kcFU%2FA%2FJsw%2BvWDa%2F7emewLaoeibaF1B9qUNnuqWK3%2BUfXYVL1v%2FomD15xxeDkPnXTOKSVcCbDGtOu0YQNpGAP7U1HU58UrqGu8xIbHtkQ3LVhb7Dx46ET3Ffcm1q0YcOizNmf3bC3VjWfAcpSv3MyTlgJ23FHQgmgvk%2Bgk8pL0mcCDOn08MDAQlf%2B%2FSlTZ1z12fnqntOhbOTL9%2FZdevbAPN%2Byby1f%2FuUtC%2Fixm8ZBo59LTXEW060hGrTDplNprWd58fwB%2Fb%2FE27BdS%2Fs7U%2BrGVCeQ46nzaw9QccnmZerGZZs3Yw9aVHt%2BKh6HN4ti6lxIhT%2FwahnZtWwzlY9QHQ2c79C%2BdxzvVDKy8GqKWQERO9YAKbpsDUTLdWV5dE8PVPjvj9pqw7ah%2FPFVtkit7aj6G5xY9mfJrCz1j1e0BcnPol4UjtrCdbahIVtd2HaURujnFJR8CuOuUUfhrGhgKKgjCYNSvCc1WKlEp8wHUaAYynFNyzZn%2B2MnYv36dbMDBTonl%2FT%2Fma5IKAyEGz%2B4eRnVtaX6tss2o34u8mWorFtuFgm4A6qK%2Fyp%2FgLEBVat5WnPDdKA574ubuFJ%2FIUfZ%2FY2Nt6mN%2BZNNTSTaeI56gKwkXerTe9DDHUw8%2FH35FY3nNN7GGuBKWhrV9ep%2B0k1WjNWVaHkW1yA%2BQHWNu8rtBw2a5YXuE40rs7%2FGA%2Bj09V3hA98yRnFPOGr8ltGlsFdD%2F7tRce3LH6Trcneuiy7K7J3khKu%2B3qUaXPWaX7T6%2FKfj9BX2eZq2XAcZT79u1ClJzUtHUqfqSMWBcZS43Ena0cUGLgpkKxB1QM%2B0Fxz10wgg6r5rltnFpH05pepUq3Y2HfYqeKRntmUFNz%2BXmcOs1H31U6cC6RTVLfCg7RNBF1UF2%2FwBgu0fFQtPEU1sSg3VcNsR7dWq3af87tUFn1l3ltXpaJxpNvtcZkH2WmMst3JqRpxUH%2BWC0E1qOGtP66s1MYv%2BVLu8%2FXFXvV%2FZbunYYBeVN64ls0ur6NzpV9xzlmQwB5qC4Tq70WC0tk8dWJXeHvkD0h9zJOM0vD86%2F1NJMaIAolctvlByferCsqOKDKceOfUu1PsmoFCamV5mCrMUOCi6V6FJosMF22AcrKJgQDVhfYh6tepp%2FlYgvnCEAbJQ1L0rOpajEmRcasMiPfxhgGoVo4rwreQpV6fUJHH2e8fa1s2c13Apl1b89a58ozdoap2sjgLN9uISl7P1DrulyeIkt0zr6JjWocoPOZsaXPb6jtqBblsgsaRre2xHi4nELm0MhG1%2Bx1SXwLpFi53b%2BaHRYo%2FIrbZtuWAKu5cSEXfybnnmUCaXGTpQr0xK2O2WWY76f%2BnAjNVf7nCZHU5XqIkTnpt6VtvsFlPXg1031g%2FVRdpkkyVpD7jnmax88QwDvg%2F66NnMRdRXTcGTmQc3cuINwN5IQqi0yzb%2BYFVHuVqI5s4ADfg5oE4ybDLd28mFSFmYvRoomsWXEdLU2Wl3GJy93ZNb%2Fd5gqmNaqJZSO1l6PVRy0nZIj%2F45EetjLguh1rLqR%2BSK0hO6NrsqcNX8zoUdjQYDJ7tb4os6%2Bi%2BY0qpY2AWlnLRDWdGFTfGY1gV0zNAtJ7pdo24se0D88AwLY%2FgZmE9iuP4V5v7CSR%2FRThaHLh%2BUeBkXwU6BC7lGOevK65udTv%2BtS%2FPfW7qj3ljTcj3b9OkbV85t8xsMj7Ddj7DGpthZKwKPvso%2Fc%2F1K9aLE12fMWLV1y1D9ua8lyJdWXr%2FbG%2BnoCFutf%2FmLILe39ITUV4igr3876fpX5g2zeB52sWnIL4fXHlgeUzOx5QfIvJQyrKQE9wHUqVq%2BPEaOrz0wVvNbJZVSfsuMzxN4l9PkedFzw9V5Dj%2BnzpgoT4ZxCxJfC5RWLc74YVHxKlExCYt0JAOMatREhHBSCAtSfod6x6Ls8HCWECLwXZ9nd5Dz1T24JUdWs6fU3%2B%2BfcnT49Qe%2BkBs%2BwdsMZgPXMp3U5S958snPP%2FEE7bvkOPCuTUDTUQ%2FUzirLhML9yPahoe1D5Fj5jWsaoveyP00PehdUAHk%2FseDVWsvDWXXXsyn%2F4wfpXc2V3%2FQxli3jl%2F5hj%2F83avSCfpTNxOEKLmTjxOEKuxgNlsQn0xgct724mhynupNW1Ph6o3RYS3%2F%2B2TJrzLlkFz%2Bip3qCHKf6eqW02QJLjBYuuj4sobhCWqa%2FYHGEHpcnumuWSOhxeaL7sOakNR6vvmo%2BYcfFA8UFXEPZf9UjyudIOyNwx%2Fi90DdsujS%2FFX2UAwvWSVK4NxaMhAGw3oowp%2Fuc8CTi7D2rBgZWwb%2F60faR7SPsEbjkXy4G0XaqhXPwe2cePjxjxuHD6ssQuR1fq6PF0E%2Bo2t1nePTn8TUmxz%2FA3crMoCc7egESuoTHYc7mYdg6etORoOhR7BBGD%2BqJopELrl4S6cJNRtEAsLP%2FOdvnJq0Wo0GolY2Et9VFB2Kf%2B4bZvVyxfOMz3WdFfSIryj6DwWghre7aQbdiDrkTL3A3vNDuDpk93HqXwam%2BbWmUJZfNn5ozKV5Pmmq8PF%2FjVY%2B2Tlk2M2RzSXKjmbQ4RZcQavEYrN%2F9rlXwtIQqzxQNMzPPfHYLvuPoO9TbT8bpGw5CQPGd%2BSyX%2FCyf0Vxjd2R9NmsunnXYa8xGHzn%2BsSfM5J0y0DZEXWWxkXjcR75KBLNLHi7XvX2G8VOrf4Ykg0AMdBESIpo7MgAfyakA6rkqpI6UjNs0px7cMV%2BD5BF49Tez1VGnYmq0WIijp985m4Sn2gJR9b07riPPFo97OYbUZbxJCpot7H%2FlpZBicglCPN7WOfJkcHqc3ElWqvvz%2F1E6bIQrG%2Btz6WkM1SM9FBTR7FSs8KyBBytSmNEoquJNFN5EQyTiCrnKDx1h58yxCepPHU5nxGoxEQeeOZi2m80DxNxncVhr6BmEfUarxejw%2BWSiHhWk19bSY7aKR5MsteblJpfTLtjimBouXsm3d3djjYM%2BwEW0El9dM%2FueVRWIsXwe43R7SgbVZqrnqoJ1X%2FkuF7pcgf8duv4q6vayV5U9zMV91GxO59UUjW8rHV6u799WzKMT7umRCXbYUKM%2BfoaCcwgaoqZUtmodV3p%2BX7akb4dnU9B9La38RPFUG2SCC90tVA4XwEFhyOpZZrUCsgWYHsczLFBBVGNtstoN1bw0Z%2BO4fYIbvZVt4EUcJEKOhHeincWqONw%2Bq6w5Go%2BWGOSR7LhKV%2BKBqbBPpfUvOf9QqkpDyVhBeyyZQGMsdA5FBUqvFMtUyGq9vjnsAJU4UcrxldP1CCaofyDkSAifoP5QwWx%2BSyUGxp75BzGAvtG7uQ38LehlyEQMeh0TeE6Bm7tYdXqdkt0uOb3kfYlNwmOdDyacOq%2FqlFo1v%2BPTmTi3E%2FglC9W11b34A22zmLzvb231Q0L2Bgg60OTW4YdstO%2BYOJnO38TtpH7zy9ymokWyA79qlVSn38HtpFlImFnhu3b4boNWXklOXV0Iwo7lQ1hrZyPFcwtjwFP7iEKSHSSJw509kh8kj6pr%2BH1jR7km9vcvqN9657vffefkv%2BfKxge1X%2B7RdjYUPIESN7gTvRkB%2FRMYtEkaVkdHApmdBPpnKmz0n1xSWFOyVIuLrinZwpoCRe6kyiVZoHX088F%2BUX4%2BWKS4iBTP0IWxGtZgOdMaV4KTayqHQF%2FVihBwTbgDXTCmKoOBJeNhwJMzEVjtjIFLuU38fPR7hqNG1JS7g%2FqRCuy3vmQ3W9Vu8qbVbP%2BSzazGRJH83MzP90Ck2m31mMjP8TiLn5uwD2Ugr2PFvPQjB5BnSJvQxGQZZEB%2BLopqzGzDbMmbkAPkZVJjeO5FzOSBKCgJze2ZS4Gemc9twrwY6u9H61iUQTcRvtdT9RW3tRxAWwFs2tcuJRnI6xjmBdWjbgFNRHMHiF1uHYBfUR%2Fut5Ug2jXAaT96%2B9RH%2FFToRwIzGbKmVJ1AZQnoabSB1yyIg7ByAridHApPMjyw0OiV6RjSbCuzwLAvFizBliWJua1tsuAgvNPbmljYbpt8lkWam7b3XZiOiKJskMOtmfScnsbPW208knwjuXrXK4Q1iKIgNyYXXDVT9C2Ye%2F78GQ5BEEXfFdde2RwauOysdJNL5AzCy84ard%2FnGAVN8alecnFdgu5Gbd5DJTL%2BhHZK0vApVy3OfU8XTSJg1TlssivsPYUlIqvn66PzrVTymCc4wgF6SDNR0pDf%2B9Gp%2BVnsUH5WtpHYsuhOaey8zdwLN47V8MTbm78g687%2BP3cx6tcAeNpjYGRgYGBk8s0%2FzBIfz2%2FzlUGeZQNQhOFCWfF0GP0%2F8P8c1jusIkAuBwMTSBQAYwQM6HjaY2BkYGAV%2Bd8KJgP%2FXWG9wwAUQQGLAYqPBl942n1TvUoDQRCe1VM8kWARjNrZGIurBAsRBIuA2vkAFsJiKTYW4guIjT5ARMgTxCLoA1hcb5OgDyGHrY7f7M65e8fpLF%2B%2B2W%2FnZ2eTmGfaIJi5I0qGDlZZcD51QzTTJirZPAI9JIwVA%2BwT8L5nOdMaV0AuMJ%2BicRHq8of6LSD18fzq8ds7xjpwBnQiSI9V5QVl6NwPvgM15NXn%2FAtWZyj3W0HjEXitOc%2FdIdbetPdFTZ%2BP6t%2BX7xU0%2Fk6GJtOe1%2FB3arN0%2Fpmz1J4UZc%2BD6ExwjD7vioeGd5HvhvU%2BR%2BDZcGZ6YBPNfAi0G97iBPwFXqph2cW8%2BD7kjMfwtinHb6kLb6Wygk3cZytSEoptGrlScdHtLPeri1JKueACMZfU1ViJG1Sq5E43dIt7SZZFl1zuRhb%2FGOs44xFVDbrJzB5tYs35OmaXTrEmkv0DajnMWQB42mNgYNCCwk0MLxheMPrhgUuY2JiUmOqY2pjWMD1hdmPOY%2B5hPsLCwWLEksSyiOUOawzrLrYiti%2FsCuxJ7Kc45DiSOPZxmnG2cG7jvMelweXDNYXrEbcBdxf3KR4OngheLd443g18fHwZfFv4NfiX8T8TEBIIEZggsEpQS7BMcJsQl5CFUI3QAWEp4RLhCyJaIldEbURXiJ4RYxEzE0sQ2yD2TzxIfJkEk4SeRJbENIkNEg8k%2FklqSGZITpE8InlL8p2UmVSG1A6pb9Jx0ltkjGSmyDySlZF1kc2RnSK7R%2FaZnJ5cmdwB%2BST5SwpuCvsUjRTLFHcoOShNU9qhzKespGyhXKV8SPmBCpOKgUqcyjSVR6omqgmqe9RE1OrUnqkHqO9R%2F6FholGgsUZzgeYZLTUtL60WbS7tKh0OnQydXTpvdGV0O3S%2F6Gnopekt0ruhz6fvpl%2Bnv0n%2Fh4GdQYvBJUMhwwTDdYYvjFSM4oxmGd0zVjK2M84w3mYiYZJgssLkkqmO6TzTF2Z2ZjVmd8ylzP3MJ5lfsRCwcLJoszhhyWXpZdlhecZKxirHapbVPesF1ndsJGwCbBbZ%2FLA1sn1jZ2XXY3fFXsM%2Bz36V%2FS8HD4cGh2OOTI51ThJOK5zeOUs4OzmXOS9wPuUi4JLgss7lm2uU6zY3NrcSty1u39zN3Mvct7l%2F8xDzMPLw88jyaPM44ynkaeEZ59niucqLyUvPKwgAn3OqOQAAAQAAARcApwARAAAAAAACAAAAAQABAAAAQAAuAAAAAHjarZK9TgJBEMf%2Fd6CRaAyRhMLqCgsbL4ciglTGRPEjSiSKlnLycXJ86CEniU%2FhM9jYWPgIFkYfwd6nsDD%2Bd1mBIIUx3mZnfzs3MzszuwDCeIYG8UUwQxmAFgxxPeeuyxrmcaNYxzTuFAewi0fFQSTxqXgM11pC8TgS2oPiCUS1d8Uh8ofiSczpYcVT5LjiCPlY8Qui%2BncOr7D02y6%2FBTCrP%2Fm%2Bb5bdTrPi2I26Z9qNGtbRQBMdXMJBGRW0YOCecxEWYoiTCvxrYBunqHPdoX2bLOyrMKlZg8thDETw5K7Itci1TXlGy0124QRZZLDFU%2FexhxztMozlosTpMH6ZPge0L%2BOKGnFKjJ4WRwppHPL0PP3SI2P9jLQwFOu3GRhDfkeyDo%2F%2FG7IHgzllZQxLdquvrdCyBVvat3seJlYo06gxapUxhU2JWnFygR03sSxnEkvcpf5Y5eibGq315TDp7fKWm8zbUVl71Aqq%2FZtNnlkWmLnQtno9ycvXYbA6W2pF3aKfCayyC0Ja7Fr%2FPW70%2FHO4YM0OKxFvzf0C1MyPjwAAeNpt1VWUU2cYRuHsgxenQt1d8%2F3JOUnqAyR1d%2FcCLQVKO22pu7tQd3d3d3d3d3cXmGzumrWy3pWLs%2FNdPDMpZaWu1783l1Lpf14MnfzO6FbqVupfGkD30iR60JNe9KYP09CXfvRnAAMZxGCGMG3pW6ZjemZgKDMyEzMzC7MyG7MzB3MyF3MzD%2FMyH%2FOzAAuyEAuzCIuyGIuzBGWCRIUqOQU16jRYkqVYmmVYluVYng6GMZwRNGmxAiuyEiuzCquyGquzBmuyFmuzDuuyHuuzARuyERuzCZuyGZuzBVuyFVuzDduyHdszklGMZgd2ZAw7MZZxjGdnJrALu9LJbuzOHkxkT%2FZib%2FZhX%2FZjfw7gQA7iYA7hUA7jcI7gSI7iaI7hWI7jeE7gRE7iZE5hEqdyGqdzBmdyFmdzDudyHudzARdyERdzCZdyGZdzBVdyFVdzDddyHddzAzdyEzdzC7dyG7dzB3dyF3dzD%2FdyH%2FfzAA%2FyEA%2FzCI%2FyGI%2FzBE%2FyFE%2FzDM%2FyHM%2FzAi%2FyEi%2FzCq%2FyGq%2FzBm%2FyFm%2FzDu%2FyHu%2FzAR%2FyER%2FzCZ%2FyGZ%2FzBV%2FyFV%2FzDd%2FyHd%2FzAz%2FyEz%2FzC7%2FyG7%2FzB3%2FyF3%2FzD%2F9mpYwsy7pl3bMeWc%2BsV9Y765NNk%2FXN%2BmX9swHZwGxQNjgb0nPkmInjR0V7Uq%2FOsaPL5Y7ylE3l8tQNN7kVt%2BrmbuHW3LrbcDvam1rtzVvdm50TxrU%2FDBvRtZUY1rV5a3jXFn550Wo%2FXDNWK3dFmh7X9LimxzU9qulRTY9qelTTo5rlKLt2wk7YiaprL%2ByFvbAX9pK9ZC%2FZS%2FaSvWQv2Uv2kr1kr2KvYq9ir2KvYq9ir2KvYq9ir2Kvaq9qr2qvaq9qr2qvaq9qr2qvai%2B3l9vL7eX2cnu5vdxebi%2B3l9sr7BV2CjuFncJOYaewU9gp7NTs1LyrZq9mr2avZq9mr2avZq9mr26vbq9ur26vbq9ur26vbq9ur26vYa9hr2GvYa9hr2GvYa%2FR7oXuQ%2Feh%2B2j%2FUU7e3C3cqc%2FV3fYdof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D92H7kP3ofvQfeg%2BdB%2B6D92H7kP3ofvQfRT29B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6D%2F2H%2FkP%2Fof%2FQf%2Bg%2F9B%2F6j6nuG3Ya7U5q%2F0hN3nCTW3Grbu4Wrs%2FrP%2Bk%2F6T%2FpP%2Bk%2F6T%2FpP%2Bk%2B6T7pPek86TzpPOk86TzpOuk66TrpOuk66TrpOlWmPu%2F36zrpOuk66TrpOuk66TrpOvl%2FPek76TvpO%2Bk76TvpO%2Bk76TvpO%2Bk76TvpO7V9t%2BqtVs%2FOaOURU6bo6PgPt6rZbwAAAAABVFDDFwAA%29%20format%28%27woff%27%29%2Curl%28data%3Aapplication%2Ffont%2Dsfnt%3Bbase64%2CAAEAAAAPAIAAAwBwRkZUTW0ql9wAAAD8AAAAHEdERUYBRAAEAAABGAAAACBPUy8yZ7lriQAAATgAAABgY21hcNqt44EAAAGYAAAGcmN2dCAAKAL4AAAIDAAAAARnYXNw%2F%2F8AAwAACBAAAAAIZ2x5Zn1dwm8AAAgYAACUpGhlYWQFTS%2FYAACcvAAAADZoaGVhCkQEEQAAnPQAAAAkaG10eNLHIGAAAJ0YAAADdGxvY2Fv%2B5XOAACgjAAAAjBtYXhwAWoA2AAAorwAAAAgbmFtZbMsoJsAAKLcAAADonBvc3S6o%2BU1AACmgAAACtF3ZWJmwxhUUAAAsVQAAAAGAAAAAQAAAADMPaLPAAAAANB2gXUAAAAA0HZzlwABAAAADgAAABgAAAAAAAIAAQABARYAAQAEAAAAAgAAAAMEiwGQAAUABAMMAtAAAABaAwwC0AAAAaQAMgK4AAAAAAUAAAAAAAAAAAAAAAIAAAAAAAAAAAAAAFVLV04AQAAg%2F%2F8DwP8QAAAFFAB7AAAAAQAAAAAAAAAAAAAAIAABAAAABQAAAAMAAAAsAAAACgAAAdwAAQAAAAAEaAADAAEAAAAsAAMACgAAAdwABAGwAAAAaABAAAUAKAAgACsAoAClIAogLyBfIKwgvSISIxsl%2FCYBJvonCScP4APgCeAZ4CngOeBJ4FngYOBp4HngieCX4QnhGeEp4TnhRuFJ4VnhaeF54YnhleGZ4gbiCeIW4hniIeIn4jniSeJZ4mD4%2F%2F%2F%2FAAAAIAAqAKAApSAAIC8gXyCsIL0iEiMbJfwmASb6JwknD%2BAB4AXgEOAg4DDgQOBQ4GDgYuBw4IDgkOEB4RDhIOEw4UDhSOFQ4WDhcOGA4ZDhl%2BIA4gniEOIY4iHiI%2BIw4kDiUOJg%2BP%2F%2F%2F%2F%2Fj%2F9r%2FZv9i4Ajf5N%2B132nfWd4F3P3aHdoZ2SHZE9kOIB0gHCAWIBAgCiAEH%2F4f%2BB%2F3H%2FEf6x%2FlH3wfdh9wH2ofZB9jH10fVx9RH0sfRR9EHt4e3B7WHtUezh7NHsUevx65HrMIFQABAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAADAAAAAACjAAAAAAAAAA1AAAAIAAAACAAAAADAAAAKgAAACsAAAAEAAAAoAAAAKAAAAAGAAAApQAAAKUAAAAHAAAgAAAAIAoAAAAIAAAgLwAAIC8AAAATAAAgXwAAIF8AAAAUAAAgrAAAIKwAAAAVAAAgvQAAIL0AAAAWAAAiEgAAIhIAAAAXAAAjGwAAIxsAAAAYAAAl%2FAAAJfwAAAAZAAAmAQAAJgEAAAAaAAAm%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%2FAADiUAAA4lkAAAEJAADiYAAA4mAAAAETAAD4%2FwAA%2BP8AAAEUAAH1EQAB9REAAAEVAAH2qgAB9qoAAAEWAAYCCgAAAAABAAABAAAAAAAAAAAAAAAAAAAAAQACAAAAAAAAAAIAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAQAAAAAAAwAAAAAAAAAAAAAAAAAAAAAAAAAEAAUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAHAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAYAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAVAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAEUAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAKAL4AAAAAf%2F%2FAAIAAgAoAAABaAMgAAMABwAusQEALzyyBwQA7TKxBgXcPLIDAgDtMgCxAwAvPLIFBADtMrIHBgH8PLIBAgDtMjMRIRElMxEjKAFA%2Fujw8AMg%2FOAoAtAAAQBkAGQETARMAFsAAAEyFh8BHgEdATc%2BAR8BFgYPATMyFhcWFRQGDwEOASsBFx4BDwEGJi8BFRQGBwYjIiYvAS4BPQEHDgEvASY2PwEjIiYnJjU0Nj8BPgE7AScuAT8BNhYfATU0Njc2AlgPJgsLCg%2BeBxYIagcCB57gChECBgMCAQIRCuCeBwIHaggWB54PCikiDyYLCwoPngcWCGoHAgee4AoRAgYDAgECEQrgngcCB2oIFgeeDwopBEwDAgECEQrgngcCB2oIFgeeDwopIg8mCwsKD54HFghqBwIHnuAKEQIGAwIBAhEK4J4HAgdqCBYHng8KKSIPJgsLCg%2BeBxYIagcCB57gChECBgAAAAABAAAAAARMBEwAIwAAATMyFhURITIWHQEUBiMhERQGKwEiJjURISImPQE0NjMhETQ2AcLIFR0BXhUdHRX%2Boh0VyBUd%2FqIVHR0VAV4dBEwdFf6iHRXIFR3%2BohUdHRUBXh0VyBUdAV4VHQAAAAABAHAAAARABEwARQAAATMyFgcBBgchMhYPAQ4BKwEVITIWDwEOASsBFRQGKwEiJj0BISImPwE%2BATsBNSEiJj8BPgE7ASYnASY2OwEyHwEWMj8BNgM5%2BgoFCP6UBgUBDAoGBngGGAp9ARMKBgZ4BhgKfQ8LlAsP%2Fu0KBgZ4BhgKff7tCgYGeAYYCnYFBv6UCAUK%2BhkSpAgUCKQSBEwKCP6UBgwMCKAIDGQMCKAIDK4LDw8LrgwIoAgMZAwIoAgMDAYBbAgKEqQICKQSAAABAGQABQSMBK4AOwAAATIXFhcjNC4DIyIOAwchByEGFSEHIR4EMzI%2BAzUzBgcGIyInLgEnIzczNjcjNzM%2BATc2AujycDwGtSM0QDkXEys4MjAPAXtk%2FtQGAZZk%2FtQJMDlCNBUWOUA0I64eYmunznYkQgzZZHABBdpkhhQ%2BH3UErr1oaS1LMCEPCx4uTzJkMjJkSnRCKw8PIjBKK6trdZ4wqndkLzVkV4UljQAAAgB7AAAETASwAD4ARwAAASEyHgUVHAEVFA4FKwEHITIWDwEOASsBFRQGKwEiJj0BISImPwE%2BATsBNSEiJj8BPgE7ARE0NhcRMzI2NTQmIwGsAV5DakIwFgwBAQwWMEJqQ7ICASAKBgZ4BhgKigsKlQoP%2FvUKBgZ4BhgKdf71CgYGeAYYCnUPtstALS1ABLAaJD8yTyokCwsLJCpQMkAlGmQMCKAIDK8LDg8KrwwIoAgMZAwIoAgMAdsKD8j%2B1EJWVEAAAAEAyAGQBEwCvAAPAAATITIWHQEUBiMhIiY9ATQ2%2BgMgFR0dFfzgFR0dArwdFcgVHR0VyBUdAAAAAgDIAAAD6ASwACUAQQAAARUUBisBFRQGBx4BHQEzMhYdASE1NDY7ATU0NjcuAT0BIyImPQEXFRQWFx4BFAYHDgEdASE1NCYnLgE0Njc%2BAT0BA%2BgdFTJjUVFjMhUd%2FOAdFTJjUVFjMhUdyEE3HCAgHDdBAZBBNxwgIBw3QQSwlhUdZFuVIyOVW5YdFZaWFR2WW5UjI5VbZB0VlshkPGMYDDI8MgwYYzyWljxjGAwyPDIMGGM8ZAAAAAEAAAAAAAAAAAAAAAAxAAAB%2F%2FIBLATCBEEAFgAAATIWFzYzMhYVFAYjISImNTQ2NyY1NDYB9261LCwueKqqeP0ST3FVQgLYBEF3YQ6teHmtclBFaw4MGZnXAAAAAgAAAGQEsASvABoAHgAAAB4BDwEBMzIWHQEhNTQ2OwEBJyY%2BARYfATc2AyEnAwL2IAkKiAHTHhQe%2B1AeFB4B1IcKCSAkCm9wCXoBebbDBLMTIxC7%2FRYlFSoqFSUC6rcQJBQJEJSWEPwecAIWAAAAAAQAAABkBLAETAALABcAIwA3AAATITIWBwEGIicBJjYXARYUBwEGJjURNDYJATYWFREUBicBJjQHARYGIyEiJjcBNjIfARYyPwE2MhkEfgoFCP3MCBQI%2FcwIBQMBCAgI%2FvgICgoDjAEICAoKCP74CFwBbAgFCvuCCgUIAWwIFAikCBQIpAgUBEwKCP3JCAgCNwgK2v74CBQI%2FvgIBQoCJgoF%2FvABCAgFCv3aCgUIAQgIFID%2BlAgKCggBbAgIpAgIpAgAAAAD%2F%2FD%2F8AS6BLoACQANABAAAAAyHwEWFA8BJzcTAScJAQUTA%2BAmDpkNDWPWXyL9mdYCZv4f%2FrNuBLoNmQ4mDlzWYP50%2FZrWAmb8anABTwAAAAEAAAAABLAEsAAPAAABETMyFh0BITU0NjsBEQEhArz6FR384B0V%2Bv4MBLACiv3aHRUyMhUdAiYCJgAAAAEADgAIBEwEnAAfAAABJTYWFREUBgcGLgE2NzYXEQURFAYHBi4BNjc2FxE0NgFwAoUnMFNGT4gkV09IQv2oWEFPiCRXT0hCHQP5ow8eIvzBN1EXGSltchkYEAIJm%2F2iKmAVGilucRoYEQJ%2FJioAAAACAAn%2F%2BAS7BKcAHQApAAAAMh4CFQcXFAcBFgYPAQYiJwEGIycHIi4CND4BBCIOARQeATI%2BATQmAZDItoNOAQFOARMXARY7GikT%2Fu13jgUCZLaDTk6DAXKwlFZWlLCUVlYEp06DtmQCBY15%2Fu4aJRg6FBQBEk0BAU6Dtsi2g1tWlLCUVlaUsJQAAQBkAFgErwREABkAAAE%2BAh4CFRQOAwcuBDU0PgIeAQKJMHt4dVg2Q3mEqD4%2Bp4V4Qzhadnh5A7VESAUtU3ZAOXmAf7JVVbJ%2FgHk5QHZTLQVIAAAAAf%2FTAF4EewSUABgAAAETNjIXEyEyFgcFExYGJyUFBiY3EyUmNjMBl4MHFQeBAaUVBhH%2BqoIHDxH%2Bqf6qEQ8Hgv6lEQYUAyABYRMT%2Fp8RDPn%2BbxQLDPb3DAsUAZD7DBEAAv%2FTAF4EewSUABgAIgAAARM2MhcTITIWBwUTFgYnJQUGJjcTJSY2MwUjFwc3Fyc3IycBl4MHFQeBAaUVBhH%2BqoIHDxH%2Bqf6qEQ8Hgv6lEQYUAfPwxUrBw0rA6k4DIAFhExP%2BnxEM%2Bf5vFAsM9vcMCxQBkPsMEWSO4ouM5YzTAAABAAAAAASwBLAAJgAAATIWHQEUBiMVFBYXBR4BHQEUBiMhIiY9ATQ2NyU%2BAT0BIiY9ATQ2Alh8sD4mDAkBZgkMDwr7ggoPDAkBZgkMJj6wBLCwfPouaEsKFwbmBRcKXQoPDwpdChcF5gYXCktoLvp8sAAAAA0AAAAABLAETAAPABMAIwAnACsALwAzADcARwBLAE8AUwBXAAATITIWFREUBiMhIiY1ETQ2FxUzNSkBIgYVERQWMyEyNjURNCYzFTM1BRUzNSEVMzUFFTM1IRUzNQchIgYVERQWMyEyNjURNCYFFTM1IRUzNQUVMzUhFTM1GQR%2BCg8PCvuCCg8PVWQCo%2F3aCg8PCgImCg8Pc2T8GGQDIGT8GGQDIGTh%2FdoKDw8KAiYKDw%2F872QDIGT8GGQDIGQETA8K%2B%2BYKDw8KBBoKD2RkZA8K%2FqIKDw8KAV4KD2RkyGRkZGTIZGRkZGQPCv6iCg8PCgFeCg9kZGRkZMhkZGRkAAAEAAAAAARMBEwADwAfAC8APwAAEyEyFhURFAYjISImNRE0NikBMhYVERQGIyEiJjURNDYBITIWFREUBiMhIiY1ETQ2KQEyFhURFAYjISImNRE0NjIBkBUdHRX%2BcBUdHQJtAZAVHR0V%2FnAVHR39vQGQFR0dFf5wFR0dAm0BkBUdHRX%2BcBUdHQRMHRX%2BcBUdHRUBkBUdHRX%2BcBUdHRUBkBUd%2FagdFf5wFR0dFQGQFR0dFf5wFR0dFQGQFR0AAAkAAAAABEwETAAPAB8ALwA%2FAE8AXwBvAH8AjwAAEzMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYhMzIWHQEUBisBIiY9ATQ2ATMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYhMzIWHQEUBisBIiY9ATQ2ATMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYhMzIWHQEUBisBIiY9ATQ2MsgVHR0VyBUdHQGlyBUdHRXIFR0dAaXIFR0dFcgVHR389cgVHR0VyBUdHQGlyBUdHRXIFR0dAaXIFR0dFcgVHR389cgVHR0VyBUdHQGlyBUdHRXIFR0dAaXIFR0dFcgVHR0ETB0VyBUdHRXIFR0dFcgVHR0VyBUdHRXIFR0dFcgVHf5wHRXIFR0dFcgVHR0VyBUdHRXIFR0dFcgVHR0VyBUd%2FnAdFcgVHR0VyBUdHRXIFR0dFcgVHR0VyBUdHRXIFR0ABgAAAAAEsARMAA8AHwAvAD8ATwBfAAATMzIWHQEUBisBIiY9ATQ2KQEyFh0BFAYjISImPQE0NgEzMhYdARQGKwEiJj0BNDYpATIWHQEUBiMhIiY9ATQ2ATMyFh0BFAYrASImPQE0NikBMhYdARQGIyEiJj0BNDYyyBUdHRXIFR0dAaUCvBUdHRX9RBUdHf6FyBUdHRXIFR0dAaUCvBUdHRX9RBUdHf6FyBUdHRXIFR0dAaUCvBUdHRX9RBUdHQRMHRXIFR0dFcgVHR0VyBUdHRXIFR3%2BcB0VyBUdHRXIFR0dFcgVHR0VyBUd%2FnAdFcgVHR0VyBUdHRXIFR0dFcgVHQAAAAABACYALAToBCAAFwAACQE2Mh8BFhQHAQYiJwEmND8BNjIfARYyAdECOwgUB7EICPzxBxUH%2FoAICLEHFAirBxYB3QI7CAixBxQI%2FPAICAGACBQHsQgIqwcAAQBuAG4EQgRCACMAAAEXFhQHCQEWFA8BBiInCQEGIi8BJjQ3CQEmND8BNjIXCQE2MgOIsggI%2FvUBCwgIsggVB%2F70%2FvQHFQiyCAgBC%2F71CAiyCBUHAQwBDAcVBDuzCBUH%2FvT%2B9AcVCLIICAEL%2FvUICLIIFQcBDAEMBxUIsggI%2FvUBDAcAAwAX%2F%2BsExQSZABkAJQBJAAAAMh4CFRQHARYUDwEGIicBBiMiLgI0PgEEIg4BFB4BMj4BNCYFMzIWHQEzMhYdARQGKwEVFAYrASImPQEjIiY9ATQ2OwE1NDYBmcSzgk1OASwICG0HFQj%2B1HeOYrSBTU2BAW%2BzmFhYmLOZWFj%2BvJYKD0sKDw8KSw8KlgoPSwoPDwpLDwSZTYKzYo15%2FtUIFQhsCAgBK01NgbTEs4JNWJmzmFhYmLOZIw8KSw8KlgoPSwoPDwpLDwqWCg9LCg8AAAMAF%2F%2FrBMUEmQAZACUANQAAADIeAhUUBwEWFA8BBiInAQYjIi4CND4BBCIOARQeATI%2BATQmBSEyFh0BFAYjISImPQE0NgGZxLOCTU4BLAgIbQcVCP7Ud45itIFNTYEBb7OYWFiYs5lYWP5YAV4KDw8K%2FqIKDw8EmU2Cs2KNef7VCBUIbAgIAStNTYG0xLOCTViZs5hYWJizmYcPCpYKDw8KlgoPAAAAAAIAFwAXBJkEsAAPAC0AAAEzMhYVERQGKwEiJjURNDYFNRYSFRQOAiIuAjU0EjcVDgEVFB4BMj4BNTQmAiZkFR0dFWQVHR0BD6fSW5vW6tabW9KnZ3xyxejFcnwEsB0V%2FnAVHR0VAZAVHeGmPv7ZuHXWm1tbm9Z1uAEnPqY3yHh0xXJyxXR4yAAEAGQAAASwBLAADwAfAC8APwAAATMyFhURFAYrASImNRE0NgEzMhYVERQGKwEiJjURNDYBMzIWFREUBisBIiY1ETQ2BTMyFh0BFAYrASImPQE0NgQBlgoPDwqWCg8P%2Ft6WCg8PCpYKDw%2F%2B3pYKDw8KlgoPD%2F7elgoPDwqWCg8PBLAPCvuCCg8PCgR%2BCg%2F%2BcA8K%2FRIKDw8KAu4KD%2F7UDwr%2BPgoPDwoBwgoPyA8K%2BgoPDwr6Cg8AAAAAAgAaABsElgSWAEcATwAAATIfAhYfATcWFwcXFh8CFhUUDwIGDwEXBgcnBwYPAgYjIi8CJi8BByYnNycmLwImNTQ%2FAjY%2FASc2Nxc3Nj8CNhIiBhQWMjY0AlghKSYFMS0Fhj0rUAMZDgGYBQWYAQ8YA1AwOIYFLDIFJisfISkmBTEtBYY8LFADGQ0ClwYGlwINGQNQLzqFBS0xBSYreLJ%2BfrJ%2BBJYFmAEOGQJQMDmGBSwxBiYrHiIoJgYxLAWGPSxRAxkOApcFBZcCDhkDUTA5hgUtMAYmKiAhKCYGMC0Fhj0sUAIZDgGYBf6ZfrF%2BfrEABwBkAAAEsAUUABMAFwAhACUAKQAtADEAAAEhMhYdASEyFh0BITU0NjMhNTQ2FxUhNQERFAYjISImNREXETMRMxEzETMRMxEzETMRAfQBLCk7ARMKD%2Fu0DwoBEzspASwBLDsp%2FUQpO2RkZGRkZGRkBRQ7KWQPCktLCg9kKTtkZGT%2B1PzgKTs7KQMgZP1EArz9RAK8%2FUQCvP1EArwAAQAMAAAFCATRAB8AABMBNjIXARYGKwERFAYrASImNREhERQGKwEiJjURIyImEgJsCBUHAmAIBQqvDwr6Cg%2F%2B1A8K%2BgoPrwoFAmoCYAcH%2FaAICv3BCg8PCgF3%2FokKDw8KAj8KAAIAZAAAA%2BgEsAARABcAAAERFBYzIREUBiMhIiY1ETQ2MwEjIiY9AQJYOykBLB0V%2FOAVHR0VA1L6FR0EsP5wKTv9dhUdHRUETBUd%2FnAdFfoAAwAXABcEmQSZAA8AGwAwAAAAMh4CFA4CIi4CND4BBCIOARQeATI%2BATQmBTMyFhURMzIWHQEUBisBIiY1ETQ2AePq1ptbW5vW6tabW1ubAb%2FoxXJyxejFcnL%2BfDIKD68KDw8K%2BgoPDwSZW5vW6tabW1ub1urWmztyxejFcnLF6MUNDwr%2B7Q8KMgoPDwoBXgoPAAAAAAL%2FnAAABRQEsAALAA8AACkBAyMDIQEzAzMDMwEDMwMFFP3mKfIp%2FeYBr9EVohTQ%2Fp4b4BsBkP5wBLD%2B1AEs%2FnD%2B1AEsAAAAAAIAZAAABLAEsAAVAC8AAAEzMhYVETMyFgcBBiInASY2OwERNDYBMzIWFREUBiMhIiY1ETQ2OwEyFh0BITU0NgImyBUdvxQLDf65DSYN%2FrkNCxS%2FHQJUMgoPDwr75goPDwoyCg8DhA8EsB0V%2Fj4XEP5wEBABkBAXAcIVHfzgDwr%2BogoPDwoBXgoPDwqvrwoPAAMAFwAXBJkEmQAPABsAMQAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JgUzMhYVETMyFgcDBiInAyY2OwERNDYB4%2BrWm1tbm9bq1ptbW5sBv%2BjFcnLF6MVycv58lgoPiRUKDd8NJg3fDQoViQ8EmVub1urWm1tbm9bq1ps7csXoxXJyxejFDQ8K%2Fu0XEP7tEBABExAXARMKDwAAAAMAFwAXBJkEmQAPABsAMQAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JiUTFgYrAREUBisBIiY1ESMiJjcTNjIB4%2BrWm1tbm9bq1ptbW5sBv%2BjFcnLF6MVycv7n3w0KFYkPCpYKD4kVCg3fDSYEmVub1urWm1tbm9bq1ps7csXoxXJyxejFAf7tEBf%2B7QoPDwoBExcQARMQAAAAAAIAAAAABLAEsAAZADkAABMhMhYXExYVERQGBwYjISImJyY1EzQ3Ez4BBSEiBgcDBhY7ATIWHwEeATsBMjY%2FAT4BOwEyNicDLgHhAu4KEwO6BwgFDBn7tAweAgYBB7kDEwKX%2FdQKEgJXAgwKlgoTAiYCEwr6ChMCJgITCpYKDAJXAhIEsA4K%2FXQYGf5XDB4CBggEDRkBqRkYAowKDsgOC%2F4%2BCw4OCpgKDg4KmAoODgsBwgsOAAMAFwAXBJkEmQAPABsAJwAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JgUXFhQPAQYmNRE0NgHj6tabW1ub1urWm1tbmwG%2F6MVycsXoxXJy%2Fov9ERH9EBgYBJlbm9bq1ptbW5vW6tabO3LF6MVycsXoxV2%2BDCQMvgwLFQGQFQsAAQAXABcEmQSwACgAAAE3NhYVERQGIyEiJj8BJiMiDgEUHgEyPgE1MxQOAiIuAjQ%2BAjMyA7OHBwsPCv6WCwQHhW2BdMVycsXoxXKWW5vW6tabW1ub1nXABCSHBwQL%2FpYKDwsHhUxyxejFcnLFdHXWm1tbm9bq1ptbAAAAAAIAFwABBJkEsAAaADUAAAE3NhYVERQGIyEiJj8BJiMiDgEVIzQ%2BAjMyEzMUDgIjIicHBiY1ETQ2MyEyFg8BFjMyPgEDs4cHCw8L%2FpcLBAeGboF0xXKWW5vWdcDrllub1nXAnIYHCw8LAWgKBQiFboJ0xXIEJIcHBAv%2BlwsPCweGS3LFdHXWm1v9v3XWm1t2hggFCgFoCw8LB4VMcsUAAAAKAGQAAASwBLAADwAfAC8APwBPAF8AbwB%2FAI8AnwAAEyEyFhURFAYjISImNRE0NgUhIgYVERQWMyEyNjURNCYFMzIWHQEUBisBIiY9ATQ2MyEyFh0BFAYjISImPQE0NgczMhYdARQGKwEiJj0BNDYzITIWHQEUBiMhIiY9ATQ2BzMyFh0BFAYrASImPQE0NjMhMhYdARQGIyEiJj0BNDYHMzIWHQEUBisBIiY9ATQ2MyEyFh0BFAYjISImPQE0Nn0EGgoPDwr75goPDwPA%2FK4KDw8KA1IKDw%2F9CDIKDw8KMgoPD9IBwgoPDwr%2BPgoPD74yCg8PCjIKDw%2FSAcIKDw8K%2Fj4KDw%2B%2BMgoPDwoyCg8P0gHCCg8PCv4%2BCg8PvjIKDw8KMgoPD9IBwgoPDwr%2BPgoPDwSwDwr7ggoPDwoEfgoPyA8K%2FK4KDw8KA1IKD2QPCjIKDw8KMgoPDwoyCg8PCjIKD8gPCjIKDw8KMgoPDwoyCg8PCjIKD8gPCjIKDw8KMgoPDwoyCg8PCjIKD8gPCjIKDw8KMgoPDwoyCg8PCjIKDwAAAAACAAAAAARMBLAAGQAjAAABNTQmIyEiBh0BIyIGFREUFjMhMjY1ETQmIyE1NDY7ATIWHQEDhHVT%2FtRSdmQpOzspA4QpOzsp%2FageFMgUHgMgyFN1dlLIOyn9qCk7OykCWCk7lhUdHRWWAAIAZAAABEwETAAJADcAABMzMhYVESMRNDYFMhcWFREUBw4DIyIuAScuAiMiBwYjIicmNRE%2BATc2HgMXHgIzMjc2fTIKD2QPA8AEBRADIUNAMRwaPyonKSxHHlVLBwgGBQ4WeDsXKC4TOQQpLUUdZ1AHBEwPCvvNBDMKDzACBhH%2BWwYGO1AkDQ0ODg8PDzkFAwcPAbY3VwMCAwsGFAEODg5XCAAAAwAAAAAEsASXACEAMQBBAAAAMh4CFREUBisBIiY1ETQuASAOARURFAYrASImNRE0PgEDMzIWFREUBisBIiY1ETQ2ITMyFhURFAYrASImNRE0NgHk6N6jYw8KMgoPjeT%2B%2BuSNDwoyCg9joyqgCAwMCKAIDAwCYKAIDAwIoAgMDASXY6PedP7UCg8PCgEsf9FyctF%2F%2FtQKDw8KASx03qP9wAwI%2FjQIDAwIAcwIDAwI%2FjQIDAwIAcwIDAAAAAACAAAA0wRHA90AFQA5AAABJTYWFREUBiclJisBIiY1ETQ2OwEyBTc2Mh8BFhQPARcWFA8BBiIvAQcGIi8BJjQ%2FAScmND8BNjIXAUEBAgkMDAn%2B%2FhUZ%2BgoPDwr6GQJYeAcUByIHB3h4BwciBxQHeHgHFAciBwd3dwcHIgcUBwMurAYHCv0SCgcGrA4PCgFeCg%2BEeAcHIgcUB3h4BxQHIgcHd3cHByIHFAd4eAcUByIICAAAAAACAAAA0wNyA90AFQAvAAABJTYWFREUBiclJisBIiY1ETQ2OwEyJTMWFxYVFAcGDwEiLwEuATc2NTQnJjY%2FATYBQQECCQwMCf7%2BFRn6Cg8PCvoZAdIECgZgWgYLAwkHHQcDBkhOBgMIHQcDLqwGBwr9EgoHBqwODwoBXgoPZAEJgaGafwkBAQYXBxMIZ36EaggUBxYFAAAAAAMAAADEBGID7AAbADEASwAAATMWFxYVFAYHBgcjIi8BLgE3NjU0JicmNj8BNgUlNhYVERQGJyUmKwEiJjURNDY7ATIlMxYXFhUUBwYPASIvAS4BNzY1NCcmNj8BNgPHAwsGh0RABwoDCQcqCAIGbzs3BgIJKgf9ggECCQwMCf7%2BFRn6Cg8PCvoZAdIECgZgWgYLAwkHHQcDBkhOBgMIHQcD7AEJs9lpy1QJAQYiBhQIlrJarEcJFAYhBb6sBgcK%2FRIKBwasDg8KAV4KD2QBCYGhmn8JAQEGFwcTCGd%2BhGoIFQYWBQAAAAANAAAAAASwBLAACQAVABkAHQAhACUALQA7AD8AQwBHAEsATwAAATMVIxUhFSMRIQEjFTMVIREjESM1IQURIREhESERBSM1MwUjNTMBMxEhETM1MwEzFSMVIzUjNTM1IzUhBREhEQcjNTMFIzUzASM1MwUhNSEB9GRk%2FnBkAfQCvMjI%2FtTIZAJY%2B7QBLAGQASz84GRkArxkZP1EyP4MyGQB9MhkyGRkyAEs%2FUQBLGRkZAOEZGT%2BDGRkAfT%2B1AEsA4RkZGQCWP4MZMgBLAEsyGT%2B1AEs%2FtQBLMhkZGT%2BDP4MAfRk%2FtRkZGRkyGTI%2FtQBLMhkZGT%2B1GRkZAAAAAAJAAAAAASwBLAAAwAHAAsADwATABcAGwAfACMAADcjETMTIxEzASMRMxMjETMBIxEzASE1IRcjNTMXIzUzBSM1M2RkZMhkZAGQyMjIZGQBLMjI%2FOD%2B1AEsyGRkyGRkASzIyMgD6PwYA%2Bj8GAPo%2FBgD6PwYA%2Bj7UGRkW1tbW1sAAAIAAAAKBKYEsAANABUAAAkBFhQHAQYiJwETNDYzBCYiBhQWMjYB9AKqCAj%2BMAgUCP1WAQ8KAUM7Uzs7UzsEsP1WCBQI%2FjAICAKqAdsKD807O1Q7OwAAAAADAAAACgXSBLAADQAZACEAAAkBFhQHAQYiJwETNDYzIQEWFAcBBiIvAQkBBCYiBhQWMjYB9AKqCAj%2BMAgUCP1WAQ8KAwYCqggI%2FjAIFAg4Aaj9RP7TO1M7O1M7BLD9VggUCP4wCAgCqgHbCg%2F9VggUCP4wCAg4AaoCvM07O1Q7OwAAAAABAGQAAASwBLAAJgAAASEyFREUDwEGJjURNCYjISIPAQYWMyEyFhURFAYjISImNRE0PwE2ASwDOUsSQAgKDwr9RBkSQAgFCgK8Cg8PCvyuCg8SixIEsEv8fBkSQAgFCgO2Cg8SQAgKDwr8SgoPDwoDzxkSixIAAAABAMj%2F%2FwRMBLAACgAAEyEyFhURCQERNDb6AyAVHf4%2B%2Fj4dBLAdFfuCAbz%2BQwR%2FFR0AAAAAAwAAAAAEsASwABUARQBVAAABISIGBwMGHwEeATMhMjY%2FATYnAy4BASMiBg8BDgEjISImLwEuASsBIgYVERQWOwEyNj0BNDYzITIWHQEUFjsBMjY1ETQmASEiBg8BBhYzITI2LwEuAQM2%2FkQLEAFOBw45BhcKAcIKFwY%2BDgdTARABVpYKFgROBBYK%2FdoKFgROBBYKlgoPDwqWCg8PCgLuCg8PCpYKDw%2F%2Bsf4MChMCJgILCgJYCgsCJgITBLAPCv7TGBVsCQwMCWwVGAEtCg%2F%2BcA0JnAkNDQmcCQ0PCv12Cg8PCpYKDw8KlgoPDwoCigoP%2FagOCpgKDg4KmAoOAAAAAAQAAABkBLAETAAdACEAKQAxAAABMzIeAh8BMzIWFREUBiMhIiY1ETQ2OwE%2BBAEVMzUEIgYUFjI2NCQyFhQGIiY0AfTIOF00JAcGlik7Oyn8GCk7OymWAgknM10ByGT%2Bz76Hh76H%2Fu9WPDxWPARMKTs7FRQ7Kf2oKTs7KQJYKTsIG0U1K%2F7UZGRGh76Hh74IPFY8PFYAAAAAAgA1AAAEsASvACAAIwAACQEWFx4BHwEVITUyNi8BIQYHBh4CMxUhNTY3PgE%2FAQEDIQMCqQGBFCgSJQkK%2Fl81LBFS%2Fnk6IgsJKjIe%2FpM4HAwaBwcBj6wBVKIEr%2FwaMioTFQECQkJXLd6RWSIuHAxCQhgcDCUNDQPu%2FVoByQAAAAADAGQAAAPwBLAAJwAyADsAAAEeBhUUDgMjITU%2BATURNC4EJzUFMh4CFRQOAgclMzI2NTQuAisBETMyNjU0JisBAvEFEzUwOyodN1htbDD%2BDCk7AQYLFyEaAdc5dWM%2BHy0tEP6Pi05pESpTPnbYUFJ9Xp8CgQEHGB0zOlIuQ3VONxpZBzMoAzsYFBwLEAkHRwEpSXNDM1s6KwkxYUopOzQb%2FK5lUFqBAAABAMgAAANvBLAAGQAAARcOAQcDBhYXFSE1NjcTNjQuBCcmJzUDbQJTQgeECSxK%2Fgy6Dq0DAw8MHxUXDQYEsDkTNSj8uTEoBmFhEFIDQBEaExAJCwYHAwI5AAAAAAL%2FtQAABRQEsAAlAC8AAAEjNC4FKwERFBYfARUhNTI%2BAzURIyIOBRUjESEFIxEzByczESM3BRQyCAsZEyYYGcgyGRn%2BcAQOIhoWyBkYJhMZCwgyA%2Bj7m0tLfX1LS30DhBUgFQ4IAwH8rhYZAQJkZAEFCRUOA1IBAwgOFSAVASzI%2FOCnpwMgpwACACH%2FtQSPBLAAJQAvAAABIzQuBSsBERQWHwEVITUyPgM1ESMiDgUVIxEhEwc1IRUnNxUhNQRMMggLGRMmGBnIMhkZ%2FnAEDiIaFsgZGCYTGQsIMgPoQ6f84KenAyADhBUgFQ4IAwH9dhYZAQJkZAEFCRUOAooBAwgOFSAVASz7gn1LS319S0sABAAAAAAEsARMAA8AHwAvAD8AABMhMhYdARQGIyEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2EyEyFh0BFAYjISImPQE0NhMhMhYdARQGIyEiJj0BNDYyAlgVHR0V%2FagVHR0VA%2BgVHR0V%2FBgVHR0VAyAVHR0V%2FOAVHR0VBEwVHR0V%2B7QVHR0ETB0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR0ABAAAAAAEsARMAA8AHwAvAD8AABMhMhYdARQGIyEiJj0BNDYDITIWHQEUBiMhIiY9ATQ2EyEyFh0BFAYjISImPQE0NgMhMhYdARQGIyEiJj0BNDb6ArwVHR0V%2FUQVHR2zBEwVHR0V%2B7QVHR3dArwVHR0V%2FUQVHR2zBEwVHR0V%2B7QVHR0ETB0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR0ABAAAAAAEsARMAA8AHwAvAD8AAAE1NDYzITIWHQEUBiMhIiYBNTQ2MyEyFh0BFAYjISImEzU0NjMhMhYdARQGIyEiJgE1NDYzITIWHQEUBiMhIiYB9B0VAlgVHR0V%2FagVHf5wHRUD6BUdHRX8GBUdyB0VAyAVHR0V%2FOAVHf7UHRUETBUdHRX7tBUdA7ZkFR0dFWQVHR3%2B6WQVHR0VZBUdHf7pZBUdHRVkFR0d%2FulkFR0dFWQVHR0AAAQAAAAABLAETAAPAB8ALwA%2FAAATITIWHQEUBiMhIiY9ATQ2EyEyFh0BFAYjISImPQE0NhMhMhYdARQGIyEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2MgRMFR0dFfu0FR0dFQRMFR0dFfu0FR0dFQRMFR0dFfu0FR0dFQRMFR0dFfu0FR0dBEwdFWQVHR0VZBUd%2FtQdFWQVHR0VZBUd%2FtQdFWQVHR0VZBUd%2FtQdFWQVHR0VZBUdAAgAAAAABLAETAAPAB8ALwA%2FAE8AXwBvAH8AABMzMhYdARQGKwEiJj0BNDYpATIWHQEUBiMhIiY9ATQ2ATMyFh0BFAYrASImPQE0NikBMhYdARQGIyEiJj0BNDYBMzIWHQEUBisBIiY9ATQ2KQEyFh0BFAYjISImPQE0NgEzMhYdARQGKwEiJj0BNDYpATIWHQEUBiMhIiY9ATQ2MmQVHR0VZBUdHQFBAyAVHR0V%2FOAVHR3%2B6WQVHR0VZBUdHQFBAyAVHR0V%2FOAVHR3%2B6WQVHR0VZBUdHQFBAyAVHR0V%2FOAVHR3%2B6WQVHR0VZBUdHQFBAyAVHR0V%2FOAVHR0ETB0VZBUdHRVkFR0dFWQVHR0VZBUd%2FtQdFWQVHR0VZBUdHRVkFR0dFWQVHf7UHRVkFR0dFWQVHR0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR0dFWQVHR0VZBUdAAAG%2F5wAAASwBEwAAwATACMAKgA6AEoAACEjETsCMhYdARQGKwEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2BQc1IzUzNQUhMhYdARQGIyEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2AZBkZJZkFR0dFWQVHR0VAfQVHR0V%2FgwVHR3%2B%2BqfIyAHCASwVHR0V%2FtQVHR0VAlgVHR0V%2FagVHR0ETB0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR36fUtkS68dFWQVHR0VZBUd%2FtQdFWQVHR0VZBUdAAAABgAAAAAFFARMAA8AEwAjACoAOgBKAAATMzIWHQEUBisBIiY9ATQ2ASMRMwEhMhYdARQGIyEiJj0BNDYFMxUjFSc3BSEyFh0BFAYjISImPQE0NhMhMhYdARQGIyEiJj0BNDYyZBUdHRVkFR0dA2dkZPyuAfQVHR0V%2FgwVHR0EL8jIp6f75gEsFR0dFf7UFR0dFQJYFR0dFf2oFR0dBEwdFWQVHR0VZBUd%2B7QETP7UHRVkFR0dFWQVHchkS319rx0VZBUdHRVkFR3%2B1B0VZBUdHRVkFR0AAAAAAgAAAMgEsAPoAA8AEgAAEyEyFhURFAYjISImNRE0NgkCSwLuHywsH%2F0SHywsBIT%2B1AEsA%2BgsH%2F12HywsHwKKHyz9RAEsASwAAwAAAAAEsARMAA8AFwAfAAATITIWFREUBiMhIiY1ETQ2FxE3BScBExEEMhYUBiImNCwEWBIaGhL7qBIaGkr3ASpKASXs%2FNJwTk5wTgRMGhL8DBIaGhID9BIaZP0ftoOcAT7%2B4AH0dE5vT09vAAAAAAIA2wAFBDYEkQAWAB4AAAEyHgEVFAcOAQ8BLgQnJjU0PgIWIgYUFjI2NAKIdcZzRkWyNjYJIV5YbSk8RHOft7eCgreCBJF4ynVzj23pPz4IIWZomEiEdVijeUjDgriBgbgAAAACABcAFwSZBJkADwAXAAAAMh4CFA4CIi4CND4BAREiDgEUHgEB4%2BrWm1tbm9bq1ptbW5sBS3TFcnLFBJlbm9bq1ptbW5vW6tab%2FG8DVnLF6MVyAAACAHUAAwPfBQ8AGgA1AAABHgYVFA4DBy4DNTQ%2BBQMOAhceBBcWNj8BNiYnLgInJjc2IyYCKhVJT1dOPiUzVnB9P1SbfEokP0xXUEm8FykoAwEbITEcExUWAgYCCQkFEikMGiACCAgFD0iPdXdzdYdFR4BeRiYEBTpjl1lFh3ZzeHaQ%2Ff4hS4I6JUEnIw4IBwwQIgoYBwQQQSlZtgsBAAAAAwAAAAAEywRsAAwAKgAvAAABNz4CHgEXHgEPAiUhMhcHISIGFREUFjMhMjY9ATcRFAYjISImNRE0NgkBBzcBA%2BhsAgYUFR0OFgoFBmz9BQGQMje7%2FpApOzspAfQpO8i7o%2F5wpbm5Azj%2BlqE3AWMD9XMBAgIEDw4WKgsKc8gNuzsp%2FgwpOzsptsj%2BtKW5uaUBkKW5%2Ftf%2BljKqAWMAAgAAAAAEkwRMABsANgAAASEGByMiBhURFBYzITI2NTcVFAYjISImNRE0NgUBFhQHAQYmJzUmDgMHPgY3NT4BAV4BaaQ0wyk7OykB9Ck7yLml%2FnClubkCfwFTCAj%2BrAcLARo5ZFRYGgouOUlARioTAQsETJI2Oyn%2BDCk7OymZZ6W5uaUBkKW5G%2F7TBxUH%2Fs4GBAnLAQINFjAhO2JBNB0UBwHSCgUAAAAAAgAAAAAEnQRMAB0ANQAAASEyFwchIgYVERQWMyEyNj0BNxUUBiMhIiY1ETQ2CQE2Mh8BFhQHAQYiLwEmND8BNjIfARYyAV4BXjxDsv6jKTs7KQH0KTvIuaX%2BcKW5uQHKAYsHFQdlBwf97QcVB%2FgHB2UHFQdvCBQETBexOyn%2BDCk7OylFyNulubmlAZCluf4zAYsHB2UHFQf97AcH%2BAcVB2UHB28HAAAAAQAKAAoEpgSmADsAAAkBNjIXARYGKwEVMzU0NhcBFhQHAQYmPQEjFTMyFgcBBiInASY2OwE1IxUUBicBJjQ3ATYWHQEzNSMiJgE%2BAQgIFAgBBAcFCqrICggBCAgI%2FvgICsiqCgUH%2FvwIFAj%2B%2BAgFCq%2FICgj%2B%2BAgIAQgICsivCgUDlgEICAj%2B%2BAgKyK0KBAf%2B%2FAcVB%2F73BwQKrcgKCP74CAgBCAgKyK0KBAcBCQcVBwEEBwQKrcgKAAEAyAAAA4QETAAZAAATMzIWFREBNhYVERQGJwERFAYrASImNRE0NvpkFR0B0A8VFQ%2F%2BMB0VZBUdHQRMHRX%2BSgHFDggV%2FBgVCA4Bxf5KFR0dFQPoFR0AAAABAAAAAASwBEwAIwAAEzMyFhURATYWFREBNhYVERQGJwERFAYnAREUBisBIiY1ETQ2MmQVHQHQDxUB0A8VFQ%2F%2BMBUP%2FjAdFWQVHR0ETB0V%2FkoBxQ4IFf5KAcUOCBX8GBUIDgHF%2FkoVCA4Bxf5KFR0dFQPoFR0AAAABAJ0AGQSwBDMAFQAAAREUBicBERQGJwEmNDcBNhYVEQE2FgSwFQ%2F%2BMBUP%2FhQPDwHsDxUB0A8VBBr8GBUIDgHF%2FkoVCA4B4A4qDgHgDggV%2FkoBxQ4IAAAAAQDIABYEMwQ2AAsAABMBFhQHAQYmNRE0NvMDLhIS%2FNISGRkEMv4OCx4L%2Fg4LDhUD6BUOAAIAyABkA4QD6AAPAB8AABMzMhYVERQGKwEiJjURNDYhMzIWFREUBisBIiY1ETQ2%2BsgVHR0VyBUdHQGlyBUdHRXIFR0dA%2BgdFfzgFR0dFQMgFR0dFfzgFR0dFQMgFR0AAAEAyABkBEwD6AAPAAABERQGIyEiJjURNDYzITIWBEwdFfzgFR0dFQMgFR0DtvzgFR0dFQMgFR0dAAAAAAEAAAAZBBMEMwAVAAABETQ2FwEWFAcBBiY1EQEGJjURNDYXAfQVDwHsDw%2F%2BFA8V%2FjAPFRUPAmQBthUIDv4gDioO%2FiAOCBUBtv47DggVA%2BgVCA4AAAH%2F%2FgACBLMETwAjAAABNzIWFRMUBiMHIiY1AwEGJjUDAQYmNQM0NhcBAzQ2FwEDNDYEGGQUHgUdFWQVHQL%2BMQ4VAv4yDxUFFQ8B0gIVDwHSAh0ETgEdFfwYFR0BHRUBtf46DwkVAbX%2BOQ4JFAPoFQkP%2Fj4BthQJDv49AbYVHQAAAQEsAAAD6ARMABkAAAEzMhYVERQGKwEiJjURAQYmNRE0NhcBETQ2A1JkFR0dFWQVHf4wDxUVDwHQHQRMHRX8GBUdHRUBtv47DggVA%2BgVCA7%2BOwG2FR0AAAIAZADIBLAESAALABsAAAkBFgYjISImNwE2MgEhMhYdARQGIyEiJj0BNDYCrgH1DwkW%2B%2B4WCQ8B9Q8q%2FfcD6BUdHRX8GBUdHQQ5%2FeQPFhYPAhwP%2FUgdFWQVHR0VZBUdAAEAiP%2F8A3UESgAFAAAJAgcJAQN1%2FqABYMX92AIoA4T%2Bn%2F6fxgIoAiYAAAAAAQE7%2F%2FwEKARKAAUAAAkBJwkBNwQo%2FdnGAWH%2Bn8YCI%2F3ZxgFhAWHGAAIAFwAXBJkEmQAPADMAAAAyHgIUDgIiLgI0PgEFIyIGHQEjIgYdARQWOwEVFBY7ATI2PQEzMjY9ATQmKwE1NCYB4%2BrWm1tbm9bq1ptbW5sBfWQVHZYVHR0Vlh0VZBUdlhUdHRWWHQSZW5vW6tabW1ub1urWm7odFZYdFWQVHZYVHR0Vlh0VZBUdlhUdAAAAAAIAFwAXBJkEmQAPAB8AAAAyHgIUDgIiLgI0PgEBISIGHQEUFjMhMjY9ATQmAePq1ptbW5vW6tabW1ubAkX%2BDBUdHRUB9BUdHQSZW5vW6tabW1ub1urWm%2F5%2BHRVkFR0dFWQVHQACABcAFwSZBJkADwAzAAAAMh4CFA4CIi4CND4BBCIPAScmIg8BBhQfAQcGFB8BFjI%2FARcWMj8BNjQvATc2NC8BAePq1ptbW5vW6tabW1ubAeUZCXh4CRkJjQkJeHgJCY0JGQl4eAkZCY0JCXh4CQmNBJlbm9bq1ptbW5vW6tabrQl4eAkJjQkZCXh4CRkJjQkJeHgJCY0JGQl4eAkZCY0AAgAXABcEmQSZAA8AJAAAADIeAhQOAiIuAjQ%2BAQEnJiIPAQYUHwEWMjcBNjQvASYiBwHj6tabW1ub1urWm1tbmwEVVAcVCIsHB%2FIHFQcBdwcHiwcVBwSZW5vW6tabW1ub1urWm%2F4xVQcHiwgUCPEICAF3BxUIiwcHAAAAAAMAFwAXBJkEmQAPADsASwAAADIeAhQOAiIuAjQ%2BAQUiDgMVFDsBFjc%2BATMyFhUUBgciDgUHBhY7ATI%2BAzU0LgMTIyIGHQEUFjsBMjY9ATQmAePq1ptbW5vW6tabW1ubAT8dPEIyIRSDHgUGHR8UFw4TARkOGhITDAIBDQ6tBx4oIxgiM0Q8OpYKDw8KlgoPDwSZW5vW6tabW1ub1urWm5ELHi9PMhkFEBQQFRIXFgcIBw4UHCoZCBEQKDhcNi9IKhsJ%2FeMPCpYKDw8KlgoPAAADABcAFwSZBJkADwAfAD4AAAAyHgIUDgIiLgI0PgEFIyIGHQEUFjsBMjY9ATQmAyMiBh0BFBY7ARUjIgYdARQWMyEyNj0BNCYrARE0JgHj6tabW1ub1urWm1tbmwGWlgoPDwqWCg8PCvoKDw8KS0sKDw8KAV4KDw8KSw8EmVub1urWm1tbm9bq1ptWDwqWCg8PCpYKD%2F7UDwoyCg%2FIDwoyCg8PCjIKDwETCg8AAgAAAAAEsASwAC8AXwAAATMyFh0BHgEXMzIWHQEUBisBDgEHFRQGKwEiJj0BLgEnIyImPQE0NjsBPgE3NTQ2ExUUBisBIiY9AQ4BBzMyFh0BFAYrAR4BFzU0NjsBMhYdAT4BNyMiJj0BNDY7AS4BAg2WCg9nlxvCCg8PCsIbl2cPCpYKD2eXG8IKDw8KwhuXZw%2B5DwqWCg9EZheoCg8PCqgXZkQPCpYKD0RmF6gKDw8KqBdmBLAPCsIbl2cPCpYKD2eXG8IKDw8KwhuXZw8KlgoPZ5cbwgoP%2Fs2oCg8PCqgXZkQPCpYKD0RmF6gKDw8KqBdmRA8KlgoPRGYAAwAXABcEmQSZAA8AGwA%2FAAAAMh4CFA4CIi4CND4BBCIOARQeATI%2BATQmBxcWFA8BFxYUDwEGIi8BBwYiLwEmND8BJyY0PwE2Mh8BNzYyAePq1ptbW5vW6tabW1ubAb%2FoxXJyxejFcnKaQAcHfHwHB0AHFQd8fAcVB0AHB3x8BwdABxUHfHwHFQSZW5vW6tabW1ub1urWmztyxejFcnLF6MVaQAcVB3x8BxUHQAcHfHwHB0AHFQd8fAcVB0AHB3x8BwAAAAMAFwAXBJkEmQAPABsAMAAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JgcXFhQHAQYiLwEmND8BNjIfATc2MgHj6tabW1ub1urWm1tbmwG%2F6MVycsXoxXJyg2oHB%2F7ACBQIyggIagcVB0%2FFBxUEmVub1urWm1tbm9bq1ps7csXoxXJyxejFfWoHFQf%2BvwcHywcVB2oICE%2FFBwAAAAMAFwAXBJkEmQAPABgAIQAAADIeAhQOAiIuAjQ%2BAQUiDgEVFBcBJhcBFjMyPgE1NAHj6tabW1ub1urWm1tbmwFLdMVyQQJLafX9uGhzdMVyBJlbm9bq1ptbW5vW6tabO3LFdHhpAktB0P24PnLFdHMAAAAAAQAXAFMEsAP5ABUAABMBNhYVESEyFh0BFAYjIREUBicBJjQnAgoQFwImFR0dFf3aFxD99hACRgGrDQoV%2Ft0dFcgVHf7dFQoNAasNJgAAAAABAAAAUwSZA%2FkAFQAACQEWFAcBBiY1ESEiJj0BNDYzIRE0NgJ%2FAgoQEP32EBf92hUdHRUCJhcD8f5VDSYN%2FlUNChUBIx0VyBUdASMVCgAAAAEAtwAABF0EmQAVAAAJARYGIyERFAYrASImNREhIiY3ATYyAqoBqw0KFf7dHRXIFR3%2B3RUKDQGrDSYEif32EBf92hUdHRUCJhcQAgoQAAAAAQC3ABcEXQSwABUAAAEzMhYVESEyFgcBBiInASY2MyERNDYCJsgVHQEjFQoN%2FlUNJg3%2BVQ0KFQEjHQSwHRX92hcQ%2FfYQEAIKEBcCJhUdAAABAAAAtwSZBF0AFwAACQEWFAcBBiY1EQ4DBz4ENxE0NgJ%2FAgoQEP32EBdesKWBJAUsW4fHfhcEVf5VDSYN%2FlUNChUBIwIkRHVNabGdcUYHAQYVCgACAAAAAASwBLAAFQArAAABITIWFREUBi8BBwYiLwEmND8BJyY2ASEiJjURNDYfATc2Mh8BFhQPARcWBgNSASwVHRUOXvkIFAhqBwf5Xg4I%2FiH%2B1BUdFQ5e%2BQgUCGoHB%2FleDggEsB0V%2FtQVCA5e%2BQcHaggUCPleDhX7UB0VASwVCA5e%2BQcHaggUCPleDhUAAAACAEkASQRnBGcAFQArAAABFxYUDwEXFgYjISImNRE0Nh8BNzYyASEyFhURFAYvAQcGIi8BJjQ%2FAScmNgP2agcH%2BV4OCBX%2B1BUdFQ5e%2BQgU%2FQwBLBUdFQ5e%2BQgUCGoHB%2FleDggEYGoIFAj5Xg4VHRUBLBUIDl75B%2F3xHRX%2B1BUIDl75BwdqCBQI%2BV4OFQAAAAADABcAFwSZBJkADwAfAC8AAAAyHgIUDgIiLgI0PgEFIyIGFxMeATsBMjY3EzYmAyMiBh0BFBY7ATI2PQE0JgHj6tabW1ub1urWm1tbmwGz0BQYBDoEIxQ2FCMEOgQYMZYKDw8KlgoPDwSZW5vW6tabW1ub1urWm7odFP7SFB0dFAEuFB3%2BDA8KlgoPDwqWCg8AAAAABQAAAAAEsASwAEkAVQBhAGgAbwAAATIWHwEWHwEWFxY3Nj8BNjc2MzIWHwEWHwIeATsBMhYdARQGKwEiBh0BIREjESE1NCYrASImPQE0NjsBMjY1ND8BNjc%2BBAUHBhY7ATI2LwEuAQUnJgYPAQYWOwEyNhMhIiY1ESkBERQGIyERAQQJFAUFFhbEFQ8dCAsmxBYXERUXMA0NDgQZCAEPCj0KDw8KMgoP%2FnDI%2FnAPCjIKDw8KPQsOCRkFDgIGFRYfAp2mBwQK2woKAzMDEP41sQgQAzMDCgrnCwMe%2FokKDwGQAlgPCv6JBLAEAgIKDXYNCxUJDRZ2DQoHIREQFRh7LAkLDwoyCg8PCq8BLP7UrwoPDwoyCg8GBQQwgBkUAwgWEQ55ogcKDgqVCgSqnQcECo8KDgr8cg8KAXf%2BiQoPAZAAAAAAAgAAAAwErwSmACsASQAAATYWFQYCDgQuAScmByYOAQ8BBiY1NDc%2BATc%2BAScuAT4BNz4GFyYGBw4BDwEOBAcOARY2Nz4CNz4DNz4BBI0IGgItQmxhi2KORDg9EQQRMxuZGhYqCFUYEyADCQIQOjEnUmFch3vAJQgdHyaiPT44XHRZUhcYDhItIRmKcVtGYWtbKRYEBKYDEwiy%2Ft3IlVgxEQgLCwwBAQIbG5kYEyJAJghKFRE8Hzdff4U%2FM0o1JSMbL0QJGCYvcSEhHjZST2c1ODwEJygeW0AxJUBff1UyFAABAF0AHgRyBM8ATwAAAQ4BHgQXLgc%2BATceAwYHDgQHBicmNzY3PgQuAScWDgMmJy4BJyY%2BBDcGHgM3PgEuAicmPgMCjScfCic4R0IgBBsKGAoQAwEJEg5gikggBhANPkpTPhZINx8SBgsNJysiCRZOQQoVNU1bYC9QZwICBAUWITsoCAYdJzIYHw8YIiYHDyJJYlkEz0OAZVxEOSQMBzgXOB42IzElKRIqg5Gnl0o3Z0c6IAYWCwYNAwQFIDhHXGF1OWiqb0sdBxUknF0XNTQ8PEUiNWNROBYJDS5AQVUhVZloUSkAAAAAA%2F%2FcAGoE1ARGABsAPwBRAAAAMh4FFA4FIi4FND4EBSYGFxYVFAYiJjU0NzYmBwYHDgEXHgQyPgM3NiYnJgUHDgEXFhcWNj8BNiYnJicuAQIGpJ17bk85HBw6T257naKde25POhwcOU9uewIPDwYIGbD4sBcIBw5GWg0ECxYyWl%2BDiINfWjIWCwQMWv3%2FIw8JCSU4EC0OIw4DDywtCyIERi1JXGJcSSpJXGJcSS0tSVxiXEkqSVxiXEncDwYTOT58sLB8OzcTBg9FcxAxEiRGXkQxMEVeRSQSMRF1HiQPLxJEMA0EDyIPJQ8sSRIEAAAABP%2FcAAAE1ASwABQAJwA7AEwAACEjNy4ENTQ%2BBTMyFzczEzceARUUDgMHNz4BNzYmJyYlBgcOARceBBc3LgE1NDc2JhcHDgEXFhcWNj8CJyYnLgECUJQfW6l2WSwcOU9ue51SPUEglCYvbIknUGqYUi5NdiYLBAw2%2FVFGWg0ECxIqSExoNSlrjxcIB3wjDwkJJTgQLQ4MFgMsLQsieBRhdHpiGxVJXGJcSS0Pef5StVXWNBpacm5jGq0xiD8SMRFGckVzEDESHjxRQTkNmhKnbjs3EwZwJA8vEkQwDQQPC1YELEkSBAAAAAP%2FngAABRIEqwALABgAKAAAJwE2FhcBFgYjISImJSE1NDY7ATIWHQEhAQczMhYPAQ4BKwEiJi8BJjZaAoIUOBQCghUbJfryJRsBCgFZDwqWCg8BWf5DaNAUGAQ6BCMUNhQjBDoEGGQEKh8FIfvgIEdEhEsKDw8KSwLT3x0U%2FBQdHRT8FB0AAAABAGQAFQSwBLAAKAAAADIWFREBHgEdARQGJyURFh0BFAYvAQcGJj0BNDcRBQYmPQE0NjcBETQCTHxYAWsPFhgR%2FplkGhPNzRMaZP6ZERgWDwFrBLBYPv6t%2FrsOMRQpFA0M%2Bf75XRRAFRAJgIAJEBVAFF0BB%2FkMDRQpFDEOAUUBUz4AAAARAAAAAARMBLAAHQAnACsALwAzADcAOwA%2FAEMARwBLAE8AUwBXAFsAXwBjAAABMzIWHQEzMhYdASE1NDY7ATU0NjsBMhYdASE1NDYBERQGIyEiJjURFxUzNTMVMzUzFTM1MxUzNTMVMzUFFTM1MxUzNTMVMzUzFTM1MxUzNQUVMzUzFTM1MxUzNTMVMzUzFTM1A1JkFR0yFR37tB0VMh0VZBUdAfQdAQ8dFfwYFR1kZGRkZGRkZGRk%2FHxkZGRkZGRkZGT8fGRkZGRkZGRkZASwHRUyHRWWlhUdMhUdHRUyMhUd%2FnD9EhUdHRUC7shkZGRkZGRkZGRkyGRkZGRkZGRkZGTIZGRkZGRkZGRkZAAAAAMAAAAZBXcElwAZACUANwAAARcWFA8BBiY9ASMBISImPQE0NjsBATM1NDYBBycjIiY9ATQ2MyEBFxYUDwEGJj0BIyc3FzM1NDYEb%2FkPD%2FkOFZ%2F9qP7dFR0dFdECWPEV%2FamNetEVHR0VASMDGvkPD%2FkOFfG1jXqfFQSN5g4qDuYOCBWW%2FagdFWQVHQJYlhUI%2FpiNeh0VZBUd%2Fk3mDioO5g4IFZa1jXqWFQgAAAABAAAAAASwBEwAEgAAEyEyFhURFAYjIQERIyImNRE0NmQD6Ck7Oyn9rP7QZCk7OwRMOyn9qCk7%2FtQBLDspAlgpOwAAAAMAZAAABEwEsAAJABMAPwAAEzMyFh0BITU0NiEzMhYdASE1NDYBERQOBSIuBTURIRUUFRwBHgYyPgYmNTQ9AZbIFR3%2B1B0C0cgVHf7UHQEPBhgoTGacwJxmTCgYBgEsAwcNFB8nNkI2Jx8TDwUFAQSwHRX6%2BhUdHRX6%2BhUd%2FnD%2B1ClJalZcPigoPlxWakkpASz6CRIVKyclIRsWEAgJEBccISUnKhURCPoAAAAB%2F%2F8A1ARMA8IABQAAAQcJAScBBEzG%2Fp%2F%2Bn8UCJwGbxwFh%2Fp%2FHAicAAQAAAO4ETQPcAAUAAAkCNwkBBE392v3ZxgFhAWEDFf3ZAifH%2Fp8BYQAAAAAC%2F1EAZAVfA%2BgAFAApAAABITIWFREzMhYPAQYiLwEmNjsBESElFxYGKwERIRchIiY1ESMiJj8BNjIBlALqFR2WFQgO5g4qDuYOCBWW%2FoP%2BHOYOCBWWAYHX%2FRIVHZYVCA7mDioD6B0V%2FdkVDvkPD%2FkOFQGRuPkOFf5wyB0VAiYVDvkPAAABAAYAAASeBLAAMAAAEzMyFh8BITIWBwMOASMhFyEyFhQGKwEVFAYiJj0BIRUUBiImPQEjIiYvAQMjIiY0NjheERwEJgOAGB4FZAUsIf2HMAIXFR0dFTIdKh3%2B1B0qHR8SHQYFyTYUHh4EsBYQoiUY%2FiUVK8gdKh0yFR0dFTIyFR0dFTIUCQoDwR0qHQAAAAACAAAAAASwBEwACwAPAAABFSE1MzQ2MyEyFhUFIREhBLD7UMg7KQEsKTv9RASw%2B1AD6GRkKTs7Kcj84AACAAAAAAXcBEwADAAQAAATAxEzNDYzITIWFSEVBQEhAcjIyDspASwqOgH0ASz%2B1PtQASwDIP5wAlgpOzspyGT9RAK8AAEBRQAAA2sErwAbAAABFxYGKwERMzIWDwEGIi8BJjY7AREjIiY%2FATYyAnvmDggVlpYVCA7mDioO5g4IFZaWFQgO5g4qBKD5DhX9pxUO%2BQ8P%2BQ4VAlkVDvkPAAAAAQABAUQErwNrABsAAAEXFhQPAQYmPQEhFRQGLwEmND8BNhYdASE1NDYDqPkODvkPFf2oFQ%2F5Dg75DxUCWBUDYOUPKQ%2FlDwkUl5cUCQ%2FlDykP5Q8JFZWVFQkAAAAEAAAAAASwBLAACQAZAB0AIQAAAQMuASMhIgYHAwUhIgYdARQWMyEyNj0BNCYFNTMVMzUzFQSRrAUkFP1gFCQFrAQt%2FBgpOzspA%2BgpOzv%2Bq2RkZAGQAtwXLSgV%2FR1kOylkKTs7KWQpO8hkZGRkAAAAA%2F%2BcAGQEsARMAAsAIwAxAAAAMhYVERQGIiY1ETQDJSMTFgYjIisBIiYnAj0BNDU0PgE7ASUBFSIuAz0BND4CNwRpKh0dKh1k%2FV0mLwMRFQUCVBQdBDcCCwzIAqP8GAQOIhoWFR0dCwRMHRX8rhUdHRUDUhX8mcj%2B7BAIHBUBUQ76AgQQDw36%2FtT6AQsTKRwyGigUDAEAAAACAEoAAARmBLAALAA1AAABMzIWDwEeARcTFzMyFhQGBw4EIyIuBC8BLgE0NjsBNxM%2BATcnJjYDFjMyNw4BIiYCKV4UEgYSU3oPP3YRExwaEggeZGqfTzl0XFU%2BLwwLEhocExF2Pw96UxIGEyQyNDUxDDdGOASwFRMlE39N%2FrmtHSkoBwQLHBYSCg4REg4FBAgoKR2tAUdNfhQgExr7vgYGMT09AAEAFAAUBJwEnAAXAAABNwcXBxcHFycHJwcnBzcnNyc3Jxc3FzcDIOBO6rS06k7gLZubLeBO6rS06k7gLZubA7JO4C2bmy3gTuq0tOpO4C2bmy3gTuq0tAADAAAAZASwBLAAIQAtAD0AAAEzMhYdAQchMhYdARQHAw4BKwEiJi8BIyImNRE0PwI%2BARcPAREzFzMTNSE3NQEzMhYVERQGKwEiJjURNDYCijIoPBwBSCg8He4QLBf6B0YfHz0tNxSRYA0xG2SWZIjW%2Bv4%2BMv12ZBUdHRVkFR0dBLBRLJZ9USxkLR3%2BqBghMhkZJCcBkCQbxMYcKGTU1f6JZAF3feGv%2FtQdFf4MFR0dFQH0FR0AAAAAAwAAAAAEsARMACAAMAA8AAABMzIWFxMWHQEUBiMhFh0BFAYrASImLwImNRE0NjsBNgUzMhYVERQGKwEiJjURNDYhByMRHwEzNSchNQMCWPoXLBDuHTwo%2FrgcPCgyGzENYJEUNy09fP3pZBUdHRVkFR0dAl%2BIZJZkMjIBwvoETCEY%2FqgdLWQsUXYHlixRKBzGxBskAZAnJGRkHRX%2BDBUdHRUB9BUdZP6J1dSv4X0BdwADAAAAZAUOBE8AGwA3AEcAAAElNh8BHgEPASEyFhQGKwEDDgEjISImNRE0NjcXERchEz4BOwEyNiYjISoDLgQnJj8BJwUzMhYVERQGKwEiJjURNDYBZAFrHxZuDQEMVAEuVGxuVGqDBhsP%2FqoHphwOOmQBJYMGGw%2FLFRMSFv44AgoCCQMHAwUDAQwRklb9T2QVHR0VZBUdHQNp5hAWcA0mD3lMkE7%2BrRUoog0CDRElCkj%2BCVkBUxUoMjIBAgIDBQIZFrdT5B0V%2FgwVHR0VAfQVHQAAAAP%2FnABkBLAETwAdADYARgAAAQUeBBURFAYjISImJwMjIiY0NjMhJyY2PwE2BxcWBw4FKgIjIRUzMhYXEyE3ESUFMzIWFREUBisBIiY1ETQ2AdsBbgIIFBANrAf%2Bqg8bBoNqVW1sVAEuVQsBDW4WSpIRDAIDBQMHAwkDCgH%2BJd0PHAaCASZq%2FqoCUGQVHR0VZBUdHQRP5gEFEBEXC%2F3zDaIoFQFTTpBMeQ8mDXAWrrcWGQIFAwICAWQoFf6tWQH37OQdFf4MFR0dFQH0FR0AAAADAGEAAARMBQ4AGwA3AEcAAAAyFh0BBR4BFREUBiMhIiYvAQMmPwE%2BAR8BETQXNTQmBhURHAMOBAcGLwEHEyE3ESUuAQMhMhYdARQGIyEiJj0BNDYB3pBOAVMVKKIN%2FfMRJQoJ5hAWcA0mD3nGMjIBAgIDBQIZFrdT7AH3Wf6tFSiWAfQVHR0V%2FgwVHR0FDm5UaoMGGw%2F%2BqgemHA4OAWsfFm4NAQxUAS5U1ssVExIW%2FjgCCgIJAwcDBQMBDBGSVv6tZAElgwYb%2FQsdFWQVHR0VZBUdAAP%2F%2FQAGA%2BgFFAAPAC0ASQAAASEyNj0BNCYjISIGHQEUFgEVFAYiJjURBwYmLwEmNxM%2BBDMhMhYVERQGBwEDFzc2Fx4FHAIVERQWNj0BNDY3JREnAV4B9BUdHRX%2BDBUdHQEPTpBMeQ8mDXAWEOYBBRARFwsCDQ2iKBX9iexTtxYZAgUDAgIBMjIoFQFTWQRMHRVkFR0dFWQVHfzmalRubFQBLlQMAQ1uFh8BawIIEw8Mpgf%2Bqg8bBgHP%2Fq1WkhEMAQMFAwcDCQIKAv44FhITFcsPGwaDASVkAAIAFgAWBJoEmgAPACUAAAAyHgIUDgIiLgI0PgEBJSYGHQEhIgYdARQWMyEVFBY3JTY0AeLs1ptbW5vW7NabW1ubAob%2B7RAX%2Fu0KDw8KARMXEAETEASaW5vW7NabW1ub1uzWm%2F453w0KFYkPCpYKD4kVCg3fDSYAAAIAFgAWBJoEmgAPACUAAAAyHgIUDgIiLgI0PgENAQYUFwUWNj0BITI2PQE0JiMhNTQmAeLs1ptbW5vW7NabW1ubASX%2B7RAQARMQFwETCg8PCv7tFwSaW5vW7NabW1ub1uzWm%2BjfDSYN3w0KFYkPCpYKD4kVCgAAAAIAFgAWBJoEmgAPACUAAAAyHgIUDgIiLgI0PgEBAyYiBwMGFjsBERQWOwEyNjURMzI2AeLs1ptbW5vW7NabW1ubAkvfDSYN3w0KFYkPCpYKD4kVCgSaW5vW7NabW1ub1uzWm%2F5AARMQEP7tEBf%2B7QoPDwoBExcAAAIAFgAWBJoEmgAPACUAAAAyHgIUDgIiLgI0PgEFIyIGFREjIgYXExYyNxM2JisBETQmAeLs1ptbW5vW7NabW1ubAZeWCg%2BJFQoN3w0mDd8NChWJDwSaW5vW7NabW1ub1uzWm7sPCv7tFxD%2B7RAQARMQFwETCg8AAAMAGAAYBJgEmAAPAJYApgAAADIeAhQOAiIuAjQ%2BASUOAwcGJgcOAQcGFgcOAQcGFgcUFgcyHgEXHgIXHgI3Fg4BFx4CFxQGFBcWNz4CNy4BJy4BJyIOAgcGJyY2NS4BJzYuAQYHBicmNzY3HgIXHgMfAT4CJyY%2BATc%2BAzcmNzIWMjY3LgMnND4CJiceAT8BNi4CJwYHFB4BFS4CJz4BNxYyPgEB5OjVm1xcm9Xo1ZtcXJsBZA8rHDoKDz0PFD8DAxMBAzEFCRwGIgEMFhkHECIvCxU%2FOR0HFBkDDRQjEwcFaHUeISQDDTAMD0UREi4oLBAzDwQBBikEAQMLGhIXExMLBhAGKBsGBxYVEwYFAgsFAwMNFwQGCQcYFgYQCCARFwkKKiFBCwQCAQMDHzcLDAUdLDgNEiEQEgg%2FKhADGgMKEgoRBJhcm9Xo1ZtcXJvV6NWbEQwRBwkCAwYFBycPCxcHInIWInYcCUcYChQECA4QBAkuHgQPJioRFRscBAcSCgwCch0kPiAIAQcHEAsBAgsLIxcBMQENCQIPHxkCFBkdHB4QBgEBBwoMGBENBAMMJSAQEhYXDQ4qFBkKEhIDCQsXJxQiBgEOCQwHAQ0DBAUcJAwSCwRnETIoAwEJCwsLJQcKDBEAAAAAAQAAAAIErwSFABYAAAE2FwUXNxYGBw4BJwEGIi8BJjQ3ASY2AvSkjv79kfsGUE08hjv9rA8rD28PDwJYIk8EhVxliuh%2BWYcrIgsW%2FawQEG4PKxACV2XJAAYAAABgBLAErAAPABMAIwAnADcAOwAAEyEyFh0BFAYjISImPQE0NgUjFTMFITIWHQEUBiMhIiY9ATQ2BSEVIQUhMhYdARQGIyEiJj0BNDYFIRUhZAPoKTs7KfwYKTs7BBHIyPwYA%2BgpOzsp%2FBgpOzsEEf4MAfT8GAPoKTs7KfwYKTs7BBH%2B1AEsBKw7KWQpOzspZCk7ZGTIOylkKTs7KWQpO2RkyDspZCk7OylkKTtkZAAAAAIAZAAABEwEsAALABEAABMhMhYUBiMhIiY0NgERBxEBIZYDhBUdHRX8fBUdHQI7yP6iA4QEsB0qHR0qHf1E%2FtTIAfQB9AAAAAMAAABkBLAEsAAXABsAJQAAATMyFh0BITIWFREhNSMVIRE0NjMhNTQ2FxUzNQEVFAYjISImPQEB9MgpOwEsKTv%2BDMj%2BDDspASw7KcgB9Dsp%2FBgpOwSwOylkOyn%2BcGRkAZApO2QpO2RkZP1EyCk7OynIAAAABAAAAAAEsASwABUAKwBBAFcAABMhMhYPARcWFA8BBiIvAQcGJjURNDYpATIWFREUBi8BBwYiLwEmND8BJyY2ARcWFA8BFxYGIyEiJjURNDYfATc2MgU3NhYVERQGIyEiJj8BJyY0PwE2MhcyASwVCA5exwcHaggUCMdeDhUdAzUBLBUdFQ5exwgUCGoHB8deDgj%2BL2oHB8deDggV%2FtQVHRUOXscIFALLXg4VHRX%2B1BUIDl7HBwdqCBQIBLAVDl7HCBQIagcHx14OCBUBLBUdHRX%2B1BUIDl7HBwdqCBQIx14OFf0maggUCMdeDhUdFQEsFQgOXscHzl4OCBX%2B1BUdFQ5exwgUCGoHBwAAAAYAAAAABKgEqAAPABsAIwA7AEMASwAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JiQyFhQGIiY0JDIWFAYjIicHFhUUBiImNTQ2PwImNTQEMhYUBiImNCQyFhQGIiY0Advy3Z9fX5%2Fd8t2gXl6gAcbgv29vv%2BC%2Fb2%2F%2BLS0gIC0gAUwtICAWDg83ETNIMykfegEJ%2FoctICAtIAIdLSAgLSAEqF%2Bf3fLdoF5eoN3y3Z9Xb7%2Fgv29vv%2BC%2FBiAtISEtICAtIQqRFxwkMzMkIDEFfgEODhekIC0gIC0gIC0gIC0AAf%2FYAFoEuQS8AFsAACUBNjc2JicmIyIOAwcABw4EFx4BMzI3ATYnLgEjIgcGBwEOASY0NwA3PgEzMhceARcWBgcOBgcGIyImJyY2NwE2NzYzMhceARcWBgcBDgEnLgECIgHVWwgHdl8WGSJBMD8hIP6IDx4eLRMNBQlZN0ozAiQkEAcdEhoYDRr%2Bqw8pHA4BRyIjQS4ODyw9DQ4YIwwod26La1YOOEBGdiIwGkQB%2F0coW2tQSE5nDxE4Qv4eDyoQEAOtAdZbZWKbEQQUGjIhH%2F6JDxsdNSg3HT5CMwIkJCcQFBcMGv6uDwEcKQ4BTSIjIQEINykvYyMLKnhuiWZMBxtAOU6%2BRAH%2FSBg3ISSGV121Qv4kDwIPDyYAAAACAGQAWASvBEQAGQBEAAABPgIeAhUUDgMHLgQ1ND4CHgEFIg4DIi4DIyIGFRQeAhcWFx4EMj4DNzY3PgQ1NCYCiTB7eHVYNkN5hKg%2BPqeFeEM4WnZ4eQEjIT8yLSohJyktPyJDbxtBMjMPBw86KzEhDSIzKUAMBAgrKT8dF2oDtURIBS1TdkA5eYB%2FslVVsn%2BAeTlAdlMtBUgtJjY1JiY1NiZvTRc4SjQxDwcOPCouGBgwKEALBAkpKkQqMhNPbQACADn%2F8gR3BL4AFwAuAAAAMh8BFhUUBg8BJi8BNycBFwcvASY0NwEDNxYfARYUBwEGIi8BJjQ%2FARYfAQcXAQKru0KNQjgiHR8uEl%2F3%2FnvUaRONQkIBGxJpCgmNQkL%2B5UK6Qo1CQjcdLhJf9wGFBL5CjUJeKmsiHTUuEl%2F4%2FnvUahKNQrpCARv%2BRmkICY1CukL%2B5UJCjUK7Qjc3LxFf%2BAGFAAAAAAMAyAAAA%2BgEsAARABUAHQAAADIeAhURFAYjISImNRE0PgEHESERACIGFBYyNjQCBqqaZDo7Kf2oKTs8Zj4CWP7%2FVj09Vj0EsB4uMhX8Ryk7OykDuRUzLar9RAK8%2FRY9Vj09VgABAAAAAASwBLAAFgAACQEWFAYiLwEBEScBBRMBJyEBJyY0NjIDhgEbDx0qDiT%2B6dT%2BzP7oywEz0gEsAQsjDx0qBKH%2B5g8qHQ8j%2FvX%2B1NL%2BzcsBGAE01AEXJA4qHQAAAAADAScAEQQJBOAAMgBAAEsAAAEVHgQXIy4DJxEXHgQVFAYHFSM1JicuASczHgEXEScuBDU0PgI3NRkBDgMVFB4DFxYXET4ENC4CArwmRVI8LAKfBA0dMydAIjxQNyiym2SWVygZA4sFV0obLkJOMCAyVWg6HSoqFQ4TJhkZCWgWKTEiGBkzNwTgTgUTLD9pQiQuLBsH%2Fs0NBxMtPGQ%2Bi6oMTU8QVyhrVk1iEAFPCA4ZLzlYNkZwSCoGTf4SARIEDh02Jh0rGRQIBgPQ%2FsoCCRYgNEM0JRkAAAABAGQAZgOUBK0ASgAAATIeARUjNC4CIyIGBwYVFB4BFxYXMxUjFgYHBgc%2BATM2FjMyNxcOAyMiLgEHDgEPASc%2BBTc%2BAScjNTMmJy4CPgE3NgIxVJlemSc8OxolVBQpGxoYBgPxxQgVFS02ImIWIIwiUzUyHzY4HCAXanQmJ1YYFzcEGAcTDBEJMAwk3aYXFQcKAg4tJGEErVCLTig%2FIhIdFSw5GkowKgkFZDKCHj4yCg8BIh6TExcIASIfBAMaDAuRAxAFDQsRCjePR2QvORQrREFMIVgAAAACABn%2F%2FwSXBLAADwAfAAABMzIWDwEGIi8BJjY7AREzBRcWBisBESMRIyImPwE2MgGQlhUIDuYOKg7mDggVlsgCF%2BYOCBWWyJYVCA7mDioBLBYO%2Bg8P%2Bg4WA4QQ%2BQ4V%2FHwDhBUO%2BQ8AAAQAGf%2F%2FA%2BgEsAAHABcAGwAlAAABIzUjFSMRIQEzMhYPAQYiLwEmNjsBETMFFTM1EwczFSE1NyM1IQPoZGRkASz9qJYVCA7mDioO5g4IFZbIAZFkY8jI%2FtTIyAEsArxkZAH0%2FHwWDvoPD%2FoOFgOEZMjI%2FRL6ZJb6ZAAAAAAEABn%2F%2FwPoBLAADwAZACEAJQAAATMyFg8BBiIvASY2OwERMwUHMxUhNTcjNSERIzUjFSMRIQcVMzUBkJYVCA7mDioO5g4IFZbIAljIyP7UyMgBLGRkZAEsx2QBLBYO%2Bg8P%2Bg4WA4SW%2BmSW%2BmT7UGRkAfRkyMgAAAAEABn%2F%2FwRMBLAADwAVABsAHwAAATMyFg8BBiIvASY2OwERMwEjESM1MxMjNSMRIQcVMzUBkJYVCA7mDioO5g4IFZbIAlhkZMhkZMgBLMdkASwWDvoPD%2FoOFgOE%2FgwBkGT7UGQBkGTIyAAAAAAEABn%2F%2FwRMBLAADwAVABkAHwAAATMyFg8BBiIvASY2OwERMwEjNSMRIQcVMzUDIxEjNTMBkJYVCA7mDioO5g4IFZbIArxkyAEsx2QBZGTIASwWDvoPD%2FoOFgOE%2FgxkAZBkyMj7tAGQZAAAAAAFABn%2F%2FwSwBLAADwATABcAGwAfAAABMzIWDwEGIi8BJjY7AREzBSM1MxMhNSETITUhEyE1IQGQlhUIDuYOKg7mDggVlsgB9MjIZP7UASxk%2FnABkGT%2BDAH0ASwWDvoPD%2FoOFgOEyMj%2BDMj%2BDMj%2BDMgABQAZ%2F%2F8EsASwAA8AEwAXABsAHwAAATMyFg8BBiIvASY2OwERMwUhNSEDITUhAyE1IQMjNTMBkJYVCA7mDioO5g4IFZbIAyD%2BDAH0ZP5wAZBk%2FtQBLGTIyAEsFg76Dw%2F6DhYDhMjI%2FgzI%2FgzI%2FgzIAAIAAAAABEwETAAPAB8AAAEhMhYVERQGIyEiJjURNDYFISIGFREUFjMhMjY1ETQmAV4BkKK8u6P%2BcKW5uQJn%2FgwpOzspAfQpOzsETLuj%2FnClubmlAZClucg7Kf4MKTs7KQH0KTsAAAAAAwAAAAAETARMAA8AHwArAAABITIWFREUBiMhIiY1ETQ2BSEiBhURFBYzITI2NRE0JgUXFhQPAQYmNRE0NgFeAZClubml%2FnCju7wCZP4MKTs7KQH0KTs7%2Fm%2F9ERH9EBgYBEy5pf5wpbm5pQGQo7vIOyn%2BDCk7OykB9Ck7gr4MJAy%2BDAsVAZAVCwAAAAADAAAAAARMBEwADwAfACsAAAEhMhYVERQGIyEiJjURNDYFISIGFREUFjMhMjY1ETQmBSEyFg8BBiIvASY2AV4BkKO7uaX%2BcKW5uQJn%2FgwpOzspAfQpOzv%2BFQGQFQsMvgwkDL4MCwRMvKL%2BcKW5uaUBkKO7yDsp%2FgwpOzspAfQpO8gYEP0REf0QGAAAAAMAAAAABEwETAAPAB8AKwAAASEyFhURFAYjISImNRE0NgUhIgYVERQWMyEyNjURNCYFFxYGIyEiJj8BNjIBXgGQpbm5pf5wo7u5Amf%2BDCk7OykB9Ck7O%2F77vgwLFf5wFQsMvgwkBEy5pf5wo7u8ogGQpbnIOyn%2BDCk7OykB9Ck7z%2F0QGBgQ%2FREAAAAAAgAAAAAFFARMAB8ANQAAASEyFhURFAYjISImPQE0NjMhMjY1ETQmIyEiJj0BNDYHARYUBwEGJj0BIyImPQE0NjsBNTQ2AiYBkKW5uaX%2BcBUdHRUBwik7Oyn%2BPhUdHb8BRBAQ%2FrwQFvoVHR0V%2BhYETLml%2FnCluR0VZBUdOykB9Ck7HRVkFR3p%2FuQOJg7%2B5A4KFZYdFcgVHZYVCgAAAQDZAAID1wSeACMAAAEXFgcGAgclMhYHIggBBwYrAScmNz4BPwEhIicmNzYANjc2MwMZCQgDA5gCASwYEQ4B%2Fvf%2B8wQMDgkJCQUCUCcn%2FtIXCAoQSwENuwUJEASeCQoRC%2F5TBwEjEv7K%2FsUFDwgLFQnlbm4TFRRWAS%2FTBhAAAAACAAAAAAT%2BBEwAHwA1AAABITIWHQEUBiMhIgYVERQWMyEyFh0BFAYjISImNRE0NgUBFhQHAQYmPQEjIiY9ATQ2OwE1NDYBXgGQFR0dFf4%2BKTs7KQHCFR0dFf5wpbm5AvEBRBAQ%2FrwQFvoVHR0V%2BhYETB0VZBUdOyn%2BDCk7HRVkFR25pQGQpbnp%2FuQOJg7%2B5A4KFZYdFcgVHZYVCgACAAAAAASwBLAAFQAxAAABITIWFREUBi8BAQYiLwEmNDcBJyY2ASMiBhURFBYzITI2PQE3ERQGIyEiJjURNDYzIQLuAZAVHRUObf7IDykPjQ8PAThtDgj%2B75wpOzspAfQpO8i7o%2F5wpbm5pQEsBLAdFf5wFQgObf7IDw%2BNDykPAThtDhX%2B1Dsp%2FgwpOzsplMj%2B1qW5uaUBkKW5AAADAA4ADgSiBKIADwAbACMAAAAyHgIUDgIiLgI0PgEEIg4BFB4BMj4BNCYEMhYUBiImNAHh7tmdXV2d2e7ZnV1dnQHD5sJxccLmwnFx%2FnugcnKgcgSiXZ3Z7tmdXV2d2e7ZnUdxwubCcXHC5sJzcqBycqAAAAMAAAAABEwEsAAVAB8AIwAAATMyFhURMzIWBwEGIicBJjY7ARE0NgEhMhYdASE1NDYFFTM1AcLIFR31FAoO%2FoEOJw3%2BhQ0JFfod%2FoUD6BUd%2B7QdA2dkBLAdFf6iFg%2F%2BVg8PAaoPFgFeFR38fB0V%2BvoVHWQyMgAAAAMAAAAABEwErAAVAB8AIwAACQEWBisBFRQGKwEiJj0BIyImNwE%2BAQEhMhYdASE1NDYFFTM1AkcBeg4KFfQiFsgUGPoUCw4Bfw4n%2FfkD6BUd%2B7QdA2dkBJ7%2BTQ8g%2BhQeHRX6IQ8BrxAC%2FH8dFfr6FR1kMjIAAwAAAAAETARLABQAHgAiAAAJATYyHwEWFAcBBiInASY0PwE2MhcDITIWHQEhNTQ2BRUzNQGMAXEHFQeLBwf98wcVB%2F7cBweLCBUH1APoFR37tB0DZ2QC0wFxBweLCBUH%2FfMICAEjCBQIiwcH%2FdIdFfr6FR1kMjIABAAAAAAETASbAAkAGQAjACcAABM3NjIfAQcnJjQFNzYWFQMOASMFIiY%2FASc3ASEyFh0BITU0NgUVMzWHjg4qDk3UTQ4CFtIOFQIBHRX9qxUIDtCa1P49A%2BgVHfu0HQNnZAP%2Fjg4OTdRMDyqa0g4IFf2pFB4BFQ7Qm9T9Oh0V%2BvoVHWQyMgAAAAQAAAAABEwEsAAPABkAIwAnAAABBR4BFRMUBi8BByc3JyY2EwcGIi8BJjQ%2FAQEhMhYdASE1NDYFFTM1AV4CVxQeARUO0JvUm9IOCMNMDyoOjg4OTf76A%2BgVHfu0HQNnZASwAgEdFf2rFQgO0JrUmtIOFf1QTQ4Ojg4qDk3%2BWB0V%2BvoVHWQyMgACAAT%2F7ASwBK8ABQAIAAAlCQERIQkBFQEEsP4d%2Fsb%2BcQSs%2FTMCq2cBFP5xAacDHPz55gO5AAAAAAIAAABkBEwEsAAVABkAAAERFAYrAREhESMiJjURNDY7AREhETMHIzUzBEwdFZb9RJYVHR0V%2BgH0ZMhkZAPo%2FK4VHQGQ%2FnAdFQPoFB7%2B1AEsyMgAAAMAAABFBN0EsAAWABoALwAAAQcBJyYiDwEhESMiJjURNDY7AREhETMHIzUzARcWFAcBBiIvASY0PwE2Mh8BATYyBEwC%2FtVfCRkJlf7IlhUdHRX6AfRkyGRkAbBqBwf%2BXAgUCMoICGoHFQdPASkHFQPolf7VXwkJk%2F5wHRUD6BQe%2FtQBLMjI%2Fc5qBxUH%2FlsHB8sHFQdqCAhPASkHAAMAAAANBQcEsAAWABoAPgAAAREHJy4BBwEhESMiJjURNDY7AREhETMHIzUzARcWFA8BFxYUDwEGIi8BBwYiLwEmND8BJyY0PwE2Mh8BNzYyBExnhg8lEP72%2FreWFR0dFfoB9GTIZGQB9kYPD4ODDw9GDykPg4MPKQ9GDw%2BDgw8PRg8pD4ODDykD6P7zZ4YPAw7%2B9v5wHRUD6BQe%2FtQBLMjI%2FYxGDykPg4MPKQ9GDw%2BDgw8PRg8pD4ODDykPRg8Pg4MPAAADAAAAFQSXBLAAFQAZAC8AAAERISIGHQEhESMiJjURNDY7AREhETMHIzUzEzMyFh0BMzIWDwEGIi8BJjY7ATU0NgRM%2FqIVHf4MlhUdHRX6AfRkyGRklmQVHZYVCA7mDioO5g4IFZYdA%2Bj%2B1B0Vlv5wHRUD6BQe%2FtQBLMjI%2FagdFfoVDuYODuYOFfoVHQAAAAADAAAAAASXBLAAFQAZAC8AAAERJyYiBwEhESMiJjURNDY7AREhETMHIzUzExcWBisBFRQGKwEiJj0BIyImPwE2MgRMpQ4qDv75%2Fm6WFR0dFfoB9GTIZGTr5g4IFZYdFWQVHZYVCA7mDioD6P5wpQ8P%2Fvf%2BcB0VA%2BgUHv7UASzIyP2F5Q8V%2BhQeHhT6FQ%2FlDwADAAAAyASwBEwACQATABcAABMhMhYdASE1NDYBERQGIyEiJjURExUhNTIETBUd%2B1AdBJMdFfu0FR1kAZAETB0VlpYVHf7U%2FdoVHR0VAib%2B1MjIAAAGAAMAfQStBJcADwAZAB0ALQAxADsAAAEXFhQPAQYmPQEhNSE1NDYBIyImPQE0NjsBFyM1MwE3NhYdASEVIRUUBi8BJjQFIzU7AjIWHQEUBisBA6f4Dg74DhX%2BcAGQFf0vMhUdHRUyyGRk%2FoL3DhUBkP5wFQ73DwOBZGRkMxQdHRQzBI3mDioO5g4IFZbIlhUI%2FoUdFWQVHcjI%2FcvmDggVlsiWFQgO5g4qecgdFWQVHQAAAAACAGQAAASwBLAAFgBRAAABJTYWFREUBisBIiY1ES4ENRE0NiUyFh8BERQOAg8BERQGKwEiJjURLgQ1ETQ%2BAzMyFh8BETMRPAE%2BAjMyFh8BETMRND4DA14BFBklHRXIFR0EDiIaFiX%2B4RYZAgEVHR0LCh0VyBUdBA4iGhYBBwoTDRQZAgNkBQkVDxcZAQFkAQUJFQQxdBIUH%2FuuFR0dFQGNAQgbHzUeAWcfRJEZDA3%2BPhw%2FMSkLC%2F5BFR0dFQG%2FBA8uLkAcAcICBxENCxkMDf6iAV4CBxENCxkMDf6iAV4CBxENCwABAGQAAASwBEwAMwAAARUiDgMVERQWHwEVITUyNjURIREUFjMVITUyPgM1ETQmLwE1IRUiBhURIRE0JiM1BLAEDiIaFjIZGf5wSxn%2BDBlL%2FnAEDiIaFjIZGQGQSxkB9BlLBEw4AQUKFA78iBYZAQI4OA0lAYr%2BdiUNODgBBQoUDgN4FhkBAjg4DSX%2BdgGKJQ04AAAABgAAAAAETARMAAwAHAAgACQAKAA0AAABITIWHQEjBTUnITchBSEyFhURFAYjISImNRE0NhcVITUBBTUlBRUhNQUVFAYjIQchJyE3MwKjAXcVHWn%2B2cj%2BcGQBd%2F4lASwpOzsp%2FtQpOzspASwCvP5wAZD8GAEsArwdFf6JZP6JZAGQyGkD6B0VlmJiyGTIOyn%2BDCk7OykB9Ck7ZMjI%2FveFo4XGyMhm%2BBUdZGTIAAEAEAAQBJ8EnwAmAAATNzYWHwEWBg8BHgEXNz4BHwEeAQ8BBiIuBicuBTcRohEuDosOBhF3ZvyNdxEzE8ATBxGjAw0uMUxPZWZ4O0p3RjITCwED76IRBhPCFDERdo78ZXYRBA6IDi8RogEECBUgNUNjO0qZfHNVQBAAAAACAAAAAASwBEwAIwBBAAAAMh4EHwEVFAYvAS4BPQEmIAcVFAYPAQYmPQE%2BBRIyHgIfARUBHgEdARQGIyEiJj0BNDY3ATU0PgIB%2FLimdWQ%2FLAkJHRTKFB2N%2FsKNHRTKFB0DDTE7ZnTKcFImFgEBAW0OFR0V%2B7QVHRUOAW0CFiYETBUhKCgiCgrIFRgDIgMiFZIYGJIVIgMiAxgVyAQNJyQrIP7kExwcCgoy%2FtEPMhTUFR0dFdQUMg8BLzIEDSEZAAADAAAAAASwBLAADQAdACcAAAEHIScRMxUzNTMVMzUzASEyFhQGKwEXITcjIiY0NgMhMhYdASE1NDYETMj9qMjIyMjIyPyuArwVHR0VDIn8SokMFR0dswRMFR37UB0CvMjIAfTIyMjI%2FOAdKh1kZB0qHf7UHRUyMhUdAAAAAwBkAAAEsARMAAkAEwAdAAABIyIGFREhETQmASMiBhURIRE0JgEhETQ2OwEyFhUCvGQpOwEsOwFnZCk7ASw7%2FRv%2B1DspZCk7BEw7KfwYA%2BgpO%2F7UOyn9RAK8KTv84AGQKTs7KQAAAAAF%2F5wAAASwBEwADwATAB8AJQApAAATITIWFREUBiMhIiY1ETQ2FxEhEQUjFTMRITUzNSMRIQURByMRMwcRMxHIArx8sLB8%2FUR8sLAYA4T%2BDMjI%2FtTIyAEsAZBkyMhkZARMsHz%2BDHywsHwB9HywyP1EArzIZP7UZGQBLGT%2B1GQB9GT%2B1AEsAAAABf%2BcAAAEsARMAA8AEwAfACUAKQAAEyEyFhURFAYjISImNRE0NhcRIREBIzUjFSMRMxUzNTMFEQcjETMHETMRyAK8fLCwfP1EfLCwGAOE%2FgxkZGRkZGQBkGTIyGRkBEywfP4MfLCwfAH0fLDI%2FUQCvP2oyMgB9MjIZP7UZAH0ZP7UASwABP%2BcAAAEsARMAA8AEwAbACMAABMhMhYVERQGIyEiJjURNDYXESERBSMRMxUhESEFIxEzFSERIcgCvHywsHz9RHywsBgDhP4MyMj%2B1AEsAZDIyP7UASwETLB8%2Fgx8sLB8AfR8sMj9RAK8yP7UZAH0ZP7UZAH0AAAABP%2BcAAAEsARMAA8AEwAWABkAABMhMhYVERQGIyEiJjURNDYXESERAS0BDQERyAK8fLCwfP1EfLCwGAOE%2Fgz%2B1AEsAZD%2B1ARMsHz%2BDHywsHwB9HywyP1EArz%2BDJaWlpYBLAAAAAX%2FnAAABLAETAAPABMAFwAgACkAABMhMhYVERQGIyEiJjURNDYXESERAyERIQcjIgYVFBY7AQERMzI2NTQmI8gCvHywsHz9RHywsBgDhGT9RAK8ZIImOTYpgv4Mgik2OSYETLB8%2Fgx8sLB8AfR8sMj9RAK8%2FagB9GRWQUFUASz%2B1FRBQVYAAAAF%2F5wAAASwBEwADwATAB8AJQApAAATITIWFREUBiMhIiY1ETQ2FxEhEQUjFTMRITUzNSMRIQEjESM1MwMjNTPIArx8sLB8%2FUR8sLAYA4T%2BDMjI%2FtTIyAEsAZBkZMjIZGQETLB8%2Fgx8sLB8AfR8sMj9RAK8yGT%2B1GRkASz%2BDAGQZP4MZAAG%2F5wAAASwBEwADwATABkAHwAjACcAABMhMhYVERQGIyEiJjURNDYXESERBTMRIREzASMRIzUzBRUzNQEjNTPIArx8sLB8%2FUR8sLAYA4T9RMj%2B1GQCWGRkyP2oZAEsZGQETLB8%2Fgx8sLB8AfR8sMj9RAK8yP5wAfT%2BDAGQZMjIyP7UZAAF%2F5wAAASwBEwADwATABwAIgAmAAATITIWFREUBiMhIiY1ETQ2FxEhEQEHIzU3NSM1IQEjESM1MwMjNTPIArx8sLB8%2FUR8sLAYA4T%2BDMdkx8gBLAGQZGTIx2RkBEywfP4MfLCwfAH0fLDI%2FUQCvP5wyDLIlmT%2BDAGQZP4MZAAAAAMACQAJBKcEpwAPABsAJQAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JgchFSEVISc1NyEB4PDbnl5entvw255eXp4BxeTCcXHC5MJxcWz%2B1AEs%2FtRkZAEsBKdentvw255eXp7b8NueTHHC5MJxccLkwtDIZGTIZAAAAAAEAAkACQSnBKcADwAbACcAKwAAADIeAhQOAiIuAjQ%2BAQQiDgEUHgEyPgE0JgcVBxcVIycjFSMRIQcVMzUB4PDbnl5entvw255eXp4BxeTCcXHC5MJxcWwyZGRklmQBLMjIBKdentvw255eXp7b8NueTHHC5MJxccLkwtBkMmQyZGQBkGRkZAAAAv%2Fy%2F50EwgRBACAANgAAATIWFzYzMhYUBisBNTQmIyEiBh0BIyImNTQ2NyY1ND4BEzMyFhURMzIWDwEGIi8BJjY7ARE0NgH3brUsLC54qqp4gB0V%2FtQVHd5QcFZBAmKqepYKD4kVCg3fDSYN3w0KFYkPBEF3YQ6t8a36FR0dFfpzT0VrDhMSZKpi%2FbMPCv7tFxD0EBD0EBcBEwoPAAAAAAL%2F8v%2BcBMMEQQAcADMAAAEyFhc2MzIWFxQGBwEmIgcBIyImNTQ2NyY1ND4BExcWBisBERQGKwEiJjURIyImNzY3NjIB9m62LCsueaoBeFr%2Bhg0lDf6DCU9xVkECYqnm3w0KFYkPCpYKD4kVCg3HGBMZBEF3YQ%2BteGOkHAFoEBD%2Bk3NPRWsOExNkqWP9kuQQF%2F7tCg8PCgETFxDMGBMAAAABAGQAAARMBG0AGAAAJTUhATMBMwkBMwEzASEVIyIGHQEhNTQmIwK8AZD%2B8qr%2B8qr%2B1P7Uqv7yqv7yAZAyFR0BkB0VZGQBLAEsAU3%2Bs%2F7U%2FtRkHRUyMhUdAAAAAAEAeQAABDcEmwAvAAABMhYXHgEVFAYHFhUUBiMiJxUyFh0BITU0NjM1BiMiJjU0Ny4BNTQ2MzIXNCY1NDYCWF6TGll7OzIJaUo3LRUd%2FtQdFS03SmkELzlpSgUSAqMEm3FZBoNaPWcfHRpKaR77HRUyMhUd%2Bx5pShIUFVg1SmkCAhAFdKMAAAAGACcAFASJBJwAEQAqAEIASgBiAHsAAAEWEgIHDgEiJicmAhI3PgEyFgUiBw4BBwYWHwEWMzI3Njc2Nz4BLwEmJyYXIgcOAQcGFh8BFjMyNz4BNz4BLwEmJyYWJiIGFBYyNjciBw4BBw4BHwEWFxYzMjc%2BATc2Ji8BJhciBwYHBgcOAR8BFhcWMzI3PgE3NiYvASYD8m9PT29T2dzZU29PT29T2dzZ%2Fj0EBHmxIgQNDCQDBBcGG0dGYAsNAwkDCwccBAVQdRgEDA0iBAQWBhJROQwMAwkDCwf5Y4xjY4xjVhYGElE6CwwDCQMLBwgEBVB1GAQNDCIEjRcGG0dGYAsNAwkDCwcIBAR5sSIEDQwkAwPyb%2F7V%2FtVvU1dXU28BKwErb1NXVxwBIrF5DBYDCQEWYEZHGwMVDCMNBgSRAhh1UA0WAwkBFTpREgMVCyMMBwT6Y2OMY2MVFTpREQQVCyMMBwQCGHVQDRYDCQEkFmBGRxsDFQwjDQYEASKxeQwWAwkBAAAABQBkAAAD6ASwAAwADwAWABwAIgAAASERIzUhFSERNDYzIQEjNQMzByczNTMDISImNREFFRQGKwECvAEstP6s%2FoQPCgI%2FASzIZKLU1KJktP51Cg8DhA8KwwMg%2FoTIyALzCg%2F%2B1Mj84NTUyP4MDwoBi8jDCg8AAAAABQBkAAAD6ASwAAkADAATABoAIQAAASERCQERNDYzIQEjNRMjFSM1IzcDISImPQEpARUUBisBNQK8ASz%2Bov3aDwoCPwEsyD6iZKLUqv6dCg8BfAIIDwqbAyD9%2BAFe%2FdoERwoP%2FtTI%2FHzIyNT%2BZA8KNzcKD1AAAAAAAwAAAAAEsAP0AAgAGQAfAAABIxUzFyERIzcFMzIeAhUhFSEDETM0PgIBMwMhASEEiqJkZP7UotT9EsgbGiEOASz9qMhkDiEaAnPw8PzgASwB9AMgyGQBLNTUBBErJGT%2BogHCJCsRBP5w%2FnAB9AAAAAMAAAAABEwETAAZADIAOQAAATMyFh0BMzIWHQEUBiMhIiY9ATQ2OwE1NDYFNTIWFREUBiMhIic3ARE0NjMVFBYzITI2AQc1IzUzNQKKZBUdMhUdHRX%2B1BUdHRUyHQFzKTs7Kf2oARP2%2Fro7KVg%2BASw%2BWP201MjIBEwdFTIdFWQVHR0VZBUdMhUd%2BpY7KfzgKTsE9gFGAUQpO5Y%2BWFj95tSiZKIAAwBkAAAEvARMABkANgA9AAABMzIWHQEzMhYdARQGIyEiJj0BNDY7ATU0NgU1MhYVESMRMxQOAiMhIiY1ETQ2MxUUFjMhMjYBBzUjNTM1AcJkFR0yFR0dFf7UFR0dFTIdAXMpO8jIDiEaG%2F2oKTs7KVg%2BASw%2BWAGc1MjIBEwdFTIdFWQVHR0VZBUdMhUd%2BpY7Kf4M%2FtQkKxEEOykDICk7lj5YWP3m1KJkogAAAAP%2FogAABRYE1AALABsAHwAACQEWBiMhIiY3ATYyEyMiBhcTHgE7ATI2NxM2JgMVMzUCkgJ9FyAs%2BwQsIBcCfRZARNAUGAQ6BCMUNhQjBDoEGODIBK37sCY3NyYEUCf%2BTB0U%2FtIUHR0UAS4UHf4MZGQAAAAACQAAAAAETARMAA8AHwAvAD8ATwBfAG8AfwCPAAABMzIWHQEUBisBIiY9ATQ2EzMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYBMzIWHQEUBisBIiY9ATQ2ITMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYBMzIWHQEUBisBIiY9ATQ2ITMyFh0BFAYrASImPQE0NiEzMhYdARQGKwEiJj0BNDYBqfoKDw8K%2BgoPDwr6Cg8PCvoKDw8BmvoKDw8K%2BgoPD%2Fzq%2BgoPDwr6Cg8PAZr6Cg8PCvoKDw8BmvoKDw8K%2BgoPD%2Fzq%2BgoPDwr6Cg8PAZr6Cg8PCvoKDw8BmvoKDw8K%2BgoPDwRMDwqWCg8PCpYKD%2F7UDwqWCg8PCpYKDw8KlgoPDwqWCg%2F%2B1A8KlgoPDwqWCg8PCpYKDw8KlgoPDwqWCg8PCpYKD%2F7UDwqWCg8PCpYKDw8KlgoPDwqWCg8PCpYKDw8KlgoPAAAAAwAAAAAEsAUUABkAKQAzAAABMxUjFSEyFg8BBgchJi8BJjYzITUjNTM1MwEhMhYUBisBFyE3IyImNDYDITIWHQEhNTQ2ArxkZAFePjEcQiko%2FPwoKUIcMT4BXmRkyP4%2BArwVHR0VDIn8SooNFR0dswRMFR37UB0EsMhkTzeEUzMzU4Q3T2TIZPx8HSodZGQdKh3%2B1B0VMjIVHQAABAAAAAAEsAUUAAUAGQArADUAAAAyFhUjNAchFhUUByEyFg8BIScmNjMhJjU0AyEyFhQGKwEVBSElNSMiJjQ2AyEyFh0BITU0NgIwUDnCPAE6EgMBSCkHIq%2F9WrIiCikBSAOvArwVHR0VlgET%2FEoBE5YVHR2zBEwVHftQHQUUOykpjSUmCBEhFpGRFiERCCb%2BlR0qHcjIyMgdKh39qB0VMjIVHQAEAAAAAASwBJ0ABwAUACQALgAAADIWFAYiJjQTMzIWFRQXITY1NDYzASEyFhQGKwEXITcjIiY0NgMhMhYdASE1NDYCDZZqapZqty4iKyf%2BvCcrI%2F7NArwVHR0VDYr8SokMFR0dswRMFR37UB0EnWqWamqW%2Fus5Okxra0w6Of5yHSodZGQdKh3%2B1B0VMjIVHQAEAAAAAASwBRQADwAcACwANgAAATIeARUUBiImNTQ3FzcnNhMzMhYVFBchNjU0NjMBITIWFAYrARchNyMiJjQ2AyEyFh0BITU0NgJYL1szb5xvIpBvoyIfLiIrJ%2F68Jysj%2Fs0CvBUdHRUNivxKiQwVHR2zBEwVHftQHQUUa4s2Tm9vTj5Rj2%2BjGv4KOTpMa2tMOjn%2Bch0qHWRkHSod%2FtQdFTIyFR0AAAADAAAAAASwBRIAEgAiACwAAAEFFSEUHgMXIS4BNTQ%2BAjcBITIWFAYrARchNyMiJjQ2AyEyFh0BITU0NgJYASz%2B1CU%2FP00T%2Fe48PUJtj0r%2BogK8FR0dFQ2K%2FEqJDBUdHbMETBUd%2B1AdBLChizlmUT9IGVO9VFShdksE%2FH4dKh1kZB0qHf7UHRUyMhUdAAIAyAAAA%2BgFFAAPACkAAAAyFh0BHgEdASE1NDY3NTQDITIWFyMVMxUjFTMVIxUzFAYjISImNRE0NgIvUjsuNv5wNi5kAZA2XBqsyMjIyMh1U%2F5wU3V1BRQ7KU4aXDYyMjZcGk4p%2Fkc2LmRkZGRkU3V1UwGQU3UAAAMAZP%2F%2FBEwETAAPAC8AMwAAEyEyFhURFAYjISImNRE0NgMhMhYdARQGIyEXFhQGIi8BIQcGIiY0PwEhIiY9ATQ2BQchJ5YDhBUdHRX8fBUdHQQDtgoPDwr%2B5eANGiUNWP30Vw0mGg3g%2Ft8KDw8BqmQBRGQETB0V%2FgwVHR0VAfQVHf1EDwoyCg%2FgDSUbDVhYDRslDeAPCjIKD2RkZAAAAAAEAAAAAASwBEwAGQAjAC0ANwAAEyEyFh0BIzQmKwEiBhUjNCYrASIGFSM1NDYDITIWFREhETQ2ExUUBisBIiY9ASEVFAYrASImPQHIAyBTdWQ7KfopO2Q7KfopO2R1EQPoKTv7UDvxHRVkFR0D6B0VZBUdBEx1U8gpOzspKTs7KchTdf4MOyn%2B1AEsKTv%2BDDIVHR0VMjIVHR0VMgADAAEAAASpBKwADQARABsAAAkBFhQPASEBJjQ3ATYyCQMDITIWHQEhNTQ2AeACqh8fg%2F4f%2FfsgIAEnH1n%2BrAFWAS%2F%2Bq6IDIBUd%2FHwdBI39VR9ZH4MCBh9ZHwEoH%2F5u%2FqoBMAFV%2FBsdFTIyFR0AAAAAAgCPAAAEIQSwABcALwAAAQMuASMhIgYHAwYWMyEVFBYyNj0BMzI2AyE1NDY7ATU0NjsBETMRMzIWHQEzMhYVBCG9CCcV%2FnAVJwi9CBMVAnEdKh19FROo%2Fa0dFTIdFTDILxUdMhUdAocB%2BhMcHBP%2BBhMclhUdHRWWHP2MMhUdMhUdASz%2B1B0VMh0VAAAEAAAAAASwBLAADQAQAB8AIgAAASERFAYjIREBNTQ2MyEBIzUBIREUBiMhIiY1ETQ2MyEBIzUDhAEsDwr%2Bif7UDwoBdwEsyP2oASwPCv12Cg8PCgF3ASzIAyD9wQoPAk8BLFQKD%2F7UyP4M%2FcEKDw8KA7YKD%2F7UyAAC%2F5wAZAUUBEcARgBWAAABMzIeAhcWFxY2NzYnJjc%2BARYXFgcOASsBDgEPAQ4BKwEiJj8BBisBIicHDgErASImPwEmLwEuAT0BNDY7ATY3JyY2OwE2BSMiBh0BFBY7ATI2PQE0JgHkw0uOakkMEhEfQwoKGRMKBQ8XDCkCA1Y9Pgc4HCcDIhVkFRgDDDEqwxgpCwMiFWQVGAMaVCyfExwdFXwLLW8QBxXLdAFF%2BgoPDwr6Cg8PBEdBa4pJDgYKISAiJRsQCAYIDCw9P1c3fCbqFB0dFEYOCEAUHR0UnUplNQcmFTIVHVdPXw4TZV8PCjIKDw8KMgoPAAb%2FnP%2FmBRQEfgAJACQANAA8AFIAYgAAASU2Fh8BFgYPASUzMhYfASEyFh0BFAYHBQYmJyYjISImPQE0NhcjIgYdARQ7ATI2NTQmJyYEIgYUFjI2NAE3PgEeARceAT8BFxYGDwEGJi8BJjYlBwYfAR4BPwE2Jy4BJy4BAoEBpxMuDiAOAxCL%2FCtqQ0geZgM3FR0cE%2F0fFyIJKjr%2B1D5YWLlQExIqhhALIAsSAYBALS1ALf4PmBIgHhMQHC0aPzANITNQL3wpgigJASlmHyElDR0RPRMFAhQHCxADhPcICxAmDyoNeMgiNtQdFTIVJgeEBBQPQ1g%2ByD5YrBwVODMQEAtEERzJLUAtLUD%2B24ITChESEyMgAwWzPUkrRSgJL5cvfRxYGyYrDwkLNRAhFEgJDAQAAAAAAwBkAAAEOQSwAFEAYABvAAABMzIWHQEeARcWDgIPATIeBRUUDgUjFRQGKwEiJj0BIxUUBisBIiY9ASMiJj0BNDY7AREjIiY9ATQ2OwE1NDY7ATIWHQEzNTQ2AxUhMj4CNTc0LgMjARUhMj4CNTc0LgMjAnGWCg9PaAEBIC4uEBEGEjQwOiodFyI2LUAjGg8KlgoPZA8KlgoPrwoPDwpLSwoPDwqvDwqWCg9kD9cBBxwpEwsBAQsTKRz%2B%2BQFrHCkTCwEBCxMpHASwDwptIW1KLk0tHwYGAw8UKDJOLTtdPCoVCwJLCg8PCktLCg8PCksPCpYKDwJYDwqWCg9LCg8PCktLCg%2F%2B1MgVHR0LCgQOIhoW%2FnDIFR0dCwoEDiIaFgAAAwAEAAIEsASuABcAKQAsAAATITIWFREUBg8BDgEjISImJy4CNRE0NgQiDgQPARchNy4FAyMT1AMMVnokEhIdgVL9xFKCHAgYKHoCIIx9VkcrHQYGnAIwnAIIIClJVSGdwwSuelb%2BYDO3QkJXd3ZYHFrFMwGgVnqZFyYtLSUMDPPzBQ8sKDEj%2FsIBBQACAMgAAAOEBRQADwAZAAABMzIWFREUBiMhIiY1ETQ2ARUUBisBIiY9AQHblmesVCn%2BPilUrAFINhWWFTYFFKxn%2FgwpVFQpAfRnrPwY4RU2NhXhAAACAMgAAAOEBRQADwAZAAABMxQWMxEUBiMhIiY1ETQ2ARUUBisBIiY9AQHbYLOWVCn%2BPilUrAFINhWWFTYFFJaz%2FkIpVFQpAfRnrPwY4RU2NhXhAAACAAAAFAUOBBoAFAAaAAAJASUHFRcVJwc1NzU0Jj4CPwEnCQEFJTUFJQUO%2FYL%2Bhk5klpZkAQEBBQQvkwKCAVz%2Bov6iAV4BXgL%2F%2FuWqPOCWx5SVyJb6BA0GCgYDKEEBG%2F1ipqaTpaUAAAMAZAH0BLADIAAHAA8AFwAAEjIWFAYiJjQkMhYUBiImNCQyFhQGIiY0vHxYWHxYAeh8WFh8WAHofFhYfFgDIFh8WFh8WFh8WFh8WFh8WFh8AAAAAAMBkAAAArwETAAHAA8AFwAAADIWFAYiJjQSMhYUBiImNBIyFhQGIiY0Aeh8WFh8WFh8WFh8WFh8WFh8WARMWHxYWHz%2ByFh8WFh8%2FshYfFhYfAAAAAMAZABkBEwETAAPAB8ALwAAEyEyFh0BFAYjISImPQE0NhMhMhYdARQGIyEiJj0BNDYTITIWHQEUBiMhIiY9ATQ2fQO2Cg8PCvxKCg8PCgO2Cg8PCvxKCg8PCgO2Cg8PCvxKCg8PBEwPCpYKDw8KlgoP%2FnAPCpYKDw8KlgoP%2FnAPCpYKDw8KlgoPAAAABAAAAAAEsASwAA8AHwAvADMAAAEhMhYVERQGIyEiJjURNDYFISIGFREUFjMhMjY1ETQmBSEyFhURFAYjISImNRE0NhcVITUBXgH0ory7o%2F4Mpbm5Asv9qCk7OykCWCk7O%2F2xAfQVHR0V%2FgwVHR1HAZAEsLuj%2FgylubmlAfSlucg7Kf2oKTs7KQJYKTtkHRX%2B1BUdHRUBLBUdZMjIAAAAAAEAZABkBLAETAA7AAATITIWFAYrARUzMhYUBisBFTMyFhQGKwEVMzIWFAYjISImNDY7ATUjIiY0NjsBNSMiJjQ2OwE1IyImNDaWA%2BgVHR0VMjIVHR0VMjIVHR0VMjIVHR0V%2FBgVHR0VMjIVHR0VMjIVHR0VMjIVHR0ETB0qHcgdKh3IHSodyB0qHR0qHcgdKh3IHSodyB0qHQAAAAYBLAAFA%2BgEowAHAA0AEwAZAB8AKgAAAR4BBgcuATYBMhYVIiYlFAYjNDYBMhYVIiYlFAYjNDYDFRQGIiY9ARYzMgKKVz8%2FV1c%2FP%2F75fLB8sAK8sHyw%2FcB8sHywArywfLCwHSodKAMRBKNDsrJCQrKy%2FsCwfLB8fLB8sP7UsHywfHywfLD%2B05AVHR0VjgQAAAH%2FtQDIBJQDgQBCAAABNzYXAR4BBw4BKwEyFRQOBCsBIhE0NyYiBxYVECsBIi4DNTQzIyImJyY2NwE2HwEeAQ4BLwEHIScHBi4BNgLpRRkUASoLCAYFGg8IAQQNGyc%2FKZK4ChRUFQu4jjBJJxkHAgcPGQYGCAsBKhQaTBQVCiMUM7YDe7YsFCMKFgNuEwYS%2FtkLHw8OEw0dNkY4MhwBIBgXBAQYF%2F7gKjxTQyMNEw4PHwoBKBIHEwUjKBYGDMHBDAUWKCMAAAAAAgAAAAAEsASwACUAQwAAASM0LgUrAREUFh8BFSE1Mj4DNREjIg4FFSMRIQEjNC4DKwERFBYXMxUjNTI1ESMiDgMVIzUhBLAyCAsZEyYYGcgyGRn%2BcAQOIhoWyBkYJhMZCwgyA%2Bj9RBkIChgQEWQZDQzIMmQREBgKCBkB9AOEFSAVDggDAfyuFhkBAmRkAQUJFQ4DUgEDCA4VIBUBLP0SDxMKBQH%2BVwsNATIyGQGpAQUKEw%2BWAAAAAAMAAAAABEwErgAdACAAMAAAATUiJy4BLwEBIwEGBw4BDwEVITUiJj8BIRcWBiMVARsBARUUBiMhIiY9ATQ2MyEyFgPoGR4OFgUE%2Ft9F%2FtQSFQkfCwsBETE7EkUBJT0NISf%2B7IZ5AbEdFfwYFR0dFQPoFR0BLDIgDiIKCwLr%2FQ4jFQkTBQUyMisusKYiQTIBhwFW%2Fqr942QVHR0VZBUdHQADAAAAAASwBLAADwBHAEoAABMhMhYVERQGIyEiJjURNDYFIyIHAQYHBgcGHQEUFjMhMjY9ATQmIyInJj8BIRcWBwYjIgYdARQWMyEyNj0BNCYnIicmJyMBJhMjEzIETBUdHRX7tBUdHQJGRg0F%2FtUREhImDAsJAREIDAwINxAKCj8BCjkLEQwYCAwMCAE5CAwLCBEZGQ8B%2FuAFDsVnBLAdFfu0FR0dFQRMFR1SDP0PIBMSEAUNMggMDAgyCAwXDhmjmR8YEQwIMggMDAgyBwwBGRskAuwM%2FgUBCAAABAAAAAAEsASwAAMAEwAjACcAAAEhNSEFITIWFREUBiMhIiY1ETQ2KQEyFhURFAYjISImNRE0NhcRIREEsPtQBLD7ggGQFR0dFf5wFR0dAm0BkBUdHRX%2BcBUdHUcBLARMZMgdFfx8FR0dFQOEFR0dFf5wFR0dFQGQFR1k%2FtQBLAAEAAAAAASwBLAADwAfACMAJwAAEyEyFhURFAYjISImNRE0NgEhMhYVERQGIyEiJjURNDYXESEREyE1ITIBkBUdHRX%2BcBUdHQJtAZAVHR0V%2FnAVHR1HASzI%2B1AEsASwHRX8fBUdHRUDhBUd%2FgwdFf5wFR0dFQGQFR1k%2FtQBLP2oZAAAAAACAAAAZASwA%2BgAJwArAAATITIWFREzNTQ2MyEyFh0BMxUjFRQGIyEiJj0BIxEUBiMhIiY1ETQ2AREhETIBkBUdZB0VAZAVHWRkHRX%2BcBUdZB0V%2FnAVHR0CnwEsA%2BgdFf6ilhUdHRWWZJYVHR0Vlv6iFR0dFQMgFR3%2B1P7UASwAAAQAAAAABLAEsAADABMAFwAnAAAzIxEzFyEyFhURFAYjISImNRE0NhcRIREBITIWFREUBiMhIiY1ETQ2ZGRklgGQFR0dFf5wFR0dRwEs%2FqIDhBUdHRX8fBUdHQSwZB0V%2FnAVHR0VAZAVHWT%2B1AEs%2FgwdFf5wFR0dFQGQFR0AAAAAAgBkAAAETASwACcAKwAAATMyFhURFAYrARUhMhYVERQGIyEiJjURNDYzITUjIiY1ETQ2OwE1MwcRIRECWJYVHR0VlgHCFR0dFfx8FR0dFQFelhUdHRWWZMgBLARMHRX%2BcBUdZB0V%2FnAVHR0VAZAVHWQdFQGQFR1kyP7UASwAAAAEAAAAAASwBLAAAwATABcAJwAAISMRMwUhMhYVERQGIyEiJjURNDYXESERASEyFhURFAYjISImNRE0NgSwZGT9dgGQFR0dFf5wFR0dRwEs%2FK4DhBUdHRX8fBUdHQSwZB0V%2FnAVHR0VAZAVHWT%2B1AEs%2FgwdFf5wFR0dFQGQFR0AAAEBLAAwA28EgAAPAAAJAQYjIiY1ETQ2MzIXARYUA2H%2BEhcSDhAQDhIXAe4OAjX%2BEhcbGQPoGRsX%2FhIOKgAAAAABAUEAMgOEBH4ACwAACQE2FhURFAYnASY0AU8B7h0qKh3%2BEg4CewHuHREp%2FBgpER0B7g4qAAAAAAEAMgFBBH4DhAALAAATITIWBwEGIicBJjZkA%2BgpER3%2BEg4qDv4SHREDhCod%2FhIODgHuHSoAAAAAAQAyASwEfgNvAAsAAAkBFgYjISImNwE2MgJ7Ae4dESn8GCkRHQHuDioDYf4SHSoqHQHuDgAAAAACAAgAAASwBCgABgAKAAABFQE1LQE1ASE1IQK8%2FUwBnf5jBKj84AMgAuW2%2Fr3dwcHd%2B9jIAAAAAAIAAABkBLAEsAALADEAAAEjFTMVIREzNSM1IQEzND4FOwERFAYPARUhNSIuAzURMzIeBRUzESEEsMjI%2FtTIyAEs%2B1AyCAsZEyYYGWQyGRkBkAQOIhoWZBkYJhMZCwgy%2FOADhGRkASxkZP4MFSAVDggDAf3aFhkBAmRkAQUJFQ4CJgEDCA4VIBUBLAAAAgAAAAAETAPoACUAMQAAASM0LgUrAREUFh8BFSE1Mj4DNREjIg4FFSMRIQEjFTMVIREzNSM1IQMgMggLGRMmGBlkMhkZ%2FnAEDiIaFmQZGCYTGQsIMgMgASzIyP7UyMgBLAK8FSAVDggDAf3aFhkCAWRkAQUJFQ4CJgEDCA4VIBUBLPzgZGQBLGRkAAABAMgAZgNyBEoAEgAAATMyFgcJARYGKwEiJwEmNDcBNgK9oBAKDP4wAdAMChCgDQr%2BKQcHAdcKBEoWDP4w%2FjAMFgkB1wgUCAHXCQAAAQE%2BAGYD6ARKABIAAAEzMhcBFhQHAQYrASImNwkBJjYBU6ANCgHXBwf%2BKQoNoBAKDAHQ%2FjAMCgRKCf4pCBQI%2FikJFgwB0AHQDBYAAAEAZgDIBEoDcgASAAAAFh0BFAcBBiInASY9ATQ2FwkBBDQWCf4pCBQI%2FikJFgwB0AHQA3cKEKANCv4pBwcB1woNoBAKDP4wAdAAAAABAGYBPgRKA%2BgAEgAACQEWHQEUBicJAQYmPQE0NwE2MgJqAdcJFgz%2BMP4wDBYJAdcIFAPh%2FikKDaAQCgwB0P4wDAoQoA0KAdcHAAAAAgDZ%2F%2FkEPQSwAAUAOgAAARQGIzQ2BTMyFh8BNjc%2BAh4EBgcOBgcGIiYjIgYiJy4DLwEuAT4EHgEXJyY2A%2BiwfLD%2BVmQVJgdPBQsiKFAzRyorDwURAQQSFyozTSwNOkkLDkc3EDlfNyYHBw8GDyUqPjdGMR%2BTDA0EsHywfLDIHBPCAQIGBwcFDx81S21DBxlLR1xKQhEFBQcHGWt0bCQjP2hJNyATBwMGBcASGAAAAAACAMgAFQOEBLAAFgAaAAATITIWFREUBisBEQcGJjURIyImNRE0NhcVITX6AlgVHR0Vlv8TGpYVHR2rASwEsB0V%2FnAVHf4MsgkQFQKKHRUBkBUdZGRkAAAAAgDIABkETASwAA4AEgAAEyEyFhURBRElIREjETQ2ARU3NfoC7ic9%2FUQCWP1EZB8BDWQEsFEs%2FFt1A7Z9%2FBgEARc0%2FV1kFGQAAQAAAAECTW%2FDBF9fDzz1AB8EsAAAAADQdnOXAAAAANB2c5f%2FUf%2BcBdwFFAAAAAgAAgAAAAAAAAABAAAFFP%2BFAAAFFP9R%2FtQF3AABAAAAAAAAAAAAAAAAAAAAowG4ACgAAAAAAZAAAASwAAAEsABkBLAAAASwAAAEsABwAooAAAUUAAACigAABRQAAAGxAAABRQAAANgAAADYAAAAogAAAQQAAABIAAABBAAAAUUAAASwAGQEsAB7BLAAyASwAMgB9AAABLD%2F8gSwAAAEsAAABLD%2F8ASwAAAEsAAOBLAACQSwAGQEsP%2FTBLD%2F0wSwAAAEsAAABLAAAASwAAAEsAAABLAAJgSwAG4EsAAXBLAAFwSwABcEsABkBLAAGgSwAGQEsAAMBLAAZASwABcEsP%2BcBLAAZASwABcEsAAXBLAAAASwABcEsAAXBLAAFwSwAGQEsAAABLAAZASwAAAEsAAABLAAAASwAAAEsAAABLAAAASwAAAEsAAABLAAZASwAMgEsAAABLAAAASwADUEsABkBLAAyASw%2F7UEsAAhBLAAAASwAAAEsAAABLAAAASwAAAEsP%2BcBLAAAASwAAAEsAAABLAA2wSwABcEsAB1BLAAAASwAAAEsAAABLAACgSwAMgEsAAABLAAnQSwAMgEsADIBLAAyASwAAAEsP%2F%2BBLABLASwAGQEsACIBLABOwSwABcEsAAXBLAAFwSwABcEsAAXBLAAFwSwAAAEsAAXBLAAFwSwABcEsAAXBLAAAASwALcEsAC3BLAAAASwAAAEsABJBLAAFwSwAAAEsAAABLAAXQSw%2F9wEsP%2FcBLD%2FnwSwAGQEsAAABLAAAASwAAAEsABkBLD%2F%2FwSwAAAEsP9RBLAABgSwAAAEsAAABLABRQSwAAEEsAAABLD%2FnASwAEoEsAAUBLAAAASwAAAEsAAABLD%2FnASwAGEEsP%2F9BLAAFgSwABYEsAAWBLAAFgSwABgEsAAABMQAAASwAGQAAAAAAAD%2F2ABkADkAyAAAAScAZAAZABkAGQAZABkAGQAZAAAAAAAAAAAAAADZAAAAAAAOAAAAAAAAAAAAAAAEAAAAAAAAAAAAAAAAAAMAZABkAAAAEAAAAAAAZP%2Bc%2F5z%2FnP%2Bc%2F5z%2FnP%2Bc%2F5wACQAJ%2F%2FL%2F8gBkAHkAJwBkAGQAAAAAAGT%2FogAAAAAAAAAAAAAAAADIAGQAAAABAI8AAP%2Bc%2F5wAZAAEAMgAyAAAAGQBkABkAAAAZAEs%2F7UAAAAAAAAAAAAAAAAAAABkAAABLAFBADIAMgAIAAAAAADIAT4AZgBmANkAyADIAAAAKgAqACoAKgCyAOgA6AFOAU4BTgFOAU4BTgFOAU4BTgFOAU4BTgFOAU4BpAIGAiICfgKGAqwC5ANGA24DjAPEBAgEMgRiBKIE3AVcBboGcgb0ByAHYgfKCB4IYgi%2BCTYJhAm2Cd4KKApMCpQK4gswC4oLygwIDFgNKg1eDbAODg5oDrQPKA%2BmD%2BYQEhBUEJAQqhEqEXYRthIKEjgSfBLAExoTdBPQFCoU1BU8FagVzBYEFjYWYBawFv4XUhemGAIYLhhqGJYYsBjgGP4ZKBloGZQZxBnaGe4aNhpoGrga9hteG7QcMhyUHOIdHB1EHWwdlB28HeYeLh52HsAfYh%2FSIEYgviEyIXYhuCJAIpYiuCMOIyIjOCN6I8Ij4CQCJDAkXiSWJOIlNCVgJbwmFCZ%2BJuYnUCe8J%2FgoNChwKKwpoCnMKiYqSiqEKworeiwILGgsuizsLRwtiC30LiguZi6iLtgvDi9GL34vsi%2F4MD4whDDSMRIxYDGuMegyJDJeMpoy3jMiMz4zaDO2NBg0YDSoNNI1LDWeNeg2PjZ8Ntw3GjdON5I31DgQOEI4hjjIOQo5SjmIOcw6HDpsOpo63jugO9w8GDxQPKI8%2BD0yPew%2BOj6MPtQ%2FKD9uP6o%2F%2BkBIQIBAxkECQX5CGEKoQu5DGENCQ3ZDoEPKRBBEYESuRPZFWkW2RgZGdEa0RvZHNkd2R7ZH9kgWSDJITkhqSIZIzEkSSThJXkmESapKAkouSlIAAQAAARcApwARAAAAAAACAAAAAQABAAAAQAAuAAAAAAAAABAAxgABAAAAAAATABIAAAADAAEECQAAAGoAEgADAAEECQABACgAfAADAAEECQACAA4ApAADAAEECQADAEwAsgADAAEECQAEADgA%2FgADAAEECQAFAHgBNgADAAEECQAGADYBrgADAAEECQAIABYB5AADAAEECQAJABYB%2BgADAAEECQALACQCEAADAAEECQAMACQCNAADAAEECQATACQCWAADAAEECQDIABYCfAADAAEECQDJADACkgADAAEECdkDABoCwnd3dy5nbHlwaGljb25zLmNvbQBDAG8AcAB5AHIAaQBnAGgAdAAgAKkAIAAyADAAMQA0ACAAYgB5ACAASgBhAG4AIABLAG8AdgBhAHIAaQBrAC4AIABBAGwAbAAgAHIAaQBnAGgAdABzACAAcgBlAHMAZQByAHYAZQBkAC4ARwBMAFkAUABIAEkAQwBPAE4AUwAgAEgAYQBsAGYAbABpAG4AZwBzAFIAZQBnAHUAbABhAHIAMQAuADAAMAA5ADsAVQBLAFcATgA7AEcATABZAFAASABJAEMATwBOAFMASABhAGwAZgBsAGkAbgBnAHMALQBSAGUAZwB1AGwAYQByAEcATABZAFAASABJAEMATwBOAFMAIABIAGEAbABmAGwAaQBuAGcAcwAgAFIAZQBnAHUAbABhAHIAVgBlAHIAcwBpAG8AbgAgADEALgAwADAAOQA7AFAAUwAgADAAMAAxAC4AMAAwADkAOwBoAG8AdABjAG8AbgB2ACAAMQAuADAALgA3ADAAOwBtAGEAawBlAG8AdABmAC4AbABpAGIAMgAuADUALgA1ADgAMwAyADkARwBMAFkAUABIAEkAQwBPAE4AUwBIAGEAbABmAGwAaQBuAGcAcwAtAFIAZQBnAHUAbABhAHIASgBhAG4AIABLAG8AdgBhAHIAaQBrAEoAYQBuACAASwBvAHYAYQByAGkAawB3AHcAdwAuAGcAbAB5AHAAaABpAGMAbwBuAHMALgBjAG8AbQB3AHcAdwAuAGcAbAB5AHAAaABpAGMAbwBuAHMALgBjAG8AbQB3AHcAdwAuAGcAbAB5AHAAaABpAGMAbwBuAHMALgBjAG8AbQBXAGUAYgBmAG8AbgB0ACAAMQAuADAAVwBlAGQAIABPAGMAdAAgADIAOQAgADAANgA6ADMANgA6ADAANwAgADIAMAAxADQARgBvAG4AdAAgAFMAcQB1AGkAcgByAGUAbAAAAAIAAAAAAAD%2FtQAyAAAAAAAAAAAAAAAAAAAAAAAAAAABFwAAAQIBAwADAA0ADgEEAJYBBQEGAQcBCAEJAQoBCwEMAQ0BDgEPARABEQESARMA7wEUARUBFgEXARgBGQEaARsBHAEdAR4BHwEgASEBIgEjASQBJQEmAScBKAEpASoBKwEsAS0BLgEvATABMQEyATMBNAE1ATYBNwE4ATkBOgE7ATwBPQE%2BAT8BQAFBAUIBQwFEAUUBRgFHAUgBSQFKAUsBTAFNAU4BTwFQAVEBUgFTAVQBVQFWAVcBWAFZAVoBWwFcAV0BXgFfAWABYQFiAWMBZAFlAWYBZwFoAWkBagFrAWwBbQFuAW8BcAFxAXIBcwF0AXUBdgF3AXgBeQF6AXsBfAF9AX4BfwGAAYEBggGDAYQBhQGGAYcBiAGJAYoBiwGMAY0BjgGPAZABkQGSAZMBlAGVAZYBlwGYAZkBmgGbAZwBnQGeAZ8BoAGhAaIBowGkAaUBpgGnAagBqQGqAasBrAGtAa4BrwGwAbEBsgGzAbQBtQG2AbcBuAG5AboBuwG8Ab0BvgG%2FAcABwQHCAcMBxAHFAcYBxwHIAckBygHLAcwBzQHOAc8B0AHRAdIB0wHUAdUB1gHXAdgB2QHaAdsB3AHdAd4B3wHgAeEB4gHjAeQB5QHmAecB6AHpAeoB6wHsAe0B7gHvAfAB8QHyAfMB9AH1AfYB9wH4AfkB%2BgH7AfwB%2FQH%2BAf8CAAIBAgICAwIEAgUCBgIHAggCCQIKAgsCDAINAg4CDwIQAhECEgZnbHlwaDEGZ2x5cGgyB3VuaTAwQTAHdW5pMjAwMAd1bmkyMDAxB3VuaTIwMDIHdW5pMjAwMwd1bmkyMDA0B3VuaTIwMDUHdW5pMjAwNgd1bmkyMDA3B3VuaTIwMDgHdW5pMjAwOQd1bmkyMDBBB3VuaTIwMkYHdW5pMjA1RgRFdXJvB3VuaTIwQkQHdW5pMjMxQgd1bmkyNUZDB3VuaTI2MDEHdW5pMjZGQQd1bmkyNzA5B3VuaTI3MEYHdW5pRTAwMQd1bmlFMDAyB3VuaUUwMDMHdW5pRTAwNQd1bmlFMDA2B3VuaUUwMDcHdW5pRTAwOAd1bmlFMDA5B3VuaUUwMTAHdW5pRTAxMQd1bmlFMDEyB3VuaUUwMTMHdW5pRTAxNAd1bmlFMDE1B3VuaUUwMTYHdW5pRTAxNwd1bmlFMDE4B3VuaUUwMTkHdW5pRTAyMAd1bmlFMDIxB3VuaUUwMjIHdW5pRTAyMwd1bmlFMDI0B3VuaUUwMjUHdW5pRTAyNgd1bmlFMDI3B3VuaUUwMjgHdW5pRTAyOQd1bmlFMDMwB3VuaUUwMzEHdW5pRTAzMgd1bmlFMDMzB3VuaUUwMzQHdW5pRTAzNQd1bmlFMDM2B3VuaUUwMzcHdW5pRTAzOAd1bmlFMDM5B3VuaUUwNDAHdW5pRTA0MQd1bmlFMDQyB3VuaUUwNDMHdW5pRTA0NAd1bmlFMDQ1B3VuaUUwNDYHdW5pRTA0Nwd1bmlFMDQ4B3VuaUUwNDkHdW5pRTA1MAd1bmlFMDUxB3VuaUUwNTIHdW5pRTA1Mwd1bmlFMDU0B3VuaUUwNTUHdW5pRTA1Ngd1bmlFMDU3B3VuaUUwNTgHdW5pRTA1OQd1bmlFMDYwB3VuaUUwNjIHdW5pRTA2Mwd1bmlFMDY0B3VuaUUwNjUHdW5pRTA2Ngd1bmlFMDY3B3VuaUUwNjgHdW5pRTA2OQd1bmlFMDcwB3VuaUUwNzEHdW5pRTA3Mgd1bmlFMDczB3VuaUUwNzQHdW5pRTA3NQd1bmlFMDc2B3VuaUUwNzcHdW5pRTA3OAd1bmlFMDc5B3VuaUUwODAHdW5pRTA4MQd1bmlFMDgyB3VuaUUwODMHdW5pRTA4NAd1bmlFMDg1B3VuaUUwODYHdW5pRTA4Nwd1bmlFMDg4B3VuaUUwODkHdW5pRTA5MAd1bmlFMDkxB3VuaUUwOTIHdW5pRTA5Mwd1bmlFMDk0B3VuaUUwOTUHdW5pRTA5Ngd1bmlFMDk3B3VuaUUxMDEHdW5pRTEwMgd1bmlFMTAzB3VuaUUxMDQHdW5pRTEwNQd1bmlFMTA2B3VuaUUxMDcHdW5pRTEwOAd1bmlFMTA5B3VuaUUxMTAHdW5pRTExMQd1bmlFMTEyB3VuaUUxMTMHdW5pRTExNAd1bmlFMTE1B3VuaUUxMTYHdW5pRTExNwd1bmlFMTE4B3VuaUUxMTkHdW5pRTEyMAd1bmlFMTIxB3VuaUUxMjIHdW5pRTEyMwd1bmlFMTI0B3VuaUUxMjUHdW5pRTEyNgd1bmlFMTI3B3VuaUUxMjgHdW5pRTEyOQd1bmlFMTMwB3VuaUUxMzEHdW5pRTEzMgd1bmlFMTMzB3VuaUUxMzQHdW5pRTEzNQd1bmlFMTM2B3VuaUUxMzcHdW5pRTEzOAd1bmlFMTM5B3VuaUUxNDAHdW5pRTE0MQd1bmlFMTQyB3VuaUUxNDMHdW5pRTE0NAd1bmlFMTQ1B3VuaUUxNDYHdW5pRTE0OAd1bmlFMTQ5B3VuaUUxNTAHdW5pRTE1MQd1bmlFMTUyB3VuaUUxNTMHdW5pRTE1NAd1bmlFMTU1B3VuaUUxNTYHdW5pRTE1Nwd1bmlFMTU4B3VuaUUxNTkHdW5pRTE2MAd1bmlFMTYxB3VuaUUxNjIHdW5pRTE2Mwd1bmlFMTY0B3VuaUUxNjUHdW5pRTE2Ngd1bmlFMTY3B3VuaUUxNjgHdW5pRTE2OQd1bmlFMTcwB3VuaUUxNzEHdW5pRTE3Mgd1bmlFMTczB3VuaUUxNzQHdW5pRTE3NQd1bmlFMTc2B3VuaUUxNzcHdW5pRTE3OAd1bmlFMTc5B3VuaUUxODAHdW5pRTE4MQd1bmlFMTgyB3VuaUUxODMHdW5pRTE4NAd1bmlFMTg1B3VuaUUxODYHdW5pRTE4Nwd1bmlFMTg4B3VuaUUxODkHdW5pRTE5MAd1bmlFMTkxB3VuaUUxOTIHdW5pRTE5Mwd1bmlFMTk0B3VuaUUxOTUHdW5pRTE5Nwd1bmlFMTk4B3VuaUUxOTkHdW5pRTIwMAd1bmlFMjAxB3VuaUUyMDIHdW5pRTIwMwd1bmlFMjA0B3VuaUUyMDUHdW5pRTIwNgd1bmlFMjA5B3VuaUUyMTAHdW5pRTIxMQd1bmlFMjEyB3VuaUUyMTMHdW5pRTIxNAd1bmlFMjE1B3VuaUUyMTYHdW5pRTIxOAd1bmlFMjE5B3VuaUUyMjEHdW5pRTIyMwd1bmlFMjI0B3VuaUUyMjUHdW5pRTIyNgd1bmlFMjI3B3VuaUUyMzAHdW5pRTIzMQd1bmlFMjMyB3VuaUUyMzMHdW5pRTIzNAd1bmlFMjM1B3VuaUUyMzYHdW5pRTIzNwd1bmlFMjM4B3VuaUUyMzkHdW5pRTI0MAd1bmlFMjQxB3VuaUUyNDIHdW5pRTI0Mwd1bmlFMjQ0B3VuaUUyNDUHdW5pRTI0Ngd1bmlFMjQ3B3VuaUUyNDgHdW5pRTI0OQd1bmlFMjUwB3VuaUUyNTEHdW5pRTI1Mgd1bmlFMjUzB3VuaUUyNTQHdW5pRTI1NQd1bmlFMjU2B3VuaUUyNTcHdW5pRTI1OAd1bmlFMjU5B3VuaUUyNjAHdW5pRjhGRgZ1MUY1MTEGdTFGNkFBAAAAAAFUUMMXAAA%3D%29%20format%28%27truetype%27%29%2Curl%28data%3Aimage%2Fsvg%2Bxml%3Bbase64%2CPD94bWwgdmVyc2lvbj0iMS4wIiBzdGFuZGFsb25lPSJubyI%2FPgo8IURPQ1RZUEUgc3ZnIFBVQkxJQyAiLS8vVzNDLy9EVEQgU1ZHIDEuMS8vRU4iICJodHRwOi8vd3d3LnczLm9yZy9HcmFwaGljcy9TVkcvMS4xL0RURC9zdmcxMS5kdGQiID4KPHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPgo8bWV0YWRhdGE%2BPC9tZXRhZGF0YT4KPGRlZnM%2BCjxmb250IGlkPSJnbHlwaGljb25zX2hhbGZsaW5nc3JlZ3VsYXIiIGhvcml6LWFkdi14PSIxMjAwIiA%2BCjxmb250LWZhY2UgdW5pdHMtcGVyLWVtPSIxMjAwIiBhc2NlbnQ9Ijk2MCIgZGVzY2VudD0iLTI0MCIgLz4KPG1pc3NpbmctZ2x5cGggaG9yaXotYWR2LXg9IjUwMCIgLz4KPGdseXBoIGhvcml6LWFkdi14PSIwIiAvPgo8Z2x5cGggaG9yaXotYWR2LXg9IjQwMCIgLz4KPGdseXBoIHVuaWNvZGU9IiAiIC8%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%2BCjxnbHlwaCB1bmljb2RlPSImI3gyMDAzOyIgaG9yaXotYWR2LXg9IjEzMDAiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3gyMDA0OyIgaG9yaXotYWR2LXg9IjQzMyIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeDIwMDU7IiBob3Jpei1hZHYteD0iMzI1IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4MjAwNjsiIGhvcml6LWFkdi14PSIyMTYiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3gyMDA3OyIgaG9yaXotYWR2LXg9IjIxNiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeDIwMDg7IiBob3Jpei1hZHYteD0iMTYyIiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4MjAwOTsiIGhvcml6LWFkdi14PSIyNjAiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3gyMDBhOyIgaG9yaXotYWR2LXg9IjcyIiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4MjAyZjsiIGhvcml6LWFkdi14PSIyNjAiIC8%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3gyNmZhOyIgZD0iTTc3NCAxMTkzLjVxMTYgLTkuNSAyMC41IC0yN3QtNS41IC0zMy41bC0xMzYgLTE4N2w0NjcgLTc0NmgzMHEyMCAwIDM1IC0xOC41dDE1IC0zOS41di00MmgtMTIwMHY0MnEwIDIxIDE1IDM5LjV0MzUgMTguNWgzMGw0NjggNzQ2bC0xMzUgMTgzcS0xMCAxNiAtNS41IDM0dDIwLjUgMjh0MzQgNS41dDI4IC0yMC41bDExMSAtMTQ4bDExMiAxNTBxOSAxNiAyNyAyMC41dDM0IC01ek02MDAgMjAwaDM3N2wtMTgyIDExMmwtMTk1IDUzNHYtNjQ2eiAiIC8%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDI0OyIgZD0iTTEzMDAgMGgtNTM4bC00MSA0MDBoLTI0MmwtNDEgLTQwMGgtNTM4bDQzMSAxMjAwaDIwOWwtMjEgLTMwMGgxNjJsLTIwIDMwMGgyMDh6TTUxNSA4MDBsLTI3IC0zMDBoMjI0bC0yNyAzMDBoLTE3MHoiIC8%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDI2OyIgZD0iTTYwMCAxMTc3cTExNyAwIDIyNCAtNDUuNXQxODQuNSAtMTIzdDEyMyAtMTg0LjV0NDUuNSAtMjI0dC00NS41IC0yMjR0LTEyMyAtMTg0LjV0LTE4NC41IC0xMjN0LTIyNCAtNDUuNXQtMjI0IDQ1LjV0LTE4NC41IDEyM3QtMTIzIDE4NC41dC00NS41IDIyNHQ0NS41IDIyNHQxMjMgMTg0LjV0MTg0LjUgMTIzdDIyNCA0NS41ek02MDAgMTAyN3EtMTE2IDAgLTIxNC41IC01N3QtMTU1LjUgLTE1NS41dC01NyAtMjE0LjV0NTcgLTIxNC41IHQxNTUuNSAtMTU1LjV0MjE0LjUgLTU3dDIxNC41IDU3dDE1NS41IDE1NS41dDU3IDIxNC41dC01NyAyMTQuNXQtMTU1LjUgMTU1LjV0LTIxNC41IDU3ek01MjUgOTAwaDE1MHExMCAwIDE3LjUgLTcuNXQ3LjUgLTE3LjV2LTI3NWgxMzdxMjEgMCAyNiAtMTEuNXQtOCAtMjcuNWwtMjIzIC0yNzVxLTEzIC0xNiAtMzIgLTE2dC0zMiAxNmwtMjIzIDI3NXEtMTMgMTYgLTggMjcuNXQyNiAxMS41aDEzN3YyNzVxMCAxMCA3LjUgMTcuNXQxNy41IDcuNXogIiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTAyNzsiIGQ9Ik02MDAgMTE3N3ExMTcgMCAyMjQgLTQ1LjV0MTg0LjUgLTEyM3QxMjMgLTE4NC41dDQ1LjUgLTIyNHQtNDUuNSAtMjI0dC0xMjMgLTE4NC41dC0xODQuNSAtMTIzdC0yMjQgLTQ1LjV0LTIyNCA0NS41dC0xODQuNSAxMjN0LTEyMyAxODQuNXQtNDUuNSAyMjR0NDUuNSAyMjR0MTIzIDE4NC41dDE4NC41IDEyM3QyMjQgNDUuNXpNNjAwIDEwMjdxLTExNiAwIC0yMTQuNSAtNTd0LTE1NS41IC0xNTUuNXQtNTcgLTIxNC41dDU3IC0yMTQuNSB0MTU1LjUgLTE1NS41dDIxNC41IC01N3QyMTQuNSA1N3QxNTUuNSAxNTUuNXQ1NyAyMTQuNXQtNTcgMjE0LjV0LTE1NS41IDE1NS41dC0yMTQuNSA1N3pNNjMyIDkxNGwyMjMgLTI3NXExMyAtMTYgOCAtMjcuNXQtMjYgLTExLjVoLTEzN3YtMjc1cTAgLTEwIC03LjUgLTE3LjV0LTE3LjUgLTcuNWgtMTUwcS0xMCAwIC0xNy41IDcuNXQtNy41IDE3LjV2Mjc1aC0xMzdxLTIxIDAgLTI2IDExLjV0OCAyNy41bDIyMyAyNzVxMTMgMTYgMzIgMTYgdDMyIC0xNnoiIC8%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDI5OyIgZD0iTTYwMCAxMTc3cTExNyAwIDIyNCAtNDUuNXQxODQuNSAtMTIzdDEyMyAtMTg0LjV0NDUuNSAtMjI0dC00NS41IC0yMjR0LTEyMyAtMTg0LjV0LTE4NC41IC0xMjN0LTIyNCAtNDUuNXQtMjI0IDQ1LjV0LTE4NC41IDEyM3QtMTIzIDE4NC41dC00NS41IDIyNHQ0NS41IDIyNHQxMjMgMTg0LjV0MTg0LjUgMTIzdDIyNCA0NS41ek02MDAgMTAyN3EtMTE2IDAgLTIxNC41IC01N3QtMTU1LjUgLTE1NS41dC01NyAtMjE0LjV0NTcgLTIxNC41IHQxNTUuNSAtMTU1LjV0MjE0LjUgLTU3dDIxNC41IDU3dDE1NS41IDE1NS41dDU3IDIxNC41dC01NyAyMTQuNXQtMTU1LjUgMTU1LjV0LTIxNC41IDU3ek01NDAgODIwbDI1MyAtMTkwcTE3IC0xMiAxNyAtMzB0LTE3IC0zMGwtMjUzIC0xOTBxLTE2IC0xMiAtMjggLTYuNXQtMTIgMjYuNXY0MDBxMCAyMSAxMiAyNi41dDI4IC02LjV6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTAzMDsiIGQ9Ik05NDcgMTA2MGwxMzUgMTM1cTcgNyAxMi41IDV0NS41IC0xM3YtMzYycTAgLTEwIC03LjUgLTE3LjV0LTE3LjUgLTcuNWgtMzYycS0xMSAwIC0xMyA1LjV0NSAxMi41bDEzMyAxMzNxLTEwOSA3NiAtMjM4IDc2cS0xMTYgMCAtMjE0LjUgLTU3dC0xNTUuNSAtMTU1LjV0LTU3IC0yMTQuNXQ1NyAtMjE0LjV0MTU1LjUgLTE1NS41dDIxNC41IC01N3QyMTQuNSA1N3QxNTUuNSAxNTUuNXQ1NyAyMTQuNWgxNTBxMCAtMTE3IC00NS41IC0yMjQgdC0xMjMgLTE4NC41dC0xODQuNSAtMTIzdC0yMjQgLTQ1LjV0LTIyNCA0NS41dC0xODQuNSAxMjN0LTEyMyAxODQuNXQtNDUuNSAyMjR0NDUuNSAyMjR0MTIzIDE4NC41dDE4NC41IDEyM3QyMjQgNDUuNXExOTIgMCAzNDcgLTExN3oiIC8%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDMyOyIgZD0iTTEyNSAxMjAwaDEwNTBxMTAgMCAxNy41IC03LjV0Ny41IC0xNy41di0xMTUwcTAgLTEwIC03LjUgLTE3LjV0LTE3LjUgLTcuNWgtMTA1MHEtMTAgMCAtMTcuNSA3LjV0LTcuNSAxNy41djExNTBxMCAxMCA3LjUgMTcuNXQxNy41IDcuNXpNMTA3NSAxMDAwaC04NTBxLTEwIDAgLTE3LjUgLTcuNXQtNy41IC0xNy41di04NTBxMCAtMTAgNy41IC0xNy41dDE3LjUgLTcuNWg4NTBxMTAgMCAxNy41IDcuNXQ3LjUgMTcuNXY4NTAgcTAgMTAgLTcuNSAxNy41dC0xNy41IDcuNXpNMzI1IDkwMGg1MHExMCAwIDE3LjUgLTcuNXQ3LjUgLTE3LjV2LTUwcTAgLTEwIC03LjUgLTE3LjV0LTE3LjUgLTcuNWgtNTBxLTEwIDAgLTE3LjUgNy41dC03LjUgMTcuNXY1MHEwIDEwIDcuNSAxNy41dDE3LjUgNy41ek01MjUgOTAwaDQ1MHExMCAwIDE3LjUgLTcuNXQ3LjUgLTE3LjV2LTUwcTAgLTEwIC03LjUgLTE3LjV0LTE3LjUgLTcuNWgtNDUwcS0xMCAwIC0xNy41IDcuNXQtNy41IDE3LjV2NTAgcTAgMTAgNy41IDE3LjV0MTcuNSA3LjV6TTMyNSA3MDBoNTBxMTAgMCAxNy41IC03LjV0Ny41IC0xNy41di01MHEwIC0xMCAtNy41IC0xNy41dC0xNy41IC03LjVoLTUwcS0xMCAwIC0xNy41IDcuNXQtNy41IDE3LjV2NTBxMCAxMCA3LjUgMTcuNXQxNy41IDcuNXpNNTI1IDcwMGg0NTBxMTAgMCAxNy41IC03LjV0Ny41IC0xNy41di01MHEwIC0xMCAtNy41IC0xNy41dC0xNy41IC03LjVoLTQ1MHEtMTAgMCAtMTcuNSA3LjV0LTcuNSAxNy41djUwIHEwIDEwIDcuNSAxNy41dDE3LjUgNy41ek0zMjUgNTAwaDUwcTEwIDAgMTcuNSAtNy41dDcuNSAtMTcuNXYtNTBxMCAtMTAgLTcuNSAtMTcuNXQtMTcuNSAtNy41aC01MHEtMTAgMCAtMTcuNSA3LjV0LTcuNSAxNy41djUwcTAgMTAgNy41IDE3LjV0MTcuNSA3LjV6TTUyNSA1MDBoNDUwcTEwIDAgMTcuNSAtNy41dDcuNSAtMTcuNXYtNTBxMCAtMTAgLTcuNSAtMTcuNXQtMTcuNSAtNy41aC00NTBxLTEwIDAgLTE3LjUgNy41dC03LjUgMTcuNXY1MCBxMCAxMCA3LjUgMTcuNXQxNy41IDcuNXpNMzI1IDMwMGg1MHExMCAwIDE3LjUgLTcuNXQ3LjUgLTE3LjV2LTUwcTAgLTEwIC03LjUgLTE3LjV0LTE3LjUgLTcuNWgtNTBxLTEwIDAgLTE3LjUgNy41dC03LjUgMTcuNXY1MHEwIDEwIDcuNSAxNy41dDE3LjUgNy41ek01MjUgMzAwaDQ1MHExMCAwIDE3LjUgLTcuNXQ3LjUgLTE3LjV2LTUwcTAgLTEwIC03LjUgLTE3LjV0LTE3LjUgLTcuNWgtNDUwcS0xMCAwIC0xNy41IDcuNXQtNy41IDE3LjV2NTAgcTAgMTAgNy41IDE3LjV0MTcuNSA3LjV6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTAzMzsiIGQ9Ik05MDAgODAwdjIwMHEwIDgzIC01OC41IDE0MS41dC0xNDEuNSA1OC41aC0zMDBxLTgyIDAgLTE0MSAtNTl0LTU5IC0xNDF2LTIwMGgtMTAwcS00MSAwIC03MC41IC0yOS41dC0yOS41IC03MC41di02MDBxMCAtNDEgMjkuNSAtNzAuNXQ3MC41IC0yOS41aDkwMHE0MSAwIDcwLjUgMjkuNXQyOS41IDcwLjV2NjAwcTAgNDEgLTI5LjUgNzAuNXQtNzAuNSAyOS41aC0xMDB6TTQwMCA4MDB2MTUwcTAgMjEgMTUgMzUuNXQzNSAxNC41aDIwMCBxMjAgMCAzNSAtMTQuNXQxNSAtMzUuNXYtMTUwaC0zMDB6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTAzNDsiIGQ9Ik0xMjUgMTEwMGg1MHExMCAwIDE3LjUgLTcuNXQ3LjUgLTE3LjV2LTEwNzVoLTEwMHYxMDc1cTAgMTAgNy41IDE3LjV0MTcuNSA3LjV6TTEwNzUgMTA1MnE0IDAgOSAtMnExNiAtNiAxNiAtMjN2LTQyMXEwIC02IC0zIC0xMnEtMzMgLTU5IC02Ni41IC05OXQtNjUuNSAtNTh0LTU2LjUgLTI0LjV0LTUyLjUgLTYuNXEtMjYgMCAtNTcuNSA2LjV0LTUyLjUgMTMuNXQtNjAgMjFxLTQxIDE1IC02MyAyMi41dC01Ny41IDE1dC02NS41IDcuNSBxLTg1IDAgLTE2MCAtNTdxLTcgLTUgLTE1IC01cS02IDAgLTExIDNxLTE0IDcgLTE0IDIydjQzOHEyMiA1NSA4MiA5OC41dDExOSA0Ni41cTIzIDIgNDMgMC41dDQzIC03dDMyLjUgLTguNXQzOCAtMTN0MzIuNSAtMTFxNDEgLTE0IDYzLjUgLTIxdDU3IC0xNHQ2My41IC03cTEwMyAwIDE4MyA4N3E3IDggMTggOHoiIC8%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDQyOyIgZD0iTTUwMCAxMjAwbDY4MiAtNjgycTggLTggOCAtMTh0LTggLTE4bC00NjQgLTQ2NHEtOCAtOCAtMTggLTh0LTE4IDhsLTY4MiA2ODJsMSA0NzVxMCAxMCA3LjUgMTcuNXQxNy41IDcuNWg0NzR6TTgwMCAxMjAwbDY4MiAtNjgycTggLTggOCAtMTh0LTggLTE4bC00NjQgLTQ2NHEtOCAtOCAtMTggLTh0LTE4IDhsLTU2IDU2bDQyNCA0MjZsLTcwMCA3MDBoMTUwek0zMTkuNSAxMDI0LjVxLTI5LjUgMjkuNSAtNzEgMjkuNXQtNzEgLTI5LjUgdC0yOS41IC03MS41dDI5LjUgLTcxLjV0NzEgLTI5LjV0NzEgMjkuNXQyOS41IDcxLjV0LTI5LjUgNzEuNXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDQzOyIgZD0iTTMwMCAxMjAwaDgyNXE3NSAwIDc1IC03NXYtOTAwcTAgLTI1IC0xOCAtNDNsLTY0IC02NHEtOCAtOCAtMTMgLTUuNXQtNSAxMi41djk1MHEwIDEwIC03LjUgMTcuNXQtMTcuNSA3LjVoLTcwMHEtMjUgMCAtNDMgLTE4bC02NCAtNjRxLTggLTggLTUuNSAtMTN0MTIuNSAtNWg3MDBxMTAgMCAxNy41IC03LjV0Ny41IC0xNy41di05NTBxMCAtMTAgLTcuNSAtMTcuNXQtMTcuNSAtNy41aC04NTBxLTEwIDAgLTE3LjUgNy41dC03LjUgMTcuNXY5NzUgcTAgMjUgMTggNDNsMTM5IDEzOXExOCAxOCA0MyAxOHoiIC8%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDQ5OyIgZD0iTTg3NyAxMjAwbDIgLTU3cS04MyAtMTkgLTExNiAtNDUuNXQtNDAgLTY2LjVsLTEzMiAtODM5cS05IC00OSAxMyAtNjl0OTYgLTI2di05N2gtNTAwdjk3cTE4NiAxNiAyMDAgOThsMTczIDgzMnEzIDE3IDMgMzB0LTEuNSAyMi41dC05IDE3LjV0LTEzLjUgMTIuNXQtMjEuNSAxMHQtMjYgOC41dC0zMy41IDEwcS0xMyAzIC0xOSA1djU3aDQyNXoiIC8%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDY2OyIgZD0iTTM1MCAxMTAwaDM2MXEtMTY0IC0xNDYgLTIxNiAtMjAwaC0xOTVxLTQxIDAgLTcwLjUgLTI5LjV0LTI5LjUgLTcwLjV2LTUwMHEwIC00MSAyOS41IC03MC41dDcwLjUgLTI5LjVoNTAwcTQxIDAgNzAuNSAyOS41dDI5LjUgNzAuNWwyMDAgMTUzdi0xMDNxMCAtMTY1IC05Mi41IC0yNTcuNXQtMjU3LjUgLTkyLjVoLTQwMHEtMTY1IDAgLTI1Ny41IDkyLjV0LTkyLjUgMjU3LjV2NDAwcTAgMTY1IDkyLjUgMjU3LjV0MjU3LjUgOTIuNXogTTgyNCAxMDczbDMzOSAtMzAxcTggLTcgOCAtMTcuNXQtOCAtMTcuNWwtMzQwIC0zMDZxLTcgLTYgLTEyLjUgLTR0LTYuNSAxMXYyMDNxLTI2IDEgLTU0LjUgMHQtNzguNSAtNy41dC05MiAtMTcuNXQtODYgLTM1dC03MCAtNTdxMTAgNTkgMzMgMTA4dDUxLjUgODEuNXQ2NSA1OC41dDY4LjUgNDAuNXQ2NyAyNC41dDU2IDEzLjV0NDAgNC41djIxMHExIDEwIDYuNSAxMi41dDEzLjUgLTQuNXoiIC8%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDY5OyIgZD0iTTI1MCAxMTAwaDEwMHEyMSAwIDM1LjUgLTE0LjV0MTQuNSAtMzUuNXYtNDM4bDQ2NCA0NTNxMTUgMTQgMjUuNSAxMHQxMC41IC0yNXYtMTAwMHEwIC0yMSAtMTAuNSAtMjV0LTI1LjUgMTBsLTQ2NCA0NTN2LTQzOHEwIC0yMSAtMTQuNSAtMzUuNXQtMzUuNSAtMTQuNWgtMTAwcS0yMSAwIC0zNS41IDE0LjV0LTE0LjUgMzUuNXYxMDAwcTAgMjEgMTQuNSAzNS41dDM1LjUgMTQuNXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDcwOyIgZD0iTTUwIDExMDBoMTAwcTIxIDAgMzUuNSAtMTQuNXQxNC41IC0zNS41di00MzhsNDY0IDQ1M3ExNSAxNCAyNS41IDEwdDEwLjUgLTI1di00MzhsNDY0IDQ1M3ExNSAxNCAyNS41IDEwdDEwLjUgLTI1di0xMDAwcTAgLTIxIC0xMC41IC0yNXQtMjUuNSAxMGwtNDY0IDQ1M3YtNDM4cTAgLTIxIC0xMC41IC0yNXQtMjUuNSAxMGwtNDY0IDQ1M3YtNDM4cTAgLTIxIC0xNC41IC0zNS41dC0zNS41IC0xNC41aC0xMDBxLTIxIDAgLTM1LjUgMTQuNSB0LTE0LjUgMzUuNXYxMDAwcTAgMjEgMTQuNSAzNS41dDM1LjUgMTQuNXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDcxOyIgZD0iTTEyMDAgMTA1MHYtMTAwMHEwIC0yMSAtMTAuNSAtMjV0LTI1LjUgMTBsLTQ2NCA0NTN2LTQzOHEwIC0yMSAtMTAuNSAtMjV0LTI1LjUgMTBsLTQ5MiA0ODBxLTE1IDE0IC0xNSAzNXQxNSAzNWw0OTIgNDgwcTE1IDE0IDI1LjUgMTB0MTAuNSAtMjV2LTQzOGw0NjQgNDUzcTE1IDE0IDI1LjUgMTB0MTAuNSAtMjV6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTA3MjsiIGQ9Ik0yNDMgMTA3NGw4MTQgLTQ5OHExOCAtMTEgMTggLTI2dC0xOCAtMjZsLTgxNCAtNDk4cS0xOCAtMTEgLTMwLjUgLTR0LTEyLjUgMjh2MTAwMHEwIDIxIDEyLjUgMjh0MzAuNSAtNHoiIC8%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDc5OyIgZD0iTTg4NSA5MDBsLTM1MiAtMzUzbDM1MiAtMzUzbC0xOTcgLTE5OGwtNTUyIDU1Mmw1NTIgNTUweiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUwODA7IiBkPSJNMTA2NCA1NDdsLTU1MSAtNTUxbC0xOTggMTk4bDM1MyAzNTNsLTM1MyAzNTNsMTk4IDE5OHoiIC8%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%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%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%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%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMDk2OyIgZD0iTTg1MCAxMjAwaDMwMHEyMSAwIDM1LjUgLTE0LjV0MTQuNSAtMzUuNXYtMzAwcTAgLTIxIC0xMC41IC0yNXQtMjQuNSAxMGwtOTQgOTRsLTI0OSAtMjQ5cS04IC03IC0xOCAtN3QtMTggN2wtMTA2IDEwNnEtNyA4IC03IDE4dDcgMThsMjQ5IDI0OWwtOTQgOTRxLTE0IDE0IC0xMCAyNC41dDI1IDEwLjV6TTM1MCAwaC0zMDBxLTIxIDAgLTM1LjUgMTQuNXQtMTQuNSAzNS41djMwMHEwIDIxIDEwLjUgMjV0MjQuNSAtMTBsOTQgLTk0bDI0OSAyNDkgcTggNyAxOCA3dDE4IC03bDEwNiAtMTA2cTcgLTggNyAtMTh0LTcgLTE4bC0yNDkgLTI0OWw5NCAtOTRxMTQgLTE0IDEwIC0yNC41dC0yNSAtMTAuNXoiIC8%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMTAzOyIgZD0iTTExNjUgMTE5MHE4IDMgMjEgLTYuNXQxMyAtMTcuNXEtMiAtMTc4IC0yNC41IC0zMjMuNXQtNTUuNSAtMjQ1LjV0LTg3IC0xNzQuNXQtMTAyLjUgLTExOC41dC0xMTggLTY4LjV0LTExOC41IC0zM3QtMTIwIC00LjV0LTEwNSA5LjV0LTkwIDE2LjVxLTYxIDEyIC03OCAxMXEtNCAxIC0xMi41IDB0LTM0IC0xNC41dC01Mi41IC00MC41bC0xNTMgLTE1M3EtMjYgLTI0IC0zNyAtMTQuNXQtMTEgNDMuNXEwIDY0IDQyIDEwMnE4IDggNTAuNSA0NSB0NjYuNSA1OHExOSAxNyAzNSA0N3QxMyA2MXEtOSA1NSAtMTAgMTAyLjV0NyAxMTF0MzcgMTMwdDc4IDEyOS41cTM5IDUxIDgwIDg4dDg5LjUgNjMuNXQ5NC41IDQ1dDExMy41IDM2dDEyOSAzMXQxNTcuNSAzN3QxODIgNDcuNXpNMTExNiAxMDk4cS04IDkgLTIyLjUgLTN0LTQ1LjUgLTUwcS0zOCAtNDcgLTExOSAtMTAzLjV0LTE0MiAtODkuNWwtNjIgLTMzcS01NiAtMzAgLTEwMiAtNTd0LTEwNCAtNjh0LTEwMi41IC04MC41dC04NS41IC05MSB0LTY0IC0xMDQuNXEtMjQgLTU2IC0zMSAtODZ0MiAtMzJ0MzEuNSAxNy41dDU1LjUgNTkuNXEyNSAzMCA5NCA3NS41dDEyNS41IDc3LjV0MTQ3LjUgODFxNzAgMzcgMTE4LjUgNjl0MTAyIDc5LjV0OTkgMTExdDg2LjUgMTQ4LjVxMjIgNTAgMjQgNjB0LTYgMTl6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTEwNDsiIGQ9Ik02NTMgMTIzMXEtMzkgLTY3IC01NC41IC0xMzF0LTEwLjUgLTExNC41dDI0LjUgLTk2LjV0NDcuNSAtODB0NjMuNSAtNjIuNXQ2OC41IC00Ni41dDY1IC0zMHEtNCA3IC0xNy41IDM1dC0xOC41IDM5LjV0LTE3IDM5LjV0LTE3IDQzdC0xMyA0MnQtOS41IDQ0LjV0LTIgNDJ0NCA0M3QxMy41IDM5dDIzIDM4LjVxOTYgLTQyIDE2NSAtMTA3LjV0MTA1IC0xMzh0NTIgLTE1NnQxMyAtMTU5dC0xOSAtMTQ5LjVxLTEzIC01NSAtNDQgLTEwNi41IHQtNjggLTg3dC03OC41IC02NC41dC03Mi41IC00NXQtNTMgLTIycS03MiAtMjIgLTEyNyAtMTFxLTMxIDYgLTEzIDE5cTYgMyAxNyA3cTEzIDUgMzIuNSAyMXQ0MSA0NHQzOC41IDYzLjV0MjEuNSA4MS41dC02LjUgOTQuNXQtNTAgMTA3dC0xMDQgMTE1LjVxMTAgLTEwNCAtMC41IC0xODl0LTM3IC0xNDAuNXQtNjUgLTkzdC04NCAtNTJ0LTkzLjUgLTExdC05NSAyNC41cS04MCAzNiAtMTMxLjUgMTE0dC01My41IDE3MXEtMiAyMyAwIDQ5LjUgdDQuNSA1Mi41dDEzLjUgNTZ0MjcuNSA2MHQ0NiA2NC41dDY5LjUgNjguNXEtOCAtNTMgLTUgLTEwMi41dDE3LjUgLTkwdDM0IC02OC41dDQ0LjUgLTM5dDQ5IC0ycTMxIDEzIDM4LjUgMzZ0LTQuNSA1NXQtMjkgNjQuNXQtMzYgNzV0LTI2IDc1LjVxLTE1IDg1IDIgMTYxLjV0NTMuNSAxMjguNXQ4NS41IDkyLjV0OTMuNSA2MXQ4MS41IDI1LjV6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTEwNTsiIGQ9Ik02MDAgMTA5NHE4MiAwIDE2MC41IC0yMi41dDE0MCAtNTl0MTE2LjUgLTgyLjV0OTQuNSAtOTV0NjggLTk1dDQyLjUgLTgyLjV0MTQgLTU3LjV0LTE0IC01Ny41dC00MyAtODIuNXQtNjguNSAtOTV0LTk0LjUgLTk1dC0xMTYuNSAtODIuNXQtMTQwIC01OXQtMTU5LjUgLTIyLjV0LTE1OS41IDIyLjV0LTE0MCA1OXQtMTE2LjUgODIuNXQtOTQuNSA5NXQtNjguNSA5NXQtNDMgODIuNXQtMTQgNTcuNXQxNCA1Ny41dDQyLjUgODIuNXQ2OCA5NSB0OTQuNSA5NXQxMTYuNSA4Mi41dDE0MCA1OXQxNjAuNSAyMi41ek04ODggODI5cS0xNSAxNSAtMTggMTJ0NSAtMjJxMjUgLTU3IDI1IC0xMTlxMCAtMTI0IC04OCAtMjEydC0yMTIgLTg4dC0yMTIgODh0LTg4IDIxMnEwIDU5IDIzIDExNHE4IDE5IDQuNSAyMnQtMTcuNSAtMTJxLTcwIC02OSAtMTYwIC0xODRxLTEzIC0xNiAtMTUgLTQwLjV0OSAtNDIuNXEyMiAtMzYgNDcgLTcxdDcwIC04MnQ5Mi41IC04MXQxMTMgLTU4LjV0MTMzLjUgLTI0LjUgdDEzMy41IDI0dDExMyA1OC41dDkyLjUgODEuNXQ3MCA4MS41dDQ3IDcwLjVxMTEgMTggOSA0Mi41dC0xNCA0MS41cS05MCAxMTcgLTE2MyAxODl6TTQ0OCA3MjdsLTM1IC0zNnEtMTUgLTE1IC0xOS41IC0zOC41dDQuNSAtNDEuNXEzNyAtNjggOTMgLTExNnExNiAtMTMgMzguNSAtMTF0MzYuNSAxN2wzNSAzNHExNCAxNSAxMi41IDMzLjV0LTE2LjUgMzMuNXEtNDQgNDQgLTg5IDExN3EtMTEgMTggLTI4IDIwdC0zMiAtMTJ6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTEwNjsiIGQ9Ik01OTIgMGgtMTQ4bDMxIDEyMHEtOTEgMjAgLTE3NS41IDY4LjV0LTE0My41IDEwNi41dC0xMDMuNSAxMTl0LTY2LjUgMTEwdC0yMiA3NnEwIDIxIDE0IDU3LjV0NDIuNSA4Mi41dDY4IDk1dDk0LjUgOTV0MTE2LjUgODIuNXQxNDAgNTl0MTYwLjUgMjIuNXE2MSAwIDEyNiAtMTVsMzIgMTIxaDE0OHpNOTQ0IDc3MGw0NyAxODFxMTA4IC04NSAxNzYuNSAtMTkydDY4LjUgLTE1OXEwIC0yNiAtMTkuNSAtNzF0LTU5LjUgLTEwMnQtOTMgLTExMiB0LTEyOSAtMTA0LjV0LTE1OCAtNzUuNWw0NiAxNzNxNzcgNDkgMTM2IDExN3Q5NyAxMzFxMTEgMTggOSA0Mi41dC0xNCA0MS41cS01NCA3MCAtMTA3IDEzMHpNMzEwIDgyNHEtNzAgLTY5IC0xNjAgLTE4NHEtMTMgLTE2IC0xNSAtNDAuNXQ5IC00Mi41cTE4IC0zMCAzOSAtNjB0NTcgLTcwLjV0NzQgLTczdDkwIC02MXQxMDUgLTQxLjVsNDEgMTU0cS0xMDcgMTggLTE3OC41IDEwMS41dC03MS41IDE5My41cTAgNTkgMjMgMTE0cTggMTkgNC41IDIyIHQtMTcuNSAtMTJ6TTQ0OCA3MjdsLTM1IC0zNnEtMTUgLTE1IC0xOS41IC0zOC41dDQuNSAtNDEuNXEzNyAtNjggOTMgLTExNnExNiAtMTMgMzguNSAtMTF0MzYuNSAxN2wxMiAxMWwyMiA4NmwtMyA0cS00NCA0NCAtODkgMTE3cS0xMSAxOCAtMjggMjB0LTMyIC0xMnoiIC8%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%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%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMTI2OyIgZD0iTTYwMCAxMTAwaDI1MHEyMyAwIDQ1IC0xNi41dDM4IC00MC41bDIzOCAtMzQ0cTI5IC0yOSAyOSAtNzR2LTEwMHEwIC00NCAtMzAgLTg0LjV0LTcwIC00MC41aC0zMjhxMjggLTExOCAyOCAtMTI1di0xNTBxMCAtNDQgLTMwIC04NC41dC03MCAtNDAuNWgtNTBxLTI3IDAgLTUxLjUgMjB0LTM3LjUgNDhsLTk2IDE5OGwtMTQ1IDE5NnEtMjAgMjcgLTIwIDYzdjQwMHEwIDM5IDI3LjUgNTd0NzIuNSAxOGg2MXExMjQgMTAwIDEzOSAxMDB6IE01MCAxMDAwaDEwMHEyMSAwIDM1LjUgLTE0LjV0MTQuNSAtMzUuNXYtNTAwcTAgLTIxIC0xNC41IC0zNS41dC0zNS41IC0xNC41aC0xMDBxLTIxIDAgLTM1LjUgMTQuNXQtMTQuNSAzNS41djUwMHEwIDIxIDE0LjUgMzUuNXQzNS41IDE0LjV6TTYzNiAxMDAwbC0xMzYgLTEwMGgtMTAwdi0zNzVsMTUwIC0yMTNsMTAwIC0yMTJoNTB2MTc1bC01MCAyMjVoNDUwdjEyNWwtMjUwIDM3NWgtMjE0eiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUxMjc7IiBkPSJNMzU2IDg3M2wzNjMgMjMwcTMxIDE2IDUzIC02bDExMCAtMTEycTEzIC0xMyAxMy41IC0zMnQtMTEuNSAtMzRsLTg0IC0xMjFoMzAycTg0IDAgMTM4IC0zOHQ1NCAtMTEwdC01NSAtMTExdC0xMzkgLTM5aC0xMDZsLTEzMSAtMzM5cS02IC0yMSAtMTkuNSAtNDF0LTI4LjUgLTIwaC0zNDJxLTcgMCAtOTAgODF0LTgzIDk0djUyNXEwIDE3IDE0IDM1LjV0MjggMjguNXpNNDAwIDc5MnYtNTAzbDEwMCAtODloMjkzbDEzMSAzMzkgcTYgMjEgMTkuNSA0MXQyOC41IDIwaDIwM3EyMSAwIDMwLjUgMjV0MC41IDUwdC0zMSAyNWgtNDU2aC03aC02aC01LjV0LTYgMC41dC01IDEuNXQtNSAydC00IDIuNXQtNCA0dC0yLjUgNC41cS0xMiAyNSA1IDQ3bDE0NiAxODNsLTg2IDgzek01MCA4MDBoMTAwcTIxIDAgMzUuNSAtMTQuNXQxNC41IC0zNS41di01MDBxMCAtMjEgLTE0LjUgLTM1LjV0LTM1LjUgLTE0LjVoLTEwMHEtMjEgMCAtMzUuNSAxNC41dC0xNC41IDM1LjV2NTAwIHEwIDIxIDE0LjUgMzUuNXQzNS41IDE0LjV6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTEyODsiIGQ9Ik00NzUgMTEwM2wzNjYgLTIzMHEyIC0xIDYgLTMuNXQxNCAtMTAuNXQxOCAtMTYuNXQxNC41IC0yMHQ2LjUgLTIyLjV2LTUyNXEwIC0xMyAtODYgLTk0dC05MyAtODFoLTM0MnEtMTUgMCAtMjguNSAyMHQtMTkuNSA0MWwtMTMxIDMzOWgtMTA2cS04NSAwIC0xMzkuNSAzOXQtNTQuNSAxMTF0NTQgMTEwdDEzOCAzOGgzMDJsLTg1IDEyMXEtMTEgMTUgLTEwLjUgMzR0MTMuNSAzMmwxMTAgMTEycTIyIDIyIDUzIDZ6TTM3MCA5NDVsMTQ2IC0xODMgcTE3IC0yMiA1IC00N3EtMiAtMiAtMy41IC00LjV0LTQgLTR0LTQgLTIuNXQtNSAtMnQtNSAtMS41dC02IC0wLjVoLTZoLTYuNWgtNmgtNDc1di0xMDBoMjIxcTE1IDAgMjkgLTIwdDIwIC00MWwxMzAgLTMzOWgyOTRsMTA2IDg5djUwM2wtMzQyIDIzNnpNMTA1MCA4MDBoMTAwcTIxIDAgMzUuNSAtMTQuNXQxNC41IC0zNS41di01MDBxMCAtMjEgLTE0LjUgLTM1LjV0LTM1LjUgLTE0LjVoLTEwMHEtMjEgMCAtMzUuNSAxNC41dC0xNC41IDM1LjUgdjUwMHEwIDIxIDE0LjUgMzUuNXQzNS41IDE0LjV6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTEyOTsiIGQ9Ik01NTAgMTI5NHE3MiAwIDExMSAtNTV0MzkgLTEzOXYtMTA2bDMzOSAtMTMxcTIxIC02IDQxIC0xOS41dDIwIC0yOC41di0zNDJxMCAtNyAtODEgLTkwdC05NCAtODNoLTUyNXEtMTcgMCAtMzUuNSAxNHQtMjguNSAyOGwtOSAxNGwtMjMwIDM2M3EtMTYgMzEgNiA1M2wxMTIgMTEwcTEzIDEzIDMyIDEzLjV0MzQgLTExLjVsMTIxIC04NHYzMDJxMCA4NCAzOCAxMzh0MTEwIDU0ek02MDAgOTcydjIwM3EwIDIxIC0yNSAzMC41dC01MCAwLjUgdC0yNSAtMzF2LTQ1NnYtN3YtNnYtNS41dC0wLjUgLTZ0LTEuNSAtNXQtMiAtNXQtMi41IC00dC00IC00dC00LjUgLTIuNXEtMjUgLTEyIC00NyA1bC0xODMgMTQ2bC04MyAtODZsMjM2IC0zMzloNTAzbDg5IDEwMHYyOTNsLTMzOSAxMzFxLTIxIDYgLTQxIDE5LjV0LTIwIDI4LjV6TTQ1MCAyMDBoNTAwcTIxIDAgMzUuNSAtMTQuNXQxNC41IC0zNS41di0xMDBxMCAtMjEgLTE0LjUgLTM1LjV0LTM1LjUgLTE0LjVoLTUwMCBxLTIxIDAgLTM1LjUgMTQuNXQtMTQuNSAzNS41djEwMHEwIDIxIDE0LjUgMzUuNXQzNS41IDE0LjV6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTEzMDsiIGQ9Ik0zNTAgMTEwMGg1MDBxMjEgMCAzNS41IDE0LjV0MTQuNSAzNS41djEwMHEwIDIxIC0xNC41IDM1LjV0LTM1LjUgMTQuNWgtNTAwcS0yMSAwIC0zNS41IC0xNC41dC0xNC41IC0zNS41di0xMDBxMCAtMjEgMTQuNSAtMzUuNXQzNS41IC0xNC41ek02MDAgMzA2di0xMDZxMCAtODQgLTM5IC0xMzl0LTExMSAtNTV0LTExMCA1NHQtMzggMTM4djMwMmwtMTIxIC04NHEtMTUgLTEyIC0zNCAtMTEuNXQtMzIgMTMuNWwtMTEyIDExMCBxLTIyIDIyIC02IDUzbDIzMCAzNjNxMSAyIDMuNSA2dDEwLjUgMTMuNXQxNi41IDE3dDIwIDEzLjV0MjIuNSA2aDUyNXExMyAwIDk0IC04M3Q4MSAtOTB2LTM0MnEwIC0xNSAtMjAgLTI4LjV0LTQxIC0xOS41ek0zMDggOTAwbC0yMzYgLTMzOWw4MyAtODZsMTgzIDE0NnEyMiAxNyA0NyA1cTIgLTEgNC41IC0yLjV0NCAtNHQyLjUgLTR0MiAtNXQxLjUgLTV0MC41IC02di01LjV2LTZ2LTd2LTQ1NnEwIC0yMiAyNSAtMzF0NTAgMC41dDI1IDMwLjUgdjIwM3EwIDE1IDIwIDI4LjV0NDEgMTkuNWwzMzkgMTMxdjI5M2wtODkgMTAwaC01MDN6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTEzMTsiIGQ9Ik02MDAgMTE3OHExMTggMCAyMjUgLTQ1LjV0MTg0LjUgLTEyM3QxMjMgLTE4NC41dDQ1LjUgLTIyNXQtNDUuNSAtMjI1dC0xMjMgLTE4NC41dC0xODQuNSAtMTIzdC0yMjUgLTQ1LjV0LTIyNSA0NS41dC0xODQuNSAxMjN0LTEyMyAxODQuNXQtNDUuNSAyMjV0NDUuNSAyMjV0MTIzIDE4NC41dDE4NC41IDEyM3QyMjUgNDUuNXpNOTE0IDYzMmwtMjc1IDIyM3EtMTYgMTMgLTI3LjUgOHQtMTEuNSAtMjZ2LTEzN2gtMjc1IHEtMTAgMCAtMTcuNSAtNy41dC03LjUgLTE3LjV2LTE1MHEwIC0xMCA3LjUgLTE3LjV0MTcuNSAtNy41aDI3NXYtMTM3cTAgLTIxIDExLjUgLTI2dDI3LjUgOGwyNzUgMjIzcTE2IDEzIDE2IDMydC0xNiAzMnoiIC8%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%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%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%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%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%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%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMTYyOyIgZD0iTTc5MyAxMTgybDkgLTlxOCAtMTAgNSAtMjdxLTMgLTExIC03OSAtMjI1LjV0LTc4IC0yMjEuNWwzMDAgMXEyNCAwIDMyLjUgLTE3LjV0LTUuNSAtMzUuNXEtMSAwIC0xMzMuNSAtMTU1dC0yNjcgLTMxMi41dC0xMzguNSAtMTYyLjVxLTEyIC0xNSAtMjYgLTE1aC05bC05IDhxLTkgMTEgLTQgMzJxMiA5IDQyIDEyMy41dDc5IDIyNC41bDM5IDExMGgtMzAycS0yMyAwIC0zMSAxOXEtMTAgMjEgNiA0MXE3NSA4NiAyMDkuNSAyMzcuNSB0MjI4IDI1N3Q5OC41IDExMS41cTkgMTYgMjUgMTZoOXoiIC8%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%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%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%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%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMTkwOyIgZD0iTTIwMCAxMTAwaDcwMHExMjQgMCAyMTIgLTg4dDg4IC0yMTJ2LTUwMHEwIC0xMjQgLTg4IC0yMTJ0LTIxMiAtODhoLTcwMHEtMTI0IDAgLTIxMiA4OHQtODggMjEydjUwMHEwIDEyNCA4OCAyMTJ0MjEyIDg4ek0xMDAgOTAwdi03MDBoOTAwdjcwMGgtOTAwek05MDAgMzAwaC03MDB2NTAwaDcwMHYtNTAwek04MDAgNzAwaC0xMzBxLTM4IDAgLTY2LjUgLTQzdC0yOC41IC0xMDh0MjcgLTEwN3Q2OCAtNDJoMTMwdjMwMHpNMzAwIDcwMHYtMzAwIGgxMzBxNDEgMCA2OCA0MnQyNyAxMDd0LTI4LjUgMTA4dC02Ni41IDQzaC0xMzB6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTE5MTsiIGQ9Ik0yMDAgMTEwMGg3MDBxMTI0IDAgMjEyIC04OHQ4OCAtMjEydi01MDBxMCAtMTI0IC04OCAtMjEydC0yMTIgLTg4aC03MDBxLTEyNCAwIC0yMTIgODh0LTg4IDIxMnY1MDBxMCAxMjQgODggMjEydDIxMiA4OHpNMTAwIDkwMHYtNzAwaDkwMHY3MDBoLTkwMHpNNTAwIDcwMGgtMjAwdi0xMDBoMjAwdi0zMDBoLTMwMHYxMDBoMjAwdjEwMGgtMjAwdjMwMGgzMDB2LTEwMHpNOTAwIDMwMGgtMTAwdjQwMGgtMTAwdjEwMGgyMDB2LTUwMHogTTcwMCAzMDBoLTEwMHYxMDBoMTAwdi0xMDB6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTE5MjsiIGQ9Ik0yMDAgMTEwMGg3MDBxMTI0IDAgMjEyIC04OHQ4OCAtMjEydi01MDBxMCAtMTI0IC04OCAtMjEydC0yMTIgLTg4aC03MDBxLTEyNCAwIC0yMTIgODh0LTg4IDIxMnY1MDBxMCAxMjQgODggMjEydDIxMiA4OHpNMTAwIDkwMHYtNzAwaDkwMHY3MDBoLTkwMHpNMzAwIDcwMGgyMDB2LTQwMGgtMzAwdjUwMGgxMDB2LTEwMHpNOTAwIDMwMGgtMTAwdjQwMGgtMTAwdjEwMGgyMDB2LTUwMHpNMzAwIDYwMHYtMjAwaDEwMHYyMDBoLTEwMHogTTcwMCAzMDBoLTEwMHYxMDBoMTAwdi0xMDB6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTE5MzsiIGQ9Ik0yMDAgMTEwMGg3MDBxMTI0IDAgMjEyIC04OHQ4OCAtMjEydi01MDBxMCAtMTI0IC04OCAtMjEydC0yMTIgLTg4aC03MDBxLTEyNCAwIC0yMTIgODh0LTg4IDIxMnY1MDBxMCAxMjQgODggMjEydDIxMiA4OHpNMTAwIDkwMHYtNzAwaDkwMHY3MDBoLTkwMHpNNTAwIDUwMGwtMTk5IC0yMDBoLTEwMHY1MGwxOTkgMjAwdjE1MGgtMjAwdjEwMGgzMDB2LTMwMHpNOTAwIDMwMGgtMTAwdjQwMGgtMTAwdjEwMGgyMDB2LTUwMHpNNzAxIDMwMGgtMTAwIHYxMDBoMTAwdi0xMDB6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTE5NDsiIGQ9Ik02MDAgMTE5MXExMjAgMCAyMjkuNSAtNDd0MTg4LjUgLTEyNnQxMjYgLTE4OC41dDQ3IC0yMjkuNXQtNDcgLTIyOS41dC0xMjYgLTE4OC41dC0xODguNSAtMTI2dC0yMjkuNSAtNDd0LTIyOS41IDQ3dC0xODguNSAxMjZ0LTEyNiAxODguNXQtNDcgMjI5LjV0NDcgMjI5LjV0MTI2IDE4OC41dDE4OC41IDEyNnQyMjkuNSA0N3pNNjAwIDEwMjFxLTExNCAwIC0yMTEgLTU2LjV0LTE1My41IC0xNTMuNXQtNTYuNSAtMjExdDU2LjUgLTIxMSB0MTUzLjUgLTE1My41dDIxMSAtNTYuNXQyMTEgNTYuNXQxNTMuNSAxNTMuNXQ1Ni41IDIxMXQtNTYuNSAyMTF0LTE1My41IDE1My41dC0yMTEgNTYuNXpNODAwIDcwMGgtMzAwdi0yMDBoMzAwdi0xMDBoLTMwMGwtMTAwIDEwMHYyMDBsMTAwIDEwMGgzMDB2LTEwMHoiIC8%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%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%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjIxOyIgZD0iTTQ4MCAxMTY1bDY4MiAtNjgzcTMxIC0zMSAzMSAtNzUuNXQtMzEgLTc1LjVsLTEzMSAtMTMxaC00ODFsLTUxNyA1MThxLTMyIDMxIC0zMiA3NS41dDMyIDc1LjVsMjk1IDI5NnEzMSAzMSA3NS41IDMxdDc2LjUgLTMxek0xMDggNzk0bDM0MiAtMzQybDMwMyAzMDRsLTM0MSAzNDF6TTI1MCAxMDBoODAwcTIxIDAgMzUuNSAtMTQuNXQxNC41IC0zNS41di01MGgtOTAwdjUwcTAgMjEgMTQuNSAzNS41dDM1LjUgMTQuNXoiIC8%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%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjQyOyIgZD0iTTEwMDAgMzAwdjUwcS0yNSAwIC01NSAzMnEtMTQgMTQgLTI1IDMxdC0xNiAyN2wtNCAxMWwtMjg5IDc0N2gtNjlsLTMwMCAtNzU0cS0xOCAtMzUgLTM5IC01NnEtOSAtOSAtMjQuNSAtMTguNXQtMjYuNSAtMTQuNWwtMTEgLTV2LTUwaDI3M3Y1MHEtNDkgMCAtNzguNSAyMS41dC0xMS41IDY3LjVsNjkgMTc2aDI5M2w2MSAtMTY2cTEzIC0zNCAtMy41IC02Ni41dC01NS41IC0zMi41di01MGgzMTJ6TTQxMiA2OTFsMTM0IDM0MmwxMjEgLTM0MiBoLTI1NXpNMTEwMCAxNTB2LTEwMHEwIC0yMSAtMTQuNSAtMzUuNXQtMzUuNSAtMTQuNWgtMTAwMHEtMjEgMCAtMzUuNSAxNC41dC0xNC41IDM1LjV2MTAwcTAgMjEgMTQuNSAzNS41dDM1LjUgMTQuNWgxMDAwcTIxIDAgMzUuNSAtMTQuNXQxNC41IC0zNS41eiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUyNDM7IiBkPSJNNTAgMTIwMGgxMTAwcTIxIDAgMzUuNSAtMTQuNXQxNC41IC0zNS41di0xMTAwcTAgLTIxIC0xNC41IC0zNS41dC0zNS41IC0xNC41aC0xMTAwcS0yMSAwIC0zNS41IDE0LjV0LTE0LjUgMzUuNXYxMTAwcTAgMjEgMTQuNSAzNS41dDM1LjUgMTQuNXpNNjExIDExMThoLTcwcS0xMyAwIC0xOCAtMTJsLTI5OSAtNzUzcS0xNyAtMzIgLTM1IC01MXEtMTggLTE4IC01NiAtMzRxLTEyIC01IC0xMiAtMTh2LTUwcTAgLTggNS41IC0xNHQxNC41IC02IGgyNzNxOCAwIDE0IDZ0NiAxNHY1MHEwIDggLTYgMTR0LTE0IDZxLTU1IDAgLTcxIDIzcS0xMCAxNCAwIDM5bDYzIDE2M2gyNjZsNTcgLTE1M3ExMSAtMzEgLTYgLTU1cS0xMiAtMTcgLTM2IC0xN3EtOCAwIC0xNCAtNnQtNiAtMTR2LTUwcTAgLTggNiAtMTR0MTQgLTZoMzEzcTggMCAxNCA2dDYgMTR2NTBxMCA3IC01LjUgMTN0LTEzLjUgN3EtMTcgMCAtNDIgMjVxLTI1IDI3IC00MCA2M2gtMWwtMjg4IDc0OHEtNSAxMiAtMTkgMTJ6TTYzOSA2MTEgaC0xOTdsMTAzIDI2NHoiIC8%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%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%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%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjUwOyIgZD0iTTg2NSA1NjVsLTQ5NCAtNDk0cS0yMyAtMjMgLTQxIC0yM3EtMTQgMCAtMjIgMTMuNXQtOCAzOC41djEwMDBxMCAyNSA4IDM4LjV0MjIgMTMuNXExOCAwIDQxIC0yM2w0OTQgLTQ5NHExNCAtMTQgMTQgLTM1dC0xNCAtMzV6IiAvPgo8Z2x5cGggdW5pY29kZT0iJiN4ZTI1MTsiIGQ9Ik0zMzUgNjM1bDQ5NCA0OTRxMjkgMjkgNTAgMjAuNXQyMSAtNDkuNXYtMTAwMHEwIC00MSAtMjEgLTQ5LjV0LTUwIDIwLjVsLTQ5NCA0OTRxLTE0IDE0IC0xNCAzNXQxNCAzNXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjUyOyIgZD0iTTEwMCA5MDBoMTAwMHE0MSAwIDQ5LjUgLTIxdC0yMC41IC01MGwtNDk0IC00OTRxLTE0IC0xNCAtMzUgLTE0dC0zNSAxNGwtNDk0IDQ5NHEtMjkgMjkgLTIwLjUgNTB0NDkuNSAyMXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjUzOyIgZD0iTTYzNSA4NjVsNDk0IC00OTRxMjkgLTI5IDIwLjUgLTUwdC00OS41IC0yMWgtMTAwMHEtNDEgMCAtNDkuNSAyMXQyMC41IDUwbDQ5NCA0OTRxMTQgMTQgMzUgMTR0MzUgLTE0eiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUyNTQ7IiBkPSJNNzAwIDc0MXYtMTgybC02OTIgLTMyM3YyMjFsNDEzIDE5M2wtNDEzIDE5M3YyMjF6TTEyMDAgMGgtODAwdjIwMGg4MDB2LTIwMHoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjU1OyIgZD0iTTEyMDAgOTAwaC0yMDB2LTEwMGgyMDB2LTEwMGgtMzAwdjMwMGgyMDB2MTAwaC0yMDB2MTAwaDMwMHYtMzAwek0wIDcwMGg1MHEwIDIxIDQgMzd0OS41IDI2LjV0MTggMTcuNXQyMiAxMXQyOC41IDUuNXQzMSAydDM3IDAuNWgxMDB2LTU1MHEwIC0yMiAtMjUgLTM0LjV0LTUwIC0xMy41bC0yNSAtMnYtMTAwaDQwMHYxMDBxLTQgMCAtMTEgMC41dC0yNCAzdC0zMCA3dC0yNCAxNXQtMTEgMjQuNXY1NTBoMTAwcTI1IDAgMzcgLTAuNXQzMSAtMiB0MjguNSAtNS41dDIyIC0xMXQxOCAtMTcuNXQ5LjUgLTI2LjV0NCAtMzdoNTB2MzAwaC04MDB2LTMwMHoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjU2OyIgZD0iTTgwMCA3MDBoLTUwcTAgMjEgLTQgMzd0LTkuNSAyNi41dC0xOCAxNy41dC0yMiAxMXQtMjguNSA1LjV0LTMxIDJ0LTM3IDAuNWgtMTAwdi01NTBxMCAtMjIgMjUgLTM0LjV0NTAgLTE0LjVsMjUgLTF2LTEwMGgtNDAwdjEwMHE0IDAgMTEgMC41dDI0IDN0MzAgN3QyNCAxNXQxMSAyNC41djU1MGgtMTAwcS0yNSAwIC0zNyAtMC41dC0zMSAtMnQtMjguNSAtNS41dC0yMiAtMTF0LTE4IC0xNy41dC05LjUgLTI2LjV0LTQgLTM3aC01MHYzMDAgaDgwMHYtMzAwek0xMTAwIDIwMGgtMjAwdi0xMDBoMjAwdi0xMDBoLTMwMHYzMDBoMjAwdjEwMGgtMjAwdjEwMGgzMDB2LTMwMHoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjU3OyIgZD0iTTcwMSAxMDk4aDE2MHExNiAwIDIxIC0xMXQtNyAtMjNsLTQ2NCAtNDY0bDQ2NCAtNDY0cTEyIC0xMiA3IC0yM3QtMjEgLTExaC0xNjBxLTEzIDAgLTIzIDlsLTQ3MSA0NzFxLTcgOCAtNyAxOHQ3IDE4bDQ3MSA0NzFxMTAgOSAyMyA5eiIgLz4KPGdseXBoIHVuaWNvZGU9IiYjeGUyNTg7IiBkPSJNMzM5IDEwOThoMTYwcTEzIDAgMjMgLTlsNDcxIC00NzFxNyAtOCA3IC0xOHQtNyAtMThsLTQ3MSAtNDcxcS0xMCAtOSAtMjMgLTloLTE2MHEtMTYgMCAtMjEgMTF0NyAyM2w0NjQgNDY0bC00NjQgNDY0cS0xMiAxMiAtNyAyM3QyMSAxMXoiIC8%2BCjxnbHlwaCB1bmljb2RlPSImI3hlMjU5OyIgZD0iTTEwODcgODgycTExIC01IDExIC0yMXYtMTYwcTAgLTEzIC05IC0yM2wtNDcxIC00NzFxLTggLTcgLTE4IC03dC0xOCA3bC00NzEgNDcxcS05IDEwIC05IDIzdjE2MHEwIDE2IDExIDIxdDIzIC03bDQ2NCAtNDY0bDQ2NCA0NjRxMTIgMTIgMjMgN3oiIC8%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%2BCjwvZGVmcz48L3N2Zz4g%29%20format%28%27svg%27%29%7D%2Eglyphicon%7Bposition%3Arelative%3Btop%3A1px%3Bdisplay%3Ainline%2Dblock%3Bfont%2Dfamily%3A%27Glyphicons%20Halflings%27%3Bfont%2Dstyle%3Anormal%3Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%3B%2Dwebkit%2Dfont%2Dsmoothing%3Aantialiased%3B%2Dmoz%2Dosx%2Dfont%2Dsmoothing%3Agrayscale%7D%2Eglyphicon%2Dasterisk%3Abefore%7Bcontent%3A%22%5C2a%22%7D%2Eglyphicon%2Dplus%3Abefore%7Bcontent%3A%22%5C2b%22%7D%2Eglyphicon%2Deur%3Abefore%2C%2Eglyphicon%2Deuro%3Abefore%7Bcontent%3A%22%5C20ac%22%7D%2Eglyphicon%2Dminus%3Abefore%7Bcontent%3A%22%5C2212%22%7D%2Eglyphicon%2Dcloud%3Abefore%7Bcontent%3A%22%5C2601%22%7D%2Eglyphicon%2Denvelope%3Abefore%7Bcontent%3A%22%5C2709%22%7D%2Eglyphicon%2Dpencil%3Abefore%7Bcontent%3A%22%5C270f%22%7D%2Eglyphicon%2Dglass%3Abefore%7Bcontent%3A%22%5Ce001%22%7D%2Eglyphicon%2Dmusic%3Abefore%7Bcontent%3A%22%5Ce002%22%7D%2Eglyphicon%2Dsearch%3Abefore%7Bcontent%3A%22%5Ce003%22%7D%2Eglyphicon%2Dheart%3Abefore%7Bcontent%3A%22%5Ce005%22%7D%2Eglyphicon%2Dstar%3Abefore%7Bcontent%3A%22%5Ce006%22%7D%2Eglyphicon%2Dstar%2Dempty%3Abefore%7Bcontent%3A%22%5Ce007%22%7D%2Eglyphicon%2Duser%3Abefore%7Bcontent%3A%22%5Ce008%22%7D%2Eglyphicon%2Dfilm%3Abefore%7Bcontent%3A%22%5Ce009%22%7D%2Eglyphicon%2Dth%2Dlarge%3Abefore%7Bcontent%3A%22%5Ce010%22%7D%2Eglyphicon%2Dth%3Abefore%7Bcontent%3A%22%5Ce011%22%7D%2Eglyphicon%2Dth%2Dlist%3Abefore%7Bcontent%3A%22%5Ce012%22%7D%2Eglyphicon%2Dok%3Abefore%7Bcontent%3A%22%5Ce013%22%7D%2Eglyphicon%2Dremove%3Abefore%7Bcontent%3A%22%5Ce014%22%7D%2Eglyphicon%2Dzoom%2Din%3Abefore%7Bcontent%3A%22%5Ce015%22%7D%2Eglyphicon%2Dzoom%2Dout%3Abefore%7Bcontent%3A%22%5Ce016%22%7D%2Eglyphicon%2Doff%3Abefore%7Bcontent%3A%22%5Ce017%22%7D%2Eglyphicon%2Dsignal%3Abefore%7Bcontent%3A%22%5Ce018%22%7D%2Eglyphicon%2Dcog%3Abefore%7Bcontent%3A%22%5Ce019%22%7D%2Eglyphicon%2Dtrash%3Abefore%7Bcontent%3A%22%5Ce020%22%7D%2Eglyphicon%2Dhome%3Abefore%7Bcontent%3A%22%5Ce021%22%7D%2Eglyphicon%2Dfile%3Abefore%7Bcontent%3A%22%5Ce022%22%7D%2Eglyphicon%2Dtime%3Abefore%7Bcontent%3A%22%5Ce023%22%7D%2Eglyphicon%2Droad%3Abefore%7Bcontent%3A%22%5Ce024%22%7D%2Eglyphicon%2Ddownload%2Dalt%3Abefore%7Bcontent%3A%22%5Ce025%22%7D%2Eglyphicon%2Ddownload%3Abefore%7Bcontent%3A%22%5Ce026%22%7D%2Eglyphicon%2Dupload%3Abefore%7Bcontent%3A%22%5Ce027%22%7D%2Eglyphicon%2Dinbox%3Abefore%7Bcontent%3A%22%5Ce028%22%7D%2Eglyphicon%2Dplay%2Dcircle%3Abefore%7Bcontent%3A%22%5Ce029%22%7D%2Eglyphicon%2Drepeat%3Abefore%7Bcontent%3A%22%5Ce030%22%7D%2Eglyphicon%2Drefresh%3Abefore%7Bcontent%3A%22%5Ce031%22%7D%2Eglyphicon%2Dlist%2Dalt%3Abefore%7Bcontent%3A%22%5Ce032%22%7D%2Eglyphicon%2Dlock%3Abefore%7Bcontent%3A%22%5Ce033%22%7D%2Eglyphicon%2Dflag%3Abefore%7Bcontent%3A%22%5Ce034%22%7D%2Eglyphicon%2Dheadphones%3Abefore%7Bcontent%3A%22%5Ce035%22%7D%2Eglyphicon%2Dvolume%2Doff%3Abefore%7Bcontent%3A%22%5Ce036%22%7D%2Eglyphicon%2Dvolume%2Ddown%3Abefore%7Bcontent%3A%22%5Ce037%22%7D%2Eglyphicon%2Dvolume%2Dup%3Abefore%7Bcontent%3A%22%5Ce038%22%7D%2Eglyphicon%2Dqrcode%3Abefore%7Bcontent%3A%22%5Ce039%22%7D%2Eglyphicon%2Dbarcode%3Abefore%7Bcontent%3A%22%5Ce040%22%7D%2Eglyphicon%2Dtag%3Abefore%7Bcontent%3A%22%5Ce041%22%7D%2Eglyphicon%2Dtags%3Abefore%7Bcontent%3A%22%5Ce042%22%7D%2Eglyphicon%2Dbook%3Abefore%7Bcontent%3A%22%5Ce043%22%7D%2Eglyphicon%2Dbookmark%3Abefore%7Bcontent%3A%22%5Ce044%22%7D%2Eglyphicon%2Dprint%3Abefore%7Bcontent%3A%22%5Ce045%22%7D%2Eglyphicon%2Dcamera%3Abefore%7Bcontent%3A%22%5Ce046%22%7D%2Eglyphicon%2Dfont%3Abefore%7Bcontent%3A%22%5Ce047%22%7D%2Eglyphicon%2Dbold%3Abefore%7Bcontent%3A%22%5Ce048%22%7D%2Eglyphicon%2Ditalic%3Abefore%7Bcontent%3A%22%5Ce049%22%7D%2Eglyphicon%2Dtext%2Dheight%3Abefore%7Bcontent%3A%22%5Ce050%22%7D%2Eglyphicon%2Dtext%2Dwidth%3Abefore%7Bcontent%3A%22%5Ce051%22%7D%2Eglyphicon%2Dalign%2Dleft%3Abefore%7Bcontent%3A%22%5Ce052%22%7D%2Eglyphicon%2Dalign%2Dcenter%3Abefore%7Bcontent%3A%22%5Ce053%22%7D%2Eglyphicon%2Dalign%2Dright%3Abefore%7Bcontent%3A%22%5Ce054%22%7D%2Eglyphicon%2Dalign%2Djustify%3Abefore%7Bcontent%3A%22%5Ce055%22%7D%2Eglyphicon%2Dlist%3Abefore%7Bcontent%3A%22%5Ce056%22%7D%2Eglyphicon%2Dindent%2Dleft%3Abefore%7Bcontent%3A%22%5Ce057%22%7D%2Eglyphicon%2Dindent%2Dright%3Abefore%7Bcontent%3A%22%5Ce058%22%7D%2Eglyphicon%2Dfacetime%2Dvideo%3Abefore%7Bcontent%3A%22%5Ce059%22%7D%2Eglyphicon%2Dpicture%3Abefore%7Bcontent%3A%22%5Ce060%22%7D%2Eglyphicon%2Dmap%2Dmarker%3Abefore%7Bcontent%3A%22%5Ce062%22%7D%2Eglyphicon%2Dadjust%3Abefore%7Bcontent%3A%22%5Ce063%22%7D%2Eglyphicon%2Dtint%3Abefore%7Bcontent%3A%22%5Ce064%22%7D%2Eglyphicon%2Dedit%3Abefore%7Bcontent%3A%22%5Ce065%22%7D%2Eglyphicon%2Dshare%3Abefore%7Bcontent%3A%22%5Ce066%22%7D%2Eglyphicon%2Dcheck%3Abefore%7Bcontent%3A%22%5Ce067%22%7D%2Eglyphicon%2Dmove%3Abefore%7Bcontent%3A%22%5Ce068%22%7D%2Eglyphicon%2Dstep%2Dbackward%3Abefore%7Bcontent%3A%22%5Ce069%22%7D%2Eglyphicon%2Dfast%2Dbackward%3Abefore%7Bcontent%3A%22%5Ce070%22%7D%2Eglyphicon%2Dbackward%3Abefore%7Bcontent%3A%22%5Ce071%22%7D%2Eglyphicon%2Dplay%3Abefore%7Bcontent%3A%22%5Ce072%22%7D%2Eglyphicon%2Dpause%3Abefore%7Bcontent%3A%22%5Ce073%22%7D%2Eglyphicon%2Dstop%3Abefore%7Bcontent%3A%22%5Ce074%22%7D%2Eglyphicon%2Dforward%3Abefore%7Bcontent%3A%22%5Ce075%22%7D%2Eglyphicon%2Dfast%2Dforward%3Abefore%7Bcontent%3A%22%5Ce076%22%7D%2Eglyphicon%2Dstep%2Dforward%3Abefore%7Bcontent%3A%22%5Ce077%22%7D%2Eglyphicon%2Deject%3Abefore%7Bcontent%3A%22%5Ce078%22%7D%2Eglyphicon%2Dchevron%2Dleft%3Abefore%7Bcontent%3A%22%5Ce079%22%7D%2Eglyphicon%2Dchevron%2Dright%3Abefore%7Bcontent%3A%22%5Ce080%22%7D%2Eglyphicon%2Dplus%2Dsign%3Abefore%7Bcontent%3A%22%5Ce081%22%7D%2Eglyphicon%2Dminus%2Dsign%3Abefore%7Bcontent%3A%22%5Ce082%22%7D%2Eglyphicon%2Dremove%2Dsign%3Abefore%7Bcontent%3A%22%5Ce083%22%7D%2Eglyphicon%2Dok%2Dsign%3Abefore%7Bcontent%3A%22%5Ce084%22%7D%2Eglyphicon%2Dquestion%2Dsign%3Abefore%7Bcontent%3A%22%5Ce085%22%7D%2Eglyphicon%2Dinfo%2Dsign%3Abefore%7Bcontent%3A%22%5Ce086%22%7D%2Eglyphicon%2Dscreenshot%3Abefore%7Bcontent%3A%22%5Ce087%22%7D%2Eglyphicon%2Dremove%2Dcircle%3Abefore%7Bcontent%3A%22%5Ce088%22%7D%2Eglyphicon%2Dok%2Dcircle%3Abefore%7Bcontent%3A%22%5Ce089%22%7D%2Eglyphicon%2Dban%2Dcircle%3Abefore%7Bcontent%3A%22%5Ce090%22%7D%2Eglyphicon%2Darrow%2Dleft%3Abefore%7Bcontent%3A%22%5Ce091%22%7D%2Eglyphicon%2Darrow%2Dright%3Abefore%7Bcontent%3A%22%5Ce092%22%7D%2Eglyphicon%2Darrow%2Dup%3Abefore%7Bcontent%3A%22%5Ce093%22%7D%2Eglyphicon%2Darrow%2Ddown%3Abefore%7Bcontent%3A%22%5Ce094%22%7D%2Eglyphicon%2Dshare%2Dalt%3Abefore%7Bcontent%3A%22%5Ce095%22%7D%2Eglyphicon%2Dresize%2Dfull%3Abefore%7Bcontent%3A%22%5Ce096%22%7D%2Eglyphicon%2Dresize%2Dsmall%3Abefore%7Bcontent%3A%22%5Ce097%22%7D%2Eglyphicon%2Dexclamation%2Dsign%3Abefore%7Bcontent%3A%22%5Ce101%22%7D%2Eglyphicon%2Dgift%3Abefore%7Bcontent%3A%22%5Ce102%22%7D%2Eglyphicon%2Dleaf%3Abefore%7Bcontent%3A%22%5Ce103%22%7D%2Eglyphicon%2Dfire%3Abefore%7Bcontent%3A%22%5Ce104%22%7D%2Eglyphicon%2Deye%2Dopen%3Abefore%7Bcontent%3A%22%5Ce105%22%7D%2Eglyphicon%2Deye%2Dclose%3Abefore%7Bcontent%3A%22%5Ce106%22%7D%2Eglyphicon%2Dwarning%2Dsign%3Abefore%7Bcontent%3A%22%5Ce107%22%7D%2Eglyphicon%2Dplane%3Abefore%7Bcontent%3A%22%5Ce108%22%7D%2Eglyphicon%2Dcalendar%3Abefore%7Bcontent%3A%22%5Ce109%22%7D%2Eglyphicon%2Drandom%3Abefore%7Bcontent%3A%22%5Ce110%22%7D%2Eglyphicon%2Dcomment%3Abefore%7Bcontent%3A%22%5Ce111%22%7D%2Eglyphicon%2Dmagnet%3Abefore%7Bcontent%3A%22%5Ce112%22%7D%2Eglyphicon%2Dchevron%2Dup%3Abefore%7Bcontent%3A%22%5Ce113%22%7D%2Eglyphicon%2Dchevron%2Ddown%3Abefore%7Bcontent%3A%22%5Ce114%22%7D%2Eglyphicon%2Dretweet%3Abefore%7Bcontent%3A%22%5Ce115%22%7D%2Eglyphicon%2Dshopping%2Dcart%3Abefore%7Bcontent%3A%22%5Ce116%22%7D%2Eglyphicon%2Dfolder%2Dclose%3Abefore%7Bcontent%3A%22%5Ce117%22%7D%2Eglyphicon%2Dfolder%2Dopen%3Abefore%7Bcontent%3A%22%5Ce118%22%7D%2Eglyphicon%2Dresize%2Dvertical%3Abefore%7Bcontent%3A%22%5Ce119%22%7D%2Eglyphicon%2Dresize%2Dhorizontal%3Abefore%7Bcontent%3A%22%5Ce120%22%7D%2Eglyphicon%2Dhdd%3Abefore%7Bcontent%3A%22%5Ce121%22%7D%2Eglyphicon%2Dbullhorn%3Abefore%7Bcontent%3A%22%5Ce122%22%7D%2Eglyphicon%2Dbell%3Abefore%7Bcontent%3A%22%5Ce123%22%7D%2Eglyphicon%2Dcertificate%3Abefore%7Bcontent%3A%22%5Ce124%22%7D%2Eglyphicon%2Dthumbs%2Dup%3Abefore%7Bcontent%3A%22%5Ce125%22%7D%2Eglyphicon%2Dthumbs%2Ddown%3Abefore%7Bcontent%3A%22%5Ce126%22%7D%2Eglyphicon%2Dhand%2Dright%3Abefore%7Bcontent%3A%22%5Ce127%22%7D%2Eglyphicon%2Dhand%2Dleft%3Abefore%7Bcontent%3A%22%5Ce128%22%7D%2Eglyphicon%2Dhand%2Dup%3Abefore%7Bcontent%3A%22%5Ce129%22%7D%2Eglyphicon%2Dhand%2Ddown%3Abefore%7Bcontent%3A%22%5Ce130%22%7D%2Eglyphicon%2Dcircle%2Darrow%2Dright%3Abefore%7Bcontent%3A%22%5Ce131%22%7D%2Eglyphicon%2Dcircle%2Darrow%2Dleft%3Abefore%7Bcontent%3A%22%5Ce132%22%7D%2Eglyphicon%2Dcircle%2Darrow%2Dup%3Abefore%7Bcontent%3A%22%5Ce133%22%7D%2Eglyphicon%2Dcircle%2Darrow%2Ddown%3Abefore%7Bcontent%3A%22%5Ce134%22%7D%2Eglyphicon%2Dglobe%3Abefore%7Bcontent%3A%22%5Ce135%22%7D%2Eglyphicon%2Dwrench%3Abefore%7Bcontent%3A%22%5Ce136%22%7D%2Eglyphicon%2Dtasks%3Abefore%7Bcontent%3A%22%5Ce137%22%7D%2Eglyphicon%2Dfilter%3Abefore%7Bcontent%3A%22%5Ce138%22%7D%2Eglyphicon%2Dbriefcase%3Abefore%7Bcontent%3A%22%5Ce139%22%7D%2Eglyphicon%2Dfullscreen%3Abefore%7Bcontent%3A%22%5Ce140%22%7D%2Eglyphicon%2Ddashboard%3Abefore%7Bcontent%3A%22%5Ce141%22%7D%2Eglyphicon%2Dpaperclip%3Abefore%7Bcontent%3A%22%5Ce142%22%7D%2Eglyphicon%2Dheart%2Dempty%3Abefore%7Bcontent%3A%22%5Ce143%22%7D%2Eglyphicon%2Dlink%3Abefore%7Bcontent%3A%22%5Ce144%22%7D%2Eglyphicon%2Dphone%3Abefore%7Bcontent%3A%22%5Ce145%22%7D%2Eglyphicon%2Dpushpin%3Abefore%7Bcontent%3A%22%5Ce146%22%7D%2Eglyphicon%2Dusd%3Abefore%7Bcontent%3A%22%5Ce148%22%7D%2Eglyphicon%2Dgbp%3Abefore%7Bcontent%3A%22%5Ce149%22%7D%2Eglyphicon%2Dsort%3Abefore%7Bcontent%3A%22%5Ce150%22%7D%2Eglyphicon%2Dsort%2Dby%2Dalphabet%3Abefore%7Bcontent%3A%22%5Ce151%22%7D%2Eglyphicon%2Dsort%2Dby%2Dalphabet%2Dalt%3Abefore%7Bcontent%3A%22%5Ce152%22%7D%2Eglyphicon%2Dsort%2Dby%2Dorder%3Abefore%7Bcontent%3A%22%5Ce153%22%7D%2Eglyphicon%2Dsort%2Dby%2Dorder%2Dalt%3Abefore%7Bcontent%3A%22%5Ce154%22%7D%2Eglyphicon%2Dsort%2Dby%2Dattributes%3Abefore%7Bcontent%3A%22%5Ce155%22%7D%2Eglyphicon%2Dsort%2Dby%2Dattributes%2Dalt%3Abefore%7Bcontent%3A%22%5Ce156%22%7D%2Eglyphicon%2Dunchecked%3Abefore%7Bcontent%3A%22%5Ce157%22%7D%2Eglyphicon%2Dexpand%3Abefore%7Bcontent%3A%22%5Ce158%22%7D%2Eglyphicon%2Dcollapse%2Ddown%3Abefore%7Bcontent%3A%22%5Ce159%22%7D%2Eglyphicon%2Dcollapse%2Dup%3Abefore%7Bcontent%3A%22%5Ce160%22%7D%2Eglyphicon%2Dlog%2Din%3Abefore%7Bcontent%3A%22%5Ce161%22%7D%2Eglyphicon%2Dflash%3Abefore%7Bcontent%3A%22%5Ce162%22%7D%2Eglyphicon%2Dlog%2Dout%3Abefore%7Bcontent%3A%22%5Ce163%22%7D%2Eglyphicon%2Dnew%2Dwindow%3Abefore%7Bcontent%3A%22%5Ce164%22%7D%2Eglyphicon%2Drecord%3Abefore%7Bcontent%3A%22%5Ce165%22%7D%2Eglyphicon%2Dsave%3Abefore%7Bcontent%3A%22%5Ce166%22%7D%2Eglyphicon%2Dopen%3Abefore%7Bcontent%3A%22%5Ce167%22%7D%2Eglyphicon%2Dsaved%3Abefore%7Bcontent%3A%22%5Ce168%22%7D%2Eglyphicon%2Dimport%3Abefore%7Bcontent%3A%22%5Ce169%22%7D%2Eglyphicon%2Dexport%3Abefore%7Bcontent%3A%22%5Ce170%22%7D%2Eglyphicon%2Dsend%3Abefore%7Bcontent%3A%22%5Ce171%22%7D%2Eglyphicon%2Dfloppy%2Ddisk%3Abefore%7Bcontent%3A%22%5Ce172%22%7D%2Eglyphicon%2Dfloppy%2Dsaved%3Abefore%7Bcontent%3A%22%5Ce173%22%7D%2Eglyphicon%2Dfloppy%2Dremove%3Abefore%7Bcontent%3A%22%5Ce174%22%7D%2Eglyphicon%2Dfloppy%2Dsave%3Abefore%7Bcontent%3A%22%5Ce175%22%7D%2Eglyphicon%2Dfloppy%2Dopen%3Abefore%7Bcontent%3A%22%5Ce176%22%7D%2Eglyphicon%2Dcredit%2Dcard%3Abefore%7Bcontent%3A%22%5Ce177%22%7D%2Eglyphicon%2Dtransfer%3Abefore%7Bcontent%3A%22%5Ce178%22%7D%2Eglyphicon%2Dcutlery%3Abefore%7Bcontent%3A%22%5Ce179%22%7D%2Eglyphicon%2Dheader%3Abefore%7Bcontent%3A%22%5Ce180%22%7D%2Eglyphicon%2Dcompressed%3Abefore%7Bcontent%3A%22%5Ce181%22%7D%2Eglyphicon%2Dearphone%3Abefore%7Bcontent%3A%22%5Ce182%22%7D%2Eglyphicon%2Dphone%2Dalt%3Abefore%7Bcontent%3A%22%5Ce183%22%7D%2Eglyphicon%2Dtower%3Abefore%7Bcontent%3A%22%5Ce184%22%7D%2Eglyphicon%2Dstats%3Abefore%7Bcontent%3A%22%5Ce185%22%7D%2Eglyphicon%2Dsd%2Dvideo%3Abefore%7Bcontent%3A%22%5Ce186%22%7D%2Eglyphicon%2Dhd%2Dvideo%3Abefore%7Bcontent%3A%22%5Ce187%22%7D%2Eglyphicon%2Dsubtitles%3Abefore%7Bcontent%3A%22%5Ce188%22%7D%2Eglyphicon%2Dsound%2Dstereo%3Abefore%7Bcontent%3A%22%5Ce189%22%7D%2Eglyphicon%2Dsound%2Ddolby%3Abefore%7Bcontent%3A%22%5Ce190%22%7D%2Eglyphicon%2Dsound%2D5%2D1%3Abefore%7Bcontent%3A%22%5Ce191%22%7D%2Eglyphicon%2Dsound%2D6%2D1%3Abefore%7Bcontent%3A%22%5Ce192%22%7D%2Eglyphicon%2Dsound%2D7%2D1%3Abefore%7Bcontent%3A%22%5Ce193%22%7D%2Eglyphicon%2Dcopyright%2Dmark%3Abefore%7Bcontent%3A%22%5Ce194%22%7D%2Eglyphicon%2Dregistration%2Dmark%3Abefore%7Bcontent%3A%22%5Ce195%22%7D%2Eglyphicon%2Dcloud%2Ddownload%3Abefore%7Bcontent%3A%22%5Ce197%22%7D%2Eglyphicon%2Dcloud%2Dupload%3Abefore%7Bcontent%3A%22%5Ce198%22%7D%2Eglyphicon%2Dtree%2Dconifer%3Abefore%7Bcontent%3A%22%5Ce199%22%7D%2Eglyphicon%2Dtree%2Ddeciduous%3Abefore%7Bcontent%3A%22%5Ce200%22%7D%2Eglyphicon%2Dcd%3Abefore%7Bcontent%3A%22%5Ce201%22%7D%2Eglyphicon%2Dsave%2Dfile%3Abefore%7Bcontent%3A%22%5Ce202%22%7D%2Eglyphicon%2Dopen%2Dfile%3Abefore%7Bcontent%3A%22%5Ce203%22%7D%2Eglyphicon%2Dlevel%2Dup%3Abefore%7Bcontent%3A%22%5Ce204%22%7D%2Eglyphicon%2Dcopy%3Abefore%7Bcontent%3A%22%5Ce205%22%7D%2Eglyphicon%2Dpaste%3Abefore%7Bcontent%3A%22%5Ce206%22%7D%2Eglyphicon%2Dalert%3Abefore%7Bcontent%3A%22%5Ce209%22%7D%2Eglyphicon%2Dequalizer%3Abefore%7Bcontent%3A%22%5Ce210%22%7D%2Eglyphicon%2Dking%3Abefore%7Bcontent%3A%22%5Ce211%22%7D%2Eglyphicon%2Dqueen%3Abefore%7Bcontent%3A%22%5Ce212%22%7D%2Eglyphicon%2Dpawn%3Abefore%7Bcontent%3A%22%5Ce213%22%7D%2Eglyphicon%2Dbishop%3Abefore%7Bcontent%3A%22%5Ce214%22%7D%2Eglyphicon%2Dknight%3Abefore%7Bcontent%3A%22%5Ce215%22%7D%2Eglyphicon%2Dbaby%2Dformula%3Abefore%7Bcontent%3A%22%5Ce216%22%7D%2Eglyphicon%2Dtent%3Abefore%7Bcontent%3A%22%5C26fa%22%7D%2Eglyphicon%2Dblackboard%3Abefore%7Bcontent%3A%22%5Ce218%22%7D%2Eglyphicon%2Dbed%3Abefore%7Bcontent%3A%22%5Ce219%22%7D%2Eglyphicon%2Dapple%3Abefore%7Bcontent%3A%22%5Cf8ff%22%7D%2Eglyphicon%2Derase%3Abefore%7Bcontent%3A%22%5Ce221%22%7D%2Eglyphicon%2Dhourglass%3Abefore%7Bcontent%3A%22%5C231b%22%7D%2Eglyphicon%2Dlamp%3Abefore%7Bcontent%3A%22%5Ce223%22%7D%2Eglyphicon%2Dduplicate%3Abefore%7Bcontent%3A%22%5Ce224%22%7D%2Eglyphicon%2Dpiggy%2Dbank%3Abefore%7Bcontent%3A%22%5Ce225%22%7D%2Eglyphicon%2Dscissors%3Abefore%7Bcontent%3A%22%5Ce226%22%7D%2Eglyphicon%2Dbitcoin%3Abefore%7Bcontent%3A%22%5Ce227%22%7D%2Eglyphicon%2Dbtc%3Abefore%7Bcontent%3A%22%5Ce227%22%7D%2Eglyphicon%2Dxbt%3Abefore%7Bcontent%3A%22%5Ce227%22%7D%2Eglyphicon%2Dyen%3Abefore%7Bcontent%3A%22%5C00a5%22%7D%2Eglyphicon%2Djpy%3Abefore%7Bcontent%3A%22%5C00a5%22%7D%2Eglyphicon%2Druble%3Abefore%7Bcontent%3A%22%5C20bd%22%7D%2Eglyphicon%2Drub%3Abefore%7Bcontent%3A%22%5C20bd%22%7D%2Eglyphicon%2Dscale%3Abefore%7Bcontent%3A%22%5Ce230%22%7D%2Eglyphicon%2Dice%2Dlolly%3Abefore%7Bcontent%3A%22%5Ce231%22%7D%2Eglyphicon%2Dice%2Dlolly%2Dtasted%3Abefore%7Bcontent%3A%22%5Ce232%22%7D%2Eglyphicon%2Deducation%3Abefore%7Bcontent%3A%22%5Ce233%22%7D%2Eglyphicon%2Doption%2Dhorizontal%3Abefore%7Bcontent%3A%22%5Ce234%22%7D%2Eglyphicon%2Doption%2Dvertical%3Abefore%7Bcontent%3A%22%5Ce235%22%7D%2Eglyphicon%2Dmenu%2Dhamburger%3Abefore%7Bcontent%3A%22%5Ce236%22%7D%2Eglyphicon%2Dmodal%2Dwindow%3Abefore%7Bcontent%3A%22%5Ce237%22%7D%2Eglyphicon%2Doil%3Abefore%7Bcontent%3A%22%5Ce238%22%7D%2Eglyphicon%2Dgrain%3Abefore%7Bcontent%3A%22%5Ce239%22%7D%2Eglyphicon%2Dsunglasses%3Abefore%7Bcontent%3A%22%5Ce240%22%7D%2Eglyphicon%2Dtext%2Dsize%3Abefore%7Bcontent%3A%22%5Ce241%22%7D%2Eglyphicon%2Dtext%2Dcolor%3Abefore%7Bcontent%3A%22%5Ce242%22%7D%2Eglyphicon%2Dtext%2Dbackground%3Abefore%7Bcontent%3A%22%5Ce243%22%7D%2Eglyphicon%2Dobject%2Dalign%2Dtop%3Abefore%7Bcontent%3A%22%5Ce244%22%7D%2Eglyphicon%2Dobject%2Dalign%2Dbottom%3Abefore%7Bcontent%3A%22%5Ce245%22%7D%2Eglyphicon%2Dobject%2Dalign%2Dhorizontal%3Abefore%7Bcontent%3A%22%5Ce246%22%7D%2Eglyphicon%2Dobject%2Dalign%2Dleft%3Abefore%7Bcontent%3A%22%5Ce247%22%7D%2Eglyphicon%2Dobject%2Dalign%2Dvertical%3Abefore%7Bcontent%3A%22%5Ce248%22%7D%2Eglyphicon%2Dobject%2Dalign%2Dright%3Abefore%7Bcontent%3A%22%5Ce249%22%7D%2Eglyphicon%2Dtriangle%2Dright%3Abefore%7Bcontent%3A%22%5Ce250%22%7D%2Eglyphicon%2Dtriangle%2Dleft%3Abefore%7Bcontent%3A%22%5Ce251%22%7D%2Eglyphicon%2Dtriangle%2Dbottom%3Abefore%7Bcontent%3A%22%5Ce252%22%7D%2Eglyphicon%2Dtriangle%2Dtop%3Abefore%7Bcontent%3A%22%5Ce253%22%7D%2Eglyphicon%2Dconsole%3Abefore%7Bcontent%3A%22%5Ce254%22%7D%2Eglyphicon%2Dsuperscript%3Abefore%7Bcontent%3A%22%5Ce255%22%7D%2Eglyphicon%2Dsubscript%3Abefore%7Bcontent%3A%22%5Ce256%22%7D%2Eglyphicon%2Dmenu%2Dleft%3Abefore%7Bcontent%3A%22%5Ce257%22%7D%2Eglyphicon%2Dmenu%2Dright%3Abefore%7Bcontent%3A%22%5Ce258%22%7D%2Eglyphicon%2Dmenu%2Ddown%3Abefore%7Bcontent%3A%22%5Ce259%22%7D%2Eglyphicon%2Dmenu%2Dup%3Abefore%7Bcontent%3A%22%5Ce260%22%7D%2A%7B%2Dwebkit%2Dbox%2Dsizing%3Aborder%2Dbox%3B%2Dmoz%2Dbox%2Dsizing%3Aborder%2Dbox%3Bbox%2Dsizing%3Aborder%2Dbox%7D%3Aafter%2C%3Abefore%7B%2Dwebkit%2Dbox%2Dsizing%3Aborder%2Dbox%3B%2Dmoz%2Dbox%2Dsizing%3Aborder%2Dbox%3Bbox%2Dsizing%3Aborder%2Dbox%7Dhtml%7Bfont%2Dsize%3A10px%3B%2Dwebkit%2Dtap%2Dhighlight%2Dcolor%3Argba%280%2C0%2C0%2C0%29%7Dbody%7Bfont%2Dfamily%3A%22Helvetica%20Neue%22%2CHelvetica%2CArial%2Csans%2Dserif%3Bfont%2Dsize%3A14px%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23fff%7Dbutton%2Cinput%2Cselect%2Ctextarea%7Bfont%2Dfamily%3Ainherit%3Bfont%2Dsize%3Ainherit%3Bline%2Dheight%3Ainherit%7Da%7Bcolor%3A%23337ab7%3Btext%2Ddecoration%3Anone%7Da%3Afocus%2Ca%3Ahover%7Bcolor%3A%2323527c%3Btext%2Ddecoration%3Aunderline%7Da%3Afocus%7Boutline%3Athin%20dotted%3Boutline%3A5px%20auto%20%2Dwebkit%2Dfocus%2Dring%2Dcolor%3Boutline%2Doffset%3A%2D2px%7Dfigure%7Bmargin%3A0%7Dimg%7Bvertical%2Dalign%3Amiddle%7D%2Ecarousel%2Dinner%3E%2Eitem%3Ea%3Eimg%2C%2Ecarousel%2Dinner%3E%2Eitem%3Eimg%2C%2Eimg%2Dresponsive%2C%2Ethumbnail%20a%3Eimg%2C%2Ethumbnail%3Eimg%7Bdisplay%3Ablock%3Bmax%2Dwidth%3A100%25%3Bheight%3Aauto%7D%2Eimg%2Drounded%7Bborder%2Dradius%3A6px%7D%2Eimg%2Dthumbnail%7Bdisplay%3Ainline%2Dblock%3Bmax%2Dwidth%3A100%25%3Bheight%3Aauto%3Bpadding%3A4px%3Bline%2Dheight%3A1%2E42857143%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20%23ddd%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dtransition%3Aall%20%2E2s%20ease%2Din%2Dout%3B%2Do%2Dtransition%3Aall%20%2E2s%20ease%2Din%2Dout%3Btransition%3Aall%20%2E2s%20ease%2Din%2Dout%7D%2Eimg%2Dcircle%7Bborder%2Dradius%3A50%25%7Dhr%7Bmargin%2Dtop%3A20px%3Bmargin%2Dbottom%3A20px%3Bborder%3A0%3Bborder%2Dtop%3A1px%20solid%20%23eee%7D%2Esr%2Donly%7Bposition%3Aabsolute%3Bwidth%3A1px%3Bheight%3A1px%3Bpadding%3A0%3Bmargin%3A%2D1px%3Boverflow%3Ahidden%3Bclip%3Arect%280%2C0%2C0%2C0%29%3Bborder%3A0%7D%2Esr%2Donly%2Dfocusable%3Aactive%2C%2Esr%2Donly%2Dfocusable%3Afocus%7Bposition%3Astatic%3Bwidth%3Aauto%3Bheight%3Aauto%3Bmargin%3A0%3Boverflow%3Avisible%3Bclip%3Aauto%7D%5Brole%3Dbutton%5D%7Bcursor%3Apointer%7D%2Eh1%2C%2Eh2%2C%2Eh3%2C%2Eh4%2C%2Eh5%2C%2Eh6%2Ch1%2Ch2%2Ch3%2Ch4%2Ch5%2Ch6%7Bfont%2Dfamily%3Ainherit%3Bfont%2Dweight%3A500%3Bline%2Dheight%3A1%2E1%3Bcolor%3Ainherit%7D%2Eh1%20%2Esmall%2C%2Eh1%20small%2C%2Eh2%20%2Esmall%2C%2Eh2%20small%2C%2Eh3%20%2Esmall%2C%2Eh3%20small%2C%2Eh4%20%2Esmall%2C%2Eh4%20small%2C%2Eh5%20%2Esmall%2C%2Eh5%20small%2C%2Eh6%20%2Esmall%2C%2Eh6%20small%2Ch1%20%2Esmall%2Ch1%20small%2Ch2%20%2Esmall%2Ch2%20small%2Ch3%20%2Esmall%2Ch3%20small%2Ch4%20%2Esmall%2Ch4%20small%2Ch5%20%2Esmall%2Ch5%20small%2Ch6%20%2Esmall%2Ch6%20small%7Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%3Bcolor%3A%23777%7D%2Eh1%2C%2Eh2%2C%2Eh3%2Ch1%2Ch2%2Ch3%7Bmargin%2Dtop%3A20px%3Bmargin%2Dbottom%3A10px%7D%2Eh1%20%2Esmall%2C%2Eh1%20small%2C%2Eh2%20%2Esmall%2C%2Eh2%20small%2C%2Eh3%20%2Esmall%2C%2Eh3%20small%2Ch1%20%2Esmall%2Ch1%20small%2Ch2%20%2Esmall%2Ch2%20small%2Ch3%20%2Esmall%2Ch3%20small%7Bfont%2Dsize%3A65%25%7D%2Eh4%2C%2Eh5%2C%2Eh6%2Ch4%2Ch5%2Ch6%7Bmargin%2Dtop%3A10px%3Bmargin%2Dbottom%3A10px%7D%2Eh4%20%2Esmall%2C%2Eh4%20small%2C%2Eh5%20%2Esmall%2C%2Eh5%20small%2C%2Eh6%20%2Esmall%2C%2Eh6%20small%2Ch4%20%2Esmall%2Ch4%20small%2Ch5%20%2Esmall%2Ch5%20small%2Ch6%20%2Esmall%2Ch6%20small%7Bfont%2Dsize%3A75%25%7D%2Eh1%2Ch1%7Bfont%2Dsize%3A36px%7D%2Eh2%2Ch2%7Bfont%2Dsize%3A30px%7D%2Eh3%2Ch3%7Bfont%2Dsize%3A24px%7D%2Eh4%2Ch4%7Bfont%2Dsize%3A18px%7D%2Eh5%2Ch5%7Bfont%2Dsize%3A14px%7D%2Eh6%2Ch6%7Bfont%2Dsize%3A12px%7Dp%7Bmargin%3A0%200%2010px%7D%2Elead%7Bmargin%2Dbottom%3A20px%3Bfont%2Dsize%3A16px%3Bfont%2Dweight%3A300%3Bline%2Dheight%3A1%2E4%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Elead%7Bfont%2Dsize%3A21px%7D%7D%2Esmall%2Csmall%7Bfont%2Dsize%3A85%25%7D%2Emark%2Cmark%7Bpadding%3A%2E2em%3Bbackground%2Dcolor%3A%23fcf8e3%7D%2Etext%2Dleft%7Btext%2Dalign%3Aleft%7D%2Etext%2Dright%7Btext%2Dalign%3Aright%7D%2Etext%2Dcenter%7Btext%2Dalign%3Acenter%7D%2Etext%2Djustify%7Btext%2Dalign%3Ajustify%7D%2Etext%2Dnowrap%7Bwhite%2Dspace%3Anowrap%7D%2Etext%2Dlowercase%7Btext%2Dtransform%3Alowercase%7D%2Etext%2Duppercase%7Btext%2Dtransform%3Auppercase%7D%2Etext%2Dcapitalize%7Btext%2Dtransform%3Acapitalize%7D%2Etext%2Dmuted%7Bcolor%3A%23777%7D%2Etext%2Dprimary%7Bcolor%3A%23337ab7%7Da%2Etext%2Dprimary%3Afocus%2Ca%2Etext%2Dprimary%3Ahover%7Bcolor%3A%23286090%7D%2Etext%2Dsuccess%7Bcolor%3A%233c763d%7Da%2Etext%2Dsuccess%3Afocus%2Ca%2Etext%2Dsuccess%3Ahover%7Bcolor%3A%232b542c%7D%2Etext%2Dinfo%7Bcolor%3A%2331708f%7Da%2Etext%2Dinfo%3Afocus%2Ca%2Etext%2Dinfo%3Ahover%7Bcolor%3A%23245269%7D%2Etext%2Dwarning%7Bcolor%3A%238a6d3b%7Da%2Etext%2Dwarning%3Afocus%2Ca%2Etext%2Dwarning%3Ahover%7Bcolor%3A%2366512c%7D%2Etext%2Ddanger%7Bcolor%3A%23a94442%7Da%2Etext%2Ddanger%3Afocus%2Ca%2Etext%2Ddanger%3Ahover%7Bcolor%3A%23843534%7D%2Ebg%2Dprimary%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23337ab7%7Da%2Ebg%2Dprimary%3Afocus%2Ca%2Ebg%2Dprimary%3Ahover%7Bbackground%2Dcolor%3A%23286090%7D%2Ebg%2Dsuccess%7Bbackground%2Dcolor%3A%23dff0d8%7Da%2Ebg%2Dsuccess%3Afocus%2Ca%2Ebg%2Dsuccess%3Ahover%7Bbackground%2Dcolor%3A%23c1e2b3%7D%2Ebg%2Dinfo%7Bbackground%2Dcolor%3A%23d9edf7%7Da%2Ebg%2Dinfo%3Afocus%2Ca%2Ebg%2Dinfo%3Ahover%7Bbackground%2Dcolor%3A%23afd9ee%7D%2Ebg%2Dwarning%7Bbackground%2Dcolor%3A%23fcf8e3%7Da%2Ebg%2Dwarning%3Afocus%2Ca%2Ebg%2Dwarning%3Ahover%7Bbackground%2Dcolor%3A%23f7ecb5%7D%2Ebg%2Ddanger%7Bbackground%2Dcolor%3A%23f2dede%7Da%2Ebg%2Ddanger%3Afocus%2Ca%2Ebg%2Ddanger%3Ahover%7Bbackground%2Dcolor%3A%23e4b9b9%7D%2Epage%2Dheader%7Bpadding%2Dbottom%3A9px%3Bmargin%3A40px%200%2020px%3Bborder%2Dbottom%3A1px%20solid%20%23eee%7Dol%2Cul%7Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A10px%7Dol%20ol%2Col%20ul%2Cul%20ol%2Cul%20ul%7Bmargin%2Dbottom%3A0%7D%2Elist%2Dunstyled%7Bpadding%2Dleft%3A0%3Blist%2Dstyle%3Anone%7D%2Elist%2Dinline%7Bpadding%2Dleft%3A0%3Bmargin%2Dleft%3A%2D5px%3Blist%2Dstyle%3Anone%7D%2Elist%2Dinline%3Eli%7Bdisplay%3Ainline%2Dblock%3Bpadding%2Dright%3A5px%3Bpadding%2Dleft%3A5px%7Ddl%7Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A20px%7Ddd%2Cdt%7Bline%2Dheight%3A1%2E42857143%7Ddt%7Bfont%2Dweight%3A700%7Ddd%7Bmargin%2Dleft%3A0%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Edl%2Dhorizontal%20dt%7Bfloat%3Aleft%3Bwidth%3A160px%3Boverflow%3Ahidden%3Bclear%3Aleft%3Btext%2Dalign%3Aright%3Btext%2Doverflow%3Aellipsis%3Bwhite%2Dspace%3Anowrap%7D%2Edl%2Dhorizontal%20dd%7Bmargin%2Dleft%3A180px%7D%7Dabbr%5Bdata%2Doriginal%2Dtitle%5D%2Cabbr%5Btitle%5D%7Bcursor%3Ahelp%3Bborder%2Dbottom%3A1px%20dotted%20%23777%7D%2Einitialism%7Bfont%2Dsize%3A90%25%3Btext%2Dtransform%3Auppercase%7Dblockquote%7Bpadding%3A10px%2020px%3Bmargin%3A0%200%2020px%3Bfont%2Dsize%3A17%2E5px%3Bborder%2Dleft%3A5px%20solid%20%23eee%7Dblockquote%20ol%3Alast%2Dchild%2Cblockquote%20p%3Alast%2Dchild%2Cblockquote%20ul%3Alast%2Dchild%7Bmargin%2Dbottom%3A0%7Dblockquote%20%2Esmall%2Cblockquote%20footer%2Cblockquote%20small%7Bdisplay%3Ablock%3Bfont%2Dsize%3A80%25%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23777%7Dblockquote%20%2Esmall%3Abefore%2Cblockquote%20footer%3Abefore%2Cblockquote%20small%3Abefore%7Bcontent%3A%27%5C2014%20%5C00A0%27%7D%2Eblockquote%2Dreverse%2Cblockquote%2Epull%2Dright%7Bpadding%2Dright%3A15px%3Bpadding%2Dleft%3A0%3Btext%2Dalign%3Aright%3Bborder%2Dright%3A5px%20solid%20%23eee%3Bborder%2Dleft%3A0%7D%2Eblockquote%2Dreverse%20%2Esmall%3Abefore%2C%2Eblockquote%2Dreverse%20footer%3Abefore%2C%2Eblockquote%2Dreverse%20small%3Abefore%2Cblockquote%2Epull%2Dright%20%2Esmall%3Abefore%2Cblockquote%2Epull%2Dright%20footer%3Abefore%2Cblockquote%2Epull%2Dright%20small%3Abefore%7Bcontent%3A%27%27%7D%2Eblockquote%2Dreverse%20%2Esmall%3Aafter%2C%2Eblockquote%2Dreverse%20footer%3Aafter%2C%2Eblockquote%2Dreverse%20small%3Aafter%2Cblockquote%2Epull%2Dright%20%2Esmall%3Aafter%2Cblockquote%2Epull%2Dright%20footer%3Aafter%2Cblockquote%2Epull%2Dright%20small%3Aafter%7Bcontent%3A%27%5C00A0%20%5C2014%27%7Daddress%7Bmargin%2Dbottom%3A20px%3Bfont%2Dstyle%3Anormal%3Bline%2Dheight%3A1%2E42857143%7Dcode%2Ckbd%2Cpre%2Csamp%7Bfont%2Dfamily%3Amonospace%7Dcode%7Bpadding%3A2px%204px%3Bfont%2Dsize%3A90%25%3Bcolor%3A%23c7254e%3Bbackground%2Dcolor%3A%23f9f2f4%3Bborder%2Dradius%3A4px%7Dkbd%7Bpadding%3A2px%204px%3Bfont%2Dsize%3A90%25%3Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23333%3Bborder%2Dradius%3A3px%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%20%2D1px%200%20rgba%280%2C0%2C0%2C%2E25%29%3Bbox%2Dshadow%3Ainset%200%20%2D1px%200%20rgba%280%2C0%2C0%2C%2E25%29%7Dkbd%20kbd%7Bpadding%3A0%3Bfont%2Dsize%3A100%25%3Bfont%2Dweight%3A700%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%7Dpre%7Bdisplay%3Ablock%3Bpadding%3A9%2E5px%3Bmargin%3A0%200%2010px%3Bfont%2Dsize%3A13px%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23333%3Bword%2Dbreak%3Abreak%2Dall%3Bword%2Dwrap%3Abreak%2Dword%3Bbackground%2Dcolor%3A%23f5f5f5%3Bborder%3A1px%20solid%20%23ccc%3Bborder%2Dradius%3A4px%7Dpre%20code%7Bpadding%3A0%3Bfont%2Dsize%3Ainherit%3Bcolor%3Ainherit%3Bwhite%2Dspace%3Apre%2Dwrap%3Bbackground%2Dcolor%3Atransparent%3Bborder%2Dradius%3A0%7D%2Epre%2Dscrollable%7Bmax%2Dheight%3A340px%3Boverflow%2Dy%3Ascroll%7D%2Econtainer%7Bpadding%2Dright%3A15px%3Bpadding%2Dleft%3A15px%3Bmargin%2Dright%3Aauto%3Bmargin%2Dleft%3Aauto%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Econtainer%7Bwidth%3A750px%7D%7D%40media%20%28min%2Dwidth%3A992px%29%7B%2Econtainer%7Bwidth%3A970px%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Econtainer%7Bwidth%3A1170px%7D%7D%2Econtainer%2Dfluid%7Bpadding%2Dright%3A15px%3Bpadding%2Dleft%3A15px%3Bmargin%2Dright%3Aauto%3Bmargin%2Dleft%3Aauto%7D%2Erow%7Bmargin%2Dright%3A%2D15px%3Bmargin%2Dleft%3A%2D15px%7D%2Ecol%2Dlg%2D1%2C%2Ecol%2Dlg%2D10%2C%2Ecol%2Dlg%2D11%2C%2Ecol%2Dlg%2D12%2C%2Ecol%2Dlg%2D2%2C%2Ecol%2Dlg%2D3%2C%2Ecol%2Dlg%2D4%2C%2Ecol%2Dlg%2D5%2C%2Ecol%2Dlg%2D6%2C%2Ecol%2Dlg%2D7%2C%2Ecol%2Dlg%2D8%2C%2Ecol%2Dlg%2D9%2C%2Ecol%2Dmd%2D1%2C%2Ecol%2Dmd%2D10%2C%2Ecol%2Dmd%2D11%2C%2Ecol%2Dmd%2D12%2C%2Ecol%2Dmd%2D2%2C%2Ecol%2Dmd%2D3%2C%2Ecol%2Dmd%2D4%2C%2Ecol%2Dmd%2D5%2C%2Ecol%2Dmd%2D6%2C%2Ecol%2Dmd%2D7%2C%2Ecol%2Dmd%2D8%2C%2Ecol%2Dmd%2D9%2C%2Ecol%2Dsm%2D1%2C%2Ecol%2Dsm%2D10%2C%2Ecol%2Dsm%2D11%2C%2Ecol%2Dsm%2D12%2C%2Ecol%2Dsm%2D2%2C%2Ecol%2Dsm%2D3%2C%2Ecol%2Dsm%2D4%2C%2Ecol%2Dsm%2D5%2C%2Ecol%2Dsm%2D6%2C%2Ecol%2Dsm%2D7%2C%2Ecol%2Dsm%2D8%2C%2Ecol%2Dsm%2D9%2C%2Ecol%2Dxs%2D1%2C%2Ecol%2Dxs%2D10%2C%2Ecol%2Dxs%2D11%2C%2Ecol%2Dxs%2D12%2C%2Ecol%2Dxs%2D2%2C%2Ecol%2Dxs%2D3%2C%2Ecol%2Dxs%2D4%2C%2Ecol%2Dxs%2D5%2C%2Ecol%2Dxs%2D6%2C%2Ecol%2Dxs%2D7%2C%2Ecol%2Dxs%2D8%2C%2Ecol%2Dxs%2D9%7Bposition%3Arelative%3Bmin%2Dheight%3A1px%3Bpadding%2Dright%3A15px%3Bpadding%2Dleft%3A15px%7D%2Ecol%2Dxs%2D1%2C%2Ecol%2Dxs%2D10%2C%2Ecol%2Dxs%2D11%2C%2Ecol%2Dxs%2D12%2C%2Ecol%2Dxs%2D2%2C%2Ecol%2Dxs%2D3%2C%2Ecol%2Dxs%2D4%2C%2Ecol%2Dxs%2D5%2C%2Ecol%2Dxs%2D6%2C%2Ecol%2Dxs%2D7%2C%2Ecol%2Dxs%2D8%2C%2Ecol%2Dxs%2D9%7Bfloat%3Aleft%7D%2Ecol%2Dxs%2D12%7Bwidth%3A100%25%7D%2Ecol%2Dxs%2D11%7Bwidth%3A91%2E66666667%25%7D%2Ecol%2Dxs%2D10%7Bwidth%3A83%2E33333333%25%7D%2Ecol%2Dxs%2D9%7Bwidth%3A75%25%7D%2Ecol%2Dxs%2D8%7Bwidth%3A66%2E66666667%25%7D%2Ecol%2Dxs%2D7%7Bwidth%3A58%2E33333333%25%7D%2Ecol%2Dxs%2D6%7Bwidth%3A50%25%7D%2Ecol%2Dxs%2D5%7Bwidth%3A41%2E66666667%25%7D%2Ecol%2Dxs%2D4%7Bwidth%3A33%2E33333333%25%7D%2Ecol%2Dxs%2D3%7Bwidth%3A25%25%7D%2Ecol%2Dxs%2D2%7Bwidth%3A16%2E66666667%25%7D%2Ecol%2Dxs%2D1%7Bwidth%3A8%2E33333333%25%7D%2Ecol%2Dxs%2Dpull%2D12%7Bright%3A100%25%7D%2Ecol%2Dxs%2Dpull%2D11%7Bright%3A91%2E66666667%25%7D%2Ecol%2Dxs%2Dpull%2D10%7Bright%3A83%2E33333333%25%7D%2Ecol%2Dxs%2Dpull%2D9%7Bright%3A75%25%7D%2Ecol%2Dxs%2Dpull%2D8%7Bright%3A66%2E66666667%25%7D%2Ecol%2Dxs%2Dpull%2D7%7Bright%3A58%2E33333333%25%7D%2Ecol%2Dxs%2Dpull%2D6%7Bright%3A50%25%7D%2Ecol%2Dxs%2Dpull%2D5%7Bright%3A41%2E66666667%25%7D%2Ecol%2Dxs%2Dpull%2D4%7Bright%3A33%2E33333333%25%7D%2Ecol%2Dxs%2Dpull%2D3%7Bright%3A25%25%7D%2Ecol%2Dxs%2Dpull%2D2%7Bright%3A16%2E66666667%25%7D%2Ecol%2Dxs%2Dpull%2D1%7Bright%3A8%2E33333333%25%7D%2Ecol%2Dxs%2Dpull%2D0%7Bright%3Aauto%7D%2Ecol%2Dxs%2Dpush%2D12%7Bleft%3A100%25%7D%2Ecol%2Dxs%2Dpush%2D11%7Bleft%3A91%2E66666667%25%7D%2Ecol%2Dxs%2Dpush%2D10%7Bleft%3A83%2E33333333%25%7D%2Ecol%2Dxs%2Dpush%2D9%7Bleft%3A75%25%7D%2Ecol%2Dxs%2Dpush%2D8%7Bleft%3A66%2E66666667%25%7D%2Ecol%2Dxs%2Dpush%2D7%7Bleft%3A58%2E33333333%25%7D%2Ecol%2Dxs%2Dpush%2D6%7Bleft%3A50%25%7D%2Ecol%2Dxs%2Dpush%2D5%7Bleft%3A41%2E66666667%25%7D%2Ecol%2Dxs%2Dpush%2D4%7Bleft%3A33%2E33333333%25%7D%2Ecol%2Dxs%2Dpush%2D3%7Bleft%3A25%25%7D%2Ecol%2Dxs%2Dpush%2D2%7Bleft%3A16%2E66666667%25%7D%2Ecol%2Dxs%2Dpush%2D1%7Bleft%3A8%2E33333333%25%7D%2Ecol%2Dxs%2Dpush%2D0%7Bleft%3Aauto%7D%2Ecol%2Dxs%2Doffset%2D12%7Bmargin%2Dleft%3A100%25%7D%2Ecol%2Dxs%2Doffset%2D11%7Bmargin%2Dleft%3A91%2E66666667%25%7D%2Ecol%2Dxs%2Doffset%2D10%7Bmargin%2Dleft%3A83%2E33333333%25%7D%2Ecol%2Dxs%2Doffset%2D9%7Bmargin%2Dleft%3A75%25%7D%2Ecol%2Dxs%2Doffset%2D8%7Bmargin%2Dleft%3A66%2E66666667%25%7D%2Ecol%2Dxs%2Doffset%2D7%7Bmargin%2Dleft%3A58%2E33333333%25%7D%2Ecol%2Dxs%2Doffset%2D6%7Bmargin%2Dleft%3A50%25%7D%2Ecol%2Dxs%2Doffset%2D5%7Bmargin%2Dleft%3A41%2E66666667%25%7D%2Ecol%2Dxs%2Doffset%2D4%7Bmargin%2Dleft%3A33%2E33333333%25%7D%2Ecol%2Dxs%2Doffset%2D3%7Bmargin%2Dleft%3A25%25%7D%2Ecol%2Dxs%2Doffset%2D2%7Bmargin%2Dleft%3A16%2E66666667%25%7D%2Ecol%2Dxs%2Doffset%2D1%7Bmargin%2Dleft%3A8%2E33333333%25%7D%2Ecol%2Dxs%2Doffset%2D0%7Bmargin%2Dleft%3A0%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Ecol%2Dsm%2D1%2C%2Ecol%2Dsm%2D10%2C%2Ecol%2Dsm%2D11%2C%2Ecol%2Dsm%2D12%2C%2Ecol%2Dsm%2D2%2C%2Ecol%2Dsm%2D3%2C%2Ecol%2Dsm%2D4%2C%2Ecol%2Dsm%2D5%2C%2Ecol%2Dsm%2D6%2C%2Ecol%2Dsm%2D7%2C%2Ecol%2Dsm%2D8%2C%2Ecol%2Dsm%2D9%7Bfloat%3Aleft%7D%2Ecol%2Dsm%2D12%7Bwidth%3A100%25%7D%2Ecol%2Dsm%2D11%7Bwidth%3A91%2E66666667%25%7D%2Ecol%2Dsm%2D10%7Bwidth%3A83%2E33333333%25%7D%2Ecol%2Dsm%2D9%7Bwidth%3A75%25%7D%2Ecol%2Dsm%2D8%7Bwidth%3A66%2E66666667%25%7D%2Ecol%2Dsm%2D7%7Bwidth%3A58%2E33333333%25%7D%2Ecol%2Dsm%2D6%7Bwidth%3A50%25%7D%2Ecol%2Dsm%2D5%7Bwidth%3A41%2E66666667%25%7D%2Ecol%2Dsm%2D4%7Bwidth%3A33%2E33333333%25%7D%2Ecol%2Dsm%2D3%7Bwidth%3A25%25%7D%2Ecol%2Dsm%2D2%7Bwidth%3A16%2E66666667%25%7D%2Ecol%2Dsm%2D1%7Bwidth%3A8%2E33333333%25%7D%2Ecol%2Dsm%2Dpull%2D12%7Bright%3A100%25%7D%2Ecol%2Dsm%2Dpull%2D11%7Bright%3A91%2E66666667%25%7D%2Ecol%2Dsm%2Dpull%2D10%7Bright%3A83%2E33333333%25%7D%2Ecol%2Dsm%2Dpull%2D9%7Bright%3A75%25%7D%2Ecol%2Dsm%2Dpull%2D8%7Bright%3A66%2E66666667%25%7D%2Ecol%2Dsm%2Dpull%2D7%7Bright%3A58%2E33333333%25%7D%2Ecol%2Dsm%2Dpull%2D6%7Bright%3A50%25%7D%2Ecol%2Dsm%2Dpull%2D5%7Bright%3A41%2E66666667%25%7D%2Ecol%2Dsm%2Dpull%2D4%7Bright%3A33%2E33333333%25%7D%2Ecol%2Dsm%2Dpull%2D3%7Bright%3A25%25%7D%2Ecol%2Dsm%2Dpull%2D2%7Bright%3A16%2E66666667%25%7D%2Ecol%2Dsm%2Dpull%2D1%7Bright%3A8%2E33333333%25%7D%2Ecol%2Dsm%2Dpull%2D0%7Bright%3Aauto%7D%2Ecol%2Dsm%2Dpush%2D12%7Bleft%3A100%25%7D%2Ecol%2Dsm%2Dpush%2D11%7Bleft%3A91%2E66666667%25%7D%2Ecol%2Dsm%2Dpush%2D10%7Bleft%3A83%2E33333333%25%7D%2Ecol%2Dsm%2Dpush%2D9%7Bleft%3A75%25%7D%2Ecol%2Dsm%2Dpush%2D8%7Bleft%3A66%2E66666667%25%7D%2Ecol%2Dsm%2Dpush%2D7%7Bleft%3A58%2E33333333%25%7D%2Ecol%2Dsm%2Dpush%2D6%7Bleft%3A50%25%7D%2Ecol%2Dsm%2Dpush%2D5%7Bleft%3A41%2E66666667%25%7D%2Ecol%2Dsm%2Dpush%2D4%7Bleft%3A33%2E33333333%25%7D%2Ecol%2Dsm%2Dpush%2D3%7Bleft%3A25%25%7D%2Ecol%2Dsm%2Dpush%2D2%7Bleft%3A16%2E66666667%25%7D%2Ecol%2Dsm%2Dpush%2D1%7Bleft%3A8%2E33333333%25%7D%2Ecol%2Dsm%2Dpush%2D0%7Bleft%3Aauto%7D%2Ecol%2Dsm%2Doffset%2D12%7Bmargin%2Dleft%3A100%25%7D%2Ecol%2Dsm%2Doffset%2D11%7Bmargin%2Dleft%3A91%2E66666667%25%7D%2Ecol%2Dsm%2Doffset%2D10%7Bmargin%2Dleft%3A83%2E33333333%25%7D%2Ecol%2Dsm%2Doffset%2D9%7Bmargin%2Dleft%3A75%25%7D%2Ecol%2Dsm%2Doffset%2D8%7Bmargin%2Dleft%3A66%2E66666667%25%7D%2Ecol%2Dsm%2Doffset%2D7%7Bmargin%2Dleft%3A58%2E33333333%25%7D%2Ecol%2Dsm%2Doffset%2D6%7Bmargin%2Dleft%3A50%25%7D%2Ecol%2Dsm%2Doffset%2D5%7Bmargin%2Dleft%3A41%2E66666667%25%7D%2Ecol%2Dsm%2Doffset%2D4%7Bmargin%2Dleft%3A33%2E33333333%25%7D%2Ecol%2Dsm%2Doffset%2D3%7Bmargin%2Dleft%3A25%25%7D%2Ecol%2Dsm%2Doffset%2D2%7Bmargin%2Dleft%3A16%2E66666667%25%7D%2Ecol%2Dsm%2Doffset%2D1%7Bmargin%2Dleft%3A8%2E33333333%25%7D%2Ecol%2Dsm%2Doffset%2D0%7Bmargin%2Dleft%3A0%7D%7D%40media%20%28min%2Dwidth%3A992px%29%7B%2Ecol%2Dmd%2D1%2C%2Ecol%2Dmd%2D10%2C%2Ecol%2Dmd%2D11%2C%2Ecol%2Dmd%2D12%2C%2Ecol%2Dmd%2D2%2C%2Ecol%2Dmd%2D3%2C%2Ecol%2Dmd%2D4%2C%2Ecol%2Dmd%2D5%2C%2Ecol%2Dmd%2D6%2C%2Ecol%2Dmd%2D7%2C%2Ecol%2Dmd%2D8%2C%2Ecol%2Dmd%2D9%7Bfloat%3Aleft%7D%2Ecol%2Dmd%2D12%7Bwidth%3A100%25%7D%2Ecol%2Dmd%2D11%7Bwidth%3A91%2E66666667%25%7D%2Ecol%2Dmd%2D10%7Bwidth%3A83%2E33333333%25%7D%2Ecol%2Dmd%2D9%7Bwidth%3A75%25%7D%2Ecol%2Dmd%2D8%7Bwidth%3A66%2E66666667%25%7D%2Ecol%2Dmd%2D7%7Bwidth%3A58%2E33333333%25%7D%2Ecol%2Dmd%2D6%7Bwidth%3A50%25%7D%2Ecol%2Dmd%2D5%7Bwidth%3A41%2E66666667%25%7D%2Ecol%2Dmd%2D4%7Bwidth%3A33%2E33333333%25%7D%2Ecol%2Dmd%2D3%7Bwidth%3A25%25%7D%2Ecol%2Dmd%2D2%7Bwidth%3A16%2E66666667%25%7D%2Ecol%2Dmd%2D1%7Bwidth%3A8%2E33333333%25%7D%2Ecol%2Dmd%2Dpull%2D12%7Bright%3A100%25%7D%2Ecol%2Dmd%2Dpull%2D11%7Bright%3A91%2E66666667%25%7D%2Ecol%2Dmd%2Dpull%2D10%7Bright%3A83%2E33333333%25%7D%2Ecol%2Dmd%2Dpull%2D9%7Bright%3A75%25%7D%2Ecol%2Dmd%2Dpull%2D8%7Bright%3A66%2E66666667%25%7D%2Ecol%2Dmd%2Dpull%2D7%7Bright%3A58%2E33333333%25%7D%2Ecol%2Dmd%2Dpull%2D6%7Bright%3A50%25%7D%2Ecol%2Dmd%2Dpull%2D5%7Bright%3A41%2E66666667%25%7D%2Ecol%2Dmd%2Dpull%2D4%7Bright%3A33%2E33333333%25%7D%2Ecol%2Dmd%2Dpull%2D3%7Bright%3A25%25%7D%2Ecol%2Dmd%2Dpull%2D2%7Bright%3A16%2E66666667%25%7D%2Ecol%2Dmd%2Dpull%2D1%7Bright%3A8%2E33333333%25%7D%2Ecol%2Dmd%2Dpull%2D0%7Bright%3Aauto%7D%2Ecol%2Dmd%2Dpush%2D12%7Bleft%3A100%25%7D%2Ecol%2Dmd%2Dpush%2D11%7Bleft%3A91%2E66666667%25%7D%2Ecol%2Dmd%2Dpush%2D10%7Bleft%3A83%2E33333333%25%7D%2Ecol%2Dmd%2Dpush%2D9%7Bleft%3A75%25%7D%2Ecol%2Dmd%2Dpush%2D8%7Bleft%3A66%2E66666667%25%7D%2Ecol%2Dmd%2Dpush%2D7%7Bleft%3A58%2E33333333%25%7D%2Ecol%2Dmd%2Dpush%2D6%7Bleft%3A50%25%7D%2Ecol%2Dmd%2Dpush%2D5%7Bleft%3A41%2E66666667%25%7D%2Ecol%2Dmd%2Dpush%2D4%7Bleft%3A33%2E33333333%25%7D%2Ecol%2Dmd%2Dpush%2D3%7Bleft%3A25%25%7D%2Ecol%2Dmd%2Dpush%2D2%7Bleft%3A16%2E66666667%25%7D%2Ecol%2Dmd%2Dpush%2D1%7Bleft%3A8%2E33333333%25%7D%2Ecol%2Dmd%2Dpush%2D0%7Bleft%3Aauto%7D%2Ecol%2Dmd%2Doffset%2D12%7Bmargin%2Dleft%3A100%25%7D%2Ecol%2Dmd%2Doffset%2D11%7Bmargin%2Dleft%3A91%2E66666667%25%7D%2Ecol%2Dmd%2Doffset%2D10%7Bmargin%2Dleft%3A83%2E33333333%25%7D%2Ecol%2Dmd%2Doffset%2D9%7Bmargin%2Dleft%3A75%25%7D%2Ecol%2Dmd%2Doffset%2D8%7Bmargin%2Dleft%3A66%2E66666667%25%7D%2Ecol%2Dmd%2Doffset%2D7%7Bmargin%2Dleft%3A58%2E33333333%25%7D%2Ecol%2Dmd%2Doffset%2D6%7Bmargin%2Dleft%3A50%25%7D%2Ecol%2Dmd%2Doffset%2D5%7Bmargin%2Dleft%3A41%2E66666667%25%7D%2Ecol%2Dmd%2Doffset%2D4%7Bmargin%2Dleft%3A33%2E33333333%25%7D%2Ecol%2Dmd%2Doffset%2D3%7Bmargin%2Dleft%3A25%25%7D%2Ecol%2Dmd%2Doffset%2D2%7Bmargin%2Dleft%3A16%2E66666667%25%7D%2Ecol%2Dmd%2Doffset%2D1%7Bmargin%2Dleft%3A8%2E33333333%25%7D%2Ecol%2Dmd%2Doffset%2D0%7Bmargin%2Dleft%3A0%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Ecol%2Dlg%2D1%2C%2Ecol%2Dlg%2D10%2C%2Ecol%2Dlg%2D11%2C%2Ecol%2Dlg%2D12%2C%2Ecol%2Dlg%2D2%2C%2Ecol%2Dlg%2D3%2C%2Ecol%2Dlg%2D4%2C%2Ecol%2Dlg%2D5%2C%2Ecol%2Dlg%2D6%2C%2Ecol%2Dlg%2D7%2C%2Ecol%2Dlg%2D8%2C%2Ecol%2Dlg%2D9%7Bfloat%3Aleft%7D%2Ecol%2Dlg%2D12%7Bwidth%3A100%25%7D%2Ecol%2Dlg%2D11%7Bwidth%3A91%2E66666667%25%7D%2Ecol%2Dlg%2D10%7Bwidth%3A83%2E33333333%25%7D%2Ecol%2Dlg%2D9%7Bwidth%3A75%25%7D%2Ecol%2Dlg%2D8%7Bwidth%3A66%2E66666667%25%7D%2Ecol%2Dlg%2D7%7Bwidth%3A58%2E33333333%25%7D%2Ecol%2Dlg%2D6%7Bwidth%3A50%25%7D%2Ecol%2Dlg%2D5%7Bwidth%3A41%2E66666667%25%7D%2Ecol%2Dlg%2D4%7Bwidth%3A33%2E33333333%25%7D%2Ecol%2Dlg%2D3%7Bwidth%3A25%25%7D%2Ecol%2Dlg%2D2%7Bwidth%3A16%2E66666667%25%7D%2Ecol%2Dlg%2D1%7Bwidth%3A8%2E33333333%25%7D%2Ecol%2Dlg%2Dpull%2D12%7Bright%3A100%25%7D%2Ecol%2Dlg%2Dpull%2D11%7Bright%3A91%2E66666667%25%7D%2Ecol%2Dlg%2Dpull%2D10%7Bright%3A83%2E33333333%25%7D%2Ecol%2Dlg%2Dpull%2D9%7Bright%3A75%25%7D%2Ecol%2Dlg%2Dpull%2D8%7Bright%3A66%2E66666667%25%7D%2Ecol%2Dlg%2Dpull%2D7%7Bright%3A58%2E33333333%25%7D%2Ecol%2Dlg%2Dpull%2D6%7Bright%3A50%25%7D%2Ecol%2Dlg%2Dpull%2D5%7Bright%3A41%2E66666667%25%7D%2Ecol%2Dlg%2Dpull%2D4%7Bright%3A33%2E33333333%25%7D%2Ecol%2Dlg%2Dpull%2D3%7Bright%3A25%25%7D%2Ecol%2Dlg%2Dpull%2D2%7Bright%3A16%2E66666667%25%7D%2Ecol%2Dlg%2Dpull%2D1%7Bright%3A8%2E33333333%25%7D%2Ecol%2Dlg%2Dpull%2D0%7Bright%3Aauto%7D%2Ecol%2Dlg%2Dpush%2D12%7Bleft%3A100%25%7D%2Ecol%2Dlg%2Dpush%2D11%7Bleft%3A91%2E66666667%25%7D%2Ecol%2Dlg%2Dpush%2D10%7Bleft%3A83%2E33333333%25%7D%2Ecol%2Dlg%2Dpush%2D9%7Bleft%3A75%25%7D%2Ecol%2Dlg%2Dpush%2D8%7Bleft%3A66%2E66666667%25%7D%2Ecol%2Dlg%2Dpush%2D7%7Bleft%3A58%2E33333333%25%7D%2Ecol%2Dlg%2Dpush%2D6%7Bleft%3A50%25%7D%2Ecol%2Dlg%2Dpush%2D5%7Bleft%3A41%2E66666667%25%7D%2Ecol%2Dlg%2Dpush%2D4%7Bleft%3A33%2E33333333%25%7D%2Ecol%2Dlg%2Dpush%2D3%7Bleft%3A25%25%7D%2Ecol%2Dlg%2Dpush%2D2%7Bleft%3A16%2E66666667%25%7D%2Ecol%2Dlg%2Dpush%2D1%7Bleft%3A8%2E33333333%25%7D%2Ecol%2Dlg%2Dpush%2D0%7Bleft%3Aauto%7D%2Ecol%2Dlg%2Doffset%2D12%7Bmargin%2Dleft%3A100%25%7D%2Ecol%2Dlg%2Doffset%2D11%7Bmargin%2Dleft%3A91%2E66666667%25%7D%2Ecol%2Dlg%2Doffset%2D10%7Bmargin%2Dleft%3A83%2E33333333%25%7D%2Ecol%2Dlg%2Doffset%2D9%7Bmargin%2Dleft%3A75%25%7D%2Ecol%2Dlg%2Doffset%2D8%7Bmargin%2Dleft%3A66%2E66666667%25%7D%2Ecol%2Dlg%2Doffset%2D7%7Bmargin%2Dleft%3A58%2E33333333%25%7D%2Ecol%2Dlg%2Doffset%2D6%7Bmargin%2Dleft%3A50%25%7D%2Ecol%2Dlg%2Doffset%2D5%7Bmargin%2Dleft%3A41%2E66666667%25%7D%2Ecol%2Dlg%2Doffset%2D4%7Bmargin%2Dleft%3A33%2E33333333%25%7D%2Ecol%2Dlg%2Doffset%2D3%7Bmargin%2Dleft%3A25%25%7D%2Ecol%2Dlg%2Doffset%2D2%7Bmargin%2Dleft%3A16%2E66666667%25%7D%2Ecol%2Dlg%2Doffset%2D1%7Bmargin%2Dleft%3A8%2E33333333%25%7D%2Ecol%2Dlg%2Doffset%2D0%7Bmargin%2Dleft%3A0%7D%7Dtable%7Bbackground%2Dcolor%3Atransparent%7Dcaption%7Bpadding%2Dtop%3A8px%3Bpadding%2Dbottom%3A8px%3Bcolor%3A%23777%3Btext%2Dalign%3Aleft%7Dth%7B%7D%2Etable%7Bwidth%3A100%25%3Bmax%2Dwidth%3A100%25%3Bmargin%2Dbottom%3A20px%7D%2Etable%3Etbody%3Etr%3Etd%2C%2Etable%3Etbody%3Etr%3Eth%2C%2Etable%3Etfoot%3Etr%3Etd%2C%2Etable%3Etfoot%3Etr%3Eth%2C%2Etable%3Ethead%3Etr%3Etd%2C%2Etable%3Ethead%3Etr%3Eth%7Bpadding%3A8px%3Bline%2Dheight%3A1%2E42857143%3Bvertical%2Dalign%3Atop%3Bborder%2Dtop%3A1px%20solid%20%23ddd%7D%2Etable%3Ethead%3Etr%3Eth%7Bvertical%2Dalign%3Abottom%3Bborder%2Dbottom%3A2px%20solid%20%23ddd%7D%2Etable%3Ecaption%2Bthead%3Etr%3Afirst%2Dchild%3Etd%2C%2Etable%3Ecaption%2Bthead%3Etr%3Afirst%2Dchild%3Eth%2C%2Etable%3Ecolgroup%2Bthead%3Etr%3Afirst%2Dchild%3Etd%2C%2Etable%3Ecolgroup%2Bthead%3Etr%3Afirst%2Dchild%3Eth%2C%2Etable%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%3Etd%2C%2Etable%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%3Eth%7Bborder%2Dtop%3A0%7D%2Etable%3Etbody%2Btbody%7Bborder%2Dtop%3A2px%20solid%20%23ddd%7D%2Etable%20%2Etable%7Bbackground%2Dcolor%3A%23fff%7D%2Etable%2Dcondensed%3Etbody%3Etr%3Etd%2C%2Etable%2Dcondensed%3Etbody%3Etr%3Eth%2C%2Etable%2Dcondensed%3Etfoot%3Etr%3Etd%2C%2Etable%2Dcondensed%3Etfoot%3Etr%3Eth%2C%2Etable%2Dcondensed%3Ethead%3Etr%3Etd%2C%2Etable%2Dcondensed%3Ethead%3Etr%3Eth%7Bpadding%3A5px%7D%2Etable%2Dbordered%7Bborder%3A1px%20solid%20%23ddd%7D%2Etable%2Dbordered%3Etbody%3Etr%3Etd%2C%2Etable%2Dbordered%3Etbody%3Etr%3Eth%2C%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%2C%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%2C%2Etable%2Dbordered%3Ethead%3Etr%3Etd%2C%2Etable%2Dbordered%3Ethead%3Etr%3Eth%7Bborder%3A1px%20solid%20%23ddd%7D%2Etable%2Dbordered%3Ethead%3Etr%3Etd%2C%2Etable%2Dbordered%3Ethead%3Etr%3Eth%7Bborder%2Dbottom%2Dwidth%3A2px%7D%2Etable%2Dstriped%3Etbody%3Etr%3Anth%2Dof%2Dtype%28odd%29%7Bbackground%2Dcolor%3A%23f9f9f9%7D%2Etable%2Dhover%3Etbody%3Etr%3Ahover%7Bbackground%2Dcolor%3A%23f5f5f5%7Dtable%20col%5Bclass%2A%3Dcol%2D%5D%7Bposition%3Astatic%3Bdisplay%3Atable%2Dcolumn%3Bfloat%3Anone%7Dtable%20td%5Bclass%2A%3Dcol%2D%5D%2Ctable%20th%5Bclass%2A%3Dcol%2D%5D%7Bposition%3Astatic%3Bdisplay%3Atable%2Dcell%3Bfloat%3Anone%7D%2Etable%3Etbody%3Etr%2Eactive%3Etd%2C%2Etable%3Etbody%3Etr%2Eactive%3Eth%2C%2Etable%3Etbody%3Etr%3Etd%2Eactive%2C%2Etable%3Etbody%3Etr%3Eth%2Eactive%2C%2Etable%3Etfoot%3Etr%2Eactive%3Etd%2C%2Etable%3Etfoot%3Etr%2Eactive%3Eth%2C%2Etable%3Etfoot%3Etr%3Etd%2Eactive%2C%2Etable%3Etfoot%3Etr%3Eth%2Eactive%2C%2Etable%3Ethead%3Etr%2Eactive%3Etd%2C%2Etable%3Ethead%3Etr%2Eactive%3Eth%2C%2Etable%3Ethead%3Etr%3Etd%2Eactive%2C%2Etable%3Ethead%3Etr%3Eth%2Eactive%7Bbackground%2Dcolor%3A%23f5f5f5%7D%2Etable%2Dhover%3Etbody%3Etr%2Eactive%3Ahover%3Etd%2C%2Etable%2Dhover%3Etbody%3Etr%2Eactive%3Ahover%3Eth%2C%2Etable%2Dhover%3Etbody%3Etr%3Ahover%3E%2Eactive%2C%2Etable%2Dhover%3Etbody%3Etr%3Etd%2Eactive%3Ahover%2C%2Etable%2Dhover%3Etbody%3Etr%3Eth%2Eactive%3Ahover%7Bbackground%2Dcolor%3A%23e8e8e8%7D%2Etable%3Etbody%3Etr%2Esuccess%3Etd%2C%2Etable%3Etbody%3Etr%2Esuccess%3Eth%2C%2Etable%3Etbody%3Etr%3Etd%2Esuccess%2C%2Etable%3Etbody%3Etr%3Eth%2Esuccess%2C%2Etable%3Etfoot%3Etr%2Esuccess%3Etd%2C%2Etable%3Etfoot%3Etr%2Esuccess%3Eth%2C%2Etable%3Etfoot%3Etr%3Etd%2Esuccess%2C%2Etable%3Etfoot%3Etr%3Eth%2Esuccess%2C%2Etable%3Ethead%3Etr%2Esuccess%3Etd%2C%2Etable%3Ethead%3Etr%2Esuccess%3Eth%2C%2Etable%3Ethead%3Etr%3Etd%2Esuccess%2C%2Etable%3Ethead%3Etr%3Eth%2Esuccess%7Bbackground%2Dcolor%3A%23dff0d8%7D%2Etable%2Dhover%3Etbody%3Etr%2Esuccess%3Ahover%3Etd%2C%2Etable%2Dhover%3Etbody%3Etr%2Esuccess%3Ahover%3Eth%2C%2Etable%2Dhover%3Etbody%3Etr%3Ahover%3E%2Esuccess%2C%2Etable%2Dhover%3Etbody%3Etr%3Etd%2Esuccess%3Ahover%2C%2Etable%2Dhover%3Etbody%3Etr%3Eth%2Esuccess%3Ahover%7Bbackground%2Dcolor%3A%23d0e9c6%7D%2Etable%3Etbody%3Etr%2Einfo%3Etd%2C%2Etable%3Etbody%3Etr%2Einfo%3Eth%2C%2Etable%3Etbody%3Etr%3Etd%2Einfo%2C%2Etable%3Etbody%3Etr%3Eth%2Einfo%2C%2Etable%3Etfoot%3Etr%2Einfo%3Etd%2C%2Etable%3Etfoot%3Etr%2Einfo%3Eth%2C%2Etable%3Etfoot%3Etr%3Etd%2Einfo%2C%2Etable%3Etfoot%3Etr%3Eth%2Einfo%2C%2Etable%3Ethead%3Etr%2Einfo%3Etd%2C%2Etable%3Ethead%3Etr%2Einfo%3Eth%2C%2Etable%3Ethead%3Etr%3Etd%2Einfo%2C%2Etable%3Ethead%3Etr%3Eth%2Einfo%7Bbackground%2Dcolor%3A%23d9edf7%7D%2Etable%2Dhover%3Etbody%3Etr%2Einfo%3Ahover%3Etd%2C%2Etable%2Dhover%3Etbody%3Etr%2Einfo%3Ahover%3Eth%2C%2Etable%2Dhover%3Etbody%3Etr%3Ahover%3E%2Einfo%2C%2Etable%2Dhover%3Etbody%3Etr%3Etd%2Einfo%3Ahover%2C%2Etable%2Dhover%3Etbody%3Etr%3Eth%2Einfo%3Ahover%7Bbackground%2Dcolor%3A%23c4e3f3%7D%2Etable%3Etbody%3Etr%2Ewarning%3Etd%2C%2Etable%3Etbody%3Etr%2Ewarning%3Eth%2C%2Etable%3Etbody%3Etr%3Etd%2Ewarning%2C%2Etable%3Etbody%3Etr%3Eth%2Ewarning%2C%2Etable%3Etfoot%3Etr%2Ewarning%3Etd%2C%2Etable%3Etfoot%3Etr%2Ewarning%3Eth%2C%2Etable%3Etfoot%3Etr%3Etd%2Ewarning%2C%2Etable%3Etfoot%3Etr%3Eth%2Ewarning%2C%2Etable%3Ethead%3Etr%2Ewarning%3Etd%2C%2Etable%3Ethead%3Etr%2Ewarning%3Eth%2C%2Etable%3Ethead%3Etr%3Etd%2Ewarning%2C%2Etable%3Ethead%3Etr%3Eth%2Ewarning%7Bbackground%2Dcolor%3A%23fcf8e3%7D%2Etable%2Dhover%3Etbody%3Etr%2Ewarning%3Ahover%3Etd%2C%2Etable%2Dhover%3Etbody%3Etr%2Ewarning%3Ahover%3Eth%2C%2Etable%2Dhover%3Etbody%3Etr%3Ahover%3E%2Ewarning%2C%2Etable%2Dhover%3Etbody%3Etr%3Etd%2Ewarning%3Ahover%2C%2Etable%2Dhover%3Etbody%3Etr%3Eth%2Ewarning%3Ahover%7Bbackground%2Dcolor%3A%23faf2cc%7D%2Etable%3Etbody%3Etr%2Edanger%3Etd%2C%2Etable%3Etbody%3Etr%2Edanger%3Eth%2C%2Etable%3Etbody%3Etr%3Etd%2Edanger%2C%2Etable%3Etbody%3Etr%3Eth%2Edanger%2C%2Etable%3Etfoot%3Etr%2Edanger%3Etd%2C%2Etable%3Etfoot%3Etr%2Edanger%3Eth%2C%2Etable%3Etfoot%3Etr%3Etd%2Edanger%2C%2Etable%3Etfoot%3Etr%3Eth%2Edanger%2C%2Etable%3Ethead%3Etr%2Edanger%3Etd%2C%2Etable%3Ethead%3Etr%2Edanger%3Eth%2C%2Etable%3Ethead%3Etr%3Etd%2Edanger%2C%2Etable%3Ethead%3Etr%3Eth%2Edanger%7Bbackground%2Dcolor%3A%23f2dede%7D%2Etable%2Dhover%3Etbody%3Etr%2Edanger%3Ahover%3Etd%2C%2Etable%2Dhover%3Etbody%3Etr%2Edanger%3Ahover%3Eth%2C%2Etable%2Dhover%3Etbody%3Etr%3Ahover%3E%2Edanger%2C%2Etable%2Dhover%3Etbody%3Etr%3Etd%2Edanger%3Ahover%2C%2Etable%2Dhover%3Etbody%3Etr%3Eth%2Edanger%3Ahover%7Bbackground%2Dcolor%3A%23ebcccc%7D%2Etable%2Dresponsive%7Bmin%2Dheight%3A%2E01%25%3Boverflow%2Dx%3Aauto%7D%40media%20screen%20and%20%28max%2Dwidth%3A767px%29%7B%2Etable%2Dresponsive%7Bwidth%3A100%25%3Bmargin%2Dbottom%3A15px%3Boverflow%2Dy%3Ahidden%3B%2Dms%2Doverflow%2Dstyle%3A%2Dms%2Dautohiding%2Dscrollbar%3Bborder%3A1px%20solid%20%23ddd%7D%2Etable%2Dresponsive%3E%2Etable%7Bmargin%2Dbottom%3A0%7D%2Etable%2Dresponsive%3E%2Etable%3Etbody%3Etr%3Etd%2C%2Etable%2Dresponsive%3E%2Etable%3Etbody%3Etr%3Eth%2C%2Etable%2Dresponsive%3E%2Etable%3Etfoot%3Etr%3Etd%2C%2Etable%2Dresponsive%3E%2Etable%3Etfoot%3Etr%3Eth%2C%2Etable%2Dresponsive%3E%2Etable%3Ethead%3Etr%3Etd%2C%2Etable%2Dresponsive%3E%2Etable%3Ethead%3Etr%3Eth%7Bwhite%2Dspace%3Anowrap%7D%2Etable%2Dresponsive%3E%2Etable%2Dbordered%7Bborder%3A0%7D%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Etd%3Afirst%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Eth%3Afirst%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%3Afirst%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%3Afirst%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Etd%3Afirst%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Eth%3Afirst%2Dchild%7Bborder%2Dleft%3A0%7D%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Etd%3Alast%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Eth%3Alast%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%3Alast%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%3Alast%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Etd%3Alast%2Dchild%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Eth%3Alast%2Dchild%7Bborder%2Dright%3A0%7D%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Alast%2Dchild%3Etd%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Alast%2Dchild%3Eth%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Alast%2Dchild%3Etd%2C%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Alast%2Dchild%3Eth%7Bborder%2Dbottom%3A0%7D%7Dfieldset%7Bmin%2Dwidth%3A0%3Bpadding%3A0%3Bmargin%3A0%3Bborder%3A0%7Dlegend%7Bdisplay%3Ablock%3Bwidth%3A100%25%3Bpadding%3A0%3Bmargin%2Dbottom%3A20px%3Bfont%2Dsize%3A21px%3Bline%2Dheight%3Ainherit%3Bcolor%3A%23333%3Bborder%3A0%3Bborder%2Dbottom%3A1px%20solid%20%23e5e5e5%7Dlabel%7Bdisplay%3Ainline%2Dblock%3Bmax%2Dwidth%3A100%25%3Bmargin%2Dbottom%3A5px%3Bfont%2Dweight%3A700%7Dinput%5Btype%3Dsearch%5D%7B%2Dwebkit%2Dbox%2Dsizing%3Aborder%2Dbox%3B%2Dmoz%2Dbox%2Dsizing%3Aborder%2Dbox%3Bbox%2Dsizing%3Aborder%2Dbox%7Dinput%5Btype%3Dcheckbox%5D%2Cinput%5Btype%3Dradio%5D%7Bmargin%3A4px%200%200%3Bmargin%2Dtop%3A1px%5C9%3Bline%2Dheight%3Anormal%7Dinput%5Btype%3Dfile%5D%7Bdisplay%3Ablock%7Dinput%5Btype%3Drange%5D%7Bdisplay%3Ablock%3Bwidth%3A100%25%7Dselect%5Bmultiple%5D%2Cselect%5Bsize%5D%7Bheight%3Aauto%7Dinput%5Btype%3Dfile%5D%3Afocus%2Cinput%5Btype%3Dcheckbox%5D%3Afocus%2Cinput%5Btype%3Dradio%5D%3Afocus%7Boutline%3Athin%20dotted%3Boutline%3A5px%20auto%20%2Dwebkit%2Dfocus%2Dring%2Dcolor%3Boutline%2Doffset%3A%2D2px%7Doutput%7Bdisplay%3Ablock%3Bpadding%2Dtop%3A7px%3Bfont%2Dsize%3A14px%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23555%7D%2Eform%2Dcontrol%7Bdisplay%3Ablock%3Bwidth%3A100%25%3Bheight%3A34px%3Bpadding%3A6px%2012px%3Bfont%2Dsize%3A14px%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23555%3Bbackground%2Dcolor%3A%23fff%3Bbackground%2Dimage%3Anone%3Bborder%3A1px%20solid%20%23ccc%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%3B%2Dwebkit%2Dtransition%3Aborder%2Dcolor%20ease%2Din%2Dout%20%2E15s%2C%2Dwebkit%2Dbox%2Dshadow%20ease%2Din%2Dout%20%2E15s%3B%2Do%2Dtransition%3Aborder%2Dcolor%20ease%2Din%2Dout%20%2E15s%2Cbox%2Dshadow%20ease%2Din%2Dout%20%2E15s%3Btransition%3Aborder%2Dcolor%20ease%2Din%2Dout%20%2E15s%2Cbox%2Dshadow%20ease%2Din%2Dout%20%2E15s%7D%2Eform%2Dcontrol%3Afocus%7Bborder%2Dcolor%3A%2366afe9%3Boutline%3A0%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%208px%20rgba%28102%2C175%2C233%2C%2E6%29%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%208px%20rgba%28102%2C175%2C233%2C%2E6%29%7D%2Eform%2Dcontrol%3A%3A%2Dmoz%2Dplaceholder%7Bcolor%3A%23999%3Bopacity%3A1%7D%2Eform%2Dcontrol%3A%2Dms%2Dinput%2Dplaceholder%7Bcolor%3A%23999%7D%2Eform%2Dcontrol%3A%3A%2Dwebkit%2Dinput%2Dplaceholder%7Bcolor%3A%23999%7D%2Eform%2Dcontrol%5Bdisabled%5D%2C%2Eform%2Dcontrol%5Breadonly%5D%2Cfieldset%5Bdisabled%5D%20%2Eform%2Dcontrol%7Bbackground%2Dcolor%3A%23eee%3Bopacity%3A1%7D%2Eform%2Dcontrol%5Bdisabled%5D%2Cfieldset%5Bdisabled%5D%20%2Eform%2Dcontrol%7Bcursor%3Anot%2Dallowed%7Dtextarea%2Eform%2Dcontrol%7Bheight%3Aauto%7Dinput%5Btype%3Dsearch%5D%7B%2Dwebkit%2Dappearance%3Anone%7D%40media%20screen%20and%20%28%2Dwebkit%2Dmin%2Ddevice%2Dpixel%2Dratio%3A0%29%7Binput%5Btype%3Ddate%5D%2Eform%2Dcontrol%2Cinput%5Btype%3Dtime%5D%2Eform%2Dcontrol%2Cinput%5Btype%3Ddatetime%2Dlocal%5D%2Eform%2Dcontrol%2Cinput%5Btype%3Dmonth%5D%2Eform%2Dcontrol%7Bline%2Dheight%3A34px%7D%2Einput%2Dgroup%2Dsm%20input%5Btype%3Ddate%5D%2C%2Einput%2Dgroup%2Dsm%20input%5Btype%3Dtime%5D%2C%2Einput%2Dgroup%2Dsm%20input%5Btype%3Ddatetime%2Dlocal%5D%2C%2Einput%2Dgroup%2Dsm%20input%5Btype%3Dmonth%5D%2Cinput%5Btype%3Ddate%5D%2Einput%2Dsm%2Cinput%5Btype%3Dtime%5D%2Einput%2Dsm%2Cinput%5Btype%3Ddatetime%2Dlocal%5D%2Einput%2Dsm%2Cinput%5Btype%3Dmonth%5D%2Einput%2Dsm%7Bline%2Dheight%3A30px%7D%2Einput%2Dgroup%2Dlg%20input%5Btype%3Ddate%5D%2C%2Einput%2Dgroup%2Dlg%20input%5Btype%3Dtime%5D%2C%2Einput%2Dgroup%2Dlg%20input%5Btype%3Ddatetime%2Dlocal%5D%2C%2Einput%2Dgroup%2Dlg%20input%5Btype%3Dmonth%5D%2Cinput%5Btype%3Ddate%5D%2Einput%2Dlg%2Cinput%5Btype%3Dtime%5D%2Einput%2Dlg%2Cinput%5Btype%3Ddatetime%2Dlocal%5D%2Einput%2Dlg%2Cinput%5Btype%3Dmonth%5D%2Einput%2Dlg%7Bline%2Dheight%3A46px%7D%7D%2Eform%2Dgroup%7Bmargin%2Dbottom%3A15px%7D%2Echeckbox%2C%2Eradio%7Bposition%3Arelative%3Bdisplay%3Ablock%3Bmargin%2Dtop%3A10px%3Bmargin%2Dbottom%3A10px%7D%2Echeckbox%20label%2C%2Eradio%20label%7Bmin%2Dheight%3A20px%3Bpadding%2Dleft%3A20px%3Bmargin%2Dbottom%3A0%3Bfont%2Dweight%3A400%3Bcursor%3Apointer%7D%2Echeckbox%20input%5Btype%3Dcheckbox%5D%2C%2Echeckbox%2Dinline%20input%5Btype%3Dcheckbox%5D%2C%2Eradio%20input%5Btype%3Dradio%5D%2C%2Eradio%2Dinline%20input%5Btype%3Dradio%5D%7Bposition%3Aabsolute%3Bmargin%2Dtop%3A4px%5C9%3Bmargin%2Dleft%3A%2D20px%7D%2Echeckbox%2B%2Echeckbox%2C%2Eradio%2B%2Eradio%7Bmargin%2Dtop%3A%2D5px%7D%2Echeckbox%2Dinline%2C%2Eradio%2Dinline%7Bposition%3Arelative%3Bdisplay%3Ainline%2Dblock%3Bpadding%2Dleft%3A20px%3Bmargin%2Dbottom%3A0%3Bfont%2Dweight%3A400%3Bvertical%2Dalign%3Amiddle%3Bcursor%3Apointer%7D%2Echeckbox%2Dinline%2B%2Echeckbox%2Dinline%2C%2Eradio%2Dinline%2B%2Eradio%2Dinline%7Bmargin%2Dtop%3A0%3Bmargin%2Dleft%3A10px%7Dfieldset%5Bdisabled%5D%20input%5Btype%3Dcheckbox%5D%2Cfieldset%5Bdisabled%5D%20input%5Btype%3Dradio%5D%2Cinput%5Btype%3Dcheckbox%5D%2Edisabled%2Cinput%5Btype%3Dcheckbox%5D%5Bdisabled%5D%2Cinput%5Btype%3Dradio%5D%2Edisabled%2Cinput%5Btype%3Dradio%5D%5Bdisabled%5D%7Bcursor%3Anot%2Dallowed%7D%2Echeckbox%2Dinline%2Edisabled%2C%2Eradio%2Dinline%2Edisabled%2Cfieldset%5Bdisabled%5D%20%2Echeckbox%2Dinline%2Cfieldset%5Bdisabled%5D%20%2Eradio%2Dinline%7Bcursor%3Anot%2Dallowed%7D%2Echeckbox%2Edisabled%20label%2C%2Eradio%2Edisabled%20label%2Cfieldset%5Bdisabled%5D%20%2Echeckbox%20label%2Cfieldset%5Bdisabled%5D%20%2Eradio%20label%7Bcursor%3Anot%2Dallowed%7D%2Eform%2Dcontrol%2Dstatic%7Bmin%2Dheight%3A34px%3Bpadding%2Dtop%3A7px%3Bpadding%2Dbottom%3A7px%3Bmargin%2Dbottom%3A0%7D%2Eform%2Dcontrol%2Dstatic%2Einput%2Dlg%2C%2Eform%2Dcontrol%2Dstatic%2Einput%2Dsm%7Bpadding%2Dright%3A0%3Bpadding%2Dleft%3A0%7D%2Einput%2Dsm%7Bheight%3A30px%3Bpadding%3A5px%2010px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%3Bborder%2Dradius%3A3px%7Dselect%2Einput%2Dsm%7Bheight%3A30px%3Bline%2Dheight%3A30px%7Dselect%5Bmultiple%5D%2Einput%2Dsm%2Ctextarea%2Einput%2Dsm%7Bheight%3Aauto%7D%2Eform%2Dgroup%2Dsm%20%2Eform%2Dcontrol%7Bheight%3A30px%3Bpadding%3A5px%2010px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%3Bborder%2Dradius%3A3px%7D%2Eform%2Dgroup%2Dsm%20select%2Eform%2Dcontrol%7Bheight%3A30px%3Bline%2Dheight%3A30px%7D%2Eform%2Dgroup%2Dsm%20select%5Bmultiple%5D%2Eform%2Dcontrol%2C%2Eform%2Dgroup%2Dsm%20textarea%2Eform%2Dcontrol%7Bheight%3Aauto%7D%2Eform%2Dgroup%2Dsm%20%2Eform%2Dcontrol%2Dstatic%7Bheight%3A30px%3Bmin%2Dheight%3A32px%3Bpadding%3A6px%2010px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%7D%2Einput%2Dlg%7Bheight%3A46px%3Bpadding%3A10px%2016px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A1%2E3333333%3Bborder%2Dradius%3A6px%7Dselect%2Einput%2Dlg%7Bheight%3A46px%3Bline%2Dheight%3A46px%7Dselect%5Bmultiple%5D%2Einput%2Dlg%2Ctextarea%2Einput%2Dlg%7Bheight%3Aauto%7D%2Eform%2Dgroup%2Dlg%20%2Eform%2Dcontrol%7Bheight%3A46px%3Bpadding%3A10px%2016px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A1%2E3333333%3Bborder%2Dradius%3A6px%7D%2Eform%2Dgroup%2Dlg%20select%2Eform%2Dcontrol%7Bheight%3A46px%3Bline%2Dheight%3A46px%7D%2Eform%2Dgroup%2Dlg%20select%5Bmultiple%5D%2Eform%2Dcontrol%2C%2Eform%2Dgroup%2Dlg%20textarea%2Eform%2Dcontrol%7Bheight%3Aauto%7D%2Eform%2Dgroup%2Dlg%20%2Eform%2Dcontrol%2Dstatic%7Bheight%3A46px%3Bmin%2Dheight%3A38px%3Bpadding%3A11px%2016px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A1%2E3333333%7D%2Ehas%2Dfeedback%7Bposition%3Arelative%7D%2Ehas%2Dfeedback%20%2Eform%2Dcontrol%7Bpadding%2Dright%3A42%2E5px%7D%2Eform%2Dcontrol%2Dfeedback%7Bposition%3Aabsolute%3Btop%3A0%3Bright%3A0%3Bz%2Dindex%3A2%3Bdisplay%3Ablock%3Bwidth%3A34px%3Bheight%3A34px%3Bline%2Dheight%3A34px%3Btext%2Dalign%3Acenter%3Bpointer%2Devents%3Anone%7D%2Eform%2Dgroup%2Dlg%20%2Eform%2Dcontrol%2B%2Eform%2Dcontrol%2Dfeedback%2C%2Einput%2Dgroup%2Dlg%2B%2Eform%2Dcontrol%2Dfeedback%2C%2Einput%2Dlg%2B%2Eform%2Dcontrol%2Dfeedback%7Bwidth%3A46px%3Bheight%3A46px%3Bline%2Dheight%3A46px%7D%2Eform%2Dgroup%2Dsm%20%2Eform%2Dcontrol%2B%2Eform%2Dcontrol%2Dfeedback%2C%2Einput%2Dgroup%2Dsm%2B%2Eform%2Dcontrol%2Dfeedback%2C%2Einput%2Dsm%2B%2Eform%2Dcontrol%2Dfeedback%7Bwidth%3A30px%3Bheight%3A30px%3Bline%2Dheight%3A30px%7D%2Ehas%2Dsuccess%20%2Echeckbox%2C%2Ehas%2Dsuccess%20%2Echeckbox%2Dinline%2C%2Ehas%2Dsuccess%20%2Econtrol%2Dlabel%2C%2Ehas%2Dsuccess%20%2Ehelp%2Dblock%2C%2Ehas%2Dsuccess%20%2Eradio%2C%2Ehas%2Dsuccess%20%2Eradio%2Dinline%2C%2Ehas%2Dsuccess%2Echeckbox%20label%2C%2Ehas%2Dsuccess%2Echeckbox%2Dinline%20label%2C%2Ehas%2Dsuccess%2Eradio%20label%2C%2Ehas%2Dsuccess%2Eradio%2Dinline%20label%7Bcolor%3A%233c763d%7D%2Ehas%2Dsuccess%20%2Eform%2Dcontrol%7Bborder%2Dcolor%3A%233c763d%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%7D%2Ehas%2Dsuccess%20%2Eform%2Dcontrol%3Afocus%7Bborder%2Dcolor%3A%232b542c%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%206px%20%2367b168%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%206px%20%2367b168%7D%2Ehas%2Dsuccess%20%2Einput%2Dgroup%2Daddon%7Bcolor%3A%233c763d%3Bbackground%2Dcolor%3A%23dff0d8%3Bborder%2Dcolor%3A%233c763d%7D%2Ehas%2Dsuccess%20%2Eform%2Dcontrol%2Dfeedback%7Bcolor%3A%233c763d%7D%2Ehas%2Dwarning%20%2Echeckbox%2C%2Ehas%2Dwarning%20%2Echeckbox%2Dinline%2C%2Ehas%2Dwarning%20%2Econtrol%2Dlabel%2C%2Ehas%2Dwarning%20%2Ehelp%2Dblock%2C%2Ehas%2Dwarning%20%2Eradio%2C%2Ehas%2Dwarning%20%2Eradio%2Dinline%2C%2Ehas%2Dwarning%2Echeckbox%20label%2C%2Ehas%2Dwarning%2Echeckbox%2Dinline%20label%2C%2Ehas%2Dwarning%2Eradio%20label%2C%2Ehas%2Dwarning%2Eradio%2Dinline%20label%7Bcolor%3A%238a6d3b%7D%2Ehas%2Dwarning%20%2Eform%2Dcontrol%7Bborder%2Dcolor%3A%238a6d3b%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%7D%2Ehas%2Dwarning%20%2Eform%2Dcontrol%3Afocus%7Bborder%2Dcolor%3A%2366512c%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%206px%20%23c0a16b%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%206px%20%23c0a16b%7D%2Ehas%2Dwarning%20%2Einput%2Dgroup%2Daddon%7Bcolor%3A%238a6d3b%3Bbackground%2Dcolor%3A%23fcf8e3%3Bborder%2Dcolor%3A%238a6d3b%7D%2Ehas%2Dwarning%20%2Eform%2Dcontrol%2Dfeedback%7Bcolor%3A%238a6d3b%7D%2Ehas%2Derror%20%2Echeckbox%2C%2Ehas%2Derror%20%2Echeckbox%2Dinline%2C%2Ehas%2Derror%20%2Econtrol%2Dlabel%2C%2Ehas%2Derror%20%2Ehelp%2Dblock%2C%2Ehas%2Derror%20%2Eradio%2C%2Ehas%2Derror%20%2Eradio%2Dinline%2C%2Ehas%2Derror%2Echeckbox%20label%2C%2Ehas%2Derror%2Echeckbox%2Dinline%20label%2C%2Ehas%2Derror%2Eradio%20label%2C%2Ehas%2Derror%2Eradio%2Dinline%20label%7Bcolor%3A%23a94442%7D%2Ehas%2Derror%20%2Eform%2Dcontrol%7Bborder%2Dcolor%3A%23a94442%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%7D%2Ehas%2Derror%20%2Eform%2Dcontrol%3Afocus%7Bborder%2Dcolor%3A%23843534%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%206px%20%23ce8483%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E075%29%2C0%200%206px%20%23ce8483%7D%2Ehas%2Derror%20%2Einput%2Dgroup%2Daddon%7Bcolor%3A%23a94442%3Bbackground%2Dcolor%3A%23f2dede%3Bborder%2Dcolor%3A%23a94442%7D%2Ehas%2Derror%20%2Eform%2Dcontrol%2Dfeedback%7Bcolor%3A%23a94442%7D%2Ehas%2Dfeedback%20label%7E%2Eform%2Dcontrol%2Dfeedback%7Btop%3A25px%7D%2Ehas%2Dfeedback%20label%2Esr%2Donly%7E%2Eform%2Dcontrol%2Dfeedback%7Btop%3A0%7D%2Ehelp%2Dblock%7Bdisplay%3Ablock%3Bmargin%2Dtop%3A5px%3Bmargin%2Dbottom%3A10px%3Bcolor%3A%23737373%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Eform%2Dinline%20%2Eform%2Dgroup%7Bdisplay%3Ainline%2Dblock%3Bmargin%2Dbottom%3A0%3Bvertical%2Dalign%3Amiddle%7D%2Eform%2Dinline%20%2Eform%2Dcontrol%7Bdisplay%3Ainline%2Dblock%3Bwidth%3Aauto%3Bvertical%2Dalign%3Amiddle%7D%2Eform%2Dinline%20%2Eform%2Dcontrol%2Dstatic%7Bdisplay%3Ainline%2Dblock%7D%2Eform%2Dinline%20%2Einput%2Dgroup%7Bdisplay%3Ainline%2Dtable%3Bvertical%2Dalign%3Amiddle%7D%2Eform%2Dinline%20%2Einput%2Dgroup%20%2Eform%2Dcontrol%2C%2Eform%2Dinline%20%2Einput%2Dgroup%20%2Einput%2Dgroup%2Daddon%2C%2Eform%2Dinline%20%2Einput%2Dgroup%20%2Einput%2Dgroup%2Dbtn%7Bwidth%3Aauto%7D%2Eform%2Dinline%20%2Einput%2Dgroup%3E%2Eform%2Dcontrol%7Bwidth%3A100%25%7D%2Eform%2Dinline%20%2Econtrol%2Dlabel%7Bmargin%2Dbottom%3A0%3Bvertical%2Dalign%3Amiddle%7D%2Eform%2Dinline%20%2Echeckbox%2C%2Eform%2Dinline%20%2Eradio%7Bdisplay%3Ainline%2Dblock%3Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A0%3Bvertical%2Dalign%3Amiddle%7D%2Eform%2Dinline%20%2Echeckbox%20label%2C%2Eform%2Dinline%20%2Eradio%20label%7Bpadding%2Dleft%3A0%7D%2Eform%2Dinline%20%2Echeckbox%20input%5Btype%3Dcheckbox%5D%2C%2Eform%2Dinline%20%2Eradio%20input%5Btype%3Dradio%5D%7Bposition%3Arelative%3Bmargin%2Dleft%3A0%7D%2Eform%2Dinline%20%2Ehas%2Dfeedback%20%2Eform%2Dcontrol%2Dfeedback%7Btop%3A0%7D%7D%2Eform%2Dhorizontal%20%2Echeckbox%2C%2Eform%2Dhorizontal%20%2Echeckbox%2Dinline%2C%2Eform%2Dhorizontal%20%2Eradio%2C%2Eform%2Dhorizontal%20%2Eradio%2Dinline%7Bpadding%2Dtop%3A7px%3Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A0%7D%2Eform%2Dhorizontal%20%2Echeckbox%2C%2Eform%2Dhorizontal%20%2Eradio%7Bmin%2Dheight%3A27px%7D%2Eform%2Dhorizontal%20%2Eform%2Dgroup%7Bmargin%2Dright%3A%2D15px%3Bmargin%2Dleft%3A%2D15px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Eform%2Dhorizontal%20%2Econtrol%2Dlabel%7Bpadding%2Dtop%3A7px%3Bmargin%2Dbottom%3A0%3Btext%2Dalign%3Aright%7D%7D%2Eform%2Dhorizontal%20%2Ehas%2Dfeedback%20%2Eform%2Dcontrol%2Dfeedback%7Bright%3A15px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Eform%2Dhorizontal%20%2Eform%2Dgroup%2Dlg%20%2Econtrol%2Dlabel%7Bpadding%2Dtop%3A14%2E33px%3Bfont%2Dsize%3A18px%7D%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Eform%2Dhorizontal%20%2Eform%2Dgroup%2Dsm%20%2Econtrol%2Dlabel%7Bpadding%2Dtop%3A6px%3Bfont%2Dsize%3A12px%7D%7D%2Ebtn%7Bdisplay%3Ainline%2Dblock%3Bpadding%3A6px%2012px%3Bmargin%2Dbottom%3A0%3Bfont%2Dsize%3A14px%3Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%2E42857143%3Btext%2Dalign%3Acenter%3Bwhite%2Dspace%3Anowrap%3Bvertical%2Dalign%3Amiddle%3B%2Dms%2Dtouch%2Daction%3Amanipulation%3Btouch%2Daction%3Amanipulation%3Bcursor%3Apointer%3B%2Dwebkit%2Duser%2Dselect%3Anone%3B%2Dmoz%2Duser%2Dselect%3Anone%3B%2Dms%2Duser%2Dselect%3Anone%3Buser%2Dselect%3Anone%3Bbackground%2Dimage%3Anone%3Bborder%3A1px%20solid%20transparent%3Bborder%2Dradius%3A4px%7D%2Ebtn%2Eactive%2Efocus%2C%2Ebtn%2Eactive%3Afocus%2C%2Ebtn%2Efocus%2C%2Ebtn%3Aactive%2Efocus%2C%2Ebtn%3Aactive%3Afocus%2C%2Ebtn%3Afocus%7Boutline%3Athin%20dotted%3Boutline%3A5px%20auto%20%2Dwebkit%2Dfocus%2Dring%2Dcolor%3Boutline%2Doffset%3A%2D2px%7D%2Ebtn%2Efocus%2C%2Ebtn%3Afocus%2C%2Ebtn%3Ahover%7Bcolor%3A%23333%3Btext%2Ddecoration%3Anone%7D%2Ebtn%2Eactive%2C%2Ebtn%3Aactive%7Bbackground%2Dimage%3Anone%3Boutline%3A0%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%203px%205px%20rgba%280%2C0%2C0%2C%2E125%29%3Bbox%2Dshadow%3Ainset%200%203px%205px%20rgba%280%2C0%2C0%2C%2E125%29%7D%2Ebtn%2Edisabled%2C%2Ebtn%5Bdisabled%5D%2Cfieldset%5Bdisabled%5D%20%2Ebtn%7Bcursor%3Anot%2Dallowed%3Bfilter%3Aalpha%28opacity%3D65%29%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%3Bopacity%3A%2E65%7Da%2Ebtn%2Edisabled%2Cfieldset%5Bdisabled%5D%20a%2Ebtn%7Bpointer%2Devents%3Anone%7D%2Ebtn%2Ddefault%7Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23fff%3Bborder%2Dcolor%3A%23ccc%7D%2Ebtn%2Ddefault%2Efocus%2C%2Ebtn%2Ddefault%3Afocus%7Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23e6e6e6%3Bborder%2Dcolor%3A%238c8c8c%7D%2Ebtn%2Ddefault%3Ahover%7Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23e6e6e6%3Bborder%2Dcolor%3A%23adadad%7D%2Ebtn%2Ddefault%2Eactive%2C%2Ebtn%2Ddefault%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddefault%7Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23e6e6e6%3Bborder%2Dcolor%3A%23adadad%7D%2Ebtn%2Ddefault%2Eactive%2Efocus%2C%2Ebtn%2Ddefault%2Eactive%3Afocus%2C%2Ebtn%2Ddefault%2Eactive%3Ahover%2C%2Ebtn%2Ddefault%3Aactive%2Efocus%2C%2Ebtn%2Ddefault%3Aactive%3Afocus%2C%2Ebtn%2Ddefault%3Aactive%3Ahover%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddefault%2Efocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddefault%3Afocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddefault%3Ahover%7Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23d4d4d4%3Bborder%2Dcolor%3A%238c8c8c%7D%2Ebtn%2Ddefault%2Eactive%2C%2Ebtn%2Ddefault%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddefault%7Bbackground%2Dimage%3Anone%7D%2Ebtn%2Ddefault%2Edisabled%2C%2Ebtn%2Ddefault%2Edisabled%2Eactive%2C%2Ebtn%2Ddefault%2Edisabled%2Efocus%2C%2Ebtn%2Ddefault%2Edisabled%3Aactive%2C%2Ebtn%2Ddefault%2Edisabled%3Afocus%2C%2Ebtn%2Ddefault%2Edisabled%3Ahover%2C%2Ebtn%2Ddefault%5Bdisabled%5D%2C%2Ebtn%2Ddefault%5Bdisabled%5D%2Eactive%2C%2Ebtn%2Ddefault%5Bdisabled%5D%2Efocus%2C%2Ebtn%2Ddefault%5Bdisabled%5D%3Aactive%2C%2Ebtn%2Ddefault%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Ddefault%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddefault%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddefault%2Eactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddefault%2Efocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddefault%3Aactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddefault%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddefault%3Ahover%7Bbackground%2Dcolor%3A%23fff%3Bborder%2Dcolor%3A%23ccc%7D%2Ebtn%2Ddefault%20%2Ebadge%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23333%7D%2Ebtn%2Dprimary%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23337ab7%3Bborder%2Dcolor%3A%232e6da4%7D%2Ebtn%2Dprimary%2Efocus%2C%2Ebtn%2Dprimary%3Afocus%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23286090%3Bborder%2Dcolor%3A%23122b40%7D%2Ebtn%2Dprimary%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23286090%3Bborder%2Dcolor%3A%23204d74%7D%2Ebtn%2Dprimary%2Eactive%2C%2Ebtn%2Dprimary%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dprimary%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23286090%3Bborder%2Dcolor%3A%23204d74%7D%2Ebtn%2Dprimary%2Eactive%2Efocus%2C%2Ebtn%2Dprimary%2Eactive%3Afocus%2C%2Ebtn%2Dprimary%2Eactive%3Ahover%2C%2Ebtn%2Dprimary%3Aactive%2Efocus%2C%2Ebtn%2Dprimary%3Aactive%3Afocus%2C%2Ebtn%2Dprimary%3Aactive%3Ahover%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dprimary%2Efocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dprimary%3Afocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dprimary%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23204d74%3Bborder%2Dcolor%3A%23122b40%7D%2Ebtn%2Dprimary%2Eactive%2C%2Ebtn%2Dprimary%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dprimary%7Bbackground%2Dimage%3Anone%7D%2Ebtn%2Dprimary%2Edisabled%2C%2Ebtn%2Dprimary%2Edisabled%2Eactive%2C%2Ebtn%2Dprimary%2Edisabled%2Efocus%2C%2Ebtn%2Dprimary%2Edisabled%3Aactive%2C%2Ebtn%2Dprimary%2Edisabled%3Afocus%2C%2Ebtn%2Dprimary%2Edisabled%3Ahover%2C%2Ebtn%2Dprimary%5Bdisabled%5D%2C%2Ebtn%2Dprimary%5Bdisabled%5D%2Eactive%2C%2Ebtn%2Dprimary%5Bdisabled%5D%2Efocus%2C%2Ebtn%2Dprimary%5Bdisabled%5D%3Aactive%2C%2Ebtn%2Dprimary%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Dprimary%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dprimary%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dprimary%2Eactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dprimary%2Efocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dprimary%3Aactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dprimary%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dprimary%3Ahover%7Bbackground%2Dcolor%3A%23337ab7%3Bborder%2Dcolor%3A%232e6da4%7D%2Ebtn%2Dprimary%20%2Ebadge%7Bcolor%3A%23337ab7%3Bbackground%2Dcolor%3A%23fff%7D%2Ebtn%2Dsuccess%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%235cb85c%3Bborder%2Dcolor%3A%234cae4c%7D%2Ebtn%2Dsuccess%2Efocus%2C%2Ebtn%2Dsuccess%3Afocus%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23449d44%3Bborder%2Dcolor%3A%23255625%7D%2Ebtn%2Dsuccess%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23449d44%3Bborder%2Dcolor%3A%23398439%7D%2Ebtn%2Dsuccess%2Eactive%2C%2Ebtn%2Dsuccess%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dsuccess%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23449d44%3Bborder%2Dcolor%3A%23398439%7D%2Ebtn%2Dsuccess%2Eactive%2Efocus%2C%2Ebtn%2Dsuccess%2Eactive%3Afocus%2C%2Ebtn%2Dsuccess%2Eactive%3Ahover%2C%2Ebtn%2Dsuccess%3Aactive%2Efocus%2C%2Ebtn%2Dsuccess%3Aactive%3Afocus%2C%2Ebtn%2Dsuccess%3Aactive%3Ahover%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dsuccess%2Efocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dsuccess%3Afocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dsuccess%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23398439%3Bborder%2Dcolor%3A%23255625%7D%2Ebtn%2Dsuccess%2Eactive%2C%2Ebtn%2Dsuccess%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dsuccess%7Bbackground%2Dimage%3Anone%7D%2Ebtn%2Dsuccess%2Edisabled%2C%2Ebtn%2Dsuccess%2Edisabled%2Eactive%2C%2Ebtn%2Dsuccess%2Edisabled%2Efocus%2C%2Ebtn%2Dsuccess%2Edisabled%3Aactive%2C%2Ebtn%2Dsuccess%2Edisabled%3Afocus%2C%2Ebtn%2Dsuccess%2Edisabled%3Ahover%2C%2Ebtn%2Dsuccess%5Bdisabled%5D%2C%2Ebtn%2Dsuccess%5Bdisabled%5D%2Eactive%2C%2Ebtn%2Dsuccess%5Bdisabled%5D%2Efocus%2C%2Ebtn%2Dsuccess%5Bdisabled%5D%3Aactive%2C%2Ebtn%2Dsuccess%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Dsuccess%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dsuccess%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dsuccess%2Eactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dsuccess%2Efocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dsuccess%3Aactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dsuccess%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dsuccess%3Ahover%7Bbackground%2Dcolor%3A%235cb85c%3Bborder%2Dcolor%3A%234cae4c%7D%2Ebtn%2Dsuccess%20%2Ebadge%7Bcolor%3A%235cb85c%3Bbackground%2Dcolor%3A%23fff%7D%2Ebtn%2Dinfo%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%235bc0de%3Bborder%2Dcolor%3A%2346b8da%7D%2Ebtn%2Dinfo%2Efocus%2C%2Ebtn%2Dinfo%3Afocus%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%2331b0d5%3Bborder%2Dcolor%3A%231b6d85%7D%2Ebtn%2Dinfo%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%2331b0d5%3Bborder%2Dcolor%3A%23269abc%7D%2Ebtn%2Dinfo%2Eactive%2C%2Ebtn%2Dinfo%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dinfo%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%2331b0d5%3Bborder%2Dcolor%3A%23269abc%7D%2Ebtn%2Dinfo%2Eactive%2Efocus%2C%2Ebtn%2Dinfo%2Eactive%3Afocus%2C%2Ebtn%2Dinfo%2Eactive%3Ahover%2C%2Ebtn%2Dinfo%3Aactive%2Efocus%2C%2Ebtn%2Dinfo%3Aactive%3Afocus%2C%2Ebtn%2Dinfo%3Aactive%3Ahover%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dinfo%2Efocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dinfo%3Afocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dinfo%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23269abc%3Bborder%2Dcolor%3A%231b6d85%7D%2Ebtn%2Dinfo%2Eactive%2C%2Ebtn%2Dinfo%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dinfo%7Bbackground%2Dimage%3Anone%7D%2Ebtn%2Dinfo%2Edisabled%2C%2Ebtn%2Dinfo%2Edisabled%2Eactive%2C%2Ebtn%2Dinfo%2Edisabled%2Efocus%2C%2Ebtn%2Dinfo%2Edisabled%3Aactive%2C%2Ebtn%2Dinfo%2Edisabled%3Afocus%2C%2Ebtn%2Dinfo%2Edisabled%3Ahover%2C%2Ebtn%2Dinfo%5Bdisabled%5D%2C%2Ebtn%2Dinfo%5Bdisabled%5D%2Eactive%2C%2Ebtn%2Dinfo%5Bdisabled%5D%2Efocus%2C%2Ebtn%2Dinfo%5Bdisabled%5D%3Aactive%2C%2Ebtn%2Dinfo%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Dinfo%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dinfo%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dinfo%2Eactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dinfo%2Efocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dinfo%3Aactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dinfo%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dinfo%3Ahover%7Bbackground%2Dcolor%3A%235bc0de%3Bborder%2Dcolor%3A%2346b8da%7D%2Ebtn%2Dinfo%20%2Ebadge%7Bcolor%3A%235bc0de%3Bbackground%2Dcolor%3A%23fff%7D%2Ebtn%2Dwarning%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23f0ad4e%3Bborder%2Dcolor%3A%23eea236%7D%2Ebtn%2Dwarning%2Efocus%2C%2Ebtn%2Dwarning%3Afocus%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23ec971f%3Bborder%2Dcolor%3A%23985f0d%7D%2Ebtn%2Dwarning%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23ec971f%3Bborder%2Dcolor%3A%23d58512%7D%2Ebtn%2Dwarning%2Eactive%2C%2Ebtn%2Dwarning%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dwarning%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23ec971f%3Bborder%2Dcolor%3A%23d58512%7D%2Ebtn%2Dwarning%2Eactive%2Efocus%2C%2Ebtn%2Dwarning%2Eactive%3Afocus%2C%2Ebtn%2Dwarning%2Eactive%3Ahover%2C%2Ebtn%2Dwarning%3Aactive%2Efocus%2C%2Ebtn%2Dwarning%3Aactive%3Afocus%2C%2Ebtn%2Dwarning%3Aactive%3Ahover%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dwarning%2Efocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dwarning%3Afocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dwarning%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23d58512%3Bborder%2Dcolor%3A%23985f0d%7D%2Ebtn%2Dwarning%2Eactive%2C%2Ebtn%2Dwarning%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Dwarning%7Bbackground%2Dimage%3Anone%7D%2Ebtn%2Dwarning%2Edisabled%2C%2Ebtn%2Dwarning%2Edisabled%2Eactive%2C%2Ebtn%2Dwarning%2Edisabled%2Efocus%2C%2Ebtn%2Dwarning%2Edisabled%3Aactive%2C%2Ebtn%2Dwarning%2Edisabled%3Afocus%2C%2Ebtn%2Dwarning%2Edisabled%3Ahover%2C%2Ebtn%2Dwarning%5Bdisabled%5D%2C%2Ebtn%2Dwarning%5Bdisabled%5D%2Eactive%2C%2Ebtn%2Dwarning%5Bdisabled%5D%2Efocus%2C%2Ebtn%2Dwarning%5Bdisabled%5D%3Aactive%2C%2Ebtn%2Dwarning%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Dwarning%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dwarning%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dwarning%2Eactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dwarning%2Efocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dwarning%3Aactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dwarning%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dwarning%3Ahover%7Bbackground%2Dcolor%3A%23f0ad4e%3Bborder%2Dcolor%3A%23eea236%7D%2Ebtn%2Dwarning%20%2Ebadge%7Bcolor%3A%23f0ad4e%3Bbackground%2Dcolor%3A%23fff%7D%2Ebtn%2Ddanger%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23d9534f%3Bborder%2Dcolor%3A%23d43f3a%7D%2Ebtn%2Ddanger%2Efocus%2C%2Ebtn%2Ddanger%3Afocus%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23c9302c%3Bborder%2Dcolor%3A%23761c19%7D%2Ebtn%2Ddanger%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23c9302c%3Bborder%2Dcolor%3A%23ac2925%7D%2Ebtn%2Ddanger%2Eactive%2C%2Ebtn%2Ddanger%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddanger%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23c9302c%3Bborder%2Dcolor%3A%23ac2925%7D%2Ebtn%2Ddanger%2Eactive%2Efocus%2C%2Ebtn%2Ddanger%2Eactive%3Afocus%2C%2Ebtn%2Ddanger%2Eactive%3Ahover%2C%2Ebtn%2Ddanger%3Aactive%2Efocus%2C%2Ebtn%2Ddanger%3Aactive%3Afocus%2C%2Ebtn%2Ddanger%3Aactive%3Ahover%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddanger%2Efocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddanger%3Afocus%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddanger%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23ac2925%3Bborder%2Dcolor%3A%23761c19%7D%2Ebtn%2Ddanger%2Eactive%2C%2Ebtn%2Ddanger%3Aactive%2C%2Eopen%3E%2Edropdown%2Dtoggle%2Ebtn%2Ddanger%7Bbackground%2Dimage%3Anone%7D%2Ebtn%2Ddanger%2Edisabled%2C%2Ebtn%2Ddanger%2Edisabled%2Eactive%2C%2Ebtn%2Ddanger%2Edisabled%2Efocus%2C%2Ebtn%2Ddanger%2Edisabled%3Aactive%2C%2Ebtn%2Ddanger%2Edisabled%3Afocus%2C%2Ebtn%2Ddanger%2Edisabled%3Ahover%2C%2Ebtn%2Ddanger%5Bdisabled%5D%2C%2Ebtn%2Ddanger%5Bdisabled%5D%2Eactive%2C%2Ebtn%2Ddanger%5Bdisabled%5D%2Efocus%2C%2Ebtn%2Ddanger%5Bdisabled%5D%3Aactive%2C%2Ebtn%2Ddanger%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Ddanger%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddanger%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddanger%2Eactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddanger%2Efocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddanger%3Aactive%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddanger%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Ddanger%3Ahover%7Bbackground%2Dcolor%3A%23d9534f%3Bborder%2Dcolor%3A%23d43f3a%7D%2Ebtn%2Ddanger%20%2Ebadge%7Bcolor%3A%23d9534f%3Bbackground%2Dcolor%3A%23fff%7D%2Ebtn%2Dlink%7Bfont%2Dweight%3A400%3Bcolor%3A%23337ab7%3Bborder%2Dradius%3A0%7D%2Ebtn%2Dlink%2C%2Ebtn%2Dlink%2Eactive%2C%2Ebtn%2Dlink%3Aactive%2C%2Ebtn%2Dlink%5Bdisabled%5D%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dlink%7Bbackground%2Dcolor%3Atransparent%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%7D%2Ebtn%2Dlink%2C%2Ebtn%2Dlink%3Aactive%2C%2Ebtn%2Dlink%3Afocus%2C%2Ebtn%2Dlink%3Ahover%7Bborder%2Dcolor%3Atransparent%7D%2Ebtn%2Dlink%3Afocus%2C%2Ebtn%2Dlink%3Ahover%7Bcolor%3A%2323527c%3Btext%2Ddecoration%3Aunderline%3Bbackground%2Dcolor%3Atransparent%7D%2Ebtn%2Dlink%5Bdisabled%5D%3Afocus%2C%2Ebtn%2Dlink%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dlink%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Ebtn%2Dlink%3Ahover%7Bcolor%3A%23777%3Btext%2Ddecoration%3Anone%7D%2Ebtn%2Dgroup%2Dlg%3E%2Ebtn%2C%2Ebtn%2Dlg%7Bpadding%3A10px%2016px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A1%2E3333333%3Bborder%2Dradius%3A6px%7D%2Ebtn%2Dgroup%2Dsm%3E%2Ebtn%2C%2Ebtn%2Dsm%7Bpadding%3A5px%2010px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%3Bborder%2Dradius%3A3px%7D%2Ebtn%2Dgroup%2Dxs%3E%2Ebtn%2C%2Ebtn%2Dxs%7Bpadding%3A1px%205px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%3Bborder%2Dradius%3A3px%7D%2Ebtn%2Dblock%7Bdisplay%3Ablock%3Bwidth%3A100%25%7D%2Ebtn%2Dblock%2B%2Ebtn%2Dblock%7Bmargin%2Dtop%3A5px%7Dinput%5Btype%3Dbutton%5D%2Ebtn%2Dblock%2Cinput%5Btype%3Dreset%5D%2Ebtn%2Dblock%2Cinput%5Btype%3Dsubmit%5D%2Ebtn%2Dblock%7Bwidth%3A100%25%7D%2Efade%7Bopacity%3A0%3B%2Dwebkit%2Dtransition%3Aopacity%20%2E15s%20linear%3B%2Do%2Dtransition%3Aopacity%20%2E15s%20linear%3Btransition%3Aopacity%20%2E15s%20linear%7D%2Efade%2Ein%7Bopacity%3A1%7D%2Ecollapse%7Bdisplay%3Anone%7D%2Ecollapse%2Ein%7Bdisplay%3Ablock%7Dtr%2Ecollapse%2Ein%7Bdisplay%3Atable%2Drow%7Dtbody%2Ecollapse%2Ein%7Bdisplay%3Atable%2Drow%2Dgroup%7D%2Ecollapsing%7Bposition%3Arelative%3Bheight%3A0%3Boverflow%3Ahidden%3B%2Dwebkit%2Dtransition%2Dtiming%2Dfunction%3Aease%3B%2Do%2Dtransition%2Dtiming%2Dfunction%3Aease%3Btransition%2Dtiming%2Dfunction%3Aease%3B%2Dwebkit%2Dtransition%2Dduration%3A%2E35s%3B%2Do%2Dtransition%2Dduration%3A%2E35s%3Btransition%2Dduration%3A%2E35s%3B%2Dwebkit%2Dtransition%2Dproperty%3Aheight%2Cvisibility%3B%2Do%2Dtransition%2Dproperty%3Aheight%2Cvisibility%3Btransition%2Dproperty%3Aheight%2Cvisibility%7D%2Ecaret%7Bdisplay%3Ainline%2Dblock%3Bwidth%3A0%3Bheight%3A0%3Bmargin%2Dleft%3A2px%3Bvertical%2Dalign%3Amiddle%3Bborder%2Dtop%3A4px%20dashed%3Bborder%2Dtop%3A4px%20solid%5C9%3Bborder%2Dright%3A4px%20solid%20transparent%3Bborder%2Dleft%3A4px%20solid%20transparent%7D%2Edropdown%2C%2Edropup%7Bposition%3Arelative%7D%2Edropdown%2Dtoggle%3Afocus%7Boutline%3A0%7D%2Edropdown%2Dmenu%7Bposition%3Aabsolute%3Btop%3A100%25%3Bleft%3A0%3Bz%2Dindex%3A1000%3Bdisplay%3Anone%3Bfloat%3Aleft%3Bmin%2Dwidth%3A160px%3Bpadding%3A5px%200%3Bmargin%3A2px%200%200%3Bfont%2Dsize%3A14px%3Btext%2Dalign%3Aleft%3Blist%2Dstyle%3Anone%3Bbackground%2Dcolor%3A%23fff%3B%2Dwebkit%2Dbackground%2Dclip%3Apadding%2Dbox%3Bbackground%2Dclip%3Apadding%2Dbox%3Bborder%3A1px%20solid%20%23ccc%3Bborder%3A1px%20solid%20rgba%280%2C0%2C0%2C%2E15%29%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dbox%2Dshadow%3A0%206px%2012px%20rgba%280%2C0%2C0%2C%2E175%29%3Bbox%2Dshadow%3A0%206px%2012px%20rgba%280%2C0%2C0%2C%2E175%29%7D%2Edropdown%2Dmenu%2Epull%2Dright%7Bright%3A0%3Bleft%3Aauto%7D%2Edropdown%2Dmenu%20%2Edivider%7Bheight%3A1px%3Bmargin%3A9px%200%3Boverflow%3Ahidden%3Bbackground%2Dcolor%3A%23e5e5e5%7D%2Edropdown%2Dmenu%3Eli%3Ea%7Bdisplay%3Ablock%3Bpadding%3A3px%2020px%3Bclear%3Aboth%3Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23333%3Bwhite%2Dspace%3Anowrap%7D%2Edropdown%2Dmenu%3Eli%3Ea%3Afocus%2C%2Edropdown%2Dmenu%3Eli%3Ea%3Ahover%7Bcolor%3A%23262626%3Btext%2Ddecoration%3Anone%3Bbackground%2Dcolor%3A%23f5f5f5%7D%2Edropdown%2Dmenu%3E%2Eactive%3Ea%2C%2Edropdown%2Dmenu%3E%2Eactive%3Ea%3Afocus%2C%2Edropdown%2Dmenu%3E%2Eactive%3Ea%3Ahover%7Bcolor%3A%23fff%3Btext%2Ddecoration%3Anone%3Bbackground%2Dcolor%3A%23337ab7%3Boutline%3A0%7D%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%2C%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Afocus%2C%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Ahover%7Bcolor%3A%23777%7D%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Afocus%2C%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Ahover%7Btext%2Ddecoration%3Anone%3Bcursor%3Anot%2Dallowed%3Bbackground%2Dcolor%3Atransparent%3Bbackground%2Dimage%3Anone%3Bfilter%3Aprogid%3ADXImageTransform%2EMicrosoft%2Egradient%28enabled%3Dfalse%29%7D%2Eopen%3E%2Edropdown%2Dmenu%7Bdisplay%3Ablock%7D%2Eopen%3Ea%7Boutline%3A0%7D%2Edropdown%2Dmenu%2Dright%7Bright%3A0%3Bleft%3Aauto%7D%2Edropdown%2Dmenu%2Dleft%7Bright%3Aauto%3Bleft%3A0%7D%2Edropdown%2Dheader%7Bdisplay%3Ablock%3Bpadding%3A3px%2020px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23777%3Bwhite%2Dspace%3Anowrap%7D%2Edropdown%2Dbackdrop%7Bposition%3Afixed%3Btop%3A0%3Bright%3A0%3Bbottom%3A0%3Bleft%3A0%3Bz%2Dindex%3A990%7D%2Epull%2Dright%3E%2Edropdown%2Dmenu%7Bright%3A0%3Bleft%3Aauto%7D%2Edropup%20%2Ecaret%2C%2Enavbar%2Dfixed%2Dbottom%20%2Edropdown%20%2Ecaret%7Bcontent%3A%22%22%3Bborder%2Dtop%3A0%3Bborder%2Dbottom%3A4px%20dashed%3Bborder%2Dbottom%3A4px%20solid%5C9%7D%2Edropup%20%2Edropdown%2Dmenu%2C%2Enavbar%2Dfixed%2Dbottom%20%2Edropdown%20%2Edropdown%2Dmenu%7Btop%3Aauto%3Bbottom%3A100%25%3Bmargin%2Dbottom%3A2px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dright%20%2Edropdown%2Dmenu%7Bright%3A0%3Bleft%3Aauto%7D%2Enavbar%2Dright%20%2Edropdown%2Dmenu%2Dleft%7Bright%3Aauto%3Bleft%3A0%7D%7D%2Ebtn%2Dgroup%2C%2Ebtn%2Dgroup%2Dvertical%7Bposition%3Arelative%3Bdisplay%3Ainline%2Dblock%3Bvertical%2Dalign%3Amiddle%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2C%2Ebtn%2Dgroup%3E%2Ebtn%7Bposition%3Arelative%3Bfloat%3Aleft%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Eactive%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%3Aactive%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%3Afocus%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%3Ahover%2C%2Ebtn%2Dgroup%3E%2Ebtn%2Eactive%2C%2Ebtn%2Dgroup%3E%2Ebtn%3Aactive%2C%2Ebtn%2Dgroup%3E%2Ebtn%3Afocus%2C%2Ebtn%2Dgroup%3E%2Ebtn%3Ahover%7Bz%2Dindex%3A2%7D%2Ebtn%2Dgroup%20%2Ebtn%2B%2Ebtn%2C%2Ebtn%2Dgroup%20%2Ebtn%2B%2Ebtn%2Dgroup%2C%2Ebtn%2Dgroup%20%2Ebtn%2Dgroup%2B%2Ebtn%2C%2Ebtn%2Dgroup%20%2Ebtn%2Dgroup%2B%2Ebtn%2Dgroup%7Bmargin%2Dleft%3A%2D1px%7D%2Ebtn%2Dtoolbar%7Bmargin%2Dleft%3A%2D5px%7D%2Ebtn%2Dtoolbar%20%2Ebtn%2C%2Ebtn%2Dtoolbar%20%2Ebtn%2Dgroup%2C%2Ebtn%2Dtoolbar%20%2Einput%2Dgroup%7Bfloat%3Aleft%7D%2Ebtn%2Dtoolbar%3E%2Ebtn%2C%2Ebtn%2Dtoolbar%3E%2Ebtn%2Dgroup%2C%2Ebtn%2Dtoolbar%3E%2Einput%2Dgroup%7Bmargin%2Dleft%3A5px%7D%2Ebtn%2Dgroup%3E%2Ebtn%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%3Anot%28%2Edropdown%2Dtoggle%29%7Bborder%2Dradius%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%3Afirst%2Dchild%7Bmargin%2Dleft%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%3Afirst%2Dchild%3Anot%28%3Alast%2Dchild%29%3Anot%28%2Edropdown%2Dtoggle%29%7Bborder%2Dtop%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dright%2Dradius%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%3Alast%2Dchild%3Anot%28%3Afirst%2Dchild%29%2C%2Ebtn%2Dgroup%3E%2Edropdown%2Dtoggle%3Anot%28%3Afirst%2Dchild%29%7Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%2Dgroup%7Bfloat%3Aleft%7D%2Ebtn%2Dgroup%3E%2Ebtn%2Dgroup%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%3E%2Ebtn%7Bborder%2Dradius%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%2Dgroup%3Afirst%2Dchild%3Anot%28%3Alast%2Dchild%29%3E%2Ebtn%3Alast%2Dchild%2C%2Ebtn%2Dgroup%3E%2Ebtn%2Dgroup%3Afirst%2Dchild%3Anot%28%3Alast%2Dchild%29%3E%2Edropdown%2Dtoggle%7Bborder%2Dtop%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dright%2Dradius%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%2Dgroup%3Alast%2Dchild%3Anot%28%3Afirst%2Dchild%29%3E%2Ebtn%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A0%7D%2Ebtn%2Dgroup%20%2Edropdown%2Dtoggle%3Aactive%2C%2Ebtn%2Dgroup%2Eopen%20%2Edropdown%2Dtoggle%7Boutline%3A0%7D%2Ebtn%2Dgroup%3E%2Ebtn%2B%2Edropdown%2Dtoggle%7Bpadding%2Dright%3A8px%3Bpadding%2Dleft%3A8px%7D%2Ebtn%2Dgroup%3E%2Ebtn%2Dlg%2B%2Edropdown%2Dtoggle%7Bpadding%2Dright%3A12px%3Bpadding%2Dleft%3A12px%7D%2Ebtn%2Dgroup%2Eopen%20%2Edropdown%2Dtoggle%7B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%203px%205px%20rgba%280%2C0%2C0%2C%2E125%29%3Bbox%2Dshadow%3Ainset%200%203px%205px%20rgba%280%2C0%2C0%2C%2E125%29%7D%2Ebtn%2Dgroup%2Eopen%20%2Edropdown%2Dtoggle%2Ebtn%2Dlink%7B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%7D%2Ebtn%20%2Ecaret%7Bmargin%2Dleft%3A0%7D%2Ebtn%2Dlg%20%2Ecaret%7Bborder%2Dwidth%3A5px%205px%200%3Bborder%2Dbottom%2Dwidth%3A0%7D%2Edropup%20%2Ebtn%2Dlg%20%2Ecaret%7Bborder%2Dwidth%3A0%205px%205px%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3E%2Ebtn%7Bdisplay%3Ablock%3Bfloat%3Anone%3Bwidth%3A100%25%3Bmax%2Dwidth%3A100%25%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3E%2Ebtn%7Bfloat%3Anone%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2B%2Ebtn%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2B%2Ebtn%2Dgroup%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%2B%2Ebtn%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%2B%2Ebtn%2Dgroup%7Bmargin%2Dtop%3A%2D1px%3Bmargin%2Dleft%3A0%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%7Bborder%2Dradius%3A0%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%3Afirst%2Dchild%3Anot%28%3Alast%2Dchild%29%7Bborder%2Dtop%2Dright%2Dradius%3A4px%3Bborder%2Dbottom%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A0%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%3Alast%2Dchild%3Anot%28%3Afirst%2Dchild%29%7Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dtop%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A4px%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%3E%2Ebtn%7Bborder%2Dradius%3A0%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Afirst%2Dchild%3Anot%28%3Alast%2Dchild%29%3E%2Ebtn%3Alast%2Dchild%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Afirst%2Dchild%3Anot%28%3Alast%2Dchild%29%3E%2Edropdown%2Dtoggle%7Bborder%2Dbottom%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A0%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Alast%2Dchild%3Anot%28%3Afirst%2Dchild%29%3E%2Ebtn%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dtop%2Dright%2Dradius%3A0%7D%2Ebtn%2Dgroup%2Djustified%7Bdisplay%3Atable%3Bwidth%3A100%25%3Btable%2Dlayout%3Afixed%3Bborder%2Dcollapse%3Aseparate%7D%2Ebtn%2Dgroup%2Djustified%3E%2Ebtn%2C%2Ebtn%2Dgroup%2Djustified%3E%2Ebtn%2Dgroup%7Bdisplay%3Atable%2Dcell%3Bfloat%3Anone%3Bwidth%3A1%25%7D%2Ebtn%2Dgroup%2Djustified%3E%2Ebtn%2Dgroup%20%2Ebtn%7Bwidth%3A100%25%7D%2Ebtn%2Dgroup%2Djustified%3E%2Ebtn%2Dgroup%20%2Edropdown%2Dmenu%7Bleft%3Aauto%7D%5Bdata%2Dtoggle%3Dbuttons%5D%3E%2Ebtn%20input%5Btype%3Dcheckbox%5D%2C%5Bdata%2Dtoggle%3Dbuttons%5D%3E%2Ebtn%20input%5Btype%3Dradio%5D%2C%5Bdata%2Dtoggle%3Dbuttons%5D%3E%2Ebtn%2Dgroup%3E%2Ebtn%20input%5Btype%3Dcheckbox%5D%2C%5Bdata%2Dtoggle%3Dbuttons%5D%3E%2Ebtn%2Dgroup%3E%2Ebtn%20input%5Btype%3Dradio%5D%7Bposition%3Aabsolute%3Bclip%3Arect%280%2C0%2C0%2C0%29%3Bpointer%2Devents%3Anone%7D%2Einput%2Dgroup%7Bposition%3Arelative%3Bdisplay%3Atable%3Bborder%2Dcollapse%3Aseparate%7D%2Einput%2Dgroup%5Bclass%2A%3Dcol%2D%5D%7Bfloat%3Anone%3Bpadding%2Dright%3A0%3Bpadding%2Dleft%3A0%7D%2Einput%2Dgroup%20%2Eform%2Dcontrol%7Bposition%3Arelative%3Bz%2Dindex%3A2%3Bfloat%3Aleft%3Bwidth%3A100%25%3Bmargin%2Dbottom%3A0%7D%2Einput%2Dgroup%2Dlg%3E%2Eform%2Dcontrol%2C%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Daddon%2C%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bheight%3A46px%3Bpadding%3A10px%2016px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A1%2E3333333%3Bborder%2Dradius%3A6px%7Dselect%2Einput%2Dgroup%2Dlg%3E%2Eform%2Dcontrol%2Cselect%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Daddon%2Cselect%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bheight%3A46px%3Bline%2Dheight%3A46px%7Dselect%5Bmultiple%5D%2Einput%2Dgroup%2Dlg%3E%2Eform%2Dcontrol%2Cselect%5Bmultiple%5D%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Daddon%2Cselect%5Bmultiple%5D%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%2Ctextarea%2Einput%2Dgroup%2Dlg%3E%2Eform%2Dcontrol%2Ctextarea%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Daddon%2Ctextarea%2Einput%2Dgroup%2Dlg%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bheight%3Aauto%7D%2Einput%2Dgroup%2Dsm%3E%2Eform%2Dcontrol%2C%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Daddon%2C%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bheight%3A30px%3Bpadding%3A5px%2010px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%3Bborder%2Dradius%3A3px%7Dselect%2Einput%2Dgroup%2Dsm%3E%2Eform%2Dcontrol%2Cselect%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Daddon%2Cselect%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bheight%3A30px%3Bline%2Dheight%3A30px%7Dselect%5Bmultiple%5D%2Einput%2Dgroup%2Dsm%3E%2Eform%2Dcontrol%2Cselect%5Bmultiple%5D%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Daddon%2Cselect%5Bmultiple%5D%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%2Ctextarea%2Einput%2Dgroup%2Dsm%3E%2Eform%2Dcontrol%2Ctextarea%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Daddon%2Ctextarea%2Einput%2Dgroup%2Dsm%3E%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bheight%3Aauto%7D%2Einput%2Dgroup%20%2Eform%2Dcontrol%2C%2Einput%2Dgroup%2Daddon%2C%2Einput%2Dgroup%2Dbtn%7Bdisplay%3Atable%2Dcell%7D%2Einput%2Dgroup%20%2Eform%2Dcontrol%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%2C%2Einput%2Dgroup%2Daddon%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%2C%2Einput%2Dgroup%2Dbtn%3Anot%28%3Afirst%2Dchild%29%3Anot%28%3Alast%2Dchild%29%7Bborder%2Dradius%3A0%7D%2Einput%2Dgroup%2Daddon%2C%2Einput%2Dgroup%2Dbtn%7Bwidth%3A1%25%3Bwhite%2Dspace%3Anowrap%3Bvertical%2Dalign%3Amiddle%7D%2Einput%2Dgroup%2Daddon%7Bpadding%3A6px%2012px%3Bfont%2Dsize%3A14px%3Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%3Bcolor%3A%23555%3Btext%2Dalign%3Acenter%3Bbackground%2Dcolor%3A%23eee%3Bborder%3A1px%20solid%20%23ccc%3Bborder%2Dradius%3A4px%7D%2Einput%2Dgroup%2Daddon%2Einput%2Dsm%7Bpadding%3A5px%2010px%3Bfont%2Dsize%3A12px%3Bborder%2Dradius%3A3px%7D%2Einput%2Dgroup%2Daddon%2Einput%2Dlg%7Bpadding%3A10px%2016px%3Bfont%2Dsize%3A18px%3Bborder%2Dradius%3A6px%7D%2Einput%2Dgroup%2Daddon%20input%5Btype%3Dcheckbox%5D%2C%2Einput%2Dgroup%2Daddon%20input%5Btype%3Dradio%5D%7Bmargin%2Dtop%3A0%7D%2Einput%2Dgroup%20%2Eform%2Dcontrol%3Afirst%2Dchild%2C%2Einput%2Dgroup%2Daddon%3Afirst%2Dchild%2C%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Ebtn%2Dgroup%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Edropdown%2Dtoggle%2C%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Ebtn%2Dgroup%3Anot%28%3Alast%2Dchild%29%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Ebtn%3Anot%28%3Alast%2Dchild%29%3Anot%28%2Edropdown%2Dtoggle%29%7Bborder%2Dtop%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dright%2Dradius%3A0%7D%2Einput%2Dgroup%2Daddon%3Afirst%2Dchild%7Bborder%2Dright%3A0%7D%2Einput%2Dgroup%20%2Eform%2Dcontrol%3Alast%2Dchild%2C%2Einput%2Dgroup%2Daddon%3Alast%2Dchild%2C%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Ebtn%2Dgroup%3Anot%28%3Afirst%2Dchild%29%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Ebtn%3Anot%28%3Afirst%2Dchild%29%2C%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Ebtn%2Dgroup%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Edropdown%2Dtoggle%7Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A0%7D%2Einput%2Dgroup%2Daddon%3Alast%2Dchild%7Bborder%2Dleft%3A0%7D%2Einput%2Dgroup%2Dbtn%7Bposition%3Arelative%3Bfont%2Dsize%3A0%3Bwhite%2Dspace%3Anowrap%7D%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%7Bposition%3Arelative%7D%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%2B%2Ebtn%7Bmargin%2Dleft%3A%2D1px%7D%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%3Aactive%2C%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%3Afocus%2C%2Einput%2Dgroup%2Dbtn%3E%2Ebtn%3Ahover%7Bz%2Dindex%3A2%7D%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Afirst%2Dchild%3E%2Ebtn%2Dgroup%7Bmargin%2Dright%3A%2D1px%7D%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Ebtn%2C%2Einput%2Dgroup%2Dbtn%3Alast%2Dchild%3E%2Ebtn%2Dgroup%7Bz%2Dindex%3A2%3Bmargin%2Dleft%3A%2D1px%7D%2Enav%7Bpadding%2Dleft%3A0%3Bmargin%2Dbottom%3A0%3Blist%2Dstyle%3Anone%7D%2Enav%3Eli%7Bposition%3Arelative%3Bdisplay%3Ablock%7D%2Enav%3Eli%3Ea%7Bposition%3Arelative%3Bdisplay%3Ablock%3Bpadding%3A10px%2015px%7D%2Enav%3Eli%3Ea%3Afocus%2C%2Enav%3Eli%3Ea%3Ahover%7Btext%2Ddecoration%3Anone%3Bbackground%2Dcolor%3A%23eee%7D%2Enav%3Eli%2Edisabled%3Ea%7Bcolor%3A%23777%7D%2Enav%3Eli%2Edisabled%3Ea%3Afocus%2C%2Enav%3Eli%2Edisabled%3Ea%3Ahover%7Bcolor%3A%23777%3Btext%2Ddecoration%3Anone%3Bcursor%3Anot%2Dallowed%3Bbackground%2Dcolor%3Atransparent%7D%2Enav%20%2Eopen%3Ea%2C%2Enav%20%2Eopen%3Ea%3Afocus%2C%2Enav%20%2Eopen%3Ea%3Ahover%7Bbackground%2Dcolor%3A%23eee%3Bborder%2Dcolor%3A%23337ab7%7D%2Enav%20%2Enav%2Ddivider%7Bheight%3A1px%3Bmargin%3A9px%200%3Boverflow%3Ahidden%3Bbackground%2Dcolor%3A%23e5e5e5%7D%2Enav%3Eli%3Ea%3Eimg%7Bmax%2Dwidth%3Anone%7D%2Enav%2Dtabs%7Bborder%2Dbottom%3A1px%20solid%20%23ddd%7D%2Enav%2Dtabs%3Eli%7Bfloat%3Aleft%3Bmargin%2Dbottom%3A%2D1px%7D%2Enav%2Dtabs%3Eli%3Ea%7Bmargin%2Dright%3A2px%3Bline%2Dheight%3A1%2E42857143%3Bborder%3A1px%20solid%20transparent%3Bborder%2Dradius%3A4px%204px%200%200%7D%2Enav%2Dtabs%3Eli%3Ea%3Ahover%7Bborder%2Dcolor%3A%23eee%20%23eee%20%23ddd%7D%2Enav%2Dtabs%3Eli%2Eactive%3Ea%2C%2Enav%2Dtabs%3Eli%2Eactive%3Ea%3Afocus%2C%2Enav%2Dtabs%3Eli%2Eactive%3Ea%3Ahover%7Bcolor%3A%23555%3Bcursor%3Adefault%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20%23ddd%3Bborder%2Dbottom%2Dcolor%3Atransparent%7D%2Enav%2Dtabs%2Enav%2Djustified%7Bwidth%3A100%25%3Bborder%2Dbottom%3A0%7D%2Enav%2Dtabs%2Enav%2Djustified%3Eli%7Bfloat%3Anone%7D%2Enav%2Dtabs%2Enav%2Djustified%3Eli%3Ea%7Bmargin%2Dbottom%3A5px%3Btext%2Dalign%3Acenter%7D%2Enav%2Dtabs%2Enav%2Djustified%3E%2Edropdown%20%2Edropdown%2Dmenu%7Btop%3Aauto%3Bleft%3Aauto%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enav%2Dtabs%2Enav%2Djustified%3Eli%7Bdisplay%3Atable%2Dcell%3Bwidth%3A1%25%7D%2Enav%2Dtabs%2Enav%2Djustified%3Eli%3Ea%7Bmargin%2Dbottom%3A0%7D%7D%2Enav%2Dtabs%2Enav%2Djustified%3Eli%3Ea%7Bmargin%2Dright%3A0%3Bborder%2Dradius%3A4px%7D%2Enav%2Dtabs%2Enav%2Djustified%3E%2Eactive%3Ea%2C%2Enav%2Dtabs%2Enav%2Djustified%3E%2Eactive%3Ea%3Afocus%2C%2Enav%2Dtabs%2Enav%2Djustified%3E%2Eactive%3Ea%3Ahover%7Bborder%3A1px%20solid%20%23ddd%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enav%2Dtabs%2Enav%2Djustified%3Eli%3Ea%7Bborder%2Dbottom%3A1px%20solid%20%23ddd%3Bborder%2Dradius%3A4px%204px%200%200%7D%2Enav%2Dtabs%2Enav%2Djustified%3E%2Eactive%3Ea%2C%2Enav%2Dtabs%2Enav%2Djustified%3E%2Eactive%3Ea%3Afocus%2C%2Enav%2Dtabs%2Enav%2Djustified%3E%2Eactive%3Ea%3Ahover%7Bborder%2Dbottom%2Dcolor%3A%23fff%7D%7D%2Enav%2Dpills%3Eli%7Bfloat%3Aleft%7D%2Enav%2Dpills%3Eli%3Ea%7Bborder%2Dradius%3A4px%7D%2Enav%2Dpills%3Eli%2Bli%7Bmargin%2Dleft%3A2px%7D%2Enav%2Dpills%3Eli%2Eactive%3Ea%2C%2Enav%2Dpills%3Eli%2Eactive%3Ea%3Afocus%2C%2Enav%2Dpills%3Eli%2Eactive%3Ea%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23337ab7%7D%2Enav%2Dstacked%3Eli%7Bfloat%3Anone%7D%2Enav%2Dstacked%3Eli%2Bli%7Bmargin%2Dtop%3A2px%3Bmargin%2Dleft%3A0%7D%2Enav%2Djustified%7Bwidth%3A100%25%7D%2Enav%2Djustified%3Eli%7Bfloat%3Anone%7D%2Enav%2Djustified%3Eli%3Ea%7Bmargin%2Dbottom%3A5px%3Btext%2Dalign%3Acenter%7D%2Enav%2Djustified%3E%2Edropdown%20%2Edropdown%2Dmenu%7Btop%3Aauto%3Bleft%3Aauto%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enav%2Djustified%3Eli%7Bdisplay%3Atable%2Dcell%3Bwidth%3A1%25%7D%2Enav%2Djustified%3Eli%3Ea%7Bmargin%2Dbottom%3A0%7D%7D%2Enav%2Dtabs%2Djustified%7Bborder%2Dbottom%3A0%7D%2Enav%2Dtabs%2Djustified%3Eli%3Ea%7Bmargin%2Dright%3A0%3Bborder%2Dradius%3A4px%7D%2Enav%2Dtabs%2Djustified%3E%2Eactive%3Ea%2C%2Enav%2Dtabs%2Djustified%3E%2Eactive%3Ea%3Afocus%2C%2Enav%2Dtabs%2Djustified%3E%2Eactive%3Ea%3Ahover%7Bborder%3A1px%20solid%20%23ddd%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enav%2Dtabs%2Djustified%3Eli%3Ea%7Bborder%2Dbottom%3A1px%20solid%20%23ddd%3Bborder%2Dradius%3A4px%204px%200%200%7D%2Enav%2Dtabs%2Djustified%3E%2Eactive%3Ea%2C%2Enav%2Dtabs%2Djustified%3E%2Eactive%3Ea%3Afocus%2C%2Enav%2Dtabs%2Djustified%3E%2Eactive%3Ea%3Ahover%7Bborder%2Dbottom%2Dcolor%3A%23fff%7D%7D%2Etab%2Dcontent%3E%2Etab%2Dpane%7Bdisplay%3Anone%7D%2Etab%2Dcontent%3E%2Eactive%7Bdisplay%3Ablock%7D%2Enav%2Dtabs%20%2Edropdown%2Dmenu%7Bmargin%2Dtop%3A%2D1px%3Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dtop%2Dright%2Dradius%3A0%7D%2Enavbar%7Bposition%3Arelative%3Bmin%2Dheight%3A50px%3Bmargin%2Dbottom%3A20px%3Bborder%3A1px%20solid%20transparent%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%7Bborder%2Dradius%3A4px%7D%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dheader%7Bfloat%3Aleft%7D%7D%2Enavbar%2Dcollapse%7Bpadding%2Dright%3A15px%3Bpadding%2Dleft%3A15px%3Boverflow%2Dx%3Avisible%3B%2Dwebkit%2Doverflow%2Dscrolling%3Atouch%3Bborder%2Dtop%3A1px%20solid%20transparent%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%200%20rgba%28255%2C255%2C255%2C%2E1%29%3Bbox%2Dshadow%3Ainset%200%201px%200%20rgba%28255%2C255%2C255%2C%2E1%29%7D%2Enavbar%2Dcollapse%2Ein%7Boverflow%2Dy%3Aauto%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dcollapse%7Bwidth%3Aauto%3Bborder%2Dtop%3A0%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%7D%2Enavbar%2Dcollapse%2Ecollapse%7Bdisplay%3Ablock%21important%3Bheight%3Aauto%21important%3Bpadding%2Dbottom%3A0%3Boverflow%3Avisible%21important%7D%2Enavbar%2Dcollapse%2Ein%7Boverflow%2Dy%3Avisible%7D%2Enavbar%2Dfixed%2Dbottom%20%2Enavbar%2Dcollapse%2C%2Enavbar%2Dfixed%2Dtop%20%2Enavbar%2Dcollapse%2C%2Enavbar%2Dstatic%2Dtop%20%2Enavbar%2Dcollapse%7Bpadding%2Dright%3A0%3Bpadding%2Dleft%3A0%7D%7D%2Enavbar%2Dfixed%2Dbottom%20%2Enavbar%2Dcollapse%2C%2Enavbar%2Dfixed%2Dtop%20%2Enavbar%2Dcollapse%7Bmax%2Dheight%3A340px%7D%40media%20%28max%2Ddevice%2Dwidth%3A480px%29%20and%20%28orientation%3Alandscape%29%7B%2Enavbar%2Dfixed%2Dbottom%20%2Enavbar%2Dcollapse%2C%2Enavbar%2Dfixed%2Dtop%20%2Enavbar%2Dcollapse%7Bmax%2Dheight%3A200px%7D%7D%2Econtainer%2Dfluid%3E%2Enavbar%2Dcollapse%2C%2Econtainer%2Dfluid%3E%2Enavbar%2Dheader%2C%2Econtainer%3E%2Enavbar%2Dcollapse%2C%2Econtainer%3E%2Enavbar%2Dheader%7Bmargin%2Dright%3A%2D15px%3Bmargin%2Dleft%3A%2D15px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Econtainer%2Dfluid%3E%2Enavbar%2Dcollapse%2C%2Econtainer%2Dfluid%3E%2Enavbar%2Dheader%2C%2Econtainer%3E%2Enavbar%2Dcollapse%2C%2Econtainer%3E%2Enavbar%2Dheader%7Bmargin%2Dright%3A0%3Bmargin%2Dleft%3A0%7D%7D%2Enavbar%2Dstatic%2Dtop%7Bz%2Dindex%3A1000%3Bborder%2Dwidth%3A0%200%201px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dstatic%2Dtop%7Bborder%2Dradius%3A0%7D%7D%2Enavbar%2Dfixed%2Dbottom%2C%2Enavbar%2Dfixed%2Dtop%7Bposition%3Afixed%3Bright%3A0%3Bleft%3A0%3Bz%2Dindex%3A1030%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dfixed%2Dbottom%2C%2Enavbar%2Dfixed%2Dtop%7Bborder%2Dradius%3A0%7D%7D%2Enavbar%2Dfixed%2Dtop%7Btop%3A0%3Bborder%2Dwidth%3A0%200%201px%7D%2Enavbar%2Dfixed%2Dbottom%7Bbottom%3A0%3Bmargin%2Dbottom%3A0%3Bborder%2Dwidth%3A1px%200%200%7D%2Enavbar%2Dbrand%7Bfloat%3Aleft%3Bheight%3A50px%3Bpadding%3A15px%2015px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A20px%7D%2Enavbar%2Dbrand%3Afocus%2C%2Enavbar%2Dbrand%3Ahover%7Btext%2Ddecoration%3Anone%7D%2Enavbar%2Dbrand%3Eimg%7Bdisplay%3Ablock%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%3E%2Econtainer%20%2Enavbar%2Dbrand%2C%2Enavbar%3E%2Econtainer%2Dfluid%20%2Enavbar%2Dbrand%7Bmargin%2Dleft%3A%2D15px%7D%7D%2Enavbar%2Dtoggle%7Bposition%3Arelative%3Bfloat%3Aright%3Bpadding%3A9px%2010px%3Bmargin%2Dtop%3A8px%3Bmargin%2Dright%3A15px%3Bmargin%2Dbottom%3A8px%3Bbackground%2Dcolor%3Atransparent%3Bbackground%2Dimage%3Anone%3Bborder%3A1px%20solid%20transparent%3Bborder%2Dradius%3A4px%7D%2Enavbar%2Dtoggle%3Afocus%7Boutline%3A0%7D%2Enavbar%2Dtoggle%20%2Eicon%2Dbar%7Bdisplay%3Ablock%3Bwidth%3A22px%3Bheight%3A2px%3Bborder%2Dradius%3A1px%7D%2Enavbar%2Dtoggle%20%2Eicon%2Dbar%2B%2Eicon%2Dbar%7Bmargin%2Dtop%3A4px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dtoggle%7Bdisplay%3Anone%7D%7D%2Enavbar%2Dnav%7Bmargin%3A7%2E5px%20%2D15px%7D%2Enavbar%2Dnav%3Eli%3Ea%7Bpadding%2Dtop%3A10px%3Bpadding%2Dbottom%3A10px%3Bline%2Dheight%3A20px%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%7Bposition%3Astatic%3Bfloat%3Anone%3Bwidth%3Aauto%3Bmargin%2Dtop%3A0%3Bbackground%2Dcolor%3Atransparent%3Bborder%3A0%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%7D%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%20%2Edropdown%2Dheader%2C%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%7Bpadding%3A5px%2015px%205px%2025px%7D%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%7Bline%2Dheight%3A20px%7D%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%3Afocus%2C%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%3Ahover%7Bbackground%2Dimage%3Anone%7D%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dnav%7Bfloat%3Aleft%3Bmargin%3A0%7D%2Enavbar%2Dnav%3Eli%7Bfloat%3Aleft%7D%2Enavbar%2Dnav%3Eli%3Ea%7Bpadding%2Dtop%3A15px%3Bpadding%2Dbottom%3A15px%7D%7D%2Enavbar%2Dform%7Bpadding%3A10px%2015px%3Bmargin%2Dtop%3A8px%3Bmargin%2Dright%3A%2D15px%3Bmargin%2Dbottom%3A8px%3Bmargin%2Dleft%3A%2D15px%3Bborder%2Dtop%3A1px%20solid%20transparent%3Bborder%2Dbottom%3A1px%20solid%20transparent%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%200%20rgba%28255%2C255%2C255%2C%2E1%29%2C0%201px%200%20rgba%28255%2C255%2C255%2C%2E1%29%3Bbox%2Dshadow%3Ainset%200%201px%200%20rgba%28255%2C255%2C255%2C%2E1%29%2C0%201px%200%20rgba%28255%2C255%2C255%2C%2E1%29%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dform%20%2Eform%2Dgroup%7Bdisplay%3Ainline%2Dblock%3Bmargin%2Dbottom%3A0%3Bvertical%2Dalign%3Amiddle%7D%2Enavbar%2Dform%20%2Eform%2Dcontrol%7Bdisplay%3Ainline%2Dblock%3Bwidth%3Aauto%3Bvertical%2Dalign%3Amiddle%7D%2Enavbar%2Dform%20%2Eform%2Dcontrol%2Dstatic%7Bdisplay%3Ainline%2Dblock%7D%2Enavbar%2Dform%20%2Einput%2Dgroup%7Bdisplay%3Ainline%2Dtable%3Bvertical%2Dalign%3Amiddle%7D%2Enavbar%2Dform%20%2Einput%2Dgroup%20%2Eform%2Dcontrol%2C%2Enavbar%2Dform%20%2Einput%2Dgroup%20%2Einput%2Dgroup%2Daddon%2C%2Enavbar%2Dform%20%2Einput%2Dgroup%20%2Einput%2Dgroup%2Dbtn%7Bwidth%3Aauto%7D%2Enavbar%2Dform%20%2Einput%2Dgroup%3E%2Eform%2Dcontrol%7Bwidth%3A100%25%7D%2Enavbar%2Dform%20%2Econtrol%2Dlabel%7Bmargin%2Dbottom%3A0%3Bvertical%2Dalign%3Amiddle%7D%2Enavbar%2Dform%20%2Echeckbox%2C%2Enavbar%2Dform%20%2Eradio%7Bdisplay%3Ainline%2Dblock%3Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A0%3Bvertical%2Dalign%3Amiddle%7D%2Enavbar%2Dform%20%2Echeckbox%20label%2C%2Enavbar%2Dform%20%2Eradio%20label%7Bpadding%2Dleft%3A0%7D%2Enavbar%2Dform%20%2Echeckbox%20input%5Btype%3Dcheckbox%5D%2C%2Enavbar%2Dform%20%2Eradio%20input%5Btype%3Dradio%5D%7Bposition%3Arelative%3Bmargin%2Dleft%3A0%7D%2Enavbar%2Dform%20%2Ehas%2Dfeedback%20%2Eform%2Dcontrol%2Dfeedback%7Btop%3A0%7D%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Enavbar%2Dform%20%2Eform%2Dgroup%7Bmargin%2Dbottom%3A5px%7D%2Enavbar%2Dform%20%2Eform%2Dgroup%3Alast%2Dchild%7Bmargin%2Dbottom%3A0%7D%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dform%7Bwidth%3Aauto%3Bpadding%2Dtop%3A0%3Bpadding%2Dbottom%3A0%3Bmargin%2Dright%3A0%3Bmargin%2Dleft%3A0%3Bborder%3A0%3B%2Dwebkit%2Dbox%2Dshadow%3Anone%3Bbox%2Dshadow%3Anone%7D%7D%2Enavbar%2Dnav%3Eli%3E%2Edropdown%2Dmenu%7Bmargin%2Dtop%3A0%3Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dtop%2Dright%2Dradius%3A0%7D%2Enavbar%2Dfixed%2Dbottom%20%2Enavbar%2Dnav%3Eli%3E%2Edropdown%2Dmenu%7Bmargin%2Dbottom%3A0%3Bborder%2Dtop%2Dleft%2Dradius%3A4px%3Bborder%2Dtop%2Dright%2Dradius%3A4px%3Bborder%2Dbottom%2Dright%2Dradius%3A0%3Bborder%2Dbottom%2Dleft%2Dradius%3A0%7D%2Enavbar%2Dbtn%7Bmargin%2Dtop%3A8px%3Bmargin%2Dbottom%3A8px%7D%2Enavbar%2Dbtn%2Ebtn%2Dsm%7Bmargin%2Dtop%3A10px%3Bmargin%2Dbottom%3A10px%7D%2Enavbar%2Dbtn%2Ebtn%2Dxs%7Bmargin%2Dtop%3A14px%3Bmargin%2Dbottom%3A14px%7D%2Enavbar%2Dtext%7Bmargin%2Dtop%3A15px%3Bmargin%2Dbottom%3A15px%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dtext%7Bfloat%3Aleft%3Bmargin%2Dright%3A15px%3Bmargin%2Dleft%3A15px%7D%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Enavbar%2Dleft%7Bfloat%3Aleft%21important%7D%2Enavbar%2Dright%7Bfloat%3Aright%21important%3Bmargin%2Dright%3A%2D15px%7D%2Enavbar%2Dright%7E%2Enavbar%2Dright%7Bmargin%2Dright%3A0%7D%7D%2Enavbar%2Ddefault%7Bbackground%2Dcolor%3A%23f8f8f8%3Bborder%2Dcolor%3A%23e7e7e7%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dbrand%7Bcolor%3A%23777%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dbrand%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dbrand%3Ahover%7Bcolor%3A%235e5e5e%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dtext%7Bcolor%3A%23777%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3Eli%3Ea%7Bcolor%3A%23777%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3Eli%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3Eli%3Ea%3Ahover%7Bcolor%3A%23333%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Eactive%3Ea%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Eactive%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Eactive%3Ea%3Ahover%7Bcolor%3A%23555%3Bbackground%2Dcolor%3A%23e7e7e7%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Edisabled%3Ea%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Edisabled%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Edisabled%3Ea%3Ahover%7Bcolor%3A%23ccc%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dtoggle%7Bborder%2Dcolor%3A%23ddd%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dtoggle%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dtoggle%3Ahover%7Bbackground%2Dcolor%3A%23ddd%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dtoggle%20%2Eicon%2Dbar%7Bbackground%2Dcolor%3A%23888%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dcollapse%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dform%7Bborder%2Dcolor%3A%23e7e7e7%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Eopen%3Ea%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Eopen%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%3E%2Eopen%3Ea%3Ahover%7Bcolor%3A%23555%3Bbackground%2Dcolor%3A%23e7e7e7%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%7Bcolor%3A%23777%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%3Ahover%7Bcolor%3A%23333%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Eactive%3Ea%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Eactive%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Eactive%3Ea%3Ahover%7Bcolor%3A%23555%3Bbackground%2Dcolor%3A%23e7e7e7%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Afocus%2C%2Enavbar%2Ddefault%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Ahover%7Bcolor%3A%23ccc%3Bbackground%2Dcolor%3Atransparent%7D%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dlink%7Bcolor%3A%23777%7D%2Enavbar%2Ddefault%20%2Enavbar%2Dlink%3Ahover%7Bcolor%3A%23333%7D%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%7Bcolor%3A%23777%7D%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%3Afocus%2C%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%3Ahover%7Bcolor%3A%23333%7D%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%5Bdisabled%5D%3Afocus%2C%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Enavbar%2Ddefault%20%2Ebtn%2Dlink%3Ahover%7Bcolor%3A%23ccc%7D%2Enavbar%2Dinverse%7Bbackground%2Dcolor%3A%23222%3Bborder%2Dcolor%3A%23080808%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dbrand%7Bcolor%3A%239d9d9d%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dbrand%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dbrand%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dtext%7Bcolor%3A%239d9d9d%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3Eli%3Ea%7Bcolor%3A%239d9d9d%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3Eli%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3Eli%3Ea%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Eactive%3Ea%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Eactive%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Eactive%3Ea%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23080808%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Edisabled%3Ea%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Edisabled%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Edisabled%3Ea%3Ahover%7Bcolor%3A%23444%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dtoggle%7Bborder%2Dcolor%3A%23333%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dtoggle%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dtoggle%3Ahover%7Bbackground%2Dcolor%3A%23333%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dtoggle%20%2Eicon%2Dbar%7Bbackground%2Dcolor%3A%23fff%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dcollapse%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dform%7Bborder%2Dcolor%3A%23101010%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Eopen%3Ea%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Eopen%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%3E%2Eopen%3Ea%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23080808%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edropdown%2Dheader%7Bborder%2Dcolor%3A%23080808%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%20%2Edivider%7Bbackground%2Dcolor%3A%23080808%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%7Bcolor%3A%239d9d9d%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3Eli%3Ea%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3Atransparent%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Eactive%3Ea%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Eactive%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Eactive%3Ea%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23080808%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Afocus%2C%2Enavbar%2Dinverse%20%2Enavbar%2Dnav%20%2Eopen%20%2Edropdown%2Dmenu%3E%2Edisabled%3Ea%3Ahover%7Bcolor%3A%23444%3Bbackground%2Dcolor%3Atransparent%7D%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dlink%7Bcolor%3A%239d9d9d%7D%2Enavbar%2Dinverse%20%2Enavbar%2Dlink%3Ahover%7Bcolor%3A%23fff%7D%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%7Bcolor%3A%239d9d9d%7D%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%3Afocus%2C%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%3Ahover%7Bcolor%3A%23fff%7D%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%5Bdisabled%5D%3Afocus%2C%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%5Bdisabled%5D%3Ahover%2Cfieldset%5Bdisabled%5D%20%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%3Afocus%2Cfieldset%5Bdisabled%5D%20%2Enavbar%2Dinverse%20%2Ebtn%2Dlink%3Ahover%7Bcolor%3A%23444%7D%2Ebreadcrumb%7Bpadding%3A8px%2015px%3Bmargin%2Dbottom%3A20px%3Blist%2Dstyle%3Anone%3Bbackground%2Dcolor%3A%23f5f5f5%3Bborder%2Dradius%3A4px%7D%2Ebreadcrumb%3Eli%7Bdisplay%3Ainline%2Dblock%7D%2Ebreadcrumb%3Eli%2Bli%3Abefore%7Bpadding%3A0%205px%3Bcolor%3A%23ccc%3Bcontent%3A%22%2F%5C00a0%22%7D%2Ebreadcrumb%3E%2Eactive%7Bcolor%3A%23777%7D%2Epagination%7Bdisplay%3Ainline%2Dblock%3Bpadding%2Dleft%3A0%3Bmargin%3A20px%200%3Bborder%2Dradius%3A4px%7D%2Epagination%3Eli%7Bdisplay%3Ainline%7D%2Epagination%3Eli%3Ea%2C%2Epagination%3Eli%3Espan%7Bposition%3Arelative%3Bfloat%3Aleft%3Bpadding%3A6px%2012px%3Bmargin%2Dleft%3A%2D1px%3Bline%2Dheight%3A1%2E42857143%3Bcolor%3A%23337ab7%3Btext%2Ddecoration%3Anone%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20%23ddd%7D%2Epagination%3Eli%3Afirst%2Dchild%3Ea%2C%2Epagination%3Eli%3Afirst%2Dchild%3Espan%7Bmargin%2Dleft%3A0%3Bborder%2Dtop%2Dleft%2Dradius%3A4px%3Bborder%2Dbottom%2Dleft%2Dradius%3A4px%7D%2Epagination%3Eli%3Alast%2Dchild%3Ea%2C%2Epagination%3Eli%3Alast%2Dchild%3Espan%7Bborder%2Dtop%2Dright%2Dradius%3A4px%3Bborder%2Dbottom%2Dright%2Dradius%3A4px%7D%2Epagination%3Eli%3Ea%3Afocus%2C%2Epagination%3Eli%3Ea%3Ahover%2C%2Epagination%3Eli%3Espan%3Afocus%2C%2Epagination%3Eli%3Espan%3Ahover%7Bz%2Dindex%3A3%3Bcolor%3A%2323527c%3Bbackground%2Dcolor%3A%23eee%3Bborder%2Dcolor%3A%23ddd%7D%2Epagination%3E%2Eactive%3Ea%2C%2Epagination%3E%2Eactive%3Ea%3Afocus%2C%2Epagination%3E%2Eactive%3Ea%3Ahover%2C%2Epagination%3E%2Eactive%3Espan%2C%2Epagination%3E%2Eactive%3Espan%3Afocus%2C%2Epagination%3E%2Eactive%3Espan%3Ahover%7Bz%2Dindex%3A2%3Bcolor%3A%23fff%3Bcursor%3Adefault%3Bbackground%2Dcolor%3A%23337ab7%3Bborder%2Dcolor%3A%23337ab7%7D%2Epagination%3E%2Edisabled%3Ea%2C%2Epagination%3E%2Edisabled%3Ea%3Afocus%2C%2Epagination%3E%2Edisabled%3Ea%3Ahover%2C%2Epagination%3E%2Edisabled%3Espan%2C%2Epagination%3E%2Edisabled%3Espan%3Afocus%2C%2Epagination%3E%2Edisabled%3Espan%3Ahover%7Bcolor%3A%23777%3Bcursor%3Anot%2Dallowed%3Bbackground%2Dcolor%3A%23fff%3Bborder%2Dcolor%3A%23ddd%7D%2Epagination%2Dlg%3Eli%3Ea%2C%2Epagination%2Dlg%3Eli%3Espan%7Bpadding%3A10px%2016px%3Bfont%2Dsize%3A18px%3Bline%2Dheight%3A1%2E3333333%7D%2Epagination%2Dlg%3Eli%3Afirst%2Dchild%3Ea%2C%2Epagination%2Dlg%3Eli%3Afirst%2Dchild%3Espan%7Bborder%2Dtop%2Dleft%2Dradius%3A6px%3Bborder%2Dbottom%2Dleft%2Dradius%3A6px%7D%2Epagination%2Dlg%3Eli%3Alast%2Dchild%3Ea%2C%2Epagination%2Dlg%3Eli%3Alast%2Dchild%3Espan%7Bborder%2Dtop%2Dright%2Dradius%3A6px%3Bborder%2Dbottom%2Dright%2Dradius%3A6px%7D%2Epagination%2Dsm%3Eli%3Ea%2C%2Epagination%2Dsm%3Eli%3Espan%7Bpadding%3A5px%2010px%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A1%2E5%7D%2Epagination%2Dsm%3Eli%3Afirst%2Dchild%3Ea%2C%2Epagination%2Dsm%3Eli%3Afirst%2Dchild%3Espan%7Bborder%2Dtop%2Dleft%2Dradius%3A3px%3Bborder%2Dbottom%2Dleft%2Dradius%3A3px%7D%2Epagination%2Dsm%3Eli%3Alast%2Dchild%3Ea%2C%2Epagination%2Dsm%3Eli%3Alast%2Dchild%3Espan%7Bborder%2Dtop%2Dright%2Dradius%3A3px%3Bborder%2Dbottom%2Dright%2Dradius%3A3px%7D%2Epager%7Bpadding%2Dleft%3A0%3Bmargin%3A20px%200%3Btext%2Dalign%3Acenter%3Blist%2Dstyle%3Anone%7D%2Epager%20li%7Bdisplay%3Ainline%7D%2Epager%20li%3Ea%2C%2Epager%20li%3Espan%7Bdisplay%3Ainline%2Dblock%3Bpadding%3A5px%2014px%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20%23ddd%3Bborder%2Dradius%3A15px%7D%2Epager%20li%3Ea%3Afocus%2C%2Epager%20li%3Ea%3Ahover%7Btext%2Ddecoration%3Anone%3Bbackground%2Dcolor%3A%23eee%7D%2Epager%20%2Enext%3Ea%2C%2Epager%20%2Enext%3Espan%7Bfloat%3Aright%7D%2Epager%20%2Eprevious%3Ea%2C%2Epager%20%2Eprevious%3Espan%7Bfloat%3Aleft%7D%2Epager%20%2Edisabled%3Ea%2C%2Epager%20%2Edisabled%3Ea%3Afocus%2C%2Epager%20%2Edisabled%3Ea%3Ahover%2C%2Epager%20%2Edisabled%3Espan%7Bcolor%3A%23777%3Bcursor%3Anot%2Dallowed%3Bbackground%2Dcolor%3A%23fff%7D%2Elabel%7Bdisplay%3Ainline%3Bpadding%3A%2E2em%20%2E6em%20%2E3em%3Bfont%2Dsize%3A75%25%3Bfont%2Dweight%3A700%3Bline%2Dheight%3A1%3Bcolor%3A%23fff%3Btext%2Dalign%3Acenter%3Bwhite%2Dspace%3Anowrap%3Bvertical%2Dalign%3Abaseline%3Bborder%2Dradius%3A%2E25em%7Da%2Elabel%3Afocus%2Ca%2Elabel%3Ahover%7Bcolor%3A%23fff%3Btext%2Ddecoration%3Anone%3Bcursor%3Apointer%7D%2Elabel%3Aempty%7Bdisplay%3Anone%7D%2Ebtn%20%2Elabel%7Bposition%3Arelative%3Btop%3A%2D1px%7D%2Elabel%2Ddefault%7Bbackground%2Dcolor%3A%23777%7D%2Elabel%2Ddefault%5Bhref%5D%3Afocus%2C%2Elabel%2Ddefault%5Bhref%5D%3Ahover%7Bbackground%2Dcolor%3A%235e5e5e%7D%2Elabel%2Dprimary%7Bbackground%2Dcolor%3A%23337ab7%7D%2Elabel%2Dprimary%5Bhref%5D%3Afocus%2C%2Elabel%2Dprimary%5Bhref%5D%3Ahover%7Bbackground%2Dcolor%3A%23286090%7D%2Elabel%2Dsuccess%7Bbackground%2Dcolor%3A%235cb85c%7D%2Elabel%2Dsuccess%5Bhref%5D%3Afocus%2C%2Elabel%2Dsuccess%5Bhref%5D%3Ahover%7Bbackground%2Dcolor%3A%23449d44%7D%2Elabel%2Dinfo%7Bbackground%2Dcolor%3A%235bc0de%7D%2Elabel%2Dinfo%5Bhref%5D%3Afocus%2C%2Elabel%2Dinfo%5Bhref%5D%3Ahover%7Bbackground%2Dcolor%3A%2331b0d5%7D%2Elabel%2Dwarning%7Bbackground%2Dcolor%3A%23f0ad4e%7D%2Elabel%2Dwarning%5Bhref%5D%3Afocus%2C%2Elabel%2Dwarning%5Bhref%5D%3Ahover%7Bbackground%2Dcolor%3A%23ec971f%7D%2Elabel%2Ddanger%7Bbackground%2Dcolor%3A%23d9534f%7D%2Elabel%2Ddanger%5Bhref%5D%3Afocus%2C%2Elabel%2Ddanger%5Bhref%5D%3Ahover%7Bbackground%2Dcolor%3A%23c9302c%7D%2Ebadge%7Bdisplay%3Ainline%2Dblock%3Bmin%2Dwidth%3A10px%3Bpadding%3A3px%207px%3Bfont%2Dsize%3A12px%3Bfont%2Dweight%3A700%3Bline%2Dheight%3A1%3Bcolor%3A%23fff%3Btext%2Dalign%3Acenter%3Bwhite%2Dspace%3Anowrap%3Bvertical%2Dalign%3Amiddle%3Bbackground%2Dcolor%3A%23777%3Bborder%2Dradius%3A10px%7D%2Ebadge%3Aempty%7Bdisplay%3Anone%7D%2Ebtn%20%2Ebadge%7Bposition%3Arelative%3Btop%3A%2D1px%7D%2Ebtn%2Dgroup%2Dxs%3E%2Ebtn%20%2Ebadge%2C%2Ebtn%2Dxs%20%2Ebadge%7Btop%3A0%3Bpadding%3A1px%205px%7Da%2Ebadge%3Afocus%2Ca%2Ebadge%3Ahover%7Bcolor%3A%23fff%3Btext%2Ddecoration%3Anone%3Bcursor%3Apointer%7D%2Elist%2Dgroup%2Ditem%2Eactive%3E%2Ebadge%2C%2Enav%2Dpills%3E%2Eactive%3Ea%3E%2Ebadge%7Bcolor%3A%23337ab7%3Bbackground%2Dcolor%3A%23fff%7D%2Elist%2Dgroup%2Ditem%3E%2Ebadge%7Bfloat%3Aright%7D%2Elist%2Dgroup%2Ditem%3E%2Ebadge%2B%2Ebadge%7Bmargin%2Dright%3A5px%7D%2Enav%2Dpills%3Eli%3Ea%3E%2Ebadge%7Bmargin%2Dleft%3A3px%7D%2Ejumbotron%7Bpadding%2Dtop%3A30px%3Bpadding%2Dbottom%3A30px%3Bmargin%2Dbottom%3A30px%3Bcolor%3Ainherit%3Bbackground%2Dcolor%3A%23eee%7D%2Ejumbotron%20%2Eh1%2C%2Ejumbotron%20h1%7Bcolor%3Ainherit%7D%2Ejumbotron%20p%7Bmargin%2Dbottom%3A15px%3Bfont%2Dsize%3A21px%3Bfont%2Dweight%3A200%7D%2Ejumbotron%3Ehr%7Bborder%2Dtop%2Dcolor%3A%23d5d5d5%7D%2Econtainer%20%2Ejumbotron%2C%2Econtainer%2Dfluid%20%2Ejumbotron%7Bborder%2Dradius%3A6px%7D%2Ejumbotron%20%2Econtainer%7Bmax%2Dwidth%3A100%25%7D%40media%20screen%20and%20%28min%2Dwidth%3A768px%29%7B%2Ejumbotron%7Bpadding%2Dtop%3A48px%3Bpadding%2Dbottom%3A48px%7D%2Econtainer%20%2Ejumbotron%2C%2Econtainer%2Dfluid%20%2Ejumbotron%7Bpadding%2Dright%3A60px%3Bpadding%2Dleft%3A60px%7D%2Ejumbotron%20%2Eh1%2C%2Ejumbotron%20h1%7Bfont%2Dsize%3A63px%7D%7D%2Ethumbnail%7Bdisplay%3Ablock%3Bpadding%3A4px%3Bmargin%2Dbottom%3A20px%3Bline%2Dheight%3A1%2E42857143%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20%23ddd%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dtransition%3Aborder%20%2E2s%20ease%2Din%2Dout%3B%2Do%2Dtransition%3Aborder%20%2E2s%20ease%2Din%2Dout%3Btransition%3Aborder%20%2E2s%20ease%2Din%2Dout%7D%2Ethumbnail%20a%3Eimg%2C%2Ethumbnail%3Eimg%7Bmargin%2Dright%3Aauto%3Bmargin%2Dleft%3Aauto%7Da%2Ethumbnail%2Eactive%2Ca%2Ethumbnail%3Afocus%2Ca%2Ethumbnail%3Ahover%7Bborder%2Dcolor%3A%23337ab7%7D%2Ethumbnail%20%2Ecaption%7Bpadding%3A9px%3Bcolor%3A%23333%7D%2Ealert%7Bpadding%3A15px%3Bmargin%2Dbottom%3A20px%3Bborder%3A1px%20solid%20transparent%3Bborder%2Dradius%3A4px%7D%2Ealert%20h4%7Bmargin%2Dtop%3A0%3Bcolor%3Ainherit%7D%2Ealert%20%2Ealert%2Dlink%7Bfont%2Dweight%3A700%7D%2Ealert%3Ep%2C%2Ealert%3Eul%7Bmargin%2Dbottom%3A0%7D%2Ealert%3Ep%2Bp%7Bmargin%2Dtop%3A5px%7D%2Ealert%2Ddismissable%2C%2Ealert%2Ddismissible%7Bpadding%2Dright%3A35px%7D%2Ealert%2Ddismissable%20%2Eclose%2C%2Ealert%2Ddismissible%20%2Eclose%7Bposition%3Arelative%3Btop%3A%2D2px%3Bright%3A%2D21px%3Bcolor%3Ainherit%7D%2Ealert%2Dsuccess%7Bcolor%3A%233c763d%3Bbackground%2Dcolor%3A%23dff0d8%3Bborder%2Dcolor%3A%23d6e9c6%7D%2Ealert%2Dsuccess%20hr%7Bborder%2Dtop%2Dcolor%3A%23c9e2b3%7D%2Ealert%2Dsuccess%20%2Ealert%2Dlink%7Bcolor%3A%232b542c%7D%2Ealert%2Dinfo%7Bcolor%3A%2331708f%3Bbackground%2Dcolor%3A%23d9edf7%3Bborder%2Dcolor%3A%23bce8f1%7D%2Ealert%2Dinfo%20hr%7Bborder%2Dtop%2Dcolor%3A%23a6e1ec%7D%2Ealert%2Dinfo%20%2Ealert%2Dlink%7Bcolor%3A%23245269%7D%2Ealert%2Dwarning%7Bcolor%3A%238a6d3b%3Bbackground%2Dcolor%3A%23fcf8e3%3Bborder%2Dcolor%3A%23faebcc%7D%2Ealert%2Dwarning%20hr%7Bborder%2Dtop%2Dcolor%3A%23f7e1b5%7D%2Ealert%2Dwarning%20%2Ealert%2Dlink%7Bcolor%3A%2366512c%7D%2Ealert%2Ddanger%7Bcolor%3A%23a94442%3Bbackground%2Dcolor%3A%23f2dede%3Bborder%2Dcolor%3A%23ebccd1%7D%2Ealert%2Ddanger%20hr%7Bborder%2Dtop%2Dcolor%3A%23e4b9c0%7D%2Ealert%2Ddanger%20%2Ealert%2Dlink%7Bcolor%3A%23843534%7D%40%2Dwebkit%2Dkeyframes%20progress%2Dbar%2Dstripes%7Bfrom%7Bbackground%2Dposition%3A40px%200%7Dto%7Bbackground%2Dposition%3A0%200%7D%7D%40%2Do%2Dkeyframes%20progress%2Dbar%2Dstripes%7Bfrom%7Bbackground%2Dposition%3A40px%200%7Dto%7Bbackground%2Dposition%3A0%200%7D%7D%40keyframes%20progress%2Dbar%2Dstripes%7Bfrom%7Bbackground%2Dposition%3A40px%200%7Dto%7Bbackground%2Dposition%3A0%200%7D%7D%2Eprogress%7Bheight%3A20px%3Bmargin%2Dbottom%3A20px%3Boverflow%3Ahidden%3Bbackground%2Dcolor%3A%23f5f5f5%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%202px%20rgba%280%2C0%2C0%2C%2E1%29%3Bbox%2Dshadow%3Ainset%200%201px%202px%20rgba%280%2C0%2C0%2C%2E1%29%7D%2Eprogress%2Dbar%7Bfloat%3Aleft%3Bwidth%3A0%3Bheight%3A100%25%3Bfont%2Dsize%3A12px%3Bline%2Dheight%3A20px%3Bcolor%3A%23fff%3Btext%2Dalign%3Acenter%3Bbackground%2Dcolor%3A%23337ab7%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%20%2D1px%200%20rgba%280%2C0%2C0%2C%2E15%29%3Bbox%2Dshadow%3Ainset%200%20%2D1px%200%20rgba%280%2C0%2C0%2C%2E15%29%3B%2Dwebkit%2Dtransition%3Awidth%20%2E6s%20ease%3B%2Do%2Dtransition%3Awidth%20%2E6s%20ease%3Btransition%3Awidth%20%2E6s%20ease%7D%2Eprogress%2Dbar%2Dstriped%2C%2Eprogress%2Dstriped%20%2Eprogress%2Dbar%7Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3Alinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3B%2Dwebkit%2Dbackground%2Dsize%3A40px%2040px%3Bbackground%2Dsize%3A40px%2040px%7D%2Eprogress%2Dbar%2Eactive%2C%2Eprogress%2Eactive%20%2Eprogress%2Dbar%7B%2Dwebkit%2Danimation%3Aprogress%2Dbar%2Dstripes%202s%20linear%20infinite%3B%2Do%2Danimation%3Aprogress%2Dbar%2Dstripes%202s%20linear%20infinite%3Banimation%3Aprogress%2Dbar%2Dstripes%202s%20linear%20infinite%7D%2Eprogress%2Dbar%2Dsuccess%7Bbackground%2Dcolor%3A%235cb85c%7D%2Eprogress%2Dstriped%20%2Eprogress%2Dbar%2Dsuccess%7Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3Alinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%7D%2Eprogress%2Dbar%2Dinfo%7Bbackground%2Dcolor%3A%235bc0de%7D%2Eprogress%2Dstriped%20%2Eprogress%2Dbar%2Dinfo%7Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3Alinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%7D%2Eprogress%2Dbar%2Dwarning%7Bbackground%2Dcolor%3A%23f0ad4e%7D%2Eprogress%2Dstriped%20%2Eprogress%2Dbar%2Dwarning%7Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3Alinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%7D%2Eprogress%2Dbar%2Ddanger%7Bbackground%2Dcolor%3A%23d9534f%7D%2Eprogress%2Dstriped%20%2Eprogress%2Dbar%2Ddanger%7Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%3Bbackground%2Dimage%3Alinear%2Dgradient%2845deg%2Crgba%28255%2C255%2C255%2C%2E15%29%2025%25%2Ctransparent%2025%25%2Ctransparent%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2050%25%2Crgba%28255%2C255%2C255%2C%2E15%29%2075%25%2Ctransparent%2075%25%2Ctransparent%29%7D%2Emedia%7Bmargin%2Dtop%3A15px%7D%2Emedia%3Afirst%2Dchild%7Bmargin%2Dtop%3A0%7D%2Emedia%2C%2Emedia%2Dbody%7Boverflow%3Ahidden%3Bzoom%3A1%7D%2Emedia%2Dbody%7Bwidth%3A10000px%7D%2Emedia%2Dobject%7Bdisplay%3Ablock%7D%2Emedia%2Dobject%2Eimg%2Dthumbnail%7Bmax%2Dwidth%3Anone%7D%2Emedia%2Dright%2C%2Emedia%3E%2Epull%2Dright%7Bpadding%2Dleft%3A10px%7D%2Emedia%2Dleft%2C%2Emedia%3E%2Epull%2Dleft%7Bpadding%2Dright%3A10px%7D%2Emedia%2Dbody%2C%2Emedia%2Dleft%2C%2Emedia%2Dright%7Bdisplay%3Atable%2Dcell%3Bvertical%2Dalign%3Atop%7D%2Emedia%2Dmiddle%7Bvertical%2Dalign%3Amiddle%7D%2Emedia%2Dbottom%7Bvertical%2Dalign%3Abottom%7D%2Emedia%2Dheading%7Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A5px%7D%2Emedia%2Dlist%7Bpadding%2Dleft%3A0%3Blist%2Dstyle%3Anone%7D%2Elist%2Dgroup%7Bpadding%2Dleft%3A0%3Bmargin%2Dbottom%3A20px%7D%2Elist%2Dgroup%2Ditem%7Bposition%3Arelative%3Bdisplay%3Ablock%3Bpadding%3A10px%2015px%3Bmargin%2Dbottom%3A%2D1px%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20%23ddd%7D%2Elist%2Dgroup%2Ditem%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A4px%3Bborder%2Dtop%2Dright%2Dradius%3A4px%7D%2Elist%2Dgroup%2Ditem%3Alast%2Dchild%7Bmargin%2Dbottom%3A0%3Bborder%2Dbottom%2Dright%2Dradius%3A4px%3Bborder%2Dbottom%2Dleft%2Dradius%3A4px%7Da%2Elist%2Dgroup%2Ditem%2Cbutton%2Elist%2Dgroup%2Ditem%7Bcolor%3A%23555%7Da%2Elist%2Dgroup%2Ditem%20%2Elist%2Dgroup%2Ditem%2Dheading%2Cbutton%2Elist%2Dgroup%2Ditem%20%2Elist%2Dgroup%2Ditem%2Dheading%7Bcolor%3A%23333%7Da%2Elist%2Dgroup%2Ditem%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%3Ahover%7Bcolor%3A%23555%3Btext%2Ddecoration%3Anone%3Bbackground%2Dcolor%3A%23f5f5f5%7Dbutton%2Elist%2Dgroup%2Ditem%7Bwidth%3A100%25%3Btext%2Dalign%3Aleft%7D%2Elist%2Dgroup%2Ditem%2Edisabled%2C%2Elist%2Dgroup%2Ditem%2Edisabled%3Afocus%2C%2Elist%2Dgroup%2Ditem%2Edisabled%3Ahover%7Bcolor%3A%23777%3Bcursor%3Anot%2Dallowed%3Bbackground%2Dcolor%3A%23eee%7D%2Elist%2Dgroup%2Ditem%2Edisabled%20%2Elist%2Dgroup%2Ditem%2Dheading%2C%2Elist%2Dgroup%2Ditem%2Edisabled%3Afocus%20%2Elist%2Dgroup%2Ditem%2Dheading%2C%2Elist%2Dgroup%2Ditem%2Edisabled%3Ahover%20%2Elist%2Dgroup%2Ditem%2Dheading%7Bcolor%3Ainherit%7D%2Elist%2Dgroup%2Ditem%2Edisabled%20%2Elist%2Dgroup%2Ditem%2Dtext%2C%2Elist%2Dgroup%2Ditem%2Edisabled%3Afocus%20%2Elist%2Dgroup%2Ditem%2Dtext%2C%2Elist%2Dgroup%2Ditem%2Edisabled%3Ahover%20%2Elist%2Dgroup%2Ditem%2Dtext%7Bcolor%3A%23777%7D%2Elist%2Dgroup%2Ditem%2Eactive%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Afocus%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Ahover%7Bz%2Dindex%3A2%3Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23337ab7%3Bborder%2Dcolor%3A%23337ab7%7D%2Elist%2Dgroup%2Ditem%2Eactive%20%2Elist%2Dgroup%2Ditem%2Dheading%2C%2Elist%2Dgroup%2Ditem%2Eactive%20%2Elist%2Dgroup%2Ditem%2Dheading%3E%2Esmall%2C%2Elist%2Dgroup%2Ditem%2Eactive%20%2Elist%2Dgroup%2Ditem%2Dheading%3Esmall%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Afocus%20%2Elist%2Dgroup%2Ditem%2Dheading%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Afocus%20%2Elist%2Dgroup%2Ditem%2Dheading%3E%2Esmall%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Afocus%20%2Elist%2Dgroup%2Ditem%2Dheading%3Esmall%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Ahover%20%2Elist%2Dgroup%2Ditem%2Dheading%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Ahover%20%2Elist%2Dgroup%2Ditem%2Dheading%3E%2Esmall%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Ahover%20%2Elist%2Dgroup%2Ditem%2Dheading%3Esmall%7Bcolor%3Ainherit%7D%2Elist%2Dgroup%2Ditem%2Eactive%20%2Elist%2Dgroup%2Ditem%2Dtext%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Afocus%20%2Elist%2Dgroup%2Ditem%2Dtext%2C%2Elist%2Dgroup%2Ditem%2Eactive%3Ahover%20%2Elist%2Dgroup%2Ditem%2Dtext%7Bcolor%3A%23c7ddef%7D%2Elist%2Dgroup%2Ditem%2Dsuccess%7Bcolor%3A%233c763d%3Bbackground%2Dcolor%3A%23dff0d8%7Da%2Elist%2Dgroup%2Ditem%2Dsuccess%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%7Bcolor%3A%233c763d%7Da%2Elist%2Dgroup%2Ditem%2Dsuccess%20%2Elist%2Dgroup%2Ditem%2Dheading%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%20%2Elist%2Dgroup%2Ditem%2Dheading%7Bcolor%3Ainherit%7Da%2Elist%2Dgroup%2Ditem%2Dsuccess%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Dsuccess%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%3Ahover%7Bcolor%3A%233c763d%3Bbackground%2Dcolor%3A%23d0e9c6%7Da%2Elist%2Dgroup%2Ditem%2Dsuccess%2Eactive%2Ca%2Elist%2Dgroup%2Ditem%2Dsuccess%2Eactive%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Dsuccess%2Eactive%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%2Eactive%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%2Eactive%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Dsuccess%2Eactive%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%233c763d%3Bborder%2Dcolor%3A%233c763d%7D%2Elist%2Dgroup%2Ditem%2Dinfo%7Bcolor%3A%2331708f%3Bbackground%2Dcolor%3A%23d9edf7%7Da%2Elist%2Dgroup%2Ditem%2Dinfo%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%7Bcolor%3A%2331708f%7Da%2Elist%2Dgroup%2Ditem%2Dinfo%20%2Elist%2Dgroup%2Ditem%2Dheading%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%20%2Elist%2Dgroup%2Ditem%2Dheading%7Bcolor%3Ainherit%7Da%2Elist%2Dgroup%2Ditem%2Dinfo%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Dinfo%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%3Ahover%7Bcolor%3A%2331708f%3Bbackground%2Dcolor%3A%23c4e3f3%7Da%2Elist%2Dgroup%2Ditem%2Dinfo%2Eactive%2Ca%2Elist%2Dgroup%2Ditem%2Dinfo%2Eactive%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Dinfo%2Eactive%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%2Eactive%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%2Eactive%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Dinfo%2Eactive%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%2331708f%3Bborder%2Dcolor%3A%2331708f%7D%2Elist%2Dgroup%2Ditem%2Dwarning%7Bcolor%3A%238a6d3b%3Bbackground%2Dcolor%3A%23fcf8e3%7Da%2Elist%2Dgroup%2Ditem%2Dwarning%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%7Bcolor%3A%238a6d3b%7Da%2Elist%2Dgroup%2Ditem%2Dwarning%20%2Elist%2Dgroup%2Ditem%2Dheading%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%20%2Elist%2Dgroup%2Ditem%2Dheading%7Bcolor%3Ainherit%7Da%2Elist%2Dgroup%2Ditem%2Dwarning%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Dwarning%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%3Ahover%7Bcolor%3A%238a6d3b%3Bbackground%2Dcolor%3A%23faf2cc%7Da%2Elist%2Dgroup%2Ditem%2Dwarning%2Eactive%2Ca%2Elist%2Dgroup%2Ditem%2Dwarning%2Eactive%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Dwarning%2Eactive%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%2Eactive%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%2Eactive%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Dwarning%2Eactive%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%238a6d3b%3Bborder%2Dcolor%3A%238a6d3b%7D%2Elist%2Dgroup%2Ditem%2Ddanger%7Bcolor%3A%23a94442%3Bbackground%2Dcolor%3A%23f2dede%7Da%2Elist%2Dgroup%2Ditem%2Ddanger%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%7Bcolor%3A%23a94442%7Da%2Elist%2Dgroup%2Ditem%2Ddanger%20%2Elist%2Dgroup%2Ditem%2Dheading%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%20%2Elist%2Dgroup%2Ditem%2Dheading%7Bcolor%3Ainherit%7Da%2Elist%2Dgroup%2Ditem%2Ddanger%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Ddanger%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%3Ahover%7Bcolor%3A%23a94442%3Bbackground%2Dcolor%3A%23ebcccc%7Da%2Elist%2Dgroup%2Ditem%2Ddanger%2Eactive%2Ca%2Elist%2Dgroup%2Ditem%2Ddanger%2Eactive%3Afocus%2Ca%2Elist%2Dgroup%2Ditem%2Ddanger%2Eactive%3Ahover%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%2Eactive%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%2Eactive%3Afocus%2Cbutton%2Elist%2Dgroup%2Ditem%2Ddanger%2Eactive%3Ahover%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23a94442%3Bborder%2Dcolor%3A%23a94442%7D%2Elist%2Dgroup%2Ditem%2Dheading%7Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A5px%7D%2Elist%2Dgroup%2Ditem%2Dtext%7Bmargin%2Dbottom%3A0%3Bline%2Dheight%3A1%2E3%7D%2Epanel%7Bmargin%2Dbottom%3A20px%3Bbackground%2Dcolor%3A%23fff%3Bborder%3A1px%20solid%20transparent%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dbox%2Dshadow%3A0%201px%201px%20rgba%280%2C0%2C0%2C%2E05%29%3Bbox%2Dshadow%3A0%201px%201px%20rgba%280%2C0%2C0%2C%2E05%29%7D%2Epanel%2Dbody%7Bpadding%3A15px%7D%2Epanel%2Dheading%7Bpadding%3A10px%2015px%3Bborder%2Dbottom%3A1px%20solid%20transparent%3Bborder%2Dtop%2Dleft%2Dradius%3A3px%3Bborder%2Dtop%2Dright%2Dradius%3A3px%7D%2Epanel%2Dheading%3E%2Edropdown%20%2Edropdown%2Dtoggle%7Bcolor%3Ainherit%7D%2Epanel%2Dtitle%7Bmargin%2Dtop%3A0%3Bmargin%2Dbottom%3A0%3Bfont%2Dsize%3A16px%3Bcolor%3Ainherit%7D%2Epanel%2Dtitle%3E%2Esmall%2C%2Epanel%2Dtitle%3E%2Esmall%3Ea%2C%2Epanel%2Dtitle%3Ea%2C%2Epanel%2Dtitle%3Esmall%2C%2Epanel%2Dtitle%3Esmall%3Ea%7Bcolor%3Ainherit%7D%2Epanel%2Dfooter%7Bpadding%3A10px%2015px%3Bbackground%2Dcolor%3A%23f5f5f5%3Bborder%2Dtop%3A1px%20solid%20%23ddd%3Bborder%2Dbottom%2Dright%2Dradius%3A3px%3Bborder%2Dbottom%2Dleft%2Dradius%3A3px%7D%2Epanel%3E%2Elist%2Dgroup%2C%2Epanel%3E%2Epanel%2Dcollapse%3E%2Elist%2Dgroup%7Bmargin%2Dbottom%3A0%7D%2Epanel%3E%2Elist%2Dgroup%20%2Elist%2Dgroup%2Ditem%2C%2Epanel%3E%2Epanel%2Dcollapse%3E%2Elist%2Dgroup%20%2Elist%2Dgroup%2Ditem%7Bborder%2Dwidth%3A1px%200%3Bborder%2Dradius%3A0%7D%2Epanel%3E%2Elist%2Dgroup%3Afirst%2Dchild%20%2Elist%2Dgroup%2Ditem%3Afirst%2Dchild%2C%2Epanel%3E%2Epanel%2Dcollapse%3E%2Elist%2Dgroup%3Afirst%2Dchild%20%2Elist%2Dgroup%2Ditem%3Afirst%2Dchild%7Bborder%2Dtop%3A0%3Bborder%2Dtop%2Dleft%2Dradius%3A3px%3Bborder%2Dtop%2Dright%2Dradius%3A3px%7D%2Epanel%3E%2Elist%2Dgroup%3Alast%2Dchild%20%2Elist%2Dgroup%2Ditem%3Alast%2Dchild%2C%2Epanel%3E%2Epanel%2Dcollapse%3E%2Elist%2Dgroup%3Alast%2Dchild%20%2Elist%2Dgroup%2Ditem%3Alast%2Dchild%7Bborder%2Dbottom%3A0%3Bborder%2Dbottom%2Dright%2Dradius%3A3px%3Bborder%2Dbottom%2Dleft%2Dradius%3A3px%7D%2Epanel%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Elist%2Dgroup%20%2Elist%2Dgroup%2Ditem%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A0%3Bborder%2Dtop%2Dright%2Dradius%3A0%7D%2Epanel%2Dheading%2B%2Elist%2Dgroup%20%2Elist%2Dgroup%2Ditem%3Afirst%2Dchild%7Bborder%2Dtop%2Dwidth%3A0%7D%2Elist%2Dgroup%2B%2Epanel%2Dfooter%7Bborder%2Dtop%2Dwidth%3A0%7D%2Epanel%3E%2Epanel%2Dcollapse%3E%2Etable%2C%2Epanel%3E%2Etable%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%7Bmargin%2Dbottom%3A0%7D%2Epanel%3E%2Epanel%2Dcollapse%3E%2Etable%20caption%2C%2Epanel%3E%2Etable%20caption%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%20caption%7Bpadding%2Dright%3A15px%3Bpadding%2Dleft%3A15px%7D%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A3px%3Bborder%2Dtop%2Dright%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A3px%3Bborder%2Dtop%2Dright%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Afirst%2Dchild%7Bborder%2Dtop%2Dleft%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Afirst%2Dchild%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Afirst%2Dchild%3Ethead%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%3Alast%2Dchild%7Bborder%2Dtop%2Dright%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%7Bborder%2Dbottom%2Dright%2Dradius%3A3px%3Bborder%2Dbottom%2Dleft%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%7Bborder%2Dbottom%2Dright%2Dradius%3A3px%3Bborder%2Dbottom%2Dleft%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Afirst%2Dchild%7Bborder%2Dbottom%2Dleft%2Dradius%3A3px%7D%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3Alast%2Dchild%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etbody%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20td%3Alast%2Dchild%2C%2Epanel%3E%2Etable%3Alast%2Dchild%3Etfoot%3Alast%2Dchild%3Etr%3Alast%2Dchild%20th%3Alast%2Dchild%7Bborder%2Dbottom%2Dright%2Dradius%3A3px%7D%2Epanel%3E%2Epanel%2Dbody%2B%2Etable%2C%2Epanel%3E%2Epanel%2Dbody%2B%2Etable%2Dresponsive%2C%2Epanel%3E%2Etable%2B%2Epanel%2Dbody%2C%2Epanel%3E%2Etable%2Dresponsive%2B%2Epanel%2Dbody%7Bborder%2Dtop%3A1px%20solid%20%23ddd%7D%2Epanel%3E%2Etable%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20td%2C%2Epanel%3E%2Etable%3Etbody%3Afirst%2Dchild%3Etr%3Afirst%2Dchild%20th%7Bborder%2Dtop%3A0%7D%2Epanel%3E%2Etable%2Dbordered%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%7Bborder%3A0%7D%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Etd%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Eth%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Ethead%3Etr%3Etd%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Ethead%3Etr%3Eth%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Etd%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Eth%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Etd%3Afirst%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Eth%3Afirst%2Dchild%7Bborder%2Dleft%3A0%7D%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Etd%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Eth%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Ethead%3Etr%3Etd%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dbordered%3Ethead%3Etr%3Eth%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Etd%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Eth%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Etd%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Eth%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Etd%3Alast%2Dchild%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Eth%3Alast%2Dchild%7Bborder%2Dright%3A0%7D%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Afirst%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Afirst%2Dchild%3Eth%2C%2Epanel%3E%2Etable%2Dbordered%3Ethead%3Etr%3Afirst%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dbordered%3Ethead%3Etr%3Afirst%2Dchild%3Eth%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Afirst%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Afirst%2Dchild%3Eth%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Afirst%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Ethead%3Etr%3Afirst%2Dchild%3Eth%7Bborder%2Dbottom%3A0%7D%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Alast%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dbordered%3Etbody%3Etr%3Alast%2Dchild%3Eth%2C%2Epanel%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Alast%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Alast%2Dchild%3Eth%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Alast%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etbody%3Etr%3Alast%2Dchild%3Eth%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Alast%2Dchild%3Etd%2C%2Epanel%3E%2Etable%2Dresponsive%3E%2Etable%2Dbordered%3Etfoot%3Etr%3Alast%2Dchild%3Eth%7Bborder%2Dbottom%3A0%7D%2Epanel%3E%2Etable%2Dresponsive%7Bmargin%2Dbottom%3A0%3Bborder%3A0%7D%2Epanel%2Dgroup%7Bmargin%2Dbottom%3A20px%7D%2Epanel%2Dgroup%20%2Epanel%7Bmargin%2Dbottom%3A0%3Bborder%2Dradius%3A4px%7D%2Epanel%2Dgroup%20%2Epanel%2B%2Epanel%7Bmargin%2Dtop%3A5px%7D%2Epanel%2Dgroup%20%2Epanel%2Dheading%7Bborder%2Dbottom%3A0%7D%2Epanel%2Dgroup%20%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Elist%2Dgroup%2C%2Epanel%2Dgroup%20%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%3A1px%20solid%20%23ddd%7D%2Epanel%2Dgroup%20%2Epanel%2Dfooter%7Bborder%2Dtop%3A0%7D%2Epanel%2Dgroup%20%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%20%2Epanel%2Dbody%7Bborder%2Dbottom%3A1px%20solid%20%23ddd%7D%2Epanel%2Ddefault%7Bborder%2Dcolor%3A%23ddd%7D%2Epanel%2Ddefault%3E%2Epanel%2Dheading%7Bcolor%3A%23333%3Bbackground%2Dcolor%3A%23f5f5f5%3Bborder%2Dcolor%3A%23ddd%7D%2Epanel%2Ddefault%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%2Dcolor%3A%23ddd%7D%2Epanel%2Ddefault%3E%2Epanel%2Dheading%20%2Ebadge%7Bcolor%3A%23f5f5f5%3Bbackground%2Dcolor%3A%23333%7D%2Epanel%2Ddefault%3E%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dbottom%2Dcolor%3A%23ddd%7D%2Epanel%2Dprimary%7Bborder%2Dcolor%3A%23337ab7%7D%2Epanel%2Dprimary%3E%2Epanel%2Dheading%7Bcolor%3A%23fff%3Bbackground%2Dcolor%3A%23337ab7%3Bborder%2Dcolor%3A%23337ab7%7D%2Epanel%2Dprimary%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%2Dcolor%3A%23337ab7%7D%2Epanel%2Dprimary%3E%2Epanel%2Dheading%20%2Ebadge%7Bcolor%3A%23337ab7%3Bbackground%2Dcolor%3A%23fff%7D%2Epanel%2Dprimary%3E%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dbottom%2Dcolor%3A%23337ab7%7D%2Epanel%2Dsuccess%7Bborder%2Dcolor%3A%23d6e9c6%7D%2Epanel%2Dsuccess%3E%2Epanel%2Dheading%7Bcolor%3A%233c763d%3Bbackground%2Dcolor%3A%23dff0d8%3Bborder%2Dcolor%3A%23d6e9c6%7D%2Epanel%2Dsuccess%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%2Dcolor%3A%23d6e9c6%7D%2Epanel%2Dsuccess%3E%2Epanel%2Dheading%20%2Ebadge%7Bcolor%3A%23dff0d8%3Bbackground%2Dcolor%3A%233c763d%7D%2Epanel%2Dsuccess%3E%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dbottom%2Dcolor%3A%23d6e9c6%7D%2Epanel%2Dinfo%7Bborder%2Dcolor%3A%23bce8f1%7D%2Epanel%2Dinfo%3E%2Epanel%2Dheading%7Bcolor%3A%2331708f%3Bbackground%2Dcolor%3A%23d9edf7%3Bborder%2Dcolor%3A%23bce8f1%7D%2Epanel%2Dinfo%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%2Dcolor%3A%23bce8f1%7D%2Epanel%2Dinfo%3E%2Epanel%2Dheading%20%2Ebadge%7Bcolor%3A%23d9edf7%3Bbackground%2Dcolor%3A%2331708f%7D%2Epanel%2Dinfo%3E%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dbottom%2Dcolor%3A%23bce8f1%7D%2Epanel%2Dwarning%7Bborder%2Dcolor%3A%23faebcc%7D%2Epanel%2Dwarning%3E%2Epanel%2Dheading%7Bcolor%3A%238a6d3b%3Bbackground%2Dcolor%3A%23fcf8e3%3Bborder%2Dcolor%3A%23faebcc%7D%2Epanel%2Dwarning%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%2Dcolor%3A%23faebcc%7D%2Epanel%2Dwarning%3E%2Epanel%2Dheading%20%2Ebadge%7Bcolor%3A%23fcf8e3%3Bbackground%2Dcolor%3A%238a6d3b%7D%2Epanel%2Dwarning%3E%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dbottom%2Dcolor%3A%23faebcc%7D%2Epanel%2Ddanger%7Bborder%2Dcolor%3A%23ebccd1%7D%2Epanel%2Ddanger%3E%2Epanel%2Dheading%7Bcolor%3A%23a94442%3Bbackground%2Dcolor%3A%23f2dede%3Bborder%2Dcolor%3A%23ebccd1%7D%2Epanel%2Ddanger%3E%2Epanel%2Dheading%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dtop%2Dcolor%3A%23ebccd1%7D%2Epanel%2Ddanger%3E%2Epanel%2Dheading%20%2Ebadge%7Bcolor%3A%23f2dede%3Bbackground%2Dcolor%3A%23a94442%7D%2Epanel%2Ddanger%3E%2Epanel%2Dfooter%2B%2Epanel%2Dcollapse%3E%2Epanel%2Dbody%7Bborder%2Dbottom%2Dcolor%3A%23ebccd1%7D%2Eembed%2Dresponsive%7Bposition%3Arelative%3Bdisplay%3Ablock%3Bheight%3A0%3Bpadding%3A0%3Boverflow%3Ahidden%7D%2Eembed%2Dresponsive%20%2Eembed%2Dresponsive%2Ditem%2C%2Eembed%2Dresponsive%20embed%2C%2Eembed%2Dresponsive%20iframe%2C%2Eembed%2Dresponsive%20object%2C%2Eembed%2Dresponsive%20video%7Bposition%3Aabsolute%3Btop%3A0%3Bbottom%3A0%3Bleft%3A0%3Bwidth%3A100%25%3Bheight%3A100%25%3Bborder%3A0%7D%2Eembed%2Dresponsive%2D16by9%7Bpadding%2Dbottom%3A56%2E25%25%7D%2Eembed%2Dresponsive%2D4by3%7Bpadding%2Dbottom%3A75%25%7D%2Ewell%7Bmin%2Dheight%3A20px%3Bpadding%3A19px%3Bmargin%2Dbottom%3A20px%3Bbackground%2Dcolor%3A%23f5f5f5%3Bborder%3A1px%20solid%20%23e3e3e3%3Bborder%2Dradius%3A4px%3B%2Dwebkit%2Dbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E05%29%3Bbox%2Dshadow%3Ainset%200%201px%201px%20rgba%280%2C0%2C0%2C%2E05%29%7D%2Ewell%20blockquote%7Bborder%2Dcolor%3A%23ddd%3Bborder%2Dcolor%3Argba%280%2C0%2C0%2C%2E15%29%7D%2Ewell%2Dlg%7Bpadding%3A24px%3Bborder%2Dradius%3A6px%7D%2Ewell%2Dsm%7Bpadding%3A9px%3Bborder%2Dradius%3A3px%7D%2Eclose%7Bfloat%3Aright%3Bfont%2Dsize%3A21px%3Bfont%2Dweight%3A700%3Bline%2Dheight%3A1%3Bcolor%3A%23000%3Btext%2Dshadow%3A0%201px%200%20%23fff%3Bfilter%3Aalpha%28opacity%3D20%29%3Bopacity%3A%2E2%7D%2Eclose%3Afocus%2C%2Eclose%3Ahover%7Bcolor%3A%23000%3Btext%2Ddecoration%3Anone%3Bcursor%3Apointer%3Bfilter%3Aalpha%28opacity%3D50%29%3Bopacity%3A%2E5%7Dbutton%2Eclose%7B%2Dwebkit%2Dappearance%3Anone%3Bpadding%3A0%3Bcursor%3Apointer%3Bbackground%3A0%200%3Bborder%3A0%7D%2Emodal%2Dopen%7Boverflow%3Ahidden%7D%2Emodal%7Bposition%3Afixed%3Btop%3A0%3Bright%3A0%3Bbottom%3A0%3Bleft%3A0%3Bz%2Dindex%3A1050%3Bdisplay%3Anone%3Boverflow%3Ahidden%3B%2Dwebkit%2Doverflow%2Dscrolling%3Atouch%3Boutline%3A0%7D%2Emodal%2Efade%20%2Emodal%2Ddialog%7B%2Dwebkit%2Dtransition%3A%2Dwebkit%2Dtransform%20%2E3s%20ease%2Dout%3B%2Do%2Dtransition%3A%2Do%2Dtransform%20%2E3s%20ease%2Dout%3Btransition%3Atransform%20%2E3s%20ease%2Dout%3B%2Dwebkit%2Dtransform%3Atranslate%280%2C%2D25%25%29%3B%2Dms%2Dtransform%3Atranslate%280%2C%2D25%25%29%3B%2Do%2Dtransform%3Atranslate%280%2C%2D25%25%29%3Btransform%3Atranslate%280%2C%2D25%25%29%7D%2Emodal%2Ein%20%2Emodal%2Ddialog%7B%2Dwebkit%2Dtransform%3Atranslate%280%2C0%29%3B%2Dms%2Dtransform%3Atranslate%280%2C0%29%3B%2Do%2Dtransform%3Atranslate%280%2C0%29%3Btransform%3Atranslate%280%2C0%29%7D%2Emodal%2Dopen%20%2Emodal%7Boverflow%2Dx%3Ahidden%3Boverflow%2Dy%3Aauto%7D%2Emodal%2Ddialog%7Bposition%3Arelative%3Bwidth%3Aauto%3Bmargin%3A10px%7D%2Emodal%2Dcontent%7Bposition%3Arelative%3Bbackground%2Dcolor%3A%23fff%3B%2Dwebkit%2Dbackground%2Dclip%3Apadding%2Dbox%3Bbackground%2Dclip%3Apadding%2Dbox%3Bborder%3A1px%20solid%20%23999%3Bborder%3A1px%20solid%20rgba%280%2C0%2C0%2C%2E2%29%3Bborder%2Dradius%3A6px%3Boutline%3A0%3B%2Dwebkit%2Dbox%2Dshadow%3A0%203px%209px%20rgba%280%2C0%2C0%2C%2E5%29%3Bbox%2Dshadow%3A0%203px%209px%20rgba%280%2C0%2C0%2C%2E5%29%7D%2Emodal%2Dbackdrop%7Bposition%3Afixed%3Btop%3A0%3Bright%3A0%3Bbottom%3A0%3Bleft%3A0%3Bz%2Dindex%3A1040%3Bbackground%2Dcolor%3A%23000%7D%2Emodal%2Dbackdrop%2Efade%7Bfilter%3Aalpha%28opacity%3D0%29%3Bopacity%3A0%7D%2Emodal%2Dbackdrop%2Ein%7Bfilter%3Aalpha%28opacity%3D50%29%3Bopacity%3A%2E5%7D%2Emodal%2Dheader%7Bmin%2Dheight%3A16%2E43px%3Bpadding%3A15px%3Bborder%2Dbottom%3A1px%20solid%20%23e5e5e5%7D%2Emodal%2Dheader%20%2Eclose%7Bmargin%2Dtop%3A%2D2px%7D%2Emodal%2Dtitle%7Bmargin%3A0%3Bline%2Dheight%3A1%2E42857143%7D%2Emodal%2Dbody%7Bposition%3Arelative%3Bpadding%3A15px%7D%2Emodal%2Dfooter%7Bpadding%3A15px%3Btext%2Dalign%3Aright%3Bborder%2Dtop%3A1px%20solid%20%23e5e5e5%7D%2Emodal%2Dfooter%20%2Ebtn%2B%2Ebtn%7Bmargin%2Dbottom%3A0%3Bmargin%2Dleft%3A5px%7D%2Emodal%2Dfooter%20%2Ebtn%2Dgroup%20%2Ebtn%2B%2Ebtn%7Bmargin%2Dleft%3A%2D1px%7D%2Emodal%2Dfooter%20%2Ebtn%2Dblock%2B%2Ebtn%2Dblock%7Bmargin%2Dleft%3A0%7D%2Emodal%2Dscrollbar%2Dmeasure%7Bposition%3Aabsolute%3Btop%3A%2D9999px%3Bwidth%3A50px%3Bheight%3A50px%3Boverflow%3Ascroll%7D%40media%20%28min%2Dwidth%3A768px%29%7B%2Emodal%2Ddialog%7Bwidth%3A600px%3Bmargin%3A30px%20auto%7D%2Emodal%2Dcontent%7B%2Dwebkit%2Dbox%2Dshadow%3A0%205px%2015px%20rgba%280%2C0%2C0%2C%2E5%29%3Bbox%2Dshadow%3A0%205px%2015px%20rgba%280%2C0%2C0%2C%2E5%29%7D%2Emodal%2Dsm%7Bwidth%3A300px%7D%7D%40media%20%28min%2Dwidth%3A992px%29%7B%2Emodal%2Dlg%7Bwidth%3A900px%7D%7D%2Etooltip%7Bposition%3Aabsolute%3Bz%2Dindex%3A1070%3Bdisplay%3Ablock%3Bfont%2Dfamily%3A%22Helvetica%20Neue%22%2CHelvetica%2CArial%2Csans%2Dserif%3Bfont%2Dsize%3A12px%3Bfont%2Dstyle%3Anormal%3Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%2E42857143%3Btext%2Dalign%3Aleft%3Btext%2Dalign%3Astart%3Btext%2Ddecoration%3Anone%3Btext%2Dshadow%3Anone%3Btext%2Dtransform%3Anone%3Bletter%2Dspacing%3Anormal%3Bword%2Dbreak%3Anormal%3Bword%2Dspacing%3Anormal%3Bword%2Dwrap%3Anormal%3Bwhite%2Dspace%3Anormal%3Bfilter%3Aalpha%28opacity%3D0%29%3Bopacity%3A0%3Bline%2Dbreak%3Aauto%7D%2Etooltip%2Ein%7Bfilter%3Aalpha%28opacity%3D90%29%3Bopacity%3A%2E9%7D%2Etooltip%2Etop%7Bpadding%3A5px%200%3Bmargin%2Dtop%3A%2D3px%7D%2Etooltip%2Eright%7Bpadding%3A0%205px%3Bmargin%2Dleft%3A3px%7D%2Etooltip%2Ebottom%7Bpadding%3A5px%200%3Bmargin%2Dtop%3A3px%7D%2Etooltip%2Eleft%7Bpadding%3A0%205px%3Bmargin%2Dleft%3A%2D3px%7D%2Etooltip%2Dinner%7Bmax%2Dwidth%3A200px%3Bpadding%3A3px%208px%3Bcolor%3A%23fff%3Btext%2Dalign%3Acenter%3Bbackground%2Dcolor%3A%23000%3Bborder%2Dradius%3A4px%7D%2Etooltip%2Darrow%7Bposition%3Aabsolute%3Bwidth%3A0%3Bheight%3A0%3Bborder%2Dcolor%3Atransparent%3Bborder%2Dstyle%3Asolid%7D%2Etooltip%2Etop%20%2Etooltip%2Darrow%7Bbottom%3A0%3Bleft%3A50%25%3Bmargin%2Dleft%3A%2D5px%3Bborder%2Dwidth%3A5px%205px%200%3Bborder%2Dtop%2Dcolor%3A%23000%7D%2Etooltip%2Etop%2Dleft%20%2Etooltip%2Darrow%7Bright%3A5px%3Bbottom%3A0%3Bmargin%2Dbottom%3A%2D5px%3Bborder%2Dwidth%3A5px%205px%200%3Bborder%2Dtop%2Dcolor%3A%23000%7D%2Etooltip%2Etop%2Dright%20%2Etooltip%2Darrow%7Bbottom%3A0%3Bleft%3A5px%3Bmargin%2Dbottom%3A%2D5px%3Bborder%2Dwidth%3A5px%205px%200%3Bborder%2Dtop%2Dcolor%3A%23000%7D%2Etooltip%2Eright%20%2Etooltip%2Darrow%7Btop%3A50%25%3Bleft%3A0%3Bmargin%2Dtop%3A%2D5px%3Bborder%2Dwidth%3A5px%205px%205px%200%3Bborder%2Dright%2Dcolor%3A%23000%7D%2Etooltip%2Eleft%20%2Etooltip%2Darrow%7Btop%3A50%25%3Bright%3A0%3Bmargin%2Dtop%3A%2D5px%3Bborder%2Dwidth%3A5px%200%205px%205px%3Bborder%2Dleft%2Dcolor%3A%23000%7D%2Etooltip%2Ebottom%20%2Etooltip%2Darrow%7Btop%3A0%3Bleft%3A50%25%3Bmargin%2Dleft%3A%2D5px%3Bborder%2Dwidth%3A0%205px%205px%3Bborder%2Dbottom%2Dcolor%3A%23000%7D%2Etooltip%2Ebottom%2Dleft%20%2Etooltip%2Darrow%7Btop%3A0%3Bright%3A5px%3Bmargin%2Dtop%3A%2D5px%3Bborder%2Dwidth%3A0%205px%205px%3Bborder%2Dbottom%2Dcolor%3A%23000%7D%2Etooltip%2Ebottom%2Dright%20%2Etooltip%2Darrow%7Btop%3A0%3Bleft%3A5px%3Bmargin%2Dtop%3A%2D5px%3Bborder%2Dwidth%3A0%205px%205px%3Bborder%2Dbottom%2Dcolor%3A%23000%7D%2Epopover%7Bposition%3Aabsolute%3Btop%3A0%3Bleft%3A0%3Bz%2Dindex%3A1060%3Bdisplay%3Anone%3Bmax%2Dwidth%3A276px%3Bpadding%3A1px%3Bfont%2Dfamily%3A%22Helvetica%20Neue%22%2CHelvetica%2CArial%2Csans%2Dserif%3Bfont%2Dsize%3A14px%3Bfont%2Dstyle%3Anormal%3Bfont%2Dweight%3A400%3Bline%2Dheight%3A1%2E42857143%3Btext%2Dalign%3Aleft%3Btext%2Dalign%3Astart%3Btext%2Ddecoration%3Anone%3Btext%2Dshadow%3Anone%3Btext%2Dtransform%3Anone%3Bletter%2Dspacing%3Anormal%3Bword%2Dbreak%3Anormal%3Bword%2Dspacing%3Anormal%3Bword%2Dwrap%3Anormal%3Bwhite%2Dspace%3Anormal%3Bbackground%2Dcolor%3A%23fff%3B%2Dwebkit%2Dbackground%2Dclip%3Apadding%2Dbox%3Bbackground%2Dclip%3Apadding%2Dbox%3Bborder%3A1px%20solid%20%23ccc%3Bborder%3A1px%20solid%20rgba%280%2C0%2C0%2C%2E2%29%3Bborder%2Dradius%3A6px%3B%2Dwebkit%2Dbox%2Dshadow%3A0%205px%2010px%20rgba%280%2C0%2C0%2C%2E2%29%3Bbox%2Dshadow%3A0%205px%2010px%20rgba%280%2C0%2C0%2C%2E2%29%3Bline%2Dbreak%3Aauto%7D%2Epopover%2Etop%7Bmargin%2Dtop%3A%2D10px%7D%2Epopover%2Eright%7Bmargin%2Dleft%3A10px%7D%2Epopover%2Ebottom%7Bmargin%2Dtop%3A10px%7D%2Epopover%2Eleft%7Bmargin%2Dleft%3A%2D10px%7D%2Epopover%2Dtitle%7Bpadding%3A8px%2014px%3Bmargin%3A0%3Bfont%2Dsize%3A14px%3Bbackground%2Dcolor%3A%23f7f7f7%3Bborder%2Dbottom%3A1px%20solid%20%23ebebeb%3Bborder%2Dradius%3A5px%205px%200%200%7D%2Epopover%2Dcontent%7Bpadding%3A9px%2014px%7D%2Epopover%3E%2Earrow%2C%2Epopover%3E%2Earrow%3Aafter%7Bposition%3Aabsolute%3Bdisplay%3Ablock%3Bwidth%3A0%3Bheight%3A0%3Bborder%2Dcolor%3Atransparent%3Bborder%2Dstyle%3Asolid%7D%2Epopover%3E%2Earrow%7Bborder%2Dwidth%3A11px%7D%2Epopover%3E%2Earrow%3Aafter%7Bcontent%3A%22%22%3Bborder%2Dwidth%3A10px%7D%2Epopover%2Etop%3E%2Earrow%7Bbottom%3A%2D11px%3Bleft%3A50%25%3Bmargin%2Dleft%3A%2D11px%3Bborder%2Dtop%2Dcolor%3A%23999%3Bborder%2Dtop%2Dcolor%3Argba%280%2C0%2C0%2C%2E25%29%3Bborder%2Dbottom%2Dwidth%3A0%7D%2Epopover%2Etop%3E%2Earrow%3Aafter%7Bbottom%3A1px%3Bmargin%2Dleft%3A%2D10px%3Bcontent%3A%22%20%22%3Bborder%2Dtop%2Dcolor%3A%23fff%3Bborder%2Dbottom%2Dwidth%3A0%7D%2Epopover%2Eright%3E%2Earrow%7Btop%3A50%25%3Bleft%3A%2D11px%3Bmargin%2Dtop%3A%2D11px%3Bborder%2Dright%2Dcolor%3A%23999%3Bborder%2Dright%2Dcolor%3Argba%280%2C0%2C0%2C%2E25%29%3Bborder%2Dleft%2Dwidth%3A0%7D%2Epopover%2Eright%3E%2Earrow%3Aafter%7Bbottom%3A%2D10px%3Bleft%3A1px%3Bcontent%3A%22%20%22%3Bborder%2Dright%2Dcolor%3A%23fff%3Bborder%2Dleft%2Dwidth%3A0%7D%2Epopover%2Ebottom%3E%2Earrow%7Btop%3A%2D11px%3Bleft%3A50%25%3Bmargin%2Dleft%3A%2D11px%3Bborder%2Dtop%2Dwidth%3A0%3Bborder%2Dbottom%2Dcolor%3A%23999%3Bborder%2Dbottom%2Dcolor%3Argba%280%2C0%2C0%2C%2E25%29%7D%2Epopover%2Ebottom%3E%2Earrow%3Aafter%7Btop%3A1px%3Bmargin%2Dleft%3A%2D10px%3Bcontent%3A%22%20%22%3Bborder%2Dtop%2Dwidth%3A0%3Bborder%2Dbottom%2Dcolor%3A%23fff%7D%2Epopover%2Eleft%3E%2Earrow%7Btop%3A50%25%3Bright%3A%2D11px%3Bmargin%2Dtop%3A%2D11px%3Bborder%2Dright%2Dwidth%3A0%3Bborder%2Dleft%2Dcolor%3A%23999%3Bborder%2Dleft%2Dcolor%3Argba%280%2C0%2C0%2C%2E25%29%7D%2Epopover%2Eleft%3E%2Earrow%3Aafter%7Bright%3A1px%3Bbottom%3A%2D10px%3Bcontent%3A%22%20%22%3Bborder%2Dright%2Dwidth%3A0%3Bborder%2Dleft%2Dcolor%3A%23fff%7D%2Ecarousel%7Bposition%3Arelative%7D%2Ecarousel%2Dinner%7Bposition%3Arelative%3Bwidth%3A100%25%3Boverflow%3Ahidden%7D%2Ecarousel%2Dinner%3E%2Eitem%7Bposition%3Arelative%3Bdisplay%3Anone%3B%2Dwebkit%2Dtransition%3A%2E6s%20ease%2Din%2Dout%20left%3B%2Do%2Dtransition%3A%2E6s%20ease%2Din%2Dout%20left%3Btransition%3A%2E6s%20ease%2Din%2Dout%20left%7D%2Ecarousel%2Dinner%3E%2Eitem%3Ea%3Eimg%2C%2Ecarousel%2Dinner%3E%2Eitem%3Eimg%7Bline%2Dheight%3A1%7D%40media%20all%20and%20%28transform%2D3d%29%2C%28%2Dwebkit%2Dtransform%2D3d%29%7B%2Ecarousel%2Dinner%3E%2Eitem%7B%2Dwebkit%2Dtransition%3A%2Dwebkit%2Dtransform%20%2E6s%20ease%2Din%2Dout%3B%2Do%2Dtransition%3A%2Do%2Dtransform%20%2E6s%20ease%2Din%2Dout%3Btransition%3Atransform%20%2E6s%20ease%2Din%2Dout%3B%2Dwebkit%2Dbackface%2Dvisibility%3Ahidden%3Bbackface%2Dvisibility%3Ahidden%3B%2Dwebkit%2Dperspective%3A1000px%3Bperspective%3A1000px%7D%2Ecarousel%2Dinner%3E%2Eitem%2Eactive%2Eright%2C%2Ecarousel%2Dinner%3E%2Eitem%2Enext%7Bleft%3A0%3B%2Dwebkit%2Dtransform%3Atranslate3d%28100%25%2C0%2C0%29%3Btransform%3Atranslate3d%28100%25%2C0%2C0%29%7D%2Ecarousel%2Dinner%3E%2Eitem%2Eactive%2Eleft%2C%2Ecarousel%2Dinner%3E%2Eitem%2Eprev%7Bleft%3A0%3B%2Dwebkit%2Dtransform%3Atranslate3d%28%2D100%25%2C0%2C0%29%3Btransform%3Atranslate3d%28%2D100%25%2C0%2C0%29%7D%2Ecarousel%2Dinner%3E%2Eitem%2Eactive%2C%2Ecarousel%2Dinner%3E%2Eitem%2Enext%2Eleft%2C%2Ecarousel%2Dinner%3E%2Eitem%2Eprev%2Eright%7Bleft%3A0%3B%2Dwebkit%2Dtransform%3Atranslate3d%280%2C0%2C0%29%3Btransform%3Atranslate3d%280%2C0%2C0%29%7D%7D%2Ecarousel%2Dinner%3E%2Eactive%2C%2Ecarousel%2Dinner%3E%2Enext%2C%2Ecarousel%2Dinner%3E%2Eprev%7Bdisplay%3Ablock%7D%2Ecarousel%2Dinner%3E%2Eactive%7Bleft%3A0%7D%2Ecarousel%2Dinner%3E%2Enext%2C%2Ecarousel%2Dinner%3E%2Eprev%7Bposition%3Aabsolute%3Btop%3A0%3Bwidth%3A100%25%7D%2Ecarousel%2Dinner%3E%2Enext%7Bleft%3A100%25%7D%2Ecarousel%2Dinner%3E%2Eprev%7Bleft%3A%2D100%25%7D%2Ecarousel%2Dinner%3E%2Enext%2Eleft%2C%2Ecarousel%2Dinner%3E%2Eprev%2Eright%7Bleft%3A0%7D%2Ecarousel%2Dinner%3E%2Eactive%2Eleft%7Bleft%3A%2D100%25%7D%2Ecarousel%2Dinner%3E%2Eactive%2Eright%7Bleft%3A100%25%7D%2Ecarousel%2Dcontrol%7Bposition%3Aabsolute%3Btop%3A0%3Bbottom%3A0%3Bleft%3A0%3Bwidth%3A15%25%3Bfont%2Dsize%3A20px%3Bcolor%3A%23fff%3Btext%2Dalign%3Acenter%3Btext%2Dshadow%3A0%201px%202px%20rgba%280%2C0%2C0%2C%2E6%29%3Bfilter%3Aalpha%28opacity%3D50%29%3Bopacity%3A%2E5%7D%2Ecarousel%2Dcontrol%2Eleft%7Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%28left%2Crgba%280%2C0%2C0%2C%2E5%29%200%2Crgba%280%2C0%2C0%2C%2E0001%29%20100%25%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%28left%2Crgba%280%2C0%2C0%2C%2E5%29%200%2Crgba%280%2C0%2C0%2C%2E0001%29%20100%25%29%3Bbackground%2Dimage%3A%2Dwebkit%2Dgradient%28linear%2Cleft%20top%2Cright%20top%2Cfrom%28rgba%280%2C0%2C0%2C%2E5%29%29%2Cto%28rgba%280%2C0%2C0%2C%2E0001%29%29%29%3Bbackground%2Dimage%3Alinear%2Dgradient%28to%20right%2Crgba%280%2C0%2C0%2C%2E5%29%200%2Crgba%280%2C0%2C0%2C%2E0001%29%20100%25%29%3Bfilter%3Aprogid%3ADXImageTransform%2EMicrosoft%2Egradient%28startColorstr%3D%27%2380000000%27%2C%20endColorstr%3D%27%2300000000%27%2C%20GradientType%3D1%29%3Bbackground%2Drepeat%3Arepeat%2Dx%7D%2Ecarousel%2Dcontrol%2Eright%7Bright%3A0%3Bleft%3Aauto%3Bbackground%2Dimage%3A%2Dwebkit%2Dlinear%2Dgradient%28left%2Crgba%280%2C0%2C0%2C%2E0001%29%200%2Crgba%280%2C0%2C0%2C%2E5%29%20100%25%29%3Bbackground%2Dimage%3A%2Do%2Dlinear%2Dgradient%28left%2Crgba%280%2C0%2C0%2C%2E0001%29%200%2Crgba%280%2C0%2C0%2C%2E5%29%20100%25%29%3Bbackground%2Dimage%3A%2Dwebkit%2Dgradient%28linear%2Cleft%20top%2Cright%20top%2Cfrom%28rgba%280%2C0%2C0%2C%2E0001%29%29%2Cto%28rgba%280%2C0%2C0%2C%2E5%29%29%29%3Bbackground%2Dimage%3Alinear%2Dgradient%28to%20right%2Crgba%280%2C0%2C0%2C%2E0001%29%200%2Crgba%280%2C0%2C0%2C%2E5%29%20100%25%29%3Bfilter%3Aprogid%3ADXImageTransform%2EMicrosoft%2Egradient%28startColorstr%3D%27%2300000000%27%2C%20endColorstr%3D%27%2380000000%27%2C%20GradientType%3D1%29%3Bbackground%2Drepeat%3Arepeat%2Dx%7D%2Ecarousel%2Dcontrol%3Afocus%2C%2Ecarousel%2Dcontrol%3Ahover%7Bcolor%3A%23fff%3Btext%2Ddecoration%3Anone%3Bfilter%3Aalpha%28opacity%3D90%29%3Boutline%3A0%3Bopacity%3A%2E9%7D%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dleft%2C%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dright%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dnext%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dprev%7Bposition%3Aabsolute%3Btop%3A50%25%3Bz%2Dindex%3A5%3Bdisplay%3Ainline%2Dblock%3Bmargin%2Dtop%3A%2D10px%7D%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dleft%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dprev%7Bleft%3A50%25%3Bmargin%2Dleft%3A%2D10px%7D%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dright%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dnext%7Bright%3A50%25%3Bmargin%2Dright%3A%2D10px%7D%2Ecarousel%2Dcontrol%20%2Eicon%2Dnext%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dprev%7Bwidth%3A20px%3Bheight%3A20px%3Bfont%2Dfamily%3Aserif%3Bline%2Dheight%3A1%7D%2Ecarousel%2Dcontrol%20%2Eicon%2Dprev%3Abefore%7Bcontent%3A%27%5C2039%27%7D%2Ecarousel%2Dcontrol%20%2Eicon%2Dnext%3Abefore%7Bcontent%3A%27%5C203a%27%7D%2Ecarousel%2Dindicators%7Bposition%3Aabsolute%3Bbottom%3A10px%3Bleft%3A50%25%3Bz%2Dindex%3A15%3Bwidth%3A60%25%3Bpadding%2Dleft%3A0%3Bmargin%2Dleft%3A%2D30%25%3Btext%2Dalign%3Acenter%3Blist%2Dstyle%3Anone%7D%2Ecarousel%2Dindicators%20li%7Bdisplay%3Ainline%2Dblock%3Bwidth%3A10px%3Bheight%3A10px%3Bmargin%3A1px%3Btext%2Dindent%3A%2D999px%3Bcursor%3Apointer%3Bbackground%2Dcolor%3A%23000%5C9%3Bbackground%2Dcolor%3Argba%280%2C0%2C0%2C0%29%3Bborder%3A1px%20solid%20%23fff%3Bborder%2Dradius%3A10px%7D%2Ecarousel%2Dindicators%20%2Eactive%7Bwidth%3A12px%3Bheight%3A12px%3Bmargin%3A0%3Bbackground%2Dcolor%3A%23fff%7D%2Ecarousel%2Dcaption%7Bposition%3Aabsolute%3Bright%3A15%25%3Bbottom%3A20px%3Bleft%3A15%25%3Bz%2Dindex%3A10%3Bpadding%2Dtop%3A20px%3Bpadding%2Dbottom%3A20px%3Bcolor%3A%23fff%3Btext%2Dalign%3Acenter%3Btext%2Dshadow%3A0%201px%202px%20rgba%280%2C0%2C0%2C%2E6%29%7D%2Ecarousel%2Dcaption%20%2Ebtn%7Btext%2Dshadow%3Anone%7D%40media%20screen%20and%20%28min%2Dwidth%3A768px%29%7B%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dleft%2C%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dright%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dnext%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dprev%7Bwidth%3A30px%3Bheight%3A30px%3Bmargin%2Dtop%3A%2D15px%3Bfont%2Dsize%3A30px%7D%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dleft%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dprev%7Bmargin%2Dleft%3A%2D15px%7D%2Ecarousel%2Dcontrol%20%2Eglyphicon%2Dchevron%2Dright%2C%2Ecarousel%2Dcontrol%20%2Eicon%2Dnext%7Bmargin%2Dright%3A%2D15px%7D%2Ecarousel%2Dcaption%7Bright%3A20%25%3Bleft%3A20%25%3Bpadding%2Dbottom%3A30px%7D%2Ecarousel%2Dindicators%7Bbottom%3A20px%7D%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Aafter%2C%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Abefore%2C%2Ebtn%2Dtoolbar%3Aafter%2C%2Ebtn%2Dtoolbar%3Abefore%2C%2Eclearfix%3Aafter%2C%2Eclearfix%3Abefore%2C%2Econtainer%2Dfluid%3Aafter%2C%2Econtainer%2Dfluid%3Abefore%2C%2Econtainer%3Aafter%2C%2Econtainer%3Abefore%2C%2Edl%2Dhorizontal%20dd%3Aafter%2C%2Edl%2Dhorizontal%20dd%3Abefore%2C%2Eform%2Dhorizontal%20%2Eform%2Dgroup%3Aafter%2C%2Eform%2Dhorizontal%20%2Eform%2Dgroup%3Abefore%2C%2Emodal%2Dfooter%3Aafter%2C%2Emodal%2Dfooter%3Abefore%2C%2Enav%3Aafter%2C%2Enav%3Abefore%2C%2Enavbar%2Dcollapse%3Aafter%2C%2Enavbar%2Dcollapse%3Abefore%2C%2Enavbar%2Dheader%3Aafter%2C%2Enavbar%2Dheader%3Abefore%2C%2Enavbar%3Aafter%2C%2Enavbar%3Abefore%2C%2Epager%3Aafter%2C%2Epager%3Abefore%2C%2Epanel%2Dbody%3Aafter%2C%2Epanel%2Dbody%3Abefore%2C%2Erow%3Aafter%2C%2Erow%3Abefore%7Bdisplay%3Atable%3Bcontent%3A%22%20%22%7D%2Ebtn%2Dgroup%2Dvertical%3E%2Ebtn%2Dgroup%3Aafter%2C%2Ebtn%2Dtoolbar%3Aafter%2C%2Eclearfix%3Aafter%2C%2Econtainer%2Dfluid%3Aafter%2C%2Econtainer%3Aafter%2C%2Edl%2Dhorizontal%20dd%3Aafter%2C%2Eform%2Dhorizontal%20%2Eform%2Dgroup%3Aafter%2C%2Emodal%2Dfooter%3Aafter%2C%2Enav%3Aafter%2C%2Enavbar%2Dcollapse%3Aafter%2C%2Enavbar%2Dheader%3Aafter%2C%2Enavbar%3Aafter%2C%2Epager%3Aafter%2C%2Epanel%2Dbody%3Aafter%2C%2Erow%3Aafter%7Bclear%3Aboth%7D%2Ecenter%2Dblock%7Bdisplay%3Ablock%3Bmargin%2Dright%3Aauto%3Bmargin%2Dleft%3Aauto%7D%2Epull%2Dright%7Bfloat%3Aright%21important%7D%2Epull%2Dleft%7Bfloat%3Aleft%21important%7D%2Ehide%7Bdisplay%3Anone%21important%7D%2Eshow%7Bdisplay%3Ablock%21important%7D%2Einvisible%7Bvisibility%3Ahidden%7D%2Etext%2Dhide%7Bfont%3A0%2F0%20a%3Bcolor%3Atransparent%3Btext%2Dshadow%3Anone%3Bbackground%2Dcolor%3Atransparent%3Bborder%3A0%7D%2Ehidden%7Bdisplay%3Anone%21important%7D%2Eaffix%7Bposition%3Afixed%7D%40%2Dms%2Dviewport%7Bwidth%3Adevice%2Dwidth%7D%2Evisible%2Dlg%2C%2Evisible%2Dmd%2C%2Evisible%2Dsm%2C%2Evisible%2Dxs%7Bdisplay%3Anone%21important%7D%2Evisible%2Dlg%2Dblock%2C%2Evisible%2Dlg%2Dinline%2C%2Evisible%2Dlg%2Dinline%2Dblock%2C%2Evisible%2Dmd%2Dblock%2C%2Evisible%2Dmd%2Dinline%2C%2Evisible%2Dmd%2Dinline%2Dblock%2C%2Evisible%2Dsm%2Dblock%2C%2Evisible%2Dsm%2Dinline%2C%2Evisible%2Dsm%2Dinline%2Dblock%2C%2Evisible%2Dxs%2Dblock%2C%2Evisible%2Dxs%2Dinline%2C%2Evisible%2Dxs%2Dinline%2Dblock%7Bdisplay%3Anone%21important%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Evisible%2Dxs%7Bdisplay%3Ablock%21important%7Dtable%2Evisible%2Dxs%7Bdisplay%3Atable%21important%7Dtr%2Evisible%2Dxs%7Bdisplay%3Atable%2Drow%21important%7Dtd%2Evisible%2Dxs%2Cth%2Evisible%2Dxs%7Bdisplay%3Atable%2Dcell%21important%7D%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Evisible%2Dxs%2Dblock%7Bdisplay%3Ablock%21important%7D%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Evisible%2Dxs%2Dinline%7Bdisplay%3Ainline%21important%7D%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Evisible%2Dxs%2Dinline%2Dblock%7Bdisplay%3Ainline%2Dblock%21important%7D%7D%40media%20%28min%2Dwidth%3A768px%29%20and%20%28max%2Dwidth%3A991px%29%7B%2Evisible%2Dsm%7Bdisplay%3Ablock%21important%7Dtable%2Evisible%2Dsm%7Bdisplay%3Atable%21important%7Dtr%2Evisible%2Dsm%7Bdisplay%3Atable%2Drow%21important%7Dtd%2Evisible%2Dsm%2Cth%2Evisible%2Dsm%7Bdisplay%3Atable%2Dcell%21important%7D%7D%40media%20%28min%2Dwidth%3A768px%29%20and%20%28max%2Dwidth%3A991px%29%7B%2Evisible%2Dsm%2Dblock%7Bdisplay%3Ablock%21important%7D%7D%40media%20%28min%2Dwidth%3A768px%29%20and%20%28max%2Dwidth%3A991px%29%7B%2Evisible%2Dsm%2Dinline%7Bdisplay%3Ainline%21important%7D%7D%40media%20%28min%2Dwidth%3A768px%29%20and%20%28max%2Dwidth%3A991px%29%7B%2Evisible%2Dsm%2Dinline%2Dblock%7Bdisplay%3Ainline%2Dblock%21important%7D%7D%40media%20%28min%2Dwidth%3A992px%29%20and%20%28max%2Dwidth%3A1199px%29%7B%2Evisible%2Dmd%7Bdisplay%3Ablock%21important%7Dtable%2Evisible%2Dmd%7Bdisplay%3Atable%21important%7Dtr%2Evisible%2Dmd%7Bdisplay%3Atable%2Drow%21important%7Dtd%2Evisible%2Dmd%2Cth%2Evisible%2Dmd%7Bdisplay%3Atable%2Dcell%21important%7D%7D%40media%20%28min%2Dwidth%3A992px%29%20and%20%28max%2Dwidth%3A1199px%29%7B%2Evisible%2Dmd%2Dblock%7Bdisplay%3Ablock%21important%7D%7D%40media%20%28min%2Dwidth%3A992px%29%20and%20%28max%2Dwidth%3A1199px%29%7B%2Evisible%2Dmd%2Dinline%7Bdisplay%3Ainline%21important%7D%7D%40media%20%28min%2Dwidth%3A992px%29%20and%20%28max%2Dwidth%3A1199px%29%7B%2Evisible%2Dmd%2Dinline%2Dblock%7Bdisplay%3Ainline%2Dblock%21important%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Evisible%2Dlg%7Bdisplay%3Ablock%21important%7Dtable%2Evisible%2Dlg%7Bdisplay%3Atable%21important%7Dtr%2Evisible%2Dlg%7Bdisplay%3Atable%2Drow%21important%7Dtd%2Evisible%2Dlg%2Cth%2Evisible%2Dlg%7Bdisplay%3Atable%2Dcell%21important%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Evisible%2Dlg%2Dblock%7Bdisplay%3Ablock%21important%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Evisible%2Dlg%2Dinline%7Bdisplay%3Ainline%21important%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Evisible%2Dlg%2Dinline%2Dblock%7Bdisplay%3Ainline%2Dblock%21important%7D%7D%40media%20%28max%2Dwidth%3A767px%29%7B%2Ehidden%2Dxs%7Bdisplay%3Anone%21important%7D%7D%40media%20%28min%2Dwidth%3A768px%29%20and%20%28max%2Dwidth%3A991px%29%7B%2Ehidden%2Dsm%7Bdisplay%3Anone%21important%7D%7D%40media%20%28min%2Dwidth%3A992px%29%20and%20%28max%2Dwidth%3A1199px%29%7B%2Ehidden%2Dmd%7Bdisplay%3Anone%21important%7D%7D%40media%20%28min%2Dwidth%3A1200px%29%7B%2Ehidden%2Dlg%7Bdisplay%3Anone%21important%7D%7D%2Evisible%2Dprint%7Bdisplay%3Anone%21important%7D%40media%20print%7B%2Evisible%2Dprint%7Bdisplay%3Ablock%21important%7Dtable%2Evisible%2Dprint%7Bdisplay%3Atable%21important%7Dtr%2Evisible%2Dprint%7Bdisplay%3Atable%2Drow%21important%7Dtd%2Evisible%2Dprint%2Cth%2Evisible%2Dprint%7Bdisplay%3Atable%2Dcell%21important%7D%7D%2Evisible%2Dprint%2Dblock%7Bdisplay%3Anone%21important%7D%40media%20print%7B%2Evisible%2Dprint%2Dblock%7Bdisplay%3Ablock%21important%7D%7D%2Evisible%2Dprint%2Dinline%7Bdisplay%3Anone%21important%7D%40media%20print%7B%2Evisible%2Dprint%2Dinline%7Bdisplay%3Ainline%21important%7D%7D%2Evisible%2Dprint%2Dinline%2Dblock%7Bdisplay%3Anone%21important%7D%40media%20print%7B%2Evisible%2Dprint%2Dinline%2Dblock%7Bdisplay%3Ainline%2Dblock%21important%7D%7D%40media%20print%7B%2Ehidden%2Dprint%7Bdisplay%3Anone%21important%7D%7D%0A" rel="stylesheet" />
<script src="data:application/javascript;base64,/*!
 * Bootstrap v3.3.5 (http://getbootstrap.com)
 * Copyright 2011-2015 Twitter, Inc.
 * Licensed under the MIT license
 */
if("undefined"==typeof jQuery)throw new Error("Bootstrap's JavaScript requires jQuery");+function(a){"use strict";var b=a.fn.jquery.split(" ")[0].split(".");if(b[0]<2&&b[1]<9||1==b[0]&&9==b[1]&&b[2]<1)throw new Error("Bootstrap's JavaScript requires jQuery version 1.9.1 or higher")}(jQuery),+function(a){"use strict";function b(){var a=document.createElement("bootstrap"),b={WebkitTransition:"webkitTransitionEnd",MozTransition:"transitionend",OTransition:"oTransitionEnd otransitionend",transition:"transitionend"};for(var c in b)if(void 0!==a.style[c])return{end:b[c]};return!1}a.fn.emulateTransitionEnd=function(b){var c=!1,d=this;a(this).one("bsTransitionEnd",function(){c=!0});var e=function(){c||a(d).trigger(a.support.transition.end)};return setTimeout(e,b),this},a(function(){a.support.transition=b(),a.support.transition&&(a.event.special.bsTransitionEnd={bindType:a.support.transition.end,delegateType:a.support.transition.end,handle:function(b){return a(b.target).is(this)?b.handleObj.handler.apply(this,arguments):void 0}})})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var c=a(this),e=c.data("bs.alert");e||c.data("bs.alert",e=new d(this)),"string"==typeof b&&e[b].call(c)})}var c='[data-dismiss="alert"]',d=function(b){a(b).on("click",c,this.close)};d.VERSION="3.3.5",d.TRANSITION_DURATION=150,d.prototype.close=function(b){function c(){g.detach().trigger("closed.bs.alert").remove()}var e=a(this),f=e.attr("data-target");f||(f=e.attr("href"),f=f&&f.replace(/.*(?=#[^\s]*$)/,""));var g=a(f);b&&b.preventDefault(),g.length||(g=e.closest(".alert")),g.trigger(b=a.Event("close.bs.alert")),b.isDefaultPrevented()||(g.removeClass("in"),a.support.transition&&g.hasClass("fade")?g.one("bsTransitionEnd",c).emulateTransitionEnd(d.TRANSITION_DURATION):c())};var e=a.fn.alert;a.fn.alert=b,a.fn.alert.Constructor=d,a.fn.alert.noConflict=function(){return a.fn.alert=e,this},a(document).on("click.bs.alert.data-api",c,d.prototype.close)}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.button"),f="object"==typeof b&&b;e||d.data("bs.button",e=new c(this,f)),"toggle"==b?e.toggle():b&&e.setState(b)})}var c=function(b,d){this.$element=a(b),this.options=a.extend({},c.DEFAULTS,d),this.isLoading=!1};c.VERSION="3.3.5",c.DEFAULTS={loadingText:"loading..."},c.prototype.setState=function(b){var c="disabled",d=this.$element,e=d.is("input")?"val":"html",f=d.data();b+="Text",null==f.resetText&&d.data("resetText",d[e]()),setTimeout(a.proxy(function(){d[e](null==f[b]?this.options[b]:f[b]),"loadingText"==b?(this.isLoading=!0,d.addClass(c).attr(c,c)):this.isLoading&&(this.isLoading=!1,d.removeClass(c).removeAttr(c))},this),0)},c.prototype.toggle=function(){var a=!0,b=this.$element.closest('[data-toggle="buttons"]');if(b.length){var c=this.$element.find("input");"radio"==c.prop("type")?(c.prop("checked")&&(a=!1),b.find(".active").removeClass("active"),this.$element.addClass("active")):"checkbox"==c.prop("type")&&(c.prop("checked")!==this.$element.hasClass("active")&&(a=!1),this.$element.toggleClass("active")),c.prop("checked",this.$element.hasClass("active")),a&&c.trigger("change")}else this.$element.attr("aria-pressed",!this.$element.hasClass("active")),this.$element.toggleClass("active")};var d=a.fn.button;a.fn.button=b,a.fn.button.Constructor=c,a.fn.button.noConflict=function(){return a.fn.button=d,this},a(document).on("click.bs.button.data-api",'[data-toggle^="button"]',function(c){var d=a(c.target);d.hasClass("btn")||(d=d.closest(".btn")),b.call(d,"toggle"),a(c.target).is('input[type="radio"]')||a(c.target).is('input[type="checkbox"]')||c.preventDefault()}).on("focus.bs.button.data-api blur.bs.button.data-api",'[data-toggle^="button"]',function(b){a(b.target).closest(".btn").toggleClass("focus",/^focus(in)?$/.test(b.type))})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.carousel"),f=a.extend({},c.DEFAULTS,d.data(),"object"==typeof b&&b),g="string"==typeof b?b:f.slide;e||d.data("bs.carousel",e=new c(this,f)),"number"==typeof b?e.to(b):g?e[g]():f.interval&&e.pause().cycle()})}var c=function(b,c){this.$element=a(b),this.$indicators=this.$element.find(".carousel-indicators"),this.options=c,this.paused=null,this.sliding=null,this.interval=null,this.$active=null,this.$items=null,this.options.keyboard&&this.$element.on("keydown.bs.carousel",a.proxy(this.keydown,this)),"hover"==this.options.pause&&!("ontouchstart"in document.documentElement)&&this.$element.on("mouseenter.bs.carousel",a.proxy(this.pause,this)).on("mouseleave.bs.carousel",a.proxy(this.cycle,this))};c.VERSION="3.3.5",c.TRANSITION_DURATION=600,c.DEFAULTS={interval:5e3,pause:"hover",wrap:!0,keyboard:!0},c.prototype.keydown=function(a){if(!/input|textarea/i.test(a.target.tagName)){switch(a.which){case 37:this.prev();break;case 39:this.next();break;default:return}a.preventDefault()}},c.prototype.cycle=function(b){return b||(this.paused=!1),this.interval&&clearInterval(this.interval),this.options.interval&&!this.paused&&(this.interval=setInterval(a.proxy(this.next,this),this.options.interval)),this},c.prototype.getItemIndex=function(a){return this.$items=a.parent().children(".item"),this.$items.index(a||this.$active)},c.prototype.getItemForDirection=function(a,b){var c=this.getItemIndex(b),d="prev"==a&&0===c||"next"==a&&c==this.$items.length-1;if(d&&!this.options.wrap)return b;var e="prev"==a?-1:1,f=(c+e)%this.$items.length;return this.$items.eq(f)},c.prototype.to=function(a){var b=this,c=this.getItemIndex(this.$active=this.$element.find(".item.active"));return a>this.$items.length-1||0>a?void 0:this.sliding?this.$element.one("slid.bs.carousel",function(){b.to(a)}):c==a?this.pause().cycle():this.slide(a>c?"next":"prev",this.$items.eq(a))},c.prototype.pause=function(b){return b||(this.paused=!0),this.$element.find(".next, .prev").length&&a.support.transition&&(this.$element.trigger(a.support.transition.end),this.cycle(!0)),this.interval=clearInterval(this.interval),this},c.prototype.next=function(){return this.sliding?void 0:this.slide("next")},c.prototype.prev=function(){return this.sliding?void 0:this.slide("prev")},c.prototype.slide=function(b,d){var e=this.$element.find(".item.active"),f=d||this.getItemForDirection(b,e),g=this.interval,h="next"==b?"left":"right",i=this;if(f.hasClass("active"))return this.sliding=!1;var j=f[0],k=a.Event("slide.bs.carousel",{relatedTarget:j,direction:h});if(this.$element.trigger(k),!k.isDefaultPrevented()){if(this.sliding=!0,g&&this.pause(),this.$indicators.length){this.$indicators.find(".active").removeClass("active");var l=a(this.$indicators.children()[this.getItemIndex(f)]);l&&l.addClass("active")}var m=a.Event("slid.bs.carousel",{relatedTarget:j,direction:h});return a.support.transition&&this.$element.hasClass("slide")?(f.addClass(b),f[0].offsetWidth,e.addClass(h),f.addClass(h),e.one("bsTransitionEnd",function(){f.removeClass([b,h].join(" ")).addClass("active"),e.removeClass(["active",h].join(" ")),i.sliding=!1,setTimeout(function(){i.$element.trigger(m)},0)}).emulateTransitionEnd(c.TRANSITION_DURATION)):(e.removeClass("active"),f.addClass("active"),this.sliding=!1,this.$element.trigger(m)),g&&this.cycle(),this}};var d=a.fn.carousel;a.fn.carousel=b,a.fn.carousel.Constructor=c,a.fn.carousel.noConflict=function(){return a.fn.carousel=d,this};var e=function(c){var d,e=a(this),f=a(e.attr("data-target")||(d=e.attr("href"))&&d.replace(/.*(?=#[^\s]+$)/,""));if(f.hasClass("carousel")){var g=a.extend({},f.data(),e.data()),h=e.attr("data-slide-to");h&&(g.interval=!1),b.call(f,g),h&&f.data("bs.carousel").to(h),c.preventDefault()}};a(document).on("click.bs.carousel.data-api","[data-slide]",e).on("click.bs.carousel.data-api","[data-slide-to]",e),a(window).on("load",function(){a('[data-ride="carousel"]').each(function(){var c=a(this);b.call(c,c.data())})})}(jQuery),+function(a){"use strict";function b(b){var c,d=b.attr("data-target")||(c=b.attr("href"))&&c.replace(/.*(?=#[^\s]+$)/,"");return a(d)}function c(b){return this.each(function(){var c=a(this),e=c.data("bs.collapse"),f=a.extend({},d.DEFAULTS,c.data(),"object"==typeof b&&b);!e&&f.toggle&&/show|hide/.test(b)&&(f.toggle=!1),e||c.data("bs.collapse",e=new d(this,f)),"string"==typeof b&&e[b]()})}var d=function(b,c){this.$element=a(b),this.options=a.extend({},d.DEFAULTS,c),this.$trigger=a('[data-toggle="collapse"][href="#'+b.id+'"],[data-toggle="collapse"][data-target="#'+b.id+'"]'),this.transitioning=null,this.options.parent?this.$parent=this.getParent():this.addAriaAndCollapsedClass(this.$element,this.$trigger),this.options.toggle&&this.toggle()};d.VERSION="3.3.5",d.TRANSITION_DURATION=350,d.DEFAULTS={toggle:!0},d.prototype.dimension=function(){var a=this.$element.hasClass("width");return a?"width":"height"},d.prototype.show=function(){if(!this.transitioning&&!this.$element.hasClass("in")){var b,e=this.$parent&&this.$parent.children(".panel").children(".in, .collapsing");if(!(e&&e.length&&(b=e.data("bs.collapse"),b&&b.transitioning))){var f=a.Event("show.bs.collapse");if(this.$element.trigger(f),!f.isDefaultPrevented()){e&&e.length&&(c.call(e,"hide"),b||e.data("bs.collapse",null));var g=this.dimension();this.$element.removeClass("collapse").addClass("collapsing")[g](0).attr("aria-expanded",!0),this.$trigger.removeClass("collapsed").attr("aria-expanded",!0),this.transitioning=1;var h=function(){this.$element.removeClass("collapsing").addClass("collapse in")[g](""),this.transitioning=0,this.$element.trigger("shown.bs.collapse")};if(!a.support.transition)return h.call(this);var i=a.camelCase(["scroll",g].join("-"));this.$element.one("bsTransitionEnd",a.proxy(h,this)).emulateTransitionEnd(d.TRANSITION_DURATION)[g](this.$element[0][i])}}}},d.prototype.hide=function(){if(!this.transitioning&&this.$element.hasClass("in")){var b=a.Event("hide.bs.collapse");if(this.$element.trigger(b),!b.isDefaultPrevented()){var c=this.dimension();this.$element[c](this.$element[c]())[0].offsetHeight,this.$element.addClass("collapsing").removeClass("collapse in").attr("aria-expanded",!1),this.$trigger.addClass("collapsed").attr("aria-expanded",!1),this.transitioning=1;var e=function(){this.transitioning=0,this.$element.removeClass("collapsing").addClass("collapse").trigger("hidden.bs.collapse")};return a.support.transition?void this.$element[c](0).one("bsTransitionEnd",a.proxy(e,this)).emulateTransitionEnd(d.TRANSITION_DURATION):e.call(this)}}},d.prototype.toggle=function(){this[this.$element.hasClass("in")?"hide":"show"]()},d.prototype.getParent=function(){return a(this.options.parent).find('[data-toggle="collapse"][data-parent="'+this.options.parent+'"]').each(a.proxy(function(c,d){var e=a(d);this.addAriaAndCollapsedClass(b(e),e)},this)).end()},d.prototype.addAriaAndCollapsedClass=function(a,b){var c=a.hasClass("in");a.attr("aria-expanded",c),b.toggleClass("collapsed",!c).attr("aria-expanded",c)};var e=a.fn.collapse;a.fn.collapse=c,a.fn.collapse.Constructor=d,a.fn.collapse.noConflict=function(){return a.fn.collapse=e,this},a(document).on("click.bs.collapse.data-api",'[data-toggle="collapse"]',function(d){var e=a(this);e.attr("data-target")||d.preventDefault();var f=b(e),g=f.data("bs.collapse"),h=g?"toggle":e.data();c.call(f,h)})}(jQuery),+function(a){"use strict";function b(b){var c=b.attr("data-target");c||(c=b.attr("href"),c=c&&/#[A-Za-z]/.test(c)&&c.replace(/.*(?=#[^\s]*$)/,""));var d=c&&a(c);return d&&d.length?d:b.parent()}function c(c){c&&3===c.which||(a(e).remove(),a(f).each(function(){var d=a(this),e=b(d),f={relatedTarget:this};e.hasClass("open")&&(c&&"click"==c.type&&/input|textarea/i.test(c.target.tagName)&&a.contains(e[0],c.target)||(e.trigger(c=a.Event("hide.bs.dropdown",f)),c.isDefaultPrevented()||(d.attr("aria-expanded","false"),e.removeClass("open").trigger("hidden.bs.dropdown",f))))}))}function d(b){return this.each(function(){var c=a(this),d=c.data("bs.dropdown");d||c.data("bs.dropdown",d=new g(this)),"string"==typeof b&&d[b].call(c)})}var e=".dropdown-backdrop",f='[data-toggle="dropdown"]',g=function(b){a(b).on("click.bs.dropdown",this.toggle)};g.VERSION="3.3.5",g.prototype.toggle=function(d){var e=a(this);if(!e.is(".disabled, :disabled")){var f=b(e),g=f.hasClass("open");if(c(),!g){"ontouchstart"in document.documentElement&&!f.closest(".navbar-nav").length&&a(document.createElement("div")).addClass("dropdown-backdrop").insertAfter(a(this)).on("click",c);var h={relatedTarget:this};if(f.trigger(d=a.Event("show.bs.dropdown",h)),d.isDefaultPrevented())return;e.trigger("focus").attr("aria-expanded","true"),f.toggleClass("open").trigger("shown.bs.dropdown",h)}return!1}},g.prototype.keydown=function(c){if(/(38|40|27|32)/.test(c.which)&&!/input|textarea/i.test(c.target.tagName)){var d=a(this);if(c.preventDefault(),c.stopPropagation(),!d.is(".disabled, :disabled")){var e=b(d),g=e.hasClass("open");if(!g&&27!=c.which||g&&27==c.which)return 27==c.which&&e.find(f).trigger("focus"),d.trigger("click");var h=" li:not(.disabled):visible a",i=e.find(".dropdown-menu"+h);if(i.length){var j=i.index(c.target);38==c.which&&j>0&&j--,40==c.which&&j<i.length-1&&j++,~j||(j=0),i.eq(j).trigger("focus")}}}};var h=a.fn.dropdown;a.fn.dropdown=d,a.fn.dropdown.Constructor=g,a.fn.dropdown.noConflict=function(){return a.fn.dropdown=h,this},a(document).on("click.bs.dropdown.data-api",c).on("click.bs.dropdown.data-api",".dropdown form",function(a){a.stopPropagation()}).on("click.bs.dropdown.data-api",f,g.prototype.toggle).on("keydown.bs.dropdown.data-api",f,g.prototype.keydown).on("keydown.bs.dropdown.data-api",".dropdown-menu",g.prototype.keydown)}(jQuery),+function(a){"use strict";function b(b,d){return this.each(function(){var e=a(this),f=e.data("bs.modal"),g=a.extend({},c.DEFAULTS,e.data(),"object"==typeof b&&b);f||e.data("bs.modal",f=new c(this,g)),"string"==typeof b?f[b](d):g.show&&f.show(d)})}var c=function(b,c){this.options=c,this.$body=a(document.body),this.$element=a(b),this.$dialog=this.$element.find(".modal-dialog"),this.$backdrop=null,this.isShown=null,this.originalBodyPad=null,this.scrollbarWidth=0,this.ignoreBackdropClick=!1,this.options.remote&&this.$element.find(".modal-content").load(this.options.remote,a.proxy(function(){this.$element.trigger("loaded.bs.modal")},this))};c.VERSION="3.3.5",c.TRANSITION_DURATION=300,c.BACKDROP_TRANSITION_DURATION=150,c.DEFAULTS={backdrop:!0,keyboard:!0,show:!0},c.prototype.toggle=function(a){return this.isShown?this.hide():this.show(a)},c.prototype.show=function(b){var d=this,e=a.Event("show.bs.modal",{relatedTarget:b});this.$element.trigger(e),this.isShown||e.isDefaultPrevented()||(this.isShown=!0,this.checkScrollbar(),this.setScrollbar(),this.$body.addClass("modal-open"),this.escape(),this.resize(),this.$element.on("click.dismiss.bs.modal",'[data-dismiss="modal"]',a.proxy(this.hide,this)),this.$dialog.on("mousedown.dismiss.bs.modal",function(){d.$element.one("mouseup.dismiss.bs.modal",function(b){a(b.target).is(d.$element)&&(d.ignoreBackdropClick=!0)})}),this.backdrop(function(){var e=a.support.transition&&d.$element.hasClass("fade");d.$element.parent().length||d.$element.appendTo(d.$body),d.$element.show().scrollTop(0),d.adjustDialog(),e&&d.$element[0].offsetWidth,d.$element.addClass("in"),d.enforceFocus();var f=a.Event("shown.bs.modal",{relatedTarget:b});e?d.$dialog.one("bsTransitionEnd",function(){d.$element.trigger("focus").trigger(f)}).emulateTransitionEnd(c.TRANSITION_DURATION):d.$element.trigger("focus").trigger(f)}))},c.prototype.hide=function(b){b&&b.preventDefault(),b=a.Event("hide.bs.modal"),this.$element.trigger(b),this.isShown&&!b.isDefaultPrevented()&&(this.isShown=!1,this.escape(),this.resize(),a(document).off("focusin.bs.modal"),this.$element.removeClass("in").off("click.dismiss.bs.modal").off("mouseup.dismiss.bs.modal"),this.$dialog.off("mousedown.dismiss.bs.modal"),a.support.transition&&this.$element.hasClass("fade")?this.$element.one("bsTransitionEnd",a.proxy(this.hideModal,this)).emulateTransitionEnd(c.TRANSITION_DURATION):this.hideModal())},c.prototype.enforceFocus=function(){a(document).off("focusin.bs.modal").on("focusin.bs.modal",a.proxy(function(a){this.$element[0]===a.target||this.$element.has(a.target).length||this.$element.trigger("focus")},this))},c.prototype.escape=function(){this.isShown&&this.options.keyboard?this.$element.on("keydown.dismiss.bs.modal",a.proxy(function(a){27==a.which&&this.hide()},this)):this.isShown||this.$element.off("keydown.dismiss.bs.modal")},c.prototype.resize=function(){this.isShown?a(window).on("resize.bs.modal",a.proxy(this.handleUpdate,this)):a(window).off("resize.bs.modal")},c.prototype.hideModal=function(){var a=this;this.$element.hide(),this.backdrop(function(){a.$body.removeClass("modal-open"),a.resetAdjustments(),a.resetScrollbar(),a.$element.trigger("hidden.bs.modal")})},c.prototype.removeBackdrop=function(){this.$backdrop&&this.$backdrop.remove(),this.$backdrop=null},c.prototype.backdrop=function(b){var d=this,e=this.$element.hasClass("fade")?"fade":"";if(this.isShown&&this.options.backdrop){var f=a.support.transition&&e;if(this.$backdrop=a(document.createElement("div")).addClass("modal-backdrop "+e).appendTo(this.$body),this.$element.on("click.dismiss.bs.modal",a.proxy(function(a){return this.ignoreBackdropClick?void(this.ignoreBackdropClick=!1):void(a.target===a.currentTarget&&("static"==this.options.backdrop?this.$element[0].focus():this.hide()))},this)),f&&this.$backdrop[0].offsetWidth,this.$backdrop.addClass("in"),!b)return;f?this.$backdrop.one("bsTransitionEnd",b).emulateTransitionEnd(c.BACKDROP_TRANSITION_DURATION):b()}else if(!this.isShown&&this.$backdrop){this.$backdrop.removeClass("in");var g=function(){d.removeBackdrop(),b&&b()};a.support.transition&&this.$element.hasClass("fade")?this.$backdrop.one("bsTransitionEnd",g).emulateTransitionEnd(c.BACKDROP_TRANSITION_DURATION):g()}else b&&b()},c.prototype.handleUpdate=function(){this.adjustDialog()},c.prototype.adjustDialog=function(){var a=this.$element[0].scrollHeight>document.documentElement.clientHeight;this.$element.css({paddingLeft:!this.bodyIsOverflowing&&a?this.scrollbarWidth:"",paddingRight:this.bodyIsOverflowing&&!a?this.scrollbarWidth:""})},c.prototype.resetAdjustments=function(){this.$element.css({paddingLeft:"",paddingRight:""})},c.prototype.checkScrollbar=function(){var a=window.innerWidth;if(!a){var b=document.documentElement.getBoundingClientRect();a=b.right-Math.abs(b.left)}this.bodyIsOverflowing=document.body.clientWidth<a,this.scrollbarWidth=this.measureScrollbar()},c.prototype.setScrollbar=function(){var a=parseInt(this.$body.css("padding-right")||0,10);this.originalBodyPad=document.body.style.paddingRight||"",this.bodyIsOverflowing&&this.$body.css("padding-right",a+this.scrollbarWidth)},c.prototype.resetScrollbar=function(){this.$body.css("padding-right",this.originalBodyPad)},c.prototype.measureScrollbar=function(){var a=document.createElement("div");a.className="modal-scrollbar-measure",this.$body.append(a);var b=a.offsetWidth-a.clientWidth;return this.$body[0].removeChild(a),b};var d=a.fn.modal;a.fn.modal=b,a.fn.modal.Constructor=c,a.fn.modal.noConflict=function(){return a.fn.modal=d,this},a(document).on("click.bs.modal.data-api",'[data-toggle="modal"]',function(c){var d=a(this),e=d.attr("href"),f=a(d.attr("data-target")||e&&e.replace(/.*(?=#[^\s]+$)/,"")),g=f.data("bs.modal")?"toggle":a.extend({remote:!/#/.test(e)&&e},f.data(),d.data());d.is("a")&&c.preventDefault(),f.one("show.bs.modal",function(a){a.isDefaultPrevented()||f.one("hidden.bs.modal",function(){d.is(":visible")&&d.trigger("focus")})}),b.call(f,g,this)})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.tooltip"),f="object"==typeof b&&b;(e||!/destroy|hide/.test(b))&&(e||d.data("bs.tooltip",e=new c(this,f)),"string"==typeof b&&e[b]())})}var c=function(a,b){this.type=null,this.options=null,this.enabled=null,this.timeout=null,this.hoverState=null,this.$element=null,this.inState=null,this.init("tooltip",a,b)};c.VERSION="3.3.5",c.TRANSITION_DURATION=150,c.DEFAULTS={animation:!0,placement:"top",selector:!1,template:'<div class="tooltip" role="tooltip"><div class="tooltip-arrow"></div><div class="tooltip-inner"></div></div>',trigger:"hover focus",title:"",delay:0,html:!1,container:!1,viewport:{selector:"body",padding:0}},c.prototype.init=function(b,c,d){if(this.enabled=!0,this.type=b,this.$element=a(c),this.options=this.getOptions(d),this.$viewport=this.options.viewport&&a(a.isFunction(this.options.viewport)?this.options.viewport.call(this,this.$element):this.options.viewport.selector||this.options.viewport),this.inState={click:!1,hover:!1,focus:!1},this.$element[0]instanceof document.constructor&&!this.options.selector)throw new Error("`selector` option must be specified when initializing "+this.type+" on the window.document object!");for(var e=this.options.trigger.split(" "),f=e.length;f--;){var g=e[f];if("click"==g)this.$element.on("click."+this.type,this.options.selector,a.proxy(this.toggle,this));else if("manual"!=g){var h="hover"==g?"mouseenter":"focusin",i="hover"==g?"mouseleave":"focusout";this.$element.on(h+"."+this.type,this.options.selector,a.proxy(this.enter,this)),this.$element.on(i+"."+this.type,this.options.selector,a.proxy(this.leave,this))}}this.options.selector?this._options=a.extend({},this.options,{trigger:"manual",selector:""}):this.fixTitle()},c.prototype.getDefaults=function(){return c.DEFAULTS},c.prototype.getOptions=function(b){return b=a.extend({},this.getDefaults(),this.$element.data(),b),b.delay&&"number"==typeof b.delay&&(b.delay={show:b.delay,hide:b.delay}),b},c.prototype.getDelegateOptions=function(){var b={},c=this.getDefaults();return this._options&&a.each(this._options,function(a,d){c[a]!=d&&(b[a]=d)}),b},c.prototype.enter=function(b){var c=b instanceof this.constructor?b:a(b.currentTarget).data("bs."+this.type);return c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c)),b instanceof a.Event&&(c.inState["focusin"==b.type?"focus":"hover"]=!0),c.tip().hasClass("in")||"in"==c.hoverState?void(c.hoverState="in"):(clearTimeout(c.timeout),c.hoverState="in",c.options.delay&&c.options.delay.show?void(c.timeout=setTimeout(function(){"in"==c.hoverState&&c.show()},c.options.delay.show)):c.show())},c.prototype.isInStateTrue=function(){for(var a in this.inState)if(this.inState[a])return!0;return!1},c.prototype.leave=function(b){var c=b instanceof this.constructor?b:a(b.currentTarget).data("bs."+this.type);return c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c)),b instanceof a.Event&&(c.inState["focusout"==b.type?"focus":"hover"]=!1),c.isInStateTrue()?void 0:(clearTimeout(c.timeout),c.hoverState="out",c.options.delay&&c.options.delay.hide?void(c.timeout=setTimeout(function(){"out"==c.hoverState&&c.hide()},c.options.delay.hide)):c.hide())},c.prototype.show=function(){var b=a.Event("show.bs."+this.type);if(this.hasContent()&&this.enabled){this.$element.trigger(b);var d=a.contains(this.$element[0].ownerDocument.documentElement,this.$element[0]);if(b.isDefaultPrevented()||!d)return;var e=this,f=this.tip(),g=this.getUID(this.type);this.setContent(),f.attr("id",g),this.$element.attr("aria-describedby",g),this.options.animation&&f.addClass("fade");var h="function"==typeof this.options.placement?this.options.placement.call(this,f[0],this.$element[0]):this.options.placement,i=/\s?auto?\s?/i,j=i.test(h);j&&(h=h.replace(i,"")||"top"),f.detach().css({top:0,left:0,display:"block"}).addClass(h).data("bs."+this.type,this),this.options.container?f.appendTo(this.options.container):f.insertAfter(this.$element),this.$element.trigger("inserted.bs."+this.type);var k=this.getPosition(),l=f[0].offsetWidth,m=f[0].offsetHeight;if(j){var n=h,o=this.getPosition(this.$viewport);h="bottom"==h&&k.bottom+m>o.bottom?"top":"top"==h&&k.top-m<o.top?"bottom":"right"==h&&k.right+l>o.width?"left":"left"==h&&k.left-l<o.left?"right":h,f.removeClass(n).addClass(h)}var p=this.getCalculatedOffset(h,k,l,m);this.applyPlacement(p,h);var q=function(){var a=e.hoverState;e.$element.trigger("shown.bs."+e.type),e.hoverState=null,"out"==a&&e.leave(e)};a.support.transition&&this.$tip.hasClass("fade")?f.one("bsTransitionEnd",q).emulateTransitionEnd(c.TRANSITION_DURATION):q()}},c.prototype.applyPlacement=function(b,c){var d=this.tip(),e=d[0].offsetWidth,f=d[0].offsetHeight,g=parseInt(d.css("margin-top"),10),h=parseInt(d.css("margin-left"),10);isNaN(g)&&(g=0),isNaN(h)&&(h=0),b.top+=g,b.left+=h,a.offset.setOffset(d[0],a.extend({using:function(a){d.css({top:Math.round(a.top),left:Math.round(a.left)})}},b),0),d.addClass("in");var i=d[0].offsetWidth,j=d[0].offsetHeight;"top"==c&&j!=f&&(b.top=b.top+f-j);var k=this.getViewportAdjustedDelta(c,b,i,j);k.left?b.left+=k.left:b.top+=k.top;var l=/top|bottom/.test(c),m=l?2*k.left-e+i:2*k.top-f+j,n=l?"offsetWidth":"offsetHeight";d.offset(b),this.replaceArrow(m,d[0][n],l)},c.prototype.replaceArrow=function(a,b,c){this.arrow().css(c?"left":"top",50*(1-a/b)+"%").css(c?"top":"left","")},c.prototype.setContent=function(){var a=this.tip(),b=this.getTitle();a.find(".tooltip-inner")[this.options.html?"html":"text"](b),a.removeClass("fade in top bottom left right")},c.prototype.hide=function(b){function d(){"in"!=e.hoverState&&f.detach(),e.$element.removeAttr("aria-describedby").trigger("hidden.bs."+e.type),b&&b()}var e=this,f=a(this.$tip),g=a.Event("hide.bs."+this.type);return this.$element.trigger(g),g.isDefaultPrevented()?void 0:(f.removeClass("in"),a.support.transition&&f.hasClass("fade")?f.one("bsTransitionEnd",d).emulateTransitionEnd(c.TRANSITION_DURATION):d(),this.hoverState=null,this)},c.prototype.fixTitle=function(){var a=this.$element;(a.attr("title")||"string"!=typeof a.attr("data-original-title"))&&a.attr("data-original-title",a.attr("title")||"").attr("title","")},c.prototype.hasContent=function(){return this.getTitle()},c.prototype.getPosition=function(b){b=b||this.$element;var c=b[0],d="BODY"==c.tagName,e=c.getBoundingClientRect();null==e.width&&(e=a.extend({},e,{width:e.right-e.left,height:e.bottom-e.top}));var f=d?{top:0,left:0}:b.offset(),g={scroll:d?document.documentElement.scrollTop||document.body.scrollTop:b.scrollTop()},h=d?{width:a(window).width(),height:a(window).height()}:null;return a.extend({},e,g,h,f)},c.prototype.getCalculatedOffset=function(a,b,c,d){return"bottom"==a?{top:b.top+b.height,left:b.left+b.width/2-c/2}:"top"==a?{top:b.top-d,left:b.left+b.width/2-c/2}:"left"==a?{top:b.top+b.height/2-d/2,left:b.left-c}:{top:b.top+b.height/2-d/2,left:b.left+b.width}},c.prototype.getViewportAdjustedDelta=function(a,b,c,d){var e={top:0,left:0};if(!this.$viewport)return e;var f=this.options.viewport&&this.options.viewport.padding||0,g=this.getPosition(this.$viewport);if(/right|left/.test(a)){var h=b.top-f-g.scroll,i=b.top+f-g.scroll+d;h<g.top?e.top=g.top-h:i>g.top+g.height&&(e.top=g.top+g.height-i)}else{var j=b.left-f,k=b.left+f+c;j<g.left?e.left=g.left-j:k>g.right&&(e.left=g.left+g.width-k)}return e},c.prototype.getTitle=function(){var a,b=this.$element,c=this.options;return a=b.attr("data-original-title")||("function"==typeof c.title?c.title.call(b[0]):c.title)},c.prototype.getUID=function(a){do a+=~~(1e6*Math.random());while(document.getElementById(a));return a},c.prototype.tip=function(){if(!this.$tip&&(this.$tip=a(this.options.template),1!=this.$tip.length))throw new Error(this.type+" `template` option must consist of exactly 1 top-level element!");return this.$tip},c.prototype.arrow=function(){return this.$arrow=this.$arrow||this.tip().find(".tooltip-arrow")},c.prototype.enable=function(){this.enabled=!0},c.prototype.disable=function(){this.enabled=!1},c.prototype.toggleEnabled=function(){this.enabled=!this.enabled},c.prototype.toggle=function(b){var c=this;b&&(c=a(b.currentTarget).data("bs."+this.type),c||(c=new this.constructor(b.currentTarget,this.getDelegateOptions()),a(b.currentTarget).data("bs."+this.type,c))),b?(c.inState.click=!c.inState.click,c.isInStateTrue()?c.enter(c):c.leave(c)):c.tip().hasClass("in")?c.leave(c):c.enter(c)},c.prototype.destroy=function(){var a=this;clearTimeout(this.timeout),this.hide(function(){a.$element.off("."+a.type).removeData("bs."+a.type),a.$tip&&a.$tip.detach(),a.$tip=null,a.$arrow=null,a.$viewport=null})};var d=a.fn.tooltip;a.fn.tooltip=b,a.fn.tooltip.Constructor=c,a.fn.tooltip.noConflict=function(){return a.fn.tooltip=d,this}}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.popover"),f="object"==typeof b&&b;(e||!/destroy|hide/.test(b))&&(e||d.data("bs.popover",e=new c(this,f)),"string"==typeof b&&e[b]())})}var c=function(a,b){this.init("popover",a,b)};if(!a.fn.tooltip)throw new Error("Popover requires tooltip.js");c.VERSION="3.3.5",c.DEFAULTS=a.extend({},a.fn.tooltip.Constructor.DEFAULTS,{placement:"right",trigger:"click",content:"",template:'<div class="popover" role="tooltip"><div class="arrow"></div><h3 class="popover-title"></h3><div class="popover-content"></div></div>'}),c.prototype=a.extend({},a.fn.tooltip.Constructor.prototype),c.prototype.constructor=c,c.prototype.getDefaults=function(){return c.DEFAULTS},c.prototype.setContent=function(){var a=this.tip(),b=this.getTitle(),c=this.getContent();a.find(".popover-title")[this.options.html?"html":"text"](b),a.find(".popover-content").children().detach().end()[this.options.html?"string"==typeof c?"html":"append":"text"](c),a.removeClass("fade top bottom left right in"),a.find(".popover-title").html()||a.find(".popover-title").hide()},c.prototype.hasContent=function(){return this.getTitle()||this.getContent()},c.prototype.getContent=function(){var a=this.$element,b=this.options;return a.attr("data-content")||("function"==typeof b.content?b.content.call(a[0]):b.content)},c.prototype.arrow=function(){return this.$arrow=this.$arrow||this.tip().find(".arrow")};var d=a.fn.popover;a.fn.popover=b,a.fn.popover.Constructor=c,a.fn.popover.noConflict=function(){return a.fn.popover=d,this}}(jQuery),+function(a){"use strict";function b(c,d){this.$body=a(document.body),this.$scrollElement=a(a(c).is(document.body)?window:c),this.options=a.extend({},b.DEFAULTS,d),this.selector=(this.options.target||"")+" .nav li > a",this.offsets=[],this.targets=[],this.activeTarget=null,this.scrollHeight=0,this.$scrollElement.on("scroll.bs.scrollspy",a.proxy(this.process,this)),this.refresh(),this.process()}function c(c){return this.each(function(){var d=a(this),e=d.data("bs.scrollspy"),f="object"==typeof c&&c;e||d.data("bs.scrollspy",e=new b(this,f)),"string"==typeof c&&e[c]()})}b.VERSION="3.3.5",b.DEFAULTS={offset:10},b.prototype.getScrollHeight=function(){return this.$scrollElement[0].scrollHeight||Math.max(this.$body[0].scrollHeight,document.documentElement.scrollHeight)},b.prototype.refresh=function(){var b=this,c="offset",d=0;this.offsets=[],this.targets=[],this.scrollHeight=this.getScrollHeight(),a.isWindow(this.$scrollElement[0])||(c="position",d=this.$scrollElement.scrollTop()),this.$body.find(this.selector).map(function(){var b=a(this),e=b.data("target")||b.attr("href"),f=/^#./.test(e)&&a(e);return f&&f.length&&f.is(":visible")&&[[f[c]().top+d,e]]||null}).sort(function(a,b){return a[0]-b[0]}).each(function(){b.offsets.push(this[0]),b.targets.push(this[1])})},b.prototype.process=function(){var a,b=this.$scrollElement.scrollTop()+this.options.offset,c=this.getScrollHeight(),d=this.options.offset+c-this.$scrollElement.height(),e=this.offsets,f=this.targets,g=this.activeTarget;if(this.scrollHeight!=c&&this.refresh(),b>=d)return g!=(a=f[f.length-1])&&this.activate(a);if(g&&b<e[0])return this.activeTarget=null,this.clear();for(a=e.length;a--;)g!=f[a]&&b>=e[a]&&(void 0===e[a+1]||b<e[a+1])&&this.activate(f[a])},b.prototype.activate=function(b){this.activeTarget=b,this.clear();var c=this.selector+'[data-target="'+b+'"],'+this.selector+'[href="'+b+'"]',d=a(c).parents("li").addClass("active");d.parent(".dropdown-menu").length&&(d=d.closest("li.dropdown").addClass("active")),
d.trigger("activate.bs.scrollspy")},b.prototype.clear=function(){a(this.selector).parentsUntil(this.options.target,".active").removeClass("active")};var d=a.fn.scrollspy;a.fn.scrollspy=c,a.fn.scrollspy.Constructor=b,a.fn.scrollspy.noConflict=function(){return a.fn.scrollspy=d,this},a(window).on("load.bs.scrollspy.data-api",function(){a('[data-spy="scroll"]').each(function(){var b=a(this);c.call(b,b.data())})})}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.tab");e||d.data("bs.tab",e=new c(this)),"string"==typeof b&&e[b]()})}var c=function(b){this.element=a(b)};c.VERSION="3.3.5",c.TRANSITION_DURATION=150,c.prototype.show=function(){var b=this.element,c=b.closest("ul:not(.dropdown-menu)"),d=b.data("target");if(d||(d=b.attr("href"),d=d&&d.replace(/.*(?=#[^\s]*$)/,"")),!b.parent("li").hasClass("active")){var e=c.find(".active:last a"),f=a.Event("hide.bs.tab",{relatedTarget:b[0]}),g=a.Event("show.bs.tab",{relatedTarget:e[0]});if(e.trigger(f),b.trigger(g),!g.isDefaultPrevented()&&!f.isDefaultPrevented()){var h=a(d);this.activate(b.closest("li"),c),this.activate(h,h.parent(),function(){e.trigger({type:"hidden.bs.tab",relatedTarget:b[0]}),b.trigger({type:"shown.bs.tab",relatedTarget:e[0]})})}}},c.prototype.activate=function(b,d,e){function f(){g.removeClass("active").find("> .dropdown-menu > .active").removeClass("active").end().find('[data-toggle="tab"]').attr("aria-expanded",!1),b.addClass("active").find('[data-toggle="tab"]').attr("aria-expanded",!0),h?(b[0].offsetWidth,b.addClass("in")):b.removeClass("fade"),b.parent(".dropdown-menu").length&&b.closest("li.dropdown").addClass("active").end().find('[data-toggle="tab"]').attr("aria-expanded",!0),e&&e()}var g=d.find("> .active"),h=e&&a.support.transition&&(g.length&&g.hasClass("fade")||!!d.find("> .fade").length);g.length&&h?g.one("bsTransitionEnd",f).emulateTransitionEnd(c.TRANSITION_DURATION):f(),g.removeClass("in")};var d=a.fn.tab;a.fn.tab=b,a.fn.tab.Constructor=c,a.fn.tab.noConflict=function(){return a.fn.tab=d,this};var e=function(c){c.preventDefault(),b.call(a(this),"show")};a(document).on("click.bs.tab.data-api",'[data-toggle="tab"]',e).on("click.bs.tab.data-api",'[data-toggle="pill"]',e)}(jQuery),+function(a){"use strict";function b(b){return this.each(function(){var d=a(this),e=d.data("bs.affix"),f="object"==typeof b&&b;e||d.data("bs.affix",e=new c(this,f)),"string"==typeof b&&e[b]()})}var c=function(b,d){this.options=a.extend({},c.DEFAULTS,d),this.$target=a(this.options.target).on("scroll.bs.affix.data-api",a.proxy(this.checkPosition,this)).on("click.bs.affix.data-api",a.proxy(this.checkPositionWithEventLoop,this)),this.$element=a(b),this.affixed=null,this.unpin=null,this.pinnedOffset=null,this.checkPosition()};c.VERSION="3.3.5",c.RESET="affix affix-top affix-bottom",c.DEFAULTS={offset:0,target:window},c.prototype.getState=function(a,b,c,d){var e=this.$target.scrollTop(),f=this.$element.offset(),g=this.$target.height();if(null!=c&&"top"==this.affixed)return c>e?"top":!1;if("bottom"==this.affixed)return null!=c?e+this.unpin<=f.top?!1:"bottom":a-d>=e+g?!1:"bottom";var h=null==this.affixed,i=h?e:f.top,j=h?g:b;return null!=c&&c>=e?"top":null!=d&&i+j>=a-d?"bottom":!1},c.prototype.getPinnedOffset=function(){if(this.pinnedOffset)return this.pinnedOffset;this.$element.removeClass(c.RESET).addClass("affix");var a=this.$target.scrollTop(),b=this.$element.offset();return this.pinnedOffset=b.top-a},c.prototype.checkPositionWithEventLoop=function(){setTimeout(a.proxy(this.checkPosition,this),1)},c.prototype.checkPosition=function(){if(this.$element.is(":visible")){var b=this.$element.height(),d=this.options.offset,e=d.top,f=d.bottom,g=Math.max(a(document).height(),a(document.body).height());"object"!=typeof d&&(f=e=d),"function"==typeof e&&(e=d.top(this.$element)),"function"==typeof f&&(f=d.bottom(this.$element));var h=this.getState(g,b,e,f);if(this.affixed!=h){null!=this.unpin&&this.$element.css("top","");var i="affix"+(h?"-"+h:""),j=a.Event(i+".bs.affix");if(this.$element.trigger(j),j.isDefaultPrevented())return;this.affixed=h,this.unpin="bottom"==h?this.getPinnedOffset():null,this.$element.removeClass(c.RESET).addClass(i).trigger(i.replace("affix","affixed")+".bs.affix")}"bottom"==h&&this.$element.offset({top:g-b-f})}};var d=a.fn.affix;a.fn.affix=b,a.fn.affix.Constructor=c,a.fn.affix.noConflict=function(){return a.fn.affix=d,this},a(window).on("load",function(){a('[data-spy="affix"]').each(function(){var c=a(this),d=c.data();d.offset=d.offset||{},null!=d.offsetBottom&&(d.offset.bottom=d.offsetBottom),null!=d.offsetTop&&(d.offset.top=d.offsetTop),b.call(c,d)})})}(jQuery);"></script>
<script src="data:application/javascript;base64,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"></script>
<script src="data:application/javascript;base64,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"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="data:application/javascript;base64,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"></script>
<link href="data:text/css,%2Ehljs%2Dliteral%20%7B%0Acolor%3A%20%23990073%3B%0A%7D%0A%2Ehljs%2Dnumber%20%7B%0Acolor%3A%20%23099%3B%0A%7D%0A%2Ehljs%2Dcomment%20%7B%0Acolor%3A%20%23998%3B%0Afont%2Dstyle%3A%20italic%3B%0A%7D%0A%2Ehljs%2Dkeyword%20%7B%0Acolor%3A%20%23900%3B%0Afont%2Dweight%3A%20bold%3B%0A%7D%0A%2Ehljs%2Dstring%20%7B%0Acolor%3A%20%23d14%3B%0A%7D%0A" rel="stylesheet" />
<script src="data:application/javascript;base64,/*! highlight.js v9.12.0 | BSD3 License | git.io/hljslicense */
!function(e){var n="object"==typeof window&&window||"object"==typeof self&&self;"undefined"!=typeof exports?e(exports):n&&(n.hljs=e({}),"function"==typeof define&&define.amd&&define([],function(){return n.hljs}))}(function(e){function n(e){return e.replace(/&/g,"&amp;").replace(/</g,"&lt;").replace(/>/g,"&gt;")}function t(e){return e.nodeName.toLowerCase()}function r(e,n){var t=e&&e.exec(n);return t&&0===t.index}function a(e){return k.test(e)}function i(e){var n,t,r,i,o=e.className+" ";if(o+=e.parentNode?e.parentNode.className:"",t=B.exec(o))return w(t[1])?t[1]:"no-highlight";for(o=o.split(/\s+/),n=0,r=o.length;r>n;n++)if(i=o[n],a(i)||w(i))return i}function o(e){var n,t={},r=Array.prototype.slice.call(arguments,1);for(n in e)t[n]=e[n];return r.forEach(function(e){for(n in e)t[n]=e[n]}),t}function u(e){var n=[];return function r(e,a){for(var i=e.firstChild;i;i=i.nextSibling)3===i.nodeType?a+=i.nodeValue.length:1===i.nodeType&&(n.push({event:"start",offset:a,node:i}),a=r(i,a),t(i).match(/br|hr|img|input/)||n.push({event:"stop",offset:a,node:i}));return a}(e,0),n}function c(e,r,a){function i(){return e.length&&r.length?e[0].offset!==r[0].offset?e[0].offset<r[0].offset?e:r:"start"===r[0].event?e:r:e.length?e:r}function o(e){function r(e){return" "+e.nodeName+'="'+n(e.value).replace('"',"&quot;")+'"'}s+="<"+t(e)+E.map.call(e.attributes,r).join("")+">"}function u(e){s+="</"+t(e)+">"}function c(e){("start"===e.event?o:u)(e.node)}for(var l=0,s="",f=[];e.length||r.length;){var g=i();if(s+=n(a.substring(l,g[0].offset)),l=g[0].offset,g===e){f.reverse().forEach(u);do c(g.splice(0,1)[0]),g=i();while(g===e&&g.length&&g[0].offset===l);f.reverse().forEach(o)}else"start"===g[0].event?f.push(g[0].node):f.pop(),c(g.splice(0,1)[0])}return s+n(a.substr(l))}function l(e){return e.v&&!e.cached_variants&&(e.cached_variants=e.v.map(function(n){return o(e,{v:null},n)})),e.cached_variants||e.eW&&[o(e)]||[e]}function s(e){function n(e){return e&&e.source||e}function t(t,r){return new RegExp(n(t),"m"+(e.cI?"i":"")+(r?"g":""))}function r(a,i){if(!a.compiled){if(a.compiled=!0,a.k=a.k||a.bK,a.k){var o={},u=function(n,t){e.cI&&(t=t.toLowerCase()),t.split(" ").forEach(function(e){var t=e.split("|");o[t[0]]=[n,t[1]?Number(t[1]):1]})};"string"==typeof a.k?u("keyword",a.k):x(a.k).forEach(function(e){u(e,a.k[e])}),a.k=o}a.lR=t(a.l||/\w+/,!0),i&&(a.bK&&(a.b="\\b("+a.bK.split(" ").join("|")+")\\b"),a.b||(a.b=/\B|\b/),a.bR=t(a.b),a.e||a.eW||(a.e=/\B|\b/),a.e&&(a.eR=t(a.e)),a.tE=n(a.e)||"",a.eW&&i.tE&&(a.tE+=(a.e?"|":"")+i.tE)),a.i&&(a.iR=t(a.i)),null==a.r&&(a.r=1),a.c||(a.c=[]),a.c=Array.prototype.concat.apply([],a.c.map(function(e){return l("self"===e?a:e)})),a.c.forEach(function(e){r(e,a)}),a.starts&&r(a.starts,i);var c=a.c.map(function(e){return e.bK?"\\.?("+e.b+")\\.?":e.b}).concat([a.tE,a.i]).map(n).filter(Boolean);a.t=c.length?t(c.join("|"),!0):{exec:function(){return null}}}}r(e)}function f(e,t,a,i){function o(e,n){var t,a;for(t=0,a=n.c.length;a>t;t++)if(r(n.c[t].bR,e))return n.c[t]}function u(e,n){if(r(e.eR,n)){for(;e.endsParent&&e.parent;)e=e.parent;return e}return e.eW?u(e.parent,n):void 0}function c(e,n){return!a&&r(n.iR,e)}function l(e,n){var t=N.cI?n[0].toLowerCase():n[0];return e.k.hasOwnProperty(t)&&e.k[t]}function p(e,n,t,r){var a=r?"":I.classPrefix,i='<span class="'+a,o=t?"":C;return i+=e+'">',i+n+o}function h(){var e,t,r,a;if(!E.k)return n(k);for(a="",t=0,E.lR.lastIndex=0,r=E.lR.exec(k);r;)a+=n(k.substring(t,r.index)),e=l(E,r),e?(B+=e[1],a+=p(e[0],n(r[0]))):a+=n(r[0]),t=E.lR.lastIndex,r=E.lR.exec(k);return a+n(k.substr(t))}function d(){var e="string"==typeof E.sL;if(e&&!y[E.sL])return n(k);var t=e?f(E.sL,k,!0,x[E.sL]):g(k,E.sL.length?E.sL:void 0);return E.r>0&&(B+=t.r),e&&(x[E.sL]=t.top),p(t.language,t.value,!1,!0)}function b(){L+=null!=E.sL?d():h(),k=""}function v(e){L+=e.cN?p(e.cN,"",!0):"",E=Object.create(e,{parent:{value:E}})}function m(e,n){if(k+=e,null==n)return b(),0;var t=o(n,E);if(t)return t.skip?k+=n:(t.eB&&(k+=n),b(),t.rB||t.eB||(k=n)),v(t,n),t.rB?0:n.length;var r=u(E,n);if(r){var a=E;a.skip?k+=n:(a.rE||a.eE||(k+=n),b(),a.eE&&(k=n));do E.cN&&(L+=C),E.skip||(B+=E.r),E=E.parent;while(E!==r.parent);return r.starts&&v(r.starts,""),a.rE?0:n.length}if(c(n,E))throw new Error('Illegal lexeme "'+n+'" for mode "'+(E.cN||"<unnamed>")+'"');return k+=n,n.length||1}var N=w(e);if(!N)throw new Error('Unknown language: "'+e+'"');s(N);var R,E=i||N,x={},L="";for(R=E;R!==N;R=R.parent)R.cN&&(L=p(R.cN,"",!0)+L);var k="",B=0;try{for(var M,j,O=0;;){if(E.t.lastIndex=O,M=E.t.exec(t),!M)break;j=m(t.substring(O,M.index),M[0]),O=M.index+j}for(m(t.substr(O)),R=E;R.parent;R=R.parent)R.cN&&(L+=C);return{r:B,value:L,language:e,top:E}}catch(T){if(T.message&&-1!==T.message.indexOf("Illegal"))return{r:0,value:n(t)};throw T}}function g(e,t){t=t||I.languages||x(y);var r={r:0,value:n(e)},a=r;return t.filter(w).forEach(function(n){var t=f(n,e,!1);t.language=n,t.r>a.r&&(a=t),t.r>r.r&&(a=r,r=t)}),a.language&&(r.second_best=a),r}function p(e){return I.tabReplace||I.useBR?e.replace(M,function(e,n){return I.useBR&&"\n"===e?"<br>":I.tabReplace?n.replace(/\t/g,I.tabReplace):""}):e}function h(e,n,t){var r=n?L[n]:t,a=[e.trim()];return e.match(/\bhljs\b/)||a.push("hljs"),-1===e.indexOf(r)&&a.push(r),a.join(" ").trim()}function d(e){var n,t,r,o,l,s=i(e);a(s)||(I.useBR?(n=document.createElementNS("http://www.w3.org/1999/xhtml","div"),n.innerHTML=e.innerHTML.replace(/\n/g,"").replace(/<br[ \/]*>/g,"\n")):n=e,l=n.textContent,r=s?f(s,l,!0):g(l),t=u(n),t.length&&(o=document.createElementNS("http://www.w3.org/1999/xhtml","div"),o.innerHTML=r.value,r.value=c(t,u(o),l)),r.value=p(r.value),e.innerHTML=r.value,e.className=h(e.className,s,r.language),e.result={language:r.language,re:r.r},r.second_best&&(e.second_best={language:r.second_best.language,re:r.second_best.r}))}function b(e){I=o(I,e)}function v(){if(!v.called){v.called=!0;var e=document.querySelectorAll("pre code");E.forEach.call(e,d)}}function m(){addEventListener("DOMContentLoaded",v,!1),addEventListener("load",v,!1)}function N(n,t){var r=y[n]=t(e);r.aliases&&r.aliases.forEach(function(e){L[e]=n})}function R(){return x(y)}function w(e){return e=(e||"").toLowerCase(),y[e]||y[L[e]]}var E=[],x=Object.keys,y={},L={},k=/^(no-?highlight|plain|text)$/i,B=/\blang(?:uage)?-([\w-]+)\b/i,M=/((^(<[^>]+>|\t|)+|(?:\n)))/gm,C="</span>",I={classPrefix:"hljs-",tabReplace:null,useBR:!1,languages:void 0};return e.highlight=f,e.highlightAuto=g,e.fixMarkup=p,e.highlightBlock=d,e.configure=b,e.initHighlighting=v,e.initHighlightingOnLoad=m,e.registerLanguage=N,e.listLanguages=R,e.getLanguage=w,e.inherit=o,e.IR="[a-zA-Z]\\w*",e.UIR="[a-zA-Z_]\\w*",e.NR="\\b\\d+(\\.\\d+)?",e.CNR="(-?)(\\b0[xX][a-fA-F0-9]+|(\\b\\d+(\\.\\d*)?|\\.\\d+)([eE][-+]?\\d+)?)",e.BNR="\\b(0b[01]+)",e.RSR="!|!=|!==|%|%=|&|&&|&=|\\*|\\*=|\\+|\\+=|,|-|-=|/=|/|:|;|<<|<<=|<=|<|===|==|=|>>>=|>>=|>=|>>>|>>|>|\\?|\\[|\\{|\\(|\\^|\\^=|\\||\\|=|\\|\\||~",e.BE={b:"\\\\[\\s\\S]",r:0},e.ASM={cN:"string",b:"'",e:"'",i:"\\n",c:[e.BE]},e.QSM={cN:"string",b:'"',e:'"',i:"\\n",c:[e.BE]},e.PWM={b:/\b(a|an|the|are|I'm|isn't|don't|doesn't|won't|but|just|should|pretty|simply|enough|gonna|going|wtf|so|such|will|you|your|they|like|more)\b/},e.C=function(n,t,r){var a=e.inherit({cN:"comment",b:n,e:t,c:[]},r||{});return a.c.push(e.PWM),a.c.push({cN:"doctag",b:"(?:TODO|FIXME|NOTE|BUG|XXX):",r:0}),a},e.CLCM=e.C("//","$"),e.CBCM=e.C("/\\*","\\*/"),e.HCM=e.C("#","$"),e.NM={cN:"number",b:e.NR,r:0},e.CNM={cN:"number",b:e.CNR,r:0},e.BNM={cN:"number",b:e.BNR,r:0},e.CSSNM={cN:"number",b:e.NR+"(%|em|ex|ch|rem|vw|vh|vmin|vmax|cm|mm|in|pt|pc|px|deg|grad|rad|turn|s|ms|Hz|kHz|dpi|dpcm|dppx)?",r:0},e.RM={cN:"regexp",b:/\//,e:/\/[gimuy]*/,i:/\n/,c:[e.BE,{b:/\[/,e:/\]/,r:0,c:[e.BE]}]},e.TM={cN:"title",b:e.IR,r:0},e.UTM={cN:"title",b:e.UIR,r:0},e.METHOD_GUARD={b:"\\.\\s*"+e.UIR,r:0},e});hljs.registerLanguage("sql",function(e){var t=e.C("--","$");return{cI:!0,i:/[<>{}*#]/,c:[{bK:"begin end start commit rollback savepoint lock alter create drop rename call delete do handler insert load replace select truncate update set show pragma grant merge describe use explain help declare prepare execute deallocate release unlock purge reset change stop analyze cache flush optimize repair kill install uninstall checksum restore check backup revoke comment",e:/;/,eW:!0,l:/[\w\.]+/,k:{keyword:"abort abs absolute acc acce accep accept access accessed accessible account acos action activate add addtime admin administer advanced advise aes_decrypt aes_encrypt after agent aggregate ali alia alias allocate allow alter always analyze ancillary and any anydata anydataset anyschema anytype apply archive archived archivelog are as asc ascii asin assembly assertion associate asynchronous at atan atn2 attr attri attrib attribu attribut attribute attributes audit authenticated authentication authid authors auto autoallocate autodblink autoextend automatic availability avg backup badfile basicfile before begin beginning benchmark between bfile bfile_base big bigfile bin binary_double binary_float binlog bit_and bit_count bit_length bit_or bit_xor bitmap blob_base block blocksize body both bound buffer_cache buffer_pool build bulk by byte byteordermark bytes cache caching call calling cancel capacity cascade cascaded case cast catalog category ceil ceiling chain change changed char_base char_length character_length characters characterset charindex charset charsetform charsetid check checksum checksum_agg child choose chr chunk class cleanup clear client clob clob_base clone close cluster_id cluster_probability cluster_set clustering coalesce coercibility col collate collation collect colu colum column column_value columns columns_updated comment commit compact compatibility compiled complete composite_limit compound compress compute concat concat_ws concurrent confirm conn connec connect connect_by_iscycle connect_by_isleaf connect_by_root connect_time connection consider consistent constant constraint constraints constructor container content contents context contributors controlfile conv convert convert_tz corr corr_k corr_s corresponding corruption cos cost count count_big counted covar_pop covar_samp cpu_per_call cpu_per_session crc32 create creation critical cross cube cume_dist curdate current current_date current_time current_timestamp current_user cursor curtime customdatum cycle data database databases datafile datafiles datalength date_add date_cache date_format date_sub dateadd datediff datefromparts datename datepart datetime2fromparts day day_to_second dayname dayofmonth dayofweek dayofyear days db_role_change dbtimezone ddl deallocate declare decode decompose decrement decrypt deduplicate def defa defau defaul default defaults deferred defi defin define degrees delayed delegate delete delete_all delimited demand dense_rank depth dequeue des_decrypt des_encrypt des_key_file desc descr descri describ describe descriptor deterministic diagnostics difference dimension direct_load directory disable disable_all disallow disassociate discardfile disconnect diskgroup distinct distinctrow distribute distributed div do document domain dotnet double downgrade drop dumpfile duplicate duration each edition editionable editions element ellipsis else elsif elt empty enable enable_all enclosed encode encoding encrypt end end-exec endian enforced engine engines enqueue enterprise entityescaping eomonth error errors escaped evalname evaluate event eventdata events except exception exceptions exchange exclude excluding execu execut execute exempt exists exit exp expire explain export export_set extended extent external external_1 external_2 externally extract failed failed_login_attempts failover failure far fast feature_set feature_value fetch field fields file file_name_convert filesystem_like_logging final finish first first_value fixed flash_cache flashback floor flush following follows for forall force form forma format found found_rows freelist freelists freepools fresh from from_base64 from_days ftp full function general generated get get_format get_lock getdate getutcdate global global_name globally go goto grant grants greatest group group_concat group_id grouping grouping_id groups gtid_subtract guarantee guard handler hash hashkeys having hea head headi headin heading heap help hex hierarchy high high_priority hosts hour http id ident_current ident_incr ident_seed identified identity idle_time if ifnull ignore iif ilike ilm immediate import in include including increment index indexes indexing indextype indicator indices inet6_aton inet6_ntoa inet_aton inet_ntoa infile initial initialized initially initrans inmemory inner innodb input insert install instance instantiable instr interface interleaved intersect into invalidate invisible is is_free_lock is_ipv4 is_ipv4_compat is_not is_not_null is_used_lock isdate isnull isolation iterate java join json json_exists keep keep_duplicates key keys kill language large last last_day last_insert_id last_value lax lcase lead leading least leaves left len lenght length less level levels library like like2 like4 likec limit lines link list listagg little ln load load_file lob lobs local localtime localtimestamp locate locator lock locked log log10 log2 logfile logfiles logging logical logical_reads_per_call logoff logon logs long loop low low_priority lower lpad lrtrim ltrim main make_set makedate maketime managed management manual map mapping mask master master_pos_wait match matched materialized max maxextents maximize maxinstances maxlen maxlogfiles maxloghistory maxlogmembers maxsize maxtrans md5 measures median medium member memcompress memory merge microsecond mid migration min minextents minimum mining minus minute minvalue missing mod mode model modification modify module monitoring month months mount move movement multiset mutex name name_const names nan national native natural nav nchar nclob nested never new newline next nextval no no_write_to_binlog noarchivelog noaudit nobadfile nocheck nocompress nocopy nocycle nodelay nodiscardfile noentityescaping noguarantee nokeep nologfile nomapping nomaxvalue nominimize nominvalue nomonitoring none noneditionable nonschema noorder nopr nopro noprom nopromp noprompt norely noresetlogs noreverse normal norowdependencies noschemacheck noswitch not nothing notice notrim novalidate now nowait nth_value nullif nulls num numb numbe nvarchar nvarchar2 object ocicoll ocidate ocidatetime ociduration ociinterval ociloblocator ocinumber ociref ocirefcursor ocirowid ocistring ocitype oct octet_length of off offline offset oid oidindex old on online only opaque open operations operator optimal optimize option optionally or oracle oracle_date oradata ord ordaudio orddicom orddoc order ordimage ordinality ordvideo organization orlany orlvary out outer outfile outline output over overflow overriding package pad parallel parallel_enable parameters parent parse partial partition partitions pascal passing password password_grace_time password_lock_time password_reuse_max password_reuse_time password_verify_function patch path patindex pctincrease pctthreshold pctused pctversion percent percent_rank percentile_cont percentile_disc performance period period_add period_diff permanent physical pi pipe pipelined pivot pluggable plugin policy position post_transaction pow power pragma prebuilt precedes preceding precision prediction prediction_cost prediction_details prediction_probability prediction_set prepare present preserve prior priority private private_sga privileges procedural procedure procedure_analyze processlist profiles project prompt protection public publishingservername purge quarter query quick quiesce quota quotename radians raise rand range rank raw read reads readsize rebuild record records recover recovery recursive recycle redo reduced ref reference referenced references referencing refresh regexp_like register regr_avgx regr_avgy regr_count regr_intercept regr_r2 regr_slope regr_sxx regr_sxy reject rekey relational relative relaylog release release_lock relies_on relocate rely rem remainder rename repair repeat replace replicate replication required reset resetlogs resize resource respect restore restricted result result_cache resumable resume retention return returning returns reuse reverse revoke right rlike role roles rollback rolling rollup round row row_count rowdependencies rowid rownum rows rtrim rules safe salt sample save savepoint sb1 sb2 sb4 scan schema schemacheck scn scope scroll sdo_georaster sdo_topo_geometry search sec_to_time second section securefile security seed segment select self sequence sequential serializable server servererror session session_user sessions_per_user set sets settings sha sha1 sha2 share shared shared_pool short show shrink shutdown si_averagecolor si_colorhistogram si_featurelist si_positionalcolor si_stillimage si_texture siblings sid sign sin size size_t sizes skip slave sleep smalldatetimefromparts smallfile snapshot some soname sort soundex source space sparse spfile split sql sql_big_result sql_buffer_result sql_cache sql_calc_found_rows sql_small_result sql_variant_property sqlcode sqldata sqlerror sqlname sqlstate sqrt square standalone standby start starting startup statement static statistics stats_binomial_test stats_crosstab stats_ks_test stats_mode stats_mw_test stats_one_way_anova stats_t_test_ stats_t_test_indep stats_t_test_one stats_t_test_paired stats_wsr_test status std stddev stddev_pop stddev_samp stdev stop storage store stored str str_to_date straight_join strcmp strict string struct stuff style subdate subpartition subpartitions substitutable substr substring subtime subtring_index subtype success sum suspend switch switchoffset switchover sync synchronous synonym sys sys_xmlagg sysasm sysaux sysdate sysdatetimeoffset sysdba sysoper system system_user sysutcdatetime table tables tablespace tan tdo template temporary terminated tertiary_weights test than then thread through tier ties time time_format time_zone timediff timefromparts timeout timestamp timestampadd timestampdiff timezone_abbr timezone_minute timezone_region to to_base64 to_date to_days to_seconds todatetimeoffset trace tracking transaction transactional translate translation treat trigger trigger_nestlevel triggers trim truncate try_cast try_convert try_parse type ub1 ub2 ub4 ucase unarchived unbounded uncompress under undo unhex unicode uniform uninstall union unique unix_timestamp unknown unlimited unlock unpivot unrecoverable unsafe unsigned until untrusted unusable unused update updated upgrade upped upper upsert url urowid usable usage use use_stored_outlines user user_data user_resources users using utc_date utc_timestamp uuid uuid_short validate validate_password_strength validation valist value values var var_samp varcharc vari varia variab variabl variable variables variance varp varraw varrawc varray verify version versions view virtual visible void wait wallet warning warnings week weekday weekofyear wellformed when whene whenev wheneve whenever where while whitespace with within without work wrapped xdb xml xmlagg xmlattributes xmlcast xmlcolattval xmlelement xmlexists xmlforest xmlindex xmlnamespaces xmlpi xmlquery xmlroot xmlschema xmlserialize xmltable xmltype xor year year_to_month years yearweek",literal:"true false null",built_in:"array bigint binary bit blob boolean char character date dec decimal float int int8 integer interval number numeric real record serial serial8 smallint text varchar varying void"},c:[{cN:"string",b:"'",e:"'",c:[e.BE,{b:"''"}]},{cN:"string",b:'"',e:'"',c:[e.BE,{b:'""'}]},{cN:"string",b:"`",e:"`",c:[e.BE]},e.CNM,e.CBCM,t]},e.CBCM,t]}});hljs.registerLanguage("r",function(e){var r="([a-zA-Z]|\\.[a-zA-Z.])[a-zA-Z0-9._]*";return{c:[e.HCM,{b:r,l:r,k:{keyword:"function if in break next repeat else for return switch while try tryCatch stop warning require library attach detach source setMethod setGeneric setGroupGeneric setClass ...",literal:"NULL NA TRUE FALSE T F Inf NaN NA_integer_|10 NA_real_|10 NA_character_|10 NA_complex_|10"},r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"\\d+(?:[eE][+\\-]?\\d*)?L\\b",r:0},{cN:"number",b:"\\d+\\.(?!\\d)(?:i\\b)?",r:0},{cN:"number",b:"\\d+(?:\\.\\d*)?(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{cN:"number",b:"\\.\\d+(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{b:"`",e:"`",r:0},{cN:"string",c:[e.BE],v:[{b:'"',e:'"'},{b:"'",e:"'"}]}]}});hljs.registerLanguage("perl",function(e){var t="getpwent getservent quotemeta msgrcv scalar kill dbmclose undef lc ma syswrite tr send umask sysopen shmwrite vec qx utime local oct semctl localtime readpipe do return format read sprintf dbmopen pop getpgrp not getpwnam rewinddir qqfileno qw endprotoent wait sethostent bless s|0 opendir continue each sleep endgrent shutdown dump chomp connect getsockname die socketpair close flock exists index shmgetsub for endpwent redo lstat msgctl setpgrp abs exit select print ref gethostbyaddr unshift fcntl syscall goto getnetbyaddr join gmtime symlink semget splice x|0 getpeername recv log setsockopt cos last reverse gethostbyname getgrnam study formline endhostent times chop length gethostent getnetent pack getprotoent getservbyname rand mkdir pos chmod y|0 substr endnetent printf next open msgsnd readdir use unlink getsockopt getpriority rindex wantarray hex system getservbyport endservent int chr untie rmdir prototype tell listen fork shmread ucfirst setprotoent else sysseek link getgrgid shmctl waitpid unpack getnetbyname reset chdir grep split require caller lcfirst until warn while values shift telldir getpwuid my getprotobynumber delete and sort uc defined srand accept package seekdir getprotobyname semop our rename seek if q|0 chroot sysread setpwent no crypt getc chown sqrt write setnetent setpriority foreach tie sin msgget map stat getlogin unless elsif truncate exec keys glob tied closedirioctl socket readlink eval xor readline binmode setservent eof ord bind alarm pipe atan2 getgrent exp time push setgrent gt lt or ne m|0 break given say state when",r={cN:"subst",b:"[$@]\\{",e:"\\}",k:t},s={b:"->{",e:"}"},n={v:[{b:/\$\d/},{b:/[\$%@](\^\w\b|#\w+(::\w+)*|{\w+}|\w+(::\w*)*)/},{b:/[\$%@][^\s\w{]/,r:0}]},i=[e.BE,r,n],o=[n,e.HCM,e.C("^\\=\\w","\\=cut",{eW:!0}),s,{cN:"string",c:i,v:[{b:"q[qwxr]?\\s*\\(",e:"\\)",r:5},{b:"q[qwxr]?\\s*\\[",e:"\\]",r:5},{b:"q[qwxr]?\\s*\\{",e:"\\}",r:5},{b:"q[qwxr]?\\s*\\|",e:"\\|",r:5},{b:"q[qwxr]?\\s*\\<",e:"\\>",r:5},{b:"qw\\s+q",e:"q",r:5},{b:"'",e:"'",c:[e.BE]},{b:'"',e:'"'},{b:"`",e:"`",c:[e.BE]},{b:"{\\w+}",c:[],r:0},{b:"-?\\w+\\s*\\=\\>",c:[],r:0}]},{cN:"number",b:"(\\b0[0-7_]+)|(\\b0x[0-9a-fA-F_]+)|(\\b[1-9][0-9_]*(\\.[0-9_]+)?)|[0_]\\b",r:0},{b:"(\\/\\/|"+e.RSR+"|\\b(split|return|print|reverse|grep)\\b)\\s*",k:"split return print reverse grep",r:0,c:[e.HCM,{cN:"regexp",b:"(s|tr|y)/(\\\\.|[^/])*/(\\\\.|[^/])*/[a-z]*",r:10},{cN:"regexp",b:"(m|qr)?/",e:"/[a-z]*",c:[e.BE],r:0}]},{cN:"function",bK:"sub",e:"(\\s*\\(.*?\\))?[;{]",eE:!0,r:5,c:[e.TM]},{b:"-\\w\\b",r:0},{b:"^__DATA__$",e:"^__END__$",sL:"mojolicious",c:[{b:"^@@.*",e:"$",cN:"comment"}]}];return r.c=o,s.c=o,{aliases:["pl","pm"],l:/[\w\.]+/,k:t,c:o}});hljs.registerLanguage("ini",function(e){var b={cN:"string",c:[e.BE],v:[{b:"'''",e:"'''",r:10},{b:'"""',e:'"""',r:10},{b:'"',e:'"'},{b:"'",e:"'"}]};return{aliases:["toml"],cI:!0,i:/\S/,c:[e.C(";","$"),e.HCM,{cN:"section",b:/^\s*\[+/,e:/\]+/},{b:/^[a-z0-9\[\]_-]+\s*=\s*/,e:"$",rB:!0,c:[{cN:"attr",b:/[a-z0-9\[\]_-]+/},{b:/=/,eW:!0,r:0,c:[{cN:"literal",b:/\bon|off|true|false|yes|no\b/},{cN:"variable",v:[{b:/\$[\w\d"][\w\d_]*/},{b:/\$\{(.*?)}/}]},b,{cN:"number",b:/([\+\-]+)?[\d]+_[\d_]+/},e.NM]}]}]}});hljs.registerLanguage("diff",function(e){return{aliases:["patch"],c:[{cN:"meta",r:10,v:[{b:/^@@ +\-\d+,\d+ +\+\d+,\d+ +@@$/},{b:/^\*\*\* +\d+,\d+ +\*\*\*\*$/},{b:/^\-\-\- +\d+,\d+ +\-\-\-\-$/}]},{cN:"comment",v:[{b:/Index: /,e:/$/},{b:/={3,}/,e:/$/},{b:/^\-{3}/,e:/$/},{b:/^\*{3} /,e:/$/},{b:/^\+{3}/,e:/$/},{b:/\*{5}/,e:/\*{5}$/}]},{cN:"addition",b:"^\\+",e:"$"},{cN:"deletion",b:"^\\-",e:"$"},{cN:"addition",b:"^\\!",e:"$"}]}});hljs.registerLanguage("go",function(e){var t={keyword:"break default func interface select case map struct chan else goto package switch const fallthrough if range type continue for import return var go defer bool byte complex64 complex128 float32 float64 int8 int16 int32 int64 string uint8 uint16 uint32 uint64 int uint uintptr rune",literal:"true false iota nil",built_in:"append cap close complex copy imag len make new panic print println real recover delete"};return{aliases:["golang"],k:t,i:"</",c:[e.CLCM,e.CBCM,{cN:"string",v:[e.QSM,{b:"'",e:"[^\\\\]'"},{b:"`",e:"`"}]},{cN:"number",v:[{b:e.CNR+"[dflsi]",r:1},e.CNM]},{b:/:=/},{cN:"function",bK:"func",e:/\s*\{/,eE:!0,c:[e.TM,{cN:"params",b:/\(/,e:/\)/,k:t,i:/["']/}]}]}});hljs.registerLanguage("bash",function(e){var t={cN:"variable",v:[{b:/\$[\w\d#@][\w\d_]*/},{b:/\$\{(.*?)}/}]},s={cN:"string",b:/"/,e:/"/,c:[e.BE,t,{cN:"variable",b:/\$\(/,e:/\)/,c:[e.BE]}]},a={cN:"string",b:/'/,e:/'/};return{aliases:["sh","zsh"],l:/\b-?[a-z\._]+\b/,k:{keyword:"if then else elif fi for while in do done case esac function",literal:"true false",built_in:"break cd continue eval exec exit export getopts hash pwd readonly return shift test times trap umask unset alias bind builtin caller command declare echo enable help let local logout mapfile printf read readarray source type typeset ulimit unalias set shopt autoload bg bindkey bye cap chdir clone comparguments compcall compctl compdescribe compfiles compgroups compquote comptags comptry compvalues dirs disable disown echotc echoti emulate fc fg float functions getcap getln history integer jobs kill limit log noglob popd print pushd pushln rehash sched setcap setopt stat suspend ttyctl unfunction unhash unlimit unsetopt vared wait whence where which zcompile zformat zftp zle zmodload zparseopts zprof zpty zregexparse zsocket zstyle ztcp",_:"-ne -eq -lt -gt -f -d -e -s -l -a"},c:[{cN:"meta",b:/^#![^\n]+sh\s*$/,r:10},{cN:"function",b:/\w[\w\d_]*\s*\(\s*\)\s*\{/,rB:!0,c:[e.inherit(e.TM,{b:/\w[\w\d_]*/})],r:0},e.HCM,s,a,t]}});hljs.registerLanguage("python",function(e){var r={keyword:"and elif is global as in if from raise for except finally print import pass return exec else break not with class assert yield try while continue del or def lambda async await nonlocal|10 None True False",built_in:"Ellipsis NotImplemented"},b={cN:"meta",b:/^(>>>|\.\.\.) /},c={cN:"subst",b:/\{/,e:/\}/,k:r,i:/#/},a={cN:"string",c:[e.BE],v:[{b:/(u|b)?r?'''/,e:/'''/,c:[b],r:10},{b:/(u|b)?r?"""/,e:/"""/,c:[b],r:10},{b:/(fr|rf|f)'''/,e:/'''/,c:[b,c]},{b:/(fr|rf|f)"""/,e:/"""/,c:[b,c]},{b:/(u|r|ur)'/,e:/'/,r:10},{b:/(u|r|ur)"/,e:/"/,r:10},{b:/(b|br)'/,e:/'/},{b:/(b|br)"/,e:/"/},{b:/(fr|rf|f)'/,e:/'/,c:[c]},{b:/(fr|rf|f)"/,e:/"/,c:[c]},e.ASM,e.QSM]},s={cN:"number",r:0,v:[{b:e.BNR+"[lLjJ]?"},{b:"\\b(0o[0-7]+)[lLjJ]?"},{b:e.CNR+"[lLjJ]?"}]},i={cN:"params",b:/\(/,e:/\)/,c:["self",b,s,a]};return c.c=[a,s,b],{aliases:["py","gyp"],k:r,i:/(<\/|->|\?)|=>/,c:[b,s,a,e.HCM,{v:[{cN:"function",bK:"def"},{cN:"class",bK:"class"}],e:/:/,i:/[${=;\n,]/,c:[e.UTM,i,{b:/->/,eW:!0,k:"None"}]},{cN:"meta",b:/^[\t ]*@/,e:/$/},{b:/\b(print|exec)\(/}]}});hljs.registerLanguage("julia",function(e){var r={keyword:"in isa where baremodule begin break catch ccall const continue do else elseif end export false finally for function global if import importall let local macro module quote return true try using while type immutable abstract bitstype typealias ",literal:"true false ARGS C_NULL DevNull ENDIAN_BOM ENV I Inf Inf16 Inf32 Inf64 InsertionSort JULIA_HOME LOAD_PATH MergeSort NaN NaN16 NaN32 NaN64 PROGRAM_FILE QuickSort RoundDown RoundFromZero RoundNearest RoundNearestTiesAway RoundNearestTiesUp RoundToZero RoundUp STDERR STDIN STDOUT VERSION catalan e|0 eu|0 eulergamma golden im nothing pi γ π φ ",built_in:"ANY AbstractArray AbstractChannel AbstractFloat AbstractMatrix AbstractRNG AbstractSerializer AbstractSet AbstractSparseArray AbstractSparseMatrix AbstractSparseVector AbstractString AbstractUnitRange AbstractVecOrMat AbstractVector Any ArgumentError Array AssertionError Associative Base64DecodePipe Base64EncodePipe Bidiagonal BigFloat BigInt BitArray BitMatrix BitVector Bool BoundsError BufferStream CachingPool CapturedException CartesianIndex CartesianRange Cchar Cdouble Cfloat Channel Char Cint Cintmax_t Clong Clonglong ClusterManager Cmd CodeInfo Colon Complex Complex128 Complex32 Complex64 CompositeException Condition ConjArray ConjMatrix ConjVector Cptrdiff_t Cshort Csize_t Cssize_t Cstring Cuchar Cuint Cuintmax_t Culong Culonglong Cushort Cwchar_t Cwstring DataType Date DateFormat DateTime DenseArray DenseMatrix DenseVecOrMat DenseVector Diagonal Dict DimensionMismatch Dims DirectIndexString Display DivideError DomainError EOFError EachLine Enum Enumerate ErrorException Exception ExponentialBackOff Expr Factorization FileMonitor Float16 Float32 Float64 Function Future GlobalRef GotoNode HTML Hermitian IO IOBuffer IOContext IOStream IPAddr IPv4 IPv6 IndexCartesian IndexLinear IndexStyle InexactError InitError Int Int128 Int16 Int32 Int64 Int8 IntSet Integer InterruptException InvalidStateException Irrational KeyError LabelNode LinSpace LineNumberNode LoadError LowerTriangular MIME Matrix MersenneTwister Method MethodError MethodTable Module NTuple NewvarNode NullException Nullable Number ObjectIdDict OrdinalRange OutOfMemoryError OverflowError Pair ParseError PartialQuickSort PermutedDimsArray Pipe PollingFileWatcher ProcessExitedException Ptr QuoteNode RandomDevice Range RangeIndex Rational RawFD ReadOnlyMemoryError Real ReentrantLock Ref Regex RegexMatch RemoteChannel RemoteException RevString RoundingMode RowVector SSAValue SegmentationFault SerializationState Set SharedArray SharedMatrix SharedVector Signed SimpleVector Slot SlotNumber SparseMatrixCSC SparseVector StackFrame StackOverflowError StackTrace StepRange StepRangeLen StridedArray StridedMatrix StridedVecOrMat StridedVector String SubArray SubString SymTridiagonal Symbol Symmetric SystemError TCPSocket Task Text TextDisplay Timer Tridiagonal Tuple Type TypeError TypeMapEntry TypeMapLevel TypeName TypeVar TypedSlot UDPSocket UInt UInt128 UInt16 UInt32 UInt64 UInt8 UndefRefError UndefVarError UnicodeError UniformScaling Union UnionAll UnitRange Unsigned UpperTriangular Val Vararg VecElement VecOrMat Vector VersionNumber Void WeakKeyDict WeakRef WorkerConfig WorkerPool "},t="[A-Za-z_\\u00A1-\\uFFFF][A-Za-z_0-9\\u00A1-\\uFFFF]*",a={l:t,k:r,i:/<\//},n={cN:"number",b:/(\b0x[\d_]*(\.[\d_]*)?|0x\.\d[\d_]*)p[-+]?\d+|\b0[box][a-fA-F0-9][a-fA-F0-9_]*|(\b\d[\d_]*(\.[\d_]*)?|\.\d[\d_]*)([eEfF][-+]?\d+)?/,r:0},o={cN:"string",b:/'(.|\\[xXuU][a-zA-Z0-9]+)'/},i={cN:"subst",b:/\$\(/,e:/\)/,k:r},l={cN:"variable",b:"\\$"+t},c={cN:"string",c:[e.BE,i,l],v:[{b:/\w*"""/,e:/"""\w*/,r:10},{b:/\w*"/,e:/"\w*/}]},s={cN:"string",c:[e.BE,i,l],b:"`",e:"`"},d={cN:"meta",b:"@"+t},u={cN:"comment",v:[{b:"#=",e:"=#",r:10},{b:"#",e:"$"}]};return a.c=[n,o,c,s,d,u,e.HCM,{cN:"keyword",b:"\\b(((abstract|primitive)\\s+)type|(mutable\\s+)?struct)\\b"},{b:/<:/}],i.c=a.c,a});hljs.registerLanguage("coffeescript",function(e){var c={keyword:"in if for while finally new do return else break catch instanceof throw try this switch continue typeof delete debugger super yield import export from as default await then unless until loop of by when and or is isnt not",literal:"true false null undefined yes no on off",built_in:"npm require console print module global window document"},n="[A-Za-z$_][0-9A-Za-z$_]*",r={cN:"subst",b:/#\{/,e:/}/,k:c},i=[e.BNM,e.inherit(e.CNM,{starts:{e:"(\\s*/)?",r:0}}),{cN:"string",v:[{b:/'''/,e:/'''/,c:[e.BE]},{b:/'/,e:/'/,c:[e.BE]},{b:/"""/,e:/"""/,c:[e.BE,r]},{b:/"/,e:/"/,c:[e.BE,r]}]},{cN:"regexp",v:[{b:"///",e:"///",c:[r,e.HCM]},{b:"//[gim]*",r:0},{b:/\/(?![ *])(\\\/|.)*?\/[gim]*(?=\W|$)/}]},{b:"@"+n},{sL:"javascript",eB:!0,eE:!0,v:[{b:"```",e:"```"},{b:"`",e:"`"}]}];r.c=i;var s=e.inherit(e.TM,{b:n}),t="(\\(.*\\))?\\s*\\B[-=]>",o={cN:"params",b:"\\([^\\(]",rB:!0,c:[{b:/\(/,e:/\)/,k:c,c:["self"].concat(i)}]};return{aliases:["coffee","cson","iced"],k:c,i:/\/\*/,c:i.concat([e.C("###","###"),e.HCM,{cN:"function",b:"^\\s*"+n+"\\s*=\\s*"+t,e:"[-=]>",rB:!0,c:[s,o]},{b:/[:\(,=]\s*/,r:0,c:[{cN:"function",b:t,e:"[-=]>",rB:!0,c:[o]}]},{cN:"class",bK:"class",e:"$",i:/[:="\[\]]/,c:[{bK:"extends",eW:!0,i:/[:="\[\]]/,c:[s]},s]},{b:n+":",e:":",rB:!0,rE:!0,r:0}])}});hljs.registerLanguage("cpp",function(t){var e={cN:"keyword",b:"\\b[a-z\\d_]*_t\\b"},r={cN:"string",v:[{b:'(u8?|U)?L?"',e:'"',i:"\\n",c:[t.BE]},{b:'(u8?|U)?R"',e:'"',c:[t.BE]},{b:"'\\\\?.",e:"'",i:"."}]},s={cN:"number",v:[{b:"\\b(0b[01']+)"},{b:"(-?)\\b([\\d']+(\\.[\\d']*)?|\\.[\\d']+)(u|U|l|L|ul|UL|f|F|b|B)"},{b:"(-?)(\\b0[xX][a-fA-F0-9']+|(\\b[\\d']+(\\.[\\d']*)?|\\.[\\d']+)([eE][-+]?[\\d']+)?)"}],r:0},i={cN:"meta",b:/#\s*[a-z]+\b/,e:/$/,k:{"meta-keyword":"if else elif endif define undef warning error line pragma ifdef ifndef include"},c:[{b:/\\\n/,r:0},t.inherit(r,{cN:"meta-string"}),{cN:"meta-string",b:/<[^\n>]*>/,e:/$/,i:"\\n"},t.CLCM,t.CBCM]},a=t.IR+"\\s*\\(",c={keyword:"int float while private char catch import module export virtual operator sizeof dynamic_cast|10 typedef const_cast|10 const for static_cast|10 union namespace unsigned long volatile static protected bool template mutable if public friend do goto auto void enum else break extern using asm case typeid short reinterpret_cast|10 default double register explicit signed typename try this switch continue inline delete alignof constexpr decltype noexcept static_assert thread_local restrict _Bool complex _Complex _Imaginary atomic_bool atomic_char atomic_schar atomic_uchar atomic_short atomic_ushort atomic_int atomic_uint atomic_long atomic_ulong atomic_llong atomic_ullong new throw return and or not",built_in:"std string cin cout cerr clog stdin stdout stderr stringstream istringstream ostringstream auto_ptr deque list queue stack vector map set bitset multiset multimap unordered_set unordered_map unordered_multiset unordered_multimap array shared_ptr abort abs acos asin atan2 atan calloc ceil cosh cos exit exp fabs floor fmod fprintf fputs free frexp fscanf isalnum isalpha iscntrl isdigit isgraph islower isprint ispunct isspace isupper isxdigit tolower toupper labs ldexp log10 log malloc realloc memchr memcmp memcpy memset modf pow printf putchar puts scanf sinh sin snprintf sprintf sqrt sscanf strcat strchr strcmp strcpy strcspn strlen strncat strncmp strncpy strpbrk strrchr strspn strstr tanh tan vfprintf vprintf vsprintf endl initializer_list unique_ptr",literal:"true false nullptr NULL"},n=[e,t.CLCM,t.CBCM,s,r];return{aliases:["c","cc","h","c++","h++","hpp"],k:c,i:"</",c:n.concat([i,{b:"\\b(deque|list|queue|stack|vector|map|set|bitset|multiset|multimap|unordered_map|unordered_set|unordered_multiset|unordered_multimap|array)\\s*<",e:">",k:c,c:["self",e]},{b:t.IR+"::",k:c},{v:[{b:/=/,e:/;/},{b:/\(/,e:/\)/},{bK:"new throw return else",e:/;/}],k:c,c:n.concat([{b:/\(/,e:/\)/,k:c,c:n.concat(["self"]),r:0}]),r:0},{cN:"function",b:"("+t.IR+"[\\*&\\s]+)+"+a,rB:!0,e:/[{;=]/,eE:!0,k:c,i:/[^\w\s\*&]/,c:[{b:a,rB:!0,c:[t.TM],r:0},{cN:"params",b:/\(/,e:/\)/,k:c,r:0,c:[t.CLCM,t.CBCM,r,s,e]},t.CLCM,t.CBCM,i]},{cN:"class",bK:"class struct",e:/[{;:]/,c:[{b:/</,e:/>/,c:["self"]},t.TM]}]),exports:{preprocessor:i,strings:r,k:c}}});hljs.registerLanguage("ruby",function(e){var b="[a-zA-Z_]\\w*[!?=]?|[-+~]\\@|<<|>>|=~|===?|<=>|[<>]=?|\\*\\*|[-/+%^&*~`|]|\\[\\]=?",r={keyword:"and then defined module in return redo if BEGIN retry end for self when next until do begin unless END rescue else break undef not super class case require yield alias while ensure elsif or include attr_reader attr_writer attr_accessor",literal:"true false nil"},c={cN:"doctag",b:"@[A-Za-z]+"},a={b:"#<",e:">"},s=[e.C("#","$",{c:[c]}),e.C("^\\=begin","^\\=end",{c:[c],r:10}),e.C("^__END__","\\n$")],n={cN:"subst",b:"#\\{",e:"}",k:r},t={cN:"string",c:[e.BE,n],v:[{b:/'/,e:/'/},{b:/"/,e:/"/},{b:/`/,e:/`/},{b:"%[qQwWx]?\\(",e:"\\)"},{b:"%[qQwWx]?\\[",e:"\\]"},{b:"%[qQwWx]?{",e:"}"},{b:"%[qQwWx]?<",e:">"},{b:"%[qQwWx]?/",e:"/"},{b:"%[qQwWx]?%",e:"%"},{b:"%[qQwWx]?-",e:"-"},{b:"%[qQwWx]?\\|",e:"\\|"},{b:/\B\?(\\\d{1,3}|\\x[A-Fa-f0-9]{1,2}|\\u[A-Fa-f0-9]{4}|\\?\S)\b/},{b:/<<(-?)\w+$/,e:/^\s*\w+$/}]},i={cN:"params",b:"\\(",e:"\\)",endsParent:!0,k:r},d=[t,a,{cN:"class",bK:"class module",e:"$|;",i:/=/,c:[e.inherit(e.TM,{b:"[A-Za-z_]\\w*(::\\w+)*(\\?|\\!)?"}),{b:"<\\s*",c:[{b:"("+e.IR+"::)?"+e.IR}]}].concat(s)},{cN:"function",bK:"def",e:"$|;",c:[e.inherit(e.TM,{b:b}),i].concat(s)},{b:e.IR+"::"},{cN:"symbol",b:e.UIR+"(\\!|\\?)?:",r:0},{cN:"symbol",b:":(?!\\s)",c:[t,{b:b}],r:0},{cN:"number",b:"(\\b0[0-7_]+)|(\\b0x[0-9a-fA-F_]+)|(\\b[1-9][0-9_]*(\\.[0-9_]+)?)|[0_]\\b",r:0},{b:"(\\$\\W)|((\\$|\\@\\@?)(\\w+))"},{cN:"params",b:/\|/,e:/\|/,k:r},{b:"("+e.RSR+"|unless)\\s*",k:"unless",c:[a,{cN:"regexp",c:[e.BE,n],i:/\n/,v:[{b:"/",e:"/[a-z]*"},{b:"%r{",e:"}[a-z]*"},{b:"%r\\(",e:"\\)[a-z]*"},{b:"%r!",e:"![a-z]*"},{b:"%r\\[",e:"\\][a-z]*"}]}].concat(s),r:0}].concat(s);n.c=d,i.c=d;var l="[>?]>",o="[\\w#]+\\(\\w+\\):\\d+:\\d+>",u="(\\w+-)?\\d+\\.\\d+\\.\\d(p\\d+)?[^>]+>",w=[{b:/^\s*=>/,starts:{e:"$",c:d}},{cN:"meta",b:"^("+l+"|"+o+"|"+u+")",starts:{e:"$",c:d}}];return{aliases:["rb","gemspec","podspec","thor","irb"],k:r,i:/\/\*/,c:s.concat(w).concat(d)}});hljs.registerLanguage("yaml",function(e){var b="true false yes no null",a="^[ \\-]*",r="[a-zA-Z_][\\w\\-]*",t={cN:"attr",v:[{b:a+r+":"},{b:a+'"'+r+'":'},{b:a+"'"+r+"':"}]},c={cN:"template-variable",v:[{b:"{{",e:"}}"},{b:"%{",e:"}"}]},l={cN:"string",r:0,v:[{b:/'/,e:/'/},{b:/"/,e:/"/},{b:/\S+/}],c:[e.BE,c]};return{cI:!0,aliases:["yml","YAML","yaml"],c:[t,{cN:"meta",b:"^---s*$",r:10},{cN:"string",b:"[\\|>] *$",rE:!0,c:l.c,e:t.v[0].b},{b:"<%[%=-]?",e:"[%-]?%>",sL:"ruby",eB:!0,eE:!0,r:0},{cN:"type",b:"!!"+e.UIR},{cN:"meta",b:"&"+e.UIR+"$"},{cN:"meta",b:"\\*"+e.UIR+"$"},{cN:"bullet",b:"^ *-",r:0},e.HCM,{bK:b,k:{literal:b}},e.CNM,l]}});hljs.registerLanguage("css",function(e){var c="[a-zA-Z-][a-zA-Z0-9_-]*",t={b:/[A-Z\_\.\-]+\s*:/,rB:!0,e:";",eW:!0,c:[{cN:"attribute",b:/\S/,e:":",eE:!0,starts:{eW:!0,eE:!0,c:[{b:/[\w-]+\(/,rB:!0,c:[{cN:"built_in",b:/[\w-]+/},{b:/\(/,e:/\)/,c:[e.ASM,e.QSM]}]},e.CSSNM,e.QSM,e.ASM,e.CBCM,{cN:"number",b:"#[0-9A-Fa-f]+"},{cN:"meta",b:"!important"}]}}]};return{cI:!0,i:/[=\/|'\$]/,c:[e.CBCM,{cN:"selector-id",b:/#[A-Za-z0-9_-]+/},{cN:"selector-class",b:/\.[A-Za-z0-9_-]+/},{cN:"selector-attr",b:/\[/,e:/\]/,i:"$"},{cN:"selector-pseudo",b:/:(:)?[a-zA-Z0-9\_\-\+\(\)"'.]+/},{b:"@(font-face|page)",l:"[a-z-]+",k:"font-face page"},{b:"@",e:"[{;]",i:/:/,c:[{cN:"keyword",b:/\w+/},{b:/\s/,eW:!0,eE:!0,r:0,c:[e.ASM,e.QSM,e.CSSNM]}]},{cN:"selector-tag",b:c,r:0},{b:"{",e:"}",i:/\S/,c:[e.CBCM,t]}]}});hljs.registerLanguage("fortran",function(e){var t={cN:"params",b:"\\(",e:"\\)"},n={literal:".False. .True.",keyword:"kind do while private call intrinsic where elsewhere type endtype endmodule endselect endinterface end enddo endif if forall endforall only contains default return stop then public subroutine|10 function program .and. .or. .not. .le. .eq. .ge. .gt. .lt. goto save else use module select case access blank direct exist file fmt form formatted iostat name named nextrec number opened rec recl sequential status unformatted unit continue format pause cycle exit c_null_char c_alert c_backspace c_form_feed flush wait decimal round iomsg synchronous nopass non_overridable pass protected volatile abstract extends import non_intrinsic value deferred generic final enumerator class associate bind enum c_int c_short c_long c_long_long c_signed_char c_size_t c_int8_t c_int16_t c_int32_t c_int64_t c_int_least8_t c_int_least16_t c_int_least32_t c_int_least64_t c_int_fast8_t c_int_fast16_t c_int_fast32_t c_int_fast64_t c_intmax_t C_intptr_t c_float c_double c_long_double c_float_complex c_double_complex c_long_double_complex c_bool c_char c_null_ptr c_null_funptr c_new_line c_carriage_return c_horizontal_tab c_vertical_tab iso_c_binding c_loc c_funloc c_associated  c_f_pointer c_ptr c_funptr iso_fortran_env character_storage_size error_unit file_storage_size input_unit iostat_end iostat_eor numeric_storage_size output_unit c_f_procpointer ieee_arithmetic ieee_support_underflow_control ieee_get_underflow_mode ieee_set_underflow_mode newunit contiguous recursive pad position action delim readwrite eor advance nml interface procedure namelist include sequence elemental pure integer real character complex logical dimension allocatable|10 parameter external implicit|10 none double precision assign intent optional pointer target in out common equivalence data",built_in:"alog alog10 amax0 amax1 amin0 amin1 amod cabs ccos cexp clog csin csqrt dabs dacos dasin datan datan2 dcos dcosh ddim dexp dint dlog dlog10 dmax1 dmin1 dmod dnint dsign dsin dsinh dsqrt dtan dtanh float iabs idim idint idnint ifix isign max0 max1 min0 min1 sngl algama cdabs cdcos cdexp cdlog cdsin cdsqrt cqabs cqcos cqexp cqlog cqsin cqsqrt dcmplx dconjg derf derfc dfloat dgamma dimag dlgama iqint qabs qacos qasin qatan qatan2 qcmplx qconjg qcos qcosh qdim qerf qerfc qexp qgamma qimag qlgama qlog qlog10 qmax1 qmin1 qmod qnint qsign qsin qsinh qsqrt qtan qtanh abs acos aimag aint anint asin atan atan2 char cmplx conjg cos cosh exp ichar index int log log10 max min nint sign sin sinh sqrt tan tanh print write dim lge lgt lle llt mod nullify allocate deallocate adjustl adjustr all allocated any associated bit_size btest ceiling count cshift date_and_time digits dot_product eoshift epsilon exponent floor fraction huge iand ibclr ibits ibset ieor ior ishft ishftc lbound len_trim matmul maxexponent maxloc maxval merge minexponent minloc minval modulo mvbits nearest pack present product radix random_number random_seed range repeat reshape rrspacing scale scan selected_int_kind selected_real_kind set_exponent shape size spacing spread sum system_clock tiny transpose trim ubound unpack verify achar iachar transfer dble entry dprod cpu_time command_argument_count get_command get_command_argument get_environment_variable is_iostat_end ieee_arithmetic ieee_support_underflow_control ieee_get_underflow_mode ieee_set_underflow_mode is_iostat_eor move_alloc new_line selected_char_kind same_type_as extends_type_ofacosh asinh atanh bessel_j0 bessel_j1 bessel_jn bessel_y0 bessel_y1 bessel_yn erf erfc erfc_scaled gamma log_gamma hypot norm2 atomic_define atomic_ref execute_command_line leadz trailz storage_size merge_bits bge bgt ble blt dshiftl dshiftr findloc iall iany iparity image_index lcobound ucobound maskl maskr num_images parity popcnt poppar shifta shiftl shiftr this_image"};return{cI:!0,aliases:["f90","f95"],k:n,i:/\/\*/,c:[e.inherit(e.ASM,{cN:"string",r:0}),e.inherit(e.QSM,{cN:"string",r:0}),{cN:"function",bK:"subroutine function program",i:"[${=\\n]",c:[e.UTM,t]},e.C("!","$",{r:0}),{cN:"number",b:"(?=\\b|\\+|\\-|\\.)(?=\\.\\d|\\d)(?:\\d+)?(?:\\.?\\d*)(?:[de][+-]?\\d+)?\\b\\.?",r:0}]}});hljs.registerLanguage("awk",function(e){var r={cN:"variable",v:[{b:/\$[\w\d#@][\w\d_]*/},{b:/\$\{(.*?)}/}]},b="BEGIN END if else while do for in break continue delete next nextfile function func exit|10",n={cN:"string",c:[e.BE],v:[{b:/(u|b)?r?'''/,e:/'''/,r:10},{b:/(u|b)?r?"""/,e:/"""/,r:10},{b:/(u|r|ur)'/,e:/'/,r:10},{b:/(u|r|ur)"/,e:/"/,r:10},{b:/(b|br)'/,e:/'/},{b:/(b|br)"/,e:/"/},e.ASM,e.QSM]};return{k:{keyword:b},c:[r,n,e.RM,e.HCM,e.NM]}});hljs.registerLanguage("makefile",function(e){var i={cN:"variable",v:[{b:"\\$\\("+e.UIR+"\\)",c:[e.BE]},{b:/\$[@%<?\^\+\*]/}]},r={cN:"string",b:/"/,e:/"/,c:[e.BE,i]},a={cN:"variable",b:/\$\([\w-]+\s/,e:/\)/,k:{built_in:"subst patsubst strip findstring filter filter-out sort word wordlist firstword lastword dir notdir suffix basename addsuffix addprefix join wildcard realpath abspath error warning shell origin flavor foreach if or and call eval file value"},c:[i]},n={b:"^"+e.UIR+"\\s*[:+?]?=",i:"\\n",rB:!0,c:[{b:"^"+e.UIR,e:"[:+?]?=",eE:!0}]},t={cN:"meta",b:/^\.PHONY:/,e:/$/,k:{"meta-keyword":".PHONY"},l:/[\.\w]+/},l={cN:"section",b:/^[^\s]+:/,e:/$/,c:[i]};return{aliases:["mk","mak"],k:"define endef undefine ifdef ifndef ifeq ifneq else endif include -include sinclude override export unexport private vpath",l:/[\w-]+/,c:[e.HCM,i,r,a,n,t,l]}});hljs.registerLanguage("java",function(e){var a="[À-ʸa-zA-Z_$][À-ʸa-zA-Z_$0-9]*",t=a+"(<"+a+"(\\s*,\\s*"+a+")*>)?",r="false synchronized int abstract float private char boolean static null if const for true while long strictfp finally protected import native final void enum else break transient catch instanceof byte super volatile case assert short package default double public try this switch continue throws protected public private module requires exports do",s="\\b(0[bB]([01]+[01_]+[01]+|[01]+)|0[xX]([a-fA-F0-9]+[a-fA-F0-9_]+[a-fA-F0-9]+|[a-fA-F0-9]+)|(([\\d]+[\\d_]+[\\d]+|[\\d]+)(\\.([\\d]+[\\d_]+[\\d]+|[\\d]+))?|\\.([\\d]+[\\d_]+[\\d]+|[\\d]+))([eE][-+]?\\d+)?)[lLfF]?",c={cN:"number",b:s,r:0};return{aliases:["jsp"],k:r,i:/<\/|#/,c:[e.C("/\\*\\*","\\*/",{r:0,c:[{b:/\w+@/,r:0},{cN:"doctag",b:"@[A-Za-z]+"}]}),e.CLCM,e.CBCM,e.ASM,e.QSM,{cN:"class",bK:"class interface",e:/[{;=]/,eE:!0,k:"class interface",i:/[:"\[\]]/,c:[{bK:"extends implements"},e.UTM]},{bK:"new throw return else",r:0},{cN:"function",b:"("+t+"\\s+)+"+e.UIR+"\\s*\\(",rB:!0,e:/[{;=]/,eE:!0,k:r,c:[{b:e.UIR+"\\s*\\(",rB:!0,r:0,c:[e.UTM]},{cN:"params",b:/\(/,e:/\)/,k:r,r:0,c:[e.ASM,e.QSM,e.CNM,e.CBCM]},e.CLCM,e.CBCM]},c,{cN:"meta",b:"@[A-Za-z]+"}]}});hljs.registerLanguage("stan",function(e){return{c:[e.HCM,e.CLCM,e.CBCM,{b:e.UIR,l:e.UIR,k:{name:"for in while repeat until if then else",symbol:"bernoulli bernoulli_logit binomial binomial_logit beta_binomial hypergeometric categorical categorical_logit ordered_logistic neg_binomial neg_binomial_2 neg_binomial_2_log poisson poisson_log multinomial normal exp_mod_normal skew_normal student_t cauchy double_exponential logistic gumbel lognormal chi_square inv_chi_square scaled_inv_chi_square exponential inv_gamma weibull frechet rayleigh wiener pareto pareto_type_2 von_mises uniform multi_normal multi_normal_prec multi_normal_cholesky multi_gp multi_gp_cholesky multi_student_t gaussian_dlm_obs dirichlet lkj_corr lkj_corr_cholesky wishart inv_wishart","selector-tag":"int real vector simplex unit_vector ordered positive_ordered row_vector matrix cholesky_factor_corr cholesky_factor_cov corr_matrix cov_matrix",title:"functions model data parameters quantities transformed generated",literal:"true false"},r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"0[xX][0-9a-fA-F]+[Li]?\\b",r:0},{cN:"number",b:"\\d+(?:[eE][+\\-]?\\d*)?L\\b",r:0},{cN:"number",b:"\\d+\\.(?!\\d)(?:i\\b)?",r:0},{cN:"number",b:"\\d+(?:\\.\\d*)?(?:[eE][+\\-]?\\d*)?i?\\b",r:0},{cN:"number",b:"\\.\\d+(?:[eE][+\\-]?\\d*)?i?\\b",r:0}]}});hljs.registerLanguage("javascript",function(e){var r="[A-Za-z$_][0-9A-Za-z$_]*",t={keyword:"in of if for while finally var new function do return void else break catch instanceof with throw case default try this switch continue typeof delete let yield const export super debugger as async await static import from as",literal:"true false null undefined NaN Infinity",built_in:"eval isFinite isNaN parseFloat parseInt decodeURI decodeURIComponent encodeURI encodeURIComponent escape unescape Object Function Boolean Error EvalError InternalError RangeError ReferenceError StopIteration SyntaxError TypeError URIError Number Math Date String RegExp Array Float32Array Float64Array Int16Array Int32Array Int8Array Uint16Array Uint32Array Uint8Array Uint8ClampedArray ArrayBuffer DataView JSON Intl arguments require module console window document Symbol Set Map WeakSet WeakMap Proxy Reflect Promise"},a={cN:"number",v:[{b:"\\b(0[bB][01]+)"},{b:"\\b(0[oO][0-7]+)"},{b:e.CNR}],r:0},n={cN:"subst",b:"\\$\\{",e:"\\}",k:t,c:[]},c={cN:"string",b:"`",e:"`",c:[e.BE,n]};n.c=[e.ASM,e.QSM,c,a,e.RM];var s=n.c.concat([e.CBCM,e.CLCM]);return{aliases:["js","jsx"],k:t,c:[{cN:"meta",r:10,b:/^\s*['"]use (strict|asm)['"]/},{cN:"meta",b:/^#!/,e:/$/},e.ASM,e.QSM,c,e.CLCM,e.CBCM,a,{b:/[{,]\s*/,r:0,c:[{b:r+"\\s*:",rB:!0,r:0,c:[{cN:"attr",b:r,r:0}]}]},{b:"("+e.RSR+"|\\b(case|return|throw)\\b)\\s*",k:"return throw case",c:[e.CLCM,e.CBCM,e.RM,{cN:"function",b:"(\\(.*?\\)|"+r+")\\s*=>",rB:!0,e:"\\s*=>",c:[{cN:"params",v:[{b:r},{b:/\(\s*\)/},{b:/\(/,e:/\)/,eB:!0,eE:!0,k:t,c:s}]}]},{b:/</,e:/(\/\w+|\w+\/)>/,sL:"xml",c:[{b:/<\w+\s*\/>/,skip:!0},{b:/<\w+/,e:/(\/\w+|\w+\/)>/,skip:!0,c:[{b:/<\w+\s*\/>/,skip:!0},"self"]}]}],r:0},{cN:"function",bK:"function",e:/\{/,eE:!0,c:[e.inherit(e.TM,{b:r}),{cN:"params",b:/\(/,e:/\)/,eB:!0,eE:!0,c:s}],i:/\[|%/},{b:/\$[(.]/},e.METHOD_GUARD,{cN:"class",bK:"class",e:/[{;=]/,eE:!0,i:/[:"\[\]]/,c:[{bK:"extends"},e.UTM]},{bK:"constructor",e:/\{/,eE:!0}],i:/#(?!!)/}});hljs.registerLanguage("tex",function(c){var e={cN:"tag",b:/\\/,r:0,c:[{cN:"name",v:[{b:/[a-zA-Zа-яА-я]+[*]?/},{b:/[^a-zA-Zа-яА-я0-9]/}],starts:{eW:!0,r:0,c:[{cN:"string",v:[{b:/\[/,e:/\]/},{b:/\{/,e:/\}/}]},{b:/\s*=\s*/,eW:!0,r:0,c:[{cN:"number",b:/-?\d*\.?\d+(pt|pc|mm|cm|in|dd|cc|ex|em)?/}]}]}}]};return{c:[e,{cN:"formula",c:[e],r:0,v:[{b:/\$\$/,e:/\$\$/},{b:/\$/,e:/\$/}]},c.C("%","$",{r:0})]}});hljs.registerLanguage("xml",function(s){var e="[A-Za-z0-9\\._:-]+",t={eW:!0,i:/</,r:0,c:[{cN:"attr",b:e,r:0},{b:/=\s*/,r:0,c:[{cN:"string",endsParent:!0,v:[{b:/"/,e:/"/},{b:/'/,e:/'/},{b:/[^\s"'=<>`]+/}]}]}]};return{aliases:["html","xhtml","rss","atom","xjb","xsd","xsl","plist"],cI:!0,c:[{cN:"meta",b:"<!DOCTYPE",e:">",r:10,c:[{b:"\\[",e:"\\]"}]},s.C("<!--","-->",{r:10}),{b:"<\\!\\[CDATA\\[",e:"\\]\\]>",r:10},{b:/<\?(php)?/,e:/\?>/,sL:"php",c:[{b:"/\\*",e:"\\*/",skip:!0}]},{cN:"tag",b:"<style(?=\\s|>|$)",e:">",k:{name:"style"},c:[t],starts:{e:"</style>",rE:!0,sL:["css","xml"]}},{cN:"tag",b:"<script(?=\\s|>|$)",e:">",k:{name:"script"},c:[t],starts:{e:"</script>",rE:!0,sL:["actionscript","javascript","handlebars","xml"]}},{cN:"meta",v:[{b:/<\?xml/,e:/\?>/,r:10},{b:/<\?\w+/,e:/\?>/}]},{cN:"tag",b:"</?",e:"/?>",c:[{cN:"name",b:/[^\/><\s]+/,r:0},t]}]}});hljs.registerLanguage("markdown",function(e){return{aliases:["md","mkdown","mkd"],c:[{cN:"section",v:[{b:"^#{1,6}",e:"$"},{b:"^.+?\\n[=-]{2,}$"}]},{b:"<",e:">",sL:"xml",r:0},{cN:"bullet",b:"^([*+-]|(\\d+\\.))\\s+"},{cN:"strong",b:"[*_]{2}.+?[*_]{2}"},{cN:"emphasis",v:[{b:"\\*.+?\\*"},{b:"_.+?_",r:0}]},{cN:"quote",b:"^>\\s+",e:"$"},{cN:"code",v:[{b:"^```w*s*$",e:"^```s*$"},{b:"`.+?`"},{b:"^( {4}|	)",e:"$",r:0}]},{b:"^[-\\*]{3,}",e:"$"},{b:"\\[.+?\\][\\(\\[].*?[\\)\\]]",rB:!0,c:[{cN:"string",b:"\\[",e:"\\]",eB:!0,rE:!0,r:0},{cN:"link",b:"\\]\\(",e:"\\)",eB:!0,eE:!0},{cN:"symbol",b:"\\]\\[",e:"\\]",eB:!0,eE:!0}],r:10},{b:/^\[[^\n]+\]:/,rB:!0,c:[{cN:"symbol",b:/\[/,e:/\]/,eB:!0,eE:!0},{cN:"link",b:/:\s*/,e:/$/,eB:!0}]}]}});hljs.registerLanguage("json",function(e){var i={literal:"true false null"},n=[e.QSM,e.CNM],r={e:",",eW:!0,eE:!0,c:n,k:i},t={b:"{",e:"}",c:[{cN:"attr",b:/"/,e:/"/,c:[e.BE],i:"\\n"},e.inherit(r,{b:/:/})],i:"\\S"},c={b:"\\[",e:"\\]",c:[e.inherit(r)],i:"\\S"};return n.splice(n.length,0,t,c),{c:n,k:i,i:"\\S"}});"></script>
<link href="data:text/css,%2Epagedtable%20%7B%0Aoverflow%3A%20auto%3B%0Apadding%2Dleft%3A%208px%3B%0Apadding%2Dright%3A%208px%3B%0A%7D%0A%2Epagedtable%2Dwrapper%20%7B%0Aborder%3A%201px%20solid%20%23ccc%3B%0Aborder%2Dradius%3A%204px%3B%0Amargin%2Dbottom%3A%2010px%3B%0A%7D%0A%2Epagedtable%20table%20%7B%0Awidth%3A%20100%25%3B%0Amax%2Dwidth%3A%20100%25%3B%0Amargin%3A%200%3B%0A%7D%0A%2Epagedtable%20th%20%7B%0Apadding%3A%200%205px%200%205px%3B%0Aborder%3A%20none%3B%0Aborder%2Dbottom%3A%202px%20solid%20%23dddddd%3B%0Amin%2Dwidth%3A%2045px%3B%0A%7D%0A%2Epagedtable%2Dempty%20th%20%7B%0Adisplay%3A%20none%3B%0A%7D%0A%2Epagedtable%20td%20%7B%0Apadding%3A%200%204px%200%204px%3B%0A%7D%0A%2Epagedtable%20%2Eeven%20%7B%0Abackground%2Dcolor%3A%20rgba%28140%2C%20140%2C%20140%2C%200%2E1%29%3B%0A%7D%0A%2Epagedtable%2Dpadding%2Dcol%20%7B%0Adisplay%3A%20none%3B%0A%7D%0A%2Epagedtable%20a%20%7B%0A%2Dwebkit%2Dtouch%2Dcallout%3A%20none%3B%0A%2Dwebkit%2Duser%2Dselect%3A%20none%3B%0A%2Dkhtml%2Duser%2Dselect%3A%20none%3B%0A%2Dmoz%2Duser%2Dselect%3A%20none%3B%0A%2Dms%2Duser%2Dselect%3A%20none%3B%0Auser%2Dselect%3A%20none%3B%0A%7D%0A%2Epagedtable%2Dindex%2Dnav%20%7B%0Acursor%3A%20pointer%3B%0Apadding%3A%200%205px%200%205px%3B%0Afloat%3A%20right%3B%0Aborder%3A%200%3B%0A%7D%0A%2Epagedtable%2Dindex%2Dnav%2Ddisabled%20%7B%0Acursor%3A%20default%3B%0Atext%2Ddecoration%3A%20none%3B%0Acolor%3A%20%23999%3B%0A%7D%0Aa%2Epagedtable%2Dindex%2Dnav%2Ddisabled%3Ahover%20%7B%0Atext%2Ddecoration%3A%20none%3B%0Acolor%3A%20%23999%3B%0A%7D%0A%2Epagedtable%2Dindexes%20%7B%0Acursor%3A%20pointer%3B%0Afloat%3A%20right%3B%0Aborder%3A%200%3B%0A%7D%0A%2Epagedtable%2Dindex%2Dcurrent%20%7B%0Acursor%3A%20default%3B%0Atext%2Ddecoration%3A%20none%3B%0Afont%2Dweight%3A%20bold%3B%0Acolor%3A%20%23333%3B%0Aborder%3A%200%3B%0A%7D%0Aa%2Epagedtable%2Dindex%2Dcurrent%3Ahover%20%7B%0Atext%2Ddecoration%3A%20none%3B%0Afont%2Dweight%3A%20bold%3B%0Acolor%3A%20%23333%3B%0A%7D%0A%2Epagedtable%2Dindex%20%7B%0Awidth%3A%2030px%3B%0Adisplay%3A%20inline%2Dblock%3B%0Atext%2Dalign%3A%20center%3B%0Aborder%3A%200%3B%0A%7D%0A%2Epagedtable%2Dindex%2Dseparator%2Dleft%20%7B%0Adisplay%3A%20inline%2Dblock%3B%0Acolor%3A%20%23333%3B%0Afont%2Dsize%3A%209px%3B%0Apadding%3A%200%200%200%200%3B%0Acursor%3A%20default%3B%0A%7D%0A%2Epagedtable%2Dindex%2Dseparator%2Dright%20%7B%0Adisplay%3A%20inline%2Dblock%3B%0Acolor%3A%20%23333%3B%0Afont%2Dsize%3A%209px%3B%0Apadding%3A%200%204px%200%200%3B%0Acursor%3A%20default%3B%0A%7D%0A%2Epagedtable%2Dfooter%20%7B%0Apadding%2Dtop%3A%204px%3B%0Apadding%2Dbottom%3A%205px%3B%0A%7D%0A%2Epagedtable%2Dnot%2Dempty%20%2Epagedtable%2Dfooter%20%7B%0Aborder%2Dtop%3A%202px%20solid%20%23dddddd%3B%0A%7D%0A%2Epagedtable%2Dinfo%20%7B%0Aoverflow%3A%20hidden%3B%0Acolor%3A%20%23999%3B%0Awhite%2Dspace%3A%20nowrap%3B%0Atext%2Doverflow%3A%20ellipsis%3B%0A%7D%0A%2Epagedtable%2Dheader%2Dname%20%7B%0Aoverflow%3A%20hidden%3B%0Atext%2Doverflow%3A%20ellipsis%3B%0A%7D%0A%2Epagedtable%2Dheader%2Dtype%20%7B%0Acolor%3A%20%23999%3B%0Afont%2Dweight%3A%20400%3B%0A%7D%0A%2Epagedtable%2Dna%2Dcell%20%7B%0Afont%2Dstyle%3A%20italic%3B%0Aopacity%3A%200%2E3%3B%0A%7D%0A" rel="stylesheet" />
<script src="data:application/javascript;base64,// Production steps of ECMA-262, Edition 5, 15.4.4.18
// Reference: http://es5.github.io/#x15.4.4.18
if (!Array.prototype.forEach) {

  Array.prototype.forEach = function(callback, thisArg) {

    var T, k;

    if (this === null) {
      throw new TypeError(' this is null or not defined');
    }

    // 1. Let O be the result of calling toObject() passing the
    // |this| value as the argument.
    var O = Object(this);

    // 2. Let lenValue be the result of calling the Get() internal
    // method of O with the argument "length".
    // 3. Let len be toUint32(lenValue).
    var len = O.length >>> 0;

    // 4. If isCallable(callback) is false, throw a TypeError exception.
    // See: http://es5.github.com/#x9.11
    if (typeof callback !== "function") {
      throw new TypeError(callback + ' is not a function');
    }

    // 5. If thisArg was supplied, let T be thisArg; else let
    // T be undefined.
    if (arguments.length > 1) {
      T = thisArg;
    }

    // 6. Let k be 0
    k = 0;

    // 7. Repeat, while k < len
    while (k < len) {

      var kValue;

      // a. Let Pk be ToString(k).
      //    This is implicit for LHS operands of the in operator
      // b. Let kPresent be the result of calling the HasProperty
      //    internal method of O with argument Pk.
      //    This step can be combined with c
      // c. If kPresent is true, then
      if (k in O) {

        // i. Let kValue be the result of calling the Get internal
        // method of O with argument Pk.
        kValue = O[k];

        // ii. Call the Call internal method of callback with T as
        // the this value and argument list containing kValue, k, and O.
        callback.call(T, kValue, k, O);
      }
      // d. Increase k by 1.
      k++;
    }
    // 8. return undefined
  };
}

// Production steps of ECMA-262, Edition 5, 15.4.4.19
// Reference: http://es5.github.io/#x15.4.4.19
if (!Array.prototype.map) {

  Array.prototype.map = function(callback, thisArg) {

    var T, A, k;

    if (this == null) {
      throw new TypeError(' this is null or not defined');
    }

    // 1. Let O be the result of calling ToObject passing the |this|
    //    value as the argument.
    var O = Object(this);

    // 2. Let lenValue be the result of calling the Get internal
    //    method of O with the argument "length".
    // 3. Let len be ToUint32(lenValue).
    var len = O.length >>> 0;

    // 4. If IsCallable(callback) is false, throw a TypeError exception.
    // See: http://es5.github.com/#x9.11
    if (typeof callback !== 'function') {
      throw new TypeError(callback + ' is not a function');
    }

    // 5. If thisArg was supplied, let T be thisArg; else let T be undefined.
    if (arguments.length > 1) {
      T = thisArg;
    }

    // 6. Let A be a new array created as if by the expression new Array(len)
    //    where Array is the standard built-in constructor with that name and
    //    len is the value of len.
    A = new Array(len);

    // 7. Let k be 0
    k = 0;

    // 8. Repeat, while k < len
    while (k < len) {

      var kValue, mappedValue;

      // a. Let Pk be ToString(k).
      //   This is implicit for LHS operands of the in operator
      // b. Let kPresent be the result of calling the HasProperty internal
      //    method of O with argument Pk.
      //   This step can be combined with c
      // c. If kPresent is true, then
      if (k in O) {

        // i. Let kValue be the result of calling the Get internal
        //    method of O with argument Pk.
        kValue = O[k];

        // ii. Let mappedValue be the result of calling the Call internal
        //     method of callback with T as the this value and argument
        //     list containing kValue, k, and O.
        mappedValue = callback.call(T, kValue, k, O);

        // iii. Call the DefineOwnProperty internal method of A with arguments
        // Pk, Property Descriptor
        // { Value: mappedValue,
        //   Writable: true,
        //   Enumerable: true,
        //   Configurable: true },
        // and false.

        // In browsers that support Object.defineProperty, use the following:
        // Object.defineProperty(A, k, {
        //   value: mappedValue,
        //   writable: true,
        //   enumerable: true,
        //   configurable: true
        // });

        // For best browser support, use the following:
        A[k] = mappedValue;
      }
      // d. Increase k by 1.
      k++;
    }

    // 9. return A
    return A;
  };
}

var PagedTable = function (pagedTable) {
  var me = this;

  var source = function(pagedTable) {
    var sourceElems = [].slice.call(pagedTable.children).filter(function(e) {
      return e.hasAttribute("data-pagedtable-source");
    });

    if (sourceElems === null || sourceElems.length !== 1) {
      throw("A single data-pagedtable-source was not found");
    }

    return JSON.parse(sourceElems[0].innerHTML);
  }(pagedTable);

  var options = function(source) {
    var options = typeof(source.options) !== "undefined" &&
      source.options !== null ? source.options : {};

    var columns = typeof(options.columns) !== "undefined" ? options.columns : {};
    var rows = typeof(options.rows) !== "undefined" ? options.rows : {};

    var positiveIntOrNull = function(value) {
      return parseInt(value) >= 0 ? parseInt(value) : null;
    };

    return {
      pages: positiveIntOrNull(options.pages),
      rows: {
        min: positiveIntOrNull(rows.min),
        max: positiveIntOrNull(rows.max),
        total: positiveIntOrNull(rows.total)
      },
      columns: {
        min: positiveIntOrNull(columns.min),
        max: positiveIntOrNull(columns.max),
        total: positiveIntOrNull(columns.total)
      }
    };
  }(source);

  var Measurer = function() {

    // set some default initial values that will get adjusted in runtime
    me.measures = {
      padding: 12,
      character: 8,
      height: 15,
      defaults: true
    };

    me.calculate = function(measuresCell) {
      if (!me.measures.defaults)
        return;

      var measuresCellStyle = window.getComputedStyle(measuresCell, null);

      var newPadding = parsePadding(measuresCellStyle.paddingLeft) +
            parsePadding(measuresCellStyle.paddingRight);

      var sampleString = "ABCDEFGHIJ0123456789";
      var newCharacter = Math.ceil(measuresCell.clientWidth / sampleString.length);

      if (newPadding <= 0 || newCharacter <= 0)
        return;

      me.measures.padding = newPadding;
      me.measures.character = newCharacter;
      me.measures.height = measuresCell.clientHeight;
      me.measures.defaults = false;
    };

    return me;
  };

  var Page = function(data, options) {
    var me = this;

    var defaults = {
      max: 7,
      rows: 10
    };

    var totalPages = function() {
      return Math.ceil(data.length / me.rows);
    };

    me.number = 0;
    me.max = options.pages !== null ? options.pages : defaults.max;
    me.visible = me.max;
    me.rows = options.rows.min !== null ? options.rows.min : defaults.rows;
    me.total = totalPages();

    me.setRows = function(newRows) {
      me.rows = newRows;
      me.total = totalPages();
    };

    me.setPageNumber = function(newPageNumber) {
      if (newPageNumber < 0) newPageNumber = 0;
      if (newPageNumber >= me.total) newPageNumber = me.total - 1;

      me.number = newPageNumber;
    };

    me.setVisiblePages = function(visiblePages) {
      me.visible = Math.min(me.max, visiblePages);
      me.setPageNumber(me.number);
    };

    me.getVisiblePageRange = function() {
      var start = me.number - Math.max(Math.floor((me.visible - 1) / 2), 0);
      var end = me.number + Math.floor(me.visible / 2) + 1;
      var pageCount = me.total;

      if (start < 0) {
        var diffToStart = 0 - start;
        start += diffToStart;
        end += diffToStart;
      }

      if (end > pageCount) {
        var diffToEnd = end - pageCount;
        start -= diffToEnd;
        end -= diffToEnd;
      }

      start = start < 0 ? 0 : start;
      end = end >= pageCount ? pageCount : end;

      var first = false;
      var last = false;

      if (start > 0 && me.visible > 1) {
        start = start + 1;
        first = true;
      }

      if (end < pageCount && me.visible > 2) {
        end = end - 1;
        last = true;
      }

      return {
        first: first,
        start: start,
        end: end,
        last: last
      };
    };

    me.getRowStart = function() {
      var rowStart = page.number * page.rows;
      if (rowStart < 0)
        rowStart = 0;

      return rowStart;
    };

    me.getRowEnd = function() {
      var rowStart = me.getRowStart();
      return Math.min(rowStart + me.rows, data.length);
    };

    me.getPaddingRows = function() {
      var rowStart = me.getRowStart();
      var rowEnd = me.getRowEnd();
      return data.length > me.rows ? me.rows - (rowEnd - rowStart) : 0;
    };
  };

  var Columns = function(data, columns, options) {
    var me = this;

    me.defaults = {
      min: 5
    };

    me.number = 0;
    me.visible = 0;
    me.total = columns.length;
    me.subset = [];
    me.padding = 0;
    me.min = options.columns.min !== null ? options.columns.min : me.defaults.min;
    me.max = options.columns.max !== null ? options.columns.max : null;
    me.widths = {};

    var widthsLookAhead = Math.max(100, options.rows.min);
    var paddingColChars = 10;

    me.emptyNames = function() {
      columns.forEach(function(column) {
        if (columns.label !== null && columns.label !== "")
          return false;
      });

      return true;
    };

    var parsePadding = function(value) {
      return parseInt(value) >= 0 ? parseInt(value) : 0;
    };

    me.calculateWidths = function(measures) {
      columns.forEach(function(column) {
        var maxChars = Math.max(
          column.label.toString().length,
          column.type.toString().length
        );

        for (var idxRow = 0; idxRow < Math.min(widthsLookAhead, data.length); idxRow++) {
          maxChars = Math.max(maxChars, data[idxRow][column.name.toString()].length);
        }

        me.widths[column.name] = {
          // width in characters
          chars: maxChars,
          // width for the inner html columns
          inner: maxChars * measures.character,
          // width adding outer styles like padding
          outer: maxChars * measures.character + measures.padding
        };
      });
    };

    me.getWidth = function() {
      var widthOuter = 0;
      for (var idxCol = 0; idxCol < me.subset.length; idxCol++) {
        var columnName = me.subset[idxCol].name;
        widthOuter = widthOuter + me.widths[columnName].outer;
      }

      widthOuter = widthOuter + me.padding * paddingColChars * measurer.measures.character;

      if (me.hasMoreLeftColumns()) {
        widthOuter = widthOuter + columnNavigationWidthPX + measurer.measures.padding;
      }

      if (me.hasMoreRightColumns()) {
        widthOuter = widthOuter + columnNavigationWidthPX + measurer.measures.padding;
      }

      return widthOuter;
    };

    me.updateSlice = function() {
      if (me.number + me.visible >= me.total)
        me.number = me.total - me.visible;

      if (me.number < 0) me.number = 0;

      me.subset = columns.slice(me.number, Math.min(me.number + me.visible, me.total));

      me.subset = me.subset.map(function(column) {
        Object.keys(column).forEach(function(colKey) {
          column[colKey] = column[colKey] === null ? "" : column[colKey].toString();
        });

        column.width = null;
        return column;
      });
    };

    me.setVisibleColumns = function(columnNumber, newVisibleColumns, paddingCount) {
      me.number = columnNumber;
      me.visible = newVisibleColumns;
      me.padding = paddingCount;

      me.updateSlice();
    };

    me.incColumnNumber = function(increment) {
      me.number = me.number + increment;
    };

    me.setColumnNumber = function(newNumber) {
      me.number = newNumber;
    };

    me.setPaddingCount = function(newPadding) {
      me.padding = newPadding;
    };

    me.getPaddingCount = function() {
      return me.padding;
    };

    me.hasMoreLeftColumns = function() {
      return me.number > 0;
    };

    me.hasMoreRightColumns = function() {
      return me.number + me.visible < me.total;
    };

    me.updateSlice(0);
    return me;
  };

  var data = source.data;
  var page = new Page(data, options);
  var measurer = new Measurer(data, options);
  var columns = new Columns(data, source.columns, options);

  var table = null;
  var tableDiv = null;
  var header = null;
  var footer = null;
  var tbody = null;

  // Caches pagedTable.clientWidth, specially for webkit
  var cachedPagedTableClientWidth = null;

  var onChangeCallbacks = [];

  var clearSelection = function() {
    if(document.selection && document.selection.empty) {
      document.selection.empty();
    } else if(window.getSelection) {
      var sel = window.getSelection();
      sel.removeAllRanges();
    }
  };

  var columnNavigationWidthPX = 5;

  var renderColumnNavigation = function(increment, backwards) {
    var arrow = document.createElement("div");
    arrow.setAttribute("style",
      "border-top: " + columnNavigationWidthPX + "px solid transparent;" +
      "border-bottom: " + columnNavigationWidthPX + "px solid transparent;" +
      "border-" + (backwards ? "right" : "left") + ": " + columnNavigationWidthPX + "px solid;");

    var header = document.createElement("th");
    header.appendChild(arrow);
    header.setAttribute("style",
      "cursor: pointer;" +
      "vertical-align: middle;" +
      "min-width: " + columnNavigationWidthPX + "px;" +
      "width: " + columnNavigationWidthPX + "px;");

    header.onclick = function() {
      columns.incColumnNumber(backwards ? -1 : increment);

      me.animateColumns(backwards);
      renderFooter();

      clearSelection();
      triggerOnChange();
    };

    return header;
  };

  var maxColumnWidth = function(width) {
    var padding = 80;
    var columnMax = Math.max(cachedPagedTableClientWidth - padding, 0);

    return parseInt(width) > 0 ?
      Math.min(columnMax, parseInt(width)) + "px" :
      columnMax + "px";
  };

  var clearHeader = function() {
    var thead = pagedTable.querySelectorAll("thead")[0];
    thead.innerHTML = "";
  };

  var renderHeader = function(clear) {
    cachedPagedTableClientWidth = pagedTable.clientWidth;

    var fragment = document.createDocumentFragment();

    header = document.createElement("tr");
    fragment.appendChild(header);

    if (columns.number > 0)
      header.appendChild(renderColumnNavigation(-columns.visible, true));

    columns.subset = columns.subset.map(function(columnData) {
      var column = document.createElement("th");
      column.setAttribute("align", columnData.align);
      column.style.textAlign = columnData.align;

      column.style.maxWidth = maxColumnWidth(null);
      if (columnData.width) {
        column.style.minWidth =
          column.style.maxWidth = maxColumnWidth(columnData.width);
      }

      var columnName = document.createElement("div");
      columnName.setAttribute("class", "pagedtable-header-name");
      if (columnData.label === "") {
        columnName.innerHTML = "&nbsp;";
      }
      else {
        columnName.appendChild(document.createTextNode(columnData.label));
      }
      column.appendChild(columnName);

      var columnType = document.createElement("div");
      columnType.setAttribute("class", "pagedtable-header-type");
      if (columnData.type === "") {
        columnType.innerHTML = "&nbsp;";
      }
      else {
        columnType.appendChild(document.createTextNode("<" + columnData.type + ">"));
      }
      column.appendChild(columnType);

      header.appendChild(column);

      columnData.element = column;

      return columnData;
    });

    for (var idx = 0; idx < columns.getPaddingCount(); idx++) {
      var paddingCol = document.createElement("th");
      paddingCol.setAttribute("class", "pagedtable-padding-col");
      header.appendChild(paddingCol);
    }

    if (columns.number + columns.visible < columns.total)
      header.appendChild(renderColumnNavigation(columns.visible, false));

    if (typeof(clear) == "undefined" || clear) clearHeader();
    var thead = pagedTable.querySelectorAll("thead")[0];
    thead.appendChild(fragment);
  };

  me.animateColumns = function(backwards) {
    var thead = pagedTable.querySelectorAll("thead")[0];

    var headerOld = thead.querySelectorAll("tr")[0];
    var tbodyOld = table.querySelectorAll("tbody")[0];

    me.fitColumns(backwards);

    renderHeader(false);

    header.style.opacity = "0";
    header.style.transform = backwards ? "translateX(-30px)" : "translateX(30px)";
    header.style.transition = "transform 200ms linear, opacity 200ms";
    header.style.transitionDelay = "0";

    renderBody(false);

    if (headerOld) {
      headerOld.style.position = "absolute";
      headerOld.style.transform = "translateX(0px)";
      headerOld.style.opacity = "1";
      headerOld.style.transition = "transform 100ms linear, opacity 100ms";
      headerOld.setAttribute("class", "pagedtable-remove-head");
      if (headerOld.style.transitionEnd) {
        headerOld.addEventListener("transitionend", function() {
          var headerOldByClass = thead.querySelector(".pagedtable-remove-head");
          if (headerOldByClass) thead.removeChild(headerOldByClass);
        });
      }
      else {
        thead.removeChild(headerOld);
      }
    }

    if (tbodyOld) table.removeChild(tbodyOld);

    tbody.style.opacity = "0";
    tbody.style.transition = "transform 200ms linear, opacity 200ms";
    tbody.style.transitionDelay = "0ms";

    // force relayout
    window.getComputedStyle(header).opacity;
    window.getComputedStyle(tbody).opacity;

    if (headerOld) {
      headerOld.style.transform = backwards ? "translateX(20px)" : "translateX(-30px)";
      headerOld.style.opacity = "0";
    }

    header.style.transform = "translateX(0px)";
    header.style.opacity = "1";

    tbody.style.opacity = "1";
  }

  me.onChange = function(callback) {
    onChangeCallbacks.push(callback);
  };

  var triggerOnChange = function() {
    onChangeCallbacks.forEach(function(onChange) {
      onChange();
    });
  };

  var clearBody = function() {
    if (tbody) {
      table.removeChild(tbody);
      tbody = null;
    }
  };

  var renderBody = function(clear) {
    cachedPagedTableClientWidth = pagedTable.clientWidth

    var fragment = document.createDocumentFragment();

    var pageData = data.slice(page.getRowStart(), page.getRowEnd());

    pageData.forEach(function(dataRow, idxRow) {
      var htmlRow = document.createElement("tr");
      htmlRow.setAttribute("class", (idxRow % 2 !==0) ? "even" : "odd");

      if (columns.hasMoreLeftColumns())
        htmlRow.appendChild(document.createElement("td"));

      columns.subset.forEach(function(columnData) {
        var cellName = columnData.name;
        var dataCell = dataRow[cellName];
        var htmlCell = document.createElement("td");

        if (dataCell === "NA") htmlCell.setAttribute("class", "pagedtable-na-cell");
        if (dataCell === "__NA__") dataCell = "NA";

        var cellText = document.createTextNode(dataCell);
        htmlCell.appendChild(cellText);
        if (dataCell.length > 50) {
          htmlCell.setAttribute("title", dataCell);
        }
        htmlCell.setAttribute("align", columnData.align);
        htmlCell.style.textAlign = columnData.align;
        htmlCell.style.maxWidth = maxColumnWidth(null);
        if (columnData.width) {
          htmlCell.style.minWidth = htmlCell.style.maxWidth = maxColumnWidth(columnData.width);
        }
        htmlRow.appendChild(htmlCell);
      });

      for (var idx = 0; idx < columns.getPaddingCount(); idx++) {
        var paddingCol = document.createElement("td");
        paddingCol.setAttribute("class", "pagedtable-padding-col");
        htmlRow.appendChild(paddingCol);
      }

      if (columns.hasMoreRightColumns())
        htmlRow.appendChild(document.createElement("td"));

      fragment.appendChild(htmlRow);
    });

    for (var idxPadding = 0; idxPadding < page.getPaddingRows(); idxPadding++) {
      var paddingRow = document.createElement("tr");

      var paddingCellRow = document.createElement("td");
      paddingCellRow.innerHTML = "&nbsp;";
      paddingCellRow.setAttribute("colspan", "100%");
      paddingRow.appendChild(paddingCellRow);

      fragment.appendChild(paddingRow);
    }

    if (typeof(clear) == "undefined" || clear) clearBody();
    tbody = document.createElement("tbody");
    tbody.appendChild(fragment);

    table.appendChild(tbody);
  };

  var getLabelInfo = function() {
    var pageStart = page.getRowStart();
    var pageEnd = page.getRowEnd();
    var totalRows = data.length;

    var totalRowsLabel = options.rows.total ? options.rows.total : totalRows;
    var totalRowsLabelFormat = totalRowsLabel.toString().replace(/(\d)(?=(\d\d\d)+(?!\d))/g, '$1,');

    var infoText = (pageStart + 1) + "-" + pageEnd + " of " + totalRowsLabelFormat + " rows";
    if (totalRows < page.rows) {
      infoText = totalRowsLabel + " row" + (totalRows != 1 ? "s" : "");
    }
    if (columns.total > columns.visible) {
      var totalColumnsLabel = options.columns.total ? options.columns.total : columns.total;

      infoText = infoText + " | " + (columns.number + 1) + "-" +
        (Math.min(columns.number + columns.visible, columns.total)) +
        " of " + totalColumnsLabel + " columns";
    }

    return infoText;
  };

  var clearFooter = function() {
    footer = pagedTable.querySelectorAll("div.pagedtable-footer")[0];
    footer.innerHTML = "";

    return footer;
  };

  var createPageLink = function(idxPage) {
    var pageLink = document.createElement("a");
    pageLinkClass = idxPage === page.number ? "pagedtable-index pagedtable-index-current" : "pagedtable-index";
    pageLink.setAttribute("class", pageLinkClass);
    pageLink.setAttribute("data-page-index", idxPage);
    pageLink.onclick = function() {
      page.setPageNumber(parseInt(this.getAttribute("data-page-index")));
      renderBody();
      renderFooter();

      triggerOnChange();
    };

    pageLink.appendChild(document.createTextNode(idxPage + 1));

    return pageLink;
  }

  var renderFooter = function() {
    footer = clearFooter();

    var next = document.createElement("a");
    next.appendChild(document.createTextNode("Next"));
    next.onclick = function() {
      page.setPageNumber(page.number + 1);
      renderBody();
      renderFooter();

      triggerOnChange();
    };
    if (data.length > page.rows) footer.appendChild(next);

    var pageNumbers = document.createElement("div");
    pageNumbers.setAttribute("class", "pagedtable-indexes");

    var pageRange = page.getVisiblePageRange();

    if (pageRange.first) {
      var pageLink = createPageLink(0);
      pageNumbers.appendChild(pageLink);

      var pageSeparator = document.createElement("div");
      pageSeparator.setAttribute("class", "pagedtable-index-separator-left");
      pageSeparator.appendChild(document.createTextNode("..."))
      pageNumbers.appendChild(pageSeparator);
    }

    for (var idxPage = pageRange.start; idxPage < pageRange.end; idxPage++) {
      var pageLink = createPageLink(idxPage);

      pageNumbers.appendChild(pageLink);
    }

    if (pageRange.last) {
      var pageSeparator = document.createElement("div");
      pageSeparator.setAttribute("class", "pagedtable-index-separator-right");
      pageSeparator.appendChild(document.createTextNode("..."))
      pageNumbers.appendChild(pageSeparator);

      var pageLink = createPageLink(page.total - 1);
      pageNumbers.appendChild(pageLink);
    }

    if (data.length > page.rows) footer.appendChild(pageNumbers);

    var previous = document.createElement("a");
    previous.appendChild(document.createTextNode("Previous"));
    previous.onclick = function() {
      page.setPageNumber(page.number - 1);
      renderBody();
      renderFooter();

      triggerOnChange();
    };
    if (data.length > page.rows) footer.appendChild(previous);

    var infoLabel = document.createElement("div");
    infoLabel.setAttribute("class", "pagedtable-info");
    infoLabel.setAttribute("title", getLabelInfo());
    infoLabel.appendChild(document.createTextNode(getLabelInfo()));
    footer.appendChild(infoLabel);

    var enabledClass = "pagedtable-index-nav";
    var disabledClass = "pagedtable-index-nav pagedtable-index-nav-disabled";
    previous.setAttribute("class", page.number <= 0 ? disabledClass : enabledClass);
    next.setAttribute("class", (page.number + 1) * page.rows >= data.length ? disabledClass : enabledClass);
  };

  var measuresCell = null;

  var renderMeasures = function() {
    var measuresTable = document.createElement("table");
    measuresTable.style.visibility = "hidden";
    measuresTable.style.position = "absolute";
    measuresTable.style.whiteSpace = "nowrap";
    measuresTable.style.height = "auto";
    measuresTable.style.width = "auto";

    var measuresRow = document.createElement("tr");
    measuresTable.appendChild(measuresRow);

    measuresCell = document.createElement("td");
    var sampleString = "ABCDEFGHIJ0123456789";
    measuresCell.appendChild(document.createTextNode(sampleString));

    measuresRow.appendChild(measuresCell);

    tableDiv.appendChild(measuresTable);
  }

  me.init = function() {
    tableDiv = document.createElement("div");
    pagedTable.appendChild(tableDiv);
    var pagedTableClass = data.length > 0 ?
      "pagedtable pagedtable-not-empty" :
      "pagedtable pagedtable-empty";

    if (columns.total == 0 || (columns.emptyNames() && data.length == 0)) {
      pagedTableClass = pagedTableClass + " pagedtable-empty-columns";
    }

    tableDiv.setAttribute("class", pagedTableClass);

    renderMeasures();
    measurer.calculate(measuresCell);
    columns.calculateWidths(measurer.measures);

    table = document.createElement("table");
    table.setAttribute("cellspacing", "0");
    table.setAttribute("class", "table table-condensed");
    tableDiv.appendChild(table);

    table.appendChild(document.createElement("thead"));

    var footerDiv = document.createElement("div");
    footerDiv.setAttribute("class", "pagedtable-footer");
    tableDiv.appendChild(footerDiv);

    // if the host has not yet provided horizontal space, render hidden
    if (tableDiv.clientWidth <= 0) {
      tableDiv.style.opacity = "0";
    }

    me.render();

    // retry seizing columns later if the host has not provided space
    function retryFit() {
      if (tableDiv.clientWidth <= 0) {
        setTimeout(retryFit, 100);
      } else {
        me.render();
        triggerOnChange();
      }
    }
    if (tableDiv.clientWidth <= 0) {
      retryFit();
    }
  };

  var registerWidths = function() {
    columns.subset = columns.subset.map(function(column) {
      column.width = columns.widths[column.name].inner;
      return column;
    });
  };

  var parsePadding = function(value) {
    return parseInt(value) >= 0 ? parseInt(value) : 0;
  };

  me.fixedHeight = function() {
    return options.rows.max != null;
  }

  me.fitRows = function() {
    if (me.fixedHeight())
      return;

    measurer.calculate(measuresCell);

    var rows = options.rows.min !== null ? options.rows.min : 0;
    var headerHeight = header !== null && header.offsetHeight > 0 ? header.offsetHeight : 0;
    var footerHeight = footer !== null && footer.offsetHeight > 0 ? footer.offsetHeight : 0;

    if (pagedTable.offsetHeight > 0) {
      var availableHeight = pagedTable.offsetHeight - headerHeight - footerHeight;
      rows = Math.floor((availableHeight) / measurer.measures.height);
    }

    rows = options.rows.min !== null ? Math.max(options.rows.min, rows) : rows;

    page.setRows(rows);
  }

  // The goal of this function is to add as many columns as possible
  // starting from left-to-right, when the right most limit is reached
  // it tries to add columns from the left as well.
  //
  // When startBackwards is true columns are added from right-to-left
  me.fitColumns = function(startBackwards) {
    measurer.calculate(measuresCell);
    columns.calculateWidths(measurer.measures);

    if (tableDiv.clientWidth > 0) {
      tableDiv.style.opacity = 1;
    }

    var visibleColumns = tableDiv.clientWidth <= 0 ? Math.max(columns.min, 1) : 1;
    var columnNumber = columns.number;
    var paddingCount = 0;

    // track a list of added columns as we build the visible ones to allow us
    // to remove columns when they don't fit anymore.
    var columnHistory = [];

    var lastTableHeight = 0;
    var backwards = startBackwards;

    var tableDivStyle = window.getComputedStyle(tableDiv, null);
    var tableDivPadding = parsePadding(tableDivStyle.paddingLeft) +
      parsePadding(tableDivStyle.paddingRight);

    var addPaddingCol = false;
    var currentWidth = 0;

    while (true) {
      columns.setVisibleColumns(columnNumber, visibleColumns, paddingCount);
      currentWidth = columns.getWidth();

      if (tableDiv.clientWidth - tableDivPadding < currentWidth) {
        break;
      }

      columnHistory.push({
        columnNumber: columnNumber,
        visibleColumns: visibleColumns,
        paddingCount: paddingCount
      });

      if (columnHistory.length > 100) {
        console.error("More than 100 tries to fit columns, aborting");
        break;
      }

      if (columns.max !== null &&
        columns.visible + columns.getPaddingCount() >= columns.max) {
        break;
      }

      // if we run out of right-columns
      if (!backwards && columnNumber + columns.visible >= columns.total) {
        // if we started adding right-columns, try adding left-columns
        if (!startBackwards && columnNumber > 0) {
          backwards = true;
        }
        else if (columns.min === null || visibleColumns + columns.getPaddingCount() >= columns.min) {
          break;
        }
        else {
          paddingCount = paddingCount + 1;
        }
      }

      // if we run out of left-columns
      if (backwards && columnNumber == 0) {
        // if we started adding left-columns, try adding right-columns
        if (startBackwards && columnNumber + columns.visible < columns.total) {
          backwards = false;
        }
        else if (columns.min === null || visibleColumns + columns.getPaddingCount() >= columns.min) {
          break;
        }
        else {
          paddingCount = paddingCount + 1;
        }
      }

      // when moving backwards try fitting left columns first
      if (backwards && columnNumber > 0) {
        columnNumber = columnNumber - 1;
      }

      if (columnNumber + visibleColumns < columns.total) {
        visibleColumns = visibleColumns + 1;
      }
    }

    var lastRenderableColumn = {
        columnNumber: columnNumber,
        visibleColumns: visibleColumns,
        paddingCount: paddingCount
    };

    if (columnHistory.length > 0) {
      lastRenderableColumn = columnHistory[columnHistory.length - 1];
    }

    columns.setVisibleColumns(
      lastRenderableColumn.columnNumber,
      lastRenderableColumn.visibleColumns,
      lastRenderableColumn.paddingCount);

    if (pagedTable.offsetWidth > 0) {
      page.setVisiblePages(Math.max(Math.ceil(1.0 * (pagedTable.offsetWidth - 250) / 40), 2));
    }

    registerWidths();
  };

  me.fit = function(startBackwards) {
    me.fitRows();
    me.fitColumns(startBackwards);
  }

  me.render = function() {
    me.fitColumns(false);

    // render header/footer to measure height accurately
    renderHeader();
    renderFooter();

    me.fitRows();
    renderBody();

    // re-render footer to match new rows
    renderFooter();
  }

  var resizeLastWidth = -1;
  var resizeLastHeight = -1;
  var resizeNewWidth = -1;
  var resizeNewHeight = -1;
  var resizePending = false;

  me.resize = function(newWidth, newHeight) {

    function resizeDelayed() {
      resizePending = false;

      if (
        (resizeNewWidth !== resizeLastWidth) ||
        (!me.fixedHeight() && resizeNewHeight !== resizeLastHeight)
      ) {
        resizeLastWidth = resizeNewWidth;
        resizeLastHeight = resizeNewHeight;

        setTimeout(resizeDelayed, 200);
        resizePending = true;
      } else {
        me.render();
        triggerOnChange();

        resizeLastWidth = -1;
        resizeLastHeight = -1;
      }
    }

    resizeNewWidth = newWidth;
    resizeNewHeight = newHeight;

    if (!resizePending) resizeDelayed();
  };
};

var PagedTableDoc;
(function (PagedTableDoc) {
  var allPagedTables = [];

  PagedTableDoc.initAll = function() {
    allPagedTables = [];

    var pagedTables = [].slice.call(document.querySelectorAll('[data-pagedtable="false"],[data-pagedtable=""]'));
    pagedTables.forEach(function(pagedTable, idx) {
      pagedTable.setAttribute("data-pagedtable", "true");
      pagedTable.setAttribute("pagedtable-page", 0);
      pagedTable.setAttribute("class", "pagedtable-wrapper");

      var pagedTableInstance = new PagedTable(pagedTable);
      pagedTableInstance.init();

      allPagedTables.push(pagedTableInstance);
    });
  };

  PagedTableDoc.resizeAll = function() {
    allPagedTables.forEach(function(pagedTable) {
      pagedTable.render();
    });
  };

  window.addEventListener("resize", PagedTableDoc.resizeAll);

  return PagedTableDoc;
})(PagedTableDoc || (PagedTableDoc = {}));

window.onload = function() {
  PagedTableDoc.initAll();
};
"></script>

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>

<style type="text/css">code{white-space: pre;}</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>








<style type="text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
pre code {
  padding: 0;
}
</style>



<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "";
  border: none;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div id="header">



<h1 class="title toc-ignore">GI</h1>

</div>


<div id="section" class="section level2 tabset tabset-pills tabset-fade">
<h2 class="tabset tabset-pills tabset-fade"></h2>
<div id="guidelines" class="section level3">
<h3>Guidelines</h3>
<div id="jvwpgtchwy" style="overflow-x:auto;overflow-y:auto;width:auto;height:auto;">
<style>html {
  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;
}

#jvwpgtchwy .gt_table {
  display: table;
  border-collapse: collapse;
  margin-left: auto;
  margin-right: auto;
  color: #333333;
  font-size: 16px;
  font-weight: normal;
  font-style: normal;
  background-color: #FFFFFF;
  width: auto;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #A8A8A8;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #A8A8A8;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
}

#jvwpgtchwy .gt_heading {
  background-color: #FFFFFF;
  text-align: center;
  border-bottom-color: #FFFFFF;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
}

#jvwpgtchwy .gt_title {
  color: #333333;
  font-size: 125%;
  font-weight: initial;
  padding-top: 4px;
  padding-bottom: 4px;
  border-bottom-color: #FFFFFF;
  border-bottom-width: 0;
}

#jvwpgtchwy .gt_subtitle {
  color: #333333;
  font-size: 85%;
  font-weight: initial;
  padding-top: 0;
  padding-bottom: 6px;
  border-top-color: #FFFFFF;
  border-top-width: 0;
}

#jvwpgtchwy .gt_bottom_border {
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#jvwpgtchwy .gt_col_headings {
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
}

#jvwpgtchwy .gt_col_heading {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: normal;
  text-transform: inherit;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: bottom;
  padding-top: 5px;
  padding-bottom: 6px;
  padding-left: 5px;
  padding-right: 5px;
  overflow-x: hidden;
}

#jvwpgtchwy .gt_column_spanner_outer {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: normal;
  text-transform: inherit;
  padding-top: 0;
  padding-bottom: 0;
  padding-left: 4px;
  padding-right: 4px;
}

#jvwpgtchwy .gt_column_spanner_outer:first-child {
  padding-left: 0;
}

#jvwpgtchwy .gt_column_spanner_outer:last-child {
  padding-right: 0;
}

#jvwpgtchwy .gt_column_spanner {
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  vertical-align: bottom;
  padding-top: 5px;
  padding-bottom: 5px;
  overflow-x: hidden;
  display: inline-block;
  width: 100%;
}

#jvwpgtchwy .gt_group_heading {
  padding: 8px;
  color: #FFFFFF;
  background-color: #0000FF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: middle;
}

#jvwpgtchwy .gt_empty_group_heading {
  padding: 0.5px;
  color: #FFFFFF;
  background-color: #0000FF;
  font-size: 100%;
  font-weight: initial;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  vertical-align: middle;
}

#jvwpgtchwy .gt_from_md > :first-child {
  margin-top: 0;
}

#jvwpgtchwy .gt_from_md > :last-child {
  margin-bottom: 0;
}

#jvwpgtchwy .gt_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  margin: 10px;
  border-top-style: solid;
  border-top-width: 1px;
  border-top-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: middle;
  overflow-x: hidden;
}

#jvwpgtchwy .gt_stub {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-right-style: solid;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  padding-left: 12px;
}

#jvwpgtchwy .gt_summary_row {
  color: #333333;
  background-color: #FFFFFF;
  text-transform: inherit;
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
}

#jvwpgtchwy .gt_first_summary_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
}

#jvwpgtchwy .gt_grand_summary_row {
  color: #333333;
  background-color: #FFFFFF;
  text-transform: inherit;
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
}

#jvwpgtchwy .gt_first_grand_summary_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-top-style: double;
  border-top-width: 6px;
  border-top-color: #D3D3D3;
}

#jvwpgtchwy .gt_striped {
  background-color: rgba(128, 128, 128, 0.05);
}

#jvwpgtchwy .gt_table_body {
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#jvwpgtchwy .gt_footnotes {
  color: #333333;
  background-color: #FFFFFF;
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
}

#jvwpgtchwy .gt_footnote {
  margin: 0px;
  font-size: 90%;
  padding: 4px;
}

#jvwpgtchwy .gt_sourcenotes {
  color: #333333;
  background-color: #FFFFFF;
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
}

#jvwpgtchwy .gt_sourcenote {
  font-size: 90%;
  padding: 4px;
}

#jvwpgtchwy .gt_left {
  text-align: left;
}

#jvwpgtchwy .gt_center {
  text-align: center;
}

#jvwpgtchwy .gt_right {
  text-align: right;
  font-variant-numeric: tabular-nums;
}

#jvwpgtchwy .gt_font_normal {
  font-weight: normal;
}

#jvwpgtchwy .gt_font_bold {
  font-weight: bold;
}

#jvwpgtchwy .gt_font_italic {
  font-style: italic;
}

#jvwpgtchwy .gt_super {
  font-size: 65%;
}

#jvwpgtchwy .gt_footnote_marks {
  font-style: italic;
  font-weight: normal;
  font-size: 65%;
}
</style>
<table class="gt_table">
  
  <thead class="gt_col_headings">
    <tr>
      <th class="gt_col_heading gt_columns_bottom_border gt_left" rowspan="1" colspan="1"></th>
    </tr>
  </thead>
  <tbody class="gt_table_body">
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Am J Gastroenterol</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001278" target="_blank" rel="noopener"> ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections.</a></p>
<p>The scientific evidence for these guidelines was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation process. In instances where the evidence was not appropriate for Grading of Recommendations Assessment, Development, and Evaluation but there was consensus of significant clinical merit, key concept statements were developed using expert consensus. These guidelines are meant to be broadly applicable and should be viewed as the preferred, but not the only, approach to clinical scenarios.</p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Clin Gastroenterol Hepatol</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.06.045" target="_blank" rel="noopener"> AGA Clinical Practice Update on Endoscopic Management of Perforations in Gastrointestinal Tract: Expert Review.</a></p>
<p>Recently a new suture-based device for defect closure has been introduced allowing deep submucosal and intramuscular enhanced fixation through a standard gastroscope or colonoscope. BEST PRACTICE ADVICE 15: Patients with perforations who are hemodynamically unstable or who have suffered a delayed perforation with peritoneal signs or frank peritonitis should be surgically managed without any attempt at endoscopic closure. BEST PRACTICE ADVICE 16: In any adverse event including perforation, it is paramount to ensure accurate documentation, prompt discussion with the patient and family, and swift reporting to the quality officer (or equivalent) and risk management team of the institution (in major adverse events).</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.03.020" target="_blank" rel="noopener"> AGA Clinical Practice Update on Evaluation and Management of Early Complications After Bariatric/Metabolic Surgery: Expert Review.</a></p>
<p>BEST PRACTICE ADVICE 6: Clinicians incorporating endoscopic management of bariatric/metabolic surgical complications into their clinical practice should have a detailed understanding of the pathophysiologic mechanisms initiating and perpetuating conditions such as staple-line leaks. This will allow for a prompt diagnosis and appropriate therapy to be targeted not only at the area of interest, but also any concomitant downstream stenosis. BEST PRACTICE ADVICE 7: Clinicians should recognize that the goal for endoscopic management of staple-line leaks are often not necessarily initial closure of the leak site, but rather techniques to promote drainage of material from the perigastric collection into the gastric lumen such that the leak site closes by secondary intention.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.07.006" target="_blank" rel="noopener"> AGA Clinical Practice Update on Management of Chronic Gastrointestinal Pain in Disorders of Gut-Brain Interaction: Expert Review.</a></p>
<p>BEST PRACTICE ADVICE 4: Nonpharmacologic therapies should be considered routinely as part of comprehensive pain management, and ideally brought up early on in care. BEST PRACTICE ADVICE 5: Providers should optimize medical therapies that are known to modulate pain and be able to differentiate when gastrointestinal pain is triggered by visceral factors vs centrally mediated factors. BEST PRACTICE ADVICE 6: Providers should familiarize themselves with a few effective neuromodulators, knowing the dosing, side effects, and targets of each and be able to explain to the patient why these drugs are used for the management of persistent pain.</p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Gastrointest Endosc</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.01.027" target="_blank" rel="noopener"> Advanced endoscopy fellowship training in the United States: recent trends in American Society for Gastrointestinal Endoscopy advanced endoscopy fellowship match, trainee experience, and postfellowship employment.</a></p>
<p>s There has been a steady increase in the number of advanced endoscopy applicants and training positions over recent years. Most graduating fellows reported 50% or less of their upcoming clinical practice would involve advanced endoscopic procedures. Future studies are needed to further clarify employment opportunities and personnel needs for advanced endoscopists.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2020.12.032" target="_blank" rel="noopener"> ASGE guideline on the management of cholangitis.</a></p>
<p>Grading of Recommendations, Assessment, Development, and Evaluation methodology was used to formulate recommendations on these topics. The ASGE suggests endoscopic rather than percutaneous drainage and biliary decompression within 48 hours. Additionally, the panel suggests that sphincterotomy and stone removal be combined with drainage rather than decompression alone, unless patients are too unstable to tolerate more extensive endoscopic treatment.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2020.12.035" target="_blank" rel="noopener"> ASGE guideline on the role of endoscopy in the management of malignant hilar obstruction.</a></p>
<p>However, in patients who have a short life expectancy and who place high value on avoiding repeated interventions, the panel suggests using SEMSs compared with PSs. If optimal drainage strategy has not been established, the panel suggests placing PSs. This document clearly outlines the process, analyses, and decision processes used to reach the final recommendations and represents the official ASGE recommendations on the above topics.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Core curriculum for endoscopic submucosal dissection (ESD).</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.02.020" target="_blank" rel="noopener"> Devices and techniques for flexible endoscopic management of Zenker&#39;s diverticulum (with videos).</a></p>
<p>s Flexible endoscopic approaches treat symptomatic ZD with results that are favorable compared with traditional open surgical or rigid endoscopic alternatives.</p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">J Hepatol</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.05.025" target="_blank" rel="noopener"> EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update.</a></p>
<p>Non-invasive tests are increasingly being used to improve the diagnosis and prognostication of chronic liver diseases across aetiologies. Herein, we provide the latest update to the EASL Clinical Practice Guidelines on the use of non-invasive tests for the evaluation of liver disease severity and prognosis, focusing on the topics for which relevant evidence has been published in the last 5 years.</p>
</div></td></tr>
  </tbody>
  
  
</table>
</div>
</div>
<div id="meta-analysis" class="section level3">
<h3>Meta-analysis</h3>
<p><em>meta-analyses and systematic reviews</em></p>
<div id="nliixqjohr" style="overflow-x:auto;overflow-y:auto;width:auto;height:auto;">
<style>html {
  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;
}

#nliixqjohr .gt_table {
  display: table;
  border-collapse: collapse;
  margin-left: auto;
  margin-right: auto;
  color: #333333;
  font-size: 16px;
  font-weight: normal;
  font-style: normal;
  background-color: #FFFFFF;
  width: auto;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #A8A8A8;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #A8A8A8;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
}

#nliixqjohr .gt_heading {
  background-color: #FFFFFF;
  text-align: center;
  border-bottom-color: #FFFFFF;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
}

#nliixqjohr .gt_title {
  color: #333333;
  font-size: 125%;
  font-weight: initial;
  padding-top: 4px;
  padding-bottom: 4px;
  border-bottom-color: #FFFFFF;
  border-bottom-width: 0;
}

#nliixqjohr .gt_subtitle {
  color: #333333;
  font-size: 85%;
  font-weight: initial;
  padding-top: 0;
  padding-bottom: 6px;
  border-top-color: #FFFFFF;
  border-top-width: 0;
}

#nliixqjohr .gt_bottom_border {
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#nliixqjohr .gt_col_headings {
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
}

#nliixqjohr .gt_col_heading {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: normal;
  text-transform: inherit;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: bottom;
  padding-top: 5px;
  padding-bottom: 6px;
  padding-left: 5px;
  padding-right: 5px;
  overflow-x: hidden;
}

#nliixqjohr .gt_column_spanner_outer {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: normal;
  text-transform: inherit;
  padding-top: 0;
  padding-bottom: 0;
  padding-left: 4px;
  padding-right: 4px;
}

#nliixqjohr .gt_column_spanner_outer:first-child {
  padding-left: 0;
}

#nliixqjohr .gt_column_spanner_outer:last-child {
  padding-right: 0;
}

#nliixqjohr .gt_column_spanner {
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  vertical-align: bottom;
  padding-top: 5px;
  padding-bottom: 5px;
  overflow-x: hidden;
  display: inline-block;
  width: 100%;
}

#nliixqjohr .gt_group_heading {
  padding: 8px;
  color: #FFFFFF;
  background-color: #0000FF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: middle;
}

#nliixqjohr .gt_empty_group_heading {
  padding: 0.5px;
  color: #FFFFFF;
  background-color: #0000FF;
  font-size: 100%;
  font-weight: initial;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  vertical-align: middle;
}

#nliixqjohr .gt_from_md > :first-child {
  margin-top: 0;
}

#nliixqjohr .gt_from_md > :last-child {
  margin-bottom: 0;
}

#nliixqjohr .gt_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  margin: 10px;
  border-top-style: solid;
  border-top-width: 1px;
  border-top-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: middle;
  overflow-x: hidden;
}

#nliixqjohr .gt_stub {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-right-style: solid;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  padding-left: 12px;
}

#nliixqjohr .gt_summary_row {
  color: #333333;
  background-color: #FFFFFF;
  text-transform: inherit;
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
}

#nliixqjohr .gt_first_summary_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
}

#nliixqjohr .gt_grand_summary_row {
  color: #333333;
  background-color: #FFFFFF;
  text-transform: inherit;
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
}

#nliixqjohr .gt_first_grand_summary_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-top-style: double;
  border-top-width: 6px;
  border-top-color: #D3D3D3;
}

#nliixqjohr .gt_striped {
  background-color: rgba(128, 128, 128, 0.05);
}

#nliixqjohr .gt_table_body {
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#nliixqjohr .gt_footnotes {
  color: #333333;
  background-color: #FFFFFF;
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
}

#nliixqjohr .gt_footnote {
  margin: 0px;
  font-size: 90%;
  padding: 4px;
}

#nliixqjohr .gt_sourcenotes {
  color: #333333;
  background-color: #FFFFFF;
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
}

#nliixqjohr .gt_sourcenote {
  font-size: 90%;
  padding: 4px;
}

#nliixqjohr .gt_left {
  text-align: left;
}

#nliixqjohr .gt_center {
  text-align: center;
}

#nliixqjohr .gt_right {
  text-align: right;
  font-variant-numeric: tabular-nums;
}

#nliixqjohr .gt_font_normal {
  font-weight: normal;
}

#nliixqjohr .gt_font_bold {
  font-weight: bold;
}

#nliixqjohr .gt_font_italic {
  font-style: italic;
}

#nliixqjohr .gt_super {
  font-size: 65%;
}

#nliixqjohr .gt_footnote_marks {
  font-style: italic;
  font-weight: normal;
  font-size: 65%;
}
</style>
<table class="gt_table">
  
  <thead class="gt_col_headings">
    <tr>
      <th class="gt_col_heading gt_columns_bottom_border gt_left" rowspan="1" colspan="1"></th>
    </tr>
  </thead>
  <tbody class="gt_table_body">
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Aliment Pharmacol Ther</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16328" target="_blank" rel="noopener"> An expert consensus to standardise clinical, endoscopic and histologic items and inclusion and outcome criteria for evaluation of pouchitis disease activity in clinical trials.</a></p>
<p> We conducted a RAND/UCLA appropriateness process to help inform measurement of pouchitis disease activity within clinical trials and foster the development of novel therapies.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16372" target="_blank" rel="noopener"> Role of smoking in functional dyspepsia and irritable bowel syndrome: three random population-based studies.</a></p>
<p> Smoking is an important environmental risk factor for postprandial distress syndrome, the most common FD subgroup, with over a twofold increased odds of PDS in heavy smokers. The role of smoking in IBS-diarrhoea, but not constipation, is also likely important.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16337" target="_blank" rel="noopener"> Systematic review and meta-analysis: the incidence and prevalence of paediatric coeliac disease across Europe.</a></p>
<p>s Paediatric coeliac disease incidence and prevalence have risen across Europe and appear highest in Scandinavia, Finland and Spain. The most recent evidence shows large increases in incidence in most regions, but stabilisation in some (notably Sweden and Finland). Sharp increases in the age at diagnosis may reflect increases in milder and asymptomatic cases diagnosed since reliable serology testing became widely used, through endomysial antibodies after 1990 and tissue transglutaminase antibodies around 2000.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16437" target="_blank" rel="noopener"> Systematic review and network meta-analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation.</a></p>
<p>s We found al licensed drugs for IBS-C to be superior to placebo for abdominal bloating. Linaclotide appeared to be the most efficacious at relieving abdominal bloating. Further research is needed to assess long-term efficacy of these agents and to better understand the precise mechanism of improving bloating.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16335" target="_blank" rel="noopener"> Systematic review with meta-analysis: bariatric surgery reduces the incidence of hepatocellular carcinoma.</a></p>
<p> Bariatric surgery is associated with a decreased risk of HCC.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16321" target="_blank" rel="noopener"> Systematic review with meta-analysis: risk factors for Barrett&#39;s oesophagus in individuals with gastro-oesophageal reflux symptoms.</a></p>
<p>s The prevalence of Barrett&#39;s oesophagus in individuals with gastro-oesophageal reflux symptoms was higher in those who drank alcohol, although this association was modest. The strongest association found was between hiatal hernia and Barrett&#39;s oesophagus. Other potential risk factors assessed in this study did not appear to be associated with presence of Barrett&#39;s oesophagus among individuals with gastro-oesophageal symptoms.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16473" target="_blank" rel="noopener"> Systematic review with meta-analysis: the long-term efficacy of Barrett&#39;s endoscopic therapy-stringent selection criteria and a proposal for definitions.</a></p>
<p> Using stringent criteria for appropriate study selection with sufficient follow-up, a lack of high-quality controlled intervention trials becomes evident for assessment of long-term durable remission rates of BET despite initial high success rates. We plea for a uniform documentation of study details which could be used in future trials.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16405" target="_blank" rel="noopener"> Systematic review with meta-analysis: volatile organic compound analysis to improve faecal immunochemical testing in the detection of colorectal cancer.</a></p>
<p>s In a FIT-negative symptomatic population, VOC can be a good test to rule-out the presence of CRC. The estimated probability reduction by 0.4% when both tests being negative offers adequate safety netting in primary care for the exclusion of CRC. The number needed to colonoscope to identify one CRC is eight if either FIT or VOC positive. Cost-effectiveness and clinical accuracy of this approach will need further evaluation.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16479" target="_blank" rel="noopener"> Systematic review: efficacy of escalated maintenance anti-tumour necrosis factor therapy in Crohn&#39;s disease.</a></p>
<p>s Empiric escalation of maintenance anti-TNF therapy can recapture clinical response in a majority of patients with secondary loss of response to standard maintenance doses. Proactive optimisation of maintenance dosing might prolong time to loss of response in some patients.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16445" target="_blank" rel="noopener"> Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents.</a></p>
<p> IBD societal cost of illness is increasing, driven by growing costs of medication, and varies considerably between continents. While biologic therapy was expected to decrease inpatient costs by reducing hospitalisations and surgery, these costs have not declined.</p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Am J Gastroenterol</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001222" target="_blank" rel="noopener"> Efficacy and Safety of Over-the-Counter Therapies for Chronic Constipation: An Updated Systematic Review.</a></p>
<p> The spectrum of OTC products has increased and quality of evidence has improved, but methodological issues including variability in study design, primary outcome measures, trial duration, and small sample sizes remain. We found good evidence to recommend polyethylene glycol or senna as first-line laxatives and moderate evidence supporting fiber supplements, fruits, stimulant laxatives, and magnesium-based products. For others, further validation with more rigorously designed studies is warranted.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001337" target="_blank" rel="noopener"> Fibrosis-4 Index vs Nonalcoholic Fatty Liver Disease Fibrosis Score in Identifying Advanced Fibrosis in Subjects With Nonalcoholic Fatty Liver Disease: A Meta-Analysis.</a></p>
<p> This meta-analysis suggested that currently available NITs have a limited performance in identifying AF among subjects with NAFLD. Further studies are needed to optimize existing thresholds or develop new NITs.</p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Clin Gastroenterol Hepatol</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.011" target="_blank" rel="noopener"> Proton Pump Inhibitor Use Is Not Strongly Associated With SARS-CoV-2 Related Outcomes: A Nationwide Study and Meta-analysis.</a></p>
<p>s Current PPI use may be associated with an increased risk of SARS-CoV-2 infection and hospital admission, but these results with minimally elevated estimates are most likely subject to residual confounding. No association was found for severe outcomes. The results from the meta-analysis indicated no impact of current PPI use on COVID-19 outcomes.</p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Gastrointest Endosc</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.03.935" target="_blank" rel="noopener"> Comparative analysis of glucose and carcinoembryonic antigen in the diagnosis of pancreatic mucinous cysts: a systematic review and meta-analysis.</a></p>
<p> Glucose level in PCF is more accurate than CEA for preoperative diagnosis of mucinous cysts. It may become a useful first-line test, particularly in small cysts with a limited volume of PCF. Larger studies are awaited to confirm glucose as the single test for mucinous cyst diagnosis.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.04.025" target="_blank" rel="noopener"> Pancreatic cyst fluid glucose in differentiating mucinous from nonmucinous pancreatic cysts: a systematic review and meta-analysis.</a></p>
<p>s Low pancreatic cyst fluid glucose was associated with a high sensitivity and specificity with significantly improved diagnostic accuracy compared with CEA alone for the diagnosis of mucinous versus nonmucinous pancreatic cystic lesions.</p>
</div></td></tr>
  </tbody>
  
  
</table>
</div>
</div>
<div id="open-access" class="section level3">
<h3>Open access</h3>
<p><em>Articles that are open access at time of publication, full text is typically available in PMC (link provided)</em></p>
<p><strong>There are 176 open access articles in this group, most (if not all of them) can be accessed through PMC as full text. Press on the title to get full text.</strong></p>
<div id="fptrsbovwh" style="overflow-x:auto;overflow-y:auto;width:auto;height:auto;">
<style>html {
  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;
}

#fptrsbovwh .gt_table {
  display: table;
  border-collapse: collapse;
  margin-left: auto;
  margin-right: auto;
  color: #333333;
  font-size: 16px;
  font-weight: normal;
  font-style: normal;
  background-color: #FFFFFF;
  width: auto;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #A8A8A8;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #A8A8A8;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
}

#fptrsbovwh .gt_heading {
  background-color: #FFFFFF;
  text-align: center;
  border-bottom-color: #FFFFFF;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
}

#fptrsbovwh .gt_title {
  color: #333333;
  font-size: 125%;
  font-weight: initial;
  padding-top: 4px;
  padding-bottom: 4px;
  border-bottom-color: #FFFFFF;
  border-bottom-width: 0;
}

#fptrsbovwh .gt_subtitle {
  color: #333333;
  font-size: 85%;
  font-weight: initial;
  padding-top: 0;
  padding-bottom: 6px;
  border-top-color: #FFFFFF;
  border-top-width: 0;
}

#fptrsbovwh .gt_bottom_border {
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#fptrsbovwh .gt_col_headings {
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
}

#fptrsbovwh .gt_col_heading {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: normal;
  text-transform: inherit;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: bottom;
  padding-top: 5px;
  padding-bottom: 6px;
  padding-left: 5px;
  padding-right: 5px;
  overflow-x: hidden;
}

#fptrsbovwh .gt_column_spanner_outer {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: normal;
  text-transform: inherit;
  padding-top: 0;
  padding-bottom: 0;
  padding-left: 4px;
  padding-right: 4px;
}

#fptrsbovwh .gt_column_spanner_outer:first-child {
  padding-left: 0;
}

#fptrsbovwh .gt_column_spanner_outer:last-child {
  padding-right: 0;
}

#fptrsbovwh .gt_column_spanner {
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  vertical-align: bottom;
  padding-top: 5px;
  padding-bottom: 5px;
  overflow-x: hidden;
  display: inline-block;
  width: 100%;
}

#fptrsbovwh .gt_group_heading {
  padding: 8px;
  color: #FFFFFF;
  background-color: #0000FF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: middle;
}

#fptrsbovwh .gt_empty_group_heading {
  padding: 0.5px;
  color: #FFFFFF;
  background-color: #0000FF;
  font-size: 100%;
  font-weight: initial;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  vertical-align: middle;
}

#fptrsbovwh .gt_from_md > :first-child {
  margin-top: 0;
}

#fptrsbovwh .gt_from_md > :last-child {
  margin-bottom: 0;
}

#fptrsbovwh .gt_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  margin: 10px;
  border-top-style: solid;
  border-top-width: 1px;
  border-top-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: middle;
  overflow-x: hidden;
}

#fptrsbovwh .gt_stub {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-right-style: solid;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  padding-left: 12px;
}

#fptrsbovwh .gt_summary_row {
  color: #333333;
  background-color: #FFFFFF;
  text-transform: inherit;
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
}

#fptrsbovwh .gt_first_summary_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
}

#fptrsbovwh .gt_grand_summary_row {
  color: #333333;
  background-color: #FFFFFF;
  text-transform: inherit;
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
}

#fptrsbovwh .gt_first_grand_summary_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-top-style: double;
  border-top-width: 6px;
  border-top-color: #D3D3D3;
}

#fptrsbovwh .gt_striped {
  background-color: rgba(128, 128, 128, 0.05);
}

#fptrsbovwh .gt_table_body {
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#fptrsbovwh .gt_footnotes {
  color: #333333;
  background-color: #FFFFFF;
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
}

#fptrsbovwh .gt_footnote {
  margin: 0px;
  font-size: 90%;
  padding: 4px;
}

#fptrsbovwh .gt_sourcenotes {
  color: #333333;
  background-color: #FFFFFF;
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
}

#fptrsbovwh .gt_sourcenote {
  font-size: 90%;
  padding: 4px;
}

#fptrsbovwh .gt_left {
  text-align: left;
}

#fptrsbovwh .gt_center {
  text-align: center;
}

#fptrsbovwh .gt_right {
  text-align: right;
  font-variant-numeric: tabular-nums;
}

#fptrsbovwh .gt_font_normal {
  font-weight: normal;
}

#fptrsbovwh .gt_font_bold {
  font-weight: bold;
}

#fptrsbovwh .gt_font_italic {
  font-style: italic;
}

#fptrsbovwh .gt_super {
  font-size: 65%;
}

#fptrsbovwh .gt_footnote_marks {
  font-style: italic;
  font-weight: normal;
  font-size: 65%;
}
</style>
<table class="gt_table">
  
  <thead class="gt_col_headings">
    <tr>
      <th class="gt_col_heading gt_columns_bottom_border gt_left" rowspan="1" colspan="1"></th>
    </tr>
  </thead>
  <tbody class="gt_table_body">
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Aliment Pharmacol Ther</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8251541" target="_blank" rel="noopener"> Randomised study: effects of the 5-HT<sub>4</sub> receptor agonist felcisetrag vs placebo on gut transit in patients with gastroparesis.</a></p>
<span style="text-decoration: underline;">Conclusion:</span>  I.V. felcisetrag significantly accelerated gastric, small bowel and colonic transit in patients with gastroparesis, and should be further evaluated for short-term treatment of gastric and intestinal motility disorders. ClinicalTrials.gov #NCT03281577.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8361769" target="_blank" rel="noopener"> Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents.</a></p>
<span style="text-decoration: underline;">Conclusion:</span>  IBD societal cost of illness is increasing, driven by growing costs of medication, and varies considerably between continents. While biologic therapy was expected to decrease inpatient costs by reducing hospitalisations and surgery, these costs have not declined.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8453765" target="_blank" rel="noopener"> Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study.</a></p>
<span style="text-decoration: underline;">Conclusion:</span>  Long-term treatment persistence of first anti-TNF therapy was limited in patients with inflammatory bowel diseases, primarily due to treatment failure and side effects.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8252074" target="_blank" rel="noopener"> Efficacy of ginger as antiemetic in children with acute gastroenteritis: a randomised controlled trial.</a></p>
<span style="text-decoration: underline;">Conclusion:</span>  Oral administration of ginger is effective and safe at improving vomiting in children with AGE. Trial registration The trial was registered on https //clinicaltrials.gov/ with the identifier NCT02701491.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8444861" target="_blank" rel="noopener"> Editorial: IBD medications during the COVID-19 pandemic-are they safe to use?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8014117" target="_blank" rel="noopener"> Letter: how frequently does COVID-19 mimic an IBD flare when community transmission of SARS-CoV-2 is active?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8013802" target="_blank" rel="noopener"> Letter: liver involvement and mortality in COVID-19-the role of anti-viral therapy should be considered.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8207069" target="_blank" rel="noopener"> Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8013439" target="_blank" rel="noopener"> Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8013379" target="_blank" rel="noopener"> Letter: SARS-CoV-2 infection in two inflammatory bowel disease patients treated with dual targeted therapy-Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8252518" target="_blank" rel="noopener"> Review article: diagnosis, management and patient perspectives of the spectrum of constipation disorders.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s Constipation includes multiple overlapping subtypes identifiable using detailed history, current diagnostic tools and smartphone applications. Recognition of individual subtype(s) could pave the way for optimal, evidence-based treatments by a gastroenterology provider.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8362064" target="_blank" rel="noopener"> The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s Efficacy and safety of tofacitinib were similar in patients with UC regardless of baseline BMI.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8361733" target="_blank" rel="noopener"> Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s Tegoprazan 50 and 100 mg showed superior therapeutic efficacy compared with the placebo, as well as a favourable safety profile in patients with NERD. Registration number  ClinicalTrials.gov identifier NCT02556021.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8362009" target="_blank" rel="noopener"> Characterisation of patients with supine nighttime reflux: observations made with prolonged wireless oesophageal pH monitoring.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s The majority of patients with nocturnal reflux symptoms had pathological acid exposure in at least one night of the prolonged pH recording. A high night-to-night variability in acid exposure reduces the clinical value and diagnostic yield of pH monitoring limited to 24 hours. Prolonged testing is a more appropriate diagnostic tool for patients with nocturnal reflux symptoms.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8361916" target="_blank" rel="noopener"> Novel impedance-pH parameters are associated with proton pump inhibitor response in patients with inconclusive diagnosis of gastro-oesophageal reflux disease according to Lyon Consensus.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s The present study highlights the value of MNBI and PSPW index as adjunctive metrics in characterising patients with inconclusive evidence of GERD and identifying those responsive to PPI treatment.
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Am J Gastroenterol</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8315185" target="_blank" rel="noopener"> Unreliable Estimation of Fibrosis Regression During Treatment by Liver Stiffness Measurement in Patients With Chronic Hepatitis B.</a></p>
<span style="text-decoration: underline;">Conclusion:</span>  Changes in LSM are unreliable to estimate regression of fibrosis during treatment; the established cutoff value of on-treatment LSM can optimize monitoring strategy for histological outcomes in patients with chronic hepatitis B.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8315188" target="_blank" rel="noopener"> Identifying Gender Barriers for Colorectal Cancer Screening and Assessing the Need for a Multigender Endoscopy Team: A Prospective Multicenter Study.</a></p>
<span style="text-decoration: underline;">Conclusion:</span>  Contrary to previous studies, most patients did not have an endoscopist gender preference. Interestingly, men had more same-gender endoscopist preference, whereas women had more same-gender endoscopy team member preference. Age-related and regional differences exist among patients&#39; gender preferences for their endoscopist and endoscopy team member, and addressing these preferences while creating an environment of a multigender endoscopy team may be beneficial in improving colorectal cancer screening.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8315187" target="_blank" rel="noopener"> Comparative Cost Effectiveness of Reflux-Based and Reflux-Independent Strategies for Barrett&#39;s Esophagus Screening.</a></p>
<span style="text-decoration: underline;">Conclusion:</span>  Minimally invasive nonendoscopic tests may make GERD-independent BE screening cost effective. Participation rates for these strategies need to be studied.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8172451" target="_blank" rel="noopener"> COVID-19 Vaccine Perceptions Among Patients With Chronic Disease in a Large Gastroenterology and Hepatology Practice.</a></p>
<span style="text-decoration: underline;">Conclusion:</span>  Patients have high level of trust in the COVID-19 vaccine and are likely to follow their specialist physician recommendations.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8315186" target="_blank" rel="noopener"> Tegaserod for Irritable Bowel Syndrome With Constipation in Women Younger Than 65 Years Without Cardiovascular Disease: Pooled Analyses of 4 Controlled Trials.</a></p>
<span style="text-decoration: underline;">Conclusion:</span>  Tegaserod 6 mg b.i.d. reduced IBS-C symptoms in overall and US Food and Drug Administration-indicated populations (women aged &lt;65 years with no history of cardiovascular ischemic events).
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8191753" target="_blank" rel="noopener"> Efficacy and Safety of Over-the-Counter Therapies for Chronic Constipation: An Updated Systematic Review.</a></p>
<span style="text-decoration: underline;">Conclusion:</span>  The spectrum of OTC products has increased and quality of evidence has improved, but methodological issues including variability in study design, primary outcome measures, trial duration, and small sample sizes remain. We found good evidence to recommend polyethylene glycol or senna as first-line laxatives and moderate evidence supporting fiber supplements, fruits, stimulant laxatives, and magnesium-based products. For others, further validation with more rigorously designed studies is warranted.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8484025" target="_blank" rel="noopener"> Adverse Events After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease.</a></p>
<span style="text-decoration: underline;">Conclusion:</span>  Those with IBD and other immune-mediated inflammatory diseases can be reassured that the AE risk is likely not increased, and may be reduced, while on advanced therapies.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8315189" target="_blank" rel="noopener"> Antispasmodics for Chronic Abdominal Pain: Analysis of North American Treatment Options.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> Furthermore, variability in study end points limits comparisons. Risk of selection, performance, detection, attrition, and reporting bias also differed among studies, and in many cases, risks were considered &quot;unclear.&quot; The antispasmodics evaluated in this review, which differ in geographic availability, were found to vary dramatically in efficacy and safety. Given these caveats, each agent should be considered on an individual basis, rather than prescribed based on information across the broad class of agents.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7553027" target="_blank" rel="noopener"> Association Between Famotidine Use and Clinical Outcomes in Patients With COVID-19: Assessment of Available Evidence.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8389347" target="_blank" rel="noopener"> Endoscopic Vacuum-Assisted Wound Closure of a Rectal Perforation in the Setting of Active Ulcerative Colitis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7553031" target="_blank" rel="noopener"> Gastrointestinal Hemorrhages in Patients With COVID-19 Managed With Transarterial Embolization.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7553033" target="_blank" rel="noopener"> Management of Gastrointestinal Bleeding in Coronavirus Disease: Exploring the Options.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8186259" target="_blank" rel="noopener"> Pay Attention to Distinguish Hepatitis from Novel Coronavirus Hepatitis in the Context of COVID-19 Pandemic.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8500276" target="_blank" rel="noopener"> Real-Time 3D Imaging of Post-Transplant Biliary Stricture: A Novel Application of Existing Technology.</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Clin Gastroenterol Hepatol</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7844358" target="_blank" rel="noopener"> Hepatic Vasculopathy and Regenerative Responses of the Liver in Fatal Cases of COVID-19.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> 1  Although functional impairment of the liver has been correlated with worse clinical outcomes, little is known about the pathophysiology of hepatic injury and repair in COVID-19. 2  ,  3  Histologic evaluation has been limited to small numbers of COVID-19 cases with no control subjects 2  ,  4  and demonstrated largely heterogeneous patterns of pathology. 2  ,  3 .
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7859624" target="_blank" rel="noopener"> COVID-19 Vaccination Intent and Perceptions Among Patients With Inflammatory Bowel Diseases.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> 1-4  Vaccinations were authorized for emergency use in the United States in December 2020 and aim to halt the spread of COVID-19. However, there are concerns that people will be hesitant to receive the vaccine for a variety of reasons including insufficient data in certain populations including those with IBD. We surveyed patients with IBD to identify potential concerns regarding COVID-19 vaccination.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8169727" target="_blank" rel="noopener"> COVID-19 Outcomes Among Racial and Ethnic Minority Individuals With Inflammatory Bowel Disease in the United States.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> 2  Among patients with inflammatory bowel disease (IBD), racial and ethnic minorities have worse outcomes, mediated in part by inequitable health care access. 3  Racial and ethnic minority patients with IBD and COVID-19 may be an especially vulnerable population. The purpose of this study was to evaluate racial and ethnic disparities in COVID-19 outcomes among IBD patients and the impact of non-IBD comorbidities on observed disparities.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8245666" target="_blank" rel="noopener"> Gastrointestinal Sequelae 3 and 6 Months After Hospitalization for Coronavirus Disease 2019.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> Gastrointestinal (GI) symptoms are highly prevalent in coronavirus disease 2019 (COVID-19) ranging from 17.6 % to 53 %. 1-4  The proposed mechanism for GI symptoms involves SARS-CoV-2 virus binding to the host cell&#39;s angiotensin-converting enzyme-2 receptor, commonly found in GI tract epithelial cells. 5 .
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8018784" target="_blank" rel="noopener"> An Impetus for Change: How COVID-19 Will Transform the Delivery of GI Health Care.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8088969" target="_blank" rel="noopener"> Health Equity and Telemedicine in Gastroenterology and Hepatology.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8253689" target="_blank" rel="noopener"> Increased Diagnosis of Hepatocellular Carcinoma in Hospitalized Patients with Alcohol Related Hepatitis after the Covid-19 Outbreak: A Global Multi-Center Propensity Matched Analysis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7873596" target="_blank" rel="noopener"> Liver Injury in Liver Transplant Patients With COVID-19: A Histopathologic Analysis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8139328" target="_blank" rel="noopener"> Liver Injury in Severe COVID-19 Disease: Need a Closer Look!</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8178538" target="_blank" rel="noopener"> No Durable Impact of COVID-19 on Intestinal Disease Activity in Subjects With IBD.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8120783" target="_blank" rel="noopener"> SARS-CoV-2-Induced Pancreatitis is a Rare but Real Entity.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8053356" target="_blank" rel="noopener"> Serum Lipase Elevations in COVID-19 Patients Reflect Critical Illness and not Acute Pancreatitis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7857702" target="_blank" rel="noopener"> What Gastroenterologists Should Know About COVID-19 Vaccines.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8111907" target="_blank" rel="noopener"> Proton Pump Inhibitor Use Is Not Strongly Associated With SARS-CoV-2 Related Outcomes: A Nationwide Study and Meta-analysis.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s Current PPI use may be associated with an increased risk of SARS-CoV-2 infection and hospital admission, but these results with minimally elevated estimates are most likely subject to residual confounding. No association was found for severe outcomes. The results from the meta-analysis indicated no impact of current PPI use on COVID-19 outcomes.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8123528" target="_blank" rel="noopener"> Significant Liver Injury During Hospitalization for COVID-19 Is Not Associated With Liver Insufficiency or Death.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s Liver test abnormalities known to be associated with COVID-19 are secondary to other insults, mostly ischemia or drug-induced liver injury, and do not lead to liver insufficiency or death.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8241429" target="_blank" rel="noopener"> An International Reporting Registry of Patients With Celiac Disease and COVID-19: Initial Results From SECURE-CELIAC.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> Surveillance Epidemiology Under Research Exclusion for Celiac Disease (SECURE-CELIAC) is an international, de-identified adult and pediatric database created to monitor and report on the severity of coronavirus disease 2019 (COVID-19) outcomes in patients with celiac disease (CD).
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Endoscopy</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8044597" target="_blank" rel="noopener"> The first &quot;exclusive COVID-19&quot; endoscopy project.</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Gastroenterology</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8233543" target="_blank" rel="noopener"> An Unexpected Thoracic Finding in a Patient With COVID-19.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8252826" target="_blank" rel="noopener"> BNT162b2 Messenger RNA COVID-19 Vaccine Effectiveness in Patients With Inflammatory Bowel Disease: Preliminary Real-World Data During Mass Vaccination Campaign.</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Gastrointest Endosc</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7611297" target="_blank" rel="noopener"> The risk of neoplasia in patients with Barrett&#39;s esophagus indefinite for dysplasia: a multicenter cohort study.</a></p>
<span style="text-decoration: underline;">Conclusion:</span>  Patients with BE-IND should be closely monitored, because nearly a quarter harbor or will shortly develop dysplasia. BE length is a clinical predictor of neoplastic progression; however, more-accurate molecular biomarkers for risk stratification are warranted.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8052210" target="_blank" rel="noopener"> A &quot;double-hit&quot; damage mechanism can explain self-limited GI bleeding in COVID-19 pneumonia.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8106483" target="_blank" rel="noopener"> Behind the mask: physiologic effects of facial personal protective equipment during endoscopy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7927584" target="_blank" rel="noopener"> Delayed postsphincterotomy bleeding induced by severe thrombocytopenia in a patient with COVID-19.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7937337" target="_blank" rel="noopener"> Metabolic function and weight loss after endoscopic sleeve gastroplasty: resistance is futile.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7963266" target="_blank" rel="noopener"> Update from the Editor-in-Chief.</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Gut</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8245282" target="_blank" rel="noopener"> Identification of the source events for aerosol generation during oesophago-gastro-duodenoscopy.</a></p>
<span style="text-decoration: underline;">Conclusion:</span>  Coughing evoked during OGD is the main source of the increased aerosol levels, and therefore, OGD should be regarded as a procedure with high risk of producing respiratory aerosols. OGD should be conducted with airborne personal protective equipment and appropriate precautions in those patients who are at risk of having COVID-19 or other respiratory pathogens.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8292602" target="_blank" rel="noopener"> Understanding the role of the gut in undernutrition: what can technology tell us?</a></p>
<span style="text-decoration: underline;">Conclusion:</span> Here we survey the technology landscape for potential solutions to improve assessment of gut function, focussing on devices that could be deployed at point-of-care in low-income and middle-income countries (LMICs). We assess the potential for technological innovation to assess gut morphology, function, barrier integrity and immune response in undernutrition, and highlight the approaches that are currently most suitable for deployment and development. This article focuses on EE and undernutrition in LMICs, but many of these technologies may also become useful in monitoring of other gut pathologies.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8292561" target="_blank" rel="noopener"> Large-scale genetic analyses in an understudied disease: haemorrhoidal disease.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8355886" target="_blank" rel="noopener"> Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> One additional drug, the prenylation inhibitor lonafarnib, is currently under investigation in phase III clinical trials. Other treatment strategies aim at targeting hepatitis B surface antigen, including the nucleic acid polymer REP2139Ca. These recent advances in HDV virology, immunology and treatment are important steps to make HDV a less difficult-to-treat virus and will be discussed.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8458070" target="_blank" rel="noopener"> Calprotectin: from biomarker to biological function.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> Recent studies revealed insights into biological functions of the CP subunits S100A8 and S100A9 during orchestration of an inflammatory response at mucosal surfaces across organ systems. In this review, we summarise longitudinal evidence for the evolution of CP from biomarker to rheostat of mucosal inflammation and suggest an algorithm for the interpretation of faecal CP in daily clinical practice. We propose that mechanistic insights into the biological function of CP in the gut and beyond may facilitate interpretation of current assays and guide patient-tailored medical therapy in IBD, a concept warranting controlled clinical trials.
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Hepatology</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8457150" target="_blank" rel="noopener"> Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP-Activated Protein Kinase Signaling Pathway.</a></p>
<span style="text-decoration: underline;">Conclusion:</span>  Cordycepin exerts significant protective effects against hepatic steatosis, inflammation, liver injury, and fibrosis in mice under metabolic stress through activation of the AMPK signaling pathway. Cordycepin might be an AMPK activator that can be used for the treatment of NASH.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8239872" target="_blank" rel="noopener"> Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19.</a></p>
<span style="text-decoration: underline;">Conclusion:</span>  Current or past HBV infections were not associated with more liver injury and mortality in COVID-19.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8377092" target="_blank" rel="noopener"> Microbiota-Driven Activation of Intrahepatic B Cells Aggravates NASH Through Innate and Adaptive Signaling.</a></p>
<span style="text-decoration: underline;">Conclusion:</span>  Our findings reveal that a gut microbiota-driven activation of intrahepatic B cells leads to hepatic inflammation and fibrosis during the progression of NASH through innate and adaptive immune mechanisms.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8013494" target="_blank" rel="noopener"> COVID-19 and Liver Cirrhosis: Focus on the Nonclassical Renin-Angiotensin System and Implications for Therapy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8333231" target="_blank" rel="noopener"> Discovery and Opportunities With Integrative Analytics Using Multiple-Omics Data.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8456961" target="_blank" rel="noopener"> County-Level Variation in Hepatitis C Virus Mortality and Trends in the United States, 2005-2017.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s Although many counties have experienced a shift in HCV mortality trends since 2013, the magnitude and composition of that shift have varied by place. These data provide a better understanding of geographic differences in HCV mortality and can be used by local jurisdictions to evaluate HCV mortality in their areas relative to surrounding areas and the nation.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8339171" target="_blank" rel="noopener"> The Impact of Direct-Acting Antiviral Therapy on End-Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use Disorders.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s Among the HCV SUD group, DAA treatment reduced the risk of DCC but not HCC for those who were noncirrhotic, whereas DAA treatment reduced the risk of HCC but not DCC for those with cirrhosis. Among the nontreated, patients with an SUD had a significantly higher risk of DCC and HCC compared with those without an SUD. Thus, DAA treatment should be considered for al patients with HCV and an SUD while also addressing the SUD.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8346581" target="_blank" rel="noopener"> Heterogeneity of HSCs in a Mouse Model of NASH.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s Analysis of single-cell RNA sequencing in combination with an interrogation of previous studies revealed an unanticipated heterogeneity of HSC phenotypes under normal and injured states.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8453713" target="_blank" rel="noopener"> Sirtuin 2 Prevents Liver Steatosis and Metabolic Disorders by Deacetylation of Hepatocyte Nuclear Factor 4α.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s Collectively, the present study provided evidence that SIRT2 functions as a crucial negative regulator in NAFLD and related metabolic disorders and that targeting the SIRT2-HNF4α pathway may be a promising strategy for NAFLD treatment.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8251927" target="_blank" rel="noopener"> Hexa Histidine-Tagged Recombinant Human Cytoglobin Deactivates Hepatic Stellate Cells and Inhibits Liver Fibrosis by Scavenging Reactive Oxygen Species.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s His-CYGB could have antifibrotic clinical applications for human chronic liver diseases.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7611739" target="_blank" rel="noopener"> Hypoxia-Inducible Factor 1 Alpha-Mediated RelB/APOBEC3B Down-regulation Allows Hepatitis B Virus Persistence.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s In conclusion, inhibiting HIF1α expression or stabilization represents an anti-HBV strategy in the context of immune-mediated A3B induction. High HIF1α, mediated by hypoxia or inflammation, offers a reservoir for HBV survival in vivo and should be considered as a restricting factor in the development of immune therapies.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8453838" target="_blank" rel="noopener"> An Updated Assessment of Chronic Hepatitis B Prevalence Among Foreign-Born Persons Living in the United States.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s Including FB and U.S.-born persons, the total prevalence of CHB in the USA may be as high as 2.4 million.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8456904" target="_blank" rel="noopener"> Impact of Genotype, Serum Bile Acids, and Surgical Biliary Diversion on Native Liver Survival in FIC1 Deficiency.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s Less than half of patients with FIC1 deficiency reach adulthood with native liver. The number of PPTMs did not associate with the natural history or prognosis of FIC1 deficiency. sBA concentrations at initial presentation and after SBD provide limited prognostic information on long-term NLS.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8361999" target="_blank" rel="noopener"> A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s Our ML method has shown reproducibility and sensitivity and was prognostic for disease progression, demonstrating the power of ML to advance our understanding of disease heterogeneity in NASH, risk stratify affected patients, and facilitate the development of therapies.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8446089" target="_blank" rel="noopener"> In Utero Exposure to Mercury Is Associated With Increased Susceptibility to Liver Injury and Inflammation in Childhood.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s These findings suggest that developmental exposure to Hg can contribute to inflammation and increased NAFLD risk in early life.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8349381" target="_blank" rel="noopener"> High Mobility Group Box 1 Release by Cholangiocytes Governs Biliary Atresia Pathogenesis and Correlates With Increases in Afflicted Infants.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s These results suggest that HMGB1 plays a role in virus induced BA pathogenesis and could be a target for therapeutic interventions in a subset of patients with BA and high HMGB1.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8250536" target="_blank" rel="noopener"> Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s This international, multicenter study reveals that patients with AIH were not at risk for worse outcomes with COVID-19 than other causes of CLD. Cirrhosis was the strongest predictor for severe COVID-19 in patients with AIH. Maintenance of immunosuppression during COVID-19 was not associated with increased risk for severe COVID-19 but did lower the risk for new-onset liver injury during COVID-19.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8014184" target="_blank" rel="noopener"> American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> The online companion document located at https://www. aasld. org/about-aasld/covid-19-resources will be updated as additional data become available regarding the safety and efficacy of other COVID-19 vaccines in development.
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Inflamm Bowel Dis</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8195093" target="_blank" rel="noopener"> Acceptance of SARS-CoV-2 Vaccination Among a Cohort of IBD Patients From Southern Italy: A Cross-Sectional Survey.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8376121" target="_blank" rel="noopener"> Azathioprine-induced Myelotoxicity After Switching Mesalazine Compound.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7989212" target="_blank" rel="noopener"> Barriers to Administering Vaccines in Inflammatory Bowel Disease Centers.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8135589" target="_blank" rel="noopener"> COVID-19 Hospitalizations Among U.S. Medicare Beneficiaries With Inflammatory Bowel Disease, April 1 to July 31, 2020.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8194689" target="_blank" rel="noopener"> COVID-19 Vaccination in Patients With Inflammatory Bowel Disease and History of Reaction to Injectable Therapies.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8244581" target="_blank" rel="noopener"> Impact of COVID-19 on Inflammatory Bowel Disease Clinical Trial Recruitment: A Global Survey of Principal Investigators.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7928881" target="_blank" rel="noopener"> Leukocytoclastic Vasculitis in Cutaneous Crohn Disease in the Setting of COVID-19.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8083615" target="_blank" rel="noopener"> Safety of Tofacitinib in the COVID-19 Pandemic-Enough Is Not Enough.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7928823" target="_blank" rel="noopener"> SARS-CoV-2 as a Trigger for De Novo Ulcerative Colitis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8344527" target="_blank" rel="noopener"> SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease-Fear and Desire.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7989361" target="_blank" rel="noopener"> The Effect of COVID-19 Resurgence on Morbidity and Mortality in Patients With IBD on Biologic Therapy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7928903" target="_blank" rel="noopener"> Time to Negative SARS-CoV-2 PCR Should Not Delay Care Among Patients With Inflammatory Bowel Diseases.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8314119" target="_blank" rel="noopener"> Overexpression of Cancer-Associated Stem Cell Gene OLFM4 in the Colonic Epithelium of Patients With Primary Sclerosing Cholangitis.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s Higher expression of OLFM4, a cancer stemness gene induced by IL-22, is present in PSC-UC, suggesting that IL-22 responses may result in alterations of the intestinal stem-cell niche in these patients.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8344426" target="_blank" rel="noopener"> Posttraumatic Stress in Patients With Inflammatory Bowel Disease: Prevalence and Relationships to Patient-Reported Outcomes.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s The present findings support prior research that approximately one-quarter to one-third of patients with IBD report significant symptoms of PTS directly from their disease experiences, and certain demographic groups are at higher risk. In addition, PTS is associated with several IBD outcomes. Patients with higher PTS symptoms are less likely to be in remission and may utilize more outpatient gastrointestinal services. Intervention trials to mitigate PTS symptoms in patients with IBD are warranted.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8314116" target="_blank" rel="noopener"> The Use of Readily Available Longitudinal Data to Predict the Likelihood of Surgery in Crohn Disease.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s Using machine learning methods that incorporate current and historical data can predict the future risk of CD surgery.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8376130" target="_blank" rel="noopener"> Ileocolonic Healing After Extended Small Bowel Resection in Mice: NOD2 Deficiency Impairs Anastomotic Healing and Postoperative Outcome.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s We found that Nod2 deficiency results in significantly reduced bursting pressure after ileocecal resection. This effect is mediated via an increased matrix turnover. Patients with genetic NOD2 variations may be prone to anastomotic failure after bowel resection.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8194672" target="_blank" rel="noopener"> Ensuring High and Equitable COVID-19 Vaccine Uptake Among Patients With IBD.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> They should also strongly recommend that al their patients be vaccinated with a COVID-19 vaccine. Additionally, they should be prepared to educate patients about logistics that will result in successful vaccination completion. All these measures will be crucial to ensure high uptake among their patients with IBD.
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">J Crohns Colitis</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8495488" target="_blank" rel="noopener"> Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study.</a></p>
<span style="text-decoration: underline;">Conclusion:</span>  In this real-world setting, first-line biologic therapy in biologic-naïve patients with UC and CD demonstrated that vedolizumab and anti-TNFα treatments were equally effective at controlling disease symptoms, but vedolizumab has a more favourable safety profile.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8495484" target="_blank" rel="noopener"> Anti-TNF Therapy Before Intestinal Surgery for Crohn&#39;s Disease and the Risks of Postoperative Complications.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8344884" target="_blank" rel="noopener"> Elevated adherence to vaccination against SARS-CoV-2 among patients with Inflammatory Bowel Disease.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8328286" target="_blank" rel="noopener"> Mycobacterium Avium Subspecies Paratuberculosis Infection and Biological Treatment of IBD: Cause or Consequence?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8083188" target="_blank" rel="noopener"> The impact of vedolizumab on COVID-19 outcomes among adult IBD patients in the SECURE-IBD registry.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s COVID-19 outcomes among IBD patients on VDZ are comparable to those on al other therapies. Hospitalization, but not severe COVID-19, is more likely with VDZ monotherapy than with anti-TNF monotherapy. Overall, VDZ appears to be safe in IBD patients with COVID-19.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8328300" target="_blank" rel="noopener"> TREM-1+ Macrophages Define a Pathogenic Cell Subset in the Intestine of Crohn&#39;s Disease Patients.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s High intestinal TREM-1 expression, reflecting a high frequency of TREM-1+ immature macrophages and TREM-1+CD11b+ granulocytes, is linked to the deleterious inflammatory microenvironment in IBD patients. Therefore, blocking the TREM-1 pathway, especially simultaneously with anti-TNF therapy, has potential as a new IBD therapy.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8218706" target="_blank" rel="noopener"> Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s Ontamalimab was well tolerated up to 144 weeks in patients with moderate-to-severe UC, with good safety and efficacy.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8495486" target="_blank" rel="noopener"> &#39;These Discussions Aren&#39;t Happening&#39;: Experiences of People Living with Inflammatory Bowel Disease and Talking About Sexual Well-being with Health Care Professionals.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s Patients&#39; needs and preferences, about addressing during clinical appointments concerns related to their sexual well-being, should be addressed routinely and competently by health care professionals. Understanding the implications of inflammatory bowel disease for intimate aspects of the lives of those living with the condition could improve the quality of the care provided.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8464220" target="_blank" rel="noopener"> Therapeutic Potential of a Self-Assembling Peptide Hydrogel to Treat Colonic Injuries Associated with Inflammatory Bowel Disease.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s SAPH application effectively suppressed colonic injury, downregulated inflammatory cytokine expression, and upregulated wound healing-related factor expression in the rat model; thus, it may represent a promising therapeutic strategy for IBD-related colonic ulcers.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8495487" target="_blank" rel="noopener"> Validation of the &#39;Inflammatory Bowel Disease-Distribution, Chronicity, Activity [IBD-DCA] Score&#39; for Ulcerative Colitis and Crohn´s Disease.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s The IBD-DCA score is a simple histological activity score for UC and CD, agreed and validated by a large group of IBD specialists. It provides reliable information on treatment response. Therefore, it has potential value for use in routine diagnostics as well as clinical studies.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8083263" target="_blank" rel="noopener"> Effectiveness and safety of ustekinumab in ulcerative colitis: Real-world evidence from the ENEIDA registry.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s Ustekinumab is effective both in the short and the long-term in real-life, even in a highly refractory cohort. Higher inflammatory burden at baseline correlated with lower probability of achieving remission. Safety was consistent with the known profile of ustekinumab.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7989537" target="_blank" rel="noopener"> SARS-CoV-2 Vaccination in IBD: Past Lessons, Current Evidence, and Future Challenges.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> We review current evidence on SARS-CoV-2 vaccination relevant to IBD patients, including immune responses from humoral to cellular, emerging data on new variants, and off-label vaccination schemes. We also identify clinical and scientific knowledge gaps that can be translated into both large-scale population-based studies and targeted vaccine studies to describe the precise immune responses induced by SARS-CoV-2 vaccines in IBD patients. We strongly endorse the recommendation of vaccinating IBD patients to ensure maximal protection from COVID-19 both for the individual and the community.
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">J Hepatol</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8302931" target="_blank" rel="noopener"> Prognosis of French COVID-19 patients with chronic liver disease: A national retrospective cohort study for 2020.</a></p>
<span style="text-decoration: underline;">Conclusion:</span>  Chronic liver disease increased the risk of COVID-19-related death in France in 2020. Therapeutic effort limitation may have contributed to COVID-19-related death in French residents with a liver-related complication or an alcohol use disorder.  
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8285256" target="_blank" rel="noopener"> Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy.</a></p>
<span style="text-decoration: underline;">Conclusion:</span>  IL-6 trans-signaling drives the coagulopathy and hepatic endotheliopathy associated with COVID-19 and could be a possible mechanism behind liver injury in these patients.  
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8058047" target="_blank" rel="noopener"> Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients.</a></p>
<span style="text-decoration: underline;">Conclusion:</span>  LT recipients developed substantially lower immunological response to the Pfizer-BioNTech SARS-CoV-2 mRNA-based vaccine. Factors influencing serological antibody responses include age, renal function and immunosuppressive medications. The findings require re-evaluation of vaccine regimens in this population.  
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7867401" target="_blank" rel="noopener"> EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> A small number of these SARS-CoV-2 vaccine candidates have already undergone phase III, placebo-controlled, clinical trials in healthy individuals with proof of short-term safety, immunogenicity and efficacy. However, although regulatory agencies in the US and Europe have already approved some of these vaccines for clinical use, information on immunogenicity, duration of protection and long-term safety in patients with CLD, cirrhosis, hepatobiliary cancer and liver transplant recipients has yet to be generated. This review summarises the data on vaccine safety, immunogenicity, and efficacy in this patient population in general and discusses the implications of this knowledge on the introduction of the new SARS-CoV-2 vaccines.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8310924" target="_blank" rel="noopener"> Single-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD4<sup>+</sup> T cells in primary sclerosing cholangitis.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> Lay summary The composition of intrahepatic immune cells in primary sclerosing cholangitis (PSC) and their contribution to disease pathogenesis is widely unknown. We analysed intrahepatic T cells and identified a previously uncharacterized population of liver-resident CD4 +  T cells which are expanded in the livers of patients with PSC compared to healthy liver tissue and other liver diseases. These cells are likely to contribute to the pathogenesis of PSC and could be targeted in novel therapeutic approaches.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7863751" target="_blank" rel="noopener"> Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8197609" target="_blank" rel="noopener"> Another case of autoimmune hepatitis after SARS-CoV-2 vaccination - still casualty?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8056822" target="_blank" rel="noopener"> Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8219312" target="_blank" rel="noopener"> Autoimmune hepatitis developing after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8404983" target="_blank" rel="noopener"> Autoimmune hepatitis following COVID-19 vaccination: True causality or mere association?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8186938" target="_blank" rel="noopener"> Autoimmune hepatitis following SARS-CoV-2 vaccine: May not be a casuality.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8098030" target="_blank" rel="noopener"> Comment on &quot;Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?&quot;</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8103740" target="_blank" rel="noopener"> HCV detection is possible during SARS CoV-2 testing; and throughout COVID-19 vaccination?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8159704" target="_blank" rel="noopener"> High acceptance rate of COVID-19 vaccination in liver transplant recipients.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7893247" target="_blank" rel="noopener"> Intravenous ketamine and progressive cholangiopathy in COVID-19 patients.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7979603" target="_blank" rel="noopener"> Let&#39;s leverage SARS-CoV2 vaccination to screen for hepatitis C in Spain, in Europe, around the world.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8245674" target="_blank" rel="noopener"> Letter regarding &quot;Association of liver abnormalities with in-hospital mortality in patients with COVID-19&quot;.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7977008" target="_blank" rel="noopener"> Liver injury in COVID-19 - The culprit may not be COVID-19!</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7892314" target="_blank" rel="noopener"> Primary biliary cholangitis associated with SARS-CoV-2 infection.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7977066" target="_blank" rel="noopener"> Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8146269" target="_blank" rel="noopener"> Protected or not protected, that is the question - First data on COVID-19 vaccine responses in patients with NAFLD and liver transplant recipients.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7880835" target="_blank" rel="noopener"> Remaining challenges in HCV elimination.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8056821" target="_blank" rel="noopener"> Reply to: &quot;Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients&quot;.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8272678" target="_blank" rel="noopener"> Reply to: &quot;Comment on &quot;Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?&quot;&quot;.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8223115" target="_blank" rel="noopener"> Reply to: &quot;Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered&quot;.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8180345" target="_blank" rel="noopener"> Reply to: Comments on &quot;Association of liver abnormalities with in-hospital mortality in patients with COVID-19&quot;.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8064900" target="_blank" rel="noopener"> Risk stratification in hospitalized COVID-19 patients.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8264276" target="_blank" rel="noopener"> The mRNA COVID-19 vaccine - A rare trigger of autoimmune hepatitis?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8214165" target="_blank" rel="noopener"> Hypoxia inducible factors regulate hepatitis B virus replication by activating the basal core promoter.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s Identifying a role for this conserved oxygen sensor in regulating HBV transcription suggests that this virus has evolved to exploit the HIF signaling pathway to persist in the low oxygen environment of the liver. Our studies show the importance of considering oxygen availability when studying HBV-host interactions and provide innovative routes to better understand and target chronic HBV infection.  
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8185617" target="_blank" rel="noopener"> Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s The inactivated COVID-19 vaccine appears to be safe with good immunogenicity in patients with NAFLD.  
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8310923" target="_blank" rel="noopener"> Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> While many endemic subtypes respond well to direct-acting antiviral therapies, others, for example genotypes 1l, 3b and 4r, do not respond as well as predicted. Many genotypes that are rare in high-income countries but common in other parts of the world have not yet been fully assessed in clinical trials. Further sequencing and clinical studies in sub-Saharan Africa and Asia are indicated to monitor response to treatment and to facilitate the World Health Organization&#39;s 2030 elimination strategy.
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">J Neurogastroenterol Motil</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8266501" target="_blank" rel="noopener"> Gastric Emptying Time and Volume of the Small Intestine as Objective Markers in Patients With Symptoms of Diabetic Enteropathy.</a></p>
<span style="text-decoration: underline;">Conclusion:</span>  In our study, gastric emptying time and volume of the small intestinal wall appeared to be the best objective measures in patients with DM type 1 and symptoms and gastroenteropathy.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8026365" target="_blank" rel="noopener"> Impaired Colonic Contractility and Intestinal Permeability in Symptomatic Uncomplicated Diverticular Disease.</a></p>
<span style="text-decoration: underline;">Conclusion:</span>  It could be hypothesized that in SUDD, in absence of severe inflammation, an increased intestinal mucosal permeability is related to altered colonic motility probably responsible for symptoms genesis.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8266494" target="_blank" rel="noopener"> Bile Reflux Gastropathy and Functional Dyspepsia.</a></p>
<span style="text-decoration: underline;">Conclusion:</span>  s Bile reflux gastropathy is associated with functional dyspepsia and causes more severe symptoms. Cholecystectomy predisposes to BG and abnormal pain, and could contribute to the pathogenesis of functional dyspepsia.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8266495" target="_blank" rel="noopener"> Evaluations of Gastric Acid Pocket Using Novel Vertical 8-Channel pH Monitoring System and Effects of Acid Secretion Inhibitors.</a></p>
<span style="text-decoration: underline;">Conclusion:</span>  s Gastric acid pocket observations were possible using our novel vertical 8-channel sensor catheter. The present findings showed that vonoprazan strongly suppressed acid secretion within a short period, suggesting its effectiveness for gastroesophageal reflux disease treatment.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8266506" target="_blank" rel="noopener"> Predictors of Early Readmissions in Hospitalized Patients With Gastroparesis: A Nationwide Analysis.</a></p>
<span style="text-decoration: underline;">Conclusion:</span>  s One in 5 patients was readmitted with gastroparesis within 30 days. In the diabetic group, diabetes-related complications contributed to readmissions than gastroparesis. Pyloroplasty is associated with reduced early hospital readmission. Prospective studies are needed for validation of these results.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8266493" target="_blank" rel="noopener"> Rectosigmoid Localization of Radiopaque Markers for Identifying Defecation Disorders in Patients With Chronic Constipation: A Retrospective Cohort Study.</a></p>
<span style="text-decoration: underline;">Conclusion:</span>  s Rectosigmoid accumulation of markers can differentiate DD from slow transit constipation. However, non-rectosigmoid accumulation does not exclude the presence of DD.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8266492" target="_blank" rel="noopener"> Inter-hemispheric Functional Connections Are More Vulnerable to Attack Than Structural Connection in Patients With Irritable Bowel Syndrome.</a></p>
<span style="text-decoration: underline;">Conclusion:</span>  s The functional connections between cerebral hemispheres were more susceptible to IBS than anatomical connections, and brain structure is relatively stable. Besides, the brain areas affected by IBS were concentrated in default mode network and sensorimotor network.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8266497" target="_blank" rel="noopener"> The Reflux Symptoms Before and After Peroral Endoscopic Myotomy of Chinese Patients With Achalasia.</a></p>
<span style="text-decoration: underline;">Conclusion:</span>  s The reflux symptoms of achalasia patients without treatment were mainly due to food retention. The postoperative reflux symptoms were not the sign of the excessive relaxation of lower esophageal sphincter.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8026373" target="_blank" rel="noopener"> Impact of serotonin transporter gene polymorphism on gut motility in patients with type 2 Diabetes mellitus.</a></p>
<span style="text-decoration: underline;">Conclusion:</span>  SS genotypes are prone to develop diarrhea because of faster gut motility resulting from higher serotonin levels as compared to LS and LL genotype in T2DM patients.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8266502" target="_blank" rel="noopener"> The Usefulness of Symptom-based Subtypes of Functional Dyspepsia for Predicting Underlying Pathophysiologic Mechanisms and Choosing Appropriate Therapeutic Agents.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> Although several classic pathophysiologic mechanisms are suggested to be associated with individual dyspeptic symptoms, symptom-based subtypes of FD are not specific for a certain pathogenetic factor or pathophysiologic mechanism, and may be frequently associated with multiple pathophysiologic abnormalities. Novel concepts on the pathophysiology of FD show complex interactions between pathophysiologic mechanisms and pathogenetic factors, and prediction of underlying mechanisms of individual patients simply by the symptom pattern or symptom-based subtypes may not be accurate in a considerable proportion of cases. Therefore, subtyping by the Rome criteria appears to have limited value to guide therapeutic strategy, suggesting that the addition of objective parameters or subclassification reflecting physiologic or pathologic tests may be necessary for the targeted therapeutic approaches, particularly when therapeutic agents targeting novel mechanisms are available.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8266496" target="_blank" rel="noopener"> Emergence of Celiac disease and Gluten-related disorders in Asia.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> CeD and NCGS may present with either intestinal or extra-intestinal symptoms, and a proportion of them have overlapping symptoms with irritable bowel syndrome. Hence, many of them are misdiagnosed as having irritable bowel syndrome in clinical practice. In this review, we discuss the emergence of CeD and other gluten-related disorders, both globally and in Asia, the overlapping manifestations between gluten-related disorders and irritable bowel syndrome, and the challenges associated with diagnosis and management of CeD in Asia.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8266488" target="_blank" rel="noopener"> Roles of Sex Hormones and Gender in the Gut Microbiota.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> In this review, we summarize sex- and gender-differences in gut microbiota and the interplay of microbiota and GI diseases, focusing on sex hormones. We also describe the metabolic role of the microbiota in this regard. Finally, current subjects, such as medication including probiotics, are briefly discussed.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8266498" target="_blank" rel="noopener"> A Novel Cohesinopathy Causing Chronic Intestinal Pseudo Obstruction in 2 Siblings and Literature Review.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8266503" target="_blank" rel="noopener"> Analysis of Whole Gut Motility for the Evaluation of Diabetic Gastroenteropathy: Still the Road Untraveled?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8026369" target="_blank" rel="noopener"> Integrated Relaxation Pressure During Swallowing: An Ever-changing Metric.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8266500" target="_blank" rel="noopener"> Is There a Role for Radiopaque Markers in Identifying Defecation Disorders?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8266505" target="_blank" rel="noopener"> Metastatic Intrahepatic Cholangiocarcinoma Presenting as an Achalasia-like Syndrome.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8266489" target="_blank" rel="noopener"> Role of Bile Reflux in Functional Dyspepsia: Areas That Need Further Research.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8026371" target="_blank" rel="noopener"> There Is Something More Important Than Proximal Reflux Episode in the Development of Post-reflux Swallow-induced Peristaltic Wave.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8026375" target="_blank" rel="noopener"> Transient Receptor Potential Canonical 4 Channel in Interstitial Cells of Cajal as a Target for Control of Gastrointestinal Motility.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8026372" target="_blank" rel="noopener"> What Is the Difference in Characteristics Between Belching Disorder and Gastroesophageal Reflux Disease With Belching? Centering Around Supragastric Belching.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8266504" target="_blank" rel="noopener"> Upright Integrated Relaxation Pressure Predicts Symptom Outcome for Esophagogastric Junction Outflow Obstruction.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> Only 2.9% of these patients had persistent dysphagia. A total of 81.8% of EGJOO patients had symptom resolution during follow-up. Patients with persistent dysphagia had significantly higher upright IRP (16.6 [10.3, 19.8] vs 7.8 [3.2, 11.5];   9.05 mmHg) needs further evaluation and aggressive management.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8026366" target="_blank" rel="noopener"> Colonic Gene Expression and Fecal Microbiota in Diarrhea-predominant Irritable Bowel Syndrome: Increased Toll-like Receptor 4 but Minimal Inflammation and no Response to Mesalazine.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s Biopsies from a well-characterized IBS-D cohort showed no substantial inflammation. Mesalazine has little effect on gene expression and its previous reported effect on fecal microbiota associated with much greater inflammation found in inflammatory bowel diseases is likely secondary to reduced inflammation. Increased expression of TLR4 and correlated receptors in IBS may mediate a general increase in sensitivity to external stimuli, particularly those that signal via the TLR system.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8026378" target="_blank" rel="noopener"> A Systematic Review and Meta-analysis of Randomized Control Trials: Combination Treatment With Proton Pump Inhibitor Plus Prokinetic for Gastroesophageal Reflux Disease.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s Combination of prokinetics with PPI treatment is more effective than PPI alone in GERD patients. Further high-quality trials with large sample sizes are needed to verify the effects based on prokinetic type.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8026363" target="_blank" rel="noopener"> A Resting-state Functional Magnetic Resonance Imaging Study of Whole-brain Functional Connectivity of Voxel Levels in Patients With Irritable Bowel Syndrome With Depressive Symptoms.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s DEP-IBS patients have abnormal FC in brain regions associated with the fronto-limbic and sensorimotor networks, especially insula and SMA, which explains the vicious circle between negative emotion and gastrointestinal symptoms in IBS. Identification of such alterations may facilitate earlier and more accurate diagnosis of depression in IBS, and development of effective treatment strategies.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8026381" target="_blank" rel="noopener"> High-fat Diet Enhances Gastric Contractility, but Abolishes Nesfatin-1-induced Inhibition of Gastric Emptying.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s HFD caused mild systemic inflammation, disrupted enteric innervation, enhanced gastric contractility, inhibited ileal contractility, and eliminated inhibitory effect of NES-1 on gastric motility.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8026380" target="_blank" rel="noopener"> Efficacy of S-pantoprazole 10 mg in the Symptom Control of Non-erosive Reflux Disease: A Phase III Placebo-controlled Trial.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s Low dose of S-pantoprazole (10 mg) for 4 weeks was more efficacious than placebo in providing reflux symptom relief in patients with NERD, especially acid regurgitation. More doses or longer periods of treatment with S-pantoprazole would be needed to completely eliminate symptoms.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8266507" target="_blank" rel="noopener"> Normal Values of High-resolution Manometry Parameters With Provocative Maneuvers.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s Normal values and findings from a comprehensive HRM testing protocol are reported based on evaluation of 30 healthy asymptomatic volunteers. Isolated &quot;abnormalities&quot; of IRP and contractile parameters were observed in the majority (80%) of these asymptomatic subjects, while al subjects also had normal features observed. Thus, the definition of &quot;normal&quot; should be recalibrated to focus on the entirety of the study and not individual metrics.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8026379" target="_blank" rel="noopener"> Simultaneous Evaluation of Laryngopharyngeal Reflux and Swallowing Function Using Hypopharyngeal Multichannel Intraluminal Impedance Measurements in Neurologically Impaired Patients.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s This study demonstrated the usefulness of HMII-pH monitoring in identifying NIP with pathological LPR. Considering the difficulties in performing examinations in NIPs, HMII-pH monitoring may be a potentially useful technique for the simultaneous evaluation of swallowing dysfunction, LPR, and GERD in NIP.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8266491" target="_blank" rel="noopener"> Variations in Clinical Practice of Esophageal High-resolution Manometry: A Nationwide Survey.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s We found a variation in the available HRM practice among centers, even though they broadly agreed in the data analysis. Efforts are needed to develop a standardized protocol for HRM measurement.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8026374" target="_blank" rel="noopener"> Inflammation and Overlap of Irritable Bowel Syndrome and Functional Dyspepsia.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> The pathogenesis of IBS or FD is complicated and multi-factors related, in which infectious or non-infectious inflammation and local or systemic immune response play significant roles. There are few studies focusing on the mechanism of inflammation in patients with overlap syndrome of irritable bowel syndrome and functional dyspepsia (IBS-FD). This review focuses on current advances about the role of inflammation in the pathogenesis of IBS and FD and the possible mechanism of inflammation in IBS-FD.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8026382" target="_blank" rel="noopener"> Impact of Overlapping Functional Gastrointestinal Disorders on the Quality of Life in Patients With Gastroesophageal Reflux Disease.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> The risk factors for subjects experiencing an overlap in FGIDs and GERD involve those who are female, younger age, cigarette smoking, non-erosive reflux disease, more GERD symptoms, and psychological performances including anxiety, somatization, and more frequent healthcareseeking behavior. The overlap of GERD and FGIDs is associated with a worsening of both physical and mental health, an increase in bothersome symptoms, impaired functional capacity, and a higher likelihood of consulting a physician. Acid secretion suppressors could offer therapeutic efficacy to some patients experiencing overlapping GERD and FGIDs.
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Neurogastroenterol Motil</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8365708" target="_blank" rel="noopener"> Quercetin relaxes human gastric smooth muscles directly through ATP-sensitive potassium channels and not depending on the nitric oxide pathway.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> Key results Quercetin induced noticeable, dose-dependent relaxation of the carbachol treated gastric strips. The substantial effect was noted at concentrations higher than 10 -7   mol/L and maximal at 10 -4   mol/L (81.82 ± 3.32%; n = 10; p   channels and independently to NO pathways. The present results suggest that quercetin is a potential nutraceutical in the treatment of functional gastrointestinal dyspepsia and other minor gastric muscle motility disturbance.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7995160" target="_blank" rel="noopener"> Implications of SARS-CoV-2 infection for neurogastroenterology.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> Liver and pancreas dysfunctions have also been described as non-respiratory complications of COVID-19 and add further emphasis to the common view of SARS-CoV-2 infection as a systemic disease with multiorgan involvement. Purpose The aim of this review was to highlight the current knowledge on the pathophysiology of gastrointestinal SARS-CoV-2 infection, including the crosstalk with the gut microbiota, the fecal-oral route of virus transmission, and the potential interaction of the virus with the enteric nervous system. We also review the current available data on gastrointestinal and liver manifestations, management, and outcomes of patients with COVID-19.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8188259" target="_blank" rel="noopener"> Response to &quot;retrograde slow wave activation: A missing link in gastric dysfunction?&quot;</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8420200" target="_blank" rel="noopener"> Response to Oliviero et al.&#39;s publication: &quot;Impact of COVID-19 lockdown on symptoms in patients with functional gastrointestinal disorders: Relationship with anxiety and perceived stress&quot;.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7995091" target="_blank" rel="noopener"> Impact of COVID-19 lockdown on symptoms in patients with functional gastrointestinal disorders: Relationship with anxiety and perceived stress.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s  During the COVID-19 quarantine, there was an improvement of the majority of upper gastrointestinal symptoms in our patients, and anxiety seems an important risk of worsening few of them.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8209890" target="_blank" rel="noopener"> Functional gastrointestinal and somatoform symptoms five months after SARS-CoV-2 infection: A controlled cohort study.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s  Mild gastroenterological symptoms persist 5 months after SARS-CoV-2 infection, in particular in patients reporting diarrhea in the acute phase. Infected patients are at increased risk of chronic fatigue and somatoform disorders, thus supporting the hypothesis that both functional gastrointestinal and somatoform disorders may have a common biological origin.
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8420452" target="_blank" rel="noopener"> COVID-19-related personal product shortages are associated with psychological distress in people living with gastrointestinal disorders: A cross-sectional survey.</a></p>
<span style="text-decoration: underline;">Conclusion:</span> s  The study documented a significant relationship between product shortages and psychological distress, which were associated with COVID-19 prevalence and fear. Strategies addressing COVID-19 fear could potentially modify the relationship between shortages and distress.
</div></td></tr>
  </tbody>
  
  
</table>
</div>
</div>
<div id="studies" class="section level3">
<h3>Studies</h3>
<p><em>RCT, clinical trials, retrospective studies, etc…</em></p>
<div id="vpoaphnskv" style="overflow-x:auto;overflow-y:auto;width:auto;height:auto;">
<style>html {
  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;
}

#vpoaphnskv .gt_table {
  display: table;
  border-collapse: collapse;
  margin-left: auto;
  margin-right: auto;
  color: #333333;
  font-size: 16px;
  font-weight: normal;
  font-style: normal;
  background-color: #FFFFFF;
  width: auto;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #A8A8A8;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #A8A8A8;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
}

#vpoaphnskv .gt_heading {
  background-color: #FFFFFF;
  text-align: center;
  border-bottom-color: #FFFFFF;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
}

#vpoaphnskv .gt_title {
  color: #333333;
  font-size: 125%;
  font-weight: initial;
  padding-top: 4px;
  padding-bottom: 4px;
  border-bottom-color: #FFFFFF;
  border-bottom-width: 0;
}

#vpoaphnskv .gt_subtitle {
  color: #333333;
  font-size: 85%;
  font-weight: initial;
  padding-top: 0;
  padding-bottom: 6px;
  border-top-color: #FFFFFF;
  border-top-width: 0;
}

#vpoaphnskv .gt_bottom_border {
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#vpoaphnskv .gt_col_headings {
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
}

#vpoaphnskv .gt_col_heading {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: normal;
  text-transform: inherit;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: bottom;
  padding-top: 5px;
  padding-bottom: 6px;
  padding-left: 5px;
  padding-right: 5px;
  overflow-x: hidden;
}

#vpoaphnskv .gt_column_spanner_outer {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: normal;
  text-transform: inherit;
  padding-top: 0;
  padding-bottom: 0;
  padding-left: 4px;
  padding-right: 4px;
}

#vpoaphnskv .gt_column_spanner_outer:first-child {
  padding-left: 0;
}

#vpoaphnskv .gt_column_spanner_outer:last-child {
  padding-right: 0;
}

#vpoaphnskv .gt_column_spanner {
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  vertical-align: bottom;
  padding-top: 5px;
  padding-bottom: 5px;
  overflow-x: hidden;
  display: inline-block;
  width: 100%;
}

#vpoaphnskv .gt_group_heading {
  padding: 8px;
  color: #FFFFFF;
  background-color: #0000FF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: middle;
}

#vpoaphnskv .gt_empty_group_heading {
  padding: 0.5px;
  color: #FFFFFF;
  background-color: #0000FF;
  font-size: 100%;
  font-weight: initial;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  vertical-align: middle;
}

#vpoaphnskv .gt_from_md > :first-child {
  margin-top: 0;
}

#vpoaphnskv .gt_from_md > :last-child {
  margin-bottom: 0;
}

#vpoaphnskv .gt_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  margin: 10px;
  border-top-style: solid;
  border-top-width: 1px;
  border-top-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: middle;
  overflow-x: hidden;
}

#vpoaphnskv .gt_stub {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-right-style: solid;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  padding-left: 12px;
}

#vpoaphnskv .gt_summary_row {
  color: #333333;
  background-color: #FFFFFF;
  text-transform: inherit;
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
}

#vpoaphnskv .gt_first_summary_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
}

#vpoaphnskv .gt_grand_summary_row {
  color: #333333;
  background-color: #FFFFFF;
  text-transform: inherit;
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
}

#vpoaphnskv .gt_first_grand_summary_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-top-style: double;
  border-top-width: 6px;
  border-top-color: #D3D3D3;
}

#vpoaphnskv .gt_striped {
  background-color: rgba(128, 128, 128, 0.05);
}

#vpoaphnskv .gt_table_body {
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#vpoaphnskv .gt_footnotes {
  color: #333333;
  background-color: #FFFFFF;
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
}

#vpoaphnskv .gt_footnote {
  margin: 0px;
  font-size: 90%;
  padding: 4px;
}

#vpoaphnskv .gt_sourcenotes {
  color: #333333;
  background-color: #FFFFFF;
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
}

#vpoaphnskv .gt_sourcenote {
  font-size: 90%;
  padding: 4px;
}

#vpoaphnskv .gt_left {
  text-align: left;
}

#vpoaphnskv .gt_center {
  text-align: center;
}

#vpoaphnskv .gt_right {
  text-align: right;
  font-variant-numeric: tabular-nums;
}

#vpoaphnskv .gt_font_normal {
  font-weight: normal;
}

#vpoaphnskv .gt_font_bold {
  font-weight: bold;
}

#vpoaphnskv .gt_font_italic {
  font-style: italic;
}

#vpoaphnskv .gt_super {
  font-size: 65%;
}

#vpoaphnskv .gt_footnote_marks {
  font-style: italic;
  font-weight: normal;
  font-size: 65%;
}
</style>
<table class="gt_table">
  
  <thead class="gt_col_headings">
    <tr>
      <th class="gt_col_heading gt_columns_bottom_border gt_left" rowspan="1" colspan="1"></th>
    </tr>
  </thead>
  <tbody class="gt_table_body">
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Aliment Pharmacol Ther</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16467" target="_blank" rel="noopener"> A survey of gastroenterologists in the United States on the use of central neuromodulators for treating irritable bowel syndrome.</a></p>
<p>s The majority of US gastroenterologists believe central neuromodulators are important in treating IBS, and 27% believe they are effective in most patients. High prescribers are in academic practice, focus in IBS and perceive central neuromodulators as effective. Education is needed to improve gastroenterologists&#39; prescribing behaviour.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16497" target="_blank" rel="noopener"> An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch.</a></p>
<p>s Switching from one infliximab biosimilar to another had no adverse impact on infliximab trough levels, and clinical and biochemical disease activity, regardless of whether switching for the first or second time.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16469" target="_blank" rel="noopener"> Association of central obesity with hepatocellular carcinoma in patients with chronic hepatitis B receiving antiviral therapy.</a></p>
<p>s Central obesity, evaluated by the waist-to-height ratio, was associated with a twofold increase in HCC risk among CHB patients receiving antiviral treatment, highlighting the important role of abnormal metabolic function in the progression of liver disease.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16447" target="_blank" rel="noopener"> Characterisation of patients with supine nighttime reflux: observations made with prolonged wireless oesophageal pH monitoring.</a></p>
<p>s The majority of patients with nocturnal reflux symptoms had pathological acid exposure in at least one night of the prolonged pH recording. A high night-to-night variability in acid exposure reduces the clinical value and diagnostic yield of pH monitoring limited to 24 hours. Prolonged testing is a more appropriate diagnostic tool for patients with nocturnal reflux symptoms.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16361" target="_blank" rel="noopener"> Clinical outcome after anti-tumour necrosis factor therapy discontinuation in 1000 patients with inflammatory bowel disease: the EVODIS long-term study.</a></p>
<p>s A significant proportion of patients who discontinued the anti-TNF remained in remission. In case of relapse, retreatment with the same anti-TNF was usually effective. Approximately half of the patients who did not respond after retreatment achieved remission with other therapies.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16336" target="_blank" rel="noopener"> Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis.</a></p>
<p>s Triple therapy with UDCA, OCA and fibrates is able to normalise biochemical liver tests and improve pruritus in patients with difficult-to-treat PBC.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16444" target="_blank" rel="noopener"> Comorbidity before and after a diagnosis of inflammatory bowel disease.</a></p>
<p>s Persons with IBD have a higher comorbidity burden than persons without IBD. Optimal care plans for persons with IBD should include an assessment for other comorbidities that include just about every other organ system.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16317" target="_blank" rel="noopener"> Comparative benefit and cost-effectiveness of mailed-out faecal immunochemical tests vs collection at the general practitioner.</a></p>
<p> Including the FIT in the invitation letter is likely a very cost-effective intervention to increase participation in CRC screening. These results for France are also informative for many other countries around the world where FIT needs to be collected at pharmacies or general practitioners.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16448" target="_blank" rel="noopener"> Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and/or anti-TNF: a French nationwide study 2010-2018.</a></p>
<p>s Pregnancies exposed to thiopurines more frequently resulted in stillbirths, preterm births and large for gestational age compared to pregnancies exposed to anti-TNF or unexposed pregnancies. By contrast, pregnancies exposed to anti-TNF monotherapy were not associated with these outcomes.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16377" target="_blank" rel="noopener"> Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn&#39;s disease refractory to anti-tumour necrosis factor therapy.</a></p>
<p> Ustekinumab was more effective to achieve early and long-term effectiveness than vedolizumab in Crohn&#39;s disease patients who previously failed response to anti-TNF agents.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16496" target="_blank" rel="noopener"> Decreased secondary faecal bile acids in children with ulcerative colitis and Clostridioides difficile infection.</a></p>
<p>s Bile acids can distinguish between children with UC based on their prior CDI status. Bile acid profile changes can be explained by gut microbial genes encoding for bile salt hydrolase, 7α-hydroxysteroid dehydrogenase and 7α/β-dehydroxylation. Bile acid profiles may be helpful as biomarkers to identify UC children who have had CDI and may serve as future therapeutic targets.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16353" target="_blank" rel="noopener"> Determinants of IBD-related disability: a cross-sectional survey from the GETAID.</a></p>
<p> Determinants of IBD-related disability include IBD-related factors but also psychological and social factors. This highlights the importance of a multidisciplinary team in the management of patients with IBD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16408" target="_blank" rel="noopener"> Durable virological response and functional cure of chronic hepatitis D after long-term peginterferon therapy.</a></p>
<p>s With further follow-up, an extended course of peginterferon therapy was found to result in sustained clearance of HDV RNA and favourable clinical outcomes in more than half of patients and loss of HBsAg in a third.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16333" target="_blank" rel="noopener"> Early detection of anti-drug antibodies during initiation of anti-tumour necrosis factor therapy predicts treatment discontinuation in inflammatory bowel disease.</a></p>
<p>s The prevalence of antibodies to anti-TNF is high when detected early using a drug-tolerant assay, and their appearance predicts further treatment discontinuation.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16452" target="_blank" rel="noopener"> Effect of point-of-care gastrointestinal ultrasound on decision-making and management in inflammatory bowel disease.</a></p>
<p>s Point-of-care gastrointestinal ultrasound has the potential to enhance the clinical management of inflammatory bowel disease by contributing to clinician decision-making and education of patients regarding their disease.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16315" target="_blank" rel="noopener"> Effectiveness and safety of methotrexate monotherapy in patients with Crohn&#39;s disease refractory to anti-TNF-α: results from the ENEIDA registry.</a></p>
<p>s The benefits observed suggest methotrexate monotherapy could be a valid option in Crohn&#39;s disease patients with previous failure to anti-TNFα.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16404" target="_blank" rel="noopener"> Efficacy of ginger as antiemetic in children with acute gastroenteritis: a randomised controlled trial.</a></p>
<p> Oral administration of ginger is effective and safe at improving vomiting in children with AGE. Trial registration The trial was registered on https //clinicaltrials.gov/ with the identifier NCT02701491.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16381" target="_blank" rel="noopener"> Histological disease activity in patients with microscopic colitis is not related to clinical disease activity or long-term prognosis.</a></p>
<p>s Our data indicate that the evaluated histological parameters were neither markers of disease activity at the time of diagnosis nor predictors of disease course.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16488" target="_blank" rel="noopener"> Internal medicine hospitalisations and liver disease: a comparative disease burden analysis of a multicentre cohort.</a></p>
<p> In Canada&#39;s largest urban centre, liver disease admissions resulted in premature morbidity and mortality with higher resource use compared to common cardio-respiratory conditions. Re-evaluation of approaches to caring for inpatients with liver disease is timely and justified.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16478" target="_blank" rel="noopener"> Limited long-term treatment persistence of first anti-TNF therapy in 538 patients with inflammatory bowel diseases: a 20-year real-world study.</a></p>
<p> Long-term treatment persistence of first anti-TNF therapy was limited in patients with inflammatory bowel diseases, primarily due to treatment failure and side effects.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16324" target="_blank" rel="noopener"> Liver stiffness by magnetic resonance elastography is associated with increased risk of cardiovascular disease in patients with non-alcoholic fatty liver disease.</a></p>
<p> Liver stiffness determined by MRE is an independent predictor for the presence of CAC in patients with NAFLD. Patients with NAFLD and significant fibrosis by MRE should be considered for further cardiovascular risk assessment, regardless of their FRS.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16322" target="_blank" rel="noopener"> Longitudinal follow-up of a novel classification system for irritable bowel syndrome: natural history and prognostic value.</a></p>
<p>s Longitudinal follow-up demonstrated little transition between clusters with respect to psychological burden, and these appeared to predict disease course. Directing treatment according to cluster, including earlier use of psychological therapies, and exploring how this approach influences outcomes in IBS, should be examined.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16454" target="_blank" rel="noopener"> Longitudinal follow-up study: effect of psychological co-morbidity on the prognosis of inflammatory bowel disease.</a></p>
<p>s Individuals with IBD in biochemical remission experienced a worse disease course with increasing psychological co-morbidity at baseline.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16363" target="_blank" rel="noopener"> Medication use and microscopic colitis: a multicentre retrospective cohort study.</a></p>
<p>s NSAID use was associated with MC, while use of PPIs, H2 blockers and oral diabetes medications were inversely related to MC. Our use of a control group with diarrhoea, as opposed to healthy controls, may have contributed to these inverse associations. Future studies of drug-induced microscopic colitis should include control groups with diarrhoea, and not only healthy controls.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16362" target="_blank" rel="noopener"> Menopausal hormone therapies and risk of colorectal cancer: a Swedish matched-cohort study.</a></p>
<p>s MHT use may decrease colorectal adenocarcinoma risk, for both E-MHT and EP-MHT, and especially in past users.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16438" target="_blank" rel="noopener"> Non-steroidal anti-inflammatory drugs, polygenic risk score and colorectal cancer risk.</a></p>
<p>s The regular use of NSAIDs is associated with greatly reduced CRC risk regardless of individual genetic profile. With an equivalent reduction of relative risk across al polygenic risk groups, absolute risk reduction would be expected to be strongest among those with the highest polygenic risk score.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16490" target="_blank" rel="noopener"> Nonselective beta-blockers are associated with a lower risk of hepatocellular carcinoma among cirrhotic patients in the United States.</a></p>
<p>s NSBBs, including carvedilol, were associated with a significantly decreased risk of HCC in patients with cirrhosis when compared with no beta-blocker regardless of complications status. Future randomised-controlled studies comparing the incidence of HCC among NSBBs should elucidate which NSBB would be the best option to prevent HCC in cirrhosis.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16481" target="_blank" rel="noopener"> Novel impedance-pH parameters are associated with proton pump inhibitor response in patients with inconclusive diagnosis of gastro-oesophageal reflux disease according to Lyon Consensus.</a></p>
<p>s The present study highlights the value of MNBI and PSPW index as adjunctive metrics in characterising patients with inconclusive evidence of GERD and identifying those responsive to PPI treatment.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16485" target="_blank" rel="noopener"> One-quarter of chronic hepatitis D patients reach HDV-RNA decline or undetectability during the natural course of the disease.</a></p>
<p>At inclusion, median-HDV-RNA was 5.3 (4.2-6.5) log  decline in HDV-RNA and 20% reached HDV-RNA undetectability during a mean follow-up of 5.6 years. The decline was associated with ALT decrease. These findings have implications for designing new therapies for CHD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16388" target="_blank" rel="noopener"> One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study.</a></p>
<p> Ustekinumab demonstrated efficacy in this paediatric cohort with otherwise treatment-refractory UC. Treatment failure was not due to inadequate drug exposure.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16310" target="_blank" rel="noopener"> Pancolonic endoscopic and histologic evaluation for relapse prediction in patients with ulcerative colitis in clinical remission.</a></p>
<p> Evaluating disease remission by complete colonoscopy is relevant, and the combination of pancolonic endoscopic and histological evaluations may appropriately evaluate mucosal healing.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16382" target="_blank" rel="noopener"> Pretreatment non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI as a predictor of hepatocellular carcinoma development after sustained virologic response in HCV infection.</a></p>
<p>s This study confirmed that the presence of NHHNs before DAA therapy is a strong risk factor for the development of de novo HCC after SVR.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16460" target="_blank" rel="noopener"> Randomised clinical study: acute effects of metformin versus placebo on portal pressure in patients with cirrhosis and portal hypertension.</a></p>
<p>s A single oral metformin dose acutely reduces HVPG in patients with portal hypertension without affecting systemic or liver hemodynamics or inflammatory biomarkers. This offers a promising perspective of a safe and inexpensive treatment option that should be investigated in larger-scale clinical studies with long-term outcomes in patients with cirrhosis and portal hypertension.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16309" target="_blank" rel="noopener"> Randomised clinical trial: a 12-strain bacterial mixture versus faecal microbiota transplantation versus vancomycin for recurrent Clostridioides difficile infections.</a></p>
<p>s Rectal bacteriotherapy appears as effective as vancomycin but less effective than 1-3 FMTs. FMT by enema with 1-3 infusions is superior to vancomycin for treating recurrent C difficile infections and might reduce mortality.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16446" target="_blank" rel="noopener"> Randomised clinical trial: adjunctive induction therapy with oral effervescent budesonide in newly diagnosed coeliac disease.</a></p>
<p>s In this pilot trial, induction therapy with budesonide had no significant effect on mucosal healing in patients with coeliac disease concurrently initiated on a gluten-free diet. Mucosal remission at 8 weeks occurred in approximately one in four patients and was associated with less severe histological lesions at diagnosis.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16477" target="_blank" rel="noopener"> Randomised clinical trial: comparison of tegoprazan and placebo in non-erosive reflux disease.</a></p>
<p>s Tegoprazan 50 and 100 mg showed superior therapeutic efficacy compared with the placebo, as well as a favourable safety profile in patients with NERD. Registration number  ClinicalTrials.gov identifier NCT02556021.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16451" target="_blank" rel="noopener"> Randomised clinical trial: safety, pharmacokinetics and pharmacodynamics of trazpiroben (TAK-906), a dopamine D<sub>2</sub> /D<sub>3</sub> receptor antagonist, in patients with gastroparesis.</a></p>
<p>s Trazpiroben was well tolerated with a favourable safety profile, supporting its further development for the treatment of gastroparesis. ClinicalTrials.gov identifier  NCT03268941.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16304" target="_blank" rel="noopener"> Randomised study: effects of the 5-HT<sub>4</sub> receptor agonist felcisetrag vs placebo on gut transit in patients with gastroparesis.</a></p>
<p> I.V. felcisetrag significantly accelerated gastric, small bowel and colonic transit in patients with gastroparesis, and should be further evaluated for short-term treatment of gastric and intestinal motility disorders. ClinicalTrials.gov #NCT03281577.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16371" target="_blank" rel="noopener"> Response of eosinophilic oesophagitis to proton pump inhibitors is associated with impedance-pH parameters implying anti-reflux mechanism of action.</a></p>
<p> Higher efficacy of oesophago-salivary reflex and more severe mucosal damage in the distal oesophagus are associated with EoE response to PPIs, implying an anti-reflux mechanism of action as most likely.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16457" target="_blank" rel="noopener"> Retrospective review of patients treated for cyclic vomiting syndrome with topiramate.</a></p>
<p>s Topiramate may be an effective second-line prophylaxis for patients with moderate-severe CVS, but its use is limited by side effects. Efforts to develop better-tolerated therapies for CVS are warranted.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16410" target="_blank" rel="noopener"> Risk of severe COVID-19 in patients treated with IBD medications: a French nationwide study.</a></p>
<p>s Immunomodulators and biologics prescribed in patients with IBD do not appear to increase the severity of COVID-19 infection.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16487" target="_blank" rel="noopener"> Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease.</a></p>
<p>s The dual elastography cutoffs of 8 and 12 kPa are more appropriate to identify cACLD in Asian patients with NAFLD. In combination with a simplified risk model in unclassified patients, the two-step approach showed a classification rate of about 85%.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16288" target="_blank" rel="noopener"> Standardisation of intestinal ultrasound scoring in clinical trials for luminal Crohn&#39;s disease.</a></p>
<p>s The panel identified appropriate component items and applications of IUS for CD clinical trials. Empiric evidence, and development and validation of an IUS disease activity index are needed.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16436" target="_blank" rel="noopener"> Superior treatment persistence with ustekinumab in Crohn&#39;s disease and vedolizumab in ulcerative colitis compared with anti-TNF biological agents: real-world registry data from the Persistence Australian National IBD Cohort (PANIC) study.</a></p>
<p> Persistence was highest in ustekinumab in CD and vedolizumab in UC. Factors which increased the persistence of biological agents are first-line therapy, and immunomodulator co-therapy in anti-TNF agent use.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16439" target="_blank" rel="noopener"> The impact of body mass index on efficacy and safety in the tofacitinib OCTAVE ulcerative colitis clinical programme.</a></p>
<p>s Efficacy and safety of tofacitinib were similar in patients with UC regardless of baseline BMI.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16392" target="_blank" rel="noopener"> The impact of genetic risk on liver fibrosis in non-alcoholic fatty liver disease as assessed by magnetic resonance elastography.</a></p>
<p> Knowledge of PNPLA3 and HSD17B13 genotype may assist in the non-invasive risk stratification of NAFLD with closer monitoring recommended for those with high genetic risk.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16463" target="_blank" rel="noopener"> Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort.</a></p>
<p> Tofacitinib appears as a promising option in patients hospitalised with a UC flare but needs further validation in controlled trials.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16358" target="_blank" rel="noopener"> Trends in paediatric inflammatory bowel disease-attributable direct costs: a population-based analysis.</a></p>
<p>s Over two decades, there was a significant increase in the paediatric IBD-attributable direct costs mainly driven by medication costs.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16365" target="_blank" rel="noopener"> Type D personality is associated with depressive symptoms and clinical activity in inflammatory bowel disease.</a></p>
<p>s Type D personality&#39;s prevalence amongst IBD patients was comparable with its prevalence in the general population. Type D was strongly associated with depressive symptoms and showed modest independent associations with IBD prognosis.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16344" target="_blank" rel="noopener"> Velusetrag accelerates gastric emptying in subjects with gastroparesis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 study.</a></p>
<p>s Velusetrag accelerates GE in subjects with diabetic or idiopathic gastroparesis and is generally well tolerated in this population (Clinicaltrials.gov NCT01718938).</p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Am J Gastroenterol</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001285" target="_blank" rel="noopener"> A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis.</a></p>
<p> All prognostic scores developed for PBC (GLOBE, UK-PBC, and MRS) demonstrated comparable discriminating performance for liver transplantation or death as well as good prediction accuracy.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001273" target="_blank" rel="noopener"> A Scoring Model to Predict In-Hospital Mortality in Patients With Budd-Chiari Syndrome.</a></p>
<p> Using a national administrative database, we developed a reliable in-patient mortality prediction model with an excellent accuracy. The model was able to risk stratify patients into low-, intermediate-, and high-risk groups.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001306" target="_blank" rel="noopener"> Abdominal Pain and Depression, Not Bowel Habits, Predict Health Care Utilization in Patients With Functional Bowel Disorders.</a></p>
<p> Severity of abdominal pain and depressive symptoms, but not bowel habits, is a primary driver of increased care-seeking behavior in patients with IBS, FC, and FDr.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001193" target="_blank" rel="noopener"> Accuracy of Screening Tests for Celiac Disease in Asymptomatic Patients With Type 1 Diabetes.</a></p>
<p> Thresholds extrapolated from the general population for the diagnostic evaluation of celiac disease are not suitable for use in asymptomatic T1D patients. Population-specific screening cutoffs are required.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001301" target="_blank" rel="noopener"> Adding Branched-Chain Amino Acids to an Enhanced Standard-of-Care Treatment Improves Muscle Mass of Cirrhotic Patients With Sarcopenia: A Placebo-Controlled Trial.</a></p>
<p> BCAA supplementation improves muscle mass in cirrhotic patients with sarcopenia.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001246" target="_blank" rel="noopener"> Adverse Event Profile During the Treatment of Helicobacter pylori: A Real-World Experience of 22,000 Patients From the European Registry on H. pylori Management (Hp-EuReg).</a></p>
<p> Helicobacter pylori eradication treatment frequently induces AEs, although they are usually mild and of limited duration. Their appearance does not interfere significantly with treatment compliance.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001342" target="_blank" rel="noopener"> Adverse Events After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease.</a></p>
<p> Those with IBD and other immune-mediated inflammatory diseases can be reassured that the AE risk is likely not increased, and may be reduced, while on advanced therapies.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001194" target="_blank" rel="noopener"> Anticoagulation and Transjugular Intrahepatic Portosystemic Shunt for the Management of Portal Vein Thrombosis in Cirrhosis: A Prospective Observational Study.</a></p>
<p> In patients with cirrhosis with PVT, the individualized treatment algorithm achieves a high-probability recanalization, with low rates of portal hypertensive complications and adverse events.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001195" target="_blank" rel="noopener"> Antiviral Therapy Reduces Risk of Cirrhosis in Noncirrhotic HBV Patients Among 4 Urban Safety-Net Health Systems.</a></p>
<p> Our propensity score-matched cohort of noncirrhotic CHB patients demonstrated significant reductions in risk of cirrhosis due to CHB treatment.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001295" target="_blank" rel="noopener"> Association Between Diarrhea Duration and Severity and Probiotic Efficacy in Children With Acute Gastroenteritis.</a></p>
<p> In children 3-48 months with acute gastroenteritis, the lack of effect of probiotics is not explained by the duration of symptoms or frequency of diarrheal episodes before presentation.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001358" target="_blank" rel="noopener"> Benchmarking Adenoma Detection Rates for Colonoscopy: Results From a US-Based Registry.</a></p>
<p> The average ADR from a large national US sample standardized to the US population is 39.05% and has increased over time.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001348" target="_blank" rel="noopener"> Bleeding Risk and Mortality Associated With Uninterrupted Antithrombotic Therapy During Percutaneous Endoscopic Gastrostomy Tube Placement.</a></p>
<p> The risk of significant bleeding associated with the PEG placement was minimal in patients on uninterrupted periprocedural antithrombotic therapy.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001356" target="_blank" rel="noopener"> Cap-Assisted Endoscopic Septotomy of Zenker&#39;s Diverticulum: Early and Long-Term Outcomes.</a></p>
<p> FES is a safe and effective treatment modality for patients with ZD. Recurrence rate is significant; however, endoscopic reintervention is associated with long-term relief of dysphagia.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001275" target="_blank" rel="noopener"> Characteristics and Outcomes of Children With Cystic Fibrosis Hospitalized With Cirrhosis in the United States.</a></p>
<p> Future interventions should be designed to support children with CF who have cirrhosis to improve clinical outcomes.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001347" target="_blank" rel="noopener"> Chemopreventive Effect of Statin on Hepatocellular Carcinoma in Patients With Nonalcoholic Steatohepatitis Cirrhosis.</a></p>
<p> Our findings suggest that patients with NASH and bridging fibrosis have a low risk of HCC. Dose-dependent statin use reduced HCC risk significantly in patients with NASH cirrhosis.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001264" target="_blank" rel="noopener"> Cholangiopathy After Severe COVID-19: Clinical Features and Prognostic Implications.</a></p>
<p> Cholangiopathy is a late complication of severe COVID-19 with the potential for progressive biliary injury and liver failure. Further studies are required to understand pathogenesis, natural history, and therapeutic interventions.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001192" target="_blank" rel="noopener"> Combined Use of Aspirin and Selective Serotonin Reuptake Inhibitors Is Associated With Lower Risk of Colorectal Cancer: A Nested Case-Control Study.</a></p>
<p> This study suggests that the use of aspirin and SSRIs-either as monotherapy or combined-was associated with a reduced risk of CRC. The stronger chemoprevention of combined use of aspirin and SSRIs is innovative and calls for further studies to confirm the underlying mechanisms and the plausibility of clinical recommendation.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001336" target="_blank" rel="noopener"> Comparative Cost Effectiveness of Reflux-Based and Reflux-Independent Strategies for Barrett&#39;s Esophagus Screening.</a></p>
<p> Minimally invasive nonendoscopic tests may make GERD-independent BE screening cost effective. Participation rates for these strategies need to be studied.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001238" target="_blank" rel="noopener"> Confidentiality and Conflicts of Interest: An Assessment of Twitter Posts in Gastrointestinal Endoscopy.</a></p>
<p> GI endoscopy tweets describing clinical cases or procedures may insufficiently address issues of confidentiality and COI.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001270" target="_blank" rel="noopener"> COVID-19 Vaccine Perceptions Among Patients With Chronic Disease in a Large Gastroenterology and Hepatology Practice.</a></p>
<p> Patients have high level of trust in the COVID-19 vaccine and are likely to follow their specialist physician recommendations.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001350" target="_blank" rel="noopener"> Current Challenges in Fecal Microbiota Transplantation for Clostridioides difficile Infection in Children.</a></p>
<p> The US Food and Drug Administration safety alert and COVID-19 pandemic have substantially influenced the availability and access of FMT for children.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001158" target="_blank" rel="noopener"> Decompensation in Direct-Acting Antiviral Cured Hepatitis C Virus Compensated Patients With Clinically Significant Portal Hypertension: Too Rare to Warrant Universal Β-Blocker Therapy.</a></p>
<p>lww. com/AJG/B861). JOURNAL/ajgast/04.03/00000434-202106000-00035/inline-graphic1/v/2021-05-28T144026Z/r/image-tiff.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001164" target="_blank" rel="noopener"> Development and Validation of a Clinical-Genetic Risk Score to Predict Hepatic Encephalopathy in Patients With Liver Cirrhosis.</a></p>
<p> The genetic background influenced overt HE risk and severity. The clinical-genetic HE Risk score, which combined genetic background together with albumin, bilirubin, and previous episodes of overt HE, could be a useful tool to predict overt HE in patients with cirrhosis.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001262" target="_blank" rel="noopener"> Disparate Health Care in Barrett&#39;s Esophagus: The First Step Is Awareness.</a></p>
<p> Abstract Disparities in medical treatment related to differences in race, gender, and creed are present in al fields of practice. This a complex issue requires multiple perspectives to gain advancements in patient care. This editorial examines the recently published article uses the GI Quality Improving Consortium to investigate disparities in adherence to quality indicators in Barrett&#39;s esophagus.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001240" target="_blank" rel="noopener"> Dissemination of Gastroenterology and Hepatology Research on Social Media Platforms Is Associated With Increased Citation Count.</a></p>
<p> Social media attention garnered by GI scholarly work strongly correlates with the number of citations at 5 years.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001191" target="_blank" rel="noopener"> Do Children With Functional Abdominal Pain Benefit More From a Pain-Specific Cognitive-Behavioral Intervention Than From an Unspecific Attention Control Intervention? Results of a Randomized Controlled Trial.</a></p>
<p> Both interventions were effective, which underlines the role of time and attention for treatment efficacy. However, in the longer term, CBT yielded more favorable results.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001256" target="_blank" rel="noopener"> Effect of Diameter and Number of Hepatocellular Carcinomas on Survival After Resection, Transarterial Chemoembolization, and Ablation.</a></p>
<p> Our novel prognostic model performed well in predicting OS after resection and TACE for HCC and demonstrated that resection may have a survival benefit over TACE and ablation based on the diameter and number of HCCs.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001272" target="_blank" rel="noopener"> Effect of Vitamin D Supplementation on Vitamin D Level and Bone Mineral Density in Patients With Cirrhosis: A Randomized Clinical Trial.</a></p>
<p> Supplementation with vitamin D for 1 year improves vitamin D levels but did not result in improvement in BMD at lumbar spine and left hip neck in patients with cirrhosis.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001196" target="_blank" rel="noopener"> Effects of Central Obesity on Esophageal Epithelial Barrier Function.</a></p>
<p> Central obesity impairs structural and functional integrity of the esophageal barrier independent of GER, likely predisposing to esophageal injury.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001225" target="_blank" rel="noopener"> Esophageal Epidermoid Metaplasia: Clinical Characteristics and Risk of Esophageal Squamous Neoplasia.</a></p>
<p> EEM is a premalignant underrecognized condition associated with multiple conditions. Close follow-up or endoscopic treatment may be warranted because of its ESCC association.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001286" target="_blank" rel="noopener"> Esophageal Mucosa Innervation in Children With Nonerosive Reflux Disease.</a></p>
<p> The pediatric esophageal mucosa in NERD displays deep lying nerve fibers, in contrast to adults.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001274" target="_blank" rel="noopener"> Evaluating the Risk of Irreversible Intestinal Necrosis Among Critically Ill Patients With Nonocclusive Mesenteric Ischemia.</a></p>
<p> We propose a new 4-point score aimed at stratifying risk of ITN in patients with NOMI. The Clichy score should be applied to patients with occlusive acute mesenteric ischemia only.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001149" target="_blank" rel="noopener"> Exploratory Comparative Effectiveness Trial of Green Kiwifruit, Psyllium, or Prunes in US Patients With Chronic Constipation.</a></p>
<p> Kiwifruit, prunes, and psyllium improve constipation symptoms in patients with CC. Kiwifruit was associated with the lowest rate of AEs and dissatisfaction with therapy.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001310" target="_blank" rel="noopener"> Exposure to Ranitidine and Risk of Bladder Cancer: A Nested Case-Control Study.</a></p>
<p> In this large population-based study, the use of ranitidine particularly long-term use was associated with an increased risk of bladder cancer. Further studies are necessary to attempt to replicate this finding in other settings.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001147" target="_blank" rel="noopener"> Factors Enhancing Treatment of Hepatitis C Virus-Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience.</a></p>
<p> The performance of DAAs in PWUD is excellent, if 2 conditions are met  (i) that the latest generation drugs are used and (ii) that the patients are managed within the SerDs.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001344" target="_blank" rel="noopener"> Fasting Ketonuria and the Risk of Incident Nonalcoholic Fatty Liver Disease With and Without Liver Fibrosis in Nondiabetic Adults.</a></p>
<p> Ketonuria was associated with a reduced risk of developing incident hepatic steatosis with and without intermediate-to-high probability of advanced fibrosis in a large cohort of nondiabetic healthy individuals. The role of hyperketonemia in the prevention of NAFLD requires further exploration.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001257" target="_blank" rel="noopener"> Hepatic Steatosis and Steatohepatitis in a Large North American Cohort of Adults With Chronic Hepatitis B.</a></p>
<p> Coexisting steatosis occurred in nearly a third of adults (13% had steatohepatitis) with chronic HBV in this North American cohort who underwent liver biopsies. Steatohepatitis was associated with advanced fibrosis and higher biochemical measures of hepatic inflammation over time. Therefore, in addition to viral suppression, screening for and managing metabolic abnormalities is important to prevent disease progression in HBV.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001142" target="_blank" rel="noopener"> Hepatitis Flare During Immunotherapy in Patients With Current or Past Hepatitis B Virus Infection.</a></p>
<p> Hepatitis flare occurs in approximately 40% of HBsAg-positive patients and 30% of HBsAg-negative patients during immunotherapy. HBV reactivation, HBsAg seroclearance, and HBsAg seroreversion are rare. Current or past HBV infection has no impact on the emergence of hepatic flare associated with immunotherapy.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001318" target="_blank" rel="noopener"> Identifying Gender Barriers for Colorectal Cancer Screening and Assessing the Need for a Multigender Endoscopy Team: A Prospective Multicenter Study.</a></p>
<p> Contrary to previous studies, most patients did not have an endoscopist gender preference. Interestingly, men had more same-gender endoscopist preference, whereas women had more same-gender endoscopy team member preference. Age-related and regional differences exist among patients&#39; gender preferences for their endoscopist and endoscopy team member, and addressing these preferences while creating an environment of a multigender endoscopy team may be beneficial in improving colorectal cancer screening.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001247" target="_blank" rel="noopener"> Impact of Psychological Comorbidity on the Prognosis of Irritable Bowel Syndrome.</a></p>
<p> The prognosis of individuals with Rome IV-defined IBS worsens according to incremental increases in psychological comorbidity. This has important clinical and research implications.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001311" target="_blank" rel="noopener"> Increased ACE2 Levels and Mortality Risk of Patients With COVID-19 on Proton Pump Inhibitor Therapy.</a></p>
<p> COVID-negative PPI users had higher salivary ACE2 expression. PPI use was associated with increased mortality risk in patients with COVID-19, particularly African Americans.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001201" target="_blank" rel="noopener"> Influence of Sedation on the Detection Rate of Early Cancer and Precancerous Lesions During Diagnostic Upper Gastrointestinal Endoscopies: A Multicenter Retrospective Study.</a></p>
<p> Sedation may improve the endoscopic detection rate of EC and HGIN in the UGI tract probably through enhancing the use of accessary endoscopic techniques, prolonging observation time, and taking more biopsies in different locations (see Visual Abstract, Supplementary Digital Content 2, http //links.lww.com/AJG/B926).</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001271" target="_blank" rel="noopener"> Initial Evaluation, Long-Term Monitoring, and Hepatocellular Carcinoma Surveillance of Chronic Hepatitis B in Routine Practice: A Nationwide US Study.</a></p>
<p> In this large cohort of patients with CHB infection with private insurance or Medicare with private insurance supplement, we observed poor adherence to the recommended initial evaluation and long-term monitoring. Among the predictors of adherence were specialist visits. Further efforts are needed to identify barriers and improve access to care.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001203" target="_blank" rel="noopener"> Integrative Effects and Vagal Mechanisms of Transcutaneous Electrical Acustimulation on Gastroesophageal Motility in Patients With Gastroesophageal Reflux Disease.</a></p>
<p> The TEA treatment performed in this study improves reflux-related symptoms, increases DCI, reduces the incidence of ineffective esophageal contractions during wet swallows, and improves gastric accommodation and slow waves. The improvement in GERD symptoms might be attributed to the integrative effects of TEA on these gastroesophageal functions mediated via the vagal mechanism.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001346" target="_blank" rel="noopener"> Liver-Unrelated Comorbid Conditions Do Not Affect Cognitive Performance or Hepatic Encephalopathy Progression in Cirrhosis.</a></p>
<p> Demographics, cirrhosis characteristics, and opioid use, but not other comorbid conditions, were associated with CHE diagnosis and OHE progression.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001228" target="_blank" rel="noopener"> Medication Treatment of Active Opioid Use Disorder in Veterans With Cirrhosis.</a></p>
<p> Few Veterans with active OUD and cirrhosis received MOUD, and those with alcohol use disorder, schizophrenia, and previous prescriptions for opioids were least likely to receive these effective therapies.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001326" target="_blank" rel="noopener"> Mortality in Patients With Genetic and Environmental Risk of Liver Disease.</a></p>
<p> Our data demonstrate an interplay between genetics and environment and provide a basis for hepatic surveillance programs.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001221" target="_blank" rel="noopener"> Novel Negative Pressure Protective Box in Upper Digestive Endoscopy: A Prospective Case Series.</a></p>
<p>All endoscopic procedures were successful without premature removal of TRACEY. In addition, its use did not lead to significant patient discomfort, technical hinderance, or adverse events. TRACEY seems to offer a safe and easy to use aerosol protection for upper endoscopy and a potential Severe Acute Respiratory Syndrome Coronavirus 2 mitigation strategy in endoscopy.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001343" target="_blank" rel="noopener"> Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study.</a></p>
<p> Second-line therapy with OCA or fibrates improves hepatic biochemistry and the GLOBE score in primary biliary cholangitis patients with suboptimal response to ursodeoxycholic acid. Simultaneous treatment with OCA and fibrates improved ALP as well.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001357" target="_blank" rel="noopener"> Outcomes After TIPS for Ascites and Variceal Bleeding in a Contemporary Era-An ALTA Group Study.</a></p>
<p> MELD-Na has differing relationships with patient outcomes dependent on TIPS indication. These data provide new insights into contemporary predictors of outcomes after TIPS.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001157" target="_blank" rel="noopener"> Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir.</a></p>
<p> After an average of 6 years on ETV, CVS increased from 91.9% at TAF switch to 97.2% at 96 weeks later.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001366" target="_blank" rel="noopener"> Pain Experience in Pancreatitis: Strong Association of Genetic Risk Loci for Anxiety and PTSD in Patients With Severe, Constant, and Constant-Severe Pain.</a></p>
<p> A component of constant and severe pain in patients with RAP and CP is associated with genetic predisposition to anxiety and PTSD. Identification of patients at risk eligible for trials of targeted treatment as a component of a multidisciplinary pain management strategy should be formally evaluated.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001237" target="_blank" rel="noopener"> Persistently High Rate of Venous Thromboembolic Disease in Inflammatory Bowel Disease: A Population-Based Study.</a></p>
<p> Despite advancements in IBD management in the past 30 years, the rates of VTE have only been slowly decreasing and remain significantly increased compared with controls.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001176" target="_blank" rel="noopener"> Poor Outcomes of Cirrhosis due to Nonalcoholic Steatohepatitis Compared With Hepatitis B After Decompensation With Ascites.</a></p>
<p> Patients with decompensated cirrhosis due to NASH had much poorer prognosis compared with HBV with more complications and greater healthcare resource utilization. Greater awareness is necessary for early diagnosis of NASH before decompensation.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001355" target="_blank" rel="noopener"> Population Attributable Risks of Subtypes of Esophageal and Gastric Cancers in the United States.</a></p>
<p> These factors accounted for a large proportion of esophageal and gastric cancers in the United States, highlighting opportunities for education and intervention to reduce the burden of these highly fatal cancers.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001309" target="_blank" rel="noopener"> Potent Acid Suppression With Vonoprazan vs Proton Pump Inhibitors Does Not Have Higher Association With Clostridioides difficile Infection.</a></p>
<p> We found a significant positive association between vonoprazan use and CDI; however, the magnitude of the association was not beyond that in PPI users. This is the first report on any potential adverse effects of vonoprazan.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001349" target="_blank" rel="noopener"> Potential Bias and Misconceptions in Liver Transplantation for Alcohol- and Obesity-Related Liver Disease.</a></p>
<p> There seems to be current bias and misconceptions regarding LT for patients with ALD and OLD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001219" target="_blank" rel="noopener"> Prediction of Hepatocellular Carcinoma by On-Therapy Response of Noninvasive Fibrosis Markers in Chronic Hepatitis B.</a></p>
<p> On-therapy changes in NFM are an independent indicator of HCC risk. FSAC incorporating NFM response is a reliable risk score for risk estimation for HCC with better performance than other models.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001299" target="_blank" rel="noopener"> Probiotics: To Use or Not to Use? That Is the Question.</a></p>
<p>reuteri DSM 17938 finding that this probiotic reduced the duration of diarrhea and hospitalization, to discuss the issue that the effect of probiotics is strain specific. In addition, the different findings of reviews and meta-analyses of probiotics in Irritable Bowel Syndrome in which a common conclusion of al of them was that adequately powered randomized controlled trials are required to better determine the species, strains and doses of probiotics, as well as the treatment duration that is most efficacious. Finally, the fact that probiotics are frequently prescribed despite lacking regulations by pharmaceutical authorities is addressed.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001261" target="_blank" rel="noopener"> Progress in Corticosteroid Use in the Era of Biologics With Room for Improvement.</a></p>
<p>Steroid-free remission has become a major treatment goal. Prolonged corticosteroid use is currently a sign of suboptimal quality of care. Trends over the past 2 decades, spanning the emergence of biologic therapies for IBD, are explored here in the University of Manitoba IBD Epidemiologic Database.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001230" target="_blank" rel="noopener"> Racial Disparities in Adherence to Quality Indicators in Barrett&#39;s Esophagus: An Analysis Using the GIQuIC National Benchmarking Registry.</a></p>
<p> The use of sex as a risk factor for BE screening may be inappropriate among blacks. Fewer blacks were recommended appropriate surveillance intervals, and blacks with longer segment BE were less likely to undergo Seattle biopsy protocol.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001229" target="_blank" rel="noopener"> Red Meat Consumption and Risk of Nonalcoholic Fatty Liver Disease in a Population With Low Meat Consumption: The Golestan Cohort Study.</a></p>
<p> In this population with low consumption of red meat, individuals in the highest group of red meat intake were at increased odds of NAFLD. Furthermore, this is the first study to show an association between organ meat consumption and NAFLD (see Visual Abstract, http //links.lww.com/AJG/B944).</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001323" target="_blank" rel="noopener"> Surveillance Cessation for Barrett&#39;s Esophagus: A Survey of Gastroenterologists.</a></p>
<p> Age and comorbidities seem to influence BE surveillance cessation decisions, but with variation. Clear cessation guidelines balancing the risks and benefits for BE surveillance are warranted.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001341" target="_blank" rel="noopener"> Survey Finds Gender Disparities Impact Both Women Mentors and Mentees in Gastroenterology.</a></p>
<p> Inequities exist in the experiences of women mentees and mentors in gastroenterology, which may affect career advancement and job satisfaction.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001313" target="_blank" rel="noopener"> Tegaserod for Irritable Bowel Syndrome With Constipation in Women Younger Than 65 Years Without Cardiovascular Disease: Pooled Analyses of 4 Controlled Trials.</a></p>
<p> Tegaserod 6 mg b.i.d. reduced IBS-C symptoms in overall and US Food and Drug Administration-indicated populations (women aged &lt;65 years with no history of cardiovascular ischemic events).</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001202" target="_blank" rel="noopener"> The Perils and Pitfalls of Esophageal Dysmotility in Idiopathic Pulmonary Fibrosis.</a></p>
<p> We have shown that pulmonary function is worse in patients with IEM which is associated with more proximal reflux events, the latter correlating with lower intrathoracic pressures and higher LESPs.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001212" target="_blank" rel="noopener"> The Three Villages of Hepatic Encephalopathy.</a></p>
<p>The second village consists of those affected by HE-related consequences, including the patient, caregivers, society, and medical system. The third village required to manage HE includes a multidisciplinary team of inpatient and outpatient providers, mental health experts, physical therapists, and dietary specialists. Understanding and integration of these three villages can encourage individualized care for patients and families affected by hepatic encephalopathy.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001320" target="_blank" rel="noopener"> Tip-in Endoscopic Mucosal Resection for 15- to 25-mm Colorectal Adenomas: A Single-Center, Randomized Controlled Trial (STAR Trial).</a></p>
<p> In this single-center randomized controlled trial, we found that Tip-in EMR significantly improved the en bloc resection rate for nonpolypoid lesions 15-25 mm in size, with no increase in adverse events or procedure time.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001220" target="_blank" rel="noopener"> Trends in Corticosteroid Use During the Era of Biologic Therapy: A Population-Based Analysis.</a></p>
<p> Corticosteroid use has decreased in both CD and UC over the past 2 decades, becoming more pronounced after 2007 in CD. Potential explanations include introduction and increasing penetrance of biologic therapy in CD and greater awareness of corticosteroid-related adverse events in IBD. Further work is required understand the drivers of persistent corticosteroid use in IBD and how this can be further reduced.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001292" target="_blank" rel="noopener"> Trends in the Economic Burden of Chronic Liver Diseases and Cirrhosis in the United States: 1996-2016.</a></p>
<p> Healthcare expenditures for CLDs or cirrhosis are substantial in the United States, driven disproportionately by acute care in-hospital spending.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001239" target="_blank" rel="noopener"> Unreliable Estimation of Fibrosis Regression During Treatment by Liver Stiffness Measurement in Patients With Chronic Hepatitis B.</a></p>
<p> Changes in LSM are unreliable to estimate regression of fibrosis during treatment; the established cutoff value of on-treatment LSM can optimize monitoring strategy for histological outcomes in patients with chronic hepatitis B.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001280" target="_blank" rel="noopener"> Ursodeoxycholic Acid Response Is Associated With Reduced Mortality in Primary Biliary Cholangitis With Compensated Cirrhosis.</a></p>
<p> UDCA response is associated with a reduction in decompensation, all-cause, and liver-related death or transplantation in a cohort of predominantly male patients with cirrhosis, with the highest benefit in patients with portal hypertension.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001167" target="_blank" rel="noopener"> Use of Proton Pump Inhibitors vs Histamine 2 Receptor Antagonists for the Risk of Gastric Cancer: Population-Based Cohort Study.</a></p>
<p> In this large study, long-term treatment with PPIs vs H2RAs did not show higher risk of gastric cancer even in a high-risk region.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001170" target="_blank" rel="noopener"> Variability in Practices of Compounding Budesonide for Eosinophilic Esophagitis.</a></p>
<p> Although few compounding pharmacies offer budesonide suspension and there are substantial variations in formulations, this may be a significantly more affordable treatment option for many.</p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Clin Gastroenterol Hepatol</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.03.019" target="_blank" rel="noopener"> A Blood-Based Prognostic Liver Secretome Signature Predicts Long-term Risk of Hepatic Decompensation in Cirrhosis.</a></p>
<p>Besides, risk stratification of patients with cirrhosis could help inform patient selection for trials evaluating therapies to prevent hepatic decompensation. Although various clinical scores, such as the albumin-bilirubin (ALBI) and fibrosis-4 (FIB-4) indices (ALBI-FIB4 score) have been proposed to predict long-term risk of hepatic decompensation, 3  external validation has often shown suboptimal prognostic capability and revealed room for improvement. 4 .</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.06.048" target="_blank" rel="noopener"> A Global Survey of Physicians Knowledge About Non-alcoholic Fatty Liver Disease.</a></p>
<p>s Despite the growing burden of NAFLD, a significant knowledge gap remains for the identification, diagnosis, and management of NAFLD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.06.035" target="_blank" rel="noopener"> A Magnetic Resonance Imaging Index to Predict Crohn&#39;s Disease Postoperative Recurrence: The MONITOR Index.</a></p>
<p>s The MONITOR index is an efficient, reliable, easy-to-apply tool that can be used in clinical practice to predict the POR of CD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.06.028" target="_blank" rel="noopener"> A Nonviable Probiotic in Irritable Bowel Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.</a></p>
<p>s BL is not effective across al IBS subtypes. However, BL may offer a treatment option for IBS-D that needs verification by an adequately powered drug trial; EudraCT-No.  2012-002741-38.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.04.038" target="_blank" rel="noopener"> A PNPLA3 Polymorphism Confers Lower Susceptibility to Incident Diabetes Mellitus in Subjects With Nonalcoholic Fatty Liver Disease.</a></p>
<p>s These findings clarify conflicting results regarding the association between the PNPLA3 rs738409 genotype and the risk of DM, demonstrating a clear difference between subjects with and without NAFLD; this difference might be explained by the low metabolic risk in genetic NAFLD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.056" target="_blank" rel="noopener"> A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores.</a></p>
<p>s Integration of genetics with clinical fibrosis scores refines individual risk and prediction for SLD, mainly in individuals at risk for nonalcoholic fatty liver disease. These data provide evidence from a prospective cohort that common genetic variants capture additional prognostic insights not conveyed by validated clinical/biochemical parameters.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.04.028" target="_blank" rel="noopener"> A Prospective Diet-Wide Association Study for Risk of Colorectal Cancer in EPIC.</a></p>
<p>s Our findings confirm a positive association for alcohol and an inverse association for dairy products and calcium with CRC risk, and also suggest a lower risk at higher dietary intakes of phosphorus, magnesium, potassium, riboflavin, beta carotene, and total protein.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.03.049" target="_blank" rel="noopener"> A Single Food Milk Elimination Diet Is Effective for Treatment of Eosinophilic Esophagitis in Children.</a></p>
<p>s One-food elimination of CMP-containing foods from the diet induced histologic remission in more than 50% of children with EoE and led to significant improvement in symptoms and endoscopic abnormalities. The ease of implementation and adherence supports the 1FED as first-line dietary treatment.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.04.027" target="_blank" rel="noopener"> Adenoma and Serrated Lesion Detection by Colonoscopy Indication: The ADR-ESS (ADR Extended to all Screening/Surveillance) Score.</a></p>
<p>s Comprehensive, automated colonoscopy audit based on standardized clinical documentation is feasible. Adenoma detection is a fair but imperfect proxy for SSL detection. ADR-ESS increases the precision of adenoma detection assessments and emphasizes quality across colonoscopy indications.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.02.028" target="_blank" rel="noopener"> Adenoma Detection Rate (ADR) Irrespective of Indication Is Comparable to Screening ADR: Implications for Quality Monitoring.</a></p>
<p>s In our study, the overall ADR computed from al colonoscopies was not significantly different than the conventional ADR based on screening colonoscopies. Assessing ADR for colonoscopy irrespective of indication may be adequate for quality monitoring, and could facilitate the implementation of quality measurement and reporting. Future prospective studies should evaluate the validity of using overall ADR for quality reporting in other jurisdictions before adopting this method in clinical practice.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.01.039" target="_blank" rel="noopener"> Age Dependence of Liver Enzymes: An Analysis of Over 1,300,000 Consecutive Blood Samples.</a></p>
<p>s Current guidelines and reference values for ALT imply that subsequent diagnostics are needed for a large proportion of young men. Our data strongly suggest that age adaptation should be considered.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.024" target="_blank" rel="noopener"> Aminotransferases During Treatment Predict Long-Term Survival in Patients With Autoimmune Hepatitis Type 1: A Landmark Analysis.</a></p>
<p>s Low aminotransferases during treatment are associated with a better long-term survival in autoimmune hepatitis. IgG was not associated with survival in first 12 months of treatment. Normalization of aminotransferases should be the treatment goal for autoimmune hepatitis to improve long-term survival.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.06.011" target="_blank" rel="noopener"> Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study.</a></p>
<p>s PF-06480605 demonstrated an acceptable safety profile and statistically significant EI in participants with moderate to severe UC, warranting further study in a larger participant cohort. Tissue histopathology analyses support this conclusion. Trial registration number https //clinicaltrials.gov/NCT02840721.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.04.023" target="_blank" rel="noopener"> Association of Adenoma Detection Rate and Adenoma Characteristics With Colorectal Cancer Mortality After Screening Colonoscopy.</a></p>
<p>s Our study adds important evidence for mandatory assessment and monitoring of performance quality in screening colonoscopy. High-quality colonoscopy was associated with a lower risk for CRC death, and the impact of ADR was strongest for individuals with high-risk adenomas.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.03.047" target="_blank" rel="noopener"> Association of Weight Changes With Changes in Histological Features and Blood Markers in Nonalcoholic Steatohepatitis.</a></p>
<p>s Weight change was independently and monotonically associated with changes in biochemical and histological features of NASH. Guidelines for NASH management should incorporate recommendations for both avoidance of weight gain and support to lose weight.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.054" target="_blank" rel="noopener"> Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn&#39;s Disease: A Systematic Review.</a></p>
<p>s There is a lack of well-defined studies on biomarkers of intestinal stricture. Development of reliable and accurate biomarkers of stricture is a research priority. Biomarkers can support the clinical management of CD patients and aid in the stratification and monitoring of patients during clinical trials of future antifibrotic drug candidates.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.014" target="_blank" rel="noopener"> Bowel Movement Frequency Is Not Linked With Cognitive Function in Cirrhosis.</a></p>
<p>1  There are logistic barriers for the widespread uptake of rifaximin, the second-line therapy. Moreover, although BM frequency-directed dose titration of lactulose is the usual practice, its impact on objective cognitive performance is unclear. Our aim is to determine the impact of BM frequency on cognition in patients with/without prior OHE.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.04.022" target="_blank" rel="noopener"> Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis: Results from a Phase 3 Trial.</a></p>
<p>s In patients with EoE, BOS 2.0 mg twice daily was superior to placebo in improving histologic, symptomatic, and endoscopic outcomes over 12 weeks. BOS 2.0 mg twice daily was well tolerated. ClinicalTrials.gov number  NCT02605837.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.034" target="_blank" rel="noopener"> Cancer Risk in 47,241 Individuals With Celiac Disease: A Nationwide Cohort Study.</a></p>
<p>s There is an increased risk of cancer in CD even in recent years, but this risk increase is confined to those diagnosed with CD after age 40 and is primarily present within the first year of diagnosis.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.039" target="_blank" rel="noopener"> Characteristics and Survival of Patients With Inflammatory Bowel Disease and Postcolonoscopy Colorectal Cancers.</a></p>
<p>s The characteristics of UC-related PCCRC suggest tumor biology as an important factor in the progression to cancer. However, the prognosis of PCCRC appears similar to that of dCRC.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.03.008" target="_blank" rel="noopener"> Characteristics of Patients Undergoing Endoscopic Retrograde Cholangiopancreatography for Sphincter of Oddi Disorders.</a></p>
<p>The Evaluating Predictors and Interventions in Sphincter of Oddi Dysfunction (EPISOD) study of patients without objective evidence for biliary obstruction showed no difference in outcomes between those who underwent sphincterotomy or sham treatment. 1  To date, there have been no studies examining the characteristics of patients who still are being offered endoscopic retrograde cholangiopancreatography (ERCP) for SOD since the EPISOD publication, although the absolute number appears to have declined. 2 .</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.02.005" target="_blank" rel="noopener"> Characterization of Prevalent, Post-Endoscopy, and Incident Esophageal Cancer in the United States: A Large Retrospective Cohort Study.</a></p>
<p>s Two-thirds of EACs among individuals with BE are diagnosed at the time of BE diagnosis. Additionally, PEEC accounts for 14% of these EACs. These results may guide future research studies that investigate novel BE diagnostic strategies that reduce the morbidity and mortality of EAC.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.06.037" target="_blank" rel="noopener"> Clinical Decision Support Tool for Infliximab in Crohn&#39;s Disease.</a></p>
<p>Biologic treatment options for Crohn&#39;s disease (CD) are increasing and providers will need enhanced support in integrating these therapies into routine practice. Using phase 3 clinical trial programs in CD, we have previously built and validated clinical decision support tools for achieving clinical remission (CREM) with vedolizumab and ustekinumab in CD. 1-4  We now aim to develop a clinical decision support tool for infliximab in CD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.04.006" target="_blank" rel="noopener"> Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn&#39;s Disease.</a></p>
<p>s Based on this post hoc analysis, infliximab and ustekinumab appear to have similar efficacy and speed of onset in patients with CD who are biologic-naïve.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.02.032" target="_blank" rel="noopener"> Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases.</a></p>
<p>s In an observational study of patients with IBD, vedolizumab was associated with lower risk of serious infections as compared with TNFa antagonists, in patients with UC, but not in patients with CD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.02.003" target="_blank" rel="noopener"> Day Care Attendance and Infectious Complications in Children Born to Mothers With Inflammatory Bowel Disease.</a></p>
<p>1,2  In utero exposure to biologics is not associated with adverse pregnancy outcomes 3  or infections in infants born to mothers with IBD. 1,2,4  However, prior studies did not account for day care exposure in the first year of life, which is an established risk factor for infection in the general population. We aimed to determine whether children born to mothers with IBD have an increased rate of infection when attending day care in the first year after exposure to biologic therapy in utero.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.01.043" target="_blank" rel="noopener"> DCP and AFP-L3 Are Complementary to AFP in Predicting High-Risk Explant Features: Results of a Prospective Study.</a></p>
<p>2  Because of the degree of imprecision associated with AFP, there is a quest for other biomarkers that may be complementary to or better than AFP in predicting prognosis in LT. Lectin-reactive AFP (AFP-L3) and des-gamma-carboxyprothrombin (DCP) are biomarkers that have been used in conjunction with AFP as HCC surveillance or diagnostic tools. 3  ,  4  However, the utility of these biomarkers in LT for HCC is not established.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.02.011" target="_blank" rel="noopener"> Declining US Hepatocellular Carcinoma Rates, 2014-2017.</a></p>
<p>1  Rates of hepatocellular carcinoma (HCC), the most common histologic subtype, 2  increased for decades, 3  until recent years when rates flattened, 4  and then potentially declined. Previously, we reported that US HCC rates in 2016 were 4% lower than 2015 5 ; however, it was unclear from those data whether that finding reflected a true downward trend. Here, we examine HCC rates through 2017.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.06.015" target="_blank" rel="noopener"> Deficits in Geriatric Assessment Associate With Disease Activity and Burden in Older Patients With Inflammatory Bowel Disease.</a></p>
<p> Deficits in geriatric assessment are highly prevalent in older patients with IBD. Patients with active disease are more prone to deficits, and deficits associate with lower health-related quality of life, indicating higher disease burden. Prospective data validating impact of frailty and geriatric assessment on outcomes are warranted to further improve treatment strategies.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.03.040" target="_blank" rel="noopener"> Defining the Long-Term Clinical Course and Need for Repeat Dilation for Patients With Schatzki Rings.</a></p>
<p>SRs are sharply localized lesions with clearly defined margins, whereas peptic strictures have a more gradual transition between normal and abnormal esophagus to produce a funnel-shaped narrowing. 5  ,  6  Consequently, it has been assumed that repeat dilation is less common in SRs dissimilar from medically untreated peptic strictures. The study aim was to identify clinical and radiologic predictors for repeated esophageal dilations in patients with SRs and to assess if peptic stricture-like characteristics of rings correspond to need for repeat dilation.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.04.004" target="_blank" rel="noopener"> Detection of Colorectal Neoplasms Using Linked Color Imaging: A Prospective, Randomized, Tandem Colonoscopy Trial.</a></p>
<p> Although both methods provided a similar ADR, LCI had a lower AMR than WLI. LCI could benefit endoscopists with lower ADR, an observation that warrants additional study. (UMIN Clinical Trials Registry, Number  UMIN000026359).</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.053" target="_blank" rel="noopener"> Determination of Biopsy Yield That Optimally Detects Eosinophilic Gastritis and/or Duodenitis in a Randomized Trial of Lirentelimab.</a></p>
<p>s In an analysis of patients with moderate-to-severe GI symptoms participating in a clinical trial of lirentelimab for EG/EoD, we found eosinophilia to be patchy in gastric and duodenal biopsies. Counting eosinophils in at least 8 gastric and 4 duodenal biopsies is required to identify patients with EG/EoD, so they can receive appropriate treatment. (ClinicalTrials.gov, Number  NCT03496571).</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.055" target="_blank" rel="noopener"> Development of the Comprehensive Pain Assessment Tool Short Form for Chronic Pancreatitis: Validity and Reliability Testing.</a></p>
<p> The COMPAT-SF questionnaire includes the most relevant aspects of pain in CP and is a feasible, reliable, and valid pain assessment instrument recommended to be used in future trials.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.03.029" target="_blank" rel="noopener"> Dietary Gluten Intake Is Not Associated With Risk of Inflammatory Bowel Disease in US Adults Without Celiac Disease.</a></p>
<p>s In 3 large adult US prospective cohorts, gluten intake was not associated with risk of CD or UC. Our findings are reassuring at a time when consumption of gluten has been increasingly perceived as a trigger for chronic gastrointestinal diseases.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.029" target="_blank" rel="noopener"> Differential Clinical Characteristics and Mortality Outcomes in Persons With NAFLD and/or MAFLD.</a></p>
<p>s MAFLD criteria identified a significant group of people with more comorbidities and worse prognosis compared with those with NAFLD only. These criteria should be considered in the general population to identify high-risk groups for early interventions.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.025" target="_blank" rel="noopener"> Distinct Clinical Physiologic Phenotypes of Patients With Laryngeal Symptoms Referred for Reflux Evaluation.</a></p>
<p>s DAPC identified distinct clinicophysiologic phenotypes of patients with laryngeal symptoms referred for reflux evaluation  group A, LPR and gastroesophageal reflux disease (GERD) with hiatal hernia; group B, mild LPR/GERD; group C, no LPR/No GERD; group D, reflex cough; and group E, mixed/possible obstructive esophagogastric junction. Phenotypic differences may inform targeted clinical trials design and improve outcomes.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.04.018" target="_blank" rel="noopener"> Doylestown Plus and GALAD Demonstrate High Sensitivity for HCC Detection in Patients With Cirrhosis.</a></p>
<p>2  These data highlight a need for novel surveillance strategies with higher accuracy for early HCC detection. GALAD and Doylestown Plus are novel biomarker panels that combine multiple biomarkers with patient demographic and clinical characteristics; both demonstrated promising accuracy in phase II case-control studies; 3  ,  4  however, case-control studies can overestimate biomarker performance, highlighting a need for phase III cohort and nested case-control studies. 5  Our study aimed to compare multiple biomarkers (including AFP, GALAD, and Doylestown Plus) in a nested case-control study of patients with cirrhosis.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.06.012" target="_blank" rel="noopener"> Dynamic Changes in Ultrasound Quality for Hepatocellular Carcinoma Screening in Patients With Cirrhosis.</a></p>
<p>s Nearly 1 in 5 patients with cirrhosis had moderately-severely limited ultrasound visualization for HCC nodules, particularly those with obesity or alcohol-related or nonalcoholic fatty liver disease cirrhosis. Ultrasound quality can change between exams, including improvement in many patients with limited visualization.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.07.005" target="_blank" rel="noopener"> Early Change in Epithelial Neutrophilic Infiltrate Predicts Long-Term Response to Biologics in Ulcerative Colitis.</a></p>
<p>s Our results on epithelial neutrophilic infiltrate after induction therapy as the only independent predictor for achievement of maintenance EI or HEMI helps clarify the clinical relevance of measuring histologic disease activity in ulcerative colitis. Epithelial neutrophilic infiltrate poses a means to stratify patients according to their likelihood of response to biologic treatment.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.06.006" target="_blank" rel="noopener"> Early Dynamics of MELD Scores Predict Corticosteroid Responsiveness to Severe Acute-Onset Autoimmune Hepatitis.</a></p>
<p>3,4  Consideration of a second-line drug while evaluating for liver transplantation (LT) is also recommended. 2  Established predictors of &quot;CS responsiveness&quot; to guide decision-making are nonexistent. Herein, we determined the diagnostic abilities of early dynamics to define CS responsiveness in SA-AIH using the model for end-stage liver disease (MELD) scores.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.063" target="_blank" rel="noopener"> Effect of Domperidone Therapy on Gastroparesis Symptoms: Results of a Dynamic Cohort Study by NIDDK Gastroparesis Consortium.</a></p>
<p>s Utilizing the method of pragmatic modeling to evaluate long-term treatment of GP in a large GpCRC database, DOM treatment resulted in moderately but significantly improved GP. NOTE  This project was based on data generated by 2 GpCRC Registry studies recognized under the Clinicaltrial.gov numbers  NCT00398801 and NCT01696747 symptoms compared with a group receiving standard-of-care but not DOM.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.027" target="_blank" rel="noopener"> Effect of Exclusion Diets on Symptom Severity and the Gut Microbiota in Patients With Irritable Bowel Syndrome.</a></p>
<p>s Restrictive diets likely are consumed more by IBS patients than HCs to reduce GI symptom severity. Dietary patterns influence the composition of the fecal microbiota and may explain some of the differences between IBS and HCs.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.02.043" target="_blank" rel="noopener"> Efficacy and Safety of Tofacitinib in Ulcerative Colitis Based on Prior Tumor Necrosis Factor Inhibitor Failure Status.</a></p>
<p>s Tofacitinib was efficacious in patients with UC regardless of prior TNFi failure status. HZ (nonserious and serious) rates were numerically higher in patients who had previously failed TNFi. ClinicalTrials.gov  A3921063 (NCT00787202); OCTAVE Induction 1 (NCT01465763); OCTAVE Induction 2 (NCT01458951); OCTAVE Sustain (NCT01458574); and OCTAVE Open (NCT01470612).</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.02.010" target="_blank" rel="noopener"> Endoscopic Phenotype of the J Pouch in Patients With Inflammatory Bowel Disease: A New Classification for Pouch Outcomes.</a></p>
<p>s We describe 7 unique IPAA phenotypes with different contributing factors and outcomes, and propose a new classification system for pouch management and future interventional studies.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.02.035" target="_blank" rel="noopener"> Epidemiologic and Economic Burden of Achalasia in the United States.</a></p>
<p>s Achalasia has a higher epidemiologic and economic burden in the US than previously suggested, with diagnosis particularly increasing in older patients.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.004" target="_blank" rel="noopener"> Establishing Minimal Clinically Important Differences in Quality of Life Measures in Opioid-Induced Constipation.</a></p>
<p>s Based on data derived from the anchor method, reductions in PAC-SYM and PAC-QOL scores of &gt;1.0 in patients with chronic noncancer pain and opioid-induced constipation are clinically meaningful. ClinicalTrials.gov Registration  NCT01965158; NCT01993940.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.02.030" target="_blank" rel="noopener"> Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults.</a></p>
<p>s MAFLD has an astonishingly high prevalence rate in overweight and obese adults. This calls for attention and dedicated action from primary care physicians, specialists, health policy makers and the general public alike.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.06.009" target="_blank" rel="noopener"> Factors Associated With Inpatient Endoscopy Delay and its Impact on Hospital Length-of-Stay and 30-Day Readmission.</a></p>
<p>s IED occurred frequently, unfavorably prolonged LOS, and was an independent risk factor for 30-day readmission. We provide a comprehensive analysis of actionable variables associated with IED that can be targeted to improve inpatient endoscopy delivery.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.02.008" target="_blank" rel="noopener"> Feasibility and Safety of Tethered Capsule Endomicroscopy in Patients With Barrett&#39;s Esophagus in a Multi-Center Study.</a></p>
<p>s The capabilities of TCE to be used across multiple sites, be administered to unsedated patients by either physicians or nurses who are not expert in OCT-TCE, and to rapidly and safely evaluate the microscopic structure of the esophagus make it an emerging tool for screening and surveillance of BE patients. Clinical trial registry website and trial number  NCT02994693 and NCT03459339.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.03.007" target="_blank" rel="noopener"> FIB-4 Improves LSM-Based Prediction of Complications in Overweight or Obese Patients With Compensated Advanced Chronic Liver Disease.</a></p>
<p>1  Recently, we demonstrated that this holds true also in overweight or obese patients with cACLD due to nonalcoholic steatohepatitis (NASH) studied by the XL probe. An LSM cutoff of ≥21 kPa remained associated with a high risk of complications in this population. 2 .</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.02.025" target="_blank" rel="noopener"> Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn&#39;s Disease: The IM-UNITI Trial.</a></p>
<p>s Patients receiving subcutaneous ustekinumab maintained clinical remission through 5 years. No new safety signals were observed. ClinicalTrials.gov number NCT01369355.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.07.004" target="_blank" rel="noopener"> Food Avoidance and Restriction in Irritable Bowel Syndrome: Relevance for Symptoms, Quality of Life and Nutrient Intake.</a></p>
<p>s IBS patients with severe food avoidance and restriction constitute a subgroup with more severe symptoms overall, reduced quality of life, and reduced intake of nutrients. This needs to be acknowledged in the clinical management of these patients.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.06.013" target="_blank" rel="noopener"> Genetically Predicted Adiposity, Diabetes, and Lifestyle Factors in Relation to Diverticular Disease.</a></p>
<p>s This study strengthens the causal associations of higher body mass index, type 2 diabetes, and smoking with an increased risk of diverticular disease. Coffee consumption is not associated with diverticular disease. Whether alcohol consumption affects the risk of diverticular disease needs further investigation.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.04.013" target="_blank" rel="noopener"> Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study.</a></p>
<p>s Universal multigene panel testing in CRC was associated with a modest, but significant, detection of heritable mutations over guideline-based testing. One in 10 patients had changes in their management based on test results. Uptake of cascade family testing was low, which is a concerning observation that warrants further study.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.042" target="_blank" rel="noopener"> Greater Overlap of Rome IV Disorders of Gut-Brain Interactions Leads to Increased Disease Severity and Poorer Quality of Life.</a></p>
<p>s DGBI in multiple anatomic GI regions is associated with increased psychological comorbidity, health care utilization, and IBS severity. Physician awareness of overlap could improve quality of care, prevent unnecessary interventions, and yield more positive health outcomes.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.04.039" target="_blank" rel="noopener"> Hepatobiliary Adverse Drug Reactions Associated With Remdesivir: The WHO International Pharmacovigilance Study.</a></p>
<p>Remdesivir has demonstrated clinical benefits in randomized placebo-controlled trials (RCTs) in patients with coronavirus disease 2019 (COVID-19) 1-4  and was first approved for COVID-19 patients. 5  However, whether remdesivir causes gastrointestinal adverse drug reaction (GI-ADRs) including hepatotoxicity is less clear. 1-4  ,  6  Therefore, we aimed to detect a diverse spectrum of GI-ADRs associated with remdesivir using VigiBase, the World Health Organization&#39;s international pharmacovigilance database of individual case safety reports.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.04.030" target="_blank" rel="noopener"> HepQuant SHUNT Detects Portal Hypertension in Early Stages of Clinically Compensated Chronic Liver Disease.</a></p>
<p>Physicians use portal pressure measurements in clinical practice and research but the methods are invasive, can cause complications, and are resource intensive. 1-3  Herein we describe preliminary findings of the minimally invasive HepQuant-SHUNT test in the diagnosis of portal hypertension in precirrhotic and compensated cirrhotic patients.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.06.026" target="_blank" rel="noopener"> High Risk of Fractures Within 7 Years of Diagnosis in Asian Patients With Inflammatory Bowel Diseases.</a></p>
<p>s The risk of fractures was significantly high in newly diagnosed IBD patients, especially in those with CD regardless of corticosteroid exposure.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.016" target="_blank" rel="noopener"> Histology, Size, and Number of Advanced Polyps are Associated With Guideline-Discordant Surveillance Recommendations.</a></p>
<p>Surveillance guidelines following polypectomy promote cost-effective reductions in future colorectal cancer (CRC) risk, but high nonadherence rates 1  can have negative consequences on costs and effectiveness. Professional societies recommend a 3-year interval for patients with advanced colorectal polyps (ACPs), although few studies report provider adherence to surveillance intervals. 2  This study evaluated rates and predictors of guideline-discordant recommendations for patients with ACPs.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.033" target="_blank" rel="noopener"> Ileal Pouch Anal Anastomosis for the Management of Ulcerative Colitis Is Associated With Significant Disability.</a></p>
<p>s Patients with IPAA have higher disability scores than patients with UC, even after adjustment for disease activity. Female sex and public insurance are predictive of significant disability in patients with IPAA.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.03.006" target="_blank" rel="noopener"> Incidence of Hepatitis C Virus Infections Among Users of Human Immunodeficiency Virus Pre-exposure Prophylaxis.</a></p>
<p>s The low incidence of HCV infections despite significantly higher rates of other STIs suggests that sexual transmission of HCV is uncommon in HIV-negative MSM PrEP users in this community. Performing routine risk-based HCV surveillance among PrEP users should be evaluated. The high incidence of STIs in this population indicates a vital role for periodic STI monitoring in those receiving PrEP.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.03.045" target="_blank" rel="noopener"> Interaction of Microbiome, Diet, and Hospitalizations Between Brazilian and American Patients With Cirrhosis.</a></p>
<p>s Brazilian cirrhotic patients follow a diet richer in cereals and yogurt, which is associated with higher microbial diversity and beneficial microbiota and could contribute toward lower hospitalizations compared with a Western-diet-consuming American cohort.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.04.033" target="_blank" rel="noopener"> Landscape of Adverse Events Related to Peroral Endoscopic Myotomy in 3135 Patients and a Risk-Scoring System to Predict Major Adverse Events.</a></p>
<p>s Based on a systematic landscape analysis, POEM is a safe procedure with low rates of severe AEs. Our prediction model and risk-scoring system demonstrated good performance in predicting major AEs.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.06.042" target="_blank" rel="noopener"> Liver Fibrosis in Asians With Metabolic Dysfunction-Associated Fatty Liver Disease.</a></p>
<p> Liver fibrosis in patients with MAFLD varies according to subgroup classification based on diabetes, body mass index, and metabolic risk factors.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.049" target="_blank" rel="noopener"> Long-Lasting Dissociation of Esophageal Eosinophilia and Symptoms Following Dilation in Adults With Eosinophilic Esophagitis.</a></p>
<p>s In nondilated EoE adults, eos/hpf correlates modestly with symptoms; this correlation was no longer appreciated in dilated patients, and the dilation effects lasted longer than 1 year. Dilation status should be considered in studies evaluating EoE treatment and for clinical follow-up evaluation.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.03.011" target="_blank" rel="noopener"> Long-term Outcomes in Asymptomatic Ulcerative Colitis Diagnosed During Screening Colonoscopy.</a></p>
<p>1  ,  2  Treating patients with healed mucosae has been shown to be beneficial. 3  Clinical, endoscopic, and histological findings do not necessarily correlate with each other. 4 .</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.06.020" target="_blank" rel="noopener"> Long-Term Treatment of Eosinophilic Esophagitis With Budesonide Oral Suspension.</a></p>
<p>s For induction full responders, continuing BOS numerically improved maintenance of efficacy vs withdrawal. A longer therapy duration did not raise safety concerns. (ClinicalTrials.gov  NCT02736409.).</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.04.005" target="_blank" rel="noopener"> Lubiprostone for Pediatric Functional Constipation: Randomized, Controlled, Double-Blind Study With Long-term Extension.</a></p>
<p>s Lubiprostone did not demonstrate statistically significant effectiveness over placebo in children and adolescents with PFC but did demonstrate a safety profile similar to that in adults. (ClinicalTrials.gov  Number  NCT02042183; Number  NCT02138136).</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.050" target="_blank" rel="noopener"> Microscopic Colitis and Risk of Colon Adenomas: A Multicenter Retrospective Cohort Study.</a></p>
<p>1  Cross-sectional studies have suggested that patients with MC have a lower incidence of adenomatous colon polyps compared with those without MC. 2-4  The existing literature is limited by cross-sectional design, small sample sizes, lack of longitudinal follow-up, and the use of average-risk patients, rather than those with chronic diarrhea, as controls. We aimed to explore the association between MC and colon adenomas.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.04.043" target="_blank" rel="noopener"> Natural History and Disease Impact of Rome IV Vs Rome III Irritable Bowel Syndrome: A Longitudinal Follow-Up Study.</a></p>
<p>s The natural history of IBS defined according to Rome IV criteria is more severe than that of Rome III-defined IBS. This has important implications for future treatment trials in IBS.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.06.014" target="_blank" rel="noopener"> Noninvasive Monitoring After Azathioprine Withdrawal in Patients With Inflammatory Bowel Disease in Deep Remission.</a></p>
<p>s More than half patients with UC and one-third of patients with CD relapse after AZA withdrawal despite previous deep remission. FC positivity is associated with high risk of relapse, allowing early correction of the therapeutic strategy.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.06.043" target="_blank" rel="noopener"> Nonrecurrence Rate of Underwater EMR for ≤20-mm Nonampullary Duodenal Adenomas: A Multicenter Prospective Study (D-UEMR Study).</a></p>
<p>s This multicenter, prospective cohort study demonstrated effectiveness and safety of UEMR for nonampullary duodenal adenomas ≤20 mm in size. (University Hospital Medical Network Clinical Trials Registry, Number  UMIN000030414).</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.02.038" target="_blank" rel="noopener"> Novel Application of Predictive Modeling: A Tailored Approach to Promoting HCC Surveillance in Patients With Cirrhosis.</a></p>
<p>s Predictive models can help stratify patients&#39; likelihood to respond to surveillance outreach invitations, facilitating tailored strategies to maximize effectiveness and cost-effectiveness of HCC surveillance population health programs.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.06.049" target="_blank" rel="noopener"> Obesity is Associated With Increased Risk of Crohn&#39;s disease, but not Ulcerative Colitis: A Pooled Analysis of Five Prospective Cohort Studies.</a></p>
<p>s In an adult population, obesity as measured by BMI was associated with an increased risk of older-onset CD but not UC.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.06.044" target="_blank" rel="noopener"> Obesity, Adiposity, and Risk of Symptomatic Gallstone Disease According to Genetic Susceptibility.</a></p>
<p>s While maintenance of a healthy body weight reduces gallstone disease risk among al individuals, risk reduction is higher among the subset with greater genetic susceptibility to gallstone disease.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.017" target="_blank" rel="noopener"> Optical Evaluation for Predicting Cancer in Large Nonpedunculated Colorectal Polyps Is Accurate for Flat Lesions.</a></p>
<p>s Optical evaluation performance is dependent on lesion morphology. In the absence of features suggestive of SMIC, flat lesions can be presumed benign and be managed accordingly.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.04.011" target="_blank" rel="noopener"> Overlap of Rome IV Irritable Bowel Syndrome and Functional Dyspepsia and Effect on Natural History: A Longitudinal Follow-Up Study.</a></p>
<p>s The natural history of people with IBS with overlap FD defined according to Rome IV criteria is more severe than those with IBS alone. This has important implications for future treatment trials in IBS.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.02.024" target="_blank" rel="noopener"> Patient Preferences for Hepatocellular Carcinoma Surveillance Parameters.</a></p>
<p>s Patients with cirrhosis prioritize early HCC detection over potential surveillance-related harms or inconvenience.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.04.007" target="_blank" rel="noopener"> Perianal Crohn&#39;s Disease Is Associated With Poor Disease Outcome: A Nationwide Study From the epiIIRN Cohort.</a></p>
<p>s Despite higher utilization of immunomodulators and biologics, PCD is associated with poor disease outcomes, especially in severe PCD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.06.029" target="_blank" rel="noopener"> Physical Activity Is Associated With Nonalcoholic Fatty Liver Disease and Significant Fibrosis Measured by FibroScan.</a></p>
<p>s Meeting PA Guidelines for leisure-time PA has beneficial effects on NAFLD, and over 2 times the recommended amount of PA Guidelines had lower risk for significant fibrosis or cirrhosis.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.02.041" target="_blank" rel="noopener"> Plasma-Signature-Model for End-Stage Liver Disease Score to Predict Survival in Severe Alcoholic Hepatitis.</a></p>
<p>s The high-risk ps-MELD score was associated with short-term survival in patients with severe AH.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.06.041" target="_blank" rel="noopener"> Practice Patterns and Predictors of Stopping Colonoscopy in Older Adults With Colorectal Polyps.</a></p>
<p>s Only 35% of adults ≥75 years of age are recommended to stop surveillance colonoscopy. The presence of polyps was strongly associated with fewer recommendations to stop. The variation in endoscopist recommendations highlights an opportunity to better standardize recommendations following colonoscopy in older adults.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.005" target="_blank" rel="noopener"> Predicting the Need for Step-Up Therapy After EUS-Guided Drainage of Pancreatic Fluid Collections With Lumen-Apposing Metal Stents.</a></p>
<p>s Half of al patients with PFCs drained with lumen-apposing metal stents required step-up therapy, most commonly direct endoscopic necrosectomy. Individuals with PFCs ≥10 cm in size, paracolic extension, or ≥30% solid necrosis are more likely to require step-up therapy and should be considered for early endoscopic reintervention.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.06.001" target="_blank" rel="noopener"> Predictive Performance of CAGE-B and SAGE-B Models in Asian Treatment-Naive Patients Who Started Entecavir for Chronic Hepatitis B.</a></p>
<p>s Both SAGE-B and CAGE-B showed acceptable performance in predicting HCC after 5 years of AVT in Asian patients with CHB.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.04.029" target="_blank" rel="noopener"> Predictive Value of Bowel Ultrasound in Crohn&#39;s Disease: A 12-Month Prospective Study.</a></p>
<p>s Bowel US predicts the 12-month course in CD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.03.028" target="_blank" rel="noopener"> Predictors and Outcomes of Ustekinumab Dose Intensification in Ulcerative Colitis: A Multicenter Cohort Study.</a></p>
<p>3  In Crohn&#39;s disease, approximately 50% of patients undergo ustekinumab dose intensification, which seems to be effective based on prior work from our group and others. 4-8  However, similar data in UC are lacking. In this real-world multicenter cohort study, we sought to identify predictors and outcomes of ustekinumab dose intensification in UC.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.03.031" target="_blank" rel="noopener"> Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study.</a></p>
<p>1  Studies have shown that statins are safe among patients with liver disease, including those with compensated cirrhosis, 2  and their use is associated with lower mortality, hepatic decompensation, and possibly hepatocellular carcinoma. 3  ,  4  Despite these data, statins are under prescribed among patients with liver disease due to concerns about hepatotoxicity. 5  This study aimed to assess prevalence and patient factors associated with indicated statin use in patients with NAFLD in a real-world cohort.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.06.047" target="_blank" rel="noopener"> Prevalence and Financial Burden of Digestive Diseases in a Commercially Insured Population.</a></p>
<p>s The results demonstrate digestive diseases are common, heterogeneous in cost and utilization, and collectively exact a significant financial burden on the U.S. adult population.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.04.008" target="_blank" rel="noopener"> Prevalence and Predictors of Missed Dysplasia on Index Barrett&#39;s Esophagus Diagnosing Endoscopy in a Veteran Population.</a></p>
<p>s The occurrence of missed dysplasia on an index EGD has decreased over time. However, those with long segment BE were more than 3 times as likely to have missed dysplasia, and this group could benefit from dysplasia surveillance within 18 months of BE diagnosis.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.02.006" target="_blank" rel="noopener"> Primary Sclerosing Cholangitis-Associated Pouchitis: A Distinct Clinical Phenotype.</a></p>
<p>s PSC-associated pouchitis presents with a unique clinical phenotype, characterized by increased risk of chronic pouchitis, moderate-to-severe pouch inflammation, prepouch ileitis, and less response to conventional antimicrobial therapy.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.062" target="_blank" rel="noopener"> Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine.</a></p>
<p> There is great variability in CHB disease progression rates even among &quot;lower-risk&quot; populations. Future CHB modeling studies, public health planning, and HCC surveillance recommendation should be based on more precise disease progression rates based on sex, age, and disease activity, plus treatment status.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.044" target="_blank" rel="noopener"> Psychiatric Comorbidities Are Highly Prevalent in Nonesophageal Eosinophilic Gastrointestinal Diseases.</a></p>
<p> Psychiatric diagnoses were very common in nonesophageal EGID patients with approximately 7 in 10 adults and one-third of children diagnosed. Similar proportions were found for psychiatric medication use. We also found that psychiatric illness may influence age of clinical presentation and symptoms. Providers should assess for concomitant psychiatric comorbidities in EGID patients.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.040" target="_blank" rel="noopener"> Re-evaluation of the Cardiovascular Safety Profile of Tegaserod: A Review of the Clinical Data.</a></p>
<p>s Two independent, external adjudications suggest that tegaserod is safe for women &lt;65 years of age with irritable bowel syndrome with constipation, no history of cardiovascular ischemic events, and ≤1 cardiovascular risk factor.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.03.023" target="_blank" rel="noopener"> Relationship Between Gastric Emptying Rate and Simultaneously Assessed Symptoms in Functional Dyspepsia.</a></p>
<p> The severity of symptoms in functional dyspepsia and idiopathic gastroparesis, even when assessed during the GE test meal, is not correlated to gastric emptying rate. (Ethics committee University Hospital of Leuven study number S55426).</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.057" target="_blank" rel="noopener"> Risk of Colorectal Cancer in Serrated Polyposis Syndrome: A Systematic Review and Meta-analysis.</a></p>
<p>s Our meta-analysis demonstrated that patients with SPS have an elevated risk of CRC, which is highest at the time of diagnosis and suggests the importance of early SPS recognition and screening to modify CRC risk. The persistently elevated CRC risk during surveillance supports current guidelines recommending heightened surveillance protocols.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.06.019" target="_blank" rel="noopener"> Risk of Hepatitis B Virus Reactivation in Patients Treated With Immunotherapy for Anti-cancer Treatment.</a></p>
<p>s In general, HBV reactivation was rarely observed in patients with antiviral prophylaxis while undergoing ICI treatment. However, HBV reactivation may occur in HBsAg-positive patients without antiviral prophylaxis or noncompliant with antiviral prophylaxis.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.03.039" target="_blank" rel="noopener"> Safety and Efficacy of Ustekinumab in the Inflammatory Bowel Disease of Chronic Granulomatous Disease.</a></p>
<p>Chronic granulomatous disease (CGD) is a rare primary immunodeficiency caused by mutations encoding the NADPH oxidase complex. 1  Those affected are at increased risk of bacterial and fungal infections and require antimicrobial prophylaxis. Dysregulated inflammation may cause inflammatory bowel disease (IBD), termed CGD-associated IBD or CGD colitis, a distinct entity from Crohn&#39;s disease (CD) or ulcerative colitis (UC).</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.02.042" target="_blank" rel="noopener"> Seroprevalence and Determinants of Helicobacter pylori Infection in the Hispanic Community Health Study/Study of Latinos.</a></p>
<p>s H. pylori seroprevalence in Hispanics/Latinos remains high and differed significantly by Hispanic/Latino background. H. pylori seropositivity is strongly associated with poor socioeconomic conditions. These findings highlight the ongoing importance of this bacterial infection in the U.S.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.06.036" target="_blank" rel="noopener"> Serum Leucine-Rich α<sub>2</sub> Glycoprotein: A Novel Biomarker For Small Bowel Mucosal Activity in Crohn&#39;s Disease.</a></p>
<p>Active lesions in the small bowel (SB) have been independently associated with poorer prognoses in patients with Crohn&#39;s disease (CD) 1 ; however, there has been a lack of accurate and convenient screening methods. Past studies have found that serum levels of the glycoprotein leucine-rich α  glycoprotein (LRG) correlates with endoscopic activity in ulcerative colitis, 2,3  and this is now available for routine clinical use as a biomarker in patients with inflammatory bowel disease in Japan. LRG has not yet been thoroughly verified in CD, and we investigated whether it can be used as a serum biomarker for detecting SB mucosal activity in patients with CD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.022" target="_blank" rel="noopener"> Significant Liver Injury During Hospitalization for COVID-19 Is Not Associated With Liver Insufficiency or Death.</a></p>
<p>s Liver test abnormalities known to be associated with COVID-19 are secondary to other insults, mostly ischemia or drug-induced liver injury, and do not lead to liver insufficiency or death.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.02.007" target="_blank" rel="noopener"> Spatial Evolution of Histologic and Endoscopic Healing in the Left and Right Colon in Patients With Ulcerative Colitis.</a></p>
<p>s In patients with active pancolitis undergoing treat-to-target interventions, histologic and endoscopic findings in the left colon on colonoscopy have excellent accuracy for detecting pancolonic histologic remission, histologic normalization, endoscopic improvement, and endoscopic remission. Flexible sigmoidoscopy may suffice for monitoring histologic and endoscopic activity in patients with pancolitis.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.01.036" target="_blank" rel="noopener"> Standard-Volume Plasma Exchange Improves Outcomes in Patients With Acute Liver Failure: A Randomized Controlled Trial.</a></p>
<p> In ALF patients with cerebral edema, SVPE is safe and effective and improves survival possibly by a reduction in cytokine storm and ammonia. ClinicalTrial.gov (identifier  NCT02718079).</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.052" target="_blank" rel="noopener"> Sugar-sweetened Beverages Are Associated With Increased Liver Stiffness and Steatosis Among Apparently Healthy Adults in the United States.</a></p>
<p>First, SSBs are associated with nonalcoholic fatty liver disease, and interventions to reduce SSB consumption reduce the burden of liver fat. 1  Second, formal guidance uniformly recommend against SSBs. 2  Herein, we analyze the 2017-2018 wave of the National Health and Nutrition Examination Survey (NHANES), examining a nationally representative sample of persons without comorbidities or known liver disease to examine the associations between SSB consumption and both liver fibrosis and liver fat using vibration-controlled transient elastography.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.04.031" target="_blank" rel="noopener"> Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCT.</a></p>
<p>s ITT analysis showed that either peginterferon strategies were superior to NA for the primary endpoint and HBsAg loss, but add-on peginterferon is preferred to switch due to improved safety and similar efficacy. ClincialTrials.gov number  NCT01928511.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.03.027" target="_blank" rel="noopener"> Tailoring Surveillance Colonoscopy in Patients With Advanced Adenomas.</a></p>
<p>s We derived a risk prediction model that identifies veterans at high risk of NCM within 5 years and who are thus unlikely to benefit from further surveillance.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.04.045" target="_blank" rel="noopener"> Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate.</a></p>
<p>s TAF could be substituted for TDF in patients with multidrug-resistant HBV for improved bone and renal safety without a loss of efficacy. However, increases in body weight and cholesterol levels with TAF treatment would be a concern. ClinicalTrials.gov no.  NCT03241641.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.032" target="_blank" rel="noopener"> Tenofovir is Associated With Higher Risk of Kidney Function Decline Than Entecavir in Patients With Chronic Hepatitis B.</a></p>
<p>1-3  Given the well-known renal and bone toxicity associated with TDF, 4  major international hepatitis B virus treatment guidelines recommend ETV over TDF in patients with predisposing factors to kidney function decline. 1-3  However, as evidenced by recent studies, nephrotoxicity of antiviral agents is still an issue under debate. 5-7  Therefore, we investigated the differences in the risk of kidney function decline in patients with treatment-naive CHB who were treated with ETV or TDF.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.03.041" target="_blank" rel="noopener"> The Durability of EUS-Guided Chemoablation of Mucinous Pancreatic Cysts: A Long-Term Follow-Up of the CHARM trial.</a></p>
<p>At least 20% of pancreatic cancer evolves from mucinous cystic neoplasms and intraductal papillary mucinous neoplasms, which are often discovered incidentally. 1  ,  2  Current guidelines for the management of mucinous cystic neoplasms and intraductal papillary mucinous neoplasms include long-term surveillance, which is expensive and nontherapeutic, or surgical resection, which is associated with major risk and may not be an option for patients with significant concomitant illness. 3 .</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.06.027" target="_blank" rel="noopener"> The Epidemiology of Microscopic Colitis in Olmsted County, Minnesota: Population-Based Study From 2011 to 2019.</a></p>
<p>s The incidence of MC and its subtypes was stable between 2011 and 2019, but its prevalence was higher than in previous periods. The incidence of MC continues to be associated with increasing age and female sex.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.059" target="_blank" rel="noopener"> The Placebo Response in Randomized Trials in Nonalcoholic Steatohepatitis Simply Explained.</a></p>
<p>s The analyses presented simply define the placebo response in liver fibrosis in trials in NASH in terms of sampling and observer variability, regression to the mean, and fibrosis progression. Factors relating to liver biopsy are largely unmodifiable, and the variation in placebo response rates, both simulated and observed, challenges the role of biopsy in trial endpoint assessment.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.012" target="_blank" rel="noopener"> The Role of Clips in Preventing Delayed Bleeding After Colorectal Polyp Resection: An Individual Patient Data Meta-Analysis.</a></p>
<p>s Prophylactic clipping reduces delayed bleeding after resection of nonpedunculated, proximal colorectal polyps ≥20 mm, especially in patients using antithrombotics. No benefit was found for distal polyps. Based on this study, patients can be identified who may benefit from prophylactic clipping. (PROSPERO registration number CRD42020104317.).</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.038" target="_blank" rel="noopener"> Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study.</a></p>
<p>s Tofacitinib with concomitant intravenous corticosteroids may be an effective induction strategy in biologic-experienced patients hospitalized with ASUC. Prospective trials are needed to identify the safety, optimal dose, frequency, and duration of tofacitinib for ASUC.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.01.042" target="_blank" rel="noopener"> Trajectory of Serum Bilirubin Predicts Spontaneous Recovery in a Real-World Cohort of Patients With Alcoholic Hepatitis.</a></p>
<p>s We present an intuitive method of classifying patients with AH based on the trajectory of bilirubin over the first week of admission. It is complimentary to existing scores that identify candidates for corticosteroid treatment or assess response to treatment. This method identifies a group of patients with AH who recover spontaneously and can avoid corticosteroid therapy.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.02.021" target="_blank" rel="noopener"> Transient Elastography Accurately Screens for Compensated Advanced Chronic Liver Disease in Patients With Ongoing or Recent Alcohol Withdrawal.</a></p>
<p>s TE performed during the first 2 months after alcohol cessation is an excellent method for excluding alcohol-related cACLD. Clinical trial number  NCT01789008.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.02.009" target="_blank" rel="noopener"> Transient Elastography-Assessed Hepatic Steatosis and Fibrosis Are Associated With Body Composition in the United States.</a></p>
<p>s In the United States population, increased anthropometric and DXA body composition measures were associated with higher CAP and liver stiffness. Racial-ethnic differences observed merit further research to elucidate the burden of obesity and liver health disparities.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.03.030" target="_blank" rel="noopener"> Ultrasonography Tight Control and Monitoring in Crohn&#39;s Disease During Different Biological Therapies: A Multicenter Study.</a></p>
<p>s Data indicate that BUS is useful to monitor biologics-induced bowel activity improvement/resolution in CD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.04.021" target="_blank" rel="noopener"> Universal Immunohistochemistry for Lynch Syndrome: A Systematic Review and Meta-analysis of 58,580 Colorectal Carcinomas.</a></p>
<p>s Age, completeness, and type of diagnostics affect the percentage of MMR PV and unexplained MMRd percentages. Complete diagnostics explain almost al MMRd CRCs, reducing the amount of subsequent multigene panel testing. This contributes to optimizing testing and surveillance in MMRd CRC patients and relatives.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.02.013" target="_blank" rel="noopener"> Utility and Cost-Effectiveness of a Nonendoscopic Approach to Barrett&#39;s Esophagus Surveillance After Endoscopic Therapy.</a></p>
<p>s A positive Cytosponge test was strongly associated with residual BE after ablation. While the assay needs further refinement in this context, it could serve as a cost-effective surveillance examination.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.06.040" target="_blank" rel="noopener"> Validation of Clinically Relevant Thresholds of Esophagogastric Junction Obstruction Using FLIP Panometry.</a></p>
<p>s FLIP panometry accurately identified clinically relevant conclusive EGJ obstruction as defined by CCv4.0 in patients evaluated for esophageal motor disorders. Thus, FLIP panometry is a valuable tool for both independent and complementary evaluation of esophageal motility.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.035" target="_blank" rel="noopener"> Validation of the Dallas Steatosis Index to Predict Nonalcoholic Fatty Liver Disease in the UK Biobank Population.</a></p>
<p>Nonalcoholic fatty liver disease (NAFLD) is a global public health crisis that affects one quarter of the world population. 1  Preventing either cardiometabolic or liver-related complications by achieving weight loss and resolving hepatic steatosis would be the central goal of a NAFLD screening program in the primary care setting. Despite the overwhelming prevalence and the multimodal impact on health posed by NAFLD, specialty society guidelines do not recommend screening for NAFLD in the general population, 2  partly owing to the as-yet unproven cost benefit.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.02.026" target="_blank" rel="noopener"> Vedolizumab for the Treatment of Noninflammatory Bowel Disease Related Enteropathy.</a></p>
<p>1  Its gut selective mode of action and favorable safety profile have led to reports of off-label use for non-IBD-related inflammatory intestinal disorders, such as microscopic colitis, 2  and small intestinal inflammatory conditions including autoimmune enteropathy 3  and common variable immune deficiency-related enteritis. 4  Treatment of non-IBD-related enteropathies is challenging with no approved therapies or established treatment algorithms. We conducted a literature review to assess clinical, endoscopic, and histologic improvement in patients treated with vedolizumab for non-IBD enteropathies refractory to conventional therapy.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.02.037" target="_blank" rel="noopener"> Vedolizumab Therapy in Refractory Microscopic Colitis: A Single Center Case Series.</a></p>
<p>Microscopic colitis (MC) is a disease characterized by chronic watery diarrhea secondary to colonic inflammation. Endoscopically, the mucosa is usually normal but biopsies show characteristic histologic findings. 1 .</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.04.037" target="_blank" rel="noopener"> Weight Change and the Development of Nonalcoholic Fatty Liver Disease in Metabolically Healthy Overweight Individuals.</a></p>
<p> Clinically relevant weight loss was associated with a reduced risk of developing nonalcoholic fatty liver disease with or without intermediate or high probability of advanced fibrosis in metabolically healthy overweight or obese individuals.</p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Endoscopy</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1055/a-1369-8610" target="_blank" rel="noopener"> A comparison between 25-gauge and 22-gauge Franseen needles for endoscopic ultrasound-guided sampling of pancreatic and peripancreatic masses: a randomized non-inferiority study.</a></p>
<p>s The 25G Franseen needle was inferior to the 22G needle in histologic core procurement. Therefore, for cases in which tissue architecture is pivotal for diagnosis, a 22G needle, which procures relatively higher quality specimens than the 25G needle, should be used.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1055/a-1476-8931" target="_blank" rel="noopener"> An artificial intelligence system for distinguishing between gastrointestinal stromal tumors and leiomyomas using endoscopic ultrasonography.</a></p>
<p>s  We developed an AI-based EUS diagnostic system that can effectively distinguish GISTs from GILs and improve the diagnostic accuracy of SELs.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1055/a-1469-2644" target="_blank" rel="noopener"> Cold versus hot endoscopic mucosal resection for large sessile colon polyps: a cost-effectiveness analysis.</a></p>
<p>Clip cost and LSCP recurrence rate had the greatest and the least impacts on the marginal cost difference, respectively. CONCLUSION : Cold EMR is the dominant strategy over hot EMR, with lower cost and fewer days of lost productivity. In theory, a complete transition to cold EMR for LSCPs in the USA could result in an annual cost saving approaching US$7 million to Medicare beneficiaries.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1055/a-1520-8116" target="_blank" rel="noopener"> Deep learning-based detection of eosinophilic esophagitis.</a></p>
<p>s  Complex endoscopic classification tasks including more than two classes can be solved by CNN-based algorithms. Therefore, our algorithm may assist clinicians in making the diagnosis of EoE.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1055/a-1496-8969" target="_blank" rel="noopener"> Diagnosis and management of acute lower gastrointestinal bleeding: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.</a></p>
<p>Continuation of the aspirin is recommended, whereas the P2Y12 receptor antagonist can be continued or temporarily interrupted according to the severity of bleeding and the ischemic risk. If interrupted, the P2Y12 receptor antagonist should be restarted within 5 days, if still indicated. Strong recommendation, low quality evidence.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1055/a-1523-0780" target="_blank" rel="noopener"> Difficult biliary cannulation in ERCP procedures with or without trainee involvement: a comparative study.</a></p>
<p>  By using the 75 % percentiles as cutoffs, the proposed 15-10-2 criteria for difficult cannulation could be appropriate in trainee-involved procedures.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1055/a-1490-0434" target="_blank" rel="noopener"> Digital single-operator cholangioscope for endoscopic retrograde appendicitis therapy.</a></p>
<p>  Digital SOC-assisted ERAT provided a feasible, safe, and effective alternative approach for diagnosis and management of acute uncomplicated appendicitis without the need for X-ray or ultrasonic guidance.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1055/a-1493-5627" target="_blank" rel="noopener"> Dilation-predominant approach versus routine care in patients with difficult-to-treat eosinophilic esophagitis: a retrospective comparison.</a></p>
<p>s  A dilation-predominant long-term treatment strategy allowed for symptom control or bridge to clinical trials for patients with difficult-to-treat EoE. Close follow-up and monitoring for complications are required.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1055/a-1395-7485" target="_blank" rel="noopener"> Early double-guidewire versus repeated single-guidewire technique to facilitate selective bile duct cannulation: a randomized controlled trial.</a></p>
<p>  The EDG technique significantly increased the success rate of biliary duct cannulation within 10 minutes compared with an RSG approach.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1055/a-1397-3198" target="_blank" rel="noopener"> Endoscopic management of ampullary tumors: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.</a></p>
<p>Strong recommendation, moderate quality evidence. 8: ESGE recommends long-term monitoring of patients after endoscopic papillectomy or surgical ampullectomy, based on duodenoscopy with biopsies of the scar and of any abnormal area, within the first 3 months, at 6 and 12 months, and thereafter yearly for at least 5 years. Strong recommendation, low quality evidence.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1055/a-1442-2395" target="_blank" rel="noopener"> Endoscopic management of superficial nonampullary duodenal tumors: European Society of Gastrointestinal Endoscopy (ESGE) Guideline.</a></p>
<p>In cases of no recurrence, a further follow-up endoscopy should be done 1 year later. Thereafter, surveillance intervals should be adapted to the lesion site, en bloc resection status, and initial histological result. Strong recommendation, low quality evidence.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1055/a-1392-0904" target="_blank" rel="noopener"> Endoscopic ultrasound-guided gastroenterostomy using an oroenteric catheter-assisted technique: a retrospective analysis.</a></p>
<p>Of 14 patients who died, 13 (93 %) maintained oral intake until death. EUS-GE provided good symptom relief in al 28 surviving patients until follow-up. CONCLUSIONS : OEC-assisted EUS-GE provided satisfactory relief of GOO symptoms, with high technical success (98 %) and no serious complications.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1055/a-1500-3730" target="_blank" rel="noopener"> Endoscopists&#39; diagnostic accuracy in detecting upper gastrointestinal neoplasia in the framework of artificial intelligence studies.</a></p>
<p>  We show suboptimal accuracy of endoscopists for the recognition of UGIN even within a framework that included a higher prevalence and disease awareness. Future AI validation studies represent a framework to assess endoscopist competence.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1055/a-1475-0063" target="_blank" rel="noopener"> Esophageal stenting for benign and malignant disease: European Society of Gastrointestinal Endoscopy (ESGE) Guideline - Update 2021.</a></p>
<p>Strong recommendation, low quality of evidence. 10 : ESGE recommends considering placement of a fully covered large-diameter SEMS for the treatment of esophageal variceal bleeding refractory to medical, endoscopic, and/or radiological therapy, or as initial therapy for patients with massive bleeding. Strong recommendation, moderate quality evidence.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1055/a-1544-4923" target="_blank" rel="noopener"> Gastric per-oral endoscopic myotomy (G-POEM) for the treatment of gastric sleeve stenosis: a feasibility and safety study.</a></p>
<p>s  G-POEM was feasible and safe, and may provide an alternative option for those averse to undergoing surgical revision for treatment of GSS.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1055/a-1499-7477" target="_blank" rel="noopener"> Implementation of mandatory ERCP registration in The Netherlands and compliance with European Society of Gastrointestinal Endoscopy performance measures: a multicenter database study.</a></p>
<p>s  The quality of ERCPs performed met five of the six evaluated ESGE performance measures. The 95 % target for successful biliary cannulation in patients with virgin papillary anatomy in academic centers was not met. Mandatory registration provides valuable insight into ERCP performance rates.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1055/a-1521-6318" target="_blank" rel="noopener"> Incidence and outcomes of poor healing and poor squamous regeneration after radiofrequency ablation therapy for early Barrett&#39;s neoplasia.</a></p>
<p>s In half of the patients with poor healing, additional time and acid suppression led to normal squamous regeneration and excellent treatment outcomes. In patients with poor squamous regeneration, however, the risk for treatment failure and progression to advanced disease was significantly increased.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1055/a-1399-4989" target="_blank" rel="noopener"> Individual risk calculator to predict lymph node metastases in patients with submucosal (T1b) esophageal adenocarcinoma: a multicenter cohort study.</a></p>
<p>s  A third of patients with pT1b EAC experienced metastases within 5 years. The probability of developing post-resection metastases was estimated with a personalized predicted risk score incorporating tumor invasion depth, tumor size, and lymphovascular invasion. This model requires external validation before implementation into clinical practice.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1055/a-1446-8953" target="_blank" rel="noopener"> Is transoral incisionless fundoplication (TIF) an answer to post-peroral endoscopic myotomy gastroesophageal reflux? A multicenter retrospective study.</a></p>
<p> Our experience suggests that TIF may be effective and safe in treating GER after POEM. Larger prospective trials are needed.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1055/a-1511-1657" target="_blank" rel="noopener"> Live endoscopy events (LEEs): European Society of Gastrointestinal Endoscopy Position Statement - Update 2021.</a></p>
<p>Increasingly, LEEs are streamed online and therefore the necessary measures should be taken to ensure that patients have given appropriate consent and that their anonymity has been safeguarded. ESGE recommends that an endoscopist who is not participating in the live demonstrations is named as patient advocate, and that patient safety should must be prioritized throughout. In al ESGE-organized LEEs the intended learning outcomes, procedural indications and descriptions, attendee feedback, and adverse events should be recorded and submitted in a post-event report to ESGE.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1055/a-1497-6532" target="_blank" rel="noopener"> Monitored needle acceleration in endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic masses improves sample quality and diagnostic accuracy: a randomized trial.</a></p>
<p>We aimed to evaluate whether a high needle movement acceleration value during puncture increases diagnostic accuracy. METHODS : EUS-FNA needle acceleration was measured using a PocketLab accelerometer connected by Bluetooth to a smartphone. Two passes (fast and slow, with higher and lower than 1  EUS-FNA needle acceleration may increase the diagnostic accuracy and specimen quality from solid pancreatic lesions.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1055/a-1381-7562" target="_blank" rel="noopener"> Novel cryoballoon 180° ablation system for treatment of Barrett&#39;s esophagus-related neoplasia: a first-in-human study.</a></p>
<p> Single-session CbAS 180  seems feasible, safe, and effective, and is a promising technique for the treatment of patients with BE neoplasia.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1055/a-1518-7039" target="_blank" rel="noopener"> Peroral cholecystoscopy using a multibending ultraslim endoscope through a lumen-apposing metal stent for endoscopic ultrasound-guided gallbladder drainage: a feasibility study.</a></p>
<p>s  POCC using a multibending ultraslim endoscope can be effectively and safely performed through a LAMS after EUS-GBD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1055/a-1362-9375" target="_blank" rel="noopener"> Predictive value of endoscopic esophageal findings for residual esophageal cancer after neoadjuvant chemoradiotherapy.</a></p>
<p>s  Endoscopic suspicion of residual tumor was the only endoscopic finding associated with residual disease. Based on its positive predictive value, this endoscopic finding may contribute to the diagnostic strategy used in active surveillance.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1055/a-1467-6294" target="_blank" rel="noopener"> Risk evaluation of duodenoscope-associated infections in the Netherlands calls for a heightened awareness of device-related infections: a systematic review.</a></p>
<p>s  The estimated risk of DAI in Dutch ERCP practice was at least 180 times higher than previously published risk estimates. The actual risk is likely to be (much) higher due to underreporting of infections caused by multidrug-resistant organisms and sensitive bacteria. Greater awareness by healthcare personnel involved in endoscopy and endoscope cleaning is required, as well as innovative technical solutions to contain and ultimately eliminate DAIs.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1055/a-1469-9917" target="_blank" rel="noopener"> Simple optical evaluation criteria reliably identify the post-endoscopic mucosal resection scar for benign large non-pedunculated colorectal polyps without tattoo placement.</a></p>
<p>s  The post-EMR scar can be reliably identified with simple easy-to-use optical evaluation criteria, without the need for universal tattoo placement.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1055/a-1352-4583" target="_blank" rel="noopener"> The effect of train-the-colonoscopy-trainer course on colonoscopy quality indicators.</a></p>
<p>s  Participation in a TCT course improved polyp detection rates and reduced pain experienced by women. These effects were maintained during a 5-year follow-up.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1055/a-1409-5531" target="_blank" rel="noopener"> Utilization and reproducibility of World Endoscopy Organization post-colonoscopy colorectal cancer algorithms: retrospective analysis.</a></p>
<p>s  Review of PCCRC cases using WEO recommendations was performed accurately at a local level using readily available clinical information. The high number of non-interval type B PCCRCs suggests a significant proportion of PCCRCs could be avoided by better adherence to recommended surveillance intervals.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1055/a-1459-4571" target="_blank" rel="noopener"> Water exchange-assisted versus carbon dioxide-insufflated single-balloon enteroscopy: a randomized controlled trial.</a></p>
<p>s The water exchange method improved the total enteroscopy rate and increased the intubation depth during SBE. The use of water exchange did not increase the complications of enteroscopy.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1055/a-1518-7223" target="_blank" rel="noopener"> Zenker&#39;s peroral endoscopic myotomy, or flexible or rigid septotomy for Zenker&#39;s diverticulum: a multicenter retrospective comparison.</a></p>
<p>s  There was no difference in outcomes between the three treatment approaches for symptomatic Zenker&#39;s diverticulum. Rigid endoscopic septotomy was associated with the highest rate of complications, while flexible endoscopic septotomy appeared to be the safest. Recurrence following Z-POEM was similar to flexible and rigid endoscopic septotomy. Prospective studies with long-term follow-up are required.</p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Gastroenterology</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1053/j.gastro.2021.06.056" target="_blank" rel="noopener"> Alterations in the Gut Virome in Obesity and Type 2 Diabetes Mellitus.</a></p>
<p>s Obesity is characterized by altered viral taxonomic composition and weakened viral-bacterial correlations compared with lean controls. Obesity accompanied with T2DM may aggravate the obesity-associated virus signatures, signifying that the gut virome may play an important role in the development of obesity and T2DM. Geographic factors also contributed to the variations of gut virome in obesity and T2DM.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1053/j.gastro.2021.06.049" target="_blank" rel="noopener"> Endoscopic Submucosal Dissection in Europe: Results of 1000 Neoplastic Lesions From the German Endoscopic Submucosal Dissection Registry.</a></p>
<p> In Germany, ESD achieves excellent en bloc resection rates but only modest curative resection rates. ESD requires a high level of expertise, and results vary significantly depending on the center&#39;s yearly case volume.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1053/j.gastro.2021.06.064" target="_blank" rel="noopener"> Immunogenomics of Colorectal Cancer Response to Checkpoint Blockade: Analysis of the KEYNOTE 177 Trial and Validation Cohorts.</a></p>
<p>s Our study clarified the limits of TMB as a predictor of response of CRC to anti-PD1 immunotherapy. It identified a population of antigen-presenting macrophages interacting with CD8 T cells that consistently segregate with response. We therefore concluded that anti-PD1 agents release the PD1-PDL1 interaction between CD8 T cells and macrophages to promote cytotoxic antitumor activity.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1053/j.gastro.2021.06.045" target="_blank" rel="noopener"> Metabolic Rewiring by Loss of Sirt5 Promotes Kras-Induced Pancreatic Cancer Progression.</a></p>
<p>s Collectively, we identify SIRT5 as a key tumor suppressor in PDAC, whose loss promotes tumorigenesis through increased noncanonic use of glutamine via GOT1, and that SIRT5 activation is a novel therapeutic strategy to target PDAC.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1053/j.gastro.2021.06.077" target="_blank" rel="noopener"> Multi-Omics Analyses Show Disease, Diet, and Transcriptome Interactions With the Virome.</a></p>
<p>s We found that the gut virome is stable over time but varies among subsets of patients with IBS. It can be affected by diet and potentially influences host function via interactions with gut bacteria and/or altering host gene expression.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1053/j.gastro.2021.06.073" target="_blank" rel="noopener"> Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model.</a></p>
<p>s Our preclinical findings support a clinical strategy of recurrent FSP neoantigen vaccination for LS cancer immunoprevention.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1053/j.gastro.2021.06.072" target="_blank" rel="noopener"> Targeting of the Tec Kinase ITK Drives Resolution of T Cell-Mediated Colitis and Emerges as Potential Therapeutic Option in Ulcerative Colitis.</a></p>
<p>s ITK activation was detected in UC and could be down-regulated in cultured T cells by CsA administration. Selective targeting of ITK emerges as an attractive approach for treatment of chronic intestinal inflammation and potentially UC by driving resolution of mucosal inflammation.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1053/j.gastro.2021.07.002" target="_blank" rel="noopener"> Total Vitamin D Intake and Risks of Early-Onset Colorectal Cancer and Precursors.</a></p>
<p>s In a cohort of younger women, higher total vitamin D intake was associated with decreased risks of early-onset CRC and precursors.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1053/j.gastro.2021.05.055" target="_blank" rel="noopener"> Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenocarcinoma Models.</a></p>
<p>s Tumor-specific targeted delivery of 5FU using EGFR aptamers as the carrier achieved high target specificity; overcame 5FU resistance; and proved to be effective in a syngeneic orthotopic transplantation model, in KPC mice, in a CDX model, and in patient-derived organoids and, therefore, represents a promising backbone for pancreatic cancer chemotherapy in patients. Furthermore, our approach has the potential to target virtually any cancer entity sensitive to 5FU treatment by incorporating 5FU into cancer cell-targeting aptamers as the delivery platform.</p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Gastrointest Endosc</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.03.936" target="_blank" rel="noopener"> Artificial intelligence-enhanced white-light colonoscopy with attention guidance predicts colorectal cancer invasion depth.</a></p>
<p>s We have developed an AI-enhanced attention-guided WLC system that differentiates noninvasive or superficially submucosal invasive neoplasms from deeply invasive CRC with high accuracy, sensitivity, and specificity.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.05.036" target="_blank" rel="noopener"> Automated identification and assignment of colonoscopy surveillance recommendations for individuals with colorectal polyps.</a></p>
<p>s This study demonstrates the feasibility of using machine learning to automatically extract findings and classify patients to appropriate risk categories and corresponding surveillance intervals. Incorporating this system can facilitate proactive and timely follow-up after screening colonoscopy and enable real-time quality assessment of prevention programs and providers.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.05.021" target="_blank" rel="noopener"> Barrett&#39;s esophagus with low-grade dysplasia: high rate of upstaging at Barrett&#39;s esophagus referral units suggests progression rates may be overestimated.</a></p>
<p>s BERU assessment endoscopy identified more visible lesions than community referral endoscopy and identified HGD or EAC in 27% of patients referred from the community with a recent diagnosis of LGD. Reported progression rates from LGD to HGD or EAC may be overestimated.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.04.026" target="_blank" rel="noopener"> Clinical utility of methionyl-tRNA synthetase 1 immunostaining in cytologic brushings of indeterminate biliary strictures: a multicenter prospective study.</a></p>
<p>s The high sensitivity and accuracy of MARS1 IF staining enabled the detection of malignancy in patients with biliary strictures. Further prospective studies are needed to validate our findings. (Clinical trial registration number  NCT03708445.).</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.06.028" target="_blank" rel="noopener"> Contrast-enhanced EUS for the characterization of mural nodules within pancreatic cystic neoplasms: systematic review and meta-analysis.</a></p>
<p>s This study provided robust evidence on CE-EUS value for the characterization of mural nodules within PCNs. A dedicated contrast-harmonic mode, namely CH-EUS, provided an increased diagnostic yield in the identification and characterization of malignant mural nodules.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.06.033" target="_blank" rel="noopener"> Deep learning system compared with expert endoscopists in predicting early gastric cancer and its invasion depth and differentiation status (with videos).</a></p>
<p>s The system outperformed endoscopists in identifying EGCs and was comparable with endoscopists in predicting EGC invasion depth and differentiation status in videos. This deep learning-based system could be a powerful tool to assist endoscopists in EGC diagnosis in clinical practice.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.06.021" target="_blank" rel="noopener"> Detection of elusive polyps using a large-scale artificial intelligence system (with videos).</a></p>
<p>s DEEP 2  has a high sensitivity for polyp detection and was effective in increasing the detection of polyps both in colonoscopy videos and in real procedures with a low number of false alarms. (Clinical trial registration number  NCT04693078.).</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.06.027" target="_blank" rel="noopener"> Diagnostic accuracy and interobserver agreement of digital single-operator cholangioscopy for indeterminate biliary strictures.</a></p>
<p>s This study showed low sensitivity and specificity for blinded and unblinded d-SOC video appraisal of indeterminate biliary strictures, with considerable interobserver variation. Although reaching a consensus on the optical features of biliary strictures remains important, optimizing visually directed biopsy sampling may be the most important role of cholangioscopy in biliary stricture assessment.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.03.996" target="_blank" rel="noopener"> Endoscopic characteristics influencing postpolypectomy bleeding in 1147 consecutive pedunculated colonic polyps: a multicenter retrospective study.</a></p>
<p>s The increased risk for delayed bleeding with injecting the stalk and prophylactic clipping before polypectomy suggests that simple resection with coagulation mode is a suitable strategy in endoscopic resection of pedunculated polyps. Moreover, prophylactic endoloop use was highly likely to inhibit immediate bleeding with polyp size ≥15 mm.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.06.009" target="_blank" rel="noopener"> Endoscopic versus surgical gastrojejunal revision for weight regain in Roux-en-Y gastric bypass patients: 5-year safety and efficacy comparison.</a></p>
<p>s Endoscopic revision of the GJA is associated with significantly fewer total and serious AEs and similar long-term weight loss when compared with surgical revision.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.06.016" target="_blank" rel="noopener"> Endoscopic-mediated, biliary hydrodynamic injection mediating clinically relevant levels of gene delivery in pig liver.</a></p>
<p>s Biliary hydrodynamic injection using ERCP can achieve higher transfection efficiency into hepatocytes compared with AAVs at magnitudes of less cost in a clinically relevant human-sized large animal. This technology may serve as a platform for gene therapy of human liver diseases.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.06.008" target="_blank" rel="noopener"> Evaluation of polypectomy quality indicators of large, nonpedunculated colorectal polyps in a nonexpert, bowel cancer screening cohort.</a></p>
<p>s In this performance of 2 substudies, it was shown that quality parameters for endoscopic resection of large polyps in the Dutch screening cohort are not reached, especially in ≥30 mm polyps. Endoscopic resection of large polyps could benefit from additional training, quality monitoring, and centralization either within or between centers.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.04.009" target="_blank" rel="noopener"> Expert consensus on endoscopic papillectomy using a Delphi process.</a></p>
<p>s This is the first step in developing an international consensus-based algorithm for endoscopic management of papillary adenomas. Surprisingly, in many areas consensus could not be achieved. These aspects should be the focus of future studies.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.04.028" target="_blank" rel="noopener"> Extension of early esophageal squamous cell neoplasia into ducts and submucosal glands and the role of endoscopic ablation therapy.</a></p>
<p>s ESCN extends into ducts/SMGs in most patients. In an animal model, focal RFA and CBA effectively ablated SMGs, whereas c-RFA inadequately ablated SMGs. Given this potential reason for recurrence, endoscopic resection should remain the standard of care.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.03.934" target="_blank" rel="noopener"> Feasibility and diagnostic yield of small-bowel capsule endoscopy in patients with surgically altered gastric anatomy: the SAGA study.</a></p>
<p>s SB-CE seems to be feasible and safe in selected patients with a history of major gastric surgery and comes with a high DY. The spectrum of abnormal SB findings in these patients may be different from what is known from the literature in nonoperated patients.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.06.010" target="_blank" rel="noopener"> Gastric neoplasms in patients with familial adenomatous polyposis: endoscopic and clinicopathological features.</a></p>
<p>s Gastric neoplasms in patients with familial adenomatous polyposis were stratified into 4 types according to their endoscopic findings. The endoscopic phenotype was related to the histopathological phenotype, but not to germline variants.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.05.019" target="_blank" rel="noopener"> Gender differences in gastroenterology and hepatology authorship and editorial boards.</a></p>
<p>s Although gender distribution of female first authorship approaches current distributions in the field of gastroenterology and hepatology, editor-in-chief positions, editorial board membership, and senior authorship continue to be primarily men. Future endeavors to improve proportionate gender representation include improved journal leadership selection transparency, targeted diversity statements, and enhanced mentorship.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.06.011" target="_blank" rel="noopener"> GIE Editorial Board top 10 topics: advances in GI endoscopy in 2020.</a></p>
<p>Votes from each individual board member were tallied to identify a consensus list of the 10 most significant topic areas in GI endoscopy over the calendar year of study using 4 criteria: significance, novelty, impact on national health, and impact on global health. The 10 areas identified were as follows: artificial intelligence in endoscopy, coronavirus disease 2019 and GI practice, third-space endoscopy, lumen-apposing metal stents, single-use duodenoscopes and other disposable equipment, endosonographic needle technology and techniques, endoscopic closure devices, advances in GI bleeding management, improvements in polypectomy techniques, and bariatric endoscopy. Each board member contributed a summary of important articles relevant to 1 to 2 topic areas, leading to a collective summary that is presented in this document of the &quot;top 10&quot; endoscopic advances of 2020.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.04.008" target="_blank" rel="noopener"> Guidance for setting easy-to-adopt competence criteria for optical diagnosis of diminutive colorectal polyps: a simulation approach.</a></p>
<p>s In contrast to the fixed PIVI criteria, our simulation study shows that different thresholds for the proportion of correctly diagnosed diminutive polyps lead to different clinical consequences depending on guidelines and clinical setting. However, this target proportion of diminutive colorectal polyps correctly diagnosed with optical diagnosis represents easier-to-adopt competence criteria.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.06.029" target="_blank" rel="noopener"> Hemodynamic effect through a novel endoscopic intervention in management of varices and hypersplenism (with video).</a></p>
<p>s Our experience may illustrate an alternative technique of combining EUS-guided PSE with endoscopic therapy of varices to treat patients with portal hypertension.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.05.011" target="_blank" rel="noopener"> Impact of technical innovations in EMR in the treatment of large nonpedunculated polyps involving the ileocecal valve (with video).</a></p>
<p>s With technical advances, ICV-LNPCPs can be effectively and safely managed by EMR, independent of lesion complexity. Most patients experience excellent outcomes and avoid surgery.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.04.006" target="_blank" rel="noopener"> Laparoscopic versus EUS-guided gastroenterostomy for gastric outlet obstruction: an international multicenter propensity score-matched comparison (with video).</a></p>
<p>s For patients with GOO, EUS-GE and L-GE showed almost identical technical and clinical success. However, reduced time to oral intake, shorter median hospital stay, and lower rate of adverse events suggest that the EUS-guided approach might be preferable.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.05.034" target="_blank" rel="noopener"> Linked color imaging, mucosal exposure device, their combination, and standard colonoscopy for adenoma detection: a randomized trial.</a></p>
<p>s The combination of LCI and EAC can significantly improve the detection of pADR and APC but not ADR by high-ADR performers. (Clinical trial registration number  TCTR20190319001.).</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.04.022" target="_blank" rel="noopener"> Maximizing success in single-session EUS-directed transgastric ERCP: a retrospective cohort study to identify predictive factors of stent migration.</a></p>
<p>s Use of a larger-diameter LAMS is a predictive factor for a nonmigrated stent and improved procedural success in SS-EDGE. Although larger patient cohorts are needed to adequately assess these findings, performance of LAMS dilation and fixation may also decrease risk of intraprocedural LAMS migration and improve procedural success.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.06.031" target="_blank" rel="noopener"> Near-focus narrow-band imaging classification of villous atrophy in suspected celiac disease: development and international validation.</a></p>
<p>s We developed and validated a novel NF-NBI classification to reliably diagnose VA in suspected CD. There was utility for expert and nonexpert endoscopists alike, using readily available equipment and requiring minimal training. (Clinical trial registration number  NCT04349904.).</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.04.020" target="_blank" rel="noopener"> Novel 1-L polyethylene glycol + ascorbate versus high-volume polyethylene glycol regimen for colonoscopy cleansing: a multicenter, randomized, phase IV study.</a></p>
<p>s One-liter PEG+ASC showed noninferiority compared with 4L-PEG in achieving adequate colon cleansing and provided a higher patient compliance. No differences in tolerability and safety were detected. (Clinical trial registration number  NCT03742232.).</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.04.027" target="_blank" rel="noopener"> Novel through-the-scope twin clip for the closure of GI wounds: the first experimental survival study in pigs (with videos).</a></p>
<p>s The TTS-TC was successfully used to close large-sized GI wounds. The TTS-TC is a promising tool for large-size wound closure under flexible endoscopy.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.05.014" target="_blank" rel="noopener"> Peroral endoscopic myotomy: 10-year outcomes from a large, single-center U.S. series with high follow-up completion and comprehensive analysis of long-term efficacy, safety, objective GERD, and endoscopic functional luminal assessment.</a></p>
<p>s POEM is exceptionally safe and highly effective on long-term follow-up, with &gt;90% clinical success at ≥5 years.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.04.017" target="_blank" rel="noopener"> Predictors of technical difficulty for complete closure of mucosal defects after duodenal endoscopic resection.</a></p>
<p>s This study revealed that lesion location in the medial or anterior wall and lesion size affected the incomplete closure of mucosal defects after duodenal ER, and lesion size, occupied circumference, intraoperative perforation, treatment period, and treatment method affected closure time.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.05.035" target="_blank" rel="noopener"> Preloaded 22-gauge fine-needle system facilitates placement of a higher number of fiducials for image-guided radiation therapy compared with traditional backloaded 19-gauge approach.</a></p>
<p>s EUS-FP using a preloaded 22-gauge needle is feasible, effective, and safe and allows for a higher number of fiducials placed when compared with the traditional backloaded 19-gauge needle.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.05.045" target="_blank" rel="noopener"> Single-dose versus short-course prophylactic antibiotics for peroral endoscopic myotomy: a randomized controlled trial.</a></p>
<p>s According to our study, postprophylactic short-term antimicrobial therapy after POEM is not required because of a very low residual infective risk. (Clinical trial registration number  NCT03587337.).</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.06.017" target="_blank" rel="noopener"> Single-use duodenoscope for ERCP performed by endoscopists with a range of experience in procedures of variable complexity.</a></p>
<p>s In consecutive ERCPs including high complexity procedures, endoscopists with varying ERCP experience had good procedural success and reported high device performance ratings. (Clinical trial registration number  NCT04223830.).</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.05.017" target="_blank" rel="noopener"> Technical feasibility, clinical effectiveness, and safety of esophageal stricture dilation using a novel endoscopic attachment cap in adults with eosinophilic esophagitis.</a></p>
<p>s In adults with EoE, endoscopic treatment of esophageal strictures using the BougieCap is technically feasible and safe and offers significant symptomatic improvement in the short term.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.01.042" target="_blank" rel="noopener"> The risk of neoplasia in patients with Barrett&#39;s esophagus indefinite for dysplasia: a multicenter cohort study.</a></p>
<p> Patients with BE-IND should be closely monitored, because nearly a quarter harbor or will shortly develop dysplasia. BE length is a clinical predictor of neoplastic progression; however, more-accurate molecular biomarkers for risk stratification are warranted.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.04.016" target="_blank" rel="noopener"> Toward an evidence-based approach for cholangitis diagnosis.</a></p>
<p>s There is a need for cholangitis diagnostic criteria that are supported by controlled validation studies, consistent with contemporary clinical values, and amenable to implementation. The BILE criteria are straightforward but require prospective study of their diagnostic performance and ability to avert unnecessary ERCP.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.03.998" target="_blank" rel="noopener"> Trends in performance of ERCP among patients with surgically unresectable pancreatic cancer: a Survival, Epidemiology and End Results-Medicare database study.</a></p>
<p>s In a SEER-Medicare population between 2001 and 2015, both the proportion of patients with unresectable pancreas cancer who underwent ERCP and the mean number of ERCPs per patient decreased over time. Survival improved over time despite decreased use of ERCP.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.06.030" target="_blank" rel="noopener"> Unique perspective of Muslim patients on gender preference for GI endoscopists: a multicenter survey.</a></p>
<p>s Most Muslims in Pakistan expressed a gender preference, and both female and male patients showed a preference for a same-gender endoscopist. No education was associated with having a gender preference.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.03.997" target="_blank" rel="noopener"> Use of peroral cholangioscopy to screen for neoplastic bile duct lesions in patients with bile duct stones (with videos).</a></p>
<p>s Direct POC using a dedicated, ultraslim upper endoscope usefully screens for neoplastic bile duct lesions including CCAs in selected patients with bile duct stones.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.06.014" target="_blank" rel="noopener"> Usefulness of a newly designed laser-cut metal stent with an anchoring hook and thin delivery system for EUS-guided hepaticogastrostomy in experimental settings (with video).</a></p>
<p>s The strong resistance to migration and the absence of the dilation step are important advantages of newly designed hook stents. These stents may therefore be feasible and safe for EUS-HGS.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.03.937" target="_blank" rel="noopener"> Validation of a methylated DNA marker panel for the nonendoscopic detection of Barrett&#39;s esophagus in a multisite case-control study.</a></p>
<p>s A 5 MDM panel for BE is highly accurate in training and test sets in a blinded multisite case-control analysis using a simplified assay. This panel may be reduced to only 3 MDMs in the future. (Clinical trial registration number  NCT02560623.).</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.04.018" target="_blank" rel="noopener"> Value of the diving method for capsule endoscopy in the examination of small-intestinal disease: a prospective randomized controlled trial.</a></p>
<p>s The diving method for VCE examination effectively improves the endoscopic view in the proximal and middle thirds of the small bowel and the positive findings in the distal small intestine and increases the completion rate. (Clinical trial registration number  ChiCTR-RDR-17011823.).</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.06.032" target="_blank" rel="noopener"> Vonoprazan versus proton pump inhibitors for postendoscopic submucosal dissection bleeding in the stomach: a multicenter population-based comparative study.</a></p>
<p>s Vonoprazan has a lower post-ESD bleeding rate than PPIs. Further prospective studies are required to confirm these results.</p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Gut</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1136/gutjnl-2020-322166" target="_blank" rel="noopener"> <i>Braf</i> mutation induces rapid neoplastic transformation in the aged and aberrantly methylated intestinal epithelium.</a></p>
<p> Objective Sessile serrated lesions (SSLs) are common across the age spectrum, but the  induced neoplastic transformation is dependent on age and may be related to age-associated molecular alterations that accumulate in the ageing intestine, including DNA methylation. This may have implications for surveillance and chemopreventive strategies targeting the epigenome.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1136/gutjnl-2020-323778" target="_blank" rel="noopener"> <i>Dysosmobacter welbionis</i> is a newly isolated human commensal bacterium preventing diet-induced obesity and metabolic disorders in mice.</a></p>
<p> Objective To investigate the abundance and the prevalence of   J115 T  directly and beneficially influences host metabolism and is a strong candidate for the development of next-generation beneficial bacteria targeting obesity and associated metabolic diseases.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1136/gutjnl-2020-323565" target="_blank" rel="noopener"> Altered faecal microbiome and metabolome in IgG4-related sclerosing cholangitis and primary sclerosing cholangitis.</a></p>
<p>s Our data reveal that IgG4-SC and PSC possess divergent host-microbe interplays that may be involved in disease pathogenesis. These data emphasise the uniqueness of IgG4-SC.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1136/gutjnl-2021-324471" target="_blank" rel="noopener"> Artificial intelligence and colonoscopy experience: lessons from two randomised trials.</a></p>
<p>s In less experienced examiners, CADe assistance during colonoscopy increased ADR and a number of related polyp parameters as compared with the control group. Experience appears to play a minor role as determining factor for ADR. Trial registration number NCT 04260321.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1136/gutjnl-2020-323845" target="_blank" rel="noopener"> Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea.</a></p>
<p> Objective The association between proton pump inhibitor (PPI) use and gastric cancer related to   eradication status. Long-term PPIs should be used with caution in high-risk regions for gastric cancer.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1136/gutjnl-2020-322835" target="_blank" rel="noopener"> Chromatin state dynamics confers specific therapeutic strategies in enhancer subtypes of colorectal cancer.</a></p>
<p> Our data suggest that the dynamics of active enhancer underlies CRC progression and the patient-specific enhancer patterns can be leveraged for precision combination therapy.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1136/gutjnl-2020-323219" target="_blank" rel="noopener"> Decoy bypass for appetite suppression in obese adults: role of synergistic nutrient sensing receptors GPR84 and FFAR4 on colonic endocrine cells.</a></p>
<p>s Colonic GPR84 and FFAR4 agonists reduce energy intake and increase postprandial PYY in obese adults. Human colonic EECs coexpress these receptors, which activate cells via parallel intracellular pathways and synergistically evoke hormone release. Further synergism occurs in sensory nerve responses to MCFA and EEC mediators. Thus, synergistic activation of colonic endocrine cells via nutrient receptors is an important target for metabolic regulation. Trail registration number NCT04292236.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1136/gutjnl-2021-324243" target="_blank" rel="noopener"> Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.</a></p>
<p> Sequential combinations of markers with a lower cut-off to rule-out advanced fibrosis and a higher cut-off to rule-in cirrhosis can reduce the need for liver biopsies.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1136/gutjnl-2021-324856" target="_blank" rel="noopener"> Faecal immunochemical tests safely enhance rational use of resources during the assessment of suspected symptomatic colorectal cancer in primary care: systematic review and meta-analysis.</a></p>
<p> FIT is the test of choice to evaluate patients with new-onset lower gastrointestinal symptoms in primary healthcare.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1136/gutjnl-2020-321031" target="_blank" rel="noopener"> Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy.</a></p>
<p> Our results demonstrate that GPs combined with αPD-1 mAb may be a new strategy to sensitise non-small cell lung cancer patients to anti-PD-1 immunotherapy. The gut microbiota can be used as a novel biomarker to predict the response to anti-PD-1 immunotherapy.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1136/gutjnl-2021-324140" target="_blank" rel="noopener"> Histopathological effects of electrosurgical interventions in an in vivo porcine model of colonic endoscopic mucosal resection.</a></p>
<p> For snare resection, MCC and LPCC did not produce significantly different tissue effects. The submucosal injectate may protect the underlying tissue, and technique may more strongly dictate the depth and extent of final injury. For margin ablation, APC was less uniform and complete compared with STSC.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1136/gutjnl-2021-324053" target="_blank" rel="noopener"> Host and gut microbial tryptophan metabolism and type 2 diabetes: an integrative analysis of host genetics, diet, gut microbiome and circulating metabolites in cohort studies.</a></p>
<p> Higher milk intake among lactase non-persistent individuals, and higher fibre intake were associated with a favourable profile of circulating tryptophan metabolites for T2D, potentially through the host-microbial cross-talk shifting tryptophan metabolism toward gut microbial indolepropionate production.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1136/gutjnl-2020-323314" target="_blank" rel="noopener"> Human and preclinical studies of the host-gut microbiome co-metabolite hippurate as a marker and mediator of metabolic health.</a></p>
<p> Our human and experimental studies show that a high urine hippurate concentration is a general marker of metabolic health, and in the context of obesity induced by high-fat diets, hippurate contributes to metabolic improvements, highlighting its potential as a mediator of metabolic health.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1136/gutjnl-2021-324588" target="_blank" rel="noopener"> Identification of the source events for aerosol generation during oesophago-gastro-duodenoscopy.</a></p>
<p> Coughing evoked during OGD is the main source of the increased aerosol levels, and therefore, OGD should be regarded as a procedure with high risk of producing respiratory aerosols. OGD should be conducted with airborne personal protective equipment and appropriate precautions in those patients who are at risk of having COVID-19 or other respiratory pathogens.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1136/gutjnl-2021-324060" target="_blank" rel="noopener"> Machine-learning model derived gene signature predictive of paclitaxel survival benefit in gastric cancer: results from the randomised phase III SAMIT trial.</a></p>
<p> Using machine-learning techniques on one of the largest GC trials (SAMIT), we identify a gene signature representing the first predictive biomarker for paclitaxel benefit. Trial registration number UMIN Clinical Trials Registry  C000000082 (SAMIT); ClinicalTrials.gov identifier, 02628951 (South Korean trial).</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1136/gutjnl-2020-323546" target="_blank" rel="noopener"> Multicentre derivation and validation of a colitis-associated colorectal cancer risk prediction web tool.</a></p>
<p> Multicohort validation confirms that patients with large, unresected, multifocal LGD and recent moderate/severe inflammation are at highest risk of developing AN. Personalised risk prediction provided via the Ulcerative Colitis-Cancer Risk Estimator ( ) can support treatment decision-making.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1136/gutjnl-2020-323906" target="_blank" rel="noopener"> Multitrait genetic association analysis identifies 50 new risk loci for gastro-oesophageal reflux, seven new loci for Barrett&#39;s oesophagus and provides insights into clinical heterogeneity in reflux diagnosis.</a></p>
<p> Our multitrait model identified many novel risk loci for GERD and BE. We present strong evidence for a genetic underpinning of disease heterogeneity in GERD and show that GERD loci associated with depressive symptoms are not strong predictors of BE/EA relative to obesity-driven GERD loci.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1136/gutjnl-2021-325096" target="_blank" rel="noopener"> Proton pump inhibitors and risk of colorectal cancer.</a></p>
<p> While any use of PPIs was not associated with an increased risk of colorectal cancer compared with H2RAs, prolonged use may be associated with a modest increased risk of this malignancy.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1136/gutjnl-2021-325097" target="_blank" rel="noopener"> Proton pump inhibitors and risk of gastric cancer: population-based cohort study.</a></p>
<p> The findings of this large population-based cohort study indicate that the use of PPIs is associated with an increased risk of gastric cancer compared with the use of H2RAs, although the absolute risk remains low.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1136/gutjnl-2020-323126" target="_blank" rel="noopener"> RNA helicase DDX5 enables STAT1 mRNA translation and interferon signalling in hepatitis B virus replicating hepatocytes.</a></p>
<p> RNA helicase DDX5 resolves a G-quadruplex structure in 5&#39;UTR of STAT1 mRNA, enabling STAT1 translation. We propose that DDX5 is a key regulator of the dynamic range of IFN response during innate immunity and adjuvant IFN-α therapy.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1136/gutjnl-2021-324057" target="_blank" rel="noopener"> Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicentre cohort study (GCEP).</a></p>
<p>s We suggest a risk-stratified approach and recommend that high-risk patients (OLGIM III-IV) have endoscopic surveillance in 2 years, intermediate-risk patients (OLGIM II) in 5 years.</p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Hepatology</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31750" target="_blank" rel="noopener"> A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH.</a></p>
<p>s Our ML method has shown reproducibility and sensitivity and was prognostic for disease progression, demonstrating the power of ML to advance our understanding of disease heterogeneity in NASH, risk stratify affected patients, and facilitate the development of therapies.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.32048" target="_blank" rel="noopener"> A Mammalian Target of Rapamycin-Perilipin 3 (mTORC1-Plin3) Pathway is essential to Activate Lipophagy and Protects Against Hepatosteatosis.</a></p>
<p>s These results reveal that mTORC1 regulates liver lipophagy through a mechanism dependent on Plin3 phosphorylation. We propose that stimulating this pathway can enhance lipophagy in hepatocytes to help protect the liver from lipid-mediated toxicity, thus offering a therapeutic strategy in NAFLD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31834" target="_blank" rel="noopener"> A Mouse Model of Cholangiocarcinoma Uncovers a Role for Tensin-4 in Tumor Progression.</a></p>
<p>s We developed a mouse model that faithfully recapitulates human iCCA tumorigenesis and identified a gene cascade which involves TNS4 and promotes tumor progression.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31823" target="_blank" rel="noopener"> A Prospective Study Evaluating Changes in Histology, Clinical and Virologic Outcomes in HBV-HIV Co-infected Adults in North America.</a></p>
<p>s In a North American cohort of adults with HBV-HIV on cART with virological suppression, clinical outcomes and worsening histological disease were uncommon.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31897" target="_blank" rel="noopener"> A Systematic Review of Animal Models of NAFLD Finds High-Fat, High-Fructose Diets Most Closely Resemble Human NAFLD.</a></p>
<p>s This systematic analysis provides a framework for phenotypic assessment of NAFLD models and highlights the need for increased standardization and replication.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31803" target="_blank" rel="noopener"> A Transcriptomic Signature for Risk-Stratification and Recurrence Prediction in Intrahepatic Cholangiocarcinoma.</a></p>
<p>s We report a transcriptomic signature for risk-stratification and recurrence prediction that is superior to currently used clinicopathological features in patients with ICC.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31810" target="_blank" rel="noopener"> Accuracy of Transient Elastography in Assessing Fibrosis at Diagnosis in Naïve Patients With Primary Biliary Cholangitis: A Dual Cut-Off Approach.</a></p>
<p>s In a multicenter study of treatment-naïve PBC patients, we identified two cutoffs (LSM ≤6.5 and &gt;11.0 kPa) able to discriminate at diagnosis the absence or presence, respectively, of AF in PBC patients, with external validation. In patients with LSM between these two cutoffs, VCTE is not reliable and liver biopsy should be evaluated for accurate disease staging. BMI and liver biochemistry did not affect LSMs.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31761" target="_blank" rel="noopener"> Adaptive and Constitutive Activations of Malic Enzymes Confer Liver Cancer Multilayered Protection Against Reactive Oxygen Species.</a></p>
<p>s Our study reveals the complementary regulatory mechanisms which control MEs and provide cancer cells multiple layers of defense against oxidative stress. Targeting both regulatory mechanisms represents a potential therapeutic approach for HCC treatment.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31907" target="_blank" rel="noopener"> Admission Urinary and Serum Metabolites Predict Renal Outcomes in Hospitalized Patients With Cirrhosis.</a></p>
<p>s Specific admission urinary and serum metabolites were significantly additive to clinical variables to predict AKI development and dialysis initiation in inpatients with cirrhosis. These observations can potentially facilitate earlier initiation of renoprotective measures.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31782" target="_blank" rel="noopener"> An Updated Assessment of Chronic Hepatitis B Prevalence Among Foreign-Born Persons Living in the United States.</a></p>
<p>s Including FB and U.S.-born persons, the total prevalence of CHB in the USA may be as high as 2.4 million.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31812" target="_blank" rel="noopener"> Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma-Immune Humanized Mouse Model.</a></p>
<p>s Humanized-immune-system HCC mouse models are suitable for identifying targets from cancer and immune components and for testing combinational therapies.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31914" target="_blank" rel="noopener"> Association Between Proton Pump Inhibitor Use and Biliary Tract Cancer Risk: A Swedish Population-Based Cohort Study.</a></p>
<p>s  In this study, long-term use of PPIs was associated with an increased risk of gallbladder, intrahepatic, and extrahepatic bile duct cancer compared with the general population.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31837" target="_blank" rel="noopener"> Black Patients Have Unequal Access to Listing for Liver Transplantation in the United States.</a></p>
<p>s Black patients face a disparity in access to LT due to low listing rates for transplant relative to deaths from ESLD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31742" target="_blank" rel="noopener"> Black Patients With Cirrhosis Have Higher Mortality and Lower Transplant Rates: Results From a Metropolitan Cohort Study.</a></p>
<p>s Black patients with cirrhosis have discordant outcomes. Further research is needed to determine how to address these real disparities in the field of hepatology.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31780" target="_blank" rel="noopener"> Brahma-Related Gene 1 Inhibition Prevents Liver Fibrosis and Cholangiocarcinoma by Attenuating Progenitor Expansion.</a></p>
<p>s We have demonstrated the function of Brg1 in promoting HPC expansion, liver cirrhosis, and, ultimately, iCCA development in chronically injured livers, which is largely dependent on Wnt/β-catenin signaling. Our data suggest that therapies targeting Brg1-expressing HPCs are promising for the treatment of liver cirrhosis and iCCA.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31831" target="_blank" rel="noopener"> CD47-Mediated Hedgehog/SMO/GLI1 Signaling Promotes Mesenchymal Stem Cell Immunomodulation in Mouse Liver Inflammation.</a></p>
<p>s The CD47-SIRPα signaling activates the Hedgehog/SMO/Gli1 pathway, which controls NEK7/NLRP3 activity through a direct interaction between Gli1 and NICD. NICD is a coactivator of Gli1, and the target gene Dvl2 regulated by the NICD-Gli1 complex is crucial for the modulation of NLRP3-driven inflammatory response in MSC-mediated immune regulation. Our findings provide potential therapeutic targets in MSC-mediated immunotherapy of sterile inflammatory liver injury.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31757" target="_blank" rel="noopener"> Characterization of Acute HCV Infection and Transmission Networks in People Who Currently Inject Drugs in Catalonia: Usefulness of Dried Blood Spots.</a></p>
<p>s The results obtained from plasma and DBS characterize PWID with acute infection and those involved in ongoing HCV transmission and allow estimating incidence from cross-sectional data. This information is critical for the design and assessment of targeted harm reduction programs and test-and-treat interventions and to facilitate monitoring of HCV elimination in this key population.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.32017" target="_blank" rel="noopener"> Chyme Reinfusion Restores the Regulatory Bile Salt-FGF19 Axis in Patients With Intestinal Failure.</a></p>
<p>s CR in patients with IF-TDE restored bile salt-FGF19 signaling and improved gut-liver function. Beneficial effects of CR are partly mediated by recovery of the bile salt-FGF19 axis and subsequent homeostatic regulation of bile salt synthesis.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31984" target="_blank" rel="noopener"> Clinical Course and Risk Factors for Infection in Severe Forms of Alcohol-Associated Liver Disease.</a></p>
<p>s Patients with sAH are more susceptible to develop infection than those with DAC. In life-threatening forms of ALD, patients who were infected share a similar mortality rate. Corticosteroid treatment, not sAH, seems to be the main risk factor triggering IFI.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31789" target="_blank" rel="noopener"> Clinical Implications of HBV PreS/S Mutations and the Effects of PreS2 Deletion on Mitochondria, Liver Fibrosis, and Cancer Development.</a></p>
<p>s PreS mutations were significantly associated with HCC development in patients with CHB, including those with low HBV DNA or ALT levels. Antiviral therapy reduced HCC occurrence in patients with CHB, including those with preS mutations. Intracellular accumulation of mutated HBsAg induced or promoted ER stress, calcium overload, mitochondrial dysfunction, impaired energy metabolism, liver fibrosis, and HCC.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31920" target="_blank" rel="noopener"> Clinical Study of Single-Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients With Chronic Hepatitis B.</a></p>
<p>s RO7062931 is safe and well tolerated at doses up to 4.0 mg/kg QW. Supradose-proportional exposure at doses of 3.0-4.0 mg/kg was indicative of partial saturation of the ASGPR-mediated liver uptake system. Dose-dependent declines in HBsAg demonstrated target engagement with RO7062931.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31767" target="_blank" rel="noopener"> Coagulopathy, Bleeding Events, and Outcome According to Rotational Thromboelastometry in Patients With Acute Liver Injury/Failure.</a></p>
<p>s In patients with ALI/ALF, abnormal ROTEM parameters are frequent and proportional to disease severity. Whether the increased bleeding risk associated with abnormal ROTEM indicates hemostatic failure or is a proxy for disease severity requires additional study.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31913" target="_blank" rel="noopener"> Combination of Model for End-Stage Liver Disease and Lactate Predicts Death in Patients Treated With Salvage Transjugular Intrahepatic Portosystemic Shunt for Refractory Variceal Bleeding.</a></p>
<p>s After salvage TIPS, 6-week mortality remains high and can be predicted by MELD score and lactate. Survival rate at 6 weeks was &gt;85% in patients with arterial lactate ≤2.5 mmol/L and MELD score ≤ 15, while mortality was &gt;90% for lactate ≥12 mmol/L and/or MELD score ≥ 30.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.32007" target="_blank" rel="noopener"> Comparison of Clinical Features and Outcomes Between Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma in the United States.</a></p>
<p>s We identified the demographic, socioeconomic, and clinical features associated with iCCA diagnosis over HCC among patients with PLC. Although iCCA patients presented at an advanced stage, OS was similar between iCCA and HCC in multivariable analysis. iCCA was associated with longer OS for subgroups with poor prognostic features.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.32018" target="_blank" rel="noopener"> Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America.</a></p>
<p>s Despite clear relationships between HBV RNA and HBcrAg levels and CHB phases, these markers have limited additional value in differentiating CHB phases because of their strong association with HBV DNA and, to a lesser extent, with clinical disease indicators.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31749" target="_blank" rel="noopener"> Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP-Activated Protein Kinase Signaling Pathway.</a></p>
<p> Cordycepin exerts significant protective effects against hepatic steatosis, inflammation, liver injury, and fibrosis in mice under metabolic stress through activation of the AMPK signaling pathway. Cordycepin might be an AMPK activator that can be used for the treatment of NASH.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31756" target="_blank" rel="noopener"> County-Level Variation in Hepatitis C Virus Mortality and Trends in the United States, 2005-2017.</a></p>
<p>s Although many counties have experienced a shift in HCV mortality trends since 2013, the magnitude and composition of that shift have varied by place. These data provide a better understanding of geographic differences in HCV mortality and can be used by local jurisdictions to evaluate HCV mortality in their areas relative to surrounding areas and the nation.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31890" target="_blank" rel="noopener"> Current and Past Infections of HBV Do Not Increase Mortality in Patients With COVID-19.</a></p>
<p> Current or past HBV infections were not associated with more liver injury and mortality in COVID-19.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31731" target="_blank" rel="noopener"> De Novo Colorectal and Pancreatic Cancer in Liver-Transplant Recipients: Identifying the Higher-Risk Populations.</a></p>
<p>s These data identify a high-risk cohort that warrants consideration for intensified individualized screening practices for colorectal cancer after liver transplantation. In addition to recipients with PSC, further study of recipients with NASH and HCC/CCA and females with alcohol-associated liver disease and HCC/CCA may be better tailored to colorectal cancer screening ideals. Higher-risk patient populations for pancreatic cancer (PSC and NASH with HCC/CCA) would benefit from further study to determine potential screening practices. GI malignancies occur at higher rates in liver-transplant patients compared with the general population. In the era of individualized medicine, this study identifies the highest-risk transplant recipients (PSC and NASH cirrhosis with coexisting HCC/CCA) who may benefit from altered screening practices for these malignancies.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31798" target="_blank" rel="noopener"> Determination of Effective Albumin in Patients With Decompensated Cirrhosis: Clinical and Prognostic Implications.</a></p>
<p>s This large, observational study provides the evidence in patients with decompensated cirrhosis that eAlb can be quantified and differentiated from tAlb routinely measured in clinical practice. As compared to tAlb, eAlb is more closely associated with disease severity and albumin dysfunction and carries a greater prognostic power. These results prompt future research assessing eAlb as a biomarker for predicting prognosis and treatment response.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.32046" target="_blank" rel="noopener"> Dietary N-Nitroso Compounds and Risk of Hepatocellular Carcinoma: A USA-Based Study.</a></p>
<p>s In conclusion, though some of our findings may indicate the presence of reverse causation owing to lower meat intake among cases with chronic liver diseases before HCC diagnosis, the potent dietary HCC carcinogens, NDEA, NDMA, and NPIP, and their enhanced carcinogenic effects among chronic carriers of hepatitis virus warrant further prospective investigation.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31788" target="_blank" rel="noopener"> Differentiated Cells in Prolonged Hypoxia Produce Highly Infectious Native-Like Hepatitis C Virus Particles.</a></p>
<p>s This relevant HCV cell culture model thus mimics the complete native intracellular HCV life cycle and, by extension, can be proposed as a model of choice for studies of other hepatotropic viruses.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31796" target="_blank" rel="noopener"> DNA Methylation Signatures Reveal the Diversity of Processes Remodeling Hepatocellular Carcinoma Methylomes.</a></p>
<p>s This study elucidates the diversity of processes remodeling HCC methylomes and reveals the epigenetic and transcriptional impact of driver alterations.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.32030" target="_blank" rel="noopener"> Donor Hepatic Occult Collagen Deposition Predisposes to Peritransplant Stress and Impacts Human Liver Transplantation.</a></p>
<p>s These findings from the largest clinical study cohort to date document the essential role of occult collagen deposition in donor livers on LT outcomes. High-SRA and donor BARD scores correlated with an increased incidence of hepatic IRI and EAD in LT recipients. This study provides the rationale for in-depth and prospective assessment of occult fibrosis for refined personalized LT management.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31898" target="_blank" rel="noopener"> Doxycycline Significantly Enhances Induction of Induced Pluripotent Stem Cells to Endoderm by Enhancing Survival Through Protein Kinase B Phosphorylation.</a></p>
<p>s Furthermore, this method achieves a 4-fold increase in endoderm cell number and will accelerate studies of human diseases in vitro and facilitate the expansion of iPSC-derived cells for transplantation studies.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31738" target="_blank" rel="noopener"> Dysregulation of the Lysophosphatidylcholine/Autotaxin/Lysophosphatidic Acid Axis in Acute-on-Chronic Liver Failure Is Associated With Mortality and Systemic Inflammation by Lysophosphatidic Acid-Dependent Monocyte Activation.</a></p>
<p>s ATX up-regulation in ACLF promotes LPA production from LPC. LPA suppresses MerTK/CD163 expression and increases monocyte proinflammatory cytokine production. This metabolic pathway could be investigated to therapeutically reprogram monocytes in ACLF.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31986" target="_blank" rel="noopener"> Equitable Access to Liver Transplant: Bridging the Gaps in the Social Determinants of Health.</a></p>
<p>The COVID-19 pandemic and social justice movement have highlighted the impact of social determinants of health (SDOH) and structural racism in the United States on both access to care and patient outcomes. With the evaluation for liver transplantation being a highly subjective process, there are multiple ways for SDOH to place vulnerable patients at a disadvantage. This policy corner focuses on three different methods to reverse the deleterious effects of SDOH-identify and reduce implicit bias, expand and optimize telemedicine, and improve community outreach.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.32002" target="_blank" rel="noopener"> Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP-C Treatment as Prevention Study in Prisons.</a></p>
<p>s Our results demonstrate the prevention benefits of scaling up HCV treatment in prison settings. Prison-based DAA scale-up should be an important component of HCV elimination strategies.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31888" target="_blank" rel="noopener"> Extracellular Signal-Regulated Kinase 5 Regulates the Malignant Phenotype of Cholangiocarcinoma Cells.</a></p>
<p>s ERK5 is a key mediator of growth and migration of CCA cells and supports a protumorigenic crosstalk between the tumor and the microenvironment.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.32045" target="_blank" rel="noopener"> Fatty Acid Synthase-Suppressor Screening Identifies Sorting Nexin 8 as a Therapeutic Target for NAFLD.</a></p>
<p>s These data indicate that SNX8 is a key suppressor of NAFLD that promotes FASN proteasomal degradation. Targeting the SNX8-FASN axis is a promising strategy for NAFLD prevention and treatment.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31835" target="_blank" rel="noopener"> Financial Hardship From Medical Bills Among Adults With Chronic Liver Diseases: National Estimates From the United States.</a></p>
<p>s One in 3 adults with CLD experience financial hardship from medical bills, and frequently experience financial toxicity and unplanned healthcare use. These financial determinates of health have important implications in the context of value-based care.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31857" target="_blank" rel="noopener"> Functional Characterization of Organoids Derived From Irreversibly Damaged Liver of Patients With NASH.</a></p>
<p> Expansion of primary liver stem cells/organoids derived directly from irreversibly damaged liver from patients with NASH opens up experimental avenues for personalized disease modeling and drug development that has the potential to slow human NASH progression and to counteract NASH-related SARS-CoV-2 effects.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31759" target="_blank" rel="noopener"> Gene Deconvolution Reveals Aberrant Liver Regeneration and Immune Cell Infiltration in Alcohol-Associated Hepatitis.</a></p>
<p>s These results identify distinct changes in the liver cell populations in chronic liver disease and illustrate the power of using single-cell RNA-seq data from a limited number of samples in understanding multiple different diseases.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31829" target="_blank" rel="noopener"> Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.</a></p>
<p>s TP53, KRAS, and CDKN2A alterations were independent prognostic factors in iCCA when controlling for clinical and pathologic variables, disease stage, and treatment. Because genetic profiling can be integrated into pretreatment therapeutic decision-making, combining clinical variables with targeted tumor sequencing may identify patient subgroups with poor outcome irrespective of treatment strategy.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.32038" target="_blank" rel="noopener"> Genetic variation in the mitochondrial glycerol-3-phosphate acyltransferase is associated with liver injury.</a></p>
<p>Single-cell RNA sequencing data demonstrated hepatocyte-predominant expression of GPAM in cells that co-express genes related to VLDL production (P=9.4x10 -103  ). In conclusion, genetic variation in GPAM is associated with susceptibility to liver injury. GPAM may represent a new therapeutic target in chronic liver disease.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.32043" target="_blank" rel="noopener"> Global Microbiota-Dependent Histone Acetylation Patterns Are Irreversible and Independent of Short Chain Fatty Acids.</a></p>
<p>s These results suggest that microbiota-dependent landscaping of the hepatic epigenome through global histone acetylation is static in nature, while the hepatic transcriptome is responsive to alterations in the gut microbiota.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31806" target="_blank" rel="noopener"> Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease.</a></p>
<p>s Glycemic control predicts severity of ballooned hepatocytes and HF in NAFLD/NASH, and thus optimizing glycemic control may be a means of modifying risk of NASH-related fibrosis progression.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31850" target="_blank" rel="noopener"> HBV/Pregenomic RNA Increases the Stemness and Promotes the Development of HBV-Related HCC Through Reciprocal Regulation With Insulin-Like Growth Factor 2 mRNA-Binding Protein 3.</a></p>
<p>s In conclusion, our studies reveal a significance and mechanism of HBV-pgRNA in increasing stemness features and offer a potential prognostic marker and a therapeutic target for HBV-related HCC.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31804" target="_blank" rel="noopener"> Hematological and Genetic Markers in the Rational Approach to Patients With HCV Sustained Virological Response With or Without Persisting Cryoglobulinemic Vasculitis.</a></p>
<p>s Hematological or genetic analyses could be used to foresee the CV clinical response after DAA therapy and could be valuable to assess a rational flowchart to manage CV during follow-up.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31856" target="_blank" rel="noopener"> Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge.</a></p>
<p>s We suggest that liraglutide-stimulated hepatic Fgf21 expression may require GLP-1R to be expressed in extrahepatic organs. Importantly, we revealed that hepatic FGF21 is required for liraglutide to lower body weight and improve hepatic lipid homeostasis. These observations advanced our mechanistic understanding of the function of GLP-1-based drugs in NAFLD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31881" target="_blank" rel="noopener"> Hepatic Small Ubiquitin-Related Modifier (SUMO)-Specific Protease 2 Controls Systemic Metabolism Through SUMOylation-Dependent Regulation of Liver-Adipose Tissue Crosstalk.</a></p>
<p>s Our finding demonstrated a key role of hepatic SENP2 in governing metabolic balance by regulating liver-adipose tissue crosstalk, linking the SUMOylation process to metabolic regulation.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.32031" target="_blank" rel="noopener"> Hepatic X-Box Binding Protein 1 and Unfolded Protein Response Is Impaired in Weanling Mice With Resultant Hepatic Injury.</a></p>
<p>s Weanling mice have attenuated hepatic XBP1 signaling and impaired UPR activation with resultant increased susceptibility to bile acid-induced injury.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31863" target="_blank" rel="noopener"> Hepatocyte SH3RF2 Deficiency Is a Key Aggravator for NAFLD.</a></p>
<p> SH3RF2 depletion in hepatocytes is a critical aggravator for NAFLD progression and therefore represents a promising therapeutic target for related liver diseases.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31743" target="_blank" rel="noopener"> Heterogeneity of HSCs in a Mouse Model of NASH.</a></p>
<p>s Analysis of single-cell RNA sequencing in combination with an interrogation of previous studies revealed an unanticipated heterogeneity of HSC phenotypes under normal and injured states.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31752" target="_blank" rel="noopener"> Hexa Histidine-Tagged Recombinant Human Cytoglobin Deactivates Hepatic Stellate Cells and Inhibits Liver Fibrosis by Scavenging Reactive Oxygen Species.</a></p>
<p>s His-CYGB could have antifibrotic clinical applications for human chronic liver diseases.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31745" target="_blank" rel="noopener"> High Mobility Group Box 1 Release by Cholangiocytes Governs Biliary Atresia Pathogenesis and Correlates With Increases in Afflicted Infants.</a></p>
<p>s These results suggest that HMGB1 plays a role in virus induced BA pathogenesis and could be a target for therapeutic interventions in a subset of patients with BA and high HMGB1.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31893" target="_blank" rel="noopener"> Human Leukocyte Antigen Profile Predicts Severity of Autoimmune Liver Disease in Children of European Ancestry.</a></p>
<p>s Unique HLA profiles are seen in each subgroup of juvenile AILD. HLA genotype might be useful in predicting responsiveness to immunosuppressive treatment and course.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.32009" target="_blank" rel="noopener"> Hypoxia-Inducible Exosomes Facilitate Liver-Tropic Premetastatic Niche in Colorectal Cancer.</a></p>
<p>s Hypoxia-induced exosomal miR-135a-5p correlates with the development, clinical severity, and prognosis of CRC liver metastases through the premetastatic niche; and our findings revealed that miR-135a-5p might be a promising target in halting CRC liver metastases.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31902" target="_blank" rel="noopener"> Hypoxia-Inducible Factor 1 Alpha-Mediated RelB/APOBEC3B Down-regulation Allows Hepatitis B Virus Persistence.</a></p>
<p>s In conclusion, inhibiting HIF1α expression or stabilization represents an anti-HBV strategy in the context of immune-mediated A3B induction. High HIF1α, mediated by hypoxia or inflammation, offers a reservoir for HBV survival in vivo and should be considered as a restricting factor in the development of immune therapies.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.32008" target="_blank" rel="noopener"> Immune Activation Induces Telomeric DNA Damage and Promotes Short-Lived Effector T Cell Differentiation in Chronic HCV Infection.</a></p>
<p>s These results suggest that modulation of immune activation through inhibiting Akt signaling and protecting telomeres through enhancing TRF2 expression may open therapeutic strategies to fine tune the adaptive immune responses in the setting of persistent immune activation and inflammation during chronic HCV infection.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.32023" target="_blank" rel="noopener"> Immunomodulatory Effects of Lenvatinib Plus Anti-Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma.</a></p>
<p>s Lenvatinib plus anti-PD1 exerted unique immunomodulatory effects through activation of immune pathways, reduction of Treg cell infiltrate, and inhibition of TGFß signaling. A gene signature enabled the identification of ~20% of human HCCs that, although nonresponding to single agents, could benefit from the proposed combination.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31787" target="_blank" rel="noopener"> Impact of Genotype, Serum Bile Acids, and Surgical Biliary Diversion on Native Liver Survival in FIC1 Deficiency.</a></p>
<p>s Less than half of patients with FIC1 deficiency reach adulthood with native liver. The number of PPTMs did not associate with the natural history or prognosis of FIC1 deficiency. sBA concentrations at initial presentation and after SBD provide limited prognostic information on long-term NLS.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.32016" target="_blank" rel="noopener"> Impact of Public Health Policies on Alcohol-Associated Liver Disease in Latin America: An Ecological Multinational Study.</a></p>
<p>s Our study indicates that in Latin America, countries with higher number of PHP have lower mortality due to ALD, lower prevalence of AUD, and lower alcohol-attributable road traffic mortality.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31809" target="_blank" rel="noopener"> In Utero Exposure to Mercury Is Associated With Increased Susceptibility to Liver Injury and Inflammation in Childhood.</a></p>
<p>s These findings suggest that developmental exposure to Hg can contribute to inflammation and increased NAFLD risk in early life.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31822" target="_blank" rel="noopener"> Increased Adipose Tissue Fibrogenesis, Not Impaired Expandability, Is Associated With Nonalcoholic Fatty Liver Disease.</a></p>
<p>s AT expandability is not impaired in persons with obesity and NAFLD. However, SAT fibrogenesis is greater in persons with obesity and NAFLD than in those with obesity and normal IHTG content, and is inversely correlated with both hepatic and whole-body insulin sensitivity.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31871" target="_blank" rel="noopener"> Inhibition of Secretin/Secretin Receptor Axis Ameliorates NAFLD Phenotypes.</a></p>
<p> The biliary SCT/SCTR/miR-125b axis promotes liver steatosis by up-regulating lipid biosynthesis gene Elovl1. Targeting the biliary SCT/SCTR/miR-125b axis may be key for ameliorating phenotypes of human NAFLD/NASH.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31766" target="_blank" rel="noopener"> Insufficient Radiofrequency Ablation Promotes Hepatocellular Carcinoma Metastasis Through N6-Methyladenosine mRNA Methylation-Dependent Mechanism.</a></p>
<p>s The m 6  A-YTHDF1-EGFR axis promotes HCC progression after IRFA, supporting the rationale for targeting m 6  A machinery combined with EGFR inhibitors to suppress HCC metastasis after RFA.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.32035" target="_blank" rel="noopener"> Involvement of TIGIT in Natural Killer Cell Exhaustion and Immune Escape in Patients and Mouse Model With Liver Echinococcus multilocularis Infection.</a></p>
<p>s Our results indicate that inhibitory receptor TIGIT is involved in NK cell exhaustion and immune escape from E. multilocularis infection.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31921" target="_blank" rel="noopener"> Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.</a></p>
<p>s Lenvatinib reduced tumor PD-L1 level and Treg differentiation to improve anti-PD-1 efficacy by blocking FGFR4. Levels of FGFR4 expression and Treg infiltration in tumor could serve as biomarkers for screening patients with HCC using lenvatinib plus anti-PD-1 combination therapy.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31900" target="_blank" rel="noopener"> Liver Sinusoidal Endothelial Cells Suppress Bone Morphogenetic Protein 2 Production in Response to TGFβ Pathway Activation.</a></p>
<p>s These findings reveal that TGFβ1 signaling is functionally interlinked with BMP signaling in LSECs, suggesting druggable targets for the treatment of iron overload diseases associated with deficiency of the BMP2-regulated hormone hepcidin, such as hereditary hemochromatosis, β-thalassemia, and chronic liver diseases.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31771" target="_blank" rel="noopener"> Liver-Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer.</a></p>
<p>s Liver-specific Tm6sf2 deletion impairs VLDL secretion, promoting hepatic steatosis, fibrosis, and accelerated development of HCC, which was mitigated with AAV8- mediated rescue.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31846" target="_blank" rel="noopener"> Loss-of-Function Genetic Screening Identifies Aldolase A as an Essential Driver for Liver Cancer Cell Growth Under Hypoxia.</a></p>
<p>s Our work identifies ALDOA as an essential driver for HCC cell growth under hypoxia, and we demonstrate that inhibition of ALDOA in the hypoxic TME is a promising therapeutic strategy for treating HCC.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31776" target="_blank" rel="noopener"> Male Sex Is Associated With Higher Rates of Liver-Related Mortality in Primary Biliary Cholangitis and Cirrhosis.</a></p>
<p>s In patients with PBC and well-compensated cirrhosis, male sex is associated with a higher risk of both death and liver-related death or transplantation.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.32028" target="_blank" rel="noopener"> Mast Cells Regulate Ductular Reaction and Intestinal Inflammation in Cholestasis Through Farnesoid X Receptor Signaling.</a></p>
<p>s Our studies demonstrate that MC-FXR plays a key role in liver damage and DR, including TBA regulation through alteration of intestinal and biliary FXR/FGF15 signaling.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31910" target="_blank" rel="noopener"> Maternal Early-Pregnancy Glucose Concentrations and Liver Fat Among School-Age Children.</a></p>
<p>s In this study, maternal early-pregnancy glucose concentrations were only among mothers of European ancestry associated with offspring NAFLD. The associations of higher maternal early-pregnancy glucose concentrations with offspring NAFLD may differ between ethnic groups.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31875" target="_blank" rel="noopener"> Metabotropic Glutamate Receptor 5 in Natural Killer Cells Attenuates Liver Fibrosis by Exerting Cytotoxicity to Activated Stellate Cells.</a></p>
<p>s mGluR5 plays important roles in attenuating liver fibrosis by augmenting NK cell cytotoxicity, which could be used as a potential therapeutic target for liver fibrosis.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31755" target="_blank" rel="noopener"> Microbiota-Driven Activation of Intrahepatic B Cells Aggravates NASH Through Innate and Adaptive Signaling.</a></p>
<p> Our findings reveal that a gut microbiota-driven activation of intrahepatic B cells leads to hepatic inflammation and fibrosis during the progression of NASH through innate and adaptive immune mechanisms.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.32022" target="_blank" rel="noopener"> Modeling Phenotypic Heterogeneity of Glycogen Storage Disease Type 1a Liver Disease in Mice by Somatic CRISPR/CRISPR-associated protein 9-Mediated Gene Editing.</a></p>
<p>s In conclusion, we show that somatic CRISPR/Cas9-mediated gene editing allows for the modeling of a spectrum of hepatocyte-borne GSD-1a disease symptoms in mice and to efficiently study GGIs in the liver. This approach opens perspectives for translational research and will likely contribute to personalized treatments for GSD-1a and other genetic liver diseases.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31862" target="_blank" rel="noopener"> Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.</a></p>
<p>s This study proposes predictive molecular features of chemotherapy and immunotherapy responses in advanced BTCs using clinical sequencing platforms. Our result provides an intuitive framework to guide the treatment of advanced BTCs benefiting from therapeutic agents based on the tumors&#39; molecular features.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31982" target="_blank" rel="noopener"> MRI-Based Iron Phenotyping and Patient Selection for Next-Generation Sequencing of Non-Homeostatic Iron Regulator Hemochromatosis Genes.</a></p>
<p>s In patients without homozygosity for p.Cys282Tyr, coincident pathogenic variants in HFE and non-HFE genes could explain hyperferritinemia with hepatic iron overload in a subset of patients. Unlike HFE hemochromatosis, this type of polygenic hepatic iron overload presents with variable TSAT. High ferritin in blood is an indicator of the iron storage disease, hemochromatosis. A simple genetic test establishes this diagnosis in the majority of patients affected. MRI of the abdomen can guide further genetic testing.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31864" target="_blank" rel="noopener"> Myelocytomatosis-Protein Arginine N-Methyltransferase 5 Axis Defines the Tumorigenesis and Immune Response in Hepatocellular Carcinoma.</a></p>
<p>s This study reveals that PRMT5 is an epigenetic executer of MYC, leading to repression of the transcriptional regulation of downstream genes that promote hepatocellular carcinogenesis, highlights a mechanism-based therapeutic strategy for MYC-driven HCC by PRMT5 inhibition through synergistically suppressed proliferation and enhanced antitumor immunity, and finally provides an opportunity to mitigate the resistance of &quot;immune-cold&quot; tumor to ICT.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31754" target="_blank" rel="noopener"> Myofibroblast-Specific Msi2 Knockout Inhibits HCC Progression in a Mouse Model.</a></p>
<p>s Myofibroblast-specific Msi2 knockout abrogated the tumor-promoting function of myofibroblasts and inhibited HCC progression in mouse models. Targeting myofibroblast MSI2 expression may therefore prove to be a therapeutic strategy for HCC treatment in the future.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.32032" target="_blank" rel="noopener"> NAFLD and Alcohol-Associated Liver Disease Will Be Responsible for Almost All New Diagnoses of Cirrhosis in Canada by 2040.</a></p>
<p>s Cirrhosis incidence will continue to increase over the next two decades secondary to NAFLD with a worrisome rapid rise in ALD cirrhosis among young adults. Public education, policy, and intervention targeting NAFLD risk factors and alcohol use in young adults are urgently needed.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31730" target="_blank" rel="noopener"> Nuclear factor erythroid 2-related factor 2 and β-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications.</a></p>
<p>s Coactivation of β-catenin and Nrf2 is evident in 9% of al human HCCs. Coexpression of mutant NFE2L2 and mutant CTNNB1 led to clinically relevant HCC development in mice, which responded to mTOR inhibitors. Thus, this model has both biological and therapeutic implications.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31919" target="_blank" rel="noopener"> Olaparib Inhibits Tumor Growth of Hepatoblastoma in Patient-Derived Xenograft Models.</a></p>
<p>s In this study, we showed that aggressive HBL is moderated by ALCDs, which are activated by the ph-S6-p53/PARP1 pathway. By using the PARP1 inhibitor Ola, we suppressed tumor growth in HBL-PDX models, which demonstrated its utility in future clinical models.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31797" target="_blank" rel="noopener"> Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study.</a></p>
<p>s This international, multicenter study reveals that patients with AIH were not at risk for worse outcomes with COVID-19 than other causes of CLD. Cirrhosis was the strongest predictor for severe COVID-19 in patients with AIH. Maintenance of immunosuppression during COVID-19 was not associated with increased risk for severe COVID-19 but did lower the risk for new-onset liver injury during COVID-19.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31802" target="_blank" rel="noopener"> Pathogenesis, MicroRNA-122 Gene-Regulation, and Protective Immune Responses After Acute Equine Hepacivirus Infection.</a></p>
<p>s EqHV infection in horses typically has an acute resolving course, and the protective immune response lasts for at least a year and broadly attenuates subsequent infections. This could have important implications to achieve the primary goal of an HCV vaccine; to prevent chronicity while accepting acute resolving infection after virus exposure.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31848" target="_blank" rel="noopener"> Perivenous Stellate Cells Are the Main Source of Myofibroblasts and Cancer-Associated Fibroblasts Formed After Chronic Liver Injuries.</a></p>
<p>s In conclusion, Tcf21-CreER-targeted perivenous stellate cells are the main source of myofibroblasts and CAFs in chronically injured livers. TGF-β signaling links HSC activation to liver fibrosis and tumorigenesis.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31841" target="_blank" rel="noopener"> Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Children With Chronic HCV: Part 2 of the DORA Study.</a></p>
<p>s A pediatric formulation of GLE/PIB was highly efficacious and well tolerated in chronic HCV-infected children 3 to &lt; 12 years old.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31859" target="_blank" rel="noopener"> Pharmacological Activation of Nrf2 Enhances Functional Liver Regeneration.</a></p>
<p>s Our results indicate that pharmacological activation of Nrf2 is a promising strategy for enhancing functional liver regeneration. Such an approach could therefore aid the recovery of patients undergoing liver surgery and support the treatment of acute and chronic liver disease.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31993" target="_blank" rel="noopener"> Phase 2 Study of Adjuvant Radiotherapy Following Narrow-Margin Hepatectomy in Patients With HCC.</a></p>
<p>s Adjuvant radiotherapy is an effective, well-tolerated, and promising adjuvant regimen in patients with HCC who have undergone narrow-margin hepatectomy. Our trial provides evidence and a rationale for planning a future phase 3 trial.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31983" target="_blank" rel="noopener"> Phosphorylation and Stabilization of PIN1 by JNK Promote Intrahepatic Cholangiocarcinoma Growth.</a></p>
<p>s Our findings implicate the JNK-PIN1 regulatory axis as a functionally important determinant for ICC growth, and provide a rationale for therapeutic targeting of JNK activation through PIN1 inhibition.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31879" target="_blank" rel="noopener"> Postdiagnosis Aspirin Use Associated With Decreased Biliary Tract Cancer-Specific Mortality in a Large Nationwide Cohort.</a></p>
<p>s The nationwide study revealed that postdiagnosis aspirin use was associated with improved BTC-specific mortality of various subtypes. The findings suggest that additional randomized trials are required to investigate aspirin&#39;s efficacy in BTC.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31991" target="_blank" rel="noopener"> Prevalence of HBV Infection, Vaccine-Induced Immunity, and Susceptibility Among At-Risk Populations: US Households, 2013-2018.</a></p>
<p> Despite increasing immune protection among young persons vaccinated after birth, the estimated prevalence of persons living with chronic hepatitis B in the USA has remained unchanged at 0.3% since 1999.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31783" target="_blank" rel="noopener"> Prognostic Value of the <sup>13</sup> C-Methacetin Breath Test in Adults with Acute Liver Failure and Non-acetaminophen Acute Liver Injury.</a></p>
<p>s The  13  C-MBT is a promising tool to estimate the likelihood of hepatic recovery in patients with ALF and ALI. Use of the PDR peak data from the  13  C-MBT point-of-care test may assist with medical decision making and help avoid unnecessary transplantation in critically ill patients with ALF and ALI.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31992" target="_blank" rel="noopener"> Prospective Study of Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma on Waitlist for Liver Transplant.</a></p>
<p>s SBRT was safe, with a significantly higher tumor control rate, reduced the risk of waitlist dropout, and should be used as an alternative to conventional bridging therapies.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31826" target="_blank" rel="noopener"> Proteomic Profiling of Hepatocellular Adenomas Paves the Way to Diagnostic and Prognostic Approaches.</a></p>
<p>s This work proposes a proteomic-based machine learning tool, operational on fixed biopsies, that can improve diagnosis and prognosis and therefore patient management for HCAs.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31911" target="_blank" rel="noopener"> Recurrence of Primary Sclerosing Cholangitis After Liver Transplant in Children: An International Observational Study.</a></p>
<p>s The incidence of rPSC in this cohort was higher than previously reported, and was associated with increased morbidity and mortality. Patients with rPSC appeared to have a more aggressive, immune-reactive phenotype. These findings underscore the need to understand the immune mechanisms of rPSC, to lay the foundation for developing new therapies and improve outcomes in this challenging population.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31825" target="_blank" rel="noopener"> Responsible Inclusion of Pregnant Individuals in Eradicating HCV.</a></p>
<p>Moreover, treatment of pregnant individuals may support the goal of eliminating perinatal HCV transmission and overcome the established challenges with transitioning care after delivery. The exclusion of pregnant individuals without justification denies them and their offspring access to potential health benefits, raising justice concerns considering growing data on DAA safety and global efforts to promote equitable and comprehensive HCV eradication. Finally, we propose a path forward for research and treatment programs during pregnancy to help advance the goal of HCV elimination.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.32019" target="_blank" rel="noopener"> Risk and Outcome of Venous and Arterial Thrombosis in Patients With Cirrhosis: A Danish Nation-wide Cohort Study.</a></p>
<p>s Patients with cirrhosis had an increased risk of VTE and IS, but not AMI. Among patients with cirrhosis, decompensation increased the risk of AMI, exclusively. Mortality after thrombosis was higher in patients with cirrhosis than in other patients. These findings are relevant for decisions about antithrombotic prophylaxis in patients with cirrhosis.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31839" target="_blank" rel="noopener"> Risk of HCC With Hepatitis B Viremia Among HIV/HBV-Coinfected Persons in North America.</a></p>
<p> Individuals coinfected with HIV/HBV on ART with detectable HBV viremia remain at risk for HCC. To gain maximal benefit from ART for HCC prevention, sustained HBV suppression is necessary.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31795" target="_blank" rel="noopener"> Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B.</a></p>
<p> Selgantolimod was safe and well-tolerated in virally suppressed and viremic patients with CHB and elicited cytokine responses consistent with target engagement. Further studies with longer durations of selgantolimod treatment are required to evaluate efficacy.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31843" target="_blank" rel="noopener"> Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.</a></p>
<p>s Saroglitazar 4 mg significantly improved ALT, LFC, insulin resistance, and atherogenic dyslipidemia in participants with NAFLD/NASH. (ClinicalTrials.gov identifier  NCT03061721.).</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.32010" target="_blank" rel="noopener"> Sex-Specific Regulation of Interferon-γ Cytotoxicity in Mouse Liver by Autophagy.</a></p>
<p>s Decreased hepatocyte autophagy sensitizes mice to IFNγ-induced liver injury and inflammation through overactivation of STAT1 signaling that causes NOS2 overexpression. Hepatotoxicity is restricted to female mice, suggesting that sex-specific effects of defective autophagy may underlie the increased susceptibility of females to IFNγ-mediated immune diseases.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31987" target="_blank" rel="noopener"> Single-Cell Transcriptomic Analysis Reveals a Hepatic Stellate Cell-Activation Roadmap and Myofibroblast Origin During Liver Fibrosis in Mice.</a></p>
<p>s This study provides a transcriptional roadmap for the activation of HSCs during liver fibrosis and yields comprehensive evidence that the differential transcriptomic features of HSCs and PFs, along with their relative contributions to liver fibrosis of different etiologies, should be considered in developing effective antifibrotic therapeutic strategies.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31773" target="_blank" rel="noopener"> Sirtuin 2 Prevents Liver Steatosis and Metabolic Disorders by Deacetylation of Hepatocyte Nuclear Factor 4α.</a></p>
<p>s Collectively, the present study provided evidence that SIRT2 functions as a crucial negative regulator in NAFLD and related metabolic disorders and that targeting the SIRT2-HNF4α pathway may be a promising strategy for NAFLD treatment.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31912" target="_blank" rel="noopener"> Spatiotemporal Phylodynamics of Hepatitis C Among People Who Inject Drugs in India.</a></p>
<p>s This study characterizes HCV phylodynamics among PWID in a low and middle-income country setting. Heterogeneity and recent genetic linkage of HCV across geographically disparate Indian states suggest that targeted interventions could help prevent reimportation of virus through drug trafficking routes.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.32029" target="_blank" rel="noopener"> Splicing Factor SLU7 Prevents Oxidative Stress-Mediated Hepatocyte Nuclear Factor 4α Degradation, Preserving Hepatic Differentiation and Protecting From Liver Damage.</a></p>
<p>s Our results place SLU7 at the highest level of hepatocellular identity control, identifying SLU7 as a link between stress-protective mechanisms and liver differentiation. These findings emphasize the importance of the preservation of hepatic functions in the protection from liver injury.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31811" target="_blank" rel="noopener"> State-Level HCC Incidence and Association With Obesity and Physical Activity in the United States.</a></p>
<p>s There is wide state-level variation in racial/ethnic disparity of HCC incidence. There are also disparate incidence trends across states, with HCC incidence continuing to increase in over half of the states. Regional obesity and lack of physical activity have moderate correlations with HCC incidence trends, suggesting that interventions targeting these factors may help curb rising HCC incidence.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31808" target="_blank" rel="noopener"> Steatotic Hepatocytes Release Mature VLDL Through Methionine and Tyrosine Metabolism in a Keap1-Nrf2-Dependent Manner.</a></p>
<p>s An imbalance between free fatty acids and Met and Tyr induces hepatic steatosis by disturbing the VLDL assembling through the Keap1-Nrf2 system.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31800" target="_blank" rel="noopener"> Stress-Responsive Gene FK506-Binding Protein 51 Mediates Alcohol-Induced Liver Injury Through the Hippo Pathway and Chemokine (C-X-C Motif) Ligand 1 Signaling.</a></p>
<p>s We identified an FKBP5-YAP-TEAD1-CXCL1 axis in the pathogenesis of ALD. Loss of FKBP5 ameliorates alcohol-induced liver injury through the Hippo pathway and CXCL1 signaling, suggesting its potential role as a target for the treatment of ALD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31817" target="_blank" rel="noopener"> Sulfatase 2 (SULF2) Monoclonal Antibody 5D5 Suppresses Human Cholangiocarcinoma Xenograft Growth Through Regulation of a SULF2-Platelet-Derived Growth Factor Receptor Beta-Yes-Associated Protein Signaling Axis.</a></p>
<p>s These results suggest that SULF2 monoclonal antibody 5D5 or related agents may be potentially promising therapeutic agents in CCA.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31906" target="_blank" rel="noopener"> T-Cell Immunoglobulin and Mucin Domain-Containing Protein-4 Is Critical for Kupffer Cell Homeostatic Function in the Activation and Resolution of Liver Ischemia Reperfusion Injury.</a></p>
<p>s TIM-4 is critical for KC homeostatic function in both the activation and resolution of liver IRI by efferocytosis.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.32033" target="_blank" rel="noopener"> Test-Retest Reliability and Consistency of HVPG and Impact on Trial Design: A Study in 289 Patients from 20 Randomized Controlled Trials.</a></p>
<p>s The test-retest reliability of HVPG is overall excellent. Within-individual variance was higher in studies including higher proportions of decompensated patients. These findings should be taken into account when performing power analysis for trials based on the effects on HVPG or when considering HVPG as a tool to guide therapy of PH.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31838" target="_blank" rel="noopener"> The Addition of C-Reactive Protein and von Willebrand Factor to Model for End-Stage Liver Disease-Sodium Improves Prediction of Waitlist Mortality.</a></p>
<p>s The addition of vWF-Ag and CRP-reflecting central pathophysiological mechanisms of PH, bacterial translocation, and inflammation, that are al drivers of mortality on the waiting list for LT-to the MELD-Na score improves prediction of waitlist mortality. Using the vWFAg-CRP-MELD-Na model for prioritizing organ allocation may improve prediction of waitlist mortality and decrease waitlist mortality.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.32034" target="_blank" rel="noopener"> The Association Between Breastfeeding and Nonalcoholic Fatty Liver Disease in Parous Women: A Nation-wide Cohort Study.</a></p>
<p>s Breastfeeding showed a protective effect against NAFLD in later life of parous women, suggesting a maternal benefit of breastfeeding on NAFLD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31739" target="_blank" rel="noopener"> The Clinical Significance of Hepatic CD69<sup>+</sup> CD103<sup>+</sup> CD8<sup>+</sup> Resident-Memory T Cells in Autoimmune Hepatitis.</a></p>
<p> Background and aims The diverse inflammatory response found in the liver of patients with autoimmune hepatitis (AIH) is well established, but identification of potentially pathogenic subpopulations has proven enigmatic. Approach and results We report herein that CD69 +  CD103 +  CD8 +  tissue-resident memory T cells (T  cell expansion.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31799" target="_blank" rel="noopener"> The Co-mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion-Driven Cholangiocarcinoma.</a></p>
<p>s Our work highlights the importance of the co-mutational spectrum as a significant modifier of response in tumors that harbor potent oncogenic drivers. A better understanding of the genetic underpinnings of resistance will be pivotal to improve biomarker-guided patient selection and to design clinically relevant combination strategies.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31732" target="_blank" rel="noopener"> The Impact of Direct-Acting Antiviral Therapy on End-Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use Disorders.</a></p>
<p>s Among the HCV SUD group, DAA treatment reduced the risk of DCC but not HCC for those who were noncirrhotic, whereas DAA treatment reduced the risk of HCC but not DCC for those with cirrhosis. Among the nontreated, patients with an SUD had a significantly higher risk of DCC and HCC compared with those without an SUD. Thus, DAA treatment should be considered for al patients with HCV and an SUD while also addressing the SUD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.32042" target="_blank" rel="noopener"> The Pannexin 1/Purinergic Receptor P2X4 Pathway Controls the Secretion of MicroRNA-Containing Exosomes by HCV-Infected Hepatocytes.</a></p>
<p>s These results suggested that HCV infection caused secretions of exosomes and exosomal miRNAs dependent on the caspase 3/Panx1/P2X4 pathway. Our study provides a possible therapeutic intervention using Panx1 suppression for liver disease development mediated by exosomes from HCV-infected hepatocytes.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31781" target="_blank" rel="noopener"> The Precise Relationship Between Model for End-Stage Liver Disease and Survival Without a Liver Transplant.</a></p>
<p>s We calculated without-transplant survival probabilities for each MELD score (and status 1A). The survival function is an invaluable tool for many applications in liver transplantation  awarding of exception points, calculating the relative demand for deceased donor livers in different geographic areas, calibrating the pediatric end-stage liver disease score, and deciding whether to accept an offered liver.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.32011" target="_blank" rel="noopener"> The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis.</a></p>
<p>s UDCA under-response in PBC is characterised by elevation of serum chemokines potentially related to cellular senescence and previously shown to be released by biliary epithelial cells in PBC, suggesting a potential role in the pathogenesis of high-risk disease. These also have potential for development as biomarkers for identification of high-risk disease and their clinical utility as biomarkers should be evaluated further in prospective studies.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31870" target="_blank" rel="noopener"> The Transcriptional Coactivator, ALL1-Fused Gene From Chromosome 9, Simultaneously Sustains Hypoxia Tolerance and Metabolic Advantages in Liver Cancer.</a></p>
<p>s AF9 is up-regulated to promote gene expression of hypoxia tolerance and glycolysis by simultaneously forming a complex with HIF1α and recognizing acetylated cMyc. Our results establish the oncogenic role of AF9 in human liver cancer, which could be a potential target for designing drugs against liver cancer.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.32012" target="_blank" rel="noopener"> Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study.</a></p>
<p>s Results of our study endorse the use of TZDs for selected patients at risk of NAFLD but do not support previous findings regarding the beneficial effect of GLP-1 receptor agonists. The low number of events in several subgroups may affect the generalizability of the current findings.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31915" target="_blank" rel="noopener"> TIPS for Adults Without Cirrhosis With Chronic Mesenteric Venous Thrombosis and EHPVO Refractory to Standard-of-Care Therapy.</a></p>
<p>s TIPS in chronic, noncirrhotic EHPVO with cavernomas and mesenteric venous thrombosis is technically feasible and does not adversely affect liver function. Most patients demonstrate subjective and objective benefit from TIPS. Improvement in patency rates are needed with proper timing of adjuvant anticoagulation.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31801" target="_blank" rel="noopener"> TNF-α-Induce Protein 8-Like 1 Inhibits Hepatic Steatosis, Inflammation, and Fibrosis by Suppressing Polyubiquitination of Apoptosis Signal-Regulating Kinase 1.</a></p>
<p>s TIPE1 protects against hepatic steatosis, inflammation, and fibrosis through directly binding ASK1 and restraining its TRAF6-catalyzed polyubiquitination during the development of NASH. Therefore, targeting TIPE1 could be a promising therapeutic approach for NAFLD treatment.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.32015" target="_blank" rel="noopener"> TNFAIP3 Interacting Protein 3 Is an Activator of Hippo-YAP Signaling Protecting Against Hepatic Ischemia/Reperfusion Injury.</a></p>
<p>s TNIP3 is a regulator of hepatic I/R injury that alleviates cell death and inflammation by assisting ubiquitination and degradation of LATS2 and the resultant YAP activation.TNIP3 represents a promising therapeutic target for hepatic I/R injury to improve the prognosis of liver surgery.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31994" target="_blank" rel="noopener"> Transcriptomic Analysis Reveals the MicroRNAs Responsible for Liver Regeneration Associated With Mortality in Alcohol-Associated Hepatitis.</a></p>
<p>s Patients with AH attempt to deal with hepatocyte injury by down-regulating specific miRNAs and up-regulating genes responsible for DNA synthesis and cell-cycle progression. Higher expression of these miRNAs, suggestive of a diminished capacity in liver regeneration, predicts short-term mortality in AH patients.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31995" target="_blank" rel="noopener"> Transcriptomics Identify Thrombospondin-2 as a Biomarker for NASH and Advanced Liver Fibrosis.</a></p>
<p>s TSP-2 may be a useful biomarker for NASH and advanced fibrosis diagnosis in patients with NAFLD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31793" target="_blank" rel="noopener"> Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice.</a></p>
<p>s Overall, we observed continued improvement in virologic response, ALT normalization, and no significant changes in eGFR following switch to TAF from TDF.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31872" target="_blank" rel="noopener"> Treatment of Retinoblastoma 1-Intact Hepatocellular Carcinoma With Cyclin-Dependent Kinase 4/6 Inhibitor Combination Therapy.</a></p>
<p>s In conclusion, CDK4/6 inhibitors have a potential to treat a wide variety of RB1-intact cancers including HCC when combined with an appropriate kinase inhibitor.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31832" target="_blank" rel="noopener"> Tumor Necrosis Factor α-Induced Protein 8-Like 2 Alleviates Nonalcoholic Fatty Liver Disease Through Suppressing Transforming Growth Factor Beta-Activated Kinase 1 Activation.</a></p>
<p>s TIPE2 suppresses NAFLD advancement by blocking TAK1-JNK/p38 pathway and is a promising target molecule for NAFLD therapy.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.32000" target="_blank" rel="noopener"> YAP/TAZ Suppress Drug Penetration Into Hepatocellular Carcinoma Through Stromal Activation.</a></p>
<p>s Drug delivery into liver cancer is impaired by YAP/TAZ signaling in tumor cells and subsequent activation of stroma by the signaling. Disrupting or targeting activated tumor stroma might improve drug delivery into HCC with an elevated YAP/TAZ activity.</p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Inflamm Bowel Dis</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab153" target="_blank" rel="noopener"> A Framework for Clinical Trials of Neurobiological Interventions That Target the Gut-Brain Axis in Inflammatory Bowel Disease.</a></p>
<p>These symptoms have a significant impact on health-related quality of life and functional ability in individuals with inflammatory bowel disease. Clinical studies that generate high-quality evidence on pharmacological and nonpharmacological (eg, psychosocial, behavioral) interventions are needed to ultimately improve access to safe and effective therapies that have a meaningful impact on patients and to guide medical and regulatory decisions. This review outlines a framework for designing and conducting randomized controlled trials for interventions that target neurobiological symptoms in patients with inflammatory bowel disease based on the most recent guidance published within the past 5 years from policy makers, clinicians specialized in inflammatory bowel disease, patient-reported outcomes methodologists, health economists, patient advocates, industry representatives, ethicists, and clinical trial experts.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab021" target="_blank" rel="noopener"> A Single Educational Intervention Improves Pregnancy-Related Knowledge and Emotional Health Among Women With IBD Who Are Pregnant or Wish to Conceive.</a></p>
<p>s Uptake of this gastroenterologist-led educational intervention has the potential to improve pregnancy knowledge, promote medication adherence, and enhance quality of life for women with IBD globally.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab130" target="_blank" rel="noopener"> Achieving Histologic Normalization in Ulcerative Colitis Is Associated With a Reduced Risk of Subsequent Dysplasia.</a></p>
<p>s Histologic normalization is associated with a decreased risk in patients with UC of developing subsequent dysplasia, compared with patients without histologic normalization. These findings have implications for surveillance intervals.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab039" target="_blank" rel="noopener"> Aging and IBD: A New Challenge for Clinicians and Researchers.</a></p>
<p>In addition, we see that frailty, which results from physiologic decline, is increasing in prevalence and is associated with adverse clinical outcomes in IBD. As such, in this review we explore the potential overlapping biology of IBD and aging, discuss the risk of aging-related disorders in IBD, and describe frailty and its relation to clinical outcomes within IBD. Finally, we discuss current considerations for clinical care and potential research avenues for further investigation.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab092" target="_blank" rel="noopener"> Anti-TNF Therapy and the Risk of Herpes Zoster Among Patients With Inflammatory Bowel Disease.</a></p>
<p>s Use of anti-TNF therapy was associated with an increased risk of HZ among patients with IBD, particularly among those older than 50 years and those on combination therapy. Prevention strategies for HZ ought to be considered for younger IBD patients commencing treatment.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab046" target="_blank" rel="noopener"> Anti-Tumor Necrosis Factor-Alpha Withdrawal in Children With Inflammatory Bowel Disease in Endoscopic and Histologic Remission.</a></p>
<p>s Despite the application of rigid selection criteria, ATA cessation remains inadvisable in CD. In contrast, in UC, the concurrent achievement of MH and HH may represent promising selection criteria to identify patients in whom treatment withdrawal is feasible.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab162" target="_blank" rel="noopener"> Anxiety and Depressive Symptoms Are Not Associated With Future Pediatric Crohn&#39;s Disease Activity.</a></p>
<p> We found that neither anxiety nor depressive symptoms associate with subsequent disease activity in pediatric CD. These findings contrast with adult IBD studies, thus underschoring the unique pathophysiology, natural history, and outcomes of pediatric CD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab061" target="_blank" rel="noopener"> Clinical and Host Biological Factors Predict Colectomy Risk in Children Newly Diagnosed With Ulcerative Colitis.</a></p>
<p>s A small group of children newly diagnosed with severe UC still require colectomy despite current therapies. Our gene signature observations suggest additional targets for management of those patients not responding to current medical therapies.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab026" target="_blank" rel="noopener"> Colectomy Incidence Rates in Five-Year Data From the Observational Postmarketing Ulcerative Colitis Study of Originator Infliximab.</a></p>
<p>s Colectomy was reported at a higher rate in the IFX group than in the ConvRx group, although patients in the IFX group had more severe disease at baseline and most of the colectomies occurred after patients had been off of IFX for ≥90 days.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab042" target="_blank" rel="noopener"> Collecting New Peak and Intermediate Infliximab Levels to Predict Remission in Inflammatory Bowel Diseases.</a></p>
<p>s This study showed the clinical relevance of measuring new infliximab levels to predict remission in patients with IBD. These findings lay the foundation for a personalized medicine in which biotherapies could be monitored at an early stage, thereby improving patients&#39; clinical management.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab164" target="_blank" rel="noopener"> Colorectal Cancer Prevention in Inflammatory Bowel Disease: A Systematic Analysis of the Overall Quality of Guideline Recommendations.</a></p>
<p>s Many guidelines do not provide recommendations on key aspects of CRC prevention in IBD. Over 90% of recommendations are based on low- to moderate-quality evidence; therefore, further studies on CRC prevention in IBD are needed to improve the overall quality of evidence.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab063" target="_blank" rel="noopener"> Combination of Vedolizumab With Tacrolimus Is More Efficient Than Vedolizumab Alone in the Treatment of Experimental Colitis.</a></p>
<p>s Our data show that vedolizumab reduces the number of innate and adaptive immune cells in the mucosa of patients with UC. Further, the combination of vedolizumab with tacrolimus was more efficient to reduce immune cell numbers and to increase therapeutic efficacy than vedolizumab monotreatment. This finding indicates that combination treatment using these two drugs may be beneficial for patients who do not respond to vedolizumab monotherapy.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab030" target="_blank" rel="noopener"> Computational Learning of microRNA-Based Prediction of Pouchitis Outcome After Restorative Proctocolectomy in Patients With Ulcerative Colitis.</a></p>
<p>s We developed and validated a computational miRNA-based algorithm for accurately predicting R/CP in patients with UC after IPAA.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab068" target="_blank" rel="noopener"> Demographic Factors Associated With Successful Telehealth Visits in Inflammatory Bowel Disease Patients.</a></p>
<p>s There is a high success rate for telehealth within an IBD population with defined clinic protocols. Certain patient characteristics such as age, race, and health insurance type increase the risk of failure of a video visit.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab136" target="_blank" rel="noopener"> Depressive Symptoms Predict Clinical Recurrence of Inflammatory Bowel Disease.</a></p>
<p> In IBD, depressive symptoms and inflammatory activity are intimately related. Depressive symptoms were a strong predictor of clinical deterioration, and genetic markers may play a role in this relationship.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab147" target="_blank" rel="noopener"> Development and Validation of a Pediatric MRI-Based Perianal Crohn Disease (PEMPAC) Index-A Report from the ImageKids Study.</a></p>
<p>s Using a blended judgmental and mathematical approach, we developed and validated an index for quantifying the severity of perianal disease in children with CD. The adult VAI may also be used with confidence in children.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab091" target="_blank" rel="noopener"> Development of Balanced Whole System Value Measures for Inflammatory Bowel Disease Care in the IBD Qorus Collaborative Using a Modified Delphi Process.</a></p>
<p> The modified Delphi process led to selection of 10 value measures across 4 domains  (1) patient experience; (2) functional status; (3) clinical status; and (4) health care costs and utilization. We have successfully completed a 3-stage modified Delphi process to develop a balanced set of value measures for adult IBD care. The value measure set expands upon prior efforts that have established quality measures for IBD care by adding cost and experience of care elements. This work positions IBD Qorus to better assess, study, improve, and demonstrate value at individual, system, and population levels and will inform and empower related research, improvement, and implementation efforts.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab124" target="_blank" rel="noopener"> Disease Activity Indices for Pouchitis: A Systematic Review.</a></p>
<p>s Development and validation of a specific pouchitis disease activity index is needed given that existing instruments are not valid, reliable, or responsive.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab085" target="_blank" rel="noopener"> Early-Life Exposure to Antibiotics and Risk for Crohn&#39;s Disease: A Nationwide Danish Birth Cohort Study.</a></p>
<p>s Antibiotic use in the first year of life is associated with a modestly increased risk for CD, although the absolute risk is very low.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab027" target="_blank" rel="noopener"> Effectiveness and Safety of Nonmedical Switch From Adalimumab Originator to SB5 Biosimilar in Patients With Inflammatory Bowel Diseases: Twelve-Month Follow-Up From the TABLET Registry.</a></p>
<p>s We found that SB5 seemed effective and safe in IBD, both in the naïve cohort and in the switching cohort. Further studies are needed to confirm these data in terms of mucosal healing.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab163" target="_blank" rel="noopener"> Efficacy of Vedolizumab in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients.</a></p>
<p>s In a nationwide real-world retrospective cohort study of elderly IBD patients, we found that the efficacy of VDZ was similar among younger and older IBD patients and comparable with the published data in clinical trials.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab134" target="_blank" rel="noopener"> Endoscopic Prediction of Crohn&#39;s Disease Postoperative Recurrence.</a></p>
<p>s The POCER postoperative index comprises 2 key endoscopic factors related to the anastomosis that are associated with subsequent disease progression. A higher score, comprising the adverse prognostic factors of deep or circumferentially extensive anastomotic ulceration, may help identify patients who require more intensive therapy.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab020" target="_blank" rel="noopener"> Evaluation of a U.S. National Cohort to Determine Utilization in Colectomy Rates for Ulcerative Colitis Among Ethnicities.</a></p>
<p>s Racial and geographical disparities persist for the rate of colectomy among hospitalized patients with UC. The national database analysis reveals that colectomy rates for hospitalized African American and Hispanic patients were lower than those for White patients. Further studies are important to determine the social and biologic foundations of these disparities.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab086" target="_blank" rel="noopener"> Fecal Diversion for Perianal Crohn Disease in the Era of Biologic Therapies: A Multicenter Study.</a></p>
<p>s In this multicenter study, biologics were associated with bowel restoration and avoidance of proctectomy after fecal diversion without proctectomy for PCD; however, a minority of patients achieved sustained fistula healing after initial fecal diversion or after bowel restoration. These results highlight the refractory nature of PCD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab109" target="_blank" rel="noopener"> Granulomas in Diagnostic Biopsies Associated With High Risk of Crohn&#39;s Complications-But May Be Preventable.</a></p>
<p>s Granulomas are associated with increased risk of perianal fistula but not stricture. Steroid sparing therapies seem to reduce the risk of both perianal fistula and stricture. For those with granulomas, anti-TNF-α therapy greatly reduced the risk of perianal fistula development, whereas immunomodulators did not.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab072" target="_blank" rel="noopener"> HG-9-91-01 Attenuates Murine Experimental Colitis by Promoting Interleukin-10 Production in Colonic Macrophages Through the SIK/CRTC3 Pathway.</a></p>
<p>s We found that HG-9-91-01 promoted the IL-10 expression of colonic macrophages and exhibited its anticolitis activity through the SIK/CRTC3 axis, and thus it may represent a promising strategy for inflammatory bowel disease therapy.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab069" target="_blank" rel="noopener"> Histological Inflammation in the Endoscopically Uninflamed Mucosa is Associated With Worse Outcomes in Limited Ulcerative Colitis.</a></p>
<p>s The presence of histological inflammation in the endoscopically uninflamed mucosa at the time of diagnosis was associated with worse outcomes in limited UC.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab037" target="_blank" rel="noopener"> Hit the Road JAK! The Role of New Oral Treatment in Inflammatory Bowel Disease.</a></p>
<p>Several other JAK inhibitors are currently being investigated. However, given the wide spectrum of immunosuppressive effects, special attention has been given to the safety profile of these drugs, namely with regard to the occurrence of thromboembolic events, opportunistic infections, and malignancy. In this article, we review key evidence on the efficacy and safety of JAK inhibitors concerning both UC and CD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab029" target="_blank" rel="noopener"> Human Intestinal Macrophages Are Involved in the Pathology of Both Ulcerative Colitis and Crohn Disease.</a></p>
<p>s Our data support the therapeutic targeting of macrophages to maintain remission in IBD but also indicate that a shift toward an M2 program-as proposed by some reports-may not limit the recruitment and activation of T cells because M2 features do not preclude M1 activation in patients with UC or CD and could exacerbate M2-related CD-specific features such as fibrosis and the formation of granulomas.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab081" target="_blank" rel="noopener"> Ileocolic Resection for Crohn Disease: The Influence of Different Surgical Techniques on Perioperative Outcomes, Recurrence Rates, and Endoscopic Surveillance.</a></p>
<p>Recurrence of CD after ICR is common, often clinically silent, and thus requires monitoring including periodic use of endoscopy to detect early active disease. There is emerging evidence that surgical approaches may influence CD recurrence. This review explores the various surgical considerations, the data behind each decision, and how these techniques influence subsequent endoscopic surveillance.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab022" target="_blank" rel="noopener"> Ileocolonic Healing After Extended Small Bowel Resection in Mice: NOD2 Deficiency Impairs Anastomotic Healing and Postoperative Outcome.</a></p>
<p>s We found that Nod2 deficiency results in significantly reduced bursting pressure after ileocecal resection. This effect is mediated via an increased matrix turnover. Patients with genetic NOD2 variations may be prone to anastomotic failure after bowel resection.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab132" target="_blank" rel="noopener"> Immunomodulatory Effect of Serum Exosomes From Crohn Disease on Macrophages via Let-7b-5p/TLR4 Signaling.</a></p>
<p>s Our study indicated that serum exosomes can circulate into the intestinal mucosa to aggravate colitis by regulating macrophage activation and epithelial barrier function. In addition, CD showed altered exosomal miRNA profiles. Furthermore, serum exosome-mediated let-7b-5p-mimic delivery may significantly alleviate colitis, providing potential novel insight into an exosome-based strategy for the diagnosis and treatment of CD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab110" target="_blank" rel="noopener"> Increasing Biosimilar Utilization at a Pediatric Inflammatory Bowel Disease Center and Associated Cost Savings: Show Me the Money.</a></p>
<p>s Through QI methodology, we increased biosimilar utilization from 1% to 96% with sustained improvement, without compromising patient outcomes or safety. Estimated cost savings were substantial. Similar methodology could be implemented at other institutions to increase biosimilar utilization and potentially decrease health care costs.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab096" target="_blank" rel="noopener"> Increasing Prevalence and Stable Incidence Rates of Inflammatory Bowel Disease Among First Nations: Population-Based Evidence From a Western Canadian Province.</a></p>
<p>s We provided population-based evidence of the increasing prevalence and stable incidence rates of IBD among FNs. Further studies are needed in other regions to continue understanding the patterns of IBD among Indigenous peoples.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab125" target="_blank" rel="noopener"> Intestinal Ultrasound in Pediatric Inflammatory Bowel Disease: Promising, but Work in Progress.</a></p>
<p>The most important parameters of inflammation that can be assessed using IUS are bowel wall thickness and hyperemia of the bowel wall. Research has shown that IUS has the potential to be a valuable additional point-of-care tool to guide treatment choice and to monitor and predict treatment response, although evidence of its accuracy and value in clinical practice is still limited. This review gives an update and overview of the current evidence on the use and accuracy of IUS in children with inflammatory bowel disease.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab126" target="_blank" rel="noopener"> Is Intestinal Diversion an Effective Treatment for Distal Crohn&#39;s Disease?</a></p>
<p>s The use of a &quot;temporary&quot; ileostomy is largely ineffective in achieving clinical response.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab034" target="_blank" rel="noopener"> Liver X Receptor Exerts Anti-Inflammatory Effects in Colonic Epithelial Cells via ABCA1 and Its Expression Is Decreased in Human and Experimental Inflammatory Bowel Disease.</a></p>
<p>s The LXR-ABCA1 pathway exerts anti-inflammatory effects in intestinal epithelial cells and is impaired in the colonic mucosa of patients with IBD and IL-10-/- mice.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab073" target="_blank" rel="noopener"> Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial.</a></p>
<p>s Ferric maltol achieved clinically relevant increases in hemoglobin but did not show noninferiority vs ferric carboxymaltose at week 12. Both treatments had comparable long-term effectiveness for hemoglobin and ferritin over 52 weeks and were well tolerated.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab031" target="_blank" rel="noopener"> Monocytosis Is a Biomarker of Severity in Inflammatory Bowel Disease: Analysis of a 6-Year Prospective Natural History Registry.</a></p>
<p>s Patients with IBD with monocytosis, regardless of disease type, are at increased risk for worse clinical outcomes, hospitalization, surgery, and ED use. Peripheral monocytosis may represent a routinely available biomarker of a distinct subgroup with severe disease.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab099" target="_blank" rel="noopener"> Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study.</a></p>
<p>s Multiple successive switching and switching between biosimilars of IFX seemed to be effective and safe.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab044" target="_blank" rel="noopener"> Natural History and Risk Stratification of Recurrent Crohn&#39;s Disease After Ileocolonic Resection: A Multicenter Retrospective Cohort Study.</a></p>
<p>s Our results suggest that patients with a combination of any 3 or more European Crohns &amp; Colitis Organisation- or British Society of Gastroenterology-defined risk factors would probably benefit from immediate prophylactic treatment.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab064" target="_blank" rel="noopener"> Nonhypoalbuminemic Inflammatory Bowel Disease in Dogs as Disease Model.</a></p>
<p>s Our data described dysregulated immune responses in dogs affected by IBD without protein loss. Despite fairly homogeneous dog cohorts, we were still faced with interindividual variability, and new studies with larger cohorts are needed to validate the dog as a model.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izaa362" target="_blank" rel="noopener"> Novel Genetic Variant Predicts Surgical Recurrence Risk in Crohn&#39;s Disease Patients.</a></p>
<p>s Novel genetic locus rs2060886 in TCF4 was associated with surgical recurrence risk at genome-wide significance level among CD patients after their first abdominal surgery. Early era of CD first intestinal surgery predicts higher surgical recurrence risk. These results suggest that genetic variants may help guide the CD management strategy in patients at the highest risk of repeated abdominal surgeries.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab032" target="_blank" rel="noopener"> Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease.</a></p>
<p>s We found that OSM is a diagnostic biomarker in the tissue and serum not only of newly diagnosed patients with IBD and postoperative patients with recurrent CD but also of their FDRs. Higher colonic OSM levels are furthermore associated with poor prognosis and with primary nonresponse to biologic therapies. Therefore, OSM could guide clinical decision-making.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izaa364" target="_blank" rel="noopener"> Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease.</a></p>
<p>s Reverse switching occurred in 9.9% of patients, predominantly for biosimilar-attributed adverse effects. Switching back to originator infliximab seems effective in patients who experience adverse effects, worsening gastrointestinal symptoms, or loss of response after switching from originator infliximab to CT-P13.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab025" target="_blank" rel="noopener"> Overexpression of Cancer-Associated Stem Cell Gene OLFM4 in the Colonic Epithelium of Patients With Primary Sclerosing Cholangitis.</a></p>
<p>s Higher expression of OLFM4, a cancer stemness gene induced by IL-22, is present in PSC-UC, suggesting that IL-22 responses may result in alterations of the intestinal stem-cell niche in these patients.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab084" target="_blank" rel="noopener"> Patients With Inflammatory Bowel Disease on Treatment Have Lower Rates of Celiac Disease.</a></p>
<p>s In this large dataset, we showed a bidirectional association between celiac disease and IBD that was stronger with CD. Patients with IBD treated using corticosteroids, 5-aminosalicylates, immunomodulators, or anti-tumor necrosis factor drugs had a lower association with celiac disease. Additional studies are required to determine the underlying mechanisms for IBD therapy-related modification of celiac disease incidence.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab143" target="_blank" rel="noopener"> Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study.</a></p>
<p>s Model-informed dosing of vedolizumab in CD provides a foundation for future research aiming to maximize endoscopic remission rates.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab152" target="_blank" rel="noopener"> Posttraumatic Stress in Patients With Inflammatory Bowel Disease: Prevalence and Relationships to Patient-Reported Outcomes.</a></p>
<p>s The present findings support prior research that approximately one-quarter to one-third of patients with IBD report significant symptoms of PTS directly from their disease experiences, and certain demographic groups are at higher risk. In addition, PTS is associated with several IBD outcomes. Patients with higher PTS symptoms are less likely to be in remission and may utilize more outpatient gastrointestinal services. Intervention trials to mitigate PTS symptoms in patients with IBD are warranted.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izaa273" target="_blank" rel="noopener"> PPARγ: The Central Mucus Barrier Coordinator in Ulcerative Colitis.</a></p>
<p>More important, PPARγ has been shown to affect host-microbiota interactions by modulating the energy metabolism of colonocytes and the oxygen availability of the intestinal microbiome. It is well known that gut microbiota homeostasis is essential for butyrate generation by the commensal bacteria to supply energy resources for colonocytes. Therefore, it can be speculated that PPARγ, as a central coordinator of the mucus barrier, may be a promising target for the development of effective agents to combat UC.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab083" target="_blank" rel="noopener"> Randomized Controlled Trial of Cognitive-Behavioral and Mindfulness-Based Stress Reduction on the Quality of Life of Patients With Crohn Disease.</a></p>
<p>s COBMINDEX was effective in increasing patients&#39; quality of life and reducing psychological symptoms and fatigue. Patients with severe baseline psychological symptoms benefited the most from COBMINDEX.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab116" target="_blank" rel="noopener"> Randomized Controlled Trial Substudy of Cell-specific Mechanisms of Janus Kinase 1 Inhibition With Upadacitinib in the Crohn&#39;s Disease Intestinal Mucosa: Analysis From the CELEST Study.</a></p>
<p>s Upadacitinib modulates inflammatory pathways in mucosal lesions of patients with anti-TNF-refractory Crohn&#39;s disease, including inflammatory fibroblast and interferon-γ-expressing cytotoxic T cell compartments. This substudy is the first to describe the molecular response to JAK1 inhibition in inflammatory bowel disease and differential effects relative to anti-TNF treatment. (Clinical trial identifier  NCT02365649).</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab065" target="_blank" rel="noopener"> Randomized Controlled Trial: Perioperative Dexamethasone Reduces Excessive Postoperative Inflammatory Response and Ileus After Surgery for Inflammatory Bowel Disease.</a></p>
<p> A single, intravenous 8-mg dose of dexamethasone upon induction of anesthesia reduced the incidence of prolonged postoperative ileus, the intensity of postoperative pain, and shortened the postoperative length of stay for IBD patients undergoing elective surgery. ClinicalTrials.gov  NCT03456752.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab015" target="_blank" rel="noopener"> Re-induction With Intravenous Ustekinumab in Patients With Crohn&#39;s Disease and a Loss of Response to This Therapy.</a></p>
<p> Intravenous re-induction with ustekinumab is an effective and safe strategy that recovers the response in approximately half of the patients with refractory Crohn&#39;s disease who experience a loss of response. Re-induction can be attempted before switching out of the therapy class.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab011" target="_blank" rel="noopener"> Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis.</a></p>
<p>s This meta-analysis of real-world studies confirms the effectiveness of tofacitinib in a highly refractory population of patients with moderate to severely active UC. Tofacitinib showed an acceptable safety profile. These findings were consistent with clinical trials and further support the use of tofacitinib in UC.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab062" target="_blank" rel="noopener"> Residual Short-Segment Distal Inflammation Has No Significant Impact on the Major Relapse of Extensive Ulcerative Colitis.</a></p>
<p>s Residual short-segment distal inflammation is not a risk factor for major relapses as long as endoscopic remission is achieved in the proximal colon. Therefore, reactive but not proactive treatment may be appropriate for such lesions.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab117" target="_blank" rel="noopener"> Response to Anti-α4β7 Blockade in Patients With Ulcerative Colitis Is Associated With Distinct Mucosal Gene Expression Profiles at Baseline.</a></p>
<p>s Nonresponse to vedolizumab in UC is associated with specific pretreatment gene-expression mucosal signatures and dysregulation of particular immunological and inflammatory pathways. Baseline mucosal and/or systemic molecular profiling may help in the optimal stratification of patients to receive vedolizumab for active UC.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab135" target="_blank" rel="noopener"> Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise.</a></p>
<p>Deucravacitinib, a novel, oral, selective TYK2 inhibitor, and brepocitinib and PF-06826647, TYK2 inhibitors that bind to the active site in the catalytic domain, are in development for IBD and other immune-mediated inflammatory diseases. Allosteric TYK2 inhibition is more selective than JAK1-3 inhibition and has the potential to limit toxicities typically associated with JAK1-3 inhibitors. Future studies will be important in establishing the role of selective, allosteric TYK2 inhibition in the management of IBD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab123" target="_blank" rel="noopener"> Serum Analyte Profiles Associated With Crohn&#39;s Disease and Disease Location.</a></p>
<p>s Multiple serum analytes are elevated in CD. These implicate the involvement of multiple cell types from the immune, epithelial, and endothelial systems, suggesting that circulating analytes reflect the inflammatory processes that are ongoing within the gut. Moreover, the identification of distinct profiles according to disease location supports the existence of a biological difference between ileal and colonic CD, consistent with previous genetic and clinical observations.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab082" target="_blank" rel="noopener"> Site- and Taxa-Specific Disease-Associated Oral Microbial Structures Distinguish Inflammatory Bowel Diseases.</a></p>
<p>s Collectively, these data indicate the potential of using oral microbial profiles in screening and monitoring patients with IBD. Furthermore, these results support the importance of spatial and longitudinal microbiome sampling to interpret disease-associated dysbiotic states and eventually to gain insights into disease pathogenesis.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab033" target="_blank" rel="noopener"> Suboptimal Vaccination Administration in Mothers With Inflammatory Bowel Disease and Their Biologic-Exposed Infants.</a></p>
<p>s Better education surrounding vaccine recommendations is required for both health care providers and individuals with IBD given poor pneumococcal, hepatitis A virus, and influenza vaccination rates. Inadvertent administration of the rotavirus vaccine in biologic-exposed infants did not result in more adverse events, raising the possibility of safety.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab024" target="_blank" rel="noopener"> Targeting Immune Cell Metabolism in the Treatment of Inflammatory Bowel Disease.</a></p>
<p>Insight into perturbations in immune cell metabolic pathways and their impact on inflammatory bowel disease (IBD) progression are starting to emerge. However, it remains to be determined whether the aberrations in immune metabolism that occur in gut resident immune cells contribute to disease pathogenesis or are reflected in the peripheral blood of patients with IBD. In this review, we explore what is known about the metabolic profile of T cells, monocytes, macrophages, dendritic cells, and natural killer cells in IBD and discuss the potential of manipulating immune cell metabolism as a novel approach to treating IBD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab098" target="_blank" rel="noopener"> The Effectiveness and Safety of Hyperbaric Oxygen Therapy in Various Phenotypes of Inflammatory Bowel Disease: Systematic Review With Meta-analysis.</a></p>
<p>s Limited high-quality evidence suggests that HBOT is safe and associated with substantial rates of clinical remission for multiple IBD phenotypes. Well-designed randomized controlled trials are warranted to confirm the benefit of HBOT in IBD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab089" target="_blank" rel="noopener"> The Impact of Alcohol in Inflammatory Bowel Diseases.</a></p>
<p>Nonetheless, most alcohol-mediated effects seem to facilitate intestinal inflammation and consequently impact disease onset, recurrence, and symptom control. Furthermore, alcohol use interferes with the metabolism of several medications leading to increased side effect profiles or even loss of effect. Notably, mesalamine, azathioprine, methotrexate, and biologic medications can al be affected by concomitant alcohol intake via a variety of mechanisms.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab104" target="_blank" rel="noopener"> The Importance of Monitoring the Postpartum Period in Moderate to Severe Crohn&#39;s Disease.</a></p>
<p> In a cohort of Crohn&#39;s disease patients, 30% experienced a postpartum flare despite being on medical therapy, but most were able to be managed in the outpatient setting.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab038" target="_blank" rel="noopener"> The Pathogenesis and Clinical Management of Stricturing Crohn Disease.</a></p>
<p>Although medications can improve inflammation, there is still no drug to attenuate scar formation. As such, management of stricturing disease requires a multidisciplinary and individualized approach including medical management, therapeutic endoscopy, and surgery. This review details the current understanding regarding the pathogenesis, detection, and management of stricturing Crohn disease.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izaa294" target="_blank" rel="noopener"> The Patterns of Use of Medications for Inflammatory Bowel Disease During Pregnancy in the US and Sweden Are Changing.</a></p>
<p>s In this population-based study from 2 countries, the proportion of women with IBD treatment in pregnancy remained relatively constant. TNF-inhibitor use increased substantially in both countries.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab035" target="_blank" rel="noopener"> The Use of Readily Available Longitudinal Data to Predict the Likelihood of Surgery in Crohn Disease.</a></p>
<p>s Using machine learning methods that incorporate current and historical data can predict the future risk of CD surgery.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izaa352" target="_blank" rel="noopener"> Tissue Proteomic Approaches to Understand the Pathogenesis of Inflammatory Bowel Disease.</a></p>
<p>Therefore, limited clinical progress in diagnosis, assessment of disease activity, and optimal therapeutic regimens have been made over the past few decades. This review explores recent advances and challenges in tissue proteomics with an emphasis on biomarker discovery and better understanding of the molecular mechanisms underlying IBD pathogenesis. Future multi-omic studies are required for the comprehensive molecular characterization of disease biology in real time with a future impact on early detection, disease monitoring, and prediction of the clinical outcome.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab056" target="_blank" rel="noopener"> Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program.</a></p>
<p>s For patients receiving tofacitinib, NMSC occurred infrequently. Older age, prior NMSC, and TNFi failure, which are previously reported NMSC risk factors in patients with UC, were associated with increased NMSC risk.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab007" target="_blank" rel="noopener"> Trajectories of Fatigue in Inflammatory Bowel Disease.</a></p>
<p>s The results clearly showed the existence of distinct fatigue paths over time in patients with IBD. Those reporting more chronic elevated levels of fatigue also reported greater disease activity and reduced well-being. Therefore, reducing disease activity may be important for the treatment of fatigue. In addition, given the significant association with well-being, it is possible that reducing fatigue may improve self-reported well-being.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab017" target="_blank" rel="noopener"> Trends and Outcomes of Acute Diverticulitis in Inflammatory Bowel Disease: A Propensity-matched National Study.</a></p>
<p>s Patients with IBD are at increased risk of complicated diverticulitis and worse outcomes compared with matched controls. Optimal AD management strategies in IBD are needed.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab074" target="_blank" rel="noopener"> Trends in U.S. Health Care Spending on Inflammatory Bowel Diseases, 1996-2016.</a></p>
<p>s Even after adjusting for rising prevalence, U.S. health care spending on IBD continues to progressively increase, primarily in middle-aged and older adults, with unplanned health care utilization accounting for the majority of costs.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab016" target="_blank" rel="noopener"> Ulcerative Colitis Narrative Global Survey Findings: The Impact of Living With Ulcerative Colitis-Patients&#39; and Physicians&#39; View.</a></p>
<p> of the emotional impact of UC during routine appointments was less of a priority for physicians, compared with patients. Conclusions The data from this global survey highlight that patients with UC experience diagnostic delay, poor disease control, and adverse impact on their quality of life. Patients report UC to be a mentally exhausting condition; however, emotional and mental health issues are infrequently discussed at routine appointments.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab059" target="_blank" rel="noopener"> Ultra-high Magnification Endocytoscopy and Molecular Markers for Defining Endoscopic and Histologic Remission in Ulcerative Colitis-An Exploratory Study to Define Deep Remission.</a></p>
<p>s Endocytoscopy represents an interesting tool that may sit between endoscopy and histology-but closer to the latter-identifying gene expression markers and pathways that are also identified by histology.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab093" target="_blank" rel="noopener"> Unique Regulation of Coupled NaCl Absorption by Inducible Nitric Oxide in a Spontaneous SAMP1/YitFc Mouse Model of Chronic Intestinal Inflammation.</a></p>
<p>Moreover, the altered phosphorylation levels of DRA was restored by L-NIL treatment. Inducible NO mediates the inhibition of coupled NaCl absorption by decreasing Cl:HCO3 but not Na:H exchange. Specifically, Cl:HCO3 exchanger DRA but not PAT1 is regulated at the level of its phosphorylation by iNO in the chronically inflamed intestine.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab122" target="_blank" rel="noopener"> Utilizing Deep Learning to Analyze Whole Slide Images of Colonic Biopsies for Associations Between Eosinophil Density and Clinicopathologic Features in Active Ulcerative Colitis.</a></p>
<p>s We developed a deep learning algorithm to quantify eosinophils in colonic biopsies. Eosinophil density did not correlate with histologic activity but did correlate with disease extent and corticosteroid use. Future studies applying this algorithm in larger cohorts with longitudinal follow-up are needed to further elucidate the role of eosinophils in ulcerative colitis.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab060" target="_blank" rel="noopener"> Vedolizumab Clinical Decision Support Tool Predicts Efficacy of Vedolizumab But Not Ustekinumab in Refractory Crohn&#39;s Disease.</a></p>
<p> The VDZ-CDST predicts clinical remission and SFCR at week 48 for vedolizumab but not for ustekinumab in CD patients refractory or intolerant to anti-TNF.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab053" target="_blank" rel="noopener"> Vedolizumab Tissue Concentration Correlates to Mucosal Inflammation and Objective Treatment Response in Inflammatory Bowel Disease.</a></p>
<p>s Tissue levels of VDZ may provide a better marker than serum levels for mucosal inflammation and objective treatment outcome at week 16. The potential of VDZ tissue levels for therapeutic drug monitoring in inflammatory bowel disease warrants further exploration.</p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">J Crohns Colitis</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab043" target="_blank" rel="noopener"> &#39;These Discussions Aren&#39;t Happening&#39;: Experiences of People Living with Inflammatory Bowel Disease and Talking About Sexual Well-being with Health Care Professionals.</a></p>
<p>s Patients&#39; needs and preferences, about addressing during clinical appointments concerns related to their sexual well-being, should be addressed routinely and competently by health care professionals. Understanding the implications of inflammatory bowel disease for intimate aspects of the lives of those living with the condition could improve the quality of the care provided.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab103" target="_blank" rel="noopener"> A Crohn&#39;s disease-associated IL2RA enhancer variant determines the balance of T cell immunity by regulating responsiveness to IL-2 signaling.</a></p>
<p>s rs61839660 regulates the responsiveness of T cells to IL-2 signaling by modulating CD25 expression. As low dose IL-2 is being trialed as a selective Treg modulator in CD, these findings highlight the potential for adverse effects in patients with this genotype.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab082" target="_blank" rel="noopener"> Acceptance and perceived control are independently associated with quality of life in inflammatory bowel disease: Introduction of a new segmentation model.</a></p>
<p>s The segmentation model based on disease acceptance and perceived control is valid in IBD patients and discriminates different segments that correlate independently with quality of life. This may open new strategies for patient care.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab101" target="_blank" rel="noopener"> Alteration in urease-producing bacteria in the gut microbiomes of patients with inflammatory bowel diseases.</a></p>
<p>s Unlike al non-IBD controls, patients with IBD often showed a shift towards Bacilli or Proteobacteria or a complete loss of urease production. Probiotics containing the species S. thermophilus may have a protective effect against colonization by undesirable urease-producing bacteria in a subset of patients with a pouch.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab039" target="_blank" rel="noopener"> Association between inflammatory bowel disease and psychiatric morbidity and suicide: A Swedish nationwide population-based cohort study with sibling comparisons.</a></p>
<p> Adult-onset IBD was associated with an increased risk of psychiatric disorders and suicide attempts. Psychological follow-up should be provided to patients with IBD, especially those with extraintestinal manifestations and elderly-onset IBD. This follow-up should transpire within the first year after IBD diagnosis.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab037" target="_blank" rel="noopener"> Bariatric Surgery and Risk of New-onset Inflammatory Bowel Disease: A Nationwide Cohort Study.</a></p>
<p>s This nationwide cohort study shows that bariatric surgery is associated with increased risk of development of new-onset CD, but not of UC. The underlying mechanisms remain elusive.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab035" target="_blank" rel="noopener"> Colitis Linked to Endoplasmic Reticulum Stress Induces Trypsin Activity Affecting Epithelial Functions.</a></p>
<p>s Excessive ER stress in IECs caused an increased release of trypsin activity that, in turn, altered intestinal barrier function, promoting the development of inflammatory process.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab068" target="_blank" rel="noopener"> Colonic Strictures in Inflammatory Bowel Disease: Epidemiology, Complications, and Management.</a></p>
<p>Over the past few decades, our therapeutic arsenal for IBD has been reinforced by biologics and therapeutic endoscopy. Few studies have focused on colonic strictures, and so current therapeutic strategies are based on a low level of evidence and applied by analogy with the treatment of ileal strictures. With a view to facilitating the decision making process in clinical practice, we reviewed the literature on the epidemiology, natural history, and management of colonic strictures in IBD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab111" target="_blank" rel="noopener"> Diagnostic Performance of Diffusion-weighted Imaging for Evaluation of Bowel Inflammation in Pediatric Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.</a></p>
<p>s DWI-MRE, especially when used with spasmolytics, is accurate for the detection of bowel inflammation in pediatric patients with suspected or known IBD. Quantitative measurement of ADC is not practical for this purpose.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab118" target="_blank" rel="noopener"> Disease prognostic biomarkers in Inflammatory Bowel Diseases - a reality check.</a></p>
<p>disease predictive biomarkers). Despite the widely accepted need for such biomarkers to improve the management of IBD patients, their development has proven to be challenging for a number of reasons. Based on our own experience in this field we perform a reality check on existing evidence, discuss main challenges and outline future perspectives.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab034" target="_blank" rel="noopener"> Diving into Inflammation: A Pilot Study Exploring the Dynamics of the Immune-Microbiota Axis in Ileal Tissue Layers of Patients with Crohn&#39;s Disease.</a></p>
<p>s We describe a dissimilarity of cytokine distribution and microbiota composition within CD and adjacent healthy ileal tissue layers and between first operation and surgical relapse. Our results give potential insight into the dynamics of the gut microbiota-immune axis in CD patients, leading to detection of new biomarkers.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab067" target="_blank" rel="noopener"> Dose optimisation for Loss of Response to Vedolizumab- Pharmacokinetics and Immune Mechanisms.</a></p>
<p>s These results do not support pharmacokinetics as the mechanism responsible for loss of response to vedolizumab, nor do they support a need for higher drug concentration to enhance vedolizumab&#39;s immune effects. Higher pre-escalation levels may indicate less clearance [less severe disease] and higher likelihood of subsequent re-gained response, regardless of therapy escalation.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab112" target="_blank" rel="noopener"> ECCO Topical Review: Refractory Inflammatory Bowel Disease.</a></p>
<p>A proportion of patients will have disease that is refractory to licensed therapies, resulting in significant impairment in quality of life. The treatment of these patients involves a systematic approach by the entire multidisciplinary team, with particular consideration given to medical options including unlicensed therapies, surgical interventions, and dietetic and psychological support. The purpose of this review is to guide clinicians through this process and provide an accurate summary of the available evidence for different strategies.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab100" target="_blank" rel="noopener"> Effectiveness and Safety of Adalimumab Biosimilar SB5 in IBD: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naieve SB5 Observational Cohorts.</a></p>
<p> Switching from ADA originator to SB5 appeared effective and safe in this study with over 12 months of follow-up.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab070" target="_blank" rel="noopener"> Effectiveness and safety of ustekinumab in ulcerative colitis: Real-world evidence from the ENEIDA registry.</a></p>
<p>s Ustekinumab is effective both in the short and the long-term in real-life, even in a highly refractory cohort. Higher inflammatory burden at baseline correlated with lower probability of achieving remission. Safety was consistent with the known profile of ustekinumab.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab065" target="_blank" rel="noopener"> Efficacy and Safety of Tofacitinib Retreatment for Ulcerative Colitis After Treatment Interruption: Results From the OCTAVE Clinical Trials.</a></p>
<p>s Median time to treatment failure was numerically higher in induction remitters versus induction responders but non-remitters. Following treatment interruption, efficacy was safely and successfully recaptured with tofacitinib 10mg b.d. retreatment in a substantial proportion of patients. ClinicalTrials.gov NCT01458574;NCT01470612.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab026" target="_blank" rel="noopener"> Endpoints for Perianal Crohn&#39;s Disease Trials: Past, Present and Future.</a></p>
<p> In this systematic review, significant changes in outcomes used in randomized clinical trials of perianal Crohn&#39;s disease were observed. Radiological endpoints are increasingly used in perianal fistulizing Crohn&#39;s disease trials.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab047" target="_blank" rel="noopener"> Ethnic Differences in the Smoking-related Risk of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.</a></p>
<p>s This meta-analysis did not identify any increased risk of CD in smokers in ethnicities other than non-Jewish Whites, and confirmed the protective effect of smoking on UC occurrence. Future research should characterise the genetic background of CD patients across different ethnicities to improve our understanding of the role of smoking in CD pathogenesis.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab041" target="_blank" rel="noopener"> Expression of MAdCAM-1 and Gut-homing T Cells in Inflamed Pouch Mucosa.</a></p>
<p>s Gut-homing T cells are abundant in pouch mucosa, but the classic hypothesis that the chronic inflammatory state is maintained by an accumulation of α4β7-expressing effector T cells is not supported by our data.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab038" target="_blank" rel="noopener"> Fucosylation and Sialylation of Fc-Fragment of anti-Tumour Necrosis Factor Alpha Antibodies do not Influence Their Immunogenicity in Monocyte-Derived Dendritic Cells.</a></p>
<p>s The specific modification in the Fc-glycosylation pattern of anti-TNF-alpha Abs does not affect their immunogenicity under the tested conditions. As this study was limited to mo-DCs, further investigation is required to clarify whether Ab uptake into mo-DCs might change the immunological profile of T- and B-cells, in order to ultimately reduce the formation of anti-drug antibodies and to improve the patient care.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab063" target="_blank" rel="noopener"> Histological Disease Activity Measured by the Nancy Index Is Associated with Long-term Outcomes in Patients with Ulcerative Colitis.</a></p>
<p>s UC patients with histological disease activity, as measured by the Nancy index, have a greater risk of surgery and hospitalisation.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab087" target="_blank" rel="noopener"> Histopathological features in colonic biopsies at diagnosis predict long-term disease course in patients with Crohn&#39;s disease.</a></p>
<p>s In this first study investigating the additive predictive value of histopathological features in biopsies at CD diagnosis, we found that certain features of chronic inflammation in colonic biopsies contributed to prediction of a severe disease course, thereby presenting a novel approach to improve stratification and facilitate clinical decision making.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab120" target="_blank" rel="noopener"> Hypermucinous, Goblet Cell Deficient, and Crypt Cell Dysplasias in Inflammatory Bowel Disease are Often Associated with Flat/Invisible Endoscopic Appearance and Advanced Neoplasia on Follow-Up.</a></p>
<p>s Hypermucinous, goblet cell deficient, and crypt cell dysplasias have distinct clinicopathologic features but appear to have a similar high risk of association with advanced neoplasia (HGD or adenocarcinoma). Greater than half of the lesions (66%) presented as flat/invisible dysplasia, suggesting that IBD patients may benefit from random biopsy sampling in addition to targeted biopsies. Although not uncommonly associated with conventional dysplasia, non-conventional dysplasia may be the only dysplastic subtype identified in IBD patients. Therefore, it is important to recognize these non-conventional subtypes and recommend complete removal and/or careful examination and follow-up.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab060" target="_blank" rel="noopener"> Identification of three novel susceptibility loci for inflammatory bowel disease in Koreans in an extended genome-wide association study.</a></p>
<p>s The identification of novel loci not previously associated with IBD suggest the importance of studying the inflammatory bowel disease genetics in diverse populations.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab117" target="_blank" rel="noopener"> Identification of ulcers and erosions by the novel Pillcam™ Crohn&#39;s Capsule using a convolutional neural network: a multicentre pilot study.</a></p>
<p> A deep learning model capable of automatically detecting ulcers and erosions in PillCam™ Crohn&#39;s Capsule images was developed for the first time. These findings pave the way for the development of automatic systems for detection of clinically significant lesions, optimizing diagnostic performance and efficiency of monitoring Crohn&#39;s disease activity.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab085" target="_blank" rel="noopener"> Immunological networks defining the heterogeneity of inflammatory bowel diseases.</a></p>
<p>Finally, we discuss novel stratification methodologies as a foundation for precision medicine, in particular a novel stratification strategy based on conserved genes across species. All of these dimensions of heterogeneity have potential to provide strategies for patient stratification and move IBD practice towards personalized medicine.  .</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab115" target="_blank" rel="noopener"> Importance of telomere shortening in the pathogenesis of ulcerative colitis: A new treatment from the aspect of telomeres in intestinal epithelial cells.</a></p>
<p>s This study is the first to reveal the mechanism and importance of telomere shortening in the pathogenesis of UC. MD could be a novel candidate for UC treatment beyond endoscopic mucosal healing.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab036" target="_blank" rel="noopener"> Increased Risk of High-grade Cervical Neoplasia in Women with Inflammatory Bowel Disease: A Case-controlled Cohort Study.</a></p>
<p>s Women with IBD are at increased risk for CIN2+ lesions. These results underline the importance of human papillomavirus [HPV] vaccination and adherence to cervical cancer screening guidelines in IBD women, regardless of exposure to immunosuppressants.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab056" target="_blank" rel="noopener"> Inflammatory Bowel Disease in Patients with Congenital Chloride Diarrhoea.</a></p>
<p>s A substantial proportion of patients with CLD develop IBD. This suggests the potential involvement of SL26A3-mediated anion transport in IBD pathogenesis. Patients with CLD-associated IBD may require surgery for treatment failure or colon cancer.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab113" target="_blank" rel="noopener"> Inflammatory bowel disease increases the risk of venous thromboembolism in children: a population-based matched cohort study.</a></p>
<p>s The risk of VTE is much higher in children with IBD than controls without IBD. While the absolute risk is low, we found a higher incidence rate than previously described in the pediatric literature.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab102" target="_blank" rel="noopener"> Inflammatory bowel disease-associated colorectal cancer: translational risks from mechanisms to medicines.</a></p>
<p>However, the immunopathogenesis of IBD-CRC is less well understood. The impact of novel immunosuppressive therapies, which aim to achieve deep remission, is mostly unknown. Therefore, this timely review summarises the clinical context of IBD-CRC, outlines the molecular and immunological basis of disease pathogenesis and considers the impact of novel biologic therapies.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab096" target="_blank" rel="noopener"> Integrative analysis of colonic biopsies from inflammatory bowel disease patients identifies an interaction between microbial bile-acid inducible gene abundance and human Angiopoietin-like 4 gene expression.</a></p>
<p>s Endoscopic inflammation affects the abundance of crucial microbial bile acid-metabolizing genes and their interaction with Angptl4 in intestinal mucosa of IBD patients.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab093" target="_blank" rel="noopener"> Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn&#39;s Disease: Results from the Phase 2 Open-Label Extension Study.</a></p>
<p>s Long-term maintenance treatment with subcutaneous risankizumab 180 mg every 8 weeks was well tolerated by patients with Crohn&#39;s disease, with no new safety signals.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab023" target="_blank" rel="noopener"> Long-term Safety and Efficacy of the Anti-MAdCAM-1 Monoclonal Antibody Ontamalimab [SHP647] for the Treatment of Ulcerative Colitis: The Open-label Study TURANDOT II.</a></p>
<p>s Ontamalimab was well tolerated up to 144 weeks in patients with moderate-to-severe UC, with good safety and efficacy.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab098" target="_blank" rel="noopener"> Loss of PTPN22 promotes intestinal inflammation by compromising granulocyte-mediated anti-bacterial defense.</a></p>
<p>In particular, granulocyte activation and granulocyte-mediated bacteria killing was impaired upon loss of PTPN22, resulting in elevated bacterial burden and translocation beyond the intestinal epithelial barrier in PTPN22-deficient mice. Consistently, antibiotics-induced depletion of bacteria reverted the increased colitis susceptibility in PTPN22-deficient mice, while granulocyte depletion induced a similar colitis phenotype in wild-type mice as observed in PTPN22-deficient mice. In conclusion, our data demonstrate that PTPN22 is essential for adequate granulocyte activation and anti-microbial defense to protect the inflamed intestine from bacterial invasion and exacerbated colitis.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab040" target="_blank" rel="noopener"> MALAT1 Maintains the Intestinal Mucosal Homeostasis in Crohn&#39;s Disease via the miR-146b-5p-CLDN11/NUMB Pathway.</a></p>
<p>s Downregulation of MALAT1 contributed to the pathogenesis of CD by disrupting AJC. Thus, a specific MALAT1-miR-146b-5p-NUMB/CLDN11 pathway that plays a vital role in maintaining intestinal mucosal homeostasis may serve as a novel target for CD treatment.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab064" target="_blank" rel="noopener"> Matrix Metalloproteinase MMP-12 Promotes Macrophage Transmigration Across Intestinal Epithelial Tight Junctions and Increases Severity of Experimental Colitis.</a></p>
<p>s  Together, these data demonstrate that MMP-12 mediated degradation of basement membrane laminin, macrophage transmigration, and associated loss of intestinal TJ barrier are key pathogenic factors for intestinal inflammation.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab119" target="_blank" rel="noopener"> Microscopic colitis in Denmark: regional variations in risk factors and frequency of endoscopic procedures.</a></p>
<p>s The cause of the regional differences in MC incidence in Denmark seems to be multifactorial, including variations in disease awareness and distribution of risk factors.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab086" target="_blank" rel="noopener"> MTDH promotes intestinal inflammation by positively regulating TLR signaling.</a></p>
<p>TLR stimulation was sufficient to induce the expression of MTDH, whereas the absence of MTDH was sufficient to suppress TLR-induced production of inflammatory cytokines by macrophages. From a mechanistic perspective, MTDH recruited TRAF6 to TAK1, leading to TRAF6-mediated TAK1 K63 ubiquitination and phosphorylation, ultimately facilitating TLR-induced NF-κB and MAPK signaling. Taken together, our results indicate that MTDH contributes to colitis development by promoting TLR induced proinflammatory cytokines production in CLP macrophages and might represent a potential therapeutic approach for intestine inflammation intervention.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab116" target="_blank" rel="noopener"> Nutrient, fibre and FODMAP intakes and food-related quality of life in patients with inflammatory bowel disease and their relationship with gastrointestinal symptoms of differing aetiologies.</a></p>
<p>s This study revealed significantly lower intakes of fibre, FODMAPs and micronutrients, in addition to poorer FR-QoL, in Active IBD and Inactive IBD-GI with gut symptoms compared with healthy controls. Future research should address dietary restrictions responsible for these differences.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab088" target="_blank" rel="noopener"> Obesity in Inflammatory Bowel Disease is Associated with Early Readmissions characterized by an Increased Systems and Patient-level Burden.</a></p>
<p>s Obesity in IBD appears to be associated with increased early readmission, characterized by a higher burden, despite the introduction of weight-based therapeutics. Prevention of obesity should be a focus in the treatment of IBD to decrease readmission and healthcare burden.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab069" target="_blank" rel="noopener"> Oral CBD-rich cannabis induces clinical but not endoscopic response in patients with Crohn&#39;s disease, a randomized controlled trial.</a></p>
<p>s Eight weeks of CBD-rich cannabis treatment induced significant clinical and QOL improvement without significant changes in inflammatory parameters or endoscopic scores. The oral CBD-rich cannabis extract was well absorbed. Until further studies are available, cannabis treatment in Crohn&#39;s disease should be used only in the context of clinical trials.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab045" target="_blank" rel="noopener"> Outcomes of Passable and Non-passable Strictures in Clinical Trials of Crohn&#39;s Disease: A Post-hoc Analysis.</a></p>
<p>s Patients with non-passable strictures can achieve symptomatic and endoscopic remission when receiving therapies used to treat CD, although they are less likely to obtain CR compared with patients without non-passable strictures. These findings support the importance of balancing the presence of non-passable strictures in trial arms.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab044" target="_blank" rel="noopener"> Overexpression of Vitamin D Receptor in Intestinal Epithelia Protects Against Colitis via Upregulating Tight Junction Protein Claudin 15.</a></p>
<p> We demonstrated the mechanism of VDR upregulation of Claudin-15 to protect against colitis. This might enlighten the mechanism of barrier dysfunction in IBD and potential therapeutic strategies to inhibit inflammation.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab110" target="_blank" rel="noopener"> Perception of cancer risk and management practice for colitis-associated dysplasia is influenced by colonoscopy experience and workplace results of an international clinician survey.</a></p>
<p>s Clinicians with less surveillance colonoscopy experience and from non-academic centres appear to have lower cancer risk perceptions and are less likely to advocate colectomy for higher-risk low-grade dysplasia. Further education may align current management practice with clinical guidelines.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab110" target="_blank" rel="noopener"> Perception of cancer risk and management practice for colitis-associated dysplasia is influenced by colonoscopy experience and workplace results of an international clinician survey.</a></p>
<p>s Clinicians with less surveillance colonoscopy experience and from non-academic centres appear to have lower cancer risk perceptions and are less likely to advocate colectomy for higher-risk low-grade dysplasia. Further education may align current management practice with clinical guidelines.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab057" target="_blank" rel="noopener"> Perianal Fistula-Associated Carcinoma in Crohn&#39;s Disease: A Multicentre Retrospective Case Control Study.</a></p>
<p>s In patients with adenocarcinoma or squamous cell carcinoma associated with perianal fistula in Crohn&#39;s disease, fistula characteristics determine the risk of malignancy. Early diagnosis influences outcomes, while treatment of chronic fistula activity may be key to preventing malignancy. Expert multimodal therapy is paramount for successful treatment of perianal fistula-associated malignancies.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab061" target="_blank" rel="noopener"> Potential Role of Epithelial Endoplasmic Reticulum Stress and Anterior Gradient Protein 2 Homologue in Crohn&#39;s Disease Fibrosis.</a></p>
<p>s The development of CD fibrotic strictures could involve epithelial ER stress and particularly the secretion of AGR2.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab097" target="_blank" rel="noopener"> Prevalence and Impact of Obesity on Disease-Specific Outcomes in a Population-Based Cohort of Patients with Ulcerative Colitis.</a></p>
<p>s The prevalence of obesity in the UC population is increasing, and may have negative prognostic implications, specifically regarding risk of future hospitalization and corticosteroid use. Additional prospective studies are necessary to more clearly define these associations.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab030" target="_blank" rel="noopener"> Prevalence and Progression of Incidental Terminal Ileitis on Non-diagnostic Colonoscopy: A Systematic Review and Meta-analysis.</a></p>
<p>s IDTI is not uncommon on non-diagnostic colonoscopies. Based on limited data, the rate of its progression to overt CD seems low, and watchful waiting is likely a reasonable strategy. Further long-term follow-up studies are needed to inform the natural history of incidental terminal ileitis, factors that predict progression to CD, and therapeutic implications.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab090" target="_blank" rel="noopener"> Rectal Cancer Incidence is Low Following Rectal Diversion or Subtotal Colectomy for IBD: Results of a Population-based Study.</a></p>
<p>s Among patients with a retained rectum following surgery for IBD, the risk of rectal cancer is low and appears to be lower when surveillance endoscopy is performed. Expectant management with surveillance endoscopy may be a reasonable alternative to completion proctectomy in selected patients.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab031" target="_blank" rel="noopener"> Restored Macrophage Function Ameliorates Disease Pathophysiology in a Mouse Model for IL10 Receptor-deficient Very Early Onset Inflammatory Bowel Disease.</a></p>
<p>s In summary, we show that the correction of the IL10 receptor defect in macrophages, either by genetic therapy or transfer of WT macrophages to the peritoneum, can ameliorate disease-related symptoms and potentially represent novel treatment approaches for VEO-IBD patients.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab050" target="_blank" rel="noopener"> Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy.</a></p>
<p>Inflammatory bowel diseases [IBD] are a heterogeneous spectrum with two extreme phenotypes, Crohn&#39;s disease [CD] and ulcerative colitis [UC], which both represent numerous phenotypical variations. Hence, we should no longer approach al IBD patients similarly, but rather aim to rethink clinical classifications and modify treatment algorithms to usher in a new era of precision medicine in IBD. This scientific ECCO workshop aims to provide a state-of-the-art overview on prognostic and predictive markers, shed light on key questions in biomarker development, propose best practices in IBD biomarker development [including trial design], and discuss the potential for multi-omic data integration to help drive further advances to make precision medicine a reality in IBD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab048" target="_blank" rel="noopener"> Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Prediction and Prevention of Inflammatory Bowel Disease.</a></p>
<p>Therefore, new strategies to prevent the global increase of IBD are urgently required. Data are being progressively acquired on the period preceding disease diagnosis, which support the concept that IBD has a preclinical period that may reveal the triggers of disease and may be amenable to early intervention. Having a better knowledge of this preclinical period will increase the potential not only for improved understanding of disease pathogenesis and improved therapeutics, but also for disease prediction and prevention.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab051" target="_blank" rel="noopener"> Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-What, Why, and How.</a></p>
<p>This prompted the European Crohn&#39;s and Colitis Organisation to focus the Seventh Scientific Workshop on this emerging theme. The articles in this special issue of the Journal address the various complementary aspects of PM in IBD, including what PM is; why it is needed and how it can be used; how PM can contribute to prediction and prevention of IBD; how IBD PM can aid in prognosis and improve response to therapy; and the challenges and future directions of PM in IBD. This first article of this series is structured on three simple concepts [what, why, and how] and addresses the definition of PM, discusses the rationale for the need of PM in IBD, and outlines the methodology required to implement PM in IBD in a correct and clinically meaningful way.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab094" target="_blank" rel="noopener"> SATB2 defect promotes colitis and colitis-associated colorectal cancer by impairing Cl -/HCO3  - exchange and homeostasis of gut microbiota.</a></p>
<p> SATB2 plays a vital role in maintaining intestinal homeostasis and its deficiency promotes the development of colitis and CAC by influencing the intestinal luminal environment and gut flora.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab032" target="_blank" rel="noopener"> Schlafen 11 Is a Novel Target for Mucosal Regeneration in Ulcerative Colitis.</a></p>
<p>s In vitro and in vivo UC-mimicking models were uniquely established using human colonic organoids. They revealed that SLFN11 is significant for mucosal injury in UC, and demonstrated its potential as a novel target for mucosal regeneration.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab109" target="_blank" rel="noopener"> Sequential use of high-dose tofacitinib after infliximab salvage therapy in acute severe ulcerative colitis.</a></p>
<p>s High-dose tofacitinib may have a role as salvage therapy in the setting of steroid-refractory ASUC. Prospective studies are required to determine the safety and efficacy of high-dose tofacitinib to determine whether it can be routinely recommended as primary or sequential salvage therapy in the setting of steroid-refractory ASUC.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab095" target="_blank" rel="noopener"> Shifting health care use from hospitalizations and surgeries to outpatient visits in children with inflammatory bowel disease: a population-based cohort study from Ontario, Canada.</a></p>
<p>s Hospitalizations and surgeries decreased over time while outpatient visits increased after 2005. Decreasing hospitalizations were mirrored in children without IBD, likely resulting from a combination of changes in disease management and health system factors.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab024" target="_blank" rel="noopener"> Subclinical Pulmonary Involvement in Active IBD Responds to Biologic Therapy.</a></p>
<p>s  patients with active IBD present with significant obstructive abnormalities in their PFTs. Obstruction is related to inflammatory activity, with anti-TNF improving PFTs. Pulmonary obstruction and possibly chronic bronchopulmonary inflammation is an overlooked problem in active IBD that is probably obscured by intestinal symptoms.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab078" target="_blank" rel="noopener"> Suppressing Kv1.3 Ion Channel Activity with a Novel Small Molecule Inhibitor Ameliorates Inflammation in a Humanized Mouse Model of Ulcerative Colitis.</a></p>
<p> Inhibition of Kv1.3 (by DES1, for instance) appears to be a potential therapeutic intervention strategy for UC patients.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab025" target="_blank" rel="noopener"> Systematic Review and Meta-analysis of Outcomes After Ileal Pouch-anal Anastomosis in Primary Sclerosing Cholangitis and Ulcerative Colitis.</a></p>
<p>s Patients with PSC-UC were more likely to experience pouchitis and pouch failure than patients with UC alone. The risks of inflammatory complications after IPAA must be weighed against the potential complications with other surgical procedures, and future studies comparing outcomes among these procedures may inform decision making in this population.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab079" target="_blank" rel="noopener"> Systematic review: Sweet syndrome associated with inflammatory bowel disease.</a></p>
<p>s SS may precede or occur with IBD diagnosis in almost one third of cases. Azathioprine and IBD-associated SS present and behave distinctly, especially with regard to gender, age at diagnosis and recurrence risk. Corticosteroids and TNF-α inhibitors have demonstrated efficacy in treating SS in IBD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab029" target="_blank" rel="noopener"> The Burden of Inflammatory Bowel Disease in Europe in 2020.</a></p>
<p>The health economic burden associated with IBD is high in Europe. Direct health care costs [approximately €3500 in CD and €2000 in UC per patient per year] have shifted from hospitalisation and surgery towards drug-related expenditures with the increasing use of biologic therapy and other novel agents, and substantial indirect costs arise from work productivity loss [approximately €1900 per patient yearly]. The aim of this paper is to provide an updated review of the burden of IBD in Europe by discussing current data on epidemiology, disease course, risk for surgery, hospitalisation, and mortality and cancer risks, as well as the economic aspects, patient disability, and work impairment, by discussing the latest population-based studies from the region.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab121" target="_blank" rel="noopener"> The deubiquitinating enzyme OTUD5 sustains inflammatory cytokine response in inflammatory bowel disease.</a></p>
<p>s Our data show that OTUD5 is overexpressed in both CD and UC and suggest the involvement of such a protein in the amplification of the aberrant cytokine response in IBD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab071" target="_blank" rel="noopener"> The impact of vedolizumab on COVID-19 outcomes among adult IBD patients in the SECURE-IBD registry.</a></p>
<p>s COVID-19 outcomes among IBD patients on VDZ are comparable to those on al other therapies. Hospitalization, but not severe COVID-19, is more likely with VDZ monotherapy than with anti-TNF monotherapy. Overall, VDZ appears to be safe in IBD patients with COVID-19.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab033" target="_blank" rel="noopener"> Therapeutic Potential of a Self-Assembling Peptide Hydrogel to Treat Colonic Injuries Associated with Inflammatory Bowel Disease.</a></p>
<p>s SAPH application effectively suppressed colonic injury, downregulated inflammatory cytokine expression, and upregulated wound healing-related factor expression in the rat model; thus, it may represent a promising therapeutic strategy for IBD-related colonic ulcers.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab106" target="_blank" rel="noopener"> Transmural Response and Transmural Healing Defined by Intestinal Ultrasound - New Potential Therapeutic Targets?</a></p>
<p>s IUS response and TH in a relevant proportion of patients suggests that IUS is a useful method to assess transmural inflammatory activity in daily clinical practice. TR and TH are predictive for the sonographic outcome at week 52.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab022" target="_blank" rel="noopener"> TREM-1+ Macrophages Define a Pathogenic Cell Subset in the Intestine of Crohn&#39;s Disease Patients.</a></p>
<p>s High intestinal TREM-1 expression, reflecting a high frequency of TREM-1+ immature macrophages and TREM-1+CD11b+ granulocytes, is linked to the deleterious inflammatory microenvironment in IBD patients. Therefore, blocking the TREM-1 pathway, especially simultaneously with anti-TNF therapy, has potential as a new IBD therapy.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab099" target="_blank" rel="noopener"> Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis.</a></p>
<p>s Induction treatment with upadacitinib demonstrated significant reductions in bowel urgency and abdominal pain compared to placebo. These symptoms also correlate to clinical and HRQOL outcomes, supporting their use to monitor disease severity and other treatment outcomes.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab081" target="_blank" rel="noopener"> Ustekinumab for Crohn&#39;s Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, a Nationwide Prospective Observational Cohort Study.</a></p>
<p> After 104 weeks of ustekinumab treatment, one third of CD patients were in corticosteroid-free clinical remission.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab089" target="_blank" rel="noopener"> Ustekinumab in Pediatric Patients with Moderately to Severely Active Crohn&#39;s Disease Pharmacokinetics, Safety, and Efficacy Results from UniStar, a Phase 1 Study.</a></p>
<p>s The pharmacokinetics/safety profiles were generally consistent with those observed in adults with Crohn&#39;s disease. These results suggest a different dosing regimen may be required for patients &lt;40kg than that employed in this study; additional pharmacokinetic analyses may be needed in this population.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab042" target="_blank" rel="noopener"> Validated Indices for Histopathologic Activity Predict Development of Colorectal Neoplasia in Ulcerative Colitis.</a></p>
<p>s Persistent histologic activity during multiple surveillance episodes is an independent predictor of colorectal neoplasia. Mean RHI and mean NHI during a 5-year colonoscopic surveillance period can be used to assess risk for colorectal neoplasia and optimize UC surveillance.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab055" target="_blank" rel="noopener"> Validation of the &#39;Inflammatory Bowel Disease-Distribution, Chronicity, Activity [IBD-DCA] Score&#39; for Ulcerative Colitis and Crohn´s Disease.</a></p>
<p>s The IBD-DCA score is a simple histological activity score for UC and CD, agreed and validated by a large group of IBD specialists. It provides reliable information on treatment response. Therefore, it has potential value for use in routine diagnostics as well as clinical studies.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab077" target="_blank" rel="noopener"> Variants in STXBP3 Are Associated With Very Early Onset Inflammatory Bowel Disease, Bilateral Sensorineural Hearing Loss and Immune Dysregulation.</a></p>
<p> Overall, we describe a novel genetic syndrome and identify a critical role for STXBP3 in VEOIBD, sensorineural hearing loss and immune dysregulation.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab058" target="_blank" rel="noopener"> Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study.</a></p>
<p> In this real-world setting, first-line biologic therapy in biologic-naïve patients with UC and CD demonstrated that vedolizumab and anti-TNFα treatments were equally effective at controlling disease symptoms, but vedolizumab has a more favourable safety profile.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab114" target="_blank" rel="noopener"> Vitamin D is Associated with α4β7+ Immunophenotypes and Predicts Vedolizumab Therapy Failure in Patients with Inflammatory Bowel Disease.</a></p>
<p>s Low serum 25(OH)D is associated with α4β7+ immunophenotypes and predicts future vedolizumab failure in patients with IBD.</p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">J Hepatol</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.06.036" target="_blank" rel="noopener"> 24-Norursodeoxycholic acid reshapes immunometabolism in CD8<sup>+</sup> T cells and alleviates hepatic inflammation.</a></p>
<p>s NorUDCA has a direct modulatory impact on CD8 +  T cells and attenuates excessive CD8 +  T cell-driven hepatic immunopathology. These findings are relevant for treatment of immune-mediated liver diseases such as PSC.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.03.013" target="_blank" rel="noopener"> A novel microRNA-based prognostic model outperforms standard prognostic models in patients with acetaminophen-induced acute liver failure.</a></p>
<p>s Our findings demonstrate that a regeneration-linked microRNA signature combined with readily available clinical parameters can outperform existing prognostic models for ALF in identifying patients with poor prognosis who may benefit from transplantation.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.03.012" target="_blank" rel="noopener"> A pilot study of golexanolone, a new GABA-A receptor-modulating steroid antagonist, in patients with covert hepatic encephalopathy.</a></p>
<p> Golexanolone was well tolerated and associated with improvement in cognitive performance. These results implicate GABA-A receptor-modulating neurosteroids in the pathogenesis of HE and support the therapeutic potential of golexanolone.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.04.055" target="_blank" rel="noopener"> An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs.</a></p>
<p>s This study has identified additional risk loci for PBC, provided a hierarchy of agents that could be trialled in this condition, and emphasised the value of genetic and genomic approaches to drug discovery in complex disorders.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.03.025" target="_blank" rel="noopener"> Assembly and infection efficacy of hepatitis B virus surface protein exchanges in 8 hepatitis D virus genotype isolates.</a></p>
<p>s HDVs from different genotypes replicate with variable efficacies. Variations in HDV genomes and HBV envelope proteins are both major determinants of HDV egress and entry efficacy, and consequently assembly inhibition by lonafarnib or entry inhibition by bulevirtide. These differences possibly influence HDV pathogenicity, immune responses and the efficacy of novel drug regimens.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.04.010" target="_blank" rel="noopener"> Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis.</a></p>
<p>s In a large retrospective cohort study of treatment effects in patients with PBC, the addition of BZF to UDCA was associated with improved prognosis.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.04.022" target="_blank" rel="noopener"> Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis.</a></p>
<p>s BIs have a marked impact on the natural history of compensated cirrhosis, significantly increasing the risk of decompensation, mainly that of ascites, and increasing the risk of death, which usually occurs after decompensation. Our results suggest that BIs may constitute a target to prevent decompensation.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.03.026" target="_blank" rel="noopener"> Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis.</a></p>
<p> Bacterial infections develop in almost one-fifth of patients with AVB despite antibiotic prophylaxis. Respiratory infection is the most frequent, is an early event after admission, and is associated with advanced liver failure, severe hepatic encephalopathy and use of nasogastric tube, orotracheal intubation for endoscopy or esophageal balloon tamponade.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.05.022" target="_blank" rel="noopener"> Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: Data from Global Burden of Disease 2009-2019.</a></p>
<p>s NAFLD is posing a substantial burden in Asia and MENA. About half of the global burden of LC-NAFLD is accounted for by these regions.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.04.047" target="_blank" rel="noopener"> CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.</a></p>
<p>s Nivolumab showed clinical activity and favourable safety with manageable toxicities, suggesting it could be suitable for patients with Child-Pugh B aHCC.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.05.014" target="_blank" rel="noopener"> Co-expression gene network analysis reveals novel regulatory pathways involved in porto-sinusoidal vascular disease.</a></p>
<p> PSVD has a unique transcriptomic profile and we have identified deregulation of pathways involved in vascular homeostasis as the main pathogenic event of disease development.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.05.029" target="_blank" rel="noopener"> Development and prognostic relevance of a histologic grading and staging system for alcohol-related liver disease.</a></p>
<p> The SALVE grading and staging system is a reproducible and prognostically relevant method for the histological assessment of disease activity and fibrosis in ALD.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.05.026" target="_blank" rel="noopener"> Development and validation of a new prognostic score for hepatitis B virus-related acute-on-chronic liver failure.</a></p>
<p> A new prognostic score based on 6 predictors, without an assessment of organ failure, can accurately predict short-term mortality in patients with HBV-ACLF and might be used to guide clinical management.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.04.044" target="_blank" rel="noopener"> Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis.</a></p>
<p>s When elastography index tests are acquired successfully, they have acceptable diagnostic accuracy for advanced fibrosis and cirrhosis. The potential clinical impact of these index tests cannot be assessed fully as intention-to-diagnose analyses and validation of pre-specified thresholds are lacking.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.04.011" target="_blank" rel="noopener"> Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in non-alcoholic fatty liver disease.</a></p>
<p>s We identified a new molecular role for AGXT2 in NAFLD. Our overall approach will serve as an efficient tool for uncovering novel genetic factors that contribute to liver steatosis and fibrosis in patients with NAFLD.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.06.025" target="_blank" rel="noopener"> DNMT1-mediated methylation of BEX1 regulates stemness and tumorigenicity in liver cancer.</a></p>
<p> BEX1, under the regulation of DNMT1, is necessary for the self-renewal and maintenance of liver CSCs through activation of Wnt/β-catenin signaling, rendering BEX1 a potentially valuable therapeutic target in both HB and CSC-HCC.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.03.029" target="_blank" rel="noopener"> Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis.</a></p>
<p>s Reduced TGR5 levels in BECs from patients with PSC and Abcb4 -/-  mice promote development of a reactive BEC phenotype, aggravate biliary injury and thus contribute to the pathogenesis of sclerosing cholangitis. Restoration of biliary TGR5-expression levels represents a previously unknown mechanism of action of norUDCA.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.04.053" target="_blank" rel="noopener"> Dual and opposing roles of the androgen receptor in VETC-dependent and invasion-dependent metastasis of hepatocellular carcinoma.</a></p>
<p> AR plays dual and opposing roles in VETC-dependent and invasion-dependent metastasis, which highlights the complex functions of AR and the importance of individualized cancer therapy.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.04.033" target="_blank" rel="noopener"> Dysregulation of the ESRP2-NF2-YAP/TAZ axis promotes hepatobiliary carcinogenesis in non-alcoholic fatty liver disease.</a></p>
<p> Herein, we report on a novel mechanism by which chronic inflammation leads to sustained activation of YAP/TAZ activity; this imposes a selection pressure that favors liver cells with mutations enabling survival during chronic oncogenic stress.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.05.033" target="_blank" rel="noopener"> EASL-CLIF criteria outperform NACSELD criteria for diagnosis and prognostication in ACLF.</a></p>
<p>s There is a clear discordance in the prevalence and 30-day mortality rates of patients with ACLF identified by the EASL-CLIF and NACSELD criteria. EASL-CLIF criteria have a better sensitivity to detect ACLF and have a better prognostic capability.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.03.021" target="_blank" rel="noopener"> Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI.</a></p>
<p> The trajectory of biochemical recovery from DILI is predicted by the extent of drug metabolism, serum bilirubin and ALP at DILI onset. The model can be used to compute an estimated DILI recovery and, when a significant delay is predicted, clinicians may consider additional investigations such as histologic evaluation or extended follow-up.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.04.012" target="_blank" rel="noopener"> Falls are common, morbid, and predictable in patients with cirrhosis.</a></p>
<p> Our prospective study of patients with cirrhosis without a baseline history of HE demonstrates that falls are common, morbid, and predictable. These data highlight both the value of expanding screening to patients with cirrhosis and the potential for benefit in studies of interventions to address fall-risk in this vulnerable population.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.05.018" target="_blank" rel="noopener"> Focal adhesion kinase (FAK) promotes cholangiocarcinoma development and progression via YAP activation.</a></p>
<p>s FAK activation contributes to the initiation and progression of iCCA by inducing the YAP proto-oncogene. Targeting FAK, either alone or in combination with anti-CDK4/6 inhibitors, may be an effective strategy for iCCA treatment.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.03.028" target="_blank" rel="noopener"> FOSL1 promotes cholangiocarcinoma via transcriptional effectors that could be therapeutically targeted.</a></p>
<p>s Our data illustrate the functional and clinical relevance of FOSL1 in CCA and unveil potential targets amenable to pharmacological inhibition that could enable the implementation of novel therapeutic strategies.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.04.035" target="_blank" rel="noopener"> Global burden of acute viral hepatitis and its association with socioeconomic development status, 1990-2019.</a></p>
<p>s The socioeconomic development status and burden of AVH are associated. Therefore, the GBD 2019 data should be used by policymakers to guide cost-effective interventions for AVH.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.04.037" target="_blank" rel="noopener"> Glutaminolysis-induced mTORC1 activation drives non-alcoholic steatohepatitis progression.</a></p>
<p> We provide evidence supporting the multifaceted potential of the increased glutaminolysis-induced α-ketoglutarate production and the mammalian target of rapamycin complex 1 dysregulation as a conceivable source of the inefficient adaptive responses leading to steatohepatitis.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.04.013" target="_blank" rel="noopener"> Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis.</a></p>
<p> Overall, these data provide a detailed description of the lipidomic changes with worsening NAFLD, showing significant changes with steatosis but no additional changes with NASH. Alterations in the liver lipidome are paralleled by similar changes in plasma. Further investigation is warranted into the potential utility of plasma lipids as non-invasive biomarkers of NAFLD in obesity.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2020.12.034" target="_blank" rel="noopener"> Hypoxia inducible factors regulate hepatitis B virus replication by activating the basal core promoter.</a></p>
<p>s Identifying a role for this conserved oxygen sensor in regulating HBV transcription suggests that this virus has evolved to exploit the HIF signaling pathway to persist in the low oxygen environment of the liver. Our studies show the importance of considering oxygen availability when studying HBV-host interactions and provide innovative routes to better understand and target chronic HBV infection.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.06.019" target="_blank" rel="noopener"> Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study.</a></p>
<p> Corticosteroids improve 30-day survival only among patients with severe AH, especially with MELD scores between 25 and 39.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.04.018" target="_blank" rel="noopener"> Impact of alcohol on the progression of HCV-related liver disease: A systematic review and meta-analysis.</a></p>
<p>s Alcohol use has a marked impact on the progression of HCV infections to cirrhosis and more severe liver outcomes.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.05.028" target="_blank" rel="noopener"> Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study.</a></p>
<p>s DAA treatment is associated with a substantial reduction in all-cause, liver- and drug-related mortality. The association of IDU and related syndemic factors with a higher risk of drug-related mortality calls for an integrated social support, addiction, and HCV care approach among people who inject drugs.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.06.015" target="_blank" rel="noopener"> Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival.</a></p>
<p> This study shows that although limited tumour progression without reaching major adverse predictors (vascular invasion, extrahepatic spread, cancer symptoms) has an expected impact on recurrence rate, overall survival remains above the minimum proposed benchmark of 65% at 5 years. The clinically relevant increase in tumour recurrence must be considered when analysing the benefit of this approach in the face of limited organ supply.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.04.057" target="_blank" rel="noopener"> Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir.</a></p>
<p> Baseline NS5A RASs were highly prevalent. The presence of an increasing number of linked NS5A RASs in GT1a showed a trend in decreasing SVR12 rates, although no specific NS5A RASs or their linkage pattern were associated with lower SVR12 rates.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.04.050" target="_blank" rel="noopener"> Liver injury in COVID-19 and IL-6 trans-signaling-induced endotheliopathy.</a></p>
<p> IL-6 trans-signaling drives the coagulopathy and hepatic endotheliopathy associated with COVID-19 and could be a possible mechanism behind liver injury in these patients.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.03.030" target="_blank" rel="noopener"> Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: Results of the ELITA/EF-CLIF collaborative study (ECLIS).</a></p>
<p>Results A total of 2,677 patients received a LT: 1,216 (45.4%) for decompensated cirrhosis. Of these, 234 (19.2%) had ACLF at LT: 58 (4.8%) had ACLF-1, 78 (6.4%) had ACLF-2, and 98 (8.1%) had ACLF-3. Wide variations were observed amongst countries: France and Germany had high rates of ACLF-2/3 (27-41%); Italy, Switzerland, Poland and the Netherlands had medium rates (9-15%); and the United Kingdom and Spain had low rates (3-5%) (p  80% after 1 year and some factors have been identified to help select patients with favourable outcomes.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.05.008" target="_blank" rel="noopener"> Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease.</a></p>
<p>s Overall, NFS, HFS and FIB-4 outperformed APRI and BARD for both cross-sectional identification of fibrosis and prediction of long-term outcomes, confirming that they are useful tools for the clinical management of patients with NAFLD at increased risk of fibrosis and liver-related complications or death.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.05.041" target="_blank" rel="noopener"> Loss of hepatocyte identity following aberrant YAP activation: A key mechanism in alcoholic hepatitis.</a></p>
<p> Aberrant activation of YAP plays an important role in hepatocyte transdifferentiation in AH, through a loss of hepatocyte identity and impaired regeneration. Thus, targeting YAP is a promising strategy for the treatment of patients with AH.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.04.020" target="_blank" rel="noopener"> Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients.</a></p>
<p> LT recipients developed substantially lower immunological response to the Pfizer-BioNTech SARS-CoV-2 mRNA-based vaccine. Factors influencing serological antibody responses include age, renal function and immunosuppressive medications. The findings require re-evaluation of vaccine regimens in this population.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.04.049" target="_blank" rel="noopener"> Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis.</a></p>
<p>s NASH-HCCs display unique molecular features including higher rates of ACVR2A mutations and the presence of a newly identified mutational signature.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2020.12.028" target="_blank" rel="noopener"> Multimodal investigation of rat hepatitis E virus antigenicity: Implications for infection, diagnostics, and vaccine efficacy.</a></p>
<p>s Antigenic divergence significantly decreases sensitivity of hepatitis E serodiagnostic assays for HEV-C1 infection. Species-specific immunoblots are useful for diagnosing HEV-C1 and for differentiating the serological profiles of HEV-A and HEV-C1. Prior HEV-A exposure is not protective against HEV-C1. HEV-C1 p241 is an immunogenic vaccine candidate against HEV-C1.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.02.037" target="_blank" rel="noopener"> Muscle fat content is strongly associated with NASH: A longitudinal study in patients with morbid obesity.</a></p>
<p>Lay summary The fat content in skeletal muscles is highly reflective of the severity of non-alcoholic fatty liver disease (NAFLD) in patients with morbid obesity. In particular, muscle fat content is strongly associated with non-alcoholic steatohepatitis (NASH) and decreases upon NASH improvement. These data indicate that muscle fatty infiltration could be a marker and possible pathophysiological contributor to NASH.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.06.034" target="_blank" rel="noopener"> Non-alcoholic fatty liver disease in children and young adults is associated with increased long-term mortality.</a></p>
<p>s Swedish children and young adults with biopsy-confirmed NAFLD have significantly higher rates of overall, cancer-, liver- and cardiometabolic-specific mortality compared to matched general population controls.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.06.038" target="_blank" rel="noopener"> Novel function of SART1 in HNF4α transcriptional regulation contributes to its antiviral role during HBV infection.</a></p>
<p>s We identify SART1 as a novel host factor suppressing HBV cccDNA transcription. Besides its effect on interferon-stimulated genes, SART1 exerts an anti-HBV activity by suppressing HNF4α expression, which is essential for transcription of HBV cccDNA.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.05.020" target="_blank" rel="noopener"> Optimizing the use of twitter for research dissemination: The &quot;Three Facts and a Story&quot; randomized-controlled trial.</a></p>
<p> Tweets featuring the authors and their motivations may increase engagement with published research.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.04.052" target="_blank" rel="noopener"> Prognosis of French COVID-19 patients with chronic liver disease: A national retrospective cohort study for 2020.</a></p>
<p> Chronic liver disease increased the risk of COVID-19-related death in France in 2020. Therapeutic effort limitation may have contributed to COVID-19-related death in French residents with a liver-related complication or an alcohol use disorder.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.05.037" target="_blank" rel="noopener"> Prognostic performance of 7 biomarkers compared to liver biopsy in early alcohol-related liver disease.</a></p>
<p> TE, ELF and 2D-SWE are highly accurate prognostic markers in patients with alcohol-related liver disease. Easy-to-use cut-offs can distinguish between substantially different risk profiles.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.04.036" target="_blank" rel="noopener"> Resolution of hepatitis E virus infection in CD8+ T cell-depleted rhesus macaques.</a></p>
<p>s Liver infiltration of functional CD8+ T cells coincident with HEV clearance in untreated rhesus macaques, and a 1-week delay in HEV clearance in CD8+ T cell-depleted rhesus macaques, support a role for this subset in timely control of virus replication. Resolution of infection in the absence of CD8+ T cells nonetheless indicates that neutralizing antibodies and/or CD4+ T cells may act autonomously to inhibit HEV replication. HEV susceptibility to multiple adaptive effector mechanisms may explain why persistence occurs only with generalized immune suppression. The findings also suggest that neutralizing antibodies and/or CD4+ T cells should be considered as a component of immunotherapy for chronic infection.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.04.026" target="_blank" rel="noopener"> Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): A multicenter study.</a></p>
<p>s The inactivated COVID-19 vaccine appears to be safe with good immunogenicity in patients with NAFLD.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.03.016" target="_blank" rel="noopener"> Single-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD4<sup>+</sup> T cells in primary sclerosing cholangitis.</a></p>
<p>Lay summary The composition of intrahepatic immune cells in primary sclerosing cholangitis (PSC) and their contribution to disease pathogenesis is widely unknown. We analysed intrahepatic T cells and identified a previously uncharacterized population of liver-resident CD4 +  T cells which are expanded in the livers of patients with PSC compared to healthy liver tissue and other liver diseases. These cells are likely to contribute to the pathogenesis of PSC and could be targeted in novel therapeutic approaches.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.06.028" target="_blank" rel="noopener"> Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.</a></p>
<p>s Our study offers insight into the collective behavior of tumor cell communities in liver cancer as well as potential drivers of tumor evolution in response to therapy.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.06.023" target="_blank" rel="noopener"> Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer.</a></p>
<p>s This study has provided valuable insights into transcriptomic heterogeneity and the global cellular network in the TME, which coordinately functions to promote the progression of GBC with ErbB pathway mutations; thus, unveiling novel cellular and molecular targets for cancer therapy.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.04.056" target="_blank" rel="noopener"> Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection.</a></p>
<p>s In this randomised study in recent HCV infection, a 6-week course of sofosbuvir-velpatasvir did not meet the criteria for non-inferiority to standard 12-week therapy.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.05.015" target="_blank" rel="noopener"> Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.</a></p>
<p> Our analysis suggests that sorafenib treatment is associated with improved survival in patients with advanced hepatocellular carcinoma mainly by decreasing the rate of tumour growth and liver function deterioration among patients with HCV infection.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.04.042" target="_blank" rel="noopener"> Surveillance of patients with cirrhosis remains suboptimal in the United States.</a></p>
<p>s Despite modest improvements in more recent years, routine monitoring and surveillance for patients with cirrhosis is suboptimal. Further efforts including provider awareness, patient education, and system/incentive-based quality improvement measures are urgently needed.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.06.022" target="_blank" rel="noopener"> T cell engager antibodies enable T cells to control HBV infection and to target HBsAg-positive hepatoma in mice.</a></p>
<p> This study demonstrates that the administration of HBVenv-targeting T cell engager antibodies facilitates a robust T cell redirection towards HBV-positive target cells and provides a feasible and promising approach for the treatment of chronic viral hepatitis and HBV-associated HCC.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.06.037" target="_blank" rel="noopener"> T cells and monocyte-derived myeloid cells mediate immunotherapy-related hepatitis in a mouse model.</a></p>
<p> We developed a novel mouse model which offers significant value in yielding deeper mechanistic insight into immune-mediated liver toxicity associated with various immunotherapies.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.05.003" target="_blank" rel="noopener"> The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease.</a></p>
<p>Given the unique importance of this proposal, the Chinese Society of Hepatology (CSH) invited leading hepatologists and gastroenterologists representing their respective provinces and cities to reach consensus on alternative definitions for fatty liver disease from a national perspective. The CSH endorses the proposed change from NAFLD to MAFLD (supported by 95.45% of participants). We expect that the new definition will result in substantial improvements in health care for patients and advance disease awareness, public health policy, and political, scientific and funding outcomes for MAFLD in China.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.03.023" target="_blank" rel="noopener"> Towards personalised medicine in autoimmune hepatitis: Measurement of thiopurine metabolites results in higher biochemical response rates.</a></p>
<p> A strategy of personalised medicine using metabolite levels can optimise treatment regimens in AIH, resulting in fewer ADRs whilst maintaining BR.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.04.051" target="_blank" rel="noopener"> Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load.</a></p>
<p>s Transcriptionally active HBV integration can extend to the entire liver in some HBe -  patients. This can lead to ubiquitous HBsAg expression independent of HBV replication. In such patients, HBsAg is probably not a clinically useful surrogate marker for viral resolution or functional cure.  </p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.06.043" target="_blank" rel="noopener"> Untargeted lipidomics uncovers lipid signatures that distinguish severe from moderate forms of acutely decompensated cirrhosis.</a></p>
<p>s Our findings provide insights into the lipid landscape associated with decompensation of cirrhosis and ACLF progression and identify unique non-invasive diagnostic biomarkers of advanced cirrhosis.  </p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">J Neurogastroenterol Motil</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.5056/jnm20209" target="_blank" rel="noopener"> A Resting-state Functional Magnetic Resonance Imaging Study of Whole-brain Functional Connectivity of Voxel Levels in Patients With Irritable Bowel Syndrome With Depressive Symptoms.</a></p>
<p>s DEP-IBS patients have abnormal FC in brain regions associated with the fronto-limbic and sensorimotor networks, especially insula and SMA, which explains the vicious circle between negative emotion and gastrointestinal symptoms in IBS. Identification of such alterations may facilitate earlier and more accurate diagnosis of depression in IBS, and development of effective treatment strategies.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.5056/jnm20102" target="_blank" rel="noopener"> Bile Reflux Gastropathy and Functional Dyspepsia.</a></p>
<p> s Bile reflux gastropathy is associated with functional dyspepsia and causes more severe symptoms. Cholecystectomy predisposes to BG and abnormal pain, and could contribute to the pathogenesis of functional dyspepsia.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.5056/jnm20205" target="_blank" rel="noopener"> Colonic Gene Expression and Fecal Microbiota in Diarrhea-predominant Irritable Bowel Syndrome: Increased Toll-like Receptor 4 but Minimal Inflammation and no Response to Mesalazine.</a></p>
<p>s Biopsies from a well-characterized IBS-D cohort showed no substantial inflammation. Mesalazine has little effect on gene expression and its previous reported effect on fecal microbiota associated with much greater inflammation found in inflammatory bowel diseases is likely secondary to reduced inflammation. Increased expression of TLR4 and correlated receptors in IBS may mediate a general increase in sensitivity to external stimuli, particularly those that signal via the TLR system.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.5056/jnm19053" target="_blank" rel="noopener"> Efficacy of S-pantoprazole 10 mg in the Symptom Control of Non-erosive Reflux Disease: A Phase III Placebo-controlled Trial.</a></p>
<p>s Low dose of S-pantoprazole (10 mg) for 4 weeks was more efficacious than placebo in providing reflux symptom relief in patients with NERD, especially acid regurgitation. More doses or longer periods of treatment with S-pantoprazole would be needed to completely eliminate symptoms.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.5056/jnm20115" target="_blank" rel="noopener"> Evaluations of Gastric Acid Pocket Using Novel Vertical 8-Channel pH Monitoring System and Effects of Acid Secretion Inhibitors.</a></p>
<p> s Gastric acid pocket observations were possible using our novel vertical 8-channel sensor catheter. The present findings showed that vonoprazan strongly suppressed acid secretion within a short period, suggesting its effectiveness for gastroesophageal reflux disease treatment.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.5056/jnm19195" target="_blank" rel="noopener"> Gastric Emptying Time and Volume of the Small Intestine as Objective Markers in Patients With Symptoms of Diabetic Enteropathy.</a></p>
<p> In our study, gastric emptying time and volume of the small intestinal wall appeared to be the best objective measures in patients with DM type 1 and symptoms and gastroenteropathy.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.5056/jnm20206" target="_blank" rel="noopener"> High-fat Diet Enhances Gastric Contractility, but Abolishes Nesfatin-1-induced Inhibition of Gastric Emptying.</a></p>
<p>s HFD caused mild systemic inflammation, disrupted enteric innervation, enhanced gastric contractility, inhibited ileal contractility, and eliminated inhibitory effect of NES-1 on gastric motility.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.5056/jnm20211" target="_blank" rel="noopener"> Impact of serotonin transporter gene polymorphism on gut motility in patients with type 2 Diabetes mellitus.</a></p>
<p> SS genotypes are prone to develop diarrhea because of faster gut motility resulting from higher serotonin levels as compared to LS and LL genotype in T2DM patients.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.5056/jnm20110" target="_blank" rel="noopener"> Impaired Colonic Contractility and Intestinal Permeability in Symptomatic Uncomplicated Diverticular Disease.</a></p>
<p> It could be hypothesized that in SUDD, in absence of severe inflammation, an increased intestinal mucosal permeability is related to altered colonic motility probably responsible for symptoms genesis.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.5056/jnm20134" target="_blank" rel="noopener"> Inter-hemispheric Functional Connections Are More Vulnerable to Attack Than Structural Connection in Patients With Irritable Bowel Syndrome.</a></p>
<p> s The functional connections between cerebral hemispheres were more susceptible to IBS than anatomical connections, and brain structure is relatively stable. Besides, the brain areas affected by IBS were concentrated in default mode network and sensorimotor network.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.5056/jnm20118" target="_blank" rel="noopener"> Normal Values of High-resolution Manometry Parameters With Provocative Maneuvers.</a></p>
<p>s Normal values and findings from a comprehensive HRM testing protocol are reported based on evaluation of 30 healthy asymptomatic volunteers. Isolated &quot;abnormalities&quot; of IRP and contractile parameters were observed in the majority (80%) of these asymptomatic subjects, while al subjects also had normal features observed. Thus, the definition of &quot;normal&quot; should be recalibrated to focus on the entirety of the study and not individual metrics.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.5056/jnm20158" target="_blank" rel="noopener"> Patients With Definite and Inconclusive Evidence of Reflux According to Lyon Consensus Display Similar Motility and Esophagogastric Junction Characteristics.</a></p>
<p> Esophageal motor parameters on HRM are similar between pathologic and inconclusive GERD according to the Lyon consensus.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.5056/jnm20105" target="_blank" rel="noopener"> Predictors of Early Readmissions in Hospitalized Patients With Gastroparesis: A Nationwide Analysis.</a></p>
<p> s One in 5 patients was readmitted with gastroparesis within 30 days. In the diabetic group, diabetes-related complications contributed to readmissions than gastroparesis. Pyloroplasty is associated with reduced early hospital readmission. Prospective studies are needed for validation of these results.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.5056/jnm20204" target="_blank" rel="noopener"> Rectosigmoid Localization of Radiopaque Markers for Identifying Defecation Disorders in Patients With Chronic Constipation: A Retrospective Cohort Study.</a></p>
<p> s Rectosigmoid accumulation of markers can differentiate DD from slow transit constipation. However, non-rectosigmoid accumulation does not exclude the presence of DD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.5056/jnm20125" target="_blank" rel="noopener"> Simultaneous Evaluation of Laryngopharyngeal Reflux and Swallowing Function Using Hypopharyngeal Multichannel Intraluminal Impedance Measurements in Neurologically Impaired Patients.</a></p>
<p>s This study demonstrated the usefulness of HMII-pH monitoring in identifying NIP with pathological LPR. Considering the difficulties in performing examinations in NIPs, HMII-pH monitoring may be a potentially useful technique for the simultaneous evaluation of swallowing dysfunction, LPR, and GERD in NIP.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.5056/jnm20041" target="_blank" rel="noopener"> The Reflux Symptoms Before and After Peroral Endoscopic Myotomy of Chinese Patients With Achalasia.</a></p>
<p> s The reflux symptoms of achalasia patients without treatment were mainly due to food retention. The postoperative reflux symptoms were not the sign of the excessive relaxation of lower esophageal sphincter.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.5056/jnm20106" target="_blank" rel="noopener"> Upright Integrated Relaxation Pressure Predicts Symptom Outcome for Esophagogastric Junction Outflow Obstruction.</a></p>
<p>Only 2.9% of these patients had persistent dysphagia. A total of 81.8% of EGJOO patients had symptom resolution during follow-up. Patients with persistent dysphagia had significantly higher upright IRP (16.6 [10.3, 19.8] vs 7.8 [3.2, 11.5];   9.05 mmHg) needs further evaluation and aggressive management.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.5056/jnm20217" target="_blank" rel="noopener"> Variations in Clinical Practice of Esophageal High-resolution Manometry: A Nationwide Survey.</a></p>
<p>s We found a variation in the available HRM practice among centers, even though they broadly agreed in the data analysis. Efforts are needed to develop a standardized protocol for HRM measurement.</p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Neurogastroenterol Motil</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14126" target="_blank" rel="noopener"> A comparison of rectoanal pressures during Valsalva maneuver and evacuation uncovers rectoanal discoordination in defecatory disorders.</a></p>
<p>s Assessment of rectoanal pressures during evacuation and a VM uncovers rectaoanal discoordination and facilitates the diagnosis of DD in selected patients.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14108" target="_blank" rel="noopener"> A pilot feasibility study of an unguided, internet-delivered cognitive behavioral therapy program for irritable bowel syndrome.</a></p>
<p>s  These preliminary findings warrant a larger trial to investigate an unguided, web-based CBT for IBS symptom management that is powered to detect between-group treatment effects.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14170" target="_blank" rel="noopener"> A putative anti-inflammatory role for TRPM8 in irritable bowel syndrome-An exploratory study.</a></p>
<p>s  These data indicate TRPM8 may have important anti-inflammatory properties and by this virtue can impact neuro-immune disease mechanisms in IBS.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14094" target="_blank" rel="noopener"> A randomized double-blind placebo-controlled crossover pilot study: Acute effects of the enzyme α-galactosidase on gastrointestinal symptoms in irritable bowel syndrome patients.</a></p>
<p>s  The use of α-galactosidase together with meals high in oligosaccharides was in this pilot study not superior to placebo in reducing postprandial GI symptoms or the concentration of hydrogen and methane in expired air in IBS.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14189" target="_blank" rel="noopener"> Activation of CRF<sub>1</sub> receptors expressed in brainstem autonomic nuclei stimulates colonic enteric neurons and secreto-motor function in male rats.</a></p>
<p> Background Hypothalamic corticotropin-releasing factor (CRF) receptor 1 (CRF  signaling at the level of the brainstem stimulates colonic secretory-motor function through activation of colonic enteric neurons.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14130" target="_blank" rel="noopener"> Altered interaction between enteric glial cells and mast cells in the colon of women with irritable bowel syndrome.</a></p>
<p>s  Findings suggest the involvement of EGC and MC in the control of barrier function in the human colon and indicate a potential EGC-MC interaction that seems altered in IBS, with detrimental consequences to colonic permeability. Altogether, results suggest that imbalanced EGC-MC communication contributes to the pathophysiology of IBS.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14132" target="_blank" rel="noopener"> An integrative healthcare model with heartfulness meditation and care coordination improves outcomes in cyclic vomiting syndrome.</a></p>
<p>s  An IHC model incorporating meditation and care coordination improves patient outcomes in CVS and is a useful adjunct to standard treatment. Studies to determine the independent effects of meditation and care coordination are warranted.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14135" target="_blank" rel="noopener"> Analysis of contractile segment impedance during straight leg raise maneuver using high-resolution impedance manometry increases diagnostic yield in reflux disease.</a></p>
<p>s  CSI measurement during HRIM appears to be a reliable, time-saving, and less invasive tool for complementing GERD diagnosis. Our results also suggest a simple SLR maneuver during HRIM could enhance diagnostic accuracy of CSI for GERD identification especially in IEM patients.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14137" target="_blank" rel="noopener"> Anorectal manometry to diagnose dyssynergic defecation: Systematic review and meta-analysis of diagnostic test accuracy.</a></p>
<p>s  Following the current iteration of the London consensus protocol (three simulated defecation attempts measuring anal relaxation), the role of anorectal manometry in evaluating dyssynergic defecation appears limited. Future iterations of this protocol may improve diagnostic accuracy.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14163" target="_blank" rel="noopener"> Auricular vagal nerve stimulation enhances gastrointestinal motility and improves interstitial cells of Cajal in rats treated with loperamide.</a></p>
<p>s  Loperamide induces upper GI dysmotility. aVNS accelerates upper GI transit and improving pace-making activity mediated via the ICC. Non-invasive aVNS may have a therapeutic potential for upper GI dysmotility.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14171" target="_blank" rel="noopener"> Behavioral therapy is superior to follow-up without intervention in patients with supragastric belching-A randomized study.</a></p>
<p>s  Behavioral therapy is superior to follow-up without intervention in patients with SGB in reducing belching and depression; it also improves mental well-being but has only a modest effect on anxiety and HRQoL.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14141" target="_blank" rel="noopener"> Breaks in peristaltic integrity predict abnormal esophageal bolus clearance better than contraction vigor or residual pressure at the esophagogastric junction.</a></p>
<p>s  Breaks in peristaltic integrity predict abnormal bolus clearance better than DCI or IRP in healthy asymptomatic subjects.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14165" target="_blank" rel="noopener"> Cardiac autonomic regulation and joint hypermobility in adolescents with functional abdominal pain disorders.</a></p>
<p>s  Suboptimal autonomic regulation indexed by reduced vagal efficiency may be a mechanism of symptoms in hypermobile FAPD patients with Beighton score ≥ 4. Autonomic disturbance may serve as potential intervention target for patients with JH and functional GI disorders.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14156" target="_blank" rel="noopener"> Central sensitization and severity of gastrointestinal symptoms in irritable bowel syndrome, chronic pain syndromes, and inflammatory bowel disease.</a></p>
<p>  Central sensitization was common in IBS and associated with GI symptom severity, but with stronger associations in chronic pain disorders and IBD. This implies that other mechanisms may be of equal or greater importance for GI symptom severity in IBS.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14184" target="_blank" rel="noopener"> Characteristics of high-resolution esophageal manometry in children without dysphagia.</a></p>
<p>s  This is the first study to describe HREM parameters in children without dysphagia. Most of the reported measurements were significantly different and less variable from reported adult norms. This emphasizes the need for child-specific catheters, norms, and protocols to define pediatric esophageal motility disorders.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14185" target="_blank" rel="noopener"> Characterizing clinical features and location-specific gene expression profiles associated with pain burden in children with functional dyspepsia.</a></p>
<p>s Pain burden in pediatric FD may be linked to antral EDN1, PTGES3 and duodenal HTR1A, P2Y1, SCN3A differential expression. These genes are known to be involved in pain conduction, modulation, and neurotransmission, suggesting potential therapeutic targets for managing pain in FD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14113" target="_blank" rel="noopener"> Chicago Classification update (v4.0): Technical review of high-resolution manometry metrics for EGJ barrier function.</a></p>
<p>There was no agreement on the significance of the RIP, only that it could localize either above the LES or between the LES and CD in cases of hiatus hernia. There was agreement on how to measure the EGJ-CI and that it should be referenced to gastric pressure in units of mmHg cm, but the numerical threshold indicative of a hypotensive EGJ varied widely among reports and was not agreed upon. Intragastric pressure was endorsed as an important metric worthy of further study but there was no agreement on a numerical threshold indicative of abdominal obesity.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14119" target="_blank" rel="noopener"> Chicago Classification Update (v4.0): Technical review on diagnostic criteria for distal esophageal spasm.</a></p>
<p>Recently, endoscopic treatments with botulinum toxin and peroral endoscopic myotomy have been evaluated, with conflicting results while rigorously controlled studies are lacking. Future research is required to determine the role of contractile vigor and lower esophageal sphincter hypercontractility in the occurrence of symptoms in patients with DES. The role of impedance-combined high-resolution manometry also needs to be evaluated.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14115" target="_blank" rel="noopener"> Chicago Classification Update (v4.0): Technical review on diagnostic criteria for hypercontractile esophagus.</a></p>
<p>An overall emphasis of the CCv4.0 is on clinically relevant esophageal dysmotility, and thus it is recommended that an HE diagnosis requires both conclusive manometric diagnosis and clinically relevant symptoms of dysphagia and non-cardiac chest pain. The Working Group also recognized the subtypes of HE, including single-peaked, multi-peaked contractions (Jackhammer esophagus), and hypercontractile lower esophageal sphincter. However, there are no compelling data currently for formally subdividing HE to these subgroups in clinical practice.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14134" target="_blank" rel="noopener"> Chicago Classification update (V4.0): Technical review on diagnostic criteria for ineffective esophageal motility and absent contractility.</a></p>
<p>Absent contractility requires 100% failed peristalsis, consistent with previous versions of the classification. Consideration needs to be given for the possibility of achalasia in absent contractility with dysphagia despite normal IRP, and alternate complementary tests (including timed upright barium esophagram and functional lumen imaging probe) are recommended to confirm or refute the presence of achalasia. Future research to quantify esophageal bolus retention on stationary HRM with impedance and to understand contraction vigor thresholds that predict bolus clearance will provide further refinement to diagnostic criteria for esophageal hypomotility disorders in future iterations of the Chicago Classification.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14182" target="_blank" rel="noopener"> Chicago Classification update (version 4.0): Technical review on diagnostic criteria for achalasia.</a></p>
<p>An inconclusive HRM diagnosis of achalasia can arise when there is an integrated relaxation pressure (IRP) that is borderline or at the upper limit of normal in at least one position, there is an abnormal IRP in both positions but evidence of peristalsis with PEP or premature swallows, or there is peristalsis in the secondary position after apparent achalasia in the primary position. In patients with dysphagia and an inconclusive HRM diagnosis of achalasia, supportive testing beyond HRM such as a timed barium esophagram (TBE) for functional lumen imaging probe (FLIP) is recommended. The review recommends a diagnostic algorithm for achalasia, discusses therapeutic options for the disease, and outlines future needs on this topic.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14120" target="_blank" rel="noopener"> Chicago classification version 4.0<sup>©</sup> technical review: Update on standard high-resolution manometry protocol for the assessment of esophageal motility.</a></p>
<p>Provocative tests are designed to increase the diagnostic sensitivity and specificity of HRM studies for disorders of esophageal motility. These changes attempt to minimize ambiguity in prior iterations of Chicago Classification, decrease the proportion of HRM studies that deliver inconclusive diagnoses and increase the number of patients with a clinically relevant diagnosis that can direct effective therapy. Another aim in establishing a standard manometry protocol for motility laboratories around the world is to facilitate procedural consistency, improve diagnostic reliability, and promote collaborative research.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14107" target="_blank" rel="noopener"> Chinese herbal medicine versus antispasmodics in the treatment of irritable bowel syndrome: A network meta-analysis.</a></p>
<p>s CHM and antispasmodics were efficacious for improvement of global IBS symptoms and abdominal pain. The adverse events of CHM were higher than antispasmodics; however, the heterogeneity of CHM formulas and the very low quality of the evidence warrants further investigation.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14151" target="_blank" rel="noopener"> Clinical associations of functional dyspepsia with gastric dysrhythmia on electrogastrography: A comprehensive systematic review and meta-analysis.</a></p>
<p> Abnormal gastric slow-wave rhythms are a consistent abnormality present in FD, as defined by EGG and, therefore, likely play a role in pathophysiology. The aberrant electrophysiology identified in FD warrants further investigation, including into underlying mechanisms, associated spatial patterns, and symptom correlations.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14198" target="_blank" rel="noopener"> COVID-19-related personal product shortages are associated with psychological distress in people living with gastrointestinal disorders: A cross-sectional survey.</a></p>
<p>s  The study documented a significant relationship between product shortages and psychological distress, which were associated with COVID-19 prevalence and fear. Strategies addressing COVID-19 fear could potentially modify the relationship between shortages and distress.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14103" target="_blank" rel="noopener"> Detection and characteristics of rumination syndrome in patients presenting for gastric symptom evaluation.</a></p>
<p>s  Rumination syndrome determined by Rome IV criteria was present in 12.8% of patients presenting for gastric symptom evaluation. Higher self-report PAGI-SYM heartburn/regurgitation subscale scores, particularly daytime regurgitation/reflux symptoms, were the only parameters that distinguished rumination. The PAGI-SYM heartburn/regurgitation subscale could be used to screen for rumination, in addition to GERDAQ6.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14145" target="_blank" rel="noopener"> Determining patient treatment preferences for management of acute pain episodes in irritable bowel syndrome.</a></p>
<p>s  The vast majority of patients with IBS experience breakthrough pain, and when selecting among therapies, they prioritize efficacy and most are willing to use a rapid-acting SQ treatment. These results support development of novel, effective medications-oral or SQ-for management of acute pain attacks.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14118" target="_blank" rel="noopener"> Development of quality indicators for the diagnosis and management of achalasia.</a></p>
<p>s  Using a robust methodology, achalasia quality indicators were identified, which can form the basis for establishing quality gaps and generating fully specified quality measures.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14106" target="_blank" rel="noopener"> Diagnostic yield and reliability of post-prandial high-resolution manometry and impedance-ph for detecting rumination and supragastric belching in PPI non-responders.</a></p>
<p>s  Diagnostic accuracy and inter-rater agreement are higher for MII-pH than PPHRIM, and behavioral disorders are more frequently identified on PPHRIM. Identifying behavioral disorders on MII-pH and PPHRIM has implications for clinical evaluation of PPI non-response; clinical context is essential for accurate study interpretation. Further work is needed to standardize definitions and interpretations.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14101" target="_blank" rel="noopener"> Different responses of the blockade of the P2Y1 receptor with BPTU in human and porcine intestinal tissues and in cell cultures.</a></p>
<p> Background Gastrointestinal smooth muscle relaxation is accomplished by activation of P2Y  receptors in cell cultures and in pig gastrointestinal tissue. However, the concentrations needed are higher in pig tissue compared to cell cultures and BPTU was ineffective in human colonic tissue.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14138" target="_blank" rel="noopener"> Distension-contraction profile of peristalsis in patients with nutcracker esophagus.</a></p>
<p> Abnormalities in the distension phase of peristalsis are a possible mechanism of dysphagia in patients with nutcracker esophagus.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14160" target="_blank" rel="noopener"> Divergent effects of exendin-4 and interleukin-6 on rat colonic secretory and contractile activity are associated with changes in regional vagal afferent signaling.</a></p>
<p>s  Application of Ex-4 in the presence of IL-6 had divergent modulatory effects on colonic secretion and contractile activity. Similar patterns were observed in vagal afferent signaling originating in the submucosal and myenteric neuronal layers, indicating regional afferent activity reflected immune- and endocrine-mediated changes in colonic function.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14212" target="_blank" rel="noopener"> Do resistance exercises during biofeedback therapy enhance the anal sphincter and pelvic floor muscles in anal incontinence?</a></p>
<p>s Concentric resistance biofeedback training did not improve the anal sphincter muscle function or AI symptoms beyond traditional biofeedback training. Anal sphincter muscle damage may be an important factor that limits the success of biofeedback training.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14109" target="_blank" rel="noopener"> Duodenal eosinophilia and the link to anxiety: A population-based endoscopic study.</a></p>
<p> Duodenal eosinophilia may potentially be a mechanism linked to anxiety independent of FD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14176" target="_blank" rel="noopener"> Dysphagia lusoria: utility of high-resolution impedance manometry to identify true disease.</a></p>
<p>Videofluoroscopic swallowing study (modified barium esophagram) and barium esophagram showed delayed barium tablet transit in the upper esophagus and focal smooth narrowing of the upper esophagus caused by external compression, respectively. Computed tomography imaging demonstrated external compression of proximal esophagus from an aberrant right subclavian artery with high atherosclerotic burden. In addition, high-resolution impedance manometry (HRiM) revealed a striking high-pressure pulsatile vascular band in the proximal esophagus (108 mmHg) associated with poor bolus transit, demonstrating the utility of HRiM in strengthening the diagnoses of true dysphagia lusoria.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14195" target="_blank" rel="noopener"> Early adverse life events and post-traumatic stress disorder in patients with constipation and suspected disordered defecation.</a></p>
<p>s  Early adverse life events and PTSD are prevalent in patients with constipation and suspected DD. Those with normal ARM and BET have higher rates of prior emotional abuse and poorer mental health.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14148" target="_blank" rel="noopener"> Epigastric symptom response to low FODMAP dietary advice compared with standard dietetic advice in individuals with functional dyspepsia.</a></p>
<p>s  The low FODMAP diet appears more effective for improving epigastric symptoms in people with FD compared with standard advice. A randomized controlled trial is required to substantiate these findings.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14153" target="_blank" rel="noopener"> Episode-level reflux characteristics: How experienced reviewers differentiate true reflux from artifact on pH-impedance studies.</a></p>
<p>s Acidic episodes with high proximal extent in the upright position and longer acid clearance times on pH-impedance studies have the highest concordance for identification by expert reviewers. Reflux episode identification may be influenced by reviewer opinion despite availability of established criteria.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14205" target="_blank" rel="noopener"> Esophageal mucosal sensory nerves and potential mechanoreceptors in patients with ineffective esophageal motility.</a></p>
<p>s  Our study showed that mucosal sensory afferents nerve position and mRNA expression of potential mechanoreceptors did not correlate to weak esophageal contraction.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14193" target="_blank" rel="noopener"> Esophagogastric junction outflow obstruction.</a></p>
<p>The Chicago Classification is intended for diagnosis of primary esophageal motor disorders, and thus history and endoscopic evaluation are important to exclude conditions (eg, previous surgery, strictures, or masses) that can secondarily generate the EGJOO pattern on HRM. While a manometric finding of EGJOO is often made and can be an early sign of achalasia, more often it is a manometric finding without clinical implications. The proposed changes in CC4.0 have attempted to make the diagnosis more specific, in order to reduce the number of clinically irrelevant diagnoses and avoid confusion by patients and physicians alike.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14117" target="_blank" rel="noopener"> Estrogen and serotonin enhance stress-induced visceral hypersensitivity in female rats by up-regulating brain-derived neurotrophic factor in spinal cord.</a></p>
<p>s  Serotonin-mediated activation of 5HT3A receptors in the spinal cord drives the development of enhanced female-specific VHS in our two hit CPS+CAS through up-regulation of spinal cord ERα.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14116" target="_blank" rel="noopener"> Evaluating esophageal motility beyond primary peristalsis: Assessing esophagogastric junction opening mechanics and secondary peristalsis in patients with normal manometry.</a></p>
<p>s  Symptomatic patients with normal esophageal motility on HRM predominantly have normal FLIP Panometry; however, abnormal FLIP findings can be observed. While abnormal Panometry findings appear clinically relevant via an association with abnormal bolus retention, complementary tests, such as provocative maneuvers with HRM and timed barium esophagram, are useful to determine clinical context.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14099" target="_blank" rel="noopener"> Evidence for the presence and release of BDNF in the neuronal and non-neuronal structures of the internal anal sphincter.</a></p>
<p>s  These studies showed that BDNF/TrkB was present not only in the enteric nervous system (ENS), but also in the SMCs. For the neuromodulatory effects, BDNF is released locally from the ENS ((myenteric (10.01 ± 0.23 pg/ml) and submucosal plexus (9.05 ± 0.51 pg/ml)) and the SMCs (18.63 ± 1.63 pg/ml). Collectively, these findings have pathophysiological and therapeutic implications regarding the role of BDNF/TrkB in the IAS-associated rectoanal motility disorders.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14161" target="_blank" rel="noopener"> Examining the optimal cutoff values of HADS, PHQ-9 and GAD-7 as screening instruments for depression and anxiety in irritable bowel syndrome.</a></p>
<p>s  Custom cutoff values deem the HADS subscales (HADS-D and HADS-A) concordant to PHQ-9 and GAD-7 scores. The choice of a cutoff value has substantial impact on sensitivity/specificity and is dependent on patient population, setting, and the purpose of use.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14173" target="_blank" rel="noopener"> Exploring parameters of gamma transcranial alternating current stimulation (tACS) and full-spectrum transcranial random noise stimulation (tRNS) on human pharyngeal cortical excitability.</a></p>
<p>s  Our findings suggest that the effects of tACS and tRNS are frequency-dependent and cortical (representation) site-specific with both gamma tACS and full-spectrum tRNS enhancing human pharyngeal cortical excitability. These techniques hold promise as potential treatments for neurological dysphagia.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14162" target="_blank" rel="noopener"> Expression of Myosin 5a splice variants in murine stomach.</a></p>
<p>s  Myo5a splice variants varied in their relative expression across anatomically distinguishable stomach regions and might mediate distinct physiological functions in gastric neurotransmission.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14158" target="_blank" rel="noopener"> Factors associated with hiatal hernia in neurologically impaired children.</a></p>
<p>s Timely identification of predictors of developing hiatal hernia in neurologically impaired children is important for early diagnostic confirmation to initiate optimal medical or surgical treatment of hiatal hernia to avoid serious complications such as aspiration pneumonia and malnutrition.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14164" target="_blank" rel="noopener"> Fast synaptic excitatory neurotransmission in the human submucosal plexus.</a></p>
<p> &amp; inference Acetylcholine is the most important mediator of fast excitatory postsynaptic transmission in human submucous plexus neurons whereas glutamatergic fEPSPs were rarely encountered.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14150" target="_blank" rel="noopener"> Fructose intolerance is not associated with malabsorption in patients with functional gastrointestinal disorders.</a></p>
<p>s  Fructose intolerance in FGID is not related to post-ingestion plasma concentrations of fructose and its metabolites. Factors other than malabsorption, such as altered gut microbiota or sensory function, may be important mechanisms.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14208" target="_blank" rel="noopener"> Functional anorectal studies in patients with low anterior resection syndrome.</a></p>
<p>s  The LARS patients had low anal pressures and urge volume. Most Defecation Indices differed between the LARS group and the other groups.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14187" target="_blank" rel="noopener"> Functional gastrointestinal and somatoform symptoms five months after SARS-CoV-2 infection: A controlled cohort study.</a></p>
<p>s  Mild gastroenterological symptoms persist 5 months after SARS-CoV-2 infection, in particular in patients reporting diarrhea in the acute phase. Infected patients are at increased risk of chronic fatigue and somatoform disorders, thus supporting the hypothesis that both functional gastrointestinal and somatoform disorders may have a common biological origin.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14088" target="_blank" rel="noopener"> Gastric accumulation of enteral nutrition reduces pressure changes induced by phasic contractility in an isovolumetric intragastric balloon.</a></p>
<p>s  Enteral nutrition dose-dependently decreased the contractility readout. This decrease was linked to gastric accumulation of enteral nutrition.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14199" target="_blank" rel="noopener"> Gastric electrical stimulation improves symptoms and need for supplemental nutrition in children with severe nausea and vomiting: A ten-year experience.</a></p>
<p>s  Children with severe nausea and vomiting treated with GES experienced significant and durable improvement in symptom severity and their ability to tolerate oral nutrition.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14159" target="_blank" rel="noopener"> Greater intolerance to uncertainty predicts poorer quality of life in adults with cyclic vomiting syndrome.</a></p>
<p>s  Higher degrees of IU are associated with increased anxiety and reduced QOL in patients with CVS. IU is a malleable cognitive trait that can be targeted by cognitive behavioral therapy (CBT). Our results suggest that some CVS patients may benefit from non-pharmacologic therapies such as CBT.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14147" target="_blank" rel="noopener"> Healthcare spending and utilization for pediatric Irritable Bowel Syndrome in a commercially insured population.</a></p>
<p> Patients with IBS incur significant annual spending through increased healthcare utilization.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14178" target="_blank" rel="noopener"> High-resolution impedance manometry characterizes the functional role of distal colonic motility in gas transit.</a></p>
<p>s  Initiation of the 2-8/minute cyclic motor pattern in the distal colon occurs both following a meal and/or as a localized sensorimotor response to gas. The near-absence of a flatal urge and the temporal association between propagating contractions and gas transit supports the hypothesis that the 2-8/minute cyclic motor pattern acts as a physiological &quot;brake&quot; modulating rectal filling.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14092" target="_blank" rel="noopener"> Impact of COVID-19 lockdown on symptoms in patients with functional gastrointestinal disorders: Relationship with anxiety and perceived stress.</a></p>
<p>s  During the COVID-19 quarantine, there was an improvement of the majority of upper gastrointestinal symptoms in our patients, and anxiety seems an important risk of worsening few of them.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14086" target="_blank" rel="noopener"> Impact of joint hypermobility syndrome on gastric accommodation and nutrient tolerance in functional dyspepsia.</a></p>
<p> JHS often co-exists with FD. Non-JHS-FD was characterized by decreased accommodation and lower nutrient tolerance characterized compared with JHS-FD. Clinicaltrials.gov, reference number NCT04279990.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14197" target="_blank" rel="noopener"> Increased prevalence of gastrointestinal symptoms and disorders of gut-brain interaction during the COVID-19 pandemic: An internet-based survey.</a></p>
<p>s The prevalence of GI symptoms was significantly higher during the COVID-19 lockdown than under normal circumstances the previous year. This increase was attributable to increased numbers of patients with DGBI, an effect that was associated with anxiety.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14121" target="_blank" rel="noopener"> Increased psychological distress and somatization in patients with irritable bowel syndrome compared with functional diarrhea or functional constipation, based on Rome IV criteria.</a></p>
<p>  Based on the Rome IV criteria, IBS is associated with increased levels of psychological distress and somatization compared with FD or FC. Patients reporting frequent abdominal pain should be comprehensively screened for psychosomatic disorders, with psychological therapies considered early in the disease course.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14177" target="_blank" rel="noopener"> Increased visceral sensitivity, elevated anxiety, and depression levels in patients with functional esophageal disorders and non-erosive reflux disease.</a></p>
<p>s  Increased sensation to visceral stimuli as well as anxiety and depression appears to play an important role not only in reflux hypersensitivity and functional heartburn as defined by Rome IV but also in NERD. These findings are in line with the disease concept of disorders of gut-brain interaction in which psychological comorbidities and visceral hypersensitivity play a major role.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14167" target="_blank" rel="noopener"> Lidocaine before esophageal manometry and ambulatory pH monitoring: A randomized controlled trial.</a></p>
<p>s Routine use of lidocaine before esophageal function tests does not reduce pain during catheter insertion but may provide other modest benefits with limited toxicity.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14200" target="_blank" rel="noopener"> Long-term effects of fecal microbiota transplantation (FMT) in patients with irritable bowel syndrome.</a></p>
<p>s Most of the IBS patients maintained a response at 1 year after FMT. Moreover, the improvements in symptoms and quality of life increased over time. Changes in DI, fecal bacterial profile and SCFAs were more comprehensive at 1 year than after 3 months. www.clinicaltrials.gov (NCT03822299).</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14190" target="_blank" rel="noopener"> Loss function of Bcr mutation causes gastrointestinal dysmotility and brain developmental defects.</a></p>
<p>s  BCR mutations are associated with intestinal obstruction in children. Loss of Bcr can cause intestinal dysmotility and brain developmental defects may via regulation of Rho GTPases.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14181" target="_blank" rel="noopener"> Low FODMAPs diet or usual dietary advice for the treatment of refractory gastroesophageal reflux disease: An open-labeled randomized trial.</a></p>
<p> Low FODMAPs diet and usual dietary advice have similar but limited beneficial effects on symptoms in patients with PPI refractory GERD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14186" target="_blank" rel="noopener"> Luminal short-chain fatty acids and 5-HT acutely activate myenteric neurons in the mouse proximal colon.</a></p>
<p>s  Taken together, our study demonstrates that different microbial metabolites, including SCFAs and 5-HT, can acutely stimulate Ca 2+  signaling in the mucosal epithelium and in enteric neurons.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14180" target="_blank" rel="noopener"> Manometric parameters, when measured with the 3-dimensional high-definition anorectal manometry probe, poorly predict prolonged balloon expulsion time.</a></p>
<p>s Manometric parameters, when measured with the 3D-HDAM probe, poorly predict prolonged balloon expulsion time. RAPD remains the best predictor of prolonged balloon expulsion time. The 3D-HDAM probe may not be the ideal tool to diagnose functional defecatory disorders.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14098" target="_blank" rel="noopener"> Motor patterns in the proximal and distal mouse colon which underlie formation and propulsion of feces.</a></p>
<p>s  The three motor patterns share a unique underlying fundamental property of the enteric circuits, which involve extended ensembles of enteric neurons firing at close to 2 Hz. The demonstration of distinct functional differences between proximal and distal colon in rabbit, guinea pig, and now mouse raises the possibility that this may be an organizational principle in other mammalian species, including humans.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14155" target="_blank" rel="noopener"> Mucosal eosinophils, mast cells, and intraepithelial lymphocytes in youth with rumination syndrome.</a></p>
<p>s  In conclusion, we found an increase in eosinophil and mast cell densities in the gastric antrum and an increase in intraepithelial lymphocytes in the duodenum in youth with rumination syndrome which was independent of the presence of abdominal pain or early satiety. These findings suggest a potential role for inflammation in the pathophysiology of rumination syndrome. Future studies should address whether treatment directed at these cells are beneficial in treating rumination syndrome.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14169" target="_blank" rel="noopener"> New device for active gastric mechanical stimulation.</a></p>
<p>s  We developed a new simple electromagnet system that evoked a contraction and gastric electrical response using a mechanical stimulus and decreased gastric emptying time. The system is an accessible tool and may contribute to gastroparesis studies in animals.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14146" target="_blank" rel="noopener"> Non-uniform gastric wall kinematics revealed by 4D Cine magnetic resonance imaging in humans.</a></p>
<p>s  MRI has the potential of becoming an important clinical and gastric physiology research tool, providing objective parameters for the evaluation of impaired gastric function.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14136" target="_blank" rel="noopener"> Psychometric evaluation of an experience sampling method-based patient-reported outcome measure in functional dyspepsia.</a></p>
<p>  Good validity and reliability of a novel ESM-based PROM for assessing gastrointestinal symptoms in FD patients was demonstrated. Moreover, this novel PROM allows to evaluate individual symptom patterns and can evaluate interactions between symptoms and environmental/contextual factors. ESM has the potential to increase patients&#39; disease insight, provide tools for self-management, and improve shared decision making. Hence, this novel tool may aid in the transition toward personalized health care for FD patients.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14093" target="_blank" rel="noopener"> Quercetin relaxes human gastric smooth muscles directly through ATP-sensitive potassium channels and not depending on the nitric oxide pathway.</a></p>
<p>Key results Quercetin induced noticeable, dose-dependent relaxation of the carbachol treated gastric strips. The substantial effect was noted at concentrations higher than 10 -7   mol/L and maximal at 10 -4   mol/L (81.82 ± 3.32%; n = 10; p   channels and independently to NO pathways. The present results suggest that quercetin is a potential nutraceutical in the treatment of functional gastrointestinal dyspepsia and other minor gastric muscle motility disturbance.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14168" target="_blank" rel="noopener"> Randomized controlled trial of home biofeedback therapy versus office biofeedback therapy for fecal incontinence.</a></p>
<p>s  Home biofeedback therapy is non-inferior to OBT for FI treatment. Home biofeedback is safe, effective, improves QOL, and through increased access could facilitate improved management of FI.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14139" target="_blank" rel="noopener"> Reference high-resolution manometry values after magnetic sphincter augmentation.</a></p>
<p>  This study provides HRM reference values for patients undergoing successful MSA implantation. Crural repair appears to be a key component of LES augmentation and is associated with improved clinical outcomes.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14183" target="_blank" rel="noopener"> Reflux characteristics triggering post-reflux swallow-induced peristaltic wave (PSPW) in patients with GERD symptoms.</a></p>
<p>s  Acid, mixed and proximal refluxes, and their duration are key factors in eliciting PSPWs. PSPW represents a response to reflux directly related to the potential harmfulness of reflux contents.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14105" target="_blank" rel="noopener"> Region-specific effects of the cysteine protease papain on gastric motility.</a></p>
<p>s  Papain alters gastric motility in a region-specific manner, which could at least partly explain its claimed beneficial effects in functional gastrointestinal disorders.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14154" target="_blank" rel="noopener"> Relationship between symptoms during a gastric emptying study, daily symptoms and quality of life in patients with diabetes mellitus.</a></p>
<p>s Symptoms during a GEBT and to a lesser extent during scintigraphy, but not gastric emptying predict the severity of daily symptoms and may serve as a biomarker in patients with diabetes mellitus.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14127" target="_blank" rel="noopener"> Role of enteric dopaminergic neurons in regulating peristalsis of rat proximal colon.</a></p>
<p>Blockade of cholinergic neurotransmission also prevented peristaltic waves but suppressed ripples with a colonic dilatation. Tetrodotoxin (0.6 μM) abolished peristaltic waves and increased ripples with a constriction. SCH 23390 (20 μM), a D  -like receptors to stabilize asynchronous contractile activity resulting in the generation of colonic peristalsis.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14122" target="_blank" rel="noopener"> Spectral arc length as a method to quantify pharyngeal high-resolution manometric curve smoothness.</a></p>
<p>s In this preliminary study, SPARC analysis was applied to distinguish control from post-stroke subjects. Considering alternative methods of analyzing pharyngeal HRM data may provide additional insight into the pathophysiology of dysphagia beyond what can be gleaned from measures of pressure and duration alone.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14131" target="_blank" rel="noopener"> Tapentadol results in less deterioration of gastrointestinal function and symptoms than standard opioid therapy in healthy male volunteers.</a></p>
<p>s  In this mechanistic study, tapentadol caused significantly less colonic dysmotility and gastrointestinal side effects as compared with oxycodone in equianalgesic doses.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14144" target="_blank" rel="noopener"> The antroduodenal transition time is prolonged in adults with type 1 diabetes.</a></p>
<p> The current method may assess a proxy for severity of pylorospasms in patients with diabetes and other diseases associated with upper gastrointestinal motility disorders, which ultimately may optimize future management.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14061" target="_blank" rel="noopener"> The bitter tastant denatonium benzoate has no influence on the number of transient lower esophageal sphincter relaxations in health.</a></p>
<p>s &amp; interferences Administration of the bitter tastant denatonium benzoate has no influence on the number of TLESRs or reflux episodes.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14083" target="_blank" rel="noopener"> The effect of prucalopride on gastric sensorimotor function and satiation in healthy volunteers.</a></p>
<p>s  Prucalopride does not enhances gastric accommodation but it might increase sensitivity to gastric distention. Furthermore, the increase in sensitivity seems to be related to an increase in nausea with distension. Clinicaltrials.gov  NCT04429802.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14202" target="_blank" rel="noopener"> The Intestinal Gas Questionnaire (IGQ): Psychometric validation of a new instrument for measuring gas-related symptoms and their impact on daily life among general population and irritable bowel syndrome.</a></p>
<p> The IGQ available in paper and electronic versions in 3 languages is a robust instrument for capturing and measuring GRS and their impact on daily life.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14129" target="_blank" rel="noopener"> The relationship between fruit and vegetable intake with functional dyspepsia in adults.</a></p>
<p> We found an inverse association between fruit intake and dyspepsia symptoms. In addition, high consumption of fruit was related to lower odds of early satiation and post-prandial fullness. Higher intake of vegetables was associated with lower risk of FD, only in men.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14102" target="_blank" rel="noopener"> The Spanish version of the esophageal hypervigilance and anxiety score shows strong psychometric properties: Results of a large prospective multicenter study in Spain and Latin America.</a></p>
<p>s  A widely usable Spanish EHAS version has been validated. We confirm its excellent psychometric properties in our patients, confirming the appropriateness of its use in different populations. Our findings support the appropriateness of evaluating esophageal anxiety across the whole manometric diagnosis spectrum.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14140" target="_blank" rel="noopener"> The type 3 adenylyl cyclase is crucial for intestinal mucosal neural network in the gut lamina propria.</a></p>
<p>s In AC3 -/-  mice, innervation of the lamina propria in the colonic mucosa was reduced and colonic propulsion was accelerated. AC3 is crucial for the development and function of the adult neural network of ENS. AC3 deficiency caused atrophy in the colonic mucosal neural network of mice.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14100" target="_blank" rel="noopener"> The α isoform of cGMP-dependent protein kinase 1 (PKG1α) is expressed and functionally important in intrinsic primary afferent neurons of the guinea pig enteric nervous system.</a></p>
<p>s  These data suggest that PKG1α is present and functionally important in IPANs and visceral afferent nociceptive neurons.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14133" target="_blank" rel="noopener"> Use of the functional luminal imaging probe in pediatrics: A comparison study of patients with achalasia before and after endoscopic dilation and non-achalasia controls.</a></p>
<p>s  Functional luminal imaging probe measurements of EGJ-DI in pediatric patients with achalasia are mostly consistent with adult findings. However, normal EGJ-DI is seen in symptomatic patients, including treatment-naive, highlighting the need for pediatric reference data. Balloon dilations achieve a significant increase in EGJ-DI with improvement in Eckardt scores, confirming the therapeutic value of dilations in achalasia management.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14192" target="_blank" rel="noopener"> Validation of secondary peristalsis classification using FLIP panometry in 741 subjects undergoing manometry.</a></p>
<p>s The FLIP panometry contractile response patterns reflect a pathophysiologic transition from normal to abnormal esophageal peristaltic function with shared features with primary peristaltic function/dysfunction on HRM. Thus, these patterns of the contractile response to distension can facilitate the evaluation of esophageal motility using FLIP panometry.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14191" target="_blank" rel="noopener"> What elements in the physician-patient relationship (PPR) contribute to patient satisfaction: Development of a short form PPRS-Patient Version (PPRS-Patient SF) Questionnaire.</a></p>
<p>s  Our findings strongly support the notion that the patient-physician relationship&#39;s quality is the principal driver of gastroenterology patients&#39; satisfaction with their care. The new PPRS-SF is a convenient tool for clinicians and healthcare systems to assess the essential relationship factors that ensure satisfied patients.</p>
</div></td></tr>
  </tbody>
  
  
</table>
</div>
</div>
<div id="reviewseditorials" class="section level3">
<h3>Reviews/Editorials</h3>
<div id="nxozxwuivp" style="overflow-x:auto;overflow-y:auto;width:auto;height:auto;">
<style>html {
  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;
}

#nxozxwuivp .gt_table {
  display: table;
  border-collapse: collapse;
  margin-left: auto;
  margin-right: auto;
  color: #333333;
  font-size: 16px;
  font-weight: normal;
  font-style: normal;
  background-color: #FFFFFF;
  width: auto;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #A8A8A8;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #A8A8A8;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
}

#nxozxwuivp .gt_heading {
  background-color: #FFFFFF;
  text-align: center;
  border-bottom-color: #FFFFFF;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
}

#nxozxwuivp .gt_title {
  color: #333333;
  font-size: 125%;
  font-weight: initial;
  padding-top: 4px;
  padding-bottom: 4px;
  border-bottom-color: #FFFFFF;
  border-bottom-width: 0;
}

#nxozxwuivp .gt_subtitle {
  color: #333333;
  font-size: 85%;
  font-weight: initial;
  padding-top: 0;
  padding-bottom: 6px;
  border-top-color: #FFFFFF;
  border-top-width: 0;
}

#nxozxwuivp .gt_bottom_border {
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#nxozxwuivp .gt_col_headings {
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
}

#nxozxwuivp .gt_col_heading {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: normal;
  text-transform: inherit;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: bottom;
  padding-top: 5px;
  padding-bottom: 6px;
  padding-left: 5px;
  padding-right: 5px;
  overflow-x: hidden;
}

#nxozxwuivp .gt_column_spanner_outer {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: normal;
  text-transform: inherit;
  padding-top: 0;
  padding-bottom: 0;
  padding-left: 4px;
  padding-right: 4px;
}

#nxozxwuivp .gt_column_spanner_outer:first-child {
  padding-left: 0;
}

#nxozxwuivp .gt_column_spanner_outer:last-child {
  padding-right: 0;
}

#nxozxwuivp .gt_column_spanner {
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  vertical-align: bottom;
  padding-top: 5px;
  padding-bottom: 5px;
  overflow-x: hidden;
  display: inline-block;
  width: 100%;
}

#nxozxwuivp .gt_group_heading {
  padding: 8px;
  color: #FFFFFF;
  background-color: #0000FF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: middle;
}

#nxozxwuivp .gt_empty_group_heading {
  padding: 0.5px;
  color: #FFFFFF;
  background-color: #0000FF;
  font-size: 100%;
  font-weight: initial;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  vertical-align: middle;
}

#nxozxwuivp .gt_from_md > :first-child {
  margin-top: 0;
}

#nxozxwuivp .gt_from_md > :last-child {
  margin-bottom: 0;
}

#nxozxwuivp .gt_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  margin: 10px;
  border-top-style: solid;
  border-top-width: 1px;
  border-top-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: middle;
  overflow-x: hidden;
}

#nxozxwuivp .gt_stub {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-right-style: solid;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  padding-left: 12px;
}

#nxozxwuivp .gt_summary_row {
  color: #333333;
  background-color: #FFFFFF;
  text-transform: inherit;
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
}

#nxozxwuivp .gt_first_summary_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
}

#nxozxwuivp .gt_grand_summary_row {
  color: #333333;
  background-color: #FFFFFF;
  text-transform: inherit;
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
}

#nxozxwuivp .gt_first_grand_summary_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-top-style: double;
  border-top-width: 6px;
  border-top-color: #D3D3D3;
}

#nxozxwuivp .gt_striped {
  background-color: rgba(128, 128, 128, 0.05);
}

#nxozxwuivp .gt_table_body {
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#nxozxwuivp .gt_footnotes {
  color: #333333;
  background-color: #FFFFFF;
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
}

#nxozxwuivp .gt_footnote {
  margin: 0px;
  font-size: 90%;
  padding: 4px;
}

#nxozxwuivp .gt_sourcenotes {
  color: #333333;
  background-color: #FFFFFF;
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
}

#nxozxwuivp .gt_sourcenote {
  font-size: 90%;
  padding: 4px;
}

#nxozxwuivp .gt_left {
  text-align: left;
}

#nxozxwuivp .gt_center {
  text-align: center;
}

#nxozxwuivp .gt_right {
  text-align: right;
  font-variant-numeric: tabular-nums;
}

#nxozxwuivp .gt_font_normal {
  font-weight: normal;
}

#nxozxwuivp .gt_font_bold {
  font-weight: bold;
}

#nxozxwuivp .gt_font_italic {
  font-style: italic;
}

#nxozxwuivp .gt_super {
  font-size: 65%;
}

#nxozxwuivp .gt_footnote_marks {
  font-style: italic;
  font-weight: normal;
  font-size: 65%;
}
</style>
<table class="gt_table">
  
  <thead class="gt_col_headings">
    <tr>
      <th class="gt_col_heading gt_columns_bottom_border gt_left" rowspan="1" colspan="1"></th>
    </tr>
  </thead>
  <tbody class="gt_table_body">
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Aliment Pharmacol Ther</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> A change at the top.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> AP&amp;T: Editors&#39; Declarations of Interest.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: a long way to go before precision medicine.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: an expert consensus to standardise the assessment of histologic disease activity in Crohn&#39;s disease clinical trials-a missing link.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: bariatric surgery to reduce the risk of liver cancer.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: co-morbid gastrointestinal conditions are an important consideration in IBS management.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: defining a microbial signature to predict non-response to a FODMAP diet-a step closer or is it?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: determining disability in IBD - &#39;See(k) and you shall find&#39;.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: enhancing colorectal cancer screening participation-the check is in the mail.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: felcisetrag-forward movement as a novel prokinetic for gastroparesis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: finding the ideal prokinetic for gastroparesis-we are not there yet.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: how relevant are gastro-intestinal and liver abnormalities in individuals with Turner syndrome?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8444861" target="_blank" rel="noopener"> Editorial: IBD medications during the COVID-19 pandemic-are they safe to use?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: impact of body mass index on clinical outcomes in patients with ulcerative colitis treated with tofacitinib.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: important insights into prescribing practices and training needs of gastroenterologists regarding use of central neuromodulators in IBS.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: is hyperbaric oxygen a therapeutic opportunity for refractory perianal Crohn&#39;s disease?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: is there a &#39;precursor&#39; HCC lesion and can it be detected by hepatobiliary contrast-enhanced magnetic resonance imaging?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: is tofacitinib another rescue option for acute severe ulcerative colitis?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: liver biopsy in alcoholic hepatitis-more clarity on when it may be needed.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: liver stiffness by magnetic resonance elastography and cardiovascular risk in non-alcoholic fatty liver disease-simply associated or more complicated?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: machine learning models for gastric cancer risk prediction.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: metformin for portal hypertension-old dog, new tricks?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: methotrexate in patients with Crohn&#39;s disease refractory to anti-TNF therapy-moving backwards yet forward?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: microscopic colitis linked to NSAIDs but not proton pump inhibitors.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: on the road towards treatment of gastroparesis-accelerating but do we get closer?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: opioids in inflammatory bowel disease-primum non nocere.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: outcomes following a second switch-evaluating clinical outcomes and patient perspectives in IBD.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: post-reflux swallow-induced peristaltic wave in eosinophilic oesophagitis-more questions than answers?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: proton pump inhibitor use in cirrhosis-a piece of the puzzle.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: recognising the efficacy of licensed drug therapies for IBS on bloating-a step in the right direction for targeted treatment?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: safety of thiopurines in pregnancy-considering the mother, foetus and newborn.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: similar risk of hepatocellar carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: standardising inclusion and outcome criteria for pouchitis-a fragile consensus perhaps but a first step in the right direction.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: stratifying risk of adverse outcomes in cirrhosis: the Hepquant SHUNT test.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: testing novel interventions for coeliac disease-which outcomes matter?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: the microscope holds the key to predict need for biologic therapy in immunotherapy-checkpoint inhibitor colitis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: the polygenic risk of cirrhosis development.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: thiopurines but not anti-TNF monotherapy are linked to worse pregnancy outcomes in a large population-based study.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: tissue findings fail to predict disease activity or prognosis in microscopic colitis: an opportunity to look at the molecular level.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: tobacco use in functional dyspepsia-another smoking gun?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: total anti-drug antibodies detected using drug-tolerant assays during induction with anti-TNF therapy are associated with treatment failure-out of sight but not out of mind.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: trends in paediatric inflammatory bowel disease attributable direct costs.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: type D personality and its relationship with depression and disease activity in inflammatory bowel disease.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: use of intestinal ultrasound in the scoring of Crohn&#39;s disease activity in clinical trials-is it ready for prime time yet?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: vitamin K antagonists versus direct oral anticoagulants in upper gastrointestinal bleeding.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: withdrawal of anti TNF-alpha - are we ready for biological therapy cycling?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16346" target="_blank" rel="noopener"> MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective.</a></p>
<p>s This will strengthen and improve the continuum of care cascade for patients with liver disease(s) and holds the potential to alleviate the cost burden of disease; and increase quality of life for patients following DAAs treatment.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16305" target="_blank" rel="noopener"> Review article: comprehensive analysis of cirrhotic cardiomyopathy.</a></p>
<p>s Cirrhotic cardiomyopathy is a clinically relevant syndrome that affects morbidity and mortality in patients with cirrhosis.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16369" target="_blank" rel="noopener"> Review article: diagnosis, management and patient perspectives of the spectrum of constipation disorders.</a></p>
<p>s Constipation includes multiple overlapping subtypes identifiable using detailed history, current diagnostic tools and smartphone applications. Recognition of individual subtype(s) could pave the way for optimal, evidence-based treatments by a gastroenterology provider.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16356" target="_blank" rel="noopener"> Review article: immunisation against hepatitis B virus infection and the prevention of hepatocellular carcinoma.</a></p>
<p>s To achieve the 2030 viral hepatitis elimination plan, the HBV vaccine is a priority tool for achieving the sustainable development goals of the World Health Organization.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16326" target="_blank" rel="noopener"> Review article: investigation and management of internal fistulae in Crohn&#39;s disease.</a></p>
<p>s Internal fistulae result in significantly increased morbidity in Crohn&#39;s disease, and further studies to determine optimal multi-modality management strategies incorporating medical and surgical therapy are required.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16465" target="_blank" rel="noopener"> Review article: The aetiology of fatigue in inflammatory bowel disease and potential therapeutic management strategies.</a></p>
<p>s A multimodal approach is likely required to treat IBD fatigue. Established reversible factors like anaemia, micronutrient deficiencies and active disease should initially be resolved. Psychosocial intervention shows potential efficacy in reducing fatigue perception in quiescent disease. Restoring physical deconditioning by exercise training intervention may further improve fatigue burden.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16386" target="_blank" rel="noopener"> Review article: the evolution of endpoint assessments for chemotherapy-induced nausea and vomiting and post-operative nausea and vomiting-a perspective from the US Food and Drug Administration.</a></p>
<p> The goal of this research was to inform and identify future opportunities for enhanced clinical trial design. Nausea assessment was identified as an opportunity for continued research and development due to the large heterogeneity of instruments used. Furthermore, there is a need for the development of safe and efficacious antiemetic treatments for paediatric patients.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16380" target="_blank" rel="noopener"> Review article: the role of nutrition in alcohol-associated liver disease.</a></p>
<p>s Malnutrition is common in alcohol-associated liver disease, and physicians should be aware of its association with poor clinical outcomes. Routine nutritional assessment, involvement of a dietician and nutritional supplementation are recommended to improve clinical outcomes in patients with alcohol-associated liver disease.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16489" target="_blank" rel="noopener"> Review article: time to revisit Child-Pugh score as the basis for predicting drug clearance in hepatic impairment.</a></p>
<p>s Many physiological changes in hepatic impairment determining the fate of drugs do not necessarily correlate with Child-Pugh score. Quantifying these changes in individual patients is essential in future hepatic impairment studies. Further studies assessing Child-Pugh alternatives are recommended to allow better prediction of drug exposure.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/apt.16407" target="_blank" rel="noopener"> Umbrella review of 42 systematic reviews with meta-analyses: the safety of proton pump inhibitors.</a></p>
<p>s This review identified several published associations between PPIs and adverse outcomes, however, further investigation is needed to understand their clinical significance and the likelihood of causal relationship. If higher quality evidence is generated substantiating the potential risks, it may be necessary for clinicians to consider alternative treatment strategies, especially when PPI efficacy is suboptimal.</p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Am J Gastroenterol</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001364" target="_blank" rel="noopener"> A Deep Ravine Rather Than a Shallow Gap: Many More Bridges Needed to Improve Care of Chronic Hepatitis B in the United States.</a></p>
<p> Abstract In the United States, improved screening of those who are at highest risk of chronic hepatitis B (CHB) has been a major focus of public health efforts, as has facilitating access to care for those with chronic infection. Despite this, data suggest that less than half of those at risk are tested, and another minority of those who harbor chronic infection receive longitudinal care for the disease. In this study by Tran et al., the authors find that even among those being treated for CHB, a vast minority receive basic testing and screening for staging and complications of CHB.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001266" target="_blank" rel="noopener"> Antispasmodics for Chronic Abdominal Pain: Analysis of North American Treatment Options.</a></p>
<p>Furthermore, variability in study end points limits comparisons. Risk of selection, performance, detection, attrition, and reporting bias also differed among studies, and in many cases, risks were considered &quot;unclear.&quot; The antispasmodics evaluated in this review, which differ in geographic availability, were found to vary dramatically in efficacy and safety. Given these caveats, each agent should be considered on an individual basis, rather than prescribed based on information across the broad class of agents.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001218" target="_blank" rel="noopener"> Celiac Disease: Fallacies and Facts.</a></p>
<p>The gluten-free diet (GFD) is an imperfect treatment for celiac disease; not al individuals show a response. This diet is widely used by people without celiac disease, and symptomatic improvement on a GFD is not sufficient for diagnosis. Finally, the GFD is burdensome, difficult to achieve, and thus has an incomplete efficacy, opening exciting opportunities for novel, nondietary treatments.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001242" target="_blank" rel="noopener"> Nutrient Drinking Test as Biomarker in Functional Dyspepsia.</a></p>
<p> An SDT is a potential diagnostic biomarker in FD, reflecting GA. Additional studies are required to confirm its role as a predictive biomarker for treatment outcome in FD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001204" target="_blank" rel="noopener"> Small Intestine Varices in Cirrhosis at a High-Volume Liver Transplant Center: A Retrospective Database Study and Literature Review.</a></p>
<p> A quarter of patients with cirrhosis and SIV experience bleeding, with high transfusion requirements, frequent need for secondary interventions, and high mortality. These findings highlight the need for a multidisciplinary approach and second-line therapeutic modalities in the timely management of bleeding SIV in cirrhosis.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.14309/ajg.0000000000001282" target="_blank" rel="noopener"> Spontaneous Internal Pancreatic Fistulae Complicating Acute Pancreatitis.</a></p>
<p>More than 60% of the internal PF close with medical and nonsurgical interventions. Colonic fistula, medical refractory-PF, or PF associated with disconnected pancreatic duct can require surgical intervention including bowel resection or distal pancreatectomy. In conclusion, AP-induced spontaneous internal PF is a complex complication requiring multidisciplinary care for successful management.</p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Clin Gastroenterol Hepatol</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.03.021" target="_blank" rel="noopener"> A Systematic Review of Monogenic Inflammatory Bowel Disease.</a></p>
<p>s Monogenic IBD cases, although rare, have varied extraintestinal comorbidities and limited treatment options including surgery and transplant. Early identification and improved understanding of the characteristics of the genes and underlying disease processes in monogenic IBD is important for effective management.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Adjusting Detection Measures for Colonoscopy: How Far Should We Go?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.03.048" target="_blank" rel="noopener"> Advances in the Comprehensive Management of Postoperative Crohn&#39;s Disease.</a></p>
<p>However, there are no high-quality data to guide which agent should be selected. Selecting biologics with an alternative mechanism of action in those who had failed a biologic with adequate drug concentrations and selection of different agents in those with previous intolerance are reasonable. Significantly more study is required to assess the efficacy of therapies in this setting.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.02.014" target="_blank" rel="noopener"> AGA Clinical Practice Update on Chemoprevention for Colorectal Neoplasia: Expert Review.</a></p>
<p>BEST PRACTICE ADVICE 7: Clinicians should not use folic acid to prevent colorectal neoplasia. BEST PRACTICE ADVICE 8: In individuals at average risk for CRC, clinicians should not use statins to prevent colorectal neoplasia. BEST PRACTICE ADVICE 9: In individuals with a history of CRC, clinicians should not use statins to reduce mortality.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.03.046" target="_blank" rel="noopener"> AGA Clinical Practice Update on the Optimal Management of the Malignant Alimentary Tract Obstruction: Expert Review.</a></p>
<p>BEST PRACTICE ADVICE 12: For patients with malignant colonic obstruction who are not candidates for resection, either SEMS placement or a diverting colostomy are reasonable choices depending on the patient&#39;s goals and functional status. BEST PRACTICE ADVICE 13: SEMS is a reasonable option for patients with proximal (or right-sided) malignant obstructions, both as a &quot;bridge to surgery&quot; and in the palliative setting. BEST PRACTICE ADVICE 14: SEMS placement is a reasonable alternative for patients with extracolonic malignancy who are not candidates for surgery, although their placement is more technically challenging, clinical success rates are more variable, and complications (including stent migration) are more frequent.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.06.016" target="_blank" rel="noopener"> An International Reporting Registry of Patients With Celiac Disease and COVID-19: Initial Results From SECURE-CELIAC.</a></p>
<p>Surveillance Epidemiology Under Research Exclusion for Celiac Disease (SECURE-CELIAC) is an international, de-identified adult and pediatric database created to monitor and report on the severity of coronavirus disease 2019 (COVID-19) outcomes in patients with celiac disease (CD).</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Block, Blood, or Both? Outcomes, Opportunities, and Barriers in Colorectal Cancer Universal Testing.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Bowel Movement Frequency Linked to Increased Diverticulitis Risk in 2 Prospective Cohort Studies.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Closing the Gap: the Real-World Risk of Serious Infections With Vedolizumab in Comparison With Anti-TNF Therapy in Inflammatory Bowel Disease.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.060" target="_blank" rel="noopener"> COVID-19 Outcomes Among Racial and Ethnic Minority Individuals With Inflammatory Bowel Disease in the United States.</a></p>
<p>2  Among patients with inflammatory bowel disease (IBD), racial and ethnic minorities have worse outcomes, mediated in part by inequitable health care access. 3  Racial and ethnic minority patients with IBD and COVID-19 may be an especially vulnerable population. The purpose of this study was to evaluate racial and ethnic disparities in COVID-19 outcomes among IBD patients and the impact of non-IBD comorbidities on observed disparities.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.02.004" target="_blank" rel="noopener"> COVID-19 Vaccination Intent and Perceptions Among Patients With Inflammatory Bowel Diseases.</a></p>
<p>1-4  Vaccinations were authorized for emergency use in the United States in December 2020 and aim to halt the spread of COVID-19. However, there are concerns that people will be hesitant to receive the vaccine for a variety of reasons including insufficient data in certain populations including those with IBD. We surveyed patients with IBD to identify potential concerns regarding COVID-19 vaccination.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.03.034" target="_blank" rel="noopener"> Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.</a></p>
<p>s Dual biologic or small molecule therapy may be a possible option in highly selected, refractory IBD patients at specialized centers. Higher quality combination of therapies with a significant improvement in the quality of data is required prior to more widespread use.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.03.017" target="_blank" rel="noopener"> Effect of Endoscopic Bariatric and Metabolic Therapies on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis.</a></p>
<p>s EBMTs appear effective at treating NAFLD with significant improvement in liver fibrosis. Given the worsening NAFLD pandemic and limitations of currently available therapies, EBMTs should be further investigated as a potential treatment option for this patient population.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.06.046" target="_blank" rel="noopener"> Gastrointestinal Sequelae 3 and 6 Months After Hospitalization for Coronavirus Disease 2019.</a></p>
<p>Gastrointestinal (GI) symptoms are highly prevalent in coronavirus disease 2019 (COVID-19) ranging from 17.6 % to 53 %. 1-4  The proposed mechanism for GI symptoms involves SARS-CoV-2 virus binding to the host cell&#39;s angiotensin-converting enzyme-2 receptor, commonly found in GI tract epithelial cells. 5 .</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.01.044" target="_blank" rel="noopener"> Hepatic Vasculopathy and Regenerative Responses of the Liver in Fatal Cases of COVID-19.</a></p>
<p>1  Although functional impairment of the liver has been correlated with worse clinical outcomes, little is known about the pathophysiology of hepatic injury and repair in COVID-19. 2  ,  3  Histologic evaluation has been limited to small numbers of COVID-19 cases with no control subjects 2  ,  4  and demonstrated largely heterogeneous patterns of pathology. 2  ,  3 .</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.02.040" target="_blank" rel="noopener"> Hepatocellular Carcinoma Prediction Models in Chronic Hepatitis B: A Systematic Review of 14 Models and External Validation.</a></p>
<p>s In a systematic review of available HCC models, the REAL-B model exhibited best discrimination and calibration.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.05.002" target="_blank" rel="noopener"> Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression.</a></p>
<p>s Patients with NAFLD-related cirrhosis have a risk of developing HCC similar to that reported for patients with cirrhosis from other etiologies. Evidence documenting the risk in patients with nonalcoholic steatohepatitis or simple steatosis is limited, but the incidence of HCC in these populations may lie below thresholds used to recommend a screening. Well-designed prospective studies in these subpopulations are needed. The protocol for this systematic review is registered in the Prospero database (registration number CRD42018092861).</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Is It Time to Abandon Gastric Emptying in Patients With Symptoms of Gastroparesis and Functional Dyspepsia?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Lower Surgical Risks in &quot;Contemporary&quot; IBD Cohorts: A Reflection of Better Quality of Care or Statistics?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> MAFLD and Cardiovascular Events: What Does the Evidence Show?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.04.032" target="_blank" rel="noopener"> Magnitude and Time-Trend Analysis of Post-Endoscopy Esophageal Adenocarcinoma: A Systematic Review and Meta-analysis.</a></p>
<p>s PEEC accounts for a high proportion of HGD/EACs and is proportional to reduction in incident EAC. Using best endoscopic techniques now and performing future research on improving neoplasia detection through implementation of quality measures and educational tools is needed to reduce PEEC.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Main Pancreatic Duct Dilation in IPMN: When (and Where) to Get &quot;Worried&quot;?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.04.014" target="_blank" rel="noopener"> Maternal and Perinatal Risk Factors for Pediatric Nonalcoholic Fatty Liver Disease: A Systematic Review.</a></p>
<p>s In a systematic review, we found that maternal prepregnancy overweight and obesity were associated with an increased risk of pediatric NAFLD. Breastfeeding might be protective against the development of NAFLD when the duration of breastfeeding is sufficiently long (≥6 months).</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8178538" target="_blank" rel="noopener"> No Durable Impact of COVID-19 on Intestinal Disease Activity in Subjects With IBD.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.02.036" target="_blank" rel="noopener"> Noncontrast MRI for Hepatocellular Carcinoma Detection: A Systematic Review and Meta-analysis - A Potential Surveillance Tool?</a></p>
<p> Non-contrast MRI has a moderate negative LR and high specificity with acceptable sensitivity for the detection of HCC, even in patients with cirrhosis and with lesions &lt;2 cm. Prospective trials to validate if non-contrast MRI can be used for HCC surveillance is warranted.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.03.037" target="_blank" rel="noopener"> Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn&#39;s Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies.</a></p>
<p>s This updated prediction model showed a reasonable discriminative ability, exceeding the performance of a previously published model. It might be useful to guide clinical decisions on anti-TNF therapy cessation in CD patients after further validation.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.06.034" target="_blank" rel="noopener"> Prevalence and Risk Factors for Fatigue in Adults With Inflammatory Bowel Disease: A Systematic Review With Meta-Analysis.</a></p>
<p>s The prevalence of fatigue in adults with IBD is high, emphasizing the importance of additional efforts to manage fatigue to improve the care and quality of life for patients with IBD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.03.026" target="_blank" rel="noopener"> Primer for Development of Guidelines for Helicobacter pylori Therapy Using Antimicrobial Stewardship.</a></p>
<p>It is yet not widely recognized when utilizing otherwise highly successful therapies, the routine test of cure data is an indirect, surrogate method for susceptibility testing. To systematically guide therapy, test of cure data should be collected, shared and integrated into local antimicrobial stewardship programs to provide guidance regarding best practices to both prescribers and public health individuals. Treatment recommendations should be compatible with those of the American Society of Infectious Disease white paper on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens which include criteria for ethical active-controlled superiority studies of antibacterial agents.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.01.037" target="_blank" rel="noopener"> Risk Factors for Early-Onset Colorectal Cancer: A Systematic Review and Meta-analysis.</a></p>
<p>s The results of this study advance the understanding of the etiology of EoCRC. High-quality studies conducted on generalizable populations and that comprehensively examine risk factors for EoCRC are required to inform primary and secondary prevention strategies.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Simplifying ADR Reporting: A Worthy Goal, but the Devil is in the Details.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> The Chicago Classification of Pouchitis: An Important Step Toward a Needed Consensus.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> The Transition From Rome III to Rome IV Irritable Bowel Syndrome: What We Gain and Lose.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> The Weighty Issue of Treating Obesity in Patients With Nonalcoholic Fatty Liver Disease.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Through-the-Scope Clips Are Indispensable in Treating Deep Mural Injury From Colorectal EMR.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> To Stop or Not to Stop? Predicting Relapse After Anti-TNF Cessation in Patients With Crohn&#39;s Disease.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Towards a New Horizon for Individualized Surveillance Tools in Hepatocellular Carcinoma.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.cgh.2021.03.005" target="_blank" rel="noopener"> Treatment Candidacy for Pharmacologic Therapies for NASH.</a></p>
<p>It is thus timely to consider the current situation and the way ahead in the management of NASH. In this article, we review the natural history of nonalcoholic fatty liver disease, upcoming treatments for NASH and various assessments. Based on the current knowledge, we discuss what should be the target treatment population and whether noninvasive tests are ready to guide NASH treatments both for patient selection and evaluation of treatment response.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7857702" target="_blank" rel="noopener"> What Gastroenterologists Should Know About COVID-19 Vaccines.</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Endoscopy</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Artificial intelligence for colonoscopy: the new Silk Road.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Doing our best to do no harm.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Flexible endoscopic Zenker&#39;s diverticulum treatments - too many in the tool box?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Incomplete resection rate: incomplete training, imperfect measuring?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Is artificial intelligence ready to replace expert endoscopists?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Long-standing enteroenteric anastomosis with lumen-apposing metal stents to access bilioenteric anastomotic strictures: yes we can!</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> May the force be with you: will artificial intelligence take over traditional endoscopy?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Patient education for colonoscopy in the time of computers: are you ready, player one?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Post-ERCP pancreatitis: still a major issue despite all efforts.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1055/a-1397-3005" target="_blank" rel="noopener"> Revising the European Society of Gastrointestinal Endoscopy (ESGE) research priorities: a research progress update.</a></p>
<p>s Our extensive review process has led to the removal of seven research priorities from the previous (2016) list, leaving 19 research priorities that have been redefined to make them more precise and relevant for researchers and funding bodies to target.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Why are weight loss outcomes unequal despite similar reductions in gastric volume?</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Gastroenterology</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8252826" target="_blank" rel="noopener"> BNT162b2 Messenger RNA COVID-19 Vaccine Effectiveness in Patients With Inflammatory Bowel Disease: Preliminary Real-World Data During Mass Vaccination Campaign.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Can FMT Cause or Prevent CRC? Maybe, But There Is More to Consider.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Move Over, Colon. It&#39;s Time for the Esophagus to Take Center Stage for Artificial Intelligence and Computer-Aided Detection of Barrett&#39;s!</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Quantification of Digestive Disease Damage in Crohn&#39;s Disease, Are We There Yet With the Lémann Index?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> The Rise of Aptamers: Promising Avenues in the Treatment of Solid Tumors.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Which Diet for Crohn&#39;s Disease? Food for Thought on the Specific Carbohydrate Diet, Mediterranean Diet, and Beyond.</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Gastrointest Endosc</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Artificial intelligence for the detection of gastric precancerous conditions using image-enhanced endoscopy: What kind of abilities are required for application in real-world clinical practice?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Barrett&#39;s esophagus indefinite for dysplasia carries a definite risk of neoplasia.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8106483" target="_blank" rel="noopener"> Behind the mask: physiologic effects of facial personal protective equipment during endoscopy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Challenges for colorectal cancer screening decision modeling.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic radiofrequency ablation to prolong survival for unresectable extrahepatic biliary cancer.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic resection of T1 colorectal cancer before surgery does not affect recurrence.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopist injury: shifting our focus to interventions.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopist-directed nurse-administered balanced propofol sedation for ASA class III patients: A safety net for a tough balancing act?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopomics: quantifying the gut luminal size.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> EUS-guided gallbladder drainage: Where will we go next?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.gie.2021.07.002" target="_blank" rel="noopener"> Evaluation of diagnostic yield of EUS among patients with asymptomatic common bile duct dilation: systematic review and meta-analysis.</a></p>
<p>s EUS in patients with asymptomatic CBD dilation does yield findings of choledocholithiasis and malignancy, albeit at low rates. A cost-effectiveness analysis is warranted to further guide clinical decision-making in this area.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> From bench to bedside: Is it time to incorporate molecular testing for diagnostic and management algorithms for pancreatic cystic lesions?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Improving quality in EUS: a call for a national benchmarking registry.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Larger esophageal Lugol&#39;s unstained lesions need more follow-up: size as an important predictor for risk of premalignant lesions.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7937337" target="_blank" rel="noopener"> Metabolic function and weight loss after endoscopic sleeve gastroplasty: resistance is futile.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> No tissue left behind: What can a segmental polyp recurrence rate tell us about quality of polypectomy?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Pediatric ERCP: leaving no stone unturned.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Percutaneous endoscopic gastrostomy and direct percutaneous endoscopic jejunostomy: 2 sides of the same coin.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Prioritizing an oncologic approach to endoscopic resection of pedunculated colorectal polyps.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Pyloric dilation with EsoFLIP: Time to &quot;flip&quot; treatment options for refractory gastroparesis?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Recurrence after endoscopic mucosal resection: there&#39;s more to it than meets the eye.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Rejuvenate and repopulate: renaissance of the duodenum.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Risk for individuals with index small (&lt;1 cm) hyperplastic polyps.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Risk stratification of pancreatic cysts: a convoluted path to finding the needle in the haystack.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Shining a light on the monsters under the bed.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Strategies to pre-empt recurrent bleeding after endoscopic hemostasis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> The key to reducing residual or recurrent adenoma after duodenal EMR is remembering to spice up the rim.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7963266" target="_blank" rel="noopener"> Update from the Editor-in-Chief.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> What is important for a smooth implementation of endoscopic submucosal dissection?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> You can go your own way: EUS-guided lumen-apposing metal stent as a rescue for failed ERCP.</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Gut</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1136/gutjnl-2021-324855" target="_blank" rel="noopener"> Calprotectin: from biomarker to biological function.</a></p>
<p>Recent studies revealed insights into biological functions of the CP subunits S100A8 and S100A9 during orchestration of an inflammatory response at mucosal surfaces across organ systems. In this review, we summarise longitudinal evidence for the evolution of CP from biomarker to rheostat of mucosal inflammation and suggest an algorithm for the interpretation of faecal CP in daily clinical practice. We propose that mechanistic insights into the biological function of CP in the gut and beyond may facilitate interpretation of current assays and guide patient-tailored medical therapy in IBD, a concept warranting controlled clinical trials.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1136/gutjnl-2020-323888" target="_blank" rel="noopener"> Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease.</a></p>
<p>One additional drug, the prenylation inhibitor lonafarnib, is currently under investigation in phase III clinical trials. Other treatment strategies aim at targeting hepatitis B surface antigen, including the nucleic acid polymer REP2139Ca. These recent advances in HDV virology, immunology and treatment are important steps to make HDV a less difficult-to-treat virus and will be discussed.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1136/gutjnl-2020-323609" target="_blank" rel="noopener"> Understanding the role of the gut in undernutrition: what can technology tell us?</a></p>
<p>Here we survey the technology landscape for potential solutions to improve assessment of gut function, focussing on devices that could be deployed at point-of-care in low-income and middle-income countries (LMICs). We assess the potential for technological innovation to assess gut morphology, function, barrier integrity and immune response in undernutrition, and highlight the approaches that are currently most suitable for deployment and development. This article focuses on EE and undernutrition in LMICs, but many of these technologies may also become useful in monitoring of other gut pathologies.</p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Hepatology</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> A Beautiful Day in the Neighborhood: Application of Single-Cell Transcriptomics to Unravel Liver Cell Heterogeneity in Diseased Human Livers.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31869" target="_blank" rel="noopener"> Application of Artificial Intelligence for Diagnosis and Risk Stratification in NAFLD and NASH: The State of the Art.</a></p>
<p>There is an urgency to develop innovative methods to facilitate management at key points in an individual&#39;s journey with nonalcoholic fatty liver disease fibrosis. Artificial intelligence is an exciting field that has the potential to achieve this. In this review, we highlight applications of artificial intelligence by leveraging our current knowledge of nonalcoholic fatty liver disease to diagnose and risk stratify NASH phenotypes.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Artificial Intelligence in NASH Histology: Human Teaches a Machine for the Machine to Help Humans.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8013494" target="_blank" rel="noopener"> COVID-19 and Liver Cirrhosis: Focus on the Nonclassical Renin-Angiotensin System and Implications for Therapy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8333231" target="_blank" rel="noopener"> Discovery and Opportunities With Integrative Analytics Using Multiple-Omics Data.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Exosomes and MicroRNA-223 at the Intersection of Inflammation and Fibrosis in NAFLD.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31772" target="_blank" rel="noopener"> Hepatobiliary Organoids and Their Applications for Studies of Liver Health and Disease: Are We There Yet?</a></p>
<p>CRISPR-based gene modifications and organoid exposure to infectious agents have permitted the generation of organoid models of carcinogenesis. This review summarizes currently available adult cell-derived hepatobiliary organoid models and their applications. Challenges faced by this young technology will be discussed, including the cellular immaturity of organoid-derived hepatocytes, co-culture development to better model complex tissue structure, the imperfection of extracellular matrices, and the absence of standardized protocols and model validation.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31999" target="_blank" rel="noopener"> Key Characteristics of Human Hepatotoxicants as a Basis for Identification and Characterization of the Causes of Liver Toxicity.</a></p>
<p>One of the challenges in translating mechanistic evidence into robust decisions about potential hepatotoxicity is the lack of a systematic approach to integrate these data to help identify liver toxicity hazards. Recently, marked improvements were achieved in the practice of hazard identification of carcinogens, female and male reproductive toxicants, and endocrine disrupting chemicals using the key characteristics approach. Here, we describe the methods by which key characteristics of human hepatotoxicants were identified and provide examples for how they could be used to systematically identify, organize, and use mechanistic data when identifying hepatotoxicants.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Long Noncoding RNA H19: A Key Player in Liver Diseases.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31840" target="_blank" rel="noopener"> Mechanistic Rationales Guiding Combination Hepatocellular Carcinoma Therapies Involving Immune Checkpoint Inhibitors.</a></p>
<p>However, the mechanistic rationales guiding different drug combinations to maximize this synergy remain largely ambiguous. In this review, we discuss different drug combinations used in HCC and the underlying mechanistic rationales, aiming to enhance the understanding of how these treatments can achieve synergy. This knowledge sets the foundation for the development of more effective and promising combination therapies for HCC.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> NAFLD and HCC: Time to Bridge the Gap.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> New Glance at the Role of TM6SF2 in Lipid Metabolism and Liver Cancer.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Noninvasive Tests to Phenotype Nonalcoholic Fatty Liver Disease: Sequence and Consequences of Arranging the Tools in the Tool Box.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.32027" target="_blank" rel="noopener"> On the Mechanisms of Biliary Flux.</a></p>
<p>Thus, bile canaliculi can be compared to a standing water zone that is connected to a river. The seemingly subtle difference between diffusion and flow is of relevance for therapy of a wide range of liver diseases including cholestasis and NAFLD. Here, we incorporated the latest findings on canalicular solute transport, and align them with extant knowledge to present an integrated and explanatory framework of bile flux that will undoubtedly be refined further in the future.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31770" target="_blank" rel="noopener"> Pulmonary Abnormalities in Liver Disease: Relevance to Transplantation and Outcome.</a></p>
<p>Pre-LT evaluation should include adequate screening for pulmonary diseases that may occur concomitantly with liver disease as well as for those that may arise as a complication of end-stage liver disease and PH, given that either may jeopardize safe LT and successful outcome. It is key to discriminate those patients who would benefit from LT, especially pulmonary disorders that have been reported to resolve post-LT and are considered &quot;pulmonary indications&quot; for transplant, from those who are at increased mortality risk and in whom LT is contraindicated. In conclusion, in this article, we review the impact of several pulmonary disorders, including cystic fibrosis, alpha 1-antitrypsin deficiency, hereditary hemorrhagic telangiectasia, sarcoidosis, coronavirus disease 2019, asthma, chronic obstructive pulmonary disease, pulmonary nodules, interstitial lung disease, hepatic hydrothorax, hepatopulmonary syndrome, and portopulmonary hypertension, on post-LT survival, as well as the reciprocal impact of LT on the evolution of lung function.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Saroglitazar for the Treatment of NASH: The Peroxisome Proliferator-Activated Receptor Story Goes On!</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Selective Internal Radiation Therapy Approval for Early HCC: What Comes Next?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Ten Thousand Points of Light: Heterogeneity Among the Stars of NASH Fibrosis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> The &quot;Alter Ego&quot; of Albumin in Cirrhosis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31889" target="_blank" rel="noopener"> The Emerging Role of B Cells in the Pathogenesis of NAFLD.</a></p>
<p>We discuss the possible effector functions by which B cells promote NAFLD, including the production of proinflammatory cytokines and regulation of intrahepatic T cells and macrophages. Finally, we highlight the role of regulatory and IgA +  B cells in the pathogenesis of NASH-associated HCC. In this review, we make the case that future research is needed to investigate the potential of B-cell-targeting strategies for the treatment of NAFLD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> The Importance of Glycemic Equipoise in NASH.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31985" target="_blank" rel="noopener"> We Are Not Immune: Racial and Ethnic Disparities in Autoimmune Liver Diseases.</a></p>
<p>Nonetheless, socioeconomic status, access to health care, environmental and societal factors, and implicit provider bias can al contribute to poor patient outcomes. There remains an unmet need to understand and mitigate the factors contributing to health inequity in autoimmune liver diseases. In this review, we summarize the data on racial and ethnic disparities in presentation, treatment response, and outcomes pertaining to autoimmune liver diseases in minority populations, on the premise that understanding disparities is the first step toward reaching health equity.</p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Inflamm Bowel Dis</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ibd/izab114" target="_blank" rel="noopener"> Ensuring High and Equitable COVID-19 Vaccine Uptake Among Patients With IBD.</a></p>
<p>They should also strongly recommend that al their patients be vaccinated with a COVID-19 vaccine. Additionally, they should be prepared to educate patients about logistics that will result in successful vaccination completion. All these measures will be crucial to ensure high uptake among their patients with IBD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> High Fecal Proteolytic Activity That Precedes Ulcerative Colitis Likely Results From Impaired Inactivation of Pancreatic Proteases Rather Than Bacteria.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> IBD Development After Diverticulitis May Hold Clues to IBD Pathogenesis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Pyoderma Gangrenosum in An Ulcerative Colitis Pediatric Patient During Vedolizumab Therapy Successfully Treated With Oral Cyclosporine.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Real-World Effectiveness of Ustekinumab Dose Intensification in Crohn&#39;s Disease.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8083615" target="_blank" rel="noopener"> Safety of Tofacitinib in the COVID-19 Pandemic-Enough Is Not Enough.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Tofacitinib in Acute Severe Ulcerative Colitis: Case Series and a Systematic Review.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Ustekinumab Dose Optimization in Crohn Disease: One Size Does Not Fit All.</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">J Crohns Colitis</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8495484" target="_blank" rel="noopener"> Anti-TNF Therapy Before Intestinal Surgery for Crohn&#39;s Disease and the Risks of Postoperative Complications.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> At the Crossroads of Caution and Intervention: Anti-TNF Therapy Prior to Elective CD Surgery.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Body, Soul, and Hypnotherapy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Can Serum Proteomic Profiling Annunciate Individual Disease Progression in Newly Diagnosed Inflammatory Bowel Disease Patients?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Cannabis and Inflammatory Bowel Disease: All Smoke and Mirrors?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Clinical Efficacy of Tofacitinib in Moderate to Severe Ulcerative Colitis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Gut-Brain Interactions in Patients with Inflammatory Bowel Disease and the Role of Hypnotherapy in Managing Symptoms.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Histological Scores in Inflammatory Bowel Disease: A New Kid in the Block.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Holistic approach to IBD patients.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Keeping It Simple: Using Intestinal Ultrasound to Assess Ulcerative Colitis with a Novel UC-Ultrasound Index.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8328286" target="_blank" rel="noopener"> Mycobacterium Avium Subspecies Paratuberculosis Infection and Biological Treatment of IBD: Cause or Consequence?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Response to &#39;Clinical Efficacy of Tofacitinib in Moderate to Severe Ulcerative Colitis&#39;.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1093/ecco-jcc/jjab046" target="_blank" rel="noopener"> SARS-CoV-2 Vaccination in IBD: Past Lessons, Current Evidence, and Future Challenges.</a></p>
<p>We review current evidence on SARS-CoV-2 vaccination relevant to IBD patients, including immune responses from humoral to cellular, emerging data on new variants, and off-label vaccination schemes. We also identify clinical and scientific knowledge gaps that can be translated into both large-scale population-based studies and targeted vaccine studies to describe the precise immune responses induced by SARS-CoV-2 vaccines in IBD patients. We strongly endorse the recommendation of vaccinating IBD patients to ensure maximal protection from COVID-19 both for the individual and the community.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> The Promise of Polygenic Risk Scores as a Research Tool to Analyse the Genetics Underlying IBD Phenotypes.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Tofacitinib De-escalation Strategy in Ulcerative Colitis: Is It the End of the Story?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Vitamin D Levels May Predict Response to Vedolizumab.</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">J Hepatol</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.06.017" target="_blank" rel="noopener"> &#39;Equity&#39; and &#39;Justice&#39; for patients with acute-on chronic liver failure: A call to action.</a></p>
<p>In this expert opinion, we provide evidence supporting the argument that patients with ACLF should be given priority for LT based on prognostic models that define the risk of death for these patients. We also pinpoint risk factors for poor post-LT outcomes, identify unanswered questions and describe the design of a global study, the CHANCE study, which will provide answers to the outstanding issues. We also propose the worldwide adoption of new organ allocation policies for patients with ACLF, as have been initiated in the UK and recommended in Spain.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> &quot;We can and should do better&quot; - an interview with the 2020 Nobel prize laureates who revolutionized hepatology.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2020.11.047" target="_blank" rel="noopener"> Acute-on-chronic liver failure: A distinct clinical syndrome.</a></p>
<p>Of note, although ACLF has received different operating definitions, every definition recognises that ACLF is a distinct clinical entity. This article provides an updated overview of the distinctive features of ACLF according to the definitions used to characterise it. In addition, we discuss future directions for research aimed at identifying the hallmarks of ACLF.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.06.021" target="_blank" rel="noopener"> Advanced preclinical models for evaluation of drug-induced liver injury - consensus statement by the European Drug-Induced Liver Injury Network [PRO-EURO-DILI-NET].</a></p>
<p>Despite intensive efforts utilising current animal and in vitro models, the mechanisms involved in the hepatotoxicity of APAP are still not fully understood. In this expert Consensus Statement, which is endorsed by the European Drug-Induced Liver Injury Network, we aim to facilitate and outline clinically impactful discoveries by detailing the requirements for more realistic human-based systems to assess hepatotoxicity and guide future drug safety testing. We present novel insights and discuss major players in APAP pathophysiology, and describe emerging in vitro and in vivo pre-clinical models, as well as advanced imaging and in silico technologies, which may improve prediction of clinical outcomes of DILI.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Androgen receptor, neovascularization and liver cancer metastasis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.06.010" target="_blank" rel="noopener"> Bilirubin: The yellow hormone?</a></p>
<p>Bilirubin appears to have versatile functions, from cell signaling (behaving almost like a &quot;real&quot; hormonal substance), modulation of metabolism, to immune regulation, affecting biological activities with apparent clinical and even therapeutic consequences. These activities may be the reason for the lower incidence of diseases of civilisation (cardiovascular diseases, arterial hypertension, diabetes, obesity, metabolic syndrome, certain cancers, autoimmune, and neurodegenerative diseases) observed in individuals with a chronic mild unconjugated hyperbilirubinemia, a typical sign of Gilbert&#39;s syndrome. While higher serum concentrations of unconjugated bilirubin may serve as an important protective factor against these diseases, low levels of bilirubin are associated with the opposite effect.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Build to understand biliary oncogenesis via organoids and FGFR2 fusion proteins.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Cardiac evaluation before liver transplantation: A step forward?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.05.013" target="_blank" rel="noopener"> Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections.</a></p>
<p>Approaches currently under investigation in early clinical trials are aimed at achieving a functional cure, defined as the loss of HBsAg and undetectable HBV DNA levels in serum. However, achieving a complete HBV cure requires therapies that can directly target the cccDNA pool, either via degradation, lethal mutations or functional silencing. In this review, we discuss cutting-edge technologies that could lead to non-cytolytic direct cccDNA targeting and cure of infected hepatocytes.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.04.029" target="_blank" rel="noopener"> Current knowledge and management of portal vein thrombosis in cirrhosis.</a></p>
<p>Although the negative effect of complete PVT on the surgical outcome of liver transplant recipients is clear, its impact on cirrhosis progression remains uncertain. Treatment options include anticoagulants and interventional thrombolytic therapies, which are chosen almost on a case-by-case basis depending on the characteristics of the patient and the thrombus. In this manuscript, we review current knowledge regarding the epidemiology, risk factors, diagnosis and classification, natural history, clinical consequences and treatment of non-neoplastic PVT in cirrhosis.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.04.048" target="_blank" rel="noopener"> Direct reprogramming of somatic cells into induced hepatocytes: Cracking the Enigma code.</a></p>
<p>In this review, we provide an overview of the state-of-the-art reprogramming cocktails and techniques, as well as their corresponding conversion efficiencies. Special attention is paid to the role of liver-enriched transcription factors as hepatogenic reprogramming tools and small molecules as facilitators of hepatic transdifferentiation. To conclude, we formulate recommendations to optimise, standardise and enrich the in vitro production of iHeps to reach clinical standards, and propose minimal criteria for their characterisation.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.05.019" target="_blank" rel="noopener"> Early liver transplantation for acute alcoholic hepatitis: We can&#39;t say no.</a></p>
<p>Early transplantation of patients with severe alcoholic hepatitis, using a restrictive selection process, has increasingly been used in the last decade with acceptable relapse rates. Indeed, early transplantation has gained the support of a growing number of experts from different countries, as shown by the European, American and Latin American recommendations. However, there is still great heterogeneity in its application between countries and even between centres within the same country.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> EASL international recognition award recipient 2021: Prof. Dr. Nahum Méndez-Sánchez.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.01.032" target="_blank" rel="noopener"> EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.</a></p>
<p>A small number of these SARS-CoV-2 vaccine candidates have already undergone phase III, placebo-controlled, clinical trials in healthy individuals with proof of short-term safety, immunogenicity and efficacy. However, although regulatory agencies in the US and Europe have already approved some of these vaccines for clinical use, information on immunogenicity, duration of protection and long-term safety in patients with CLD, cirrhosis, hepatobiliary cancer and liver transplant recipients has yet to be generated. This review summarises the data on vaccine safety, immunogenicity, and efficacy in this patient population in general and discusses the implications of this knowledge on the introduction of the new SARS-CoV-2 vaccines.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> EASL recognition award recipient 2021: Prof. Dieter Häussinger.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> EASL recognition award recipient 2021: Prof. Patrizia Burra.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> FXR agonists for NASH: How are they different and what difference do they make?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Hepatitis B virus - an anaerobic organism?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> In search of an evidence base for HCC surveillance: Purity or pragmatism?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2020.10.024" target="_blank" rel="noopener"> Intensive care management of acute-on-chronic liver failure.</a></p>
<p>This response recognises the features that distinguish it from other critical illness and addresses the complex interplay between the precipitating insult, the many organ systems involved and the disordered physiology of underlying chronic liver disease. An evidence base is building to support the approaches currently adopted and outcomes for patients with this condition are improving, but mortality remains unacceptably high. Herein, we review practical considerations in critical care management, as well as discussing key knowledge gaps and areas of controversy that require further focussed research.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.01.007" target="_blank" rel="noopener"> Limitations of current liver donor allocation systems and the impact of newer indications for liver transplantation.</a></p>
<p>Moreover, it is urgent to address inequalities in access to liver transplantation in patients with severe alcoholic hepatitis and non-alcoholic steatohepatitis. Several controversies still exist regarding gender and regional disparities, as well as the use of suboptimal donor grafts. In this review, we aim to provide a critical perspective on the role of liver transplantation in patients with decompensated cirrhosis and address areas of ongoing uncertainty.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2020.11.010" target="_blank" rel="noopener"> Management of bacterial and fungal infections in cirrhosis: The MDRO challenge.</a></p>
<p>Early diagnosis and adequate empirical treatment of infections is therefore key in the management of these patients. In recent decades, antibiotic resistance has become a major worldwide problem in patients with cirrhosis, warranting a more complex approach to antibiotic treatment that includes the use of broad-spectrum antibiotics, new administration strategies, novel drugs and de-escalation policies. Herein, we review epidemiological changes, the main types of multidrug-resistant organisms, mechanisms of resistance, new rapid diagnostic tools and currently available therapeutic options for bacterial and fungal infections in cirrhosis.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.01.027" target="_blank" rel="noopener"> Management of the major complications of cirrhosis: Beyond guidelines.</a></p>
<p>Many of these advances have helped inform the current EASL clinical practice guidelines 1  on the management of some of the key complications of cirrhosis, such as ascites, variceal bleeding and infection. However, there are still some aspects of management where the evidence base is less clear, and/or where opinions amongst practitioners remain divided. Some of these more controversial areas are explored in this section, wherein we present evidence culminating in a suggested management approach based on expert opinion and extending beyond the current guidelines.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.01.018" target="_blank" rel="noopener"> New clinical and pathophysiological perspectives defining the trajectory of cirrhosis.</a></p>
<p>Over the past 20 years, large, international prospective studies have indicated the importance of systemic inflammation and organ immunopathology as additional determinants of organ dysfunction in cirrhosis, which not only manifests in the liver, brain, circulation and the kidneys, but also the immune system, gut, muscles, adrenal glands, reproductive organs, heart and lungs. This review provides an overview of the traditional and emerging concepts around the initiation and maintenance of organ dysfunction in cirrhosis and proposes a new paradigm based upon a better understanding of acute decompensation of cirrhosis. The interaction between the traditional concepts and the emerging perspectives remains a matter of great interest and the basis for future research.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> New concepts and perspectives in decompensated cirrhosis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.04.045" target="_blank" rel="noopener"> Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens.</a></p>
<p>While many endemic subtypes respond well to direct-acting antiviral therapies, others, for example genotypes 1l, 3b and 4r, do not respond as well as predicted. Many genotypes that are rare in high-income countries but common in other parts of the world have not yet been fully assessed in clinical trials. Further sequencing and clinical studies in sub-Saharan Africa and Asia are indicated to monitor response to treatment and to facilitate the World Health Organization&#39;s 2030 elimination strategy.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.01.002" target="_blank" rel="noopener"> Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction.</a></p>
<p>This review amalgamates the latest knowledge on disease mechanisms that lead to tissue injury and extrahepatic organ failure - such as systemic inflammation, mitochondrial dysfunction, oxidative stress and metabolic changes - and marries these with the classical paradigms of acute decompensation to form a single paradigm. With this detailed breakdown of pathomechanisms, we identify areas for future research. Novel disease-modifying strategies that break the vicious cycle are urgently required to improve patient outcomes.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.06.030" target="_blank" rel="noopener"> Polyploidy control in hepatic health and disease.</a></p>
<p>We report on centrosomes&#39; role in limiting polyploidy by activating the p53 signalling network (via the PIDDosome multiprotein complex) and we discuss the role of this pathway in liver disease. Increased hepatocyte ploidy is a hallmark of hepatic inflammation and may play a protective role against liver cancer. Our evolving understanding of hepatocyte ploidy is discussed from the perspective of its potential clinical application for risk stratification, prognosis, and novel therapeutic strategies in liver disease and hepatocellular carcinoma.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8146269" target="_blank" rel="noopener"> Protected or not protected, that is the question - First data on COVID-19 vaccine responses in patients with NAFLD and liver transplant recipients.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.01.025" target="_blank" rel="noopener"> Sarcopenia and frailty in decompensated cirrhosis.</a></p>
<p>When available, we highlight data focusing on patients with acutely decompensated cirrhosis, such as inpatients, as this is an area of unmet clinical need. Finally, we discuss management strategies to reverse and/or prevent the development of sarcopenia and frailty, which include adequate nutritional intake of calories and protein, as well as regular exercise of at least moderate intensity, with a mix of aerobic and resistance training. Key knowledge gaps in our understanding of sarcopenia and frailty in decompensated cirrhosis remain, including best methods to measure muscle mass and function in the inpatient setting, racial/ethnic variation in the development and presentation of sarcopenia and frailty, and optimal clinical metrics to assess response to therapeutic interventions that translate into a reduction in adverse outcomes associated with these conditions.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> The ART of medicine: Counselling women with liver disease about assisted reproductive technology.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2020.11.042" target="_blank" rel="noopener"> The global burden of cirrhosis: A review of disability-adjusted life-years lost and unmet needs.</a></p>
<p>Interventions targeting hepatitis B infection are known, but not fully implemented. In more affluent countries, alcohol and hepatitis C are the dominant causes of cirrhosis, but non-alcoholic fatty liver will likely become a dominant cause of cirrhosis in parallel with the increasing prevalence of obesity. We also argue that the World Health Organization underestimates the public health burden associated with cirrhosis because it assigns zero disability to compensated cirrhosis and considers decompensated cirrhosis as only mildly disabling.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2020.11.013" target="_blank" rel="noopener"> The microbiota in cirrhosis and its role in hepatic decompensation.</a></p>
<p>g. Yaq-001), which bind microbial factors without exerting a direct effect on bacterial growth kinetics. This review focuses on the role of microbiota in decompensation and strategies targeting microbiota to prevent acute decompensation.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.06.031" target="_blank" rel="noopener"> The multifaceted role of cathepsins in liver disease.</a></p>
<p>Lysosomal protease cathepsins comprise 3 families of proteases that preferentially act within acidic cellular compartments, but they can also be found in other cellular locations. They can operate alone or as part of signalling cascades and regulatory circuits, playing important roles in apoptosis, extracellular matrix remodelling, hepatic stellate cell activation, autophagy and metastasis, contributing to the initiation, development and progression of liver disease. In this review, we comprehensively summarise current knowledge on the role of lysosomal cathepsins in liver disease, with a particular emphasis on liver fibrosis, non-alcoholic fatty liver disease and hepatocellular carcinoma.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2020.11.029" target="_blank" rel="noopener"> The multifactorial mechanisms of bacterial infection in decompensated cirrhosis.</a></p>
<p>Important research over the last few years has identified molecular targets on immune cells that may enhance their function, and theoretically prevent infections. Clinical trials are ongoing to delineate the beneficial effects of targeted molecules from their off-target effects. Herein, we review the mechanisms that predispose patients with cirrhosis to bacterial infections, the clinical implications of infections and potential targets for the prevention or treatment of infections in this vulnerable population.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.01.024" target="_blank" rel="noopener"> The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery.</a></p>
<p>In contrast, there remains an unmet clinical need for disease-modifying agents which can antagonise key pathophysiological mechanisms of decompensated cirrhosis, such as portal hypertension, gut translocation, circulatory dysfunction, systemic inflammation, and immunological dysfunction. However, in the last few years, the repurposing of &quot;old drugs&quot; that have already been prescribed for more limited indications in hepatology or for other diseases has provided a few candidates, including human albumin, statins, and poorly absorbable oral antibiotics, which are under further evaluation in large-scale randomised clinical trials. New disease-modifying agents are also expected to be identified in the next decade through the systematic repurposing of existing drugs and the development of novel molecules which are currently undergoing pre-clinical or early clinical testing.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.04.040" target="_blank" rel="noopener"> The times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analogue therapy.</a></p>
<p>In this article, we propose a concept in which NA discontinuation-associated relapse is an integral part of the stop-to-cure approach and ultimately the trigger for achieving HBsAg loss. However, the relapse in this sense becomes functionally effective only if HBV-specific immune reinvigoration and silencing of HBV transcriptional activity have been achieved during the NA treatment period. The probability of functional cure and the severity of post-discontinuation flares depend on the underlying baseline transcriptional activity of HBV when NA therapy was started, as well as the duration of NA treatment, both factors that should be considered as we move towards individualised approaches to HBV cure.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.06.018" target="_blank" rel="noopener"> Towards a new definition of decompensated cirrhosis.</a></p>
<p>Decompensation presents as AD in a portion of patients while in many others it presents as a slow development of ascites or mild grade 1 or 2 hepatic encephalopathy, or jaundice, not requiring hospitalisation. Thus, we propose that decompensation of cirrhosis occurs through 2 distinct pathways: a non-acute and an acute (which includes acute-on-chronic liver failure) pathway. Moreover, while non-acute decompensation is the most frequent pathway of the first decompensation, AD mostly represents further decompensation.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2020.12.005" target="_blank" rel="noopener"> Transition to decompensation and acute-on-chronic liver failure: Role of predisposing factors and precipitating events.</a></p>
<p>g. bacterial infection, alcoholic hepatitis, variceal haemorrhage, drug-induced liver injury, flare of liver disease) lead to acute decompensation (ascites, hepatic encephalopathy, variceal bleeding, jaundice) and/or organ failures, which characterise acute-on-chronic liver failure. In this review paper, we will discuss the current hypotheses and latest evidences regarding predisposing and precipitating factors associated with the transition to decompensated liver disease.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Unscrambling a novel pathogenic role for interleukin-20 in acute hepatitis and bacterial infection: A double-edged sword?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1016/j.jhep.2021.05.036" target="_blank" rel="noopener"> Why are there so many liver transplants from living donors in Asia and so few in Europe and the US?</a></p>
<p>On the other hand, the West chose to concentrate their efforts on optimising the use of cadaveric livers with techniques such as split LT, or by using extended criteria donors (including donation after cardiac death donors) and machine perfusion devices etc. Consequently, LDLT did not find the widespread acceptance it did in the East and hence over 90% of al LT are DDLT in this region. We review each regions&#39; perspective and attempt to provide a globally viable roadmap to bridge the widening gap between the demand and availability of livers for LT.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Why have we performed a randomized controlled trial on our own dissemination policy?</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">J Neurogastroenterol Motil</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.5056/jnm20161" target="_blank" rel="noopener"> A Systematic Review and Meta-analysis of Randomized Control Trials: Combination Treatment With Proton Pump Inhibitor Plus Prokinetic for Gastroesophageal Reflux Disease.</a></p>
<p>s Combination of prokinetics with PPI treatment is more effective than PPI alone in GERD patients. Further high-quality trials with large sample sizes are needed to verify the effects based on prokinetic type.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8266503" target="_blank" rel="noopener"> Analysis of Whole Gut Motility for the Evaluation of Diabetic Gastroenteropathy: Still the Road Untraveled?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.5056/jnm20140" target="_blank" rel="noopener"> Emergence of Celiac disease and Gluten-related disorders in Asia.</a></p>
<p>CeD and NCGS may present with either intestinal or extra-intestinal symptoms, and a proportion of them have overlapping symptoms with irritable bowel syndrome. Hence, many of them are misdiagnosed as having irritable bowel syndrome in clinical practice. In this review, we discuss the emergence of CeD and other gluten-related disorders, both globally and in Asia, the overlapping manifestations between gluten-related disorders and irritable bowel syndrome, and the challenges associated with diagnosis and management of CeD in Asia.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.5056/jnm19006" target="_blank" rel="noopener"> Impact of Overlapping Functional Gastrointestinal Disorders on the Quality of Life in Patients With Gastroesophageal Reflux Disease.</a></p>
<p>The risk factors for subjects experiencing an overlap in FGIDs and GERD involve those who are female, younger age, cigarette smoking, non-erosive reflux disease, more GERD symptoms, and psychological performances including anxiety, somatization, and more frequent healthcareseeking behavior. The overlap of GERD and FGIDs is associated with a worsening of both physical and mental health, an increase in bothersome symptoms, impaired functional capacity, and a higher likelihood of consulting a physician. Acid secretion suppressors could offer therapeutic efficacy to some patients experiencing overlapping GERD and FGIDs.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.5056/jnm20175" target="_blank" rel="noopener"> Inflammation and Overlap of Irritable Bowel Syndrome and Functional Dyspepsia.</a></p>
<p>The pathogenesis of IBS or FD is complicated and multi-factors related, in which infectious or non-infectious inflammation and local or systemic immune response play significant roles. There are few studies focusing on the mechanism of inflammation in patients with overlap syndrome of irritable bowel syndrome and functional dyspepsia (IBS-FD). This review focuses on current advances about the role of inflammation in the pathogenesis of IBS and FD and the possible mechanism of inflammation in IBS-FD.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8026369" target="_blank" rel="noopener"> Integrated Relaxation Pressure During Swallowing: An Ever-changing Metric.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8266500" target="_blank" rel="noopener"> Is There a Role for Radiopaque Markers in Identifying Defecation Disorders?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8266489" target="_blank" rel="noopener"> Role of Bile Reflux in Functional Dyspepsia: Areas That Need Further Research.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.5056/jnm20208" target="_blank" rel="noopener"> Roles of Sex Hormones and Gender in the Gut Microbiota.</a></p>
<p>In this review, we summarize sex- and gender-differences in gut microbiota and the interplay of microbiota and GI diseases, focusing on sex hormones. We also describe the metabolic role of the microbiota in this regard. Finally, current subjects, such as medication including probiotics, are briefly discussed.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.5056/jnm21042" target="_blank" rel="noopener"> The Usefulness of Symptom-based Subtypes of Functional Dyspepsia for Predicting Underlying Pathophysiologic Mechanisms and Choosing Appropriate Therapeutic Agents.</a></p>
<p>Although several classic pathophysiologic mechanisms are suggested to be associated with individual dyspeptic symptoms, symptom-based subtypes of FD are not specific for a certain pathogenetic factor or pathophysiologic mechanism, and may be frequently associated with multiple pathophysiologic abnormalities. Novel concepts on the pathophysiology of FD show complex interactions between pathophysiologic mechanisms and pathogenetic factors, and prediction of underlying mechanisms of individual patients simply by the symptom pattern or symptom-based subtypes may not be accurate in a considerable proportion of cases. Therefore, subtyping by the Rome criteria appears to have limited value to guide therapeutic strategy, suggesting that the addition of objective parameters or subclassification reflecting physiologic or pathologic tests may be necessary for the targeted therapeutic approaches, particularly when therapeutic agents targeting novel mechanisms are available.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8026372" target="_blank" rel="noopener"> What Is the Difference in Characteristics Between Belching Disorder and Gastroesophageal Reflux Disease With Belching? Centering Around Supragastric Belching.</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Neurogastroenterol Motil</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14172" target="_blank" rel="noopener"> <sup>13</sup> C-gastric emptying breath tests: Clinical use in adults and children.</a></p>
<p>Moreover, epidemiological factors can influence gastric emptying as well as production and exhalation of  13  CO  , which is the ultimate metabolic product measured for al  13  C-breath tests. Accordingly, in this issue of Neurogastroenterology &amp; Motility, Kovacic et al report performance of the  13  C-Spirulina breath test in a large group of healthy children and show significant effects of gender, pubertal status, and body size on test results. The purpose of this mini-review is to evaluate the clinical use of  13  C-GEBT in adults and children, exploring available protocols, analytical methods, and essential prerequisites for test performance, as well as the role of GE measurements in the light of the current discussion on relevance of delayed GE for symptom generation.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> A North American perspective on the ESNM consensus statement on gastroparesis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14194" target="_blank" rel="noopener"> Belching in children: Prevalence and association with gastroesophageal reflux disease.</a></p>
<p>s  Gastric belching related reflux is observed in children with increased AET. SGB is very rare in the paediatric population.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14123" target="_blank" rel="noopener"> Bisacodyl: A review of pharmacology and clinical evidence to guide use in clinical practice in patients with constipation.</a></p>
<p>This observation stimulated the authors to review the available literature on bisacodyl, which has been available on the market since the 1950 s. Purpose The aim of the current review was to provide an overview of the historic background, structure, function, and mechanism of action of bisacodyl. Additionally, we discuss the important features and studies for bisacodyl to understand its peculiar characteristics and guide its use in clinical practice, but also stimulate research on open questions.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14070" target="_blank" rel="noopener"> Chronic constipation in adults: Contemporary perspectives and clinical challenges. 2: Conservative, behavioural, medical and surgical treatment.</a></p>
<p>The first review addresses epidemiology, diagnosis, clinical associations, pathophysiology, and investigation. Purpose The present is the second of these reviews, providing contemporary perspectives and clinical challenges regarding behavioral, conservative, medical, and surgical treatments for patients presenting with constipation. It includes a management algorithm to guide clinical practice.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14125" target="_blank" rel="noopener"> Colonic 5-HT<sub>4</sub> receptors are targets for novel prokinetic drugs.</a></p>
<p>5-HT  receptors and avoiding potential unwanted side effects.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14157" target="_blank" rel="noopener"> Current status of fecal microbiota transplantation for irritable bowel syndrome.</a></p>
<p>s  The efficacy of FMT for IBS appears to be donor-dependent. The effective (super) donor would need to have a favorable microbiota signature, and 11 clinical criteria that are known to be associated with a favorable microbiota have been suggested for selecting FMT donors for IBS. Comparing the microbiota of the effective donors with those of healthy subjects would reveal the favorable microbiota signature required for a super-donor. However, the studies reviewed were not designed to compare efficacy of different donor types. The dose of the fecal transplant is also an important factor influencing the outcome of FMT for IBS. However, further studies designed to test the effect of fecal transplant dose are needed to answer this question. Administering the fecal transplant to either the small or large intestine seems to be effective, but the optimal route of administration remains to be determined. Moreover, whether single or repeated FMT is more effective is also still unclear. A 1-year follow-up of IBS patients who received FMT showed that adverse events of abdominal pain, diarrhea, and constipation were both mild and self-limiting.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14104" target="_blank" rel="noopener"> Implications of SARS-CoV-2 infection for neurogastroenterology.</a></p>
<p>Liver and pancreas dysfunctions have also been described as non-respiratory complications of COVID-19 and add further emphasis to the common view of SARS-CoV-2 infection as a systemic disease with multiorgan involvement. Purpose The aim of this review was to highlight the current knowledge on the pathophysiology of gastrointestinal SARS-CoV-2 infection, including the crosstalk with the gut microbiota, the fecal-oral route of virus transmission, and the potential interaction of the virus with the enteric nervous system. We also review the current available data on gastrointestinal and liver manifestations, management, and outcomes of patients with COVID-19.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14206" target="_blank" rel="noopener"> Motor behavior of mouse large intestine: A Minireview.</a></p>
<p>Mice with a recessive gene which reduces the number of ganglion cells of the distal colon and rectum and produces megacolon, imitating Hirschsprung disease, are discussed as a model for integrative control of the large intestinal smooth musculature by the enteric division of the autonomic nervous system (ie, the brain-in-the-gut). Investigative approaches, such as propulsion of artificial pellets in preparations of whole colon in organ baths in vitro and innovative approaches capitalizing on neurogenetic technologies (eg, optogenetics), are considered in view of potential application in the development of novel therapeutic mechanisms to selectively evoke and control gastrointestinal motility patterns, such as the small intestinal digestive motility pattern, interdigestive pattern, and reversed direction of powerful propulsive motility during emesis. This minireview relates to the paper titled: &quot;Motor patterns in the proximal and distal mouse colon which underlie formation and propulsion of feces,&quot; appearing in this issue of Neurogastroenterology and Motility.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14095" target="_blank" rel="noopener"> Of bowels, brain and behavior: A role for the gut microbiota in psychiatric comorbidities in irritable bowel syndrome.</a></p>
<p>s  Such data highlights the potential for therapeutic targeting of the gut microbiota as a valuable strategy for the management of comorbid psychiatric symptoms in IBS.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14201" target="_blank" rel="noopener"> Post-operative colonic manometry in children with Hirschsprung disease: A systematic review.</a></p>
<p>s This systematic review highlighted the paucity of evidence informing the understanding of colonic dysmotility in the post-operative HD cohort. Current literature is limited by variable methodologies, heterogeneous cohorts, and the lack of high-resolution manometry.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14215" target="_blank" rel="noopener"> The gut brain in a dish: Murine primary enteric nervous system cell cultures.</a></p>
<p>In vitro techniques allow simplified investigation of ENS function, and different culture methods have been developed over the years helping to understand the role of ENS cells in health and disease. Purpose This review focuses on summarizing and comparing available culture protocols for the generation of primary ENS cells from adult mice, including dissection of intestinal segments, enzymatic digestions, surface coatings, and culture media. In addition, the potential of human ENS cultures is also discussed.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1111/nmo.14152" target="_blank" rel="noopener"> Understanding racial disparities in the care of patients with irritable bowel syndrome: The need for a unified approach.</a></p>
<p>In an important study, Silvernale at al have recently reported racial disparities including potential referral biases, with reduced opportunities to access specialist care and differing patterns of healthcare utilization affecting ethnic minority populations with IBS. Similar disparities have also been reported for other gastrointestinal disorders. In this paper, we, therefore, discuss the potential implications of such disparities and how they can impact clinical outcomes, and discuss ways in which this problem could be addressed, and highlighting areas for future research.</p>
</div></td></tr>
  </tbody>
  
  
</table>
</div>
</div>
<div id="lettersreplies" class="section level3">
<h3>Letters&amp;Replies</h3>
<p><em>Letters to the editors and authors’ replies</em></p>
<div id="olxzyxhkry" style="overflow-x:auto;overflow-y:auto;width:auto;height:auto;">
<style>html {
  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;
}

#olxzyxhkry .gt_table {
  display: table;
  border-collapse: collapse;
  margin-left: auto;
  margin-right: auto;
  color: #333333;
  font-size: 16px;
  font-weight: normal;
  font-style: normal;
  background-color: #FFFFFF;
  width: auto;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #A8A8A8;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #A8A8A8;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
}

#olxzyxhkry .gt_heading {
  background-color: #FFFFFF;
  text-align: center;
  border-bottom-color: #FFFFFF;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
}

#olxzyxhkry .gt_title {
  color: #333333;
  font-size: 125%;
  font-weight: initial;
  padding-top: 4px;
  padding-bottom: 4px;
  border-bottom-color: #FFFFFF;
  border-bottom-width: 0;
}

#olxzyxhkry .gt_subtitle {
  color: #333333;
  font-size: 85%;
  font-weight: initial;
  padding-top: 0;
  padding-bottom: 6px;
  border-top-color: #FFFFFF;
  border-top-width: 0;
}

#olxzyxhkry .gt_bottom_border {
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#olxzyxhkry .gt_col_headings {
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
}

#olxzyxhkry .gt_col_heading {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: normal;
  text-transform: inherit;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: bottom;
  padding-top: 5px;
  padding-bottom: 6px;
  padding-left: 5px;
  padding-right: 5px;
  overflow-x: hidden;
}

#olxzyxhkry .gt_column_spanner_outer {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: normal;
  text-transform: inherit;
  padding-top: 0;
  padding-bottom: 0;
  padding-left: 4px;
  padding-right: 4px;
}

#olxzyxhkry .gt_column_spanner_outer:first-child {
  padding-left: 0;
}

#olxzyxhkry .gt_column_spanner_outer:last-child {
  padding-right: 0;
}

#olxzyxhkry .gt_column_spanner {
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  vertical-align: bottom;
  padding-top: 5px;
  padding-bottom: 5px;
  overflow-x: hidden;
  display: inline-block;
  width: 100%;
}

#olxzyxhkry .gt_group_heading {
  padding: 8px;
  color: #FFFFFF;
  background-color: #0000FF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: middle;
}

#olxzyxhkry .gt_empty_group_heading {
  padding: 0.5px;
  color: #FFFFFF;
  background-color: #0000FF;
  font-size: 100%;
  font-weight: initial;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  vertical-align: middle;
}

#olxzyxhkry .gt_from_md > :first-child {
  margin-top: 0;
}

#olxzyxhkry .gt_from_md > :last-child {
  margin-bottom: 0;
}

#olxzyxhkry .gt_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  margin: 10px;
  border-top-style: solid;
  border-top-width: 1px;
  border-top-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: middle;
  overflow-x: hidden;
}

#olxzyxhkry .gt_stub {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-right-style: solid;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  padding-left: 12px;
}

#olxzyxhkry .gt_summary_row {
  color: #333333;
  background-color: #FFFFFF;
  text-transform: inherit;
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
}

#olxzyxhkry .gt_first_summary_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
}

#olxzyxhkry .gt_grand_summary_row {
  color: #333333;
  background-color: #FFFFFF;
  text-transform: inherit;
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
}

#olxzyxhkry .gt_first_grand_summary_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-top-style: double;
  border-top-width: 6px;
  border-top-color: #D3D3D3;
}

#olxzyxhkry .gt_striped {
  background-color: rgba(128, 128, 128, 0.05);
}

#olxzyxhkry .gt_table_body {
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#olxzyxhkry .gt_footnotes {
  color: #333333;
  background-color: #FFFFFF;
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
}

#olxzyxhkry .gt_footnote {
  margin: 0px;
  font-size: 90%;
  padding: 4px;
}

#olxzyxhkry .gt_sourcenotes {
  color: #333333;
  background-color: #FFFFFF;
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
}

#olxzyxhkry .gt_sourcenote {
  font-size: 90%;
  padding: 4px;
}

#olxzyxhkry .gt_left {
  text-align: left;
}

#olxzyxhkry .gt_center {
  text-align: center;
}

#olxzyxhkry .gt_right {
  text-align: right;
  font-variant-numeric: tabular-nums;
}

#olxzyxhkry .gt_font_normal {
  font-weight: normal;
}

#olxzyxhkry .gt_font_bold {
  font-weight: bold;
}

#olxzyxhkry .gt_font_italic {
  font-style: italic;
}

#olxzyxhkry .gt_super {
  font-size: 65%;
}

#olxzyxhkry .gt_footnote_marks {
  font-style: italic;
  font-weight: normal;
  font-size: 65%;
}
</style>
<table class="gt_table">
  
  <thead class="gt_col_headings">
    <tr>
      <th class="gt_col_heading gt_columns_bottom_border gt_left" rowspan="1" colspan="1"></th>
    </tr>
  </thead>
  <tbody class="gt_table_body">
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Aliment Pharmacol Ther</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: an expert consensus to standardise the assessment of histological disease activity in Crohn&#39;s disease clinical trials-a missing link. Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game-authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: bariatric surgery to reduce the risk of liver cancer-authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: co-morbid gastrointestinal conditions are an important consideration in IBS management-authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: defining a microbial signature to predict non-response to a low FODMAP diet-a step closer or is it? Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: determining disability in inflammatory bowel disease-&quot;See(k) and you shall find&quot;. Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: finding the ideal prokinetic for gastroparesis-we are not there yet. Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: is enteral nutrition back in acute severe ulcerative colitis? Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: is there a &#39;precursor&#39; HCC lesion and can it be detected by hepatobiliary contrast-enhanced magnetic resonance imaging? Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: liver stiffness by magnetic resonance elastography and cardiovascular risk in non-alcoholic fatty liver disease-simply associated or more complicated? Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: machine learning models for gastric cancer risk prediction-authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: metformin for portal hypertension-old dog, new tricks? Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: non-selective beta blockers-in and out of circulation. Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: on the road towards treatment of gastroparesis-accelerating, but do we get closer? Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: opioids in inflammatory bowel disease-primum non nocere. Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: post-reflux swallow-induced peristaltic wave in eosinophilic oesophagitis-more questions than answers? Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: recognising the efficacy of licensed drug therapies for irritable bowel syndrome on bloating-a step in the right direction for targeted treatment? Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: similar risk of hepatocellular carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir-new clues from Europe. Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: standardising inclusion and outcome criteria for pouchitis-a fragile consensus perhaps but a first step in the right direction. Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: stratifying risk of adverse outcomes in cirrhosis-the Hepquant SHUNT test. Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: the microscope holds the key to predict need for biologic therapy in immunotherapy-checkpoint inhibitory colitis. Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: time trends in colectomy rates for ulcerative colitis in England-mixed methods brings mixed messages? Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: tissue findings fail to predict disease activity or prognosis in microscopic colitis-an opportunity to look at the molecular level-authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: tobacco use in functional dyspepsia-another smoking gun? Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: total anti-drug antibodies detected using drug-tolerant assays during induction with anti-TNF therapy are associated with treatment failure-out of sight but not out of mind. Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: towards an understanding of increased mortality in coeliac disease-authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: trends in paediatric inflammatory bowel disease attributable direct costs-authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: type D personality and its relationship with depression and disease activity in inflammatory bowel disease-authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: use of intestinal ultrasound in the scoring of Crohn&#39;s disease activity in clinical trials - is it ready for prime time yet? Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: will clusters for anxiety, depression, sleep disturbance and fatigue symptoms predict treatment outcomes in functional dyspepsia? Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Editorial: withdrawal of anti-TNFalpha-are we ready for biological therapy cycling? Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: budesonide for functional dyspepsia with duodenal eosinophilia-randomised, double-blind, placebo-controlled parallel-group trial.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: colorectal cancer surveillance in inflammatory bowel disease-a call for systematic reform.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: confounders and outcomes in studies of beta-blockers in liver disease-role of PPIs?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: Confounders and outcomes in studies of beta-blockers in liver disease-role of PPIs? Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: coronary atherosclerosis in patients with significant hepatic fibrosis in non-alcoholic fatty liver disease-a realm for non-invasive testing. Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: coronary atherosclerosis in patients with significant hepatic fibrosis in non-alcoholic fatty liver disease-the role for non-invasive testing.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: elobixibatting for the long run-authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: enhancing training opportunities for upper GI bleeding in Sheffield - a UK transferable model? Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: enhancing training opportunities for upper GI bleeding in Sheffield-a UK transferable model?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: faecal microbiota transplant in Clostridioides difficile infection: learning from the common water hyacinth.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: future studies of high-dose thiamine should consider whether its effects on fatigue are related to the inhibition of carbonic anhydrase isoenzymes.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: future studies of high-dose thiamine should consider whether its effects on fatigue are related to the inhibition of carbonic anhydrase isoenzymes. Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: genetic variation in the HLA-DQA1*05 allele predicts tumour necrosis factor-α antagonist immunogenicity - does location matter?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8014117" target="_blank" rel="noopener"> Letter: how frequently does COVID-19 mimic an IBD flare when community transmission of SARS-CoV-2 is active?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: improved parsimony of genetic risk scores for coeliac disease through refined HLA modelling.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: increased incidence of tissue transglutaminase antibody in Israel-is it always related to coeliac disease? Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: is the AHHS score really useful in clinically severe alcoholic hepatitis?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: is the radiation therapy causing an IBD flare, or the IBD predisposing to radiation toxicity?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: is the radiation therapy causing an IBD flare, or the IBD predisposing to radiation toxicity? Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8013802" target="_blank" rel="noopener"> Letter: liver involvement and mortality in COVID-19-the role of anti-viral therapy should be considered.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: opioid use, early biologic discontinuation for inflammatory bowel disease and a cautionary note for the age of legalised cannabis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: proton pump inhibitor use and bone fracture risk-a mechanistic point of view.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: proton pump inhibitor use and bone fracture risk-a mechanistic point of view. Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: real-world use of terlipressin in patients with hepatorenal syndrome.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: real-world use of terlipressin in patients with the hepatorenal syndrome-authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: risk of coeliac disease-do microbial derived factors promote and protect? Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: risk of coeliac disease-do microbial-derived factors promote and protect?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8207069" target="_blank" rel="noopener"> Letter: risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications-reassuring insights from the United Kingdom PREPARE-IBD multicentre cohort study.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: safety of immune checkpoint inhibitors in patients with pre-established microscopic colitis-a single-centre experience.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8013439" target="_blank" rel="noopener"> Letter: SARS-CoV-2 infection in two IBD patients treated with dual targeted therapy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8013379" target="_blank" rel="noopener"> Letter: SARS-CoV-2 infection in two inflammatory bowel disease patients treated with dual targeted therapy-Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: serum hepatitis B virus DNA and risk of hepatocellular carcinoma in patients with chronic hepatitis B-authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: serum hepatitis B virus DNA and risk of hepatocellular carcinoma in patients with chronic hepatitis B.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: tenofovir may be superior to entecavir for treatment-naïve chronic hepatitis B patients-authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: tenofovir versus entecavir for hepatocellular carcinoma prevention in chronic hepatitis B-related compensated cirrhosis-authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: tenofovir versus entecavir for hepatocellular carcinoma prevention in chronic hepatitis B-related compensated cirrhosis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitis-authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: the combination of histologic remission and Mayo endoscopic score 1 as a suitable therapeutic target in ulcerative colitis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: the improvement of sarcopaenia after TIPSS might result from survivor bias.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: the need to reconsider the liver-specific benefit of carvedilol.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: the use of magnetic resonance scores (Anali) for risk stratification in PSC-authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: the use of magnetic resonance scores (Anali) for risk stratification in PSC.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: ustekinumab for the treatment of post-surgical and refractory Crohn&#39;s disease.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. Authors&#39; reply.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Tranexamic acid for acute gastrointestinal bleeding: updated after the HALT-IT trial.</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Am J Gastroenterol</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> A Rare Case of Locally Advanced Squamous Cell Carcinoma of the Esophagogastric Junction With Submucosal Progression and Long-Term Survival.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Alarming Trends in Opioid Use Among Patients With GERD.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Ashwagandha-Induced Liver Injury: Self-Reports on Commercial Websites as Useful Adjunct Tools for Causality Assessment.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7553027" target="_blank" rel="noopener"> Association Between Famotidine Use and Clinical Outcomes in Patients With COVID-19: Assessment of Available Evidence.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Avoiding Beta Blockers in Patients of Hepatitis C Virus-Related Compensated Cirrhosis With Clinically Significant Portal Hypertension After Cure With Antivirals: Are We There Yet?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Bariatric Surgery and Esophageal Function: An Eternal Impasse?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Clinical Characteristics of COVID-19 Patients With Gastrointestinal Symptoms in Northern Italy: Few Issues.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Decreasing Stigmatization of Persons With Higher Weights: When Words Count.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Deglutition Syncope After Variceal Band Ligation.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Effect of Vitamin D Supplementation on Vitamin D Level and Bone Mineral Density in Patients With Cirrhosis: Several Confounding Factors.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Electro-Acupuncture vs Prucalopride for Severe Chronic Constipation: Aiming for Excellence in Mediocrity?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Ending Obesity Stigma and Discrimination: Starting From Healthcare Professionals.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Eosinophilic Esophagitis and Achalasia: Are We Putting All the Pieces Together?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Esophageal Squamous Cell Carcinoma: Time to Predict the Risk?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Famotidine and Hospitalized COVID-19 Patients: Are the Benefits True?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Future Endoscopy-Related Injuries Will Be of Different Types and Gender-Equal.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7553031" target="_blank" rel="noopener"> Gastrointestinal Hemorrhages in Patients With COVID-19 Managed With Transarterial Embolization.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Go With the Flow: Alternative Terminology in Relational Anatomy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Greenspace in Childhood: A New Avenue to Prevent Inflammatory Bowel Disease?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7553033" target="_blank" rel="noopener"> Management of Gastrointestinal Bleeding in Coronavirus Disease: Exploring the Options.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8186259" target="_blank" rel="noopener"> Pay Attention to Distinguish Hepatitis from Novel Coronavirus Hepatitis in the Context of COVID-19 Pandemic.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8500276" target="_blank" rel="noopener"> Real-Time 3D Imaging of Post-Transplant Biliary Stricture: A Novel Application of Existing Technology.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Response to Albuquerque et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Response to Ghisa et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Response to Lai.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Response to Marlicz et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Response to Nassani and El-Khoury.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Response to Sahu and Singh.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Response to Sharma and Saraya.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Response to Tetangco and Hanauer.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Social Determinants of Health in Inflammatory Bowel Diseases: Barriers and Opportunities.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Visibility of Women at the American College of Gastroenterology Annual Meetings Increasing Over Time.</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Clin Gastroenterol Hepatol</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> A Patient Perspective on Contemporary Risk of Surgery in Patients With Ulcerative Colitis and Crohn&#39;s Disease.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Advantage of Fecal MicroRNA Combination With Immunochemical Hemoglobin Test for Screening Colorectal Cancer.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Allowing Appeals Could Address Biases in Peer Review in Gastroenterology.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Biomarkers and OLGIM Stage for Prospective Preneoplastic Risk Stratification.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Bowel Movements and Risk of Diverticulitis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Budesonide Oral Suspension Improves Outcomes in Patients With Eosinophilic Esophagitis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Combination Therapy of Immunomodulators With Non-Anti-Tumor Necrosis Factor Agents in Inflammatory Bowel Disease: Need More Evidence?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Concerns and Safety of Add-on Versus Switch Peginterferon Therapy for Chronic Hepatitis B.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Defining Age-Related Thresholds for ALT and the Risk of Confounders.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Dietary Treatment of Crohn&#39;s Disease in Adults.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Digital Health Interventions for Colorectal Polyp Detection: Are We Ready for Prime Time?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With CHB: A Comment for Moving Forward.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic Bariatric and Metabolic Therapies on Nonalcoholic Fatty Liver Disease: Enough Data to be Considered Effective?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Erroneous Ammonia Measurement is Not Synonymous With a Lack of Efficacy of Ammonia-Lowering Therapies in Hepatic Encephalopathy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Fatty Liver and Type 2 Diabetes Mellitus Regression: The Weight, the Fat, and the Alcohol.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Guaiac Fecal Occult Blood Test and Reduction in Colorectal Cancer Incidence.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> High Rate of Virologic Response After Discontinuation of Nucleos(T)Ide Analogues in Caucasian Chronic Hepatitis B Patients.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Impact of the New Metabolic-Associated Fatty Liver Disease (MAFLD) on NAFLD Patients Classification in Italy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Implicit Bias in Region-Dependent Publication Potential Can Partly be Counteracted by Academic Collaboration.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8253689" target="_blank" rel="noopener"> Increased Diagnosis of Hepatocellular Carcinoma in Hospitalized Patients with Alcohol Related Hepatitis after the Covid-19 Outbreak: A Global Multi-Center Propensity Matched Analysis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Infliximab vs Ustekinumab in Biologic Naive Crohn&#39;s Disease.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Liver Injury After Dietary Supplements in Patients Living With HIV: A Call to Action.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7873596" target="_blank" rel="noopener"> Liver Injury in Liver Transplant Patients With COVID-19: A Histopathologic Analysis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8139328" target="_blank" rel="noopener"> Liver Injury in Severe COVID-19 Disease: Need a Closer Look!</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Maintenance Therapy in Crohn&#39;s Disease: Does the Drug Matter?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> No Convincing Evidence to Support a Bimodal Age of Onset in Idiopathic Chronic Pancreatitis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Nonalcoholic Fatty Liver Disease for the Incidence of Drug-Induced Liver Injury.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> On the Proposed Definition of Metabolic-Associated Fatty Liver Disease.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Patient Satisfaction, at What Cost?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Plastic Versus Metal EUS-Guided Drainage of Pancreatic Fluid Collections: Do We Really Know When to Use the Hard Way?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Predicting Need for Aggressive Endoscopic Therapy After Endoscopic Ultrasound-Guided Drainage of Pancreatic Fluid Collections With Lumen Apposing Metal Stents.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Predictive Scores in Acute Severe Ulcerative Colitis: Which, What, and When are the Decision Points We Should Target?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Predictive Value of Bowel Ultrasound in Crohn&#39;s Disease.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Prevalence of Fatty Liver Disease is Driven by Prediabetes and Diabetes: US NHANES 2017-2018.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Private Practice Model for Inpatient GI Coverage at Tertiary Care Center: An Alternative to GI Hospitalist Service.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8120783" target="_blank" rel="noopener"> SARS-CoV-2-Induced Pancreatitis is a Rare but Real Entity.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8053356" target="_blank" rel="noopener"> Serum Lipase Elevations in COVID-19 Patients Reflect Critical Illness and not Acute Pancreatitis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Stoma Formation and Antidepressant Use in Patients With Crohn&#39;s Disease.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Stratifying the Risk of IPMNs: Don&#39;t Rule Out the EUS Toolkit.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Towards a Simple Therapeutically Oriented Classification of Gastric Varices.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Towards Better Management of Functional Sphincter of Oddi Disorder: The Need to Look Beyond the Endoscope.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Trajectory of Serum Bilirubin Predicts Spontaneous Recovery in Patients With Alcoholic Hepatitis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Unanswered Questions About the Future Development of Gastroenterology Hospitalists.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Use of Lactulose in Hepatic Encephalopathy: Is It Time to Shift Targets?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> What is the Real Impact of Corticosteroids in the Contemporary Treatment of Crohn&#39;s Disease?</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Endoscopy</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Are balloon enteroscopy-assisted ERCP and laparoscopy-assisted ERCP in Roux-en-Y gastric bypass equivalent?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Comments on &quot;Endoscopic sleeve gastroplasty, laparoscopic sleeve gastrectomy, and laparoscopic greater curve plication: do they differ at 2 years?&quot;</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic full-thickness resection and post-procedural appendicitis: every advantage has its disadvantage.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Radiofrequency ablation of pancreatic serous cystic neoplasms: feasibility, but for the wrong indication.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Reply to Chandnani et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Reply to Dr. Bronswijk.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Reply to Dr. Mandavdhare.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Reply to Katakwar et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Reply to Lorenzo et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Reply to Phillpotts and Webster.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Submucosal dissection of the septum or submucosal tunneling endoscopic septum division: should we wander the free path or follow the tunnel?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> The forceps-assisted technique for difficult cannulation has been in widespread use since 1996.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> The role of endoscopic papillary large balloon dilatation without sphincterotomy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Too early to aʼMUSE!</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Zenker&#39;s peroral endoscopic myotomy (Z-POEM) for recurrent Zenker diverticulum: not so fast!</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Gastroenterology</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Noninvasive identification of lymph node metastasis in T1 colorectal cancer by transcriptomic panel based on liquid biopsy assay: additional analytical strategies are needed.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> PEG and mucosal biofilms in irritable bowel syndrome and ulcerative colitis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Rapid on-site evaluation for endoscopic ultrasound-guided fine-needle biopsy: are there any other applicable situations?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Rapid on-site evaluation in the era of EUS-FNB: really time to say goodbye?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> The Potential of Radiomics in the Assessment of Intestinal Fibrosis in Crohn&#39;s Disease.</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Gastrointest Endosc</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8052210" target="_blank" rel="noopener"> A &quot;double-hit&quot; damage mechanism can explain self-limited GI bleeding in COVID-19 pneumonia.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Comparison of pancreatic cystic fluid glucose and carcinoembryonic antigen in the diagnosis of pancreatic mucinous cysts.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Current practice guidelines for suspected choledocholithiasis: new questions for a common problem.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic papillectomy in patients with familial adenomatous polyposis: Does one size fit all?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Has the issue of the &quot;point of no return&quot; in gastric carcinogenesis already been resolved?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Illicit drug packet ingestion and the ASGE clinical guideline on removal of foreign bodies.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Impact of topical budesonide on prevention of esophageal stricture after mucosal resection.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Is it enough to consider the number of endoscopy cases to evaluate colon adenoma detection rates?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> More details are needed about the use of propensity score matching analysis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Postablation Barrett&#39;s esophagus: Treat or observe?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Prediction of technically difficult, colorectal, endoscopic submucosal dissection: Is the procedural time a good endpoint?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Safety of endoscopist-directed nurse-administered balanced propofol sedation in patients with severe systemic disease (ASA class III).</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> The diagnostic value of EUS-guided fine-needle aspiration/biopsy for solid pancreatic lesions: contrast-enhanced versus conventional EUS.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Underwater versus conventional endoscopic mucosal resection for colorectal polyps.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Use of the ACES (Appearance, Classification, Enhanced endoscopy, and Safe resection) algorithm for the recognition and management of malignant polyps-a letter in response to the Multi-Society Task Force on Colorectal Cancer recommendations.</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Gut</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Clomethiazole inhibits cytochrome P450 2E1 and improves alcoholic liver disease.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Diabetes is the strongest risk factor of hepatic fibrosis in lean patients with non-alcoholic fatty liver disease.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Guts UK 50 years old: onwards and upwards.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Hidden link in gut-joint axis: gut microbes promote rheumatoid arthritis at early stage by enhancing ascorbate degradation.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Intestinal microbiota defines the GUT-TESTIS axis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Liver injury, hypoalbuminaemia and severe SARS-CoV-2 infection.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> NGS mismapping confounds the clinical interpretation of the <i>PRSS1</i> p.Ala16Val (c.47C&gt;T) variant in chronic pancreatitis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Radiology-guided percutaneous approach is superior to EUS for performing liver biopsies.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Rapid resolution of COVID-19 after faecal microbiota transplantation.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Reducing low risk of transmissible infection in duodenoscopes: at what cost to the planet?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Reply to: &quot;Acute-on-chronic liver failure in East-Asia: an underestimated issue with limited data&quot;.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> SARS-COV-2 in endoscopy: still a long way to go.</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Hepatology</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://doi.org/10.1002/hep.31751" target="_blank" rel="noopener"> American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease.</a></p>
<p>The online companion document located at https://www. aasld. org/about-aasld/covid-19-resources will be updated as additional data become available regarding the safety and efficacy of other COVID-19 vaccines in development.</p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter to the Editor: Are We Confident That Primary Biliary Cholangitis Liver-Related Mortality Is Higher in Males?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter to the Editor: Balloon-Occluded Retrograde Transvenous Obliteration for Prevention of Gastric Variceal Rebleeding: A Paradigm Shift?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter to the Editor: Biomarkers for Predicting Renal Outcomes in Decompensated Cirrhosis: Need a Closer Look!</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter to the Editor: Cancer After Liver Transplant: Don&#39;t Forget Tobacco and Tacrolimus.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter to the Editor: Complications Associated With Anesthesia Services in Endoscopic Procedures Among Patients With Cirrhosis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter to the Editor: Does Multiple Intrahepatic Cholangiocarcinoma Worsen Prognosis as &quot;M1&quot; Stage?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter to the Editor: Endoscopic Ultrasound-Guided Coil Therapy for Secondary Prevention After Gastric Variceal Bleeding: A Promising Alternative.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter to the Editor: Entecavir Treatment Restores the Anti-HBV Immune response?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter to the Editor: Hepatocellular Carcinoma Surveillance in Cirrhosis Patients: Is the Real-World Situation Even Worse Than Reported?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter to the Editor: High Mobility Group Box Protein 1 Release Is an Identified Driver of Inflammation in the Pathogenesis of Biliary Atresia.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter to the Editor: Intravital Dynamic and Correlative Imaging Reveals Diffusion-Dominated Canalicular and Flow-Augmented Ductular Bile Flux.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter to the Editor: Is Aspirin a Drug or Just a Marker for Biliary Cancer?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter to the Editor: Is Male Sex Associated With Increased Liver-Related Mortality in Primary Biliary Cholangitis and Cirrhosis?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter to the Editor: Noninvasive Differentiation of Porto-sinusoidal Vascular Disease and Cirrhosis: The Devil Is in the Details!</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter to the Editor: Oral Vancomycin Versus No Therapy for Pediatric Primary Sclerosing Cholangitis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter to the Editor: Pregnant Women and their Providers Want Direct-Acting Antivirals, and We Are Missing the Mark.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter to the Editor: Recognizing Significant Role of Neoadjuvant Radiotherapy for HCC With Vascular Invasion.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter to the Editor: Response to Terlipressin Plus Albumin in Hepatorenal Syndrome-Need a Closer Look!</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter to the Editor: Restructuring the Gut Microbiota of Patients with Cirrhosis After HCV Eradication: A Matter of Time?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter to the Editor: Risk Stratification in Patients With Child-Pugh B Cirrhosis and Acute Variceal Bleeding.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter to the Editor: The Concept of Real-Time Spectroscopy for Liver Viability Assessment.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter to the Editor: The Differences Between the Reverse Transcriptional Efficiency of HBV Pregenomic RNA and Transcriptional Efficiency of HBV Covalently Closed Circular DNA.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter to the Editor: The Role of Surgery in Multiple Intrahepatic Cholangiocarcinoma Should Not Be Dismissed Without Further Analysis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter to the Editor: Use of New Defined Metabolic Risk Factors in Patients With Chronic Hepatitis B.</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Inflamm Bowel Dis</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8195093" target="_blank" rel="noopener"> Acceptance of SARS-CoV-2 Vaccination Among a Cohort of IBD Patients From Southern Italy: A Cross-Sectional Survey.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8376121" target="_blank" rel="noopener"> Azathioprine-induced Myelotoxicity After Switching Mesalazine Compound.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8244581" target="_blank" rel="noopener"> Impact of COVID-19 on Inflammatory Bowel Disease Clinical Trial Recruitment: A Global Survey of Principal Investigators.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7928881" target="_blank" rel="noopener"> Leukocytoclastic Vasculitis in Cutaneous Crohn Disease in the Setting of COVID-19.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7928823" target="_blank" rel="noopener"> SARS-CoV-2 as a Trigger for De Novo Ulcerative Colitis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7989361" target="_blank" rel="noopener"> The Effect of COVID-19 Resurgence on Morbidity and Mortality in Patients With IBD on Biologic Therapy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Tofacitinib in Acute Severe Ulcerative Colitis: Case Series and a Systematic Review-Authors&#39; Reply.</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">J Crohns Colitis</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8344884" target="_blank" rel="noopener"> Elevated adherence to vaccination against SARS-CoV-2 among patients with Inflammatory Bowel Disease.</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">J Hepatol</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Acute severe autoimmune hepatitis - timing for steroids and role of other immunosuppressive agents.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Acute-on-chronic liver failure: A complex clinical entity in patients with autoimmune hepatitis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7863751" target="_blank" rel="noopener"> Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> An unequivocal formula to calculate L-GrAFT score is needed.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8197609" target="_blank" rel="noopener"> Another case of autoimmune hepatitis after SARS-CoV-2 vaccination - still casualty?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Anti-epileptic drugs and hepatitis C therapy: Real-world experience.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Are the different MAFLD subtypes based on the inclusion criteria correlated with all-cause mortality?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8056822" target="_blank" rel="noopener"> Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8219312" target="_blank" rel="noopener"> Autoimmune hepatitis developing after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8404983" target="_blank" rel="noopener"> Autoimmune hepatitis following COVID-19 vaccination: True causality or mere association?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8186938" target="_blank" rel="noopener"> Autoimmune hepatitis following SARS-CoV-2 vaccine: May not be a casuality.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Bacterial infection-related acute-on-chronic liver failure: The standpoint matters!</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Baveno VI elastography criteria for ruling in cACLD works well in patients with MAFLD.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Before we can find an evidence base for HCC surveillance, we need to define our target demographic.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Ceruloplasmin variants might have different effects in different iron overload disorders.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Characterizing bacterial infections in acute-on-chronic liver failure among patients with cirrhosis from nonalcoholic steatohepatitis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8098030" target="_blank" rel="noopener"> Comment on &quot;Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?&quot;</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Comments on &#39;Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis - A randomized controlled trial&#39;.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Decrease in viral hepatitis diagnoses during the COVID-19 pandemic in the Netherlands.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Defining the prognosis of critically ill patients with alcohol-related liver disease.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Disputing issues in the paradigm change to finite antiviral therapy in HBeAg-negative patients.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Do we need a new cut-off for FIB-4 in the metabolic dysfunction-associated fatty liver disease era?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> External validation of the Freiburg index of post-TIPS survival.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> First things first! Can bacterial infections be considered as decompensating events per se?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Freiburg index of post-TIPS survival: The first score for individual prediction and a complementary tool for risk stratification.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8103740" target="_blank" rel="noopener"> HCV detection is possible during SARS CoV-2 testing; and throughout COVID-19 vaccination?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8159704" target="_blank" rel="noopener"> High acceptance rate of COVID-19 vaccination in liver transplant recipients.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Hypoxia is a key regulator in liver cancer progression.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> I shall be released (from infinite HBV nucleos(t)ide analog therapy): Japanese experience.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Intermuscular abdominal fat fraction and metabolic dysfunction-associated fatty liver disease: Does the link already exist at childhood?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7893247" target="_blank" rel="noopener"> Intravenous ketamine and progressive cholangiopathy in COVID-19 patients.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Is tissue hypoxia the principal mechanism for immune evasion and malignant progression in hepatocellular carcinoma?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7979603" target="_blank" rel="noopener"> Let&#39;s leverage SARS-CoV2 vaccination to screen for hepatitis C in Spain, in Europe, around the world.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8245674" target="_blank" rel="noopener"> Letter regarding &quot;Association of liver abnormalities with in-hospital mortality in patients with COVID-19&quot;.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7977008" target="_blank" rel="noopener"> Liver injury in COVID-19 - The culprit may not be COVID-19!</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> MAFLD supported by 95.45% participants of CSH is NOT representative.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Multiple investigations for a very common disorder: Finding the right balance in NAFLD.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> New concepts in the finite oral antiviral therapy in HBeAg-negative chronic hepatitis B.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Non-selective beta blockers and mortality in decompensated cirrhosis: Is cirrhotic cardiomyopathy the missing link?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Population-specific cut-off points of fatty liver index for the diagnosis of hepatic steatosis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7892314" target="_blank" rel="noopener"> Primary biliary cholangitis associated with SARS-CoV-2 infection.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7977066" target="_blank" rel="noopener"> Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Real-world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Redefinition of fatty liver disease from NAFLD to MAFLD raised disease awareness: Mexican experience.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Reply to: &quot;A step forward to predict the risk of post-hepatectomy portal hypertension&quot;.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Reply to: &quot;Achieving an effective pressure reduction after TIPS: The need for a new target&quot;.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Reply to: &quot;Acute severe autoimmune hepatitis - timing for steroids and role of other immunosuppressive agents&quot;.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8056821" target="_blank" rel="noopener"> Reply to: &quot;Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients&quot;.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Reply to: &quot;Chronic fatigue should not be overlooked in primary biliary cholangitis&quot;.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8272678" target="_blank" rel="noopener"> Reply to: &quot;Comment on &quot;Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?&quot;&quot;.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Reply to: &quot;Comments on &#39;Fructose- and sucrose- but not glucose-sweetened beverages promote hepatic de novo lipogenesis - A randomized controlled trial&#39; &quot;.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Reply to: &quot;Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?&quot;</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Reply to: &quot;Freiburg index of post-TIPS survival (FIPS) a valid prognostic score in patients with cirrhosis but also an advisor against TIPS?&quot;</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Reply to: &quot;Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings&quot;.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Reply to: &quot;IgG, a novel predictor for acute-on-chronic liver failure and survival in patients with decompensated cirrhosis?&quot;</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Reply to: &quot;Myofibroblast YAP/TAZ is dispensable for liver fibrosis in mice&quot;.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Reply to: &quot;Non-selective beta blockers and mortality in decompensated cirrhosis: Is cirrhotic cardiomyopathy the missing link?&quot;</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Reply to: &quot;Presepsin as a biomarker of inflammation and prognosis in decompensated liver disease&quot;.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Reply to: &quot;Prognostic value of HDL-related biomarkers in patients with HBV-related ACLF&quot;.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8223115" target="_blank" rel="noopener"> Reply to: &quot;Progressive cholangiopathy in COVID-19 patients: Other possible diagnoses than ketamine-induced cholangiopathy should be considered&quot;.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Reply to: &quot;Small esophageal varices in compensated cirrhosis patients: To treat or not to treat?&quot;</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Reply to: &quot;TIPS and liver transplantation should always be discussed together&quot;.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8180345" target="_blank" rel="noopener"> Reply to: Comments on &quot;Association of liver abnormalities with in-hospital mortality in patients with COVID-19&quot;.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Reply to: Correspondence on &quot;Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival&quot;.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Reply to: correspondence regarding &quot;Multicenter validation of the liver graft assessment following transplantation (L-GrAFT) score for assessment of early allograft dysfunction&quot;.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Risk factors and screening intervals are crucial to evaluating the cost effectiveness of abbreviated MRI in HCC screening.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8064900" target="_blank" rel="noopener"> Risk stratification in hospitalized COVID-19 patients.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Successful management of refractory ascites in non-TIPSable patients using percutaneous thoracic duct stenting.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8264276" target="_blank" rel="noopener"> The mRNA COVID-19 vaccine - A rare trigger of autoimmune hepatitis?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> The search for optimum thiopurine metabolite levels in autoimmune hepatitis continues….</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> TIPS and liver transplantation should always be discussed together.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Transient elastography in chronic liver disease: Beware of the cut-offs!</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Understanding HBcrAg components improves the interpretation of clinical HBcrAg assay results.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> We need to talk about #livertwitter.</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">J Neurogastroenterol Motil</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8266498" target="_blank" rel="noopener"> A Novel Cohesinopathy Causing Chronic Intestinal Pseudo Obstruction in 2 Siblings and Literature Review.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8266505" target="_blank" rel="noopener"> Metastatic Intrahepatic Cholangiocarcinoma Presenting as an Achalasia-like Syndrome.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8026371" target="_blank" rel="noopener"> There Is Something More Important Than Proximal Reflux Episode in the Development of Post-reflux Swallow-induced Peristaltic Wave.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8026375" target="_blank" rel="noopener"> Transient Receptor Potential Canonical 4 Channel in Interstitial Cells of Cajal as a Target for Control of Gastrointestinal Motility.</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Neurogastroenterol Motil</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> High-resolution manometry from the surgical point of view: Response to letter to the editor.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Invited response to letter to the editor by Tustumi et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Reduced gastric accommodation in patients with Parkinson&#39;s disease: A case series.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Repeated measurements in anorectal manometry.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Reply: The key to success: Targeting enzymes to their dietary counterpart.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8188259" target="_blank" rel="noopener"> Response to &quot;retrograde slow wave activation: A missing link in gastric dysfunction?&quot;</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8420200" target="_blank" rel="noopener"> Response to Oliviero et al.&#39;s publication: &quot;Impact of COVID-19 lockdown on symptoms in patients with functional gastrointestinal disorders: Relationship with anxiety and perceived stress&quot;.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Retrograde slow-wave activation: a missing link in gastric dysfunction?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> The key to success: Targeting enzymes to their dietary counterpart.</a></p>
</div></td></tr>
  </tbody>
  
  
</table>
</div>
</div>
<div id="others" class="section level3">
<h3>Others</h3>
<p><em>all remaining publications eg case reports, images of the month, etc…</em></p>
<div id="rrpuyrissz" style="overflow-x:auto;overflow-y:auto;width:auto;height:auto;">
<style>html {
  font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Helvetica Neue', 'Fira Sans', 'Droid Sans', Arial, sans-serif;
}

#rrpuyrissz .gt_table {
  display: table;
  border-collapse: collapse;
  margin-left: auto;
  margin-right: auto;
  color: #333333;
  font-size: 16px;
  font-weight: normal;
  font-style: normal;
  background-color: #FFFFFF;
  width: auto;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #A8A8A8;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #A8A8A8;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
}

#rrpuyrissz .gt_heading {
  background-color: #FFFFFF;
  text-align: center;
  border-bottom-color: #FFFFFF;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
}

#rrpuyrissz .gt_title {
  color: #333333;
  font-size: 125%;
  font-weight: initial;
  padding-top: 4px;
  padding-bottom: 4px;
  border-bottom-color: #FFFFFF;
  border-bottom-width: 0;
}

#rrpuyrissz .gt_subtitle {
  color: #333333;
  font-size: 85%;
  font-weight: initial;
  padding-top: 0;
  padding-bottom: 6px;
  border-top-color: #FFFFFF;
  border-top-width: 0;
}

#rrpuyrissz .gt_bottom_border {
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#rrpuyrissz .gt_col_headings {
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
}

#rrpuyrissz .gt_col_heading {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: normal;
  text-transform: inherit;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: bottom;
  padding-top: 5px;
  padding-bottom: 6px;
  padding-left: 5px;
  padding-right: 5px;
  overflow-x: hidden;
}

#rrpuyrissz .gt_column_spanner_outer {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: normal;
  text-transform: inherit;
  padding-top: 0;
  padding-bottom: 0;
  padding-left: 4px;
  padding-right: 4px;
}

#rrpuyrissz .gt_column_spanner_outer:first-child {
  padding-left: 0;
}

#rrpuyrissz .gt_column_spanner_outer:last-child {
  padding-right: 0;
}

#rrpuyrissz .gt_column_spanner {
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  vertical-align: bottom;
  padding-top: 5px;
  padding-bottom: 5px;
  overflow-x: hidden;
  display: inline-block;
  width: 100%;
}

#rrpuyrissz .gt_group_heading {
  padding: 8px;
  color: #FFFFFF;
  background-color: #0000FF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: middle;
}

#rrpuyrissz .gt_empty_group_heading {
  padding: 0.5px;
  color: #FFFFFF;
  background-color: #0000FF;
  font-size: 100%;
  font-weight: initial;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  vertical-align: middle;
}

#rrpuyrissz .gt_from_md > :first-child {
  margin-top: 0;
}

#rrpuyrissz .gt_from_md > :last-child {
  margin-bottom: 0;
}

#rrpuyrissz .gt_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  margin: 10px;
  border-top-style: solid;
  border-top-width: 1px;
  border-top-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 1px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 1px;
  border-right-color: #D3D3D3;
  vertical-align: middle;
  overflow-x: hidden;
}

#rrpuyrissz .gt_stub {
  color: #333333;
  background-color: #FFFFFF;
  font-size: 100%;
  font-weight: initial;
  text-transform: inherit;
  border-right-style: solid;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
  padding-left: 12px;
}

#rrpuyrissz .gt_summary_row {
  color: #333333;
  background-color: #FFFFFF;
  text-transform: inherit;
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
}

#rrpuyrissz .gt_first_summary_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
}

#rrpuyrissz .gt_grand_summary_row {
  color: #333333;
  background-color: #FFFFFF;
  text-transform: inherit;
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
}

#rrpuyrissz .gt_first_grand_summary_row {
  padding-top: 8px;
  padding-bottom: 8px;
  padding-left: 5px;
  padding-right: 5px;
  border-top-style: double;
  border-top-width: 6px;
  border-top-color: #D3D3D3;
}

#rrpuyrissz .gt_striped {
  background-color: rgba(128, 128, 128, 0.05);
}

#rrpuyrissz .gt_table_body {
  border-top-style: solid;
  border-top-width: 2px;
  border-top-color: #D3D3D3;
  border-bottom-style: solid;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
}

#rrpuyrissz .gt_footnotes {
  color: #333333;
  background-color: #FFFFFF;
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
}

#rrpuyrissz .gt_footnote {
  margin: 0px;
  font-size: 90%;
  padding: 4px;
}

#rrpuyrissz .gt_sourcenotes {
  color: #333333;
  background-color: #FFFFFF;
  border-bottom-style: none;
  border-bottom-width: 2px;
  border-bottom-color: #D3D3D3;
  border-left-style: none;
  border-left-width: 2px;
  border-left-color: #D3D3D3;
  border-right-style: none;
  border-right-width: 2px;
  border-right-color: #D3D3D3;
}

#rrpuyrissz .gt_sourcenote {
  font-size: 90%;
  padding: 4px;
}

#rrpuyrissz .gt_left {
  text-align: left;
}

#rrpuyrissz .gt_center {
  text-align: center;
}

#rrpuyrissz .gt_right {
  text-align: right;
  font-variant-numeric: tabular-nums;
}

#rrpuyrissz .gt_font_normal {
  font-weight: normal;
}

#rrpuyrissz .gt_font_bold {
  font-weight: bold;
}

#rrpuyrissz .gt_font_italic {
  font-style: italic;
}

#rrpuyrissz .gt_super {
  font-size: 65%;
}

#rrpuyrissz .gt_footnote_marks {
  font-style: italic;
  font-weight: normal;
  font-size: 65%;
}
</style>
<table class="gt_table">
  
  <thead class="gt_col_headings">
    <tr>
      <th class="gt_col_heading gt_columns_bottom_border gt_left" rowspan="1" colspan="1"></th>
    </tr>
  </thead>
  <tbody class="gt_table_body">
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Am J Gastroenterol</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> &quot;Sickeningly Sweet&quot;…. High-Fructose Corn Syrup-Caveat Emptor!</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> A Case of Malignant Atrophic Papulosis With Multiple Complications.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> A Targeted Approach to Managing Chronic Pouchitis: Incorporating Accurate Phenotyping of Pouchitis and Assessment for Coexisting Dyssynergic Defecation.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Acute Esophageal Necrosis in a Patient With COVID-19.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Acute Liver Failure due to Manufactured Alkaline Water: A Case Series of &quot;Real Water&quot;-Induced Liver Injury.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Advanced Gastroenterology Trainees Should Be Included in National Trainee Parental Leave Policies.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Anchoring Method to Prevent Migration of a Covered, Self-Expanding, Metal Stent Placed for Esophageal Perforation.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Baby Steps in the Right Direction: Toward a Parental Leave Policy for Gastroenterology Fellows.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Biliary Obstruction Caused by B-Cell Lymphoma Associated With IgG4-Related Disease.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Bleeding Colonic Worm-Like Polyps.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Clamping and Turning Method With Foreign Body Forceps to Assist Release of the Snare Trapped in a Gastric Bezoar.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Comment on &quot;Food as Medicine in the Management of Common Upper Gastrointestinal Symptoms&quot;.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Controversies in Gastroparesis: Discussing the Sticky Points.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Cronkhite-Canada Syndrome: A Rare COVID-19 Mimicker.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Definitions for Acute-on-Chronic Liver Failure: In Dubio Pro Reo.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Developing and Deploying an Automated Quality Reporting System in Your Practice: Learning From the Stanford Colonoscopy Quality Assurance Program.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Effective Mentorship as a Means to Recruit, Retain, and Promote Underrepresented Minorities in Academic Gastroenterology and Hepatology.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic Mucosal Resection With Double Band Ligation for Small Rectal Neuroendocrine Tumors.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic Retrograde Appendicitis Therapy for Treating Periappendiceal Abscess: First Human Case Report.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8389347" target="_blank" rel="noopener"> Endoscopic Vacuum-Assisted Wound Closure of a Rectal Perforation in the Setting of Active Ulcerative Colitis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Eosinophilic Esophagitis Onset Despite Six Years&#39; Treatment With Omalizumab in an Asthmatic Patient: No Protective Effect for Anti-IgE Therapy?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Eosinophilic GI Disorders After Transplantation Are a Unique Transient Entity.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Extensive Abdominal Wall Hematoma After Paracentesis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Gastroparesis After Pfizer-BioNTech COVID-19 Vaccination.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> How I Approach Screening for Pancreatic Cancer.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> How We Did It: Virtual Interviews With an Eye Toward the Future.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Hyponatremia in Cirrhosis: Role of Vasopressors.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Irritable Bowel Syndrome and Functional Dyspepsia: Different Ends of the Same Spectrum of Intestinal Barrier Dysfunction?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Letter to the Editor in Response to &quot;Endoscopic Recognition and Management Strategies for Malignant Colorectal Polyps: Recommendations of the US Multi-Society Task Force on Colorectal Cancer&quot;.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Long-Term Consequences of Undiagnosed Celiac Seropositivity.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Management of Portal Vein Thrombosis in Cirrhosis-Need a Closer Look!</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Metal Biliary Stent Erosion Through the Common Bile Duct Leading to Obstructive Jaundice and Cholangitis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Minimally Invasive T-Tube Insertion for Anastomotic Leak After Oesophagectomy and Gastrectomy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Overcoming the Challenges and Mitigating the Disparities in Our LGBTQI+ Patients.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Paraneoplastic Achalasia Associated With Neuroendocrine Tumor.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Pyodermatitis-Pyostomatitis Vegetans in Active Inflammatory Bowel Disease.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Quantity of Donor Stool for Fecal Microbiota Transplantation: The More, the Better?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Recurrent Lower Gastrointestinal Bleeding due to a Cholecystocolonic Fistula.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Reply to Philpott and Dellon.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Response to de Mattos et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Response to Debnath and Rathi.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Response to Febo-Rodriguez et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Response to Garg.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Response to Goodoory et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Response to Ianiro et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Response to Keszthelyi.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Response to Khalaf et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Response to Roldan et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Response to Uchida and Rabinowitz, et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Sarcopenia and TIPS: How Best to Measure Muscle Mass.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> The Association Between Heavy Alcohol Use and Gastric Cancer.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Understanding Device Development for Gastrointestinal Clinical Care.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Using Adult Norms for Gastric Emptying Scintigraphy Evaluation in Children.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Utilization of Endoscopy Scissors for Retrieval of Esophageal Embedded Foreign Body.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Vascular Hamartoma of the Pancreas.</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Clin Gastroenterol Hepatol</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> A Case of Pedunculated Esophageal Neuroendocrine Tumor G1.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> A Practical Guide to Establishing a Gastroenterology Hospitalist Program.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8018784" target="_blank" rel="noopener"> An Impetus for Change: How COVID-19 Will Transform the Delivery of GI Health Care.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Chest Pain of Atypical Etiology: A Type IV Paraesophageal Hernia.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Chronic Constipation With Fecal Stasis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Colonic Stenosis Caused by Transcatheter Arterial Embolization.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Cytotoxic T-Lymphocyte-Associated Antigen 4 Haploinsufficiency Mimics Difficult-to-Treat Inflammatory Bowel Disease.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Dysphagia in Dermatomyositis Due to Esophageal Adenocarcinoma.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic Removal of Ingested Wire Bristle from the Pancreas.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Gastroenterology Physician Practice Management and Private Equity: Thriving in Uncertain Times.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8088969" target="_blank" rel="noopener"> Health Equity and Telemedicine in Gastroenterology and Hepatology.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Intestinal Failure: What All Gastroenterologists Should Know.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Isolated Colonic Post-Transplantation Lymphoproliferative Disease.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Lumen-Apposing Metal Stents in Benign Gastrointestinal Luminal Strictures.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Primary Hepatic Mucosa-Associated Lymphoid Tissue Lymphoma in a Patient with Primary Biliary Cholangitis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Recent Advances in Hepatocellular Carcinoma Treatment.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Scoping Out a Better Parental Leave Policy for Gastroenterology Fellows.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> The Stanford Multidisciplinary Swallowing Disorders Center.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Therapeutic Drug Monitoring of Non-Anti-Tumor Necrosis Factor Biologics.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Three Signs of Pneumoperitoneum on a Supine Radiograph.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Training the Trainers: Setting Standards for Faculty in Gastroenterology.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Transient Empty Portal Vein With Gastric Emphysema.</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Endoscopy</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> &quot;Alongside-balloon-dilation&quot; as a novel endoscopic bailout involving external cutting of an entrapped biliary self-expandable metal stent delivery system.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> &quot;Double trouble&quot;: embedded lumen-apposing metal stent and embolization coils.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> A case of pancreatic schwannoma with a focus on contrast-enhanced endoscopic ultrasonography.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> A new therapy for refractory gastric cancer bleeding: endoscopic ultrasound-guided lauromacrogol injection.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> A novel method of papilla fixation for difficult biliary cannulation without using a pancreatic duct guidewire: non-guidewire fixation method.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> A novel technique for endoscopic removal of foreign bodies using a balloon and transparent cap.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> A rare case of bilateral Killian-Jamieson diverticula treated endoscopically.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> A simple method to determine the proper length of the gastric myotomy during peroral endoscopic myotomy for achalasia.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Accidental gastrocolonic anastomosis by apposition stent: a one-month healing delay makes it possible to treat a stabilized gastrocolonic fistula rather than a double perforation.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Across-the-papilla side-by-side placement of 6-mm fully covered metallic stents for malignant hilar biliary obstruction: a novel concept that may facilitate reintervention.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Adenocarcinoma arising from a long-standing solitary rectal ulcer syndrome.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Ampullectomy of an unusual lesion developing 20 years after endoscopic treatment of a type III choledochocele.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> An unusual cause of acute cholangitis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Aneurysm rupture after choledochoduodenostomy with lumen-apposing metal stent: endoscopic ultrasound-guided stenting of the bile duct in an endoscopically blind situation due to massive bleeding.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Application of an appendoscope in chronic appendicitis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Application of traction-method to hybrid endoscopic submucosal dissection for gastrointestinal tumors.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Argon plasma coagulation of the papilla of Vater for treatment of a Dieulafoy lesion.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Art in Endoscopy: &quot;Dinosaur birth?&quot;</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Art in Endoscopy: &quot;The smiling diverticulum&quot;.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Art in Endoscopy: &quot;This colon has a heart! Does it have feelings too?&quot;</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Art in Endoscopy: A metal daisy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Art in Endoscopy: Natural analogies.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Author commentary on Andreas Drolz et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Author commentary on Apostolos Pappas et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Author commentary on Calvin Jianyi Koh et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Author commentary on De-feng Li et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Author commentary on Dongwook Oh et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Author commentary on Emma C. Robbins et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Author commentary on Francisco Javier García-Alonso et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Author commentary on Gontrand Lopez-Nava et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Author commentary on Ina B. Pedersen et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Author commentary on Ishita Barua et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Author commentary on Jad Farha et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Author commentary on Karlijn J. Nass et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Author commentary on Kirill Basiliya et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Author commentary on Koichi Hamada et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Author commentary on Kousei Tashiro et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Author commentary on Li Huang et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Author commentary on Lillian Wang et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Author commentary on Mariko Sekiya et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Author commentary on Mélissa Gruner et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Author commentary on Olivier Ragi et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Author commentary on Omid Sanaei et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Author commentary on Satimai Aniwan et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Author commentary on Sergei Vosko et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Author commentary on Tsevelnorov Khurelbaatar et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Author commentary on Tue Kjølhede et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Author commentary on Woo Hyun Paik et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Bike handlebar grip in the rectum: minimally invasive endoscopic management.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Bile volatile organic compounds, smelling trouble.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Biliary obstruction caused by an erupted hepatic hydatid cyst.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Biliary rendezvous through the gallbladder using a lumen-apposing metal stent.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Blue rubber bleb nevus syndrome: an unusual cause of intestinal bleeding in the elderly.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Cap-assisted large cold snare removal of a giant phytobezoar.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Choking with a snare to control immediate bleeding after cold snare polypectomy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Cloacogenic polyp: a rare type of polyp.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Combined endoscopic ultrasound-guided gastrojejunostomy and anterograde biliary stenting.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Comfortable, lightly sedated colonoscopy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Complete endoscopic removal of a large appendiceal orifice polyp.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Conversion of endoscopic ultrasound-guided hepaticogastrostomy to transpapillary drainage by anterograde intervention via dedicated biliary metal stent for benign biliary stenosis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Deep biopsy via endoscopic submucosal dissection for primary gastric amyloidosis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Delayed bleeding and intratunnel hematoma after peroral endoscopic myotomy: salvage endoscopy management with full recovery.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Diagnostic endoscopic submucosal dissection for invasive cancer with the four cardinal points traction strategy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Difficult scientific evaluation of rare disease management: Peutz-Jeghers syndrome.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Double ligation-assisted endoscopic submucosal resection for rectal neuroendocrine tumors.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Double-pigtail plastic stent is effective as a rescue therapy after obstruction of choledochoduodenostomy using a lumen-apposing metal stent.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Double-wire-guided reopenable-clip closure of a mucosal defect after endoscopic papillectomy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Drainage via colonic transendoscopic enteral tubing increases our confidence in rescuing endoscopy-associated perforation.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Dual-functional use of thread delivery hood for traction-assisted rectal endoscopic submucosal dissection and defect closure.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Dynamic microangiography of the gastrointestinal mucosa using magnifying Blue Light Imaging.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Efficacy of under-gel endoscopic mucosal resection method for colonic lesion extending into the diverticulum.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Elastic-band traction technique for cannulating intradiverticular papilla during endoscopic retrograde cholangiopancreatography.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Electrohydraulic lithotripsy for hepatolithiasis in a stenotic intrahepatic bile duct after Roux-en-Y hepaticojejunostomy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Emergency endoscopic negative pressure therapy of a long oesophageal perforation in eosinophilic esophagitis with a single-lumen nasogastric tube-like open-pore film drain.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic coloenterostomy for treatment of malignant small-bowel obstruction: troubleshooting and management of complications.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic complete closure of duodenal mucosal defects using a clip with a looped thread after endoscopic resection.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic esophagogastric anastomosis using a lumen-apposing metal stent to manage an anastomotic leakage after esophagectomy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic incision and balloon dilation using the rendezvous technique for complete anastomotic obstruction after rectal low-anterior resection.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic management of acute leak after sleeve gastrectomy: principles and techniques.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic necrosectomy using endobronchial ultrasonography and transnasal gastroscopy via the percutaneous route.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic negative pressure therapy for a broad rectal fistula using pull-through open-pore film and polyurethane foam drains.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic removal of a fractured esophageal stent from the mediastinum and leak closure with endoscopic vacuum therapy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic removal of an entirely embedded esophageal fishbone.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic resection of a complex gastric duplication cyst using a submucosal tunneling technique.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic resection of a pediatric pyogenic granuloma of the major papilla.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic resection of a rectal gastrointestinal stromal tumor using the submucosal tunneling endoscopic resection (STER) technique.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic retrieval of a migrated surgical clip in a choledochojejunal anastomosis using the rendezvous technique.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic retrograde appendicitis therapy: a novel approach for peri-appendiceal abscess.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic submucosal dissection of a duodenal GI stromal tumor assisted by endoloops.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic submucosal dissection of a subepithelial neuroendocrine tumor located in the duodenum using a countertraction technique.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic transgastric cholecystectomy during direct endoscopic necrosectomy for walled-off necrosis of the pancreas.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic transpapillary gallbladder stenting for acute cholecystitis using a novel integrated inside biliary stent and nasobiliary drainage catheter system.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic Treatment of a Total Ileorectal Anastomosis Stenosis using Magnets.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic ultrasonography-guided pancreaticoduodenostomy with a lumen-apposing metal stent to treat main pancreatic duct dilatation.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic ultrasound-guided ductal access and drainage - thus far and much further.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic ultrasound-guided gastrojejunostomy does not prevent pancreaticoduodenectomy after long-term symptom-free neoadjuvant treatment.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic ultrasound-guided jejunojejunostomy with rendezvous contrast-filling assistance in afferent limb syndrome.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic ultrasound-guided one-step antegrade metal stent placement with an ultra-slim introducer for preoperative biliary drainage.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic ultrasound-guided recanalization of a complete esophageal stricture.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic ultrasound-guided renal biopsy: an alternative to transjugular renal biopsy in high-risk patients.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic ultrasound-guided rendezvous for extrahepatic bile duct recanalization after surgical transection.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic ultrasound-guided rendezvous recanalization of a completely obstructed esophagogastric anastomosis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endoscopic ultrasound-guided transportal cholangiography and jejunoduodenostomy to facilitate through-the-stent ERCP and transmural gallbladder drainage in Roux-en-Y gastrectomy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Endosonography-guided gallbladder drainage in a patient with intestinal malrotation.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Enterocutaneous fistula closure using a balloon-assisted enteroscope preloaded with an over-the-scope clip - narrowing the gap.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Eradication of neoplastic Barrett&#39;s esophagus in patients with esophageal varices with a modified endoscopic mucosal resection technique and radiofrequency ablation.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Esophageal lumen recreated with a self-expanding metal stent in a deep submucosal tunnel: a successful way to treat a refractory stricture.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> EUS-guided percutaneous endoscopic jejunostomy in cases not suitable for conventional gastrostomy: after bariatric (SADI-S) and cancer surgery.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Feasibility of a single endoscopic plication procedure for the treatment of gastroesophageal reflux disease and obesity.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Flat colorectal sessile serrated polyp: an example of what artificial intelligence does not easily detect.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Forward-viewing echoendoscope-guided pancreatic duct drainage using a diathermic dilator for a severely stenotic pancreaticojejunal anastomosis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Gastric subcentimeter subepithelial tumor: successful resection with an over-the-scope padlock clip.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Gel immersion endoscopic submucosal dissection for an anorectal tumor with hemorrhoids close to the dentate line.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Gel immersion endoscopic submucosal dissection using a novel gel product for a duodenal epithelial tumor.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Gel immersion technique for the examination and treatment of an ampullary tumor.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Green-colored areas in laterally spreading tumors on narrow-band imaging: a future target for artificial-intelligence-assisted detection of malignancies?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Guidewire-assisted technique for gastroscope insertion through stricture of Zenker&#39;s diverticulum for esophageal endoscopic submucosal dissection.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Hanging on by a thread: gastric extraction of ingested tampons.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Helpful technical notes for intraperitoneal natural orifice transluminal endoscopic surgery (NOTES) salvage in a failed EUS-guided gastroenterostomy scenario.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Ileoileal intussusception treated by polypectomy with spiral enteroscopy in Peutz-Jeghers syndrome.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Improved wire-guided basket for intrahepatic stone extraction in a patient after pancreatoduodenectomy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Intraoperative digital single-operator cholangioscopy - extra-anatomical biliary access and insights into severe sclerosing cholangitis in a pediatric patient.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Intraperitoneal endoscopic salvage using an enteral stent for a misdeployed lumen-apposing metal stent during endoscopic ultrasound-guided gastroenterostomy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Irrigation-assisted intraductal ultrasonography with a 3-Fr microcatheter during endoscopic retrograde cholangiography.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Laparoscopic bowel resection combined with hand-assisted endoscopic balloon dilation for Crohn&#39;s disease with multiple bowel strictures.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Large colorectal mucosal defect closure post-endoscopic submucosal dissection using the reopenable clip over line method and modified locking-clip technique.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Long-term endoscopic follow-up after closure of a post-bariatric surgery fistula with a cardiac septal defect occluder.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Mapping biopsy for bile duct cancer using a novel device delivery system.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Mimicry of an acute pseudocyst by a gastrointestinal duplication cyst in a 14-year-old boy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Modified search, coagulation, and clipping with polyglycolic acid sheet and fibrin glue to reduce delayed bleeding risk after endoscopic submucosal dissection near the dentate line.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Nonadhesive massive coiling endoscopic ultrasound-guided embolization in a single session for treatment of gastric varices: learning points of a technical variant.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Nontraumatic tube method for detecting a vessel responsible for colonic diverticular hemorrhage.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Novel &quot;endoloop and hemoclips&quot; technique for mucosal prolapse causing efferent loop syndrome.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Optical real-time biopsy by endocytoscopy: a case of sessile serrated lesion with dysplasia.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Over-the-scope clipping and detachable snare ligation as a novel combination hemostatic therapy for diverticular bleeding.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Pathological evaluation of a rectal endoscopic submucosal dissection specimen using micro-computed tomography.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Peroral cholangioscopy via an endoscopic ultrasound-guided hepaticojejunostomy route for distal bile duct cancer with Roux-en-Y reconstruction.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Precut esophageal endoscopic mucosal resection for cervical esophageal cancer to minimize mucosal defect.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Pristine submucosal visibility using Texture and Color Enhancement Imaging during saline-immersion rectal endoscopic submucosal dissection.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Recanalization of a distorted duodenal metal stent using a fine-gauge electrocautery dilator.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Rectal neuroendocrine tumors: is it all on first sight?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Rendezvous ERCP via endoscopic ultrasound-guided gallbladder drainage to salvage a dislodged lumen-apposing metal stent during choledochoduodenostomy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Rendezvous therapy with endoscopic and endovascular treatments for rectal arteriovenous malformation: A case report.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Reply to Ishaq et al.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Rescue lumen-apposing metal stent to treat a perforation secondary to balloon dilation of a Crohn&#39;s disease stenosis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Retroflexion in the duodenal bulb combined with tunnel and double-clip traction: the key to successful endoscopic submucosal dissection of a malignant gastric adenoma protruding through the pylorus.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Retrograde endosonography-guided hepaticojejunostomy after failed rendezvous in a patient with Roux-en-Y anastomosis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Salvage, reloading, and deployment of a metal biliary stent using an improvised delivery catheter.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Sessile serrated adenoma invading a diverticulum in the right colon: tips and tricks for a safe complete endoscopic resection.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Simultaneous endoscopic ultrasound-guided treatment of intestinal and biliary obstruction due to massive lymphoma of the duodenal papilla.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Single-operator metal stent deployment for malignant biliary obstruction using a novel thumbwheel delivery system.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Snare rotation technique: a simple tip for successful polypectomy for non-pedunculated gastrointestinal polyps.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Spiral stent placement for bile leakage after hepatobiliary surgery.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Sterile laparoscopic transgastric ERCP with single-use disposable duodenoscope.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Stretch occlusion of stone extraction balloon catheter.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Successful biliary stone removal after resolution of post-endoscopic sphincterotomy papillary stenosis using temporary covered metal stent placement.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Successful closure of huge perforation during rectal endoscopic submucosal dissection using an endoscopic string clip suturing method and polyglycolic acid sheets and fibrin glue.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Successful endoscopic papillectomy with intrapancreatic ductal radiofrequency ablation for ampulla cancer in surgically altered anatomy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Successful management of membranous duodenal stenosis by endoscopic balloon dilation and membrane resection with an insulated-tip knife.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Successful use of two guidewires with different properties using a double-lumen catheter for postoperative biliary stricture.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Suggestion of a standard maneuver in cap-assisted colonoscopy: hooking and dragging maneuver.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Technically simplified peroral endoscopic myotomy: blunt dissection making submucosal tunneling fast and safe.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> The bizarre appearance of intrathoracic extramedullary hematopoiesis during an endoscopic ultrasound examination.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> The complex advanced endoscopic approach in the treatment of choledocholitiasis and empyema of gallbladder.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8044597" target="_blank" rel="noopener"> The first &quot;exclusive COVID-19&quot; endoscopy project.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> The University of Alabama at Birmingham (UAB) Raptor method for direct percutaneous endoscopic gastrostomy with jejunal extension tube placement.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> The worst adverse event for an endoscopist after esophageal stent placement: an aortoesophageal fistula.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Traction-assisted endoscopic submucosal dissection of a duodenal gastrointestinal stromal tumor.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Traction-assisted endoscopic submucosal dissection with submucosal tunneling for Barrett&#39;s esophagus nodularity.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Transgastric natural orifice transluminal endoscopic surgery (NOTES) to remove a foreign body from the abdominal cavity of a 12-year old boy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Transmural cystoscopy with an ultra-slim basket for migrated stent removal after endosonography-guided hepatic cyst drainage.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Triple stent-in-stent placement of novel braided metal stents with a slim delivery system via balloon-assisted enteroscopy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Two for one: endoscopic drainage of a large pyogenic liver abscess at the time of ERCP.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Typical gastric mucosa with ulcer found by endoscopy in Meckel&#39;s diverticulum.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Ultimate salvation: feasibility of NOTES for complications of ERCP and endoscopic ultrasound-guided procedures.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Underwater endoscopic mucosal resection for a sporadic adenoma located at severe longitudinal ulcer scars in ulcerative colitis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Underwater endoscopic mucosal resection for en bloc resection of a neuroendocrine tumor in the duodenal bulb.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Upper gastrointestinal bleeding due to mixed adenoneuroendocrine carcinoma and radiation esophagitis treated with cap-mucosectomy combined with radiofrequency ablation.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Usefulness of a papilla fixation method with SureClips for bile duct cannulation.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Usefulness of prioritization systems during the resumption of gastrointestinal endoscopy activity during the COVID-19 pandemic.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Utility of under-gel endoscopic mucosal resection with partial submucosal injection for a laterally spreading tumor.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> When Z-POEM comes to the rescue of classical diverticulotomy and vice versa.</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Gastroenterology</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> A Pancreas-Specific Ptf1a-Driven Cre Mouse Line Causes Paternally Transmitted Germline Recombination.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8233543" target="_blank" rel="noopener"> An Unexpected Thoracic Finding in a Patient With COVID-19.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> An Unusual Pancreatic Mass with Ductal Disruption: Benign or Malignant?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Balancing the Tradeoffs Between Office and Video Doctor Visits.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> How to Promote Career Advancement and Gender Equity for Women in Gastroenterology: A Multifaceted Approach.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Peptic ulcer disease: an unusual presentation of a common problem.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Pleural effusion with gastric ulcer.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Rare Hypomorphic Sucrase Isomaltase Variants in Relation to Irritable Bowel Syndrome Risk in UK Biobank.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Silvio O. Conte Digestive Disease Research Core Centers-Connecting People, Creating Opportunities, Developing Careers.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Strategies to Improve Video Visit Use in Persons With Liver Disease.</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Gastrointest Endosc</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> A rare case of refractory and severe duodenal ulcers associated with olmesartan.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> An unexpected adverse event after intragastric balloon deployment for morbid obesity.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> An unusual large protuberant lesion of the ascending colon mucosa caused by mucinous cystadenocarcinoma of the appendix.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Cholangioscopic finding of severe hemorrhagic cholangitis associated with immune-related adverse events.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7927584" target="_blank" rel="noopener"> Delayed postsphincterotomy bleeding induced by severe thrombocytopenia in a patient with COVID-19.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Direct cholangioscopic visualization of gallbladder cancer ingrowth into an open-cell, laser-cut hilar stent.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Early case of dysphagia aortica.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Ectopic pancreas with acoustic shadow: a cholesterol crystal-related submucosal pseudotumor.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Emphysematous cholangitis with pneumoperitoneum at ERCP.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> EUS-guided colocolostomy by use of a lumen-apposing metal stent for malignant sigmoid colon obstruction.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Glucagonoma with diffuse enlargement of pancreas mimicking autoimmune pancreatitis diagnosed by EUS-guided FNA.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Keratin pearls in magnifying endoscopy of superficial esophageal squamous cell carcinoma.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> My one and only eye (still the one).</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Novel endoscopic therapy for anemia secondary to refractory anastomotic ulceration in Crohn&#39;s disease.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Pancreatic cyst dilemma: a case where genetic sequencing and immunohistochemistry impacted clinical decision making.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Peroral endoscopic myotomy and gastroesophageal reflux: A word of caution!</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Prompt intervention can avert catastrophic outcome of portal venous air embolism during ERCP.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Refeeding syndrome: a fatal adverse event of gastric peroral endoscopic pyloromyotomy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Superficial nonampullary duodenal epithelial tumor: a rare case accompanied by cancer component as subepithelial lesion.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> The &quot;nipple sign&quot; as a novel endoscopic marker for a large-caliber feeding vessel in symptomatic colonic angioectasia.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> The endoscopic &quot;hide-bound&quot; bowel sign in systemic sclerosis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Unclassified serrated lesion of the colon observed by magnifying endoscopy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Understanding the truly flat nature of cold snare protrusions in vivo (with video).</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Gut</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Are sugar-sweetened beverages contributing to the rising occurrence of colorectal cancer in young adults?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Dysphagia: revisiting investigations.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8292561" target="_blank" rel="noopener"> Large-scale genetic analyses in an understudied disease: haemorrhoidal disease.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Pancreatic cancer surveillance and its ongoing challenges: is it time to refine our eligibility criteria?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Prognostic value of DAXX/ATRX loss of expression and ALT activation in PanNETs: is it time for clinical implementation?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Should you trust the radiologist?</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Hepatology</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> A Possible Association Between a Nucleotide-Binding Domain LRR-Containing Protein Family PYD-Containing Protein 1 Mutation and an Autoinflammatory Disease Involving Liver Cirrhosis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> A Spotlight on the Drivers of Inflammation in Acute Liver Failure.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> AASLD Deepens Commitment to Diversity, Equity, and Inclusion.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Allan G. Redeker, M.D. (1924-2021).</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Bile Duct Repair in Human Liver Grafts: Effective Cholangiocyte Organoid Engraftment and Plasticity.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Diagnostic Criteria of Cirrhotic Cardiomyopathy: Out With the Old, in With the New?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Dissecting Early Relapse in Liver Cancer, One Cell at a Time.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Familial Hypobetalipoproteinemia: An Underrecognized Cause of Lean NASH.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Gene Signatures Reduce the Stress of Preclinical Drug Hepatotoxicity Screening.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Hepatic Arteriovenous Malformation: The Search for a PTEN Mutation!</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Hepatocytes Induce Change in Their Neighbors by YAP-ing at Them.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Hepatology Highlights.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Hypothermic Oxygenated Machine Perfusion Protects From Cholangiopathy in Donation after Circulatory Death Liver Transplantation.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Imaging Features of Hepatic Small Vessel Neoplasm: Case Series.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Introducing Raymond T. Chung, M.D., Our 2021 AASLD President.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Macrophage Heterogeneity in NASH: More Than Just Nomenclature.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Mevalonic Aciduria Associated With Intrahepatic Bile Duct Paucity.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Obituary for Roberto J. Groszmann-The Father of Portal Hypertension.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Primary Hepatic Squamous Cell Carcinoma With High Microsatellite Instability Shows Good Response to Programmed Cell Death 1 Inhibitor as Adjuvant Therapy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Professional Use of Social Media by Hepatology Providers.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Proximal Splenic Artery Embolization to Treat Refractory Ascites in a Patient With Cirrhosis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Recurrent Nodular Regenerative Hyperplasia Following Liver Transplantation in Common Variable Immunodeficiency.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Resolution of Loculated Chylous Ascites Using Intraperitoneal Fibrinolytic Therapy.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Sinusoidal Endothelial Cells as Orchestrators of the Gut Liver Immune Axis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Sinusoidal Obstruction Syndrome in a Young Woman With Antiphospholipid Syndrome on Oral Contraceptives.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Sofosbuvir, Glecaprevir, Pibrentasvir, and Ribavirin as a Rescue Therapy in Difficult-to-Treat HCV Patients.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Successful Management With Dual Therapy of Lenvatinib and Macitentan for HCC With Portopulmonary Hypertension.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Surgical Debulking for Refractory Hyperammonemic Encephalopathy in Fibrolamellar Hepatocellular Carcinoma.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> The Glucagon-Like Peptide-1 Receptor Agonist, Semaglutide, for the Treatment of Nonalcoholic Steatohepatitis.</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">Inflamm Bowel Dis</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> A Case of Iliopsoas Abscess and Ileitis With Enterocutaneous Fistula Caused by a Toothpick Mimicking Small Bowel Crohn&#39;s Disease.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> A Rare Autoinflammatory Syndrome Involving Acute Severe Ulcerative Colitis Combined With Iritis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> An Unusual Cause of Chest Pain With Abdominal Pain.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Assessing the Prevalence of and Risk Factors for Disordered Eating Attitudes and Behaviors in Adolescents With Inflammatory Bowel Disease.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Autoimmune Enteropathy Presenting as Ascites in a Patient With Cirrhosis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7989212" target="_blank" rel="noopener"> Barriers to Administering Vaccines in Inflammatory Bowel Disease Centers.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Cerebral Venous Thrombosis in a Child With Very-Early-Onset IBD.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Combined Targeted Treatment Using Biologic-Tofacitinib Co-Therapy in Chronic Active Ulcerative Colitis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Combining Therapies in Inflammatory Bowel Disease: End of the Line or a New Era?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Corrigendum to: Hepatitis-B Vaccine Response in Inflammatory Bowel Disease Patients: A Systematic Review and Meta-analysis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8135589" target="_blank" rel="noopener"> COVID-19 Hospitalizations Among U.S. Medicare Beneficiaries With Inflammatory Bowel Disease, April 1 to July 31, 2020.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8194689" target="_blank" rel="noopener"> COVID-19 Vaccination in Patients With Inflammatory Bowel Disease and History of Reaction to Injectable Therapies.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Crohn-Like Colitis in a Young Boy With Hirschsprung Disease.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Disease Flares in the Postpartum Period: Vigilance Is Key.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Disparity in the Care of Black Inflammatory Bowel Disease Patients.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Distinct Entity of Inflammatory Bowel Disease in Autoimmune Sclerosing Cholangitis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Do Not Stop Anti-TNF Medications in Children With IBD When They Are Working.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Dual Targeted Therapy in Patient With Extensive Crohn&#39;s Disease: Different Response at Distinct Location.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Eating Disorders: Diagnosis and Management Considerations for the IBD Practice.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Effectiveness and Safety of Combining Tofacitinib With a Biologic in Patients With Refractory Inflammatory Bowel Diseases.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> IgA-Mediated Warm Autoimmune Hemolytic Anemia as an Extraintestinal Manifestation in a Patient With Crohn Disease on Vedolizumab.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Increased Bacterial Proteolytic Activity Detected Before Diagnosis of Ulcerative Colitis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Infliximab De-escalation in Patients With Crohn&#39;s Disease in Clinical Remission Is Safe and Well-tolerated.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Is It Crohn&#39;s Disease?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Low Serum Tumor Necrosis Factor-α Antagonist Concentrations in Patients With Inflammatory Bowel Disease Who Achieve Healing From Pyoderma Gangrenosum.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Mixed Adenocarcinoma in a 44-Year-Old Male with Crohn&#39;s Disease.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Multiple Nodules in the Kidney and Spleen Presenting as the Initial Manifestation of Crohn Disease.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Onset of Suspected Ulcerative Colitis After Treatment With Tocilizumab in Patient With Celiac Disease and Juvenile Idiopathic Arthritis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Outcomes of Standard and Intensified Dosing of Ustekinumab for Chronic Pouch Disorders.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Real-World Comparison of Tofacitinib vs Ustekinumab Among Bio-Exposed Patients With Ulcerative Colitis: A Propensity Score Analysis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Response to the Letter to the Editor: &quot;Pyoderma Gangrenosum in An Ulcerative Colitis Pediatric Patient During Vedolizumab Therapy Successfully Treated With Oral Cyclosporine&quot;.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Risk of Depression During the Natural History of Inflammatory Bowel Disease: The Phantom Menace.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8344527" target="_blank" rel="noopener"> SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease-Fear and Desire.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Self-Expandable Metal Stents for Refractory Complete Rectal Obstruction in Patients With Crohn Disease.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Still the Joker in the Pack: When to Take Out Cyclosporine in the Game?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Strongyloides Stercoralis in Acute Severe Ulcerative Colitis-A Triggering Nuisance or An Opportunistic Bystander?</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Systematic Review of Inclusion and Analysis of Older Adults in Randomized Controlled Trials of Medications Used to Treat Inflammatory Bowel Diseases.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Technical Issues Are a Major Determinant of Patient Satisfaction in Virtual Visits for Inflammatory Bowel Diseases.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> The Difficulty of Distal Crohn&#39;s Disease and the Utility of Diverting Stomas.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> The Use of Biologics for the Treatment of Esophageal Crohn Disease.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7928903" target="_blank" rel="noopener"> Time to Negative SARS-CoV-2 PCR Should Not Delay Care Among Patients With Inflammatory Bowel Diseases.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Use of Vedolizumab in Immune Checkpoint Inhibitor-associated Enterocolitis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Ustekinumab for Crohn Disease With Severe Gastroduodenal Involvement.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Ustekinumab-Induced Remission of Two Cases of Refractory Cutaneous Crohn&#39;s Disease.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Vedolizumab-Induced Endoscopic and Histologic Improvement in Gastric Menetrier&#39;s Disease in a Patient With Ulcerative Colitis.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Welcoming New Associate Editors and New Initiatives.</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">J Crohns Colitis</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> A Corrigendum.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Comforting Data on the Incidence of Rectal Cancer After Subtotal Colectomy in IBD: The Risk Is Low, Yet Surveillance Matters!</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Corrigendum to: Abstracts of the 15th Congress of ECCO Vienna, Austria, February 12-15, 2020.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Effect of Ustekinumab on Extraintestinal Diseases in Refractory Crohn&#39;s Disease.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Measuring Patient Experience in Inflammatory Bowel Disease Care: A Key Component of Continuous Quality Improvement.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD - Challenges and Future Directions.</a></p>
</div></td></tr>
    <tr class="gt_group_heading_row">
      <td colspan="1" class="gt_group_heading">J Hepatol</td>
    </tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> A single cell gene expression atlas of 28 human livers.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Acute liver failure.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Medical therapies for intra-hepatic cholangiocarcinoma.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7880835" target="_blank" rel="noopener"> Remaining challenges in HCV elimination.</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> Robert W Schrier, an influential observer from outside Hepatology (1936-2021).</a></p>
</div></td></tr>
    <tr><td class="gt_row gt_left"><div class="gt_from_md"><p><a href="NA" target="_blank" rel="noopener"> The underlying cellular immune pathology of Entamoeba histolytica-induced hepatic amoebiasis.</a></p>
</div></td></tr>
  </tbody>
  
  
</table>
</div>
<script src="data:application/javascript; charset=UTF-8;base64,!function(){"use strict";function t(t,e){for(var n in e)e.hasOwnProperty(n)&&(t[n]=e[n]);return t}function e(t){return function(t){if(Array.isArray(t))return n(t)}(t)||function(t){if("undefined"!=typeof Symbol&&null!=t[Symbol.iterator]||null!=t["@@iterator"])return Array.from(t)}(t)||function(t,e){if(!t)return;if("string"==typeof t)return n(t,e);var r=Object.prototype.toString.call(t).slice(8,-1);"Object"===r&&t.constructor&&(r=t.constructor.name);if("Map"===r||"Set"===r)return Array.from(t);if("Arguments"===r||/^(?:Ui|I)nt(?:8|16|32)(?:Clamped)?Array$/.test(r))return n(t,e)}(t)||function(){throw new TypeError("Invalid attempt to spread non-iterable instance.\nIn order to be iterable, non-array objects must have a [Symbol.iterator]() method.")}()}function n(t,e){(null==e||e>t.length)&&(e=t.length);for(var n=0,r=new Array(e);n<e;n++)r[n]=t[n];return r}function r(t){for(var e=arguments.length,n=new Array(e>1?e-1:0),r=1;r<e;r++)n[r-1]=arguments[r];return n.every((function(e){return"function"==typeof t[e]}))}var o={es2017:function(){return!r(Object,"entries","values")},es2018:function(){return"function"!=typeof Promise||!r(Promise.prototype,"finally")}};var s=["es2017","es2018"];function i(t){t.setAttribute("data-hypothesis-asset","")}function a(t,e,n,r){var o=t.createElement("link");o.rel=e,o.href=r,o.type="application/annotator+".concat(n),i(o),t.head.appendChild(o)}function c(t,e,n){var r=t.createElement("link");r.rel="preload",r.as=e,r.crossOrigin="anonymous",r.href=n,i(r),t.head.appendChild(r)}function u(t,e,n){n.forEach((function(n){var r=e.assetRoot+"build/"+e.manifest[n];r.match(/\.css/)?function(t,e){var n=t.createElement("link");n.rel="stylesheet",n.type="text/css",n.href=e,i(n),t.head.appendChild(n)}(t,r):function(t,e){var n=t.createElement("script");n.type="module",n.src=e,n.async=!1,i(n),t.head.appendChild(n)}(t,r)}))}function l(t){return function(t){return t.filter((function(t){var e=o[t];if(!e)throw new Error('Unknown polyfill set "'.concat(t,'"'));return e()}))}(t).map((function(t){return"scripts/polyfills-".concat(t,".bundle.js")}))}function p(t){var e=t.match(/(https?):\/\/([^:/]+)/);return e?{protocol:e[1],hostname:e[2]}:null}function f(){var t=arguments.length>0&&void 0!==arguments[0]?arguments[0]:document,e=t.currentScript;return e?p(e.src):null}function h(t){var e=arguments.length>1&&void 0!==arguments[1]?arguments[1]:document;if(-1===t.indexOf("{"))return t;var n=f(e);if(!n)throw new Error("Could not process URL template because script origin is unknown");return t=(t=t.replace("{current_host}",n.hostname)).replace("{current_scheme}",n.protocol)}if(function(){var t=[function(){return Promise.resolve()},function(){return new Map},function(){return new URL(document.location.href)},function(){return new Request("https://hypothes.is")},function(){return Element.prototype.prepend.name},function(){document.evaluate("/html/body",document,null,XPathResult.ANY_TYPE,null)}];try{return t.forEach((function(t){return t()})),!0}catch(t){return!1}}()){var d=function(e){for(var n={},r=e.querySelectorAll("script.js-hypothesis-config"),o=0;o<r.length;o++){var s=void 0;try{s=JSON.parse(r[o].textContent||"")}catch(t){console.warn("Could not parse settings from js-hypothesis-config tags",t),s={}}t(n,s)}return n}(document),y=h(d.assetRoot||"https://cdn.hypothes.is/hypothesis/1.888.0/"),m={"scripts/annotator.bundle.js":"scripts/annotator.bundle.js?9c1ac5","scripts/boot.bundle.js":"scripts/boot.bundle.js?e75f35","scripts/sidebar.bundle.js":"scripts/sidebar.bundle.js?17e537","scripts/ui-playground.bundle.js":"scripts/ui-playground.bundle.js?b3bed4","fonts/KaTeX_AMS-Regular.woff":"fonts/KaTeX_AMS-Regular.woff?3ba481","fonts/KaTeX_Caligraphic-Bold.woff":"fonts/KaTeX_Caligraphic-Bold.woff?a02380","fonts/KaTeX_Caligraphic-Regular.woff":"fonts/KaTeX_Caligraphic-Regular.woff?fc5e4c","fonts/KaTeX_Fraktur-Bold.woff":"fonts/KaTeX_Fraktur-Bold.woff?27e611","fonts/KaTeX_Fraktur-Regular.woff":"fonts/KaTeX_Fraktur-Regular.woff?a3eb3f","fonts/KaTeX_Main-Bold.woff":"fonts/KaTeX_Main-Bold.woff?2a1a96","fonts/KaTeX_Main-BoldItalic.woff":"fonts/KaTeX_Main-BoldItalic.woff?7b4be1","fonts/KaTeX_Main-Italic.woff":"fonts/KaTeX_Main-Italic.woff?effa4e","fonts/KaTeX_Main-Regular.woff":"fonts/KaTeX_Main-Regular.woff?e0ec75","fonts/KaTeX_Math-BoldItalic.woff":"fonts/KaTeX_Math-BoldItalic.woff?6e408d","fonts/KaTeX_Math-Italic.woff":"fonts/KaTeX_Math-Italic.woff?5bbbc8","fonts/KaTeX_SansSerif-Bold.woff":"fonts/KaTeX_SansSerif-Bold.woff?05089a","fonts/KaTeX_SansSerif-Italic.woff":"fonts/KaTeX_SansSerif-Italic.woff?6793c4","fonts/KaTeX_SansSerif-Regular.woff":"fonts/KaTeX_SansSerif-Regular.woff?7742a6","fonts/KaTeX_Script-Regular.woff":"fonts/KaTeX_Script-Regular.woff?c27731","fonts/KaTeX_Size1-Regular.woff":"fonts/KaTeX_Size1-Regular.woff?f0700f","fonts/KaTeX_Size2-Regular.woff":"fonts/KaTeX_Size2-Regular.woff?4fdf5d","fonts/KaTeX_Size3-Regular.woff":"fonts/KaTeX_Size3-Regular.woff?92cf7c","fonts/KaTeX_Size4-Regular.woff":"fonts/KaTeX_Size4-Regular.woff?47e816","fonts/KaTeX_Typewriter-Regular.woff":"fonts/KaTeX_Typewriter-Regular.woff?97f6f3","styles/annotator.css":"styles/annotator.css?0b34b9","styles/katex.min.css":"styles/katex.min.css?5fa91d","styles/pdfjs-overrides.css":"styles/pdfjs-overrides.css?dd8179","styles/sidebar.css":"styles/sidebar.css?a21291","styles/ui-playground.css":"styles/ui-playground.css?dffe1a"};if(document.querySelector("hypothesis-app"))!function(t,n){c(t,"fetch",n.apiUrl),c(t,"fetch",n.apiUrl+"links");var r=l(s);u(t,n,[].concat(e(r),["scripts/sidebar.bundle.js","styles/katex.min.css","styles/sidebar.css"]))}(document,{assetRoot:y,manifest:m,apiUrl:d.apiUrl});else{var v=h(d.notebookAppUrl||"https://hypothes.is/notebook"),b=h(d.sidebarAppUrl||"https://hypothes.is/app.html");!function(t,n){if(!t.querySelector('link[type="application/annotator+html"]')){a(t,"sidebar","html",n.sidebarAppUrl),a(t,"notebook","html",n.notebookAppUrl),a(t,"hypothesis-client","javascript",n.assetRoot+"build/boot.js");var r=l(s);u(t,n,[].concat(e(r),["scripts/annotator.bundle.js","styles/annotator.css","styles/pdfjs-overrides.css"]))}}(document,{assetRoot:y,manifest:m,notebookAppUrl:v,sidebarAppUrl:b})}}else console.warn("The Hypothesis annotation tool is not supported in this browser. See https://web.hypothes.is/help/which-browsers-are-supported-by-hypothesis/.")}();

" async></script>
</div>
</div>




</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
